<SEC-DOCUMENT>0001140361-20-000764.txt : 20200731
<SEC-HEADER>0001140361-20-000764.hdr.sgml : 20200731
<ACCEPTANCE-DATETIME>20200114132731
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001140361-20-000764
CONFORMED SUBMISSION TYPE:	DRS/A
PUBLIC DOCUMENT COUNT:		7
FILED AS OF DATE:		20200114
<PUBLIC-REL-DATE>20200731
DATE AS OF CHANGE:		20200114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nano-X Imaging Ltd.
		CENTRAL INDEX KEY:			0001795251
		STANDARD INDUSTRIAL CLASSIFICATION:	X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS [3844]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-02938
		FILM NUMBER:		20525616

	BUSINESS ADDRESS:	
		STREET 1:		COMMUNICATIONS CENTER
		CITY:			NEVE ILAN
		STATE:			L3
		ZIP:			9085000
		BUSINESS PHONE:		972 02 995 0506

	MAIL ADDRESS:	
		STREET 1:		COMMUNICATIONS CENTER
		CITY:			NEVE ILAN
		STATE:			L3
		ZIP:			9085000
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS/A
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<html>
<head>
    <title> </title>
 <meta content="text/html; charset=UTF-8">
 <meta name="GeneratedBy" content="Summit Financial Printing, LLC" version="1.32">
    <!-- Licensed to: Broadridge Financial Soultions, Inc.
         Document created using EDGARfilings PROfile 6.5.0.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body>
<!-- 100-regcov -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 12px; line-height: 12px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>As confidentially submitted to the Securities and Exchange Commission on </b><b>January </b><b>14</b><b>, 2020, as Amendment No.</b><b> </b><b>1 to the confidential </b><b>submission.</b><b> This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information </b><b>herein remains strictly confidential.</b></p>

				<p class="regno" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 12px; padding-left: 0px; text-indent: 0px; text-align: right; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>Registration No. 333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </b></p>
			<div style="clear: both;"></div></div>

<div class="block-frill" style="width: 100%; margin-left: 0%; ">
				<div class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 17.37px; line-height: 5.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><div class="hr-full" style="height: 0px; border-bottom: 2pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 0px; "> </div><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 4px; "> </div></div>
			</div>

<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 16px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>UNITED STATES<br> </b><b>SECURITIES AND EXCHANGE COMMISSION<br> </b><b><font style="font-size: 13.33px;">Washington, D.C. 20549 </font></b></p>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: -2.67px; margin-bottom: 0px; "><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 17%; margin: auto; margin-bottom: 12px; margin-top: 12px; "> </div></div>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 18.67px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 1.33px; margin-bottom: 0px; "><b>Form F-1</b></p>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 18.67px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: -1.33px; margin-bottom: 0px; "><b>REGISTRATION STATEMENT</b></p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: -1.33px; margin-bottom: 0px; "><i><b>UNDER<br> </b></i><i><b>THE SECURITIES ACT OF 1933 </b></i></p>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: -2.67px; margin-bottom: 0px; "><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 17%; margin: auto; margin-bottom: 12px; margin-top: 12px; "> </div></div>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 21.33px; line-height: 15px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 1.33px; margin-bottom: 0px; "><b>NANO-X IMAGING LTD</b><br><b><font style="font-size: 12px;">(Exact Name of Registrant as Specified in its Charter)</font></b></p>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: -2.67px; margin-bottom: 0px; "><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 17%; margin: auto; margin-bottom: 12px; margin-top: 12px; "> </div></div>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="32%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 12px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; "><b>State of Israel</b></div>
							</td>
							<td width="34%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 12px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; "><b>384</b><b>4</b></div>
							</td>
							<td width="34%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 12px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; "><b>Not Applicable</b></div>
							</td>
						</tr>
						<tr>
							<td width="32%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 12px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; "><b>(State or Other Jurisdiction of<br> </b><b>Incorporation or Organization)</b></div>
							</td>
							<td width="34%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 12px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; "><b>(Primary Standard Industrial<br> </b><b>Classification Code Number)</b></div>
							</td>
							<td width="34%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 12px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; "><b>(I.R.S. Employer Identification No.</b><b> </b><b>)</b></div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 12px; line-height: 12px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>Communications Center,<br></b><b>Neve Ilan, Israel 9085000<br></b><b>+972 02 995 0506<br></b><b> </b><b>(Address, including zip code, and telephone number, including<br></b><b>area code, of Registrant&#8217;s principal executive offices)</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: bold; font-style: normal; font-size: 12px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 12px; margin-bottom: 12px; " div="yes"><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 17%; margin: auto; margin-bottom: 2.67px; margin-top: 0px; "> </div>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 12px; line-height: 12px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 10.67px; margin-bottom: 0px; "><b>here&nbsp;&nbsp;&nbsp;<br></b><b>(Name, address, including zip code, and telephone number, including area code, of agent for service)</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: bold; font-style: normal; font-size: 12px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 12px; margin-bottom: 12px; " div="yes"><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 17%; margin: auto; margin-bottom: 2.67px; margin-top: 0px; "> </div>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 12px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 1.33px; margin-bottom: 0px; "><i><b>Copies to:</b></i></p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="29%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 12px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; "><b>Andrea L. Nicol&#225;s<br></b><b>Yossi Vebman<br></b><b>Skadden, Arps, Slate, Meagher &amp;<br></b><b>Flom LLP<br></b><b>Four</b><b> Times Square<br></b><b>New York, New York 10036<br></b><b>Tel: +1-212-735-3000<br></b><b>Fax: +1-212-735-2000</b></div>
							</td>
							<td width="24%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 12px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; "><b>Ian Rostowsky<br></b><b>Omri Flicker<br></b><b>Amit, Pollak, Matalon &amp; Co.<br></b><b>APM House, 18 Raoul<br> </b><b>Wallenberg St.<br></b><b>Building D, 6</b><b>th</b><b> Floor<br></b><b>Ramat Hachayal<br></b><b>Tel Aviv 6971915, Israel<br></b><b>Tel: +972-3-568-9000<br></b><b>Fax: +972-73-297-8645</b></div>
							</td>
							<td width="24%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 12px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; "><b>Peter N. Handrinos<br></b><b>Wesley C. Holmes<br></b><b>Michael E. Sullivan<br></b><b>Latham &amp; Watkins LLP<br></b><b>200 Clarendon Street<br></b><b>Boston, Massachusetts 02116<br></b><b>Tel: +1-617-948-6000<br></b><b>Fax: +1-617-948-6001<br></b></div>
							</td>
							<td width="24%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 12px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; "><b>Chaim Friedland<br></b><b>Ari Fried<br></b><b>Gornitzky &amp; Co.<br></b><b>Zion House<br></b><b>45 Rothschild Blvd.<br></b><b>Tel Aviv 6578403, Israel<br></b><b>Tel. +972-3-710-9191<br></b><b>Fax: +972-3-560-6555</b></div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: bold; font-style: normal; font-size: 12px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 12px; margin-bottom: 12px; " div="yes"><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 17%; margin: auto; margin-bottom: 2.67px; margin-top: 0px; "> </div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 12px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 1.33px; margin-bottom: 0px; "><b>Approximate date of commencement of proposed sale to the public:</b> As soon as practicable after effectiveness of this registration statement.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 12px; line-height: 12px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 1.33px; margin-bottom: 0px; ">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. <font style="font-size: 1.33px;">&#8201;</font><font style="font-family: wingdings">o</font></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 12px; line-height: 12px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 1.33px; margin-bottom: 0px; ">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="font-size: 1.33px;">&#8201;</font><font style="font-family: wingdings">o</font></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 12px; line-height: 12px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 1.33px; margin-bottom: 0px; ">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="font-size: 1.33px;">&#8201;</font><font style="font-family: wingdings">o</font></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 12px; line-height: 12px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 1.33px; margin-bottom: 0px; ">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="font-size: 1.33px;">&#8201;</font><font style="font-family: wingdings">o</font></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 12px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 1.33px; margin-bottom: 0px; ">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 12px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 1.33px; margin-bottom: 0px; ">Emerging growth company &#9746;</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 12px; line-height: 12px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 1.33px; margin-bottom: 0px; ">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. &#9746;</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 12px; line-height: 12px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 1.33px; margin-bottom: 0px; ">&#8224; The term &#147;new or revised financial accounting standard&#148; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: bold; font-style: normal; font-size: 12px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 12px; margin-bottom: 12px; " div="yes"><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 17%; margin: auto; margin-bottom: 2.67px; margin-top: 0px; "> </div>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 1.33px; margin-bottom: 0px; "><b>CALCULATION OF REGISTRATION FEE</b></p>
				<div class="calc" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><div class="hr-full" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: -8px; margin-top: 0px; "> </div></div>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-top: 1pt solid #000000; border-bottom: 1pt solid #000000; border-collapse: collapse; ">

						<tr>
							<td width="56%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; border-bottom: 1pt solid #000000; border-right: 1px solid #000000; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.83px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 1.83px; "><b>Title of each Class of Securities to be Registered</b></div>
							</td>
							<td width="22%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; border-bottom: 1pt solid #000000; border-right: 1px solid #000000; padding-bottom: pt; text-indent: 0px; padding-left: 1.83px; padding-right: 1.83px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.83px; padding-right: 1.83px; "><b>Proposed Maximum<br> </b><b>Aggregate Offering Price</b><b><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)(2)</sup></b></div>
							</td>
							<td width="22%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; border-bottom: 1pt solid #000000; padding-bottom: pt; text-indent: 0px; padding-left: 1.83px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.83px; padding-right: 0px; "><b>Amount of<br> </b><b>Registration Fee</b><b><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></b></div>
							</td>
						</tr>


						<tr>
							<td width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 12px; text-align: left; margin-top: 0px; margin-bottom: 0px; border-right: 1px solid #000000; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.83px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 1.83px; ">Ordinary shares, par value NIS 0.01 per share</div>
							</td>
							<td width="22%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 12px; text-align: left; margin-top: 0px; margin-bottom: 0px; border-right: 1px solid #000000; padding-bottom: pt; text-indent: 0px; padding-left: 1.83px; padding-right: 1.83px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.83px; padding-right: 1.83px; ">$&nbsp;&nbsp;&nbsp;&#8201;&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="22%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 12px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.83px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.83px; padding-right: 0px; ">$&nbsp;&nbsp;&nbsp;&#8201;&nbsp;&nbsp;&nbsp;</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<div class="calc" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 12px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: -8px; margin-top: 0px; "> </div><br></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(1)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(2)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">Includes ordinary shares that the underwriters may purchase pursuant to their option to purchase additional ordinary shares. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(3)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">Calculated pursuant to Rule 457(o) under the Securities Act based on an estimate of the proposed maximum aggregate offering price. </td></tr></table><div style="clear: both"></div>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: -8px; margin-bottom: 0px; "><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 17%; margin: auto; margin-bottom: 12px; margin-top: 12px; "> </div></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 12px; line-height: 12px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until </b><b>the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in </b><b>accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the </b><b>Securities and Exchange Commission acting pursuant to said Section 8(a), may determine.</b></p>
			<div style="clear: both;"></div></div>



<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<div class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 17.37px; line-height: 5.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 0px; "> </div><div class="hr-full" style="height: 0px; border-bottom: 2pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 4px; "> </div></div>
			</div>



<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 101-cov -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-redherring" style="width: 100%; margin-left: 0%; ">
				<p class="unknown" style="color: #fc0014; font-family: Arial, Helvetica, Sans-Serif; font-size: 13.33px; line-height: 13.33px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>Information contained herein is subject to completion or amendment. A registration statement relating to these securities has been filed with the Securities </b><b>and Exchange Commission. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes </b><b>effective. This prospectus shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any State </b><b>in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such State.</b></p>
			</div>



<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h2" style="color: #fc0014; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>SUBJECT TO COMPLETION</b><b> DATED&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2020</b><b> </b></p>
				<p class="h2" style="color: #fc0014; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>PRELIMINARY PROSPECTUS</b></p>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 16px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>NANO-X IMAGING LTD</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="logo_nanox.jpg" alt="" style="height: 61.33px; width: 253.33px; scale: ">&#8201;<br></p>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 16px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ORDINARY SHARES</b></p>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 32px; margin-bottom: 0px; "><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 19%; margin: auto; margin-bottom: 12px; margin-top: 12px; "> </div></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 32px; margin-bottom: 0px; ">This is an initial public offering of ordinary shares of NANO-X IMAGING LTD. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 32px; margin-bottom: 0px; ">No public market currently exists for our ordinary shares. The initial public offering price is expected to be between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share. </p>

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 32px; margin-bottom: 0px; ">We intend to apply to list our ordinary shares on The Nasdaq Capital Market under the symbol &#8220;NNOX.&#8221;</p>

				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 32px; margin-bottom: 0px; ">We are an &#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act of 2012 and will be subject to reduced public company reporting requirements. See &#147;Prospectus Summary&#8212;Implications of Being an Emerging Growth Company and a Foreign Private Issuer.&#148; </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 32px; margin-bottom: 0px; "><b>Investing in our ordinary shares involves a high degree of risk. See &#147;Risk Factors&#148; beginning on page </b><b><a href="#tRF">9</a></b><b> </b><b>of this prospectus for a discussion of information that should be considered in connection with an </b><b>investment in our ordinary shares</b>. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 32px; margin-bottom: 0px; ">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.50px; ">&#160;</div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 7.50px; padding-right: 7.50px; "><b>Per share</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 7.50px; padding-right: 0px; "><b>Total</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.50px; ">Initial public offering price</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&nbsp;&nbsp;&nbsp;&#8201;&nbsp;&nbsp;&nbsp;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&nbsp;&nbsp;&nbsp;&#8201;&nbsp;&nbsp;&nbsp;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.50px; ">Underwriting discounts and commissions<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.50px; ">Proceeds to us (before expenses)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 16%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(1)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">Refer to &#147;Underwriting&#148; for additional information regarding underwriting compensation. </td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 32px; margin-bottom: 0px; ">We have granted a 30-day option to the underwriters to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional ordinary shares solely to cover over-allotments, if any. The underwriters expect to deliver the shares to purchasers in the offering on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2020. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 18.67px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 32px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 32px; margin-bottom: 0px; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</p>
			<div style="clear: both;"></div></div>



<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 102-toc -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>TABLE OF CONTENTS</b></p>
				<a name="TOC"></a><table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; ">&#160;</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 6.52px; padding-right: 0px; "><b>Page</b><b> </b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; "><a href="#tPRS">PROSPECTUS SUMMARY</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tPRS">1</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; "><a href="#tTO">THE OFFERING</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tTO">6</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; "><a href="#tSCF">SUMMARY CONSOLIDATED FINANCIAL DATA</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tSCF">8</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; "><a href="#tRF">RISK FACTORS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tRF">9</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; "><a href="#tSN">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tSN">52</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; "><a href="#tUP">USE OF PROCEEDS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tUP">54</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; "><a href="#tDP">DIVIDEND POLICY</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tDP">56</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; "><a href="#tC">CAPITALIZATION</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tC">57</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; "><a href="#tD">DILUTION</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tD">58</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; "><a href="#tSC">SELECTED CONSOLIDATED FINANCIAL DATA</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tSC">61</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; "><a href="#tMDA">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tMDA">62</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; "><a href="#tB">BUSINESS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tB">72</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; "><a href="#tM">MANAGEMENT</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tM">94</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; "><a href="#tPS">PRINCIPAL SHAREHOLDERS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tPS">115</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; "><a href="#tCR">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tCR">117</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; "><a href="#tDS">DESCRIPTION OF SHARE CAPITAL</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tDS">120</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; "><a href="#tSE">SHARES ELIGIBLE FOR FUTURE SALE</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tSE">127</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; "><a href="#tMT">MATERIAL TAX CONSIDERATIONS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tMT">129</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; "><a href="#tU">UNDERWRITING</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tU">139</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; "><a href="#tER">EXPENSES RELATED TO OFFERING</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tER">145</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; "><a href="#tLM">LEGAL MATTERS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tLM">146</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; "><a href="#tE">EXPERTS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tE">146</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; "><a href="#tEC">ENFORCEABILITY OF CIVIL LIABILITIES</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tEC">147</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; "><a href="#tWY">WHERE YOU CAN FIND ADDITIONAL INFORMATION</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tWY">148</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; "><a href="#tIC">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tIC">F-1</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 19%; margin: auto; margin-bottom: 12px; margin-top: 12px; "> </div></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>Through and including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 (the 25</b><b><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup></b><b> day after the date of this prospectus), all dealers </b><b>effecting transactions in these securities, whether or not participating in this offering, may be required to </b><b>deliver a prospectus. This is in addition to a dealer&#146;s obligation to deliver a prospectus when acting as an </b><b>underwriter and with respect to an unsold allotment or subscription.</b></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">i</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">You should rely only on the information contained in this prospectus and any related free-writing prospectus that we authorize to be distributed to you. We have not authorized any person, including any underwriter, to provide you with information different from that contained in this prospectus or any related free-writing prospectus that we authorize to be distributed to you. This prospectus is not an offer to sell, nor is it seeking an offer to buy, our ordinary shares in any state or jurisdiction where such offer or sale is not permitted. The information in this prospectus speaks only as of the date of this prospectus unless the information specifically indicates that another date applies, regardless of the time of delivery of this prospectus or of any sale of the ordinary shares offered hereby. Our business, financial condition, results of operations, and prospects may have changed since that date. We do not take any responsibility for, nor do we provide any assurance as to the reliability of, any information other than the information in this prospectus and any free writing prospectus prepared by us or on our behalf. Neither the delivery of this prospectus nor the sale of our ordinary shares means that information contained in this prospectus is correct after the date of this prospectus.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>You may lose all </b><b>of your investment in</b><b> our ordinary shares. If you are uncertain as to our business </b><b>and operations or you are not prepared to lose all </b><b>of your investment in</b><b> our ordinary shares, we strongly </b><b>urge you not to purchase any of our ordinary shares. We recommend that you consult legal, financial, tax </b><b>and other professional advisors or experts for further guidance before participating in the offering of our </b><b>ordinary shares as further detailed in this prospectus.</b> </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>We do not recommend that you purchase our ordinary shares unless you have prior experience with </b><b>investments in capital markets, and basic knowledge of the healthcare and medical imaging industry, and </b><b>unless you have received independent professional advice.</b></p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tMA"></a><b>Market and Industry Data</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">This prospectus includes statistics and other data relating to markets, market sizes and other industry data pertaining to our business that we have obtained from industry publications and surveys and other information available to us. Industry publications and surveys generally state that the information contained therein has been obtained from sources believed to be reliable. We have not independently verified any of the data from third-party sources nor have we ascertained the underlying economic assumptions relied upon therein. Market data and statistics are inherently predictive and speculative and are not necessarily reflective of actual market conditions. Such statistics are based on market research, which itself is based on sampling and subjective judgments by both the researchers and the respondents, including judgments about what types of products and transactions should be included in the relevant market. In addition, the value of comparisons of statistics for different markets is limited by many factors, including that (i) the markets are defined differently, (ii) the underlying information was gathered by different methods, and (iii) different assumptions were applied in compiling the data. Accordingly, the market statistics included in this prospectus should be viewed with caution. We believe that information from these industry publications included in this prospectus is reliable.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tTS"></a><b>Trademarks, Service Marks and Trade Names</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Solely for convenience, the trademarks, service marks, and trade names referred to in this prospectus are without the &#174; and &#8482; symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks and trade names. This prospectus contains additional trademarks, service marks and trade names of others, which are the property of their respective owners. We do not intend our use or display of other companies&#146; trademarks, service marks or trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Basis of Presentation</b></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We were incorporated under the laws of the State of Israel under the name &#147;NANO-X IMAGING LTD&#148; on December 20, 2018. We commenced our operations on September 3, 2019. Substantially all of our assets were acquired or assigned (the &#147;Asset Purchase&#148;) from our predecessor company, Nanox Imaging PLC (&#147;Nanox Gibraltar&#148;), a Gibraltar public company, pursuant to an asset purchase agreement (the &#147;Asset Purchase Agreement&#148;), dated as of September 3, 2019 and as amended on December 3, 2019 and December 31, 2019, between Nanox Gibraltar and us. </p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As of September 3, 2019, we and Nanox Gibraltar had the same shareholders and therefore the transaction was treated as a transaction under common control for accounting purposes. For periods and at dates prior to the </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">ii</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">Asset Purchase, the financial statements included in this prospectus were prepared based on the historical financial statements of Nanox Gibraltar, which were adjusted to reflect (a) only the net assets that were transferred in the Asset Purchase according to the Asset Purchase Agreement, (b) the consideration in the Asset Purchase as if it was created at the beginning of the earliest period presented, against a decrease in the shareholders&#146; equity, and (c) all of the share-related information and amounts of shareholders&#146; equity and earnings per share as the shares of Nano-X Imaging Ltd.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Unless derived from our financial statements or otherwise noted, the terms &#147;shekels&#148; and &#147;NIS&#148; refer to New Israeli Shekels, the lawful currency of the State of Israel, the terms &#147;dollar&#148; or &#147;$&#148; refer to U.S. dollars, the lawful currency of the United States, and &#147;Yen&#148; refers to Japanese Yen, the lawful currency of Japan. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Pursuant to the applicable provisions of the Fixing America&#146;s Surface Transportation Act, we are not required to file our financial information for the historical 2017 annual period or for any interim period for 2018 or 2019 because we plan to file our financial information for the year ended December 31, 2019 in the first public filing of our registration statement. While the 2017 annual financial information and 2018 and 2019 interim financial information is otherwise required by Regulation S-X, we believe that it will not be required to be included in our registration statement at the time of the first public filing.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">iii</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 103-sum -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 98%; margin-left: 0%; padding-left: 1%; padding-right: 1%; border: solid 1pt black; padding-bottom: 20px;">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tPRS"></a><b>PROSPECTUS SUMMARY</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>This summary highlights selected information contained elsewhere in this prospectus. Because it is only a </i><i>summary, it does not contain all of the information you should consider before making your investment decision. </i><i>Before investing in our ordinary shares, you should carefully read this entire prospectus, including our financial </i><i>statements and the related notes thereto and the information set forth under </i><i>&#147;Risk Factors,&#148; &#147;Selected </i><i>Consolidated Financial Data,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of </i><i>Operations&#148; and &#147;Business</i><i>.</i><i>&#148;</i><i> </i><i>Unless the context otherwise requires, all</i><i> references to &#147;Nanox</i><i>,&#148; &#147;we,&#148; &#147;us,&#148; </i><i>&#147;our,&#148; the &#147;Company&#148; and similar designations refer to </i><i>NANO-X IMAGING LTD</i><i>, an Israeli company, </i><i>and</i><i> its</i><i> </i><i>wholly-owned Japanese subsidiary, or, where applicable, our</i><i> predecessor company, </i><i>Nanox Imaging PLC, a </i><i>Gibraltar public limited company</i><i>,</i><i> </i><i>and its wholly-owned Japanese subsidiary</i><i>.</i></p>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Overview</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Early detection saves lives&#8212;and we at Nanox are focused on applying our proprietary medical imaging technology to make diagnostic medicine more accessible and affordable across the globe. Our vision is to increase early detection of medical conditions that are discoverable by X-ray, which we believe is key to increasing early treatment, improving health outcomes and, ultimately, saving lives. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As a first step to producing a new class of affordable medical imaging systems, we have focused on identifying and developing a novel X-ray source. Our X-ray source is based on a novel digital microelectromechanical system (&#147;MEMs&#148;) semiconductor cathode that we believe can achieve the same functionalities as legacy X-ray analog cathodes, while allowing for lower-cost production than existing medical imaging systems. We developed this technology over eight years to reach commercial applicability. This novel digital X-ray source is the basis of core technology in the Nanox.Arc, the imaging system we are developing, and we believe it also has the potential to replace the legacy X-ray source in other existing imaging systems. </p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our solution, which we refer to as the Nanox System, has two integrated components&#8212;hardware (Nanox.Arc) and software (Nanox.Cloud). We are developing a prototype of the Nanox.Arc, a medical imaging system incorporating our novel digital X-ray source. Subject to receiving regulatory clearance, the first version of the Nanox.Arc will be a three-dimensional (&#147;3D&#148;) tomosynthesis imaging system. Tomosynthesis is an imaging technique widely used for early detection, that is designed to produce a high-resolution, 3D X-ray image reconstruction of the scanned human body part for review by a professional diagnostics expert. In parallel, we are developing Nanox.Cloud, a companion cloud-based software that is designed to provide an end-to-end medical imaging service, including services such as image repository, radiologist matching, online and offline diagnostics review and annotation, connectivity to diagnostic assistive artificial intelligence (&#147;AI&#148;) systems, billing and reporting. The Nanox System is designed to enable medical screening as a service (&#147;MSaaS&#148;) to improve accessibility and affordability of early-detection services worldwide. </p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If cleared, we plan to market and deploy the Nanox System globally at a substantially lower cost than currently available medical imaging systems, such as computed tomography (&#147;CT&#148;), because our digital X-ray source will allow the Nanox.Arc to have a more simplified structure without the costly cooling equipment or the complex rotating mechanism used in legacy CT devices. See &#147;Business&#8212;Our Technology&#8212;The Nanox System.&#148; We believe that the Nanox System could increase the accessibility and affordability of early-detection medical imaging systems worldwide.</p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As we continue to develop the Nanox.Arc, we expect to take a multi-step approach to the regulatory clearance process. As a first step, we plan to submit a 510(k) application for a single-source version of the Nanox.Arc to the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) in January 2020. If we receive FDA clearance, we will continue to optimize and develop further features of the Nanox.Arc, and plan to submit additional 510(k) applications to the FDA with respect to the Nanox.Arc. We believe that neither our novel digital X-ray source nor the Nanox.Cloud will require regulatory approval or clearance. However, to date, we have not obtained feedback from the FDA regarding our regulatory strategy. We plan to introduce a working prototype of the Nanox.Arc in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and, if cleared, we plan to deploy the first Nanox.Arc in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, with wide deployment expected to be achieved in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</p>

				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Limitation of Current Medical Imaging </b><b>Systems</b><b> and </b><b>Our Market Opportunity</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The main categories of current medical imaging systems that use X-ray sources include CT, mammography, fluoroscopy, angiogram and dental. The analog X-ray source used by these systems produces X-rays by </p>
			<div style="clear: both;"></div></div>





<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">1</p>
			</div>


<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 98%; margin-left: 0%; padding-left: 1%; padding-right: 1%; border: solid 1pt black; padding-bottom: 20px;">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">accelerating electrons to high energies, causing them to hit a metal target from which the X-rays are emitted. This requires a significant amount of electrical energy to be transferred to the X-ray tube. Due to the heat generated by this process, one of the most complex mechanical challenges is cooling the analog X-ray source. In addition, for CTs, the mechanical structure is even more complex because the analog X-ray source needs to rotate in a heavy gantry at high speed. We believe these are key factors leading to the high cost and complexity of existing medical imaging systems, which in turn significantly limits the availability of medical imaging for early detection globally. According to a report from the Pan-American Health Organization and the World Health Organization (&#147;WHO&#148;) in 2012, approximately two-thirds of the world population did not have access to medical imaging, while many people with access to medical imaging face substantial wait times for scanning. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, most market participants, including medical imaging manufacturing companies, medical imaging providers and radiologists, among others, have not provided the same level of end-to-end medical imaging services. One of the reasons is that the scanning process is currently not integrated with the diagnostics process, which contributes to extended wait times for image diagnostics by experts. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We estimate that the total annual capital expenditures on existing X-ray-based medical imaging systems, not including support, maintenance, insurance and ancillary services, will reach approximately $21 billion by 2021, which we believe represents a significant market opportunity for the Nanox System.</p>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Our Solution</b><b> </b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We believe the Nanox System addresses the limitations of existing medical imaging systems on three levels:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
<b>D</b><b>igital X-ray source</b><b> with the potential to significantly reduce the costs of medical imaging </b><b>systems</b><b>.</b> We believe our digital X-ray source technology will allow us to manufacture the Nanox.Arc, if cleared, at substantially lower costs compared to medical imaging systems that use a legacy analog X-ray source without sacrificing imaging quality. The availability of a lower cost device has the potential to substantially increase medical imaging availability and improve accessibility of early-detection services broadly across the globe.
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Technology</b><b> designed to improve</b><b> upon the industry standard with integrated</b><b> radiology diagnostics </b><b>via a cloud-based </b><b>M</b><b>SaaS platform.</b> The Nanox.Arc employs our novel digital X-ray source that is designed to be energy-efficient, smaller and can be more precisely controlled compared to existing X-ray source. By integrating the Nanox.Cloud, we believe the Nanox System could provide a streamlined process where each scanned image is uploaded automatically to the cloud system and matched to a human radiology expert and decision assistive AI algorithms to provide scan reviews and diagnostics in a significantly shorter time frame than current diagnostics, which could substantially reduce wait-times for imaging results and increase early detection rates compared to currently employed imaging process protocols. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Business model designed to increase the availability of</b><b> medical imaging</b><b>.</b> Our primary business model is based on a pay-per-scan pricing structure as opposed to the existing capital expenditure-based business model of existing medical imaging manufacturing companies. We believe our business model will significantly reduce the price per scan compared to the current global average cost of $300 per scan, and has the potential to commoditize medical imaging services at prices that are affordable to a greater number of people. </td></tr></table><div style="clear: both"></div>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Our Strategy</b></p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
<b>Secure regulatory </b><b>clearance</b><b> for </b><b>our medical imaging system</b><b>. </b>We expect to take a multi-step approach to the regulatory clearance process. As a first step, we plan to submit a 510(k) application for a single-source version of the Nanox.Arc to the FDA in January 2020. If we receive FDA clearance, we will continue to optimize and develop further features of the Nanox.Arc, and plan to submit additional 510(k) applications to the FDA with respect to the Nanox.Arc.
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
<b>Jumpstart the </b><b>MSaa</b><b>S-based </b><b>medical imaging market with strategic partnerships. </b>We plan to produce and deploy an initial wave of approximately 15,000 Nanox.Arc units over &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to jumpstart the MSaaS-based medical imaging market. We are in negotiations with global manufacturers to begin commercial production and assembly of the Nanox.Arc and with strategic regional partners for the deployment, operation and marketing of the Nanox System broadly across the globe, including in the
</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>





<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">2</p>
			</div>


<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 98%; margin-left: 0%; padding-left: 1%; padding-right: 1%; border: solid 1pt black; padding-bottom: 20px;">
				<p class="bl" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">United States, certain Asian countries and the rest of the world, including the EU and Africa. We plan to work with these partners to achieve local integrations into health maintenance organizations, electronic health record systems, payment methods and insurance coverage companies. In addition, we are also actively seeking collaboration opportunities with leading cloud-based enterprises, as we anticipate an industry shift to a digital and cloud-based subscription model will bring more digital healthcare disruptors into the market. </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Maximize the commercial potential</b><b> of our technology</b><b> with </b><b>simultaneous</b><b> </b><b>business models</b><b>. </b>We plan to commercialize our novel X-ray source technology by pursuing three simultaneous business models, which we believe will provide us the flexibility and long-term sustainability to monetize our technology. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><i>Subscription Model</i><i>:</i> In certain countries, if permitted by laws in the applicable jurisdiction, our primary sales strategy will be based on a pay-per-scan pricing structure, where we expect to sell the Nanox System at low cost or at no cost, with a suggested retail price per scan that is substantially lower than the current global average charge, and receive a portion of the proceeds from each scan as the right-to-use licensing fee. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><i>Sales Model:</i> In certain countries, to accommodate specific local regulatory requirements, we expect to sell the Nanox.Arc for a one-time charge at a price that is substantially less than current market offerings. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><i>Licensing Model</i><i>:</i> For certain medical imaging market participants, we plan to tailor our X-ray source technology to their specific imaging systems to replace the legacy X-ray source. We expect to charge a one-time licensing fee upfront and receive recurring royalty payments for each system sold. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Leverage </b><b>the Nanox System to bring added value to our collaborators.</b> We expect that the Nanox System will enable us to accumulate a significant number of medical images, which have the potential to be used by collaborators, such as medical AI-analytics companies, through machine learning algorithms to increase the probability of early disease detection. </td></tr></table><div style="clear: both"></div>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Risks Associated with our Business</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Investing in our ordinary shares involves risks. You should carefully consider the risks described in &#147;Risk Factors&#148; before making a decision to invest in our ordinary shares. If any of these risks actually occurs, our business, financial condition or results of operations could be materially and adversely affected. In such case, the trading price of our ordinary shares would likely decline, and you may lose all or part of your investment. The following is a summary of some of the principal risks we face: </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">we are a development-stage company with limited operating history. We may never be able to effectuate our business plan or achieve any revenue or profitability. Therefore, at this stage of our business, potential investors have a high probability of losing their entire investment; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our efforts may never demonstrate the feasibility of our X-ray source technology for commercial applications;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">we are highly dependent on the successful development, marketing and sale of our X-ray source technology and the related products and services;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our business models depend on the successful commercial application of Nanox.Cloud, which is subject to numerous risks and uncertainties;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">products utilizing our technology may need to be approved or cleared by the FDA and similar regulatory agencies worldwide. We may not receive, or may be delayed in receiving, the necessary approval or clearance for our future products, which would adversely affect business, financial condition, results of operations and products; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">we may not be successful in implementing our business models; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">we expect to depend on third parties to manufacture the Nanox.Arc and to supply certain component parts;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>





<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">3</p>
			</div>


<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 98%; margin-left: 0%; padding-left: 1%; padding-right: 1%; border: solid 1pt black; padding-bottom: 20px;">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">it is difficult and costly to protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">patent terms may be inadequate to protect our competitive position on our future products for an adequate amount of time;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our product candidates and operations are subject to extensive government regulation and oversight both in the United States and abroad, and our failure to comply with applicable requirements could harm our business;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">under applicable employment laws, we may not be able to enforce covenants not to compete and therefore may be unable to prevent our competitors from benefiting from the expertise of some of our former employees; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">conditions in Israel could materially and adversely affect our business.</td></tr></table><div style="clear: both"></div>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Corporate Information</b></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We were incorporated under the laws of the State of Israel under the name &#147;NANO-X IMAGING LTD&#148; on December 20, 2018 and we commenced our operations on September 3, 2019. Substantially all of our assets were acquired or assigned (the &#147;Asset Purchase&#148;) from our predecessor company, Nanox Imaging PLC (&#147;Nanox Gibraltar&#148;), a Gibraltar public company, under an Asset Purchase Agreement, dated as of September 3, 2019 and as amended on December 3, 2019 and December 31, 2019, between Nanox Gibraltar and us. Our principal executive offices are located at Communications Center, Neve Ilan, Israel 9085000, and our telephone number is +972 02 995 0506. Our website address is <u>http://www.nanox.vision</u>. The information contained therein or connected thereto shall not be deemed to be incorporated into this prospectus or the registration statement of which it forms a part. Our agent for service of process in the United States is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</p>

				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Implications of Being an Emerging Growth Company and a Foreign Private Issuer</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As a company with less than $1.07 billion in revenue during our most recently completed fiscal year, we qualify as an &#147;emerging growth company&#148; as that term is defined in Section 2(a) of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), as modified by the Jumpstart Our Business Startups Act of 2012 (the &#147;JOBS Act&#148;). As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to U.S. public companies that are not emerging growth companies. These provisions include:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the option to include in an initial public offering registration statement only two years of audited financial statements and selected financial data and only two years of related disclosure;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">reduced executive compensation disclosure; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">an exemption from the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002 (the &#147;Sarbanes-Oxley Act&#148;) in the assessment of our internal control over financial reporting.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The JOBS Act also permits an emerging growth company such as us to delay adopting new or revised accounting standards until such time as those standards are applicable to private companies. We have elected to &#147;opt out&#148; of this provision and, as a result, we will comply with new or revised accounting standards as required when they are adopted for public companies. This decision to opt out of the extended transition period under the JOBS Act is irrevocable.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We will remain an emerging growth company until the earliest of:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the last day of our fiscal year during which we have total annual revenue of at least $1.07 billion;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the last day of our fiscal year following the fifth anniversary of the closing of this offering;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the date on which we have, during the previous three-year period, issued more than $1.0 billion in non-convertible debt securities; or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the date on which we are deemed to be a &#147;large accelerated filer&#148; under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), which, among other things, would occur if the market value of our ordinary shares that are held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>





<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">4</p>
			</div>


<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 98%; margin-left: 0%; padding-left: 1%; padding-right: 1%; border: solid 1pt black; padding-bottom: 20px;">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have taken advantage of reduced reporting requirements in this prospectus. Accordingly, the information contained herein may be different than the information you receive from other public companies. References to an &#147;emerging growth company&#148; in this prospectus shall have the meaning associated with that term in the JOBS Act.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, upon closing of this offering, we will report under the Exchange Act as a &#147;foreign private issuer.&#148; As a foreign private issuer, we may take advantage of certain provisions under the rules that allow us to follow Israeli law for certain corporate governance matters. Even after we no longer qualify as an emerging growth company, as long as we qualify as a foreign private issuer under the Exchange Act, we will be exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the sections of the Exchange Act requiring insiders to file public reports of their share ownership and trading activities and liability for insiders who profit from trades made in a short period of time; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the rules under the Exchange Act requiring the filing with the Securities and Exchange Commission (the &#147;SEC&#148;) of quarterly reports on Form 10-Q containing unaudited financial and other specified information, or current reports on Form 8-K, upon the occurrence of specified significant events; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Regulation Fair Disclosure (&#147;Regulation FD&#148;), which regulates selective disclosures of material information by issuers. </td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Foreign private issuers, like emerging growth companies, are also exempt from certain more stringent executive compensation disclosure rules. Thus, if we remain a foreign private issuer, even if we no longer qualify as an emerging growth company, we will continue to be exempt from the more stringent compensation disclosures required of public companies that are neither an emerging growth company nor a foreign private issuer. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We may take advantage of these exemptions until such time as we are no longer a foreign private issuer. We are required to determine our status as a foreign private issuer on an annual basis at the end of our second fiscal quarter. We would cease to be a foreign private issuer at such time as more than 50% of our outstanding voting securities are held by U.S. residents and any of the following three circumstances applies:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the majority of our executive officers or directors are U.S. citizens or residents;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">more than 50% of our assets are located in the United States; or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our business is administered principally in the United States.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>





<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">5</p>
			</div>


<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 98%; margin-left: 0%; padding-left: 1%; padding-right: 1%; border: solid 1pt black; padding-bottom: 20px;">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tTO"></a><b>THE OFFERING</b></p>
				<div style="clear: both;"></div><div class="rmk" style="float: left; width: 312px; margin-top: 8px; padding-right: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-bottom: 0px; "><b>Ordinary shares offered by us</b></div>
				<div class="rmk" style="overflow: hidden; margin-top: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; text-indent: 0px; text-align: left; margin-right: 0px; margin-bottom: 0px; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares (or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares if the underwriters exercise their option to purchase additional ordinary shares in full).</div>
				<div style="clear: both;"></div><div class="rmk" style="float: left; width: 298.67px; margin-top: 8px; padding-right: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 13.33px; text-indent: -13.33px; text-align: left; margin-right: 0px; margin-bottom: 0px; "><b>Ordinary shares to be outstanding after this </b><b>offering</b></div>
				<div class="rmk" style="overflow: hidden; margin-top: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; text-indent: 0px; text-align: left; margin-right: 0px; margin-bottom: 0px; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares (or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares if the underwriters exercise their option to purchase additional ordinary shares in full).</div>
				<div style="clear: both;"></div><div class="rmk" style="float: left; width: 312px; margin-top: 8px; padding-right: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-bottom: 0px; "><b>Option to purchase additional ordinary shares</b></div>
				<div class="rmk" style="overflow: hidden; margin-top: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; text-indent: 0px; text-align: left; margin-right: 0px; margin-bottom: 0px; ">We have granted the underwriters an option to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional ordinary shares from us within 30 days of the date of this prospectus.</div>
				<div style="clear: both;"></div><div class="rmk" style="float: left; width: 312px; margin-top: 8px; padding-right: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-bottom: 0px; "><b>Use of proceeds</b></div>
				<div class="rmk" style="overflow: hidden; margin-top: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; text-indent: 0px; text-align: left; margin-right: 0px; margin-bottom: 0px; ">
We estimate that we will receive net proceeds from this offering of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million if the underwriters exercise their option to purchase additional ordinary shares in full, based on an assumed initial public offering price of&#8201; $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.<br>&nbsp;&nbsp;&nbsp;<br>We intend to use the net proceeds from this offering, together with our existing cash, cash equivalents, and short-term investments, for (i) the manufacturing of the initial wave of Nanox.Arc units planned for global deployment, (ii) shipping, installation, deployment and maintenance costs of the Nanox.Arc, (iii) the continued research and development of the Nanox.Arc, the development of the Nanox.Cloud and regulatory clearance, (iv) sales and marketing expenses in connection with the deployment of the Nanox System and (v) general and administrative expenses and other general corporate purposes. See &#147;Use of Proceeds&#148; for additional information.
</div>
				<div style="clear: both;"></div><div class="rmk" style="float: left; width: 312px; margin-top: 8px; padding-right: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-bottom: 0px; "><b>Risk factors</b></div>
				<div class="rmk" style="overflow: hidden; margin-top: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; text-indent: 0px; text-align: left; margin-right: 0px; margin-bottom: 0px; ">See &#147;Risk Factors&#148; and other information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in our ordinary shares.</div>
				<div style="clear: both;"></div><div class="rmk" style="float: left; width: 312px; margin-top: 8px; padding-right: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-bottom: 0px; "><b>Proposed Nasdaq Capital Market symbol</b></div>
				<div class="rmk" style="overflow: hidden; margin-top: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-bottom: 0px; ">
&#8220;NNOX&#148;
</div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The number of ordinary shares to be outstanding after this offering is based on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares outstanding as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, and excludes:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares issuable upon the exercise of options to purchase ordinary shares outstanding under the NANO-X Imaging Ltd. 2019 Equity Incentive Plan (the &#147;2019 Equity Incentive Plan&#148;) as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, at a weighted average exercise price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional ordinary shares reserved for future issuance under our 2019 Equity Incentive Plan as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020;
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares issuable upon the exercise of warrants to purchase ordinary shares as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, at a weighted average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which warrants shall not expire upon the closing of this offering if not exercised; and
</td></tr></table><div style="clear: both"></div>
			</div><div style="clear: both"></div>





<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">

<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">6</p>

			</div>


<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 98%; margin-left: 0%; padding-left: 1%; padding-right: 1%; border: solid 1pt black; padding-bottom: 20px;">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">
&#8226;
</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares issuable upon the exercise of options to purchase ordinary shares to be granted to A-Labs Finance and Advisory Ltd, which provided certain consulting services for this offering, at the closing of this offering, at an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share.
</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Unless otherwise indicated, all information in this prospectus assumes or gives effect to: </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
the assumed exercise prior to the closing of this offering of certain outstanding warrants that shall otherwise expire upon such closing to purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares for an aggregate purchase price of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million;
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
no exercise of the outstanding share options or warrants (other than as described above) after &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020;
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a &nbsp;&nbsp;-for-1 share split to be effective prior to the closing of this offering; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">no exercise by the underwriters of their option to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional ordinary shares from us; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the adoption and effectiveness of our amended and restated articles of association, which will occur immediately prior to the closing of this offering.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>





<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">7</p>
			</div>


<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 98%; margin-left: 0%; padding-left: 1%; padding-right: 1%; border: solid 1pt black; padding-bottom: 20px;">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tSCF"></a><b>SUMMARY CONSOLIDATED FINANCIAL DATA</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following tables present our summary consolidated statement of operations, balance sheet data and other data for the periods or as of the dates indicated. The summary statement of operations data for the years ended December 31, 2019 and 2018 and the summary balance sheet data as of December 31, 2019 have been derived from our audited consolidated financial statements included elsewhere in this prospectus. We prepare our financial statements in accordance with U.S. GAAP. For periods and at dates prior to the Asset Purchase, our financial statements were prepared based on the historical financial statements of Nanox Gibraltar, with certain adjustments as described under &#147;Basis of Presentation.&#148; Our historical results are not necessarily indicative of results to be expected in any future periods. You should read this summary consolidated financial data section together with &#147;Selected Consolidated Financial Data,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our audited consolidated financial statements and related notes included elsewhere in this prospectus.</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="69%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2px; padding-right: 0px; "><b>Year ended December 31,</b></div></td>
</tr>
<tr>
	<td colspan="1" width="69%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2px; padding-right: 2px; "><b>2019</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2px; padding-right: 0px; "><b>2018</b></div></td>
</tr>
<tr>
	<td colspan="1" width="69%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 0px; "><b>($ in thousands, except</b><b> share and</b><br><b> </b><b>per share data)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="69%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; "><b>Consolidated Statement of Operations Data:<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="69%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Research and development expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">672</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="69%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Marketing, general and administrative expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">1,232</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="69%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Operating loss</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(1,904</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="69%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Financial expenses, net</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">5</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="69%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Net loss for the year</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">$</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">$</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(1,909</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="69%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Basic and diluted loss per ordinary share<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">$</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">$</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">(0.09</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="69%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Weighted average number of ordinary shares outstanding&#8201;&#8211;&#8201;basic and diluted<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">20,792,973</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="69%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Pro forma basic and diluted loss per ordinary share<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">$</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">$</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="69%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Pro forma weighted average number of ordinary shares outstanding &#8211; basic and diluted<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(1)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">See Note 9 to our financial statements appearing at the end of this prospectus for further details on the calculation of basic and diluted net loss per share.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(2)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">Pro forma loss per ordinary share is calculated by dividing loss for the year by the pro forma weighted average number of ordinary shares outstanding during the period, which gives effect to the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares upon the exercise of warrants held by certain of our shareholders immediately prior to the closing of this offering.</td></tr></table><div style="clear: both"></div>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="60%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2px; padding-right: 2px; "><b>Historical</b><b> </b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2px; padding-right: 2px; "><b>Pro forma</b><b><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(a)</sup></b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2px; padding-right: 0px; "><b>Pro forma,<br> </b><b>as adjusted</b><b><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(</sup></b><b><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup></b><b><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">)</sup></b></div></td>
</tr>
<tr>
	<td colspan="1" width="60%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="9" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2px; padding-right: 0px; "><b>As of December 31,</b><b> 2019</b></div></td>
</tr>
<tr>
	<td colspan="1" width="60%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="9" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 0px; "><b>($ in thousands)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="60%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; "><b>Consolidated Balance Sheet Data:<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="60%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Cash and cash equivalents</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&nbsp;&nbsp;&nbsp;&#8201;&nbsp;&nbsp;&nbsp;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&nbsp;&nbsp;&nbsp;&#8201;&nbsp;&nbsp;&nbsp;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&nbsp;&nbsp;&nbsp;&#8201;&nbsp;&nbsp;&nbsp;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="60%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Working capital<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="60%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Total assets</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="60%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Total liabilities</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="60%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Accumulated deficit</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="60%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Total shareholders&#8217; deficit</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(1)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">We define working capital as current assets less current liabilities.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(2)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">The summary pro forma balance sheet data gives effect to the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares upon the exercise of warrants held by certain of our shareholders immediately prior to the closing of this offering.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(3)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">The summary pro forma as adjusted balance sheet data gives effect to (i) the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares upon the exercise of warrants held by certain of our shareholders immediately prior to the closing of this offering, and (ii) the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares in this offering, at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>





<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">8</p>
			</div>


<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 104-risk -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tRF"></a><b>RISK FACTORS</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>We are subject to various risks that may materially harm our business, financial condition, results of </i><i>operations and prospects. An investment in our ordinary shares is speculative and involves a high degree of risk. </i><i>In evaluating an investment, and before deciding whether to invest, in our ordinary shares, you should carefully </i><i>consider the risks and uncertainties described below, together with all the other information included in this </i><i>prospectus, including our consolidated financial statements and the related notes included elsewhere in this </i><i>prospectus and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</i><i>.&#146;</i><i>&#146;</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>If any of the events described in the following risk factors actually occurs, or if additional risks and </i><i>uncertainties that are not presently known to us or that we currently deem immaterial later materialize, then our </i><i>business, financial condition, results of operations and prospects could be materially adversely affected, the </i><i>trading price of our ordinary shares could very likely decline, and you may lose all or part of your investment in </i><i>our shares. The risks and uncertainties described below are not the only ones we face. In addition, the risks </i><i>discussed below include forward-looking statements, and our actual results may differ substantially from those </i><i>discussed in these forward-looking statements.</i></p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Risks Related to Our Business</b></p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>We are a development-stage company with limited operating history. We may never be able to effectuate our </b></i><i><b>business plan or achieve any revenue or</b></i><i><b> reach</b></i><i><b> profitability. Therefore, at this stage of our business, potential </b></i><i><b>investors have a high probability of losing their entire investment.</b></i><i><b> </b></i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are a development-stage company, and are subject to all of the risks inherent in the establishment of a new business enterprise. We have a limited operating history and only a preliminary and unproven business plan upon which investors may evaluate our prospects. We have not yet demonstrated the feasibility of our digital X-ray source technology for commercial applications. We have not produced a working prototype of the Nanox.Arc or developed a beta version of the Nanox.Cloud. In addition, we have not entered into manufacturing agreements related to the production of the approximately 15,000 Nanox.Arc units planned for the initial global deployment. Even if we are able to do so, we may not be able to manufacture the Nanox.Arc at the low costs needed to support our business models, including the Subscription Model, which is our primary business model. We also have not entered into any commercial arrangement for the licensing of our X-ray source under the Licensing Model. </p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Furthermore, even if our technology becomes commercially viable, our business models may not generate sufficient revenue necessary to support our business. We estimate that effectively stimulating market interest in our Nanox System will require deploying at least 5,000 to 10,000 Nanox.Arc units. In addition, we estimate that a minimum installed base of at least 1,000 Nanox.Arc units will be needed to support our business during the initial deployment, assuming we enter into at least one licensing agreement on commercially reasonable terms. We may never achieve any of these thresholds for units deployed in the near-to-mid term at any level or at all, which may cause our business to fail. The Subscription Model is based on selling the Nanox System at low cost or no cost using a pay-per-scan pricing structure, which is pioneering for medical imaging companies and is subject to numerous risks. The medical imaging industry is also highly competitive and our technology, products, services or business models may not achieve widespread market acceptance. If we are unable to address any issues mentioned above, or encounter other problems, expenses, difficulties, complications, and delays in connection with the starting and expansion of our business, our entire business may fail, in which case you may lose your entire investment.</p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have a history of net losses and negative cash flow from operations since inception and we expect such losses and negative cash flows to continue in the foreseeable future. As of December 31, 2019, we had working capital of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and shareholders&#146; equity of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. For the years ended December 31, 2018 and 2019, we incurred net losses of approximately $1.9 million and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , respectively. As of December 31, 2019, we had an accumulated deficit of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We anticipate our losses will continue to increase from current levels because we expect to incur additional costs related to developing our business, including research and development costs, manufacturing costs, employee-related costs, costs of complying with government regulations, intellectual property development and prosecution costs, marketing and promotion costs, capital expenditures, general and administrative expenses, and costs associated with operating as a public company. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">9</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our ability to generate revenue from our operations and, ultimately, achieve profitability will depend on, among others, whether we can complete the development and commercialization of our technology, our future products and our services, including our X-ray source technology, the Nanox.Arc and the Nanox.Cloud, whether we can manufacture the Nanox.Arc on a commercial scale in such amounts and at such costs as we anticipate, and whether we can achieve market acceptance of our products, services and business models. We may never generate any revenue or operate on a profitable basis. Even if we achieve profitability, we may not be able to sustain it. </p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our efforts may never demonstrate the feasibility of our </b></i><i><b>digital </b></i><i><b>X-ray source </b></i><i><b>technology for commercial </b></i><i><b>applications.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have developed our X-ray source technology and are developing a prototype of the Nanox.Arc. Even though we believe our X-ray source has achieved commercial applicability, our technology has not been tested over extended periods of time and therefore no meaningful data exists regarding the durability, safety and effectiveness of our X-ray source over extended periods. We have not produced a working prototype of the Nanox.Arc and we may not be able to successfully integrate our X-ray source into the Nanox.Arc or any medical imaging system. In addition, there is no precedent for commercialization of technology like ours. Even if we are able to produce a fully functional prototype, the commercial scale production and deployment of Nanox.Arc will require significant additional development, sales and marketing efforts, and we may not be able to ensure the effectiveness, accuracy, consistency and safety of the Nanox.Arc in commercial settings. Any unanticipated technical or other problems and the possible insufficiency of funds and other resources needed to complete the development and commercialization of our X-ray source, the Nanox.Arc or the Nanox.Cloud may result in delays and cause us to incur additional expenses that would increase our losses. If our X-ray source is not commercially feasible now or in the long term, our business may fail. </p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Two of o</b></i><i><b>ur business models depend on the successful commercial application of </b></i><i><b>the </b></i><i><b>Nanox.Cloud, which is </b></i><i><b>subject to numerous risks and uncertainties.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition to the Nanox.Arc, we are also developing the Nanox.Cloud, a companion cloud software designed to deliver MSaaS. We have not yet developed a beta version of the Nanox.Cloud. The development and commercialization of the Nanox.Cloud has a number of risks, including:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the Nanox.Cloud requires a considerable investment of technical, financial, and legal resources, which may not be available to us;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">it may require separate regulatory clearances or approvals;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">it may not be technically viable to integrate the Nanox.Cloud with the businesses of our potential customers and collaborators, such as local operators, radiologists, cloud storage providers, medical AI software providers and others;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">market acceptance of the MSaaS model is affected by a variety of factors, including security, reliability, scalability, customization, performance, customer preference, patients&#8217; concerns with entrusting a third party to store and manage their health data, public concerns regarding privacy and compliance with restrictive laws or regulations;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our cloud-based service may raise concerns among our customer base, including concerns regarding changes to pricing over time, service availability, information security of a cloud-based solution and access to medical images while offline;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the Nanox.Cloud may be subject to computer system failures, cyber-attacks or other security breaches; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">incorrect or improper implementation or use of the Nanox.Cloud by third-party cloud-service providers under our Sales Model could result in customer dissatisfaction and harm our business and reputation;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">undetected software errors or flaws in the Nanox.Cloud could harm our reputation or decrease market acceptance of the MSaaS model; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">we may incur higher costs than we expected as we expand our cloud-based services. </td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If we are unable to successfully develop and commercialize the Nanox.Cloud, our business, financial condition, results of operations and prospects could be negatively impacted.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">10</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We are </b></i><i><b>hig</b></i><i><b>hly </b></i><i><b>dependent on the successful development, marketing and sale of our X-ray source</b></i><i><b> </b></i><i><b>technology </b></i><i><b>and the related products and services.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our core digital X-ray source technology is the basis of our business. The Nanox.Arc currently under development is being designed to integrate our X-ray source technology into a medical imaging device for commercial use. As a result, the success of our business plan is highly dependent on our ability to develop, manufacture and commercialize our X-ray source technology and related products and services, such as the Nanox.Arc and the Nanox.Cloud, and our failure to do so could cause our business to fail. Successful commercialization of medical imaging devices is a complex and uncertain process, dependent on the efforts of management, manufacturers, local operators, integrators, medical professionals, third-party payors, as well as general economic conditions, among other factors. Any factor that adversely impacts the development and commercialization of our X-ray source technology or related products and services, including the Nanox.Arc, the Nanox.Cloud and the Nanox System, will have a negative impact on our business, financial condition, results of operations and prospects. Some potential factors include:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to achieve sufficient market acceptance by hospitals and clinics, providers of medical imaging services, medical professionals such as radiologists, third-party payors and others in the medical community;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to compete with existing medical imaging technology companies;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to establish, maintain and expand our sales, marketing and distribution networks; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to obtain and/or maintain necessary regulatory approvals; and </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to effectively protect our intellectual property. </td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our inability to successfully obtain clearance or approval for and subsequently commercialize our X-ray source technology or related products and services, and/or successfully develop and commercialize additional products or any enhancements to the products which we may develop would have a material adverse effect on our business, financial condition, results of operations and prospects. </p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Products utilizing our technology </b></i><i><b>may</b></i><i><b> need to be approved or cleared by the FDA and similar regulatory </b></i><i><b>agencies worldwide</b></i><i><b>. We may not receive, or may be delayed in receiving, the necessary approval or clearance </b></i><i><b>for our future products, which would adversely affect business, financial condition, results of operations and </b></i><i><b>prospects</b></i><i><b>.</b></i><i><b> </b></i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We expect to take a multi-step approach to the regulatory clearance process. As a first step, we plan to submit a 510(k) application to the FDA for a single-source version of the Nanox.Arc in January 2020. If we receive FDA clearance, we will continue to optimize and develop further features of the Nanox.Arc, and plan to submit additional 510(k) applications to the FDA with respect to the Nanox.Arc. We may also need to seek approval from foreign regulatory authorities. With respect to our X-ray source technology and the Nanox.Cloud, although we believe that they do not require regulatory approval or clearance, regulatory agencies may not agree. To date, we have not had any discussion with the FDA or other regulatory authorities regarding the regulatory pathways for our product candidates. Efforts to achieve required governmental clearances and approvals could be costly and time consuming, and we may not be able to obtain any such required approvals in a timely and cost-efficient manner. Any delay or failure to obtain necessary regulatory clearances or approvals could have a material negative impact on our ability to generate revenues. Even if the products containing our technology receive the required regulatory clearance or approval, such products will remain subject to extensive regulatory requirements. If we fail to comply with the regulatory requirements of the FDA and other applicable U.S. and foreign regulatory authorities, or previously unknown problems with any approved commercial products, manufacturers or manufacturing processes are discovered, we could be subject to administrative or judicially imposed sanctions. </p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, the cost of compliance with new laws or regulations governing our technology or future products could adversely affect our business, financial condition, results of operations and prospects. New laws or regulations may impose restrictions or obligations on us that could force us to redesign our technology or other future products or services, and may impose restrictions that are not possible or practicable to comply with, which could cause our business to fail. See &#147;&#8212;Risks Related to Government Regulation.&#148; </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">11</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We will need to obtain additional financing to fund our future operations. If we are unable to obtain such </b></i><i><b>financing, we may be unable to complete the development and commercialization of our technology and our </b></i><i><b>products and services.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our operations have consumed substantial amounts of cash since inception. Our net losses were $1.9 million and $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for the years ended December 31, 2018 and 2019, respectively. In addition, significant resources were invested in the development of our X-ray source technology prior to us acquiring the technology. We anticipate that our future cash requirements will continue to be significant. We will need to obtain additional financing, including the proceeds from this offering, to implement our business plan as described in this prospectus. Such financings could include equity financing, which may be dilutive to shareholders, or debt financing, which would likely restrict our ability to borrow from other sources. In addition, such securities may contain rights, preferences or privileges senior to those of the rights of our current shareholders. Additional funds may not be available when we need them, on terms attractive to us, or at all. If adequate funds are not available on a timely basis, we may be required to curtail the development of our technology, products or services, or materially delay, curtail, reduce or terminate our research and development and commercialization activities. We could be forced to sell or dispose of our rights or assets. Any inability to raise adequate funds on commercially reasonable terms could have a material adverse effect on our business, financial condition, results of operation and prospects, including the possibility that a lack of funds could cause our business to fail and liquidate with little or no return to investors. </p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>The success of our primary business model, the Subscription Model, is subject to numerous risks and </b></i><i><b>uncertainties.</b></i><i><b> </b></i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We expect the Subscription Model to be our primary business model and the key to achieving our vision of increasing early-detection of medical conditions that are discoverable by X-ray. Even if we are able to successfully implement our Sales Model and/or our Licensing Model, the sustainability of our general business plan depends substantially on the sustainability of our Subscription Model. We believe that effectively stimulating market interest in our Nanox System will require deploying 5,000 to 10,000 Nanox.Arc units. In addition, we estimate that a minimum installed base of at least 1,000 Nanox.Arc units will be needed to support our business during the initial deployment, assuming we enter into at least one licensing agreement on commercially reasonable terms. The success of our Subscription Model will also depend on each device, once deployed, performing a sufficient number of scans per day to be fully utilized. We may not be successful in achieving these goals for various reasons, including: </p>

				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the process of manufacturing and deploying the Nanox System is a complex, multi-step process that depends on factors outside our control, and could cause us to expend significant time and resources prior to earning associated revenues;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the manufacturing cost of the Nanox.Arc may be higher than we expect, may increase significantly, or may increase at a higher rate than anticipated, and we may not be able to set or timely adjust our pay-per-scan pricing to compensate for any increased costs;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the manufacturing of the Nanox.Arc may take longer than we expected, and we may experience delays in the manufacturing and deployment of the Nanox System, which would have a negative impact on the timing of our revenues; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
deployment and full utilization of the Nanox System may not be achieved or may take substantially longer than we expect, and we may not be able to deploy a sufficient number of units of the Nanox System to support our business or to effectively stimulate market interest;
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a Nanox System may perform fewer scans per day than our estimates due to a number of factors, including low market acceptance rate, technical failures and downtime, service disruptions, outages or other performance problems, which would have a negative impact on our revenues and our ability to recover costs;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the implementation, integration and testing of the Nanox.Cloud with our potential customers and collaborators can be complex, time-consuming and expensive for them, which may have a negative impact on the timing of our revenues;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">
&#8226;
</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
as part of the Subscription Model, we will be responsible for maintenance of the Nanox System units we deploy, which may be more costly and time-consuming than we expect;
</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">12</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our customers may not be able to find or retain a sufficient number of radiologists to review the images generated by the Nanox System, especially as we deploy additional Nanox Systems and the volume of scans increases;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the portion of our pay-per-scan pricing allocated to our collaborators may not be acceptable to them, either now or in the future, and pricing negotiations with such collaborators may be a complex and time-consuming process;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our pay-per-scan pricing may not be sufficient to recover our costs and may not be adjusted in a timely manner, which could negatively affect our revenues or cause our revenues and results of operations to vary significantly from period to period;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">we may be unsuccessful in maintaining our target price per scan because we do not control the price charged by local operators and higher prices may adversely affect market acceptance of the Nanox System; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">regulatory authorities may challenge our Subscription Model altogether, and impose significant civil, criminal, and administrative penalties, damages, fines, and/or exclusion from government funded healthcare programs, which could adversely affect our revenues and results of operations. </td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Any of the above factors may negatively affect the implementation of our Subscription Model, or cause our Subscription Model to fail. </p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We may not be successful in </b></i><i><b>tailoring</b></i><i><b> our X-ray source </b></i><i><b>to the specific systems </b></i><i><b>of other medical imaging </b></i><i><b>companies under our Licensing Model, and/or </b></i><i><b>entering into licensing agreements on terms favorable to us.</b></i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under our proposed Licensing Model, we expect to be engaged to tailor our X-ray source to other medical imaging companies&#146; specific systems to replace the legacy X-ray source, and we expect to receive a one-time, non-recurring licensing fee upfront, as well as recurring royalty payments for each imaging system sold by such companies. We expect customization to be a complex and multi-step process that varies for each project, which will require significant research and testing activities. We may also not be able to demonstrate the feasibility, functionality or safety of our technology in other medical imaging systems, meet the potential licensees&#146; design and manufacturing requirements, or satisfy their marketing and product needs. In addition, we may not be successful in entering into licensing agreements with favorable terms as a result of a numbers of factors, many of which are outside of our control, including willingness of, and the resources available to, other medical imaging companies to in-license our novel X-ray source technology, our ability to agree with a potential partner on the value of our technology, or on the related terms, as well as the availability of other technologies at lower cost or other alternative technologies at the time. We have not entered into any licensing agreements; however, we are in negotiations regarding a commercial arrangement with FUJIFILM Corporation for the licensing of our Nanox System. Any of the above factors may negatively affect the implementation of our Licensing Model, or cause our Licensing Model to fail. </p>

				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>To the extent that we license our X-ray source technology to </b></i><i><b>other medical imaging companies</b></i><i><b>, the products </b></i><i><b>integrating our technology may need to be approved or cleared by the FDA </b></i><i><b>or</b></i><i><b> similar regulatory agencies.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The FDA may require products developed by other medical imaging companies under the Licensing Model to go through lengthier or more rigorous processes than we expected. These products may also be subject to regulations by governmental agencies in other jurisdictions, or regulation by other federal, state and local agencies. In addition, we may not have control with respect to any such further regulatory approval strategies or process. If such products do not receive, or are delayed in receiving, the necessary clearances or approvals, or if the performance of one or more clinical trials are required in connection with such clearances or approvals, the prospects of our Licensing Model may be materially affected, which could have a material adverse impact on our business and our revenues. </p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our industry is highly competitive and is subject to technological change, which may result in </b></i><i><b>new </b></i><i><b>products </b></i><i><b>or </b></i><i><b>solutions that are superior to our technology or other future products we may bring to market from time to </b></i><i><b>time. If we are unable to anticipate or keep pace with changes in the marketplace and the direction of </b></i><i><b>technological innovation and customer demands, our technology may become less useful or obsolete and our </b></i><i><b>operating results will suffer.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The medical imaging industry is rapidly evolving and subject to intense and increasing competition. To compete successfully and to be able to establish and maintain a competitive position in current and future </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">13</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">technologies, we will need to demonstrate the advantages of our technology over well-established alternative solutions, products and technologies, such as CT, as well as newer methods of medical imaging and early detection. We believe that effectively stimulating market interest for the Nanox System will require deploying 5,000 to 10,000 Nanox.Arc units. To achieve this, we will need to raise or develop financial resources, technical expertise, marketing, distribution or support capabilities and we may not be successful in doing so. </p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Also, companies offering traditional medical imaging systems, such as General Electric, Siemens, Philips, Hologic, Varian, Fuji, Toshiba and Hitachi, may be better established in the market than we are, have greater corporate, financial, operational, sales and marketing resources than we do, or have more experience in research and development than we have. In particular, the field emission technology has been used by a wide range of leading market players in an attempt to create an alternative digital source of X-ray, the most well-known attempt being the use of carbon nano tubes as the base materials for a potential field emission-based solution. In addition, early-detection technologies developed by other companies, such as blood testing and DNA screening, may also reduce the attractiveness of our technology for early detection or render it obsolete. Successful developments of these or other technologies by competitors resulting in new approaches for medical imaging, including technologies, products or services that are more effective or commercially attractive, could make our technology less useful or obsolete. We may also face opposition from certain industry leaders, who may have political influence and the ability to delay deployment of the Nanox System in certain geographical areas.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Furthermore, as the market expands, we expect the entry of additional competitors, such as cloud computing companies or leading IT companies, who may have longer operating histories, more extensive international operations, greater name recognition, and/or substantially greater technical, marketing and financial resources.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our competitive position also depends on our ability to: </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">generate widespread awareness, acceptance and adoption of our technology and future products or services; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">develop new or enhanced technologies or features that improve the convenience, efficiency, safety or perceived safety, and productivity of our technology and future products or services; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">properly identify customer needs and deliver new products or services or product enhancements to address those needs; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">limit the time required from prototype development to commercial production; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">limit the timing and cost of regulatory approvals; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">attract and retain qualified personnel and collaborators; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">protect our inventions with patents or otherwise develop proprietary products and processes; and </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">secure sufficient capital resources to expand both our continued research and development, and sales and marketing efforts. </td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If our technology is not, or our future products or services are not, competitive based on these or other factors, our business would be harmed.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We expect to depend on third parties to manufacture </b></i><i><b>the </b></i><i><b>Nanox.Arc</b></i><i><b> and to supply certain component parts</b></i><i><b>. </b></i><i><b>Our reliance on third-party manufacturers and suppliers involve certain risks that may result in, among </b></i><i><b>others, increased costs, quality or compliance issues, </b></i><i><b>or </b></i><i><b>failure </b></i><i><b>to timely</b></i><i><b> manufactur</b></i><i><b>e</b></i><i><b> the </b></i><i><b>Nanox.Arc</b></i><i><b>, any of </b></i><i><b>which </b></i><i><b>could </b></i><i><b>materially harm our business.</b></i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If cleared, we expect to rely on third-party manufacturers for the commercial production of the Nanox.Arc. We are in negotiations with a global manufacturer to assemble the Nanox.Arc, with a goal to enable the commercial production of the initial approximately 15,000 units planned for global deployment over &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have not yet entered into any such agreement. Although we have entered into arrangements with a manufacturer for the production of our X-ray tubes, we are currently negotiating with other parties for the supply of the various other components of the Nanox.Arc. Our dependence on such third-party manufacturers involves a number of risks, including: </p>

				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">insufficient capacity or delays in meeting our demand;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">inadequate manufacturing yields, inferior quality and excessive costs;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">14</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">inability to manufacture products that meet the agreed upon specifications;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">inability to obtain an adequate supply of materials;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">inability to comply with the relevant regulatory requirements for the manufacturing process;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">limited warranties on products supplied to us;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">inability to comply with our contractual obligations;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">potential increases in prices; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">increased exposure to potential misappropriation of our intellectual property. </td></tr></table><div style="clear: both"></div>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We currently expect to engage third-party manufacturers for the production of the various components of the Nanox.Arc, as well as only one general manufacturer for the assembly of the Nanox.Arc. If such manufacturers breach their agreements, are unable to meet their contractual or quality requirements, or become unwilling to perform for any reason, we may be unable, or may be unable in a timely manner, to locate alternative acceptable manufacturers and enter into favorable agreements with them. </p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, we currently manufacture the MEMs in the clean rooms located in Tokyo, Japan, and rely on third parties to supply the raw materials and certain component parts. Disruptions of our relationships with such suppliers could negatively impact our production for an extended period of time. Any inability to acquire sufficient quantities of any raw materials or components in a timely manner from these third-party suppliers could have a material negative impact on our business. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, if we are required to change the manufacturer of a critical component of our products, we will be required to verify that the new manufacturer maintains facilities, procedures and operations that comply with our quality and applicable regulatory requirements, which could further impede our ability to manufacture our products in a timely manner. Transitioning to a new supplier could be time-consuming and expensive, may result in interruptions in our operations and product delivery, could affect the performance specifications of our products or could require that we modify the design of those systems. If the change in manufacturer results in a significant change to any product, a new 510(k) clearance or approval from the FDA or similar international regulatory authorization may be necessary before we implement the change, which could cause substantial delays. The occurrence of any of these events could harm our ability to meet the demand for our products in a timely or cost-effective manner. See &#147;&#8212;Risks Related to Government Regulation.&#148; </p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We may experience development or manufacturing problems and higher costs, or delays that could limit our </b></i><i><b>revenue, if any, or increase our losses. </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Developing manufacturing procedures for new products requires developing specific production processes for those products. Developing such processes could be time consuming, and any unexpected difficulty in doing so can delay the introduction of the Nanox.Arc. Moreover, difficulties associated with adapting our technology and product design to the proprietary process technology and design rules of outside manufacturers can lead to reduced yields. Since low yields may result from either design or process technology failures, yield problems may not be effectively determined or resolved until an actual product exists that can be analyzed and tested to identify process sensitivities relating to the design rules that are used. As a result, yield problems may not be identified until well into the production process, and resolution of yield problems may require cooperation between our manufacturers and us. This risk could be compounded by the offshore location of our manufacturers, increasing the effort and time required to identify, communicate and resolve manufacturing yield problems. Manufacturing defects that we do not discover during the manufacturing or testing process may lead to costly product recalls. These risks may lead to increased costs or delayed product delivery, which would harm our profitability and customer relationships. Furthermore, our, our manufacturers&#146; or our suppliers&#146; production processes and assembly methods may have to change to accommodate any significant, future expansion of our manufacturing capacity, which may increase the manufacturing costs, delay production of our products, reduce our product margin, require supplemental filings with the FDA or other regulatory authorities, any of which may adversely impact our business. If we are unable to keep up with demand for our products by successfully manufacturing and shipping our products in a timely manner, our revenue could be impaired, and market acceptance for our products could be adversely affected. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">15</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We may not be able to successfully execute our business </b></i><i><b>m</b></i><i><b>odels</b></i><i><b>.</b></i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are pursuing three simultaneous business models to maximize the commercial potential of our X-ray source technology, each of which requires significant time and resources, in particular, our primary business model, the Subscription Model. We are a company with limited operating history and we may not have the necessary resources, expertise and experience to successfully execute any of our business models on a global scale, such as obtaining the necessary approvals or clearances from the regulatory agencies of our target markets. Our ability to execute our models is dependent on a number of factors, including the ability of our senior management team to execute our models, our ability to engage local operators and integrators in different geographic regions, our ability to begin or maintain our pace of product development, manufacturing and commercialization, our ability to meet the changing needs of the medical imaging market, and the ability of our employees to perform at a high-level. If we are unable to execute our models, if our models do not drive the growth that we anticipate, or if our market opportunity is not as large as we have estimated, it could adversely affect our business and our prospects. </p>

				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We may be unable to continue as a going concern if we do not successfully raise additional capital or if we </b></i><i><b>fail to generate sufficient revenue from operations.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Primarily as a result of our lack of revenue, history of losses to date and our lack of liquidity, there is substantial uncertainty as to our ability to continue as a going concern, which is also described in the opinion of our independent registered accountants in our audited financial statements included in this prospectus. If we are unable to raise additional capital or if we are unable to generate sufficient revenue from our operations, we may not stay in business. We have no committed sources of capital and we may not be able to obtain additional financing when needed, on terms that are acceptable, or at all. We do not own any significant assets that we expect could serve as acceptable collateral for a bank or other commercial lender. The above circumstances may discourage some investors from purchasing our ordinary shares, lending us money, or from providing alternative forms of financing. The failure to satisfy our capital requirements would materially adversely affect our business, financial condition, results of operations and prospects. Unless we raise additional funds, either through the sale or issuance of equity securities or one or more collaborative arrangements, we will not have sufficient funds to continue operations. Even if we take these actions, they may be insufficient, particularly if our costs are higher than projected, unforeseen expenses arise or the development, production or commercialization of our technology or related products or services is delayed.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We have a limited operating history. If we successfully commercially launch </b></i><i><b>the Nanox.Arc or the </b></i><i><b>Nanox.Cloud</b></i><i><b>, and </b></i><i><b>they</b></i><i><b> do not achieve widespread market acceptance, we will not be able to generate the </b></i><i><b>revenue necessary to support our business. </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have a limited operating history and have no history of marketing our X-ray source technology, the Nanox.Arc, the Nanox.Cloud or any other product using our technology. We may fail to generate significant interest in our X-ray source technology, the Nanox.Arc, the Nanox.Cloud or the imaging products using our technology, or any other product we may develop. These and other factors, including the following, may affect the rate and level of market acceptance:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">effectiveness of the sales and marketing efforts of us, and our partners such as the local partners;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">perception by medical professionals and patients of the convenience, safety, efficiency and benefits of the Nanox.Arc, the Nanox.Cloud or products using our technology, compared to competing methods of medical imaging;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">opposition from certain industry leaders, which may limit our ability to promote the Nanox.Arc or the Nanox.Cloud and to penetrate into the medical imaging market in certain geographical areas;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the existence of established medical imaging technology; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">willingness of market participants to accept the MSaaS model;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">timing of market introduction of competing products, and the sales and marketing initiatives of such products;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">press and blog coverage, social media coverage, and other publicity and public relations factors by others; </td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">16</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">lack of financing or other resources to successfully develop and commercialize our technology and implement our business plan; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the level of commitment and support that we receive from our partners, such as local operators, cloud storage providers and medical AI software providers, as well as medical professionals such as radiologists; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">coverage determinations and reimbursement levels of third party payors.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If cleared or approved for marketing by the FDA or other regulatory agencies, depending on the approved clinical indication, the Nanox.Arc will be competing with existing and future imaging products and similar offerings. The technology underlying our X-ray source and the Nanox.Arc may be perceived as inferior or inaccurate and patients may be unwilling to undergo medical screening using the Nanox.Arc or other products using our technology. Moreover, patients and medical professionals may be unwilling to depart from the current medical imaging technology. Medical professionals tend to be slow to change their medical diagnostic practices because of perceived liability risks arising from the use of new technology or products, and they may not recommend medical imaging using the Nanox.Arc or other products using our technology until there is long-term clinical evidence to convince them to alter or modify their existing imaging methods. Our efforts to educate patients, radiologists and other members of the medical community on the benefits of our products require significant resources and may not be successful. Our efforts to educate the marketplace may require more resources than are required by conventional technologies marketed by our competitors. In particular, gaining market acceptance for our products in nascent markets, such as China, India, and certain countries in Latin America, could be challenging. Moreover, in the event that the Nanox.Arc or other products using our technology are the subject of guidelines, clinical studies or scientific publications that are unfavorable or damaging, or otherwise call into question their benefits, we may have difficulty in convincing market participants to adopt our products. In addition, medical professionals, patients, providers of medical imaging services and third-party payors may not adopt or reimburse the use of the Nanox.Arc in the near term or at all. If we are unable to achieve or maintain an adequate level of market acceptance, we may not generate significant revenue or become profitable and our business, financial condition, results of operations and prospects would be significantly harmed. </p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We plan to do business globally, including in certain countries where we might have limited resources and </b></i><i><b>would be subject to additional regulatory burdens and other risks and uncertainties.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We expect to do business globally, including in the United States, China, India and Saudi Arabia, as well as the rest of the world, including the EU and Africa. Commercialization of our X-ray source technology, the Nanox.Arc or the Nanox System in foreign markets, either directly or through third parties, is subject to additional risks and uncertainties, including:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">reimbursement and insurance coverage;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our inability to find agencies, dealers or distributors in specific countries or regions;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our inability to directly control commercial activities of third parties;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">limited resources to be deployed to a specific jurisdiction;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the burden of complying with complex and changing regulatory, tax, accounting and legal requirements;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">different medical imaging practice and customs in foreign countries affecting acceptance in the marketplace;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">import or export licensing and other requirements;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">longer accounts receivable collection times;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">longer lead times for shipping;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">language barriers for technical training;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">reduced protection of intellectual property rights in some foreign countries;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">foreign currency exchange rate fluctuations; and </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">interpretations of contractual provisions governed by foreign laws in the event of a contract dispute.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">17</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Sales of the Nanox.Arc, the Nanox Cloud or the Nanox System in foreign markets could also be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions and changes in tariffs, any of which may adversely affect our business, financial condition, results of operations and prospects. </p>

<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Because </b></i><i><b>the</b></i><i><b> Nanox System is still in the development stage, it is not </b></i><i><b>yet </b></i><i><b>approved for third-party payor </b></i><i><b>coverage or reimbursement. If in the future we are approved for and are otherwise able to commercialize it, </b></i><i><b>but are unable to obtain adequate reimbursement or insurance coverage from third-party payors, we may not </b></i><i><b>be able to generate significant revenue, in which case we may need to obtain additional financing.</b></i></p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Because the Nanox System is still in the development stage, it is not yet approved for third-party payor coverage or reimbursement. Coding and coverage determinations as well as reimbursement levels and conditions are important to the commercial success of an imaging product or offering. The future availability of insurance coverage and reimbursement for newly approved medical devices is highly uncertain, and our future business will be greatly impacted by the level of reimbursement provided by third-party payors. In the United States, third-party payors decide which imaging products and services they will cover, how much they will pay and whether they will continue reimbursement. Third-party payors may not cover or provide adequate reimbursement for the Nanox System or the imaging services using the Nanox System, assuming we are able to fully develop and obtain all regulatory approvals and clearances to market it in the United States or other geographies. To date, we have not had any discussions with any third-party payors, including any regulatory agencies administering any government funded healthcare programs, regarding the coding, coverage or reimbursement for imaging services using the Nanox System. Accordingly, unless government and other third-party payors provide coverage and reimbursement for our services, patients may not use them, which would cause investors to lose their entire investment. A primary trend in the United States healthcare industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and services. Reimbursement may not be available, or continue to be available, for the Nanox System or the imaging services using the Nanox System, other products or systems using our X-ray source technology or any other products we may develop in the future, or even if reimbursement is available, such reimbursement may not be adequate. We also will be subject to foreign reimbursement policies in the international markets we expect to enter. Decisions by health insurers or other third-party payors in these markets not to cover, or to discontinue reimbursing, our products could materially and adversely affect our business. If such decisions are made, they could also have a negative impact on our ability to generate revenues, in which case we may need to obtain additional financing. </p>

				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Recent changes in the United States related to payment policies for imaging procedures could have a negative </b></i><i><b>impact on the utilization of our imaging services.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In the United States, over the past several years, the Centers for Medicare &amp; Medicaid Services (&#147;CMS&#148;), the federal agency responsible for administering the Medicare program, has implemented numerous changes to payment policies for imaging procedures in both the hospital setting and non-hospital settings, which include physician offices and freestanding imaging facilities. Some of these changes have had a negative impact on utilization of imaging services. Examples of these changes include: </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">limiting payments for imaging services in physician offices and free-standing imaging facility settings based upon rates paid to hospital outpatient departments; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">reducing payments for certain imaging procedures when performed together with other imaging procedures in the same family of procedures on the same patient on the same day in the physician office and free-standing imaging facility setting; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">making significant revisions to the methodology for determining the practice expense component of the Medicare payment applicable to the physician office and free-standing imaging facility setting which results in a reduction in payment; and </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">revising payment policies and reducing payment amounts for imaging procedures performed in the hospital outpatient setting. </td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We also expect increased regulation and oversight of advanced diagnostic testing. One provision in the Protecting Access to Medicare Act requires CMS to develop appropriate use criteria (&#147;AUC&#148;) that professionals </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">18</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">must consult when ordering advanced diagnostic imaging services (which include magnetic resonance imaging (&#147;MRI&#148;), CT, nuclear medicine (including position emission tomography) and other advanced diagnostic imaging services that the Secretary of the Department of Health and Human Services (&#147;HHS&#148;) may specify). Beginning in 2020, payment will be made to the furnishing professional for an applicable advanced diagnostic imaging service only if the claim indicates that the ordering professional consulted a qualified clinical decision support mechanism, as identified by HHS, as to whether the ordered service adheres to the applicable AUC. To the extent that these types of changes have the effect of reducing the aggregate number of diagnostic medical imaging procedures performed in the United States, our business, results of operations, financial condition and cash flows would be adversely affected. </p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Billing complexities associated with obtaining payment or reimbursement may negatively affect our revenue, </b></i><i><b>cash flow and profitability.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Billing for imaging services is complex. Payment is provided by individual patients and from a variety of payors, such as commercial insurance carriers, managed care organizations and governmental programs. Each payor typically has different billing requirements, and the billing requirements of many payors have become increasingly stringent.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Among the factors complicating our customers&#146; ability to bill and receive reimbursement from third-party payors are:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">disputes among payors as to which party is responsible for payment;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">disparity in coverage among various payors;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">disparity in information and billing requirements among payors; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">incorrect or missing billing information, which is required to be provided by the ordering physician.</td></tr></table><div style="clear: both"></div>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, we may be required to seek new billing codes for imaging services using the Nanox System, and regulatory authorities may not approve the creation of separate codes. Additionally, even if we are successful, these billing codes or the payment amounts associated with such codes may change in the future.</p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The impact of these factors may be compounded by our use of the novel Subscription Model. These billing complexities, and the related uncertainty in obtaining payment for our products, could negatively affect our revenue, cash flow and profitability. </p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Any collaborative arrangements that we may establish in the future may not be successful or we may </b></i><i><b>otherwise not realize the anticipated benefits from these collaborations. We do not control third parties with </b></i><i><b>whom we have or may have collaborative arrangements, and we will rely on them to achieve results which </b></i><i><b>may be significant to us. In addition, any current or future collaborative arrangements may place the </b></i><i><b>development and commercialization of our technology outside our control, may require us to relinquish </b></i><i><b>important rights or may otherwise be on terms unfavorable to us.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We expect to enter into certain collaborative arrangements with respect to the research, development, manufacture, and commercialization of our technology with different relevant industry participants, including, among others, local operators, integrators, radiologists, cloud storage providers and medical AI software providers and third-party payors. Any future potential collaborative arrangements may require us to rely on external consultants, advisors, and experts for assistance in several key functions, including research and development, manufacturing, regulatory and intellectual property. We cannot and will not control these third parties, but we may rely on them to achieve results, which may be significant to us. Relying upon these collaborative arrangements for our technology subjects us to a number of risks, including:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">we may not be able to control the amount and timing of resources that our collaborators may devote to our technology;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">should a collaborator fail to comply with applicable laws, rules or regulations when performing services for us, we could be held liable for such violations;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our collaborators may have a shortage of qualified personnel, particularly radiologists who can review the medical images generated by the Nanox System, especially as we deploy additional Nanox Systems and the volume of scans increases;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">19</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">we may be required to relinquish important rights, such as marketing and distribution rights;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">business combinations or significant changes in a collaborator&#8217;s business strategy may adversely affect a collaborator&#8217;s willingness or ability to complete its obligations under any arrangement;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">under certain circumstances, a collaborator could move forward with a competing product developed either independently or in collaboration with others, including our competitors;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our current or future collaborators may utilize our proprietary information in a way that could expose us to competitive harm;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our collaborators could obtain ownership or other control over intellectual property that is material to our business; and </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">collaborative arrangements are often terminated or allowed to expire, which could delay the ability to commercialize our technology. </td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, if disputes arise between us and any of our collaborators, it could result in the delay or termination of the development, manufacturing or commercialization of products containing our technology, lead to protracted and costly legal proceedings, or cause collaborators to act in their own interest, which may not be in our interest. As a result, the collaborative arrangements that we may enter into, may not achieve their intended goals.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If any of these scenarios materialize, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We also may have other future products where it is desirable or essential to enter into agreements with a collaborator who has greater financial resources or different expertise than us, but for which we are unable to find an appropriate collaborator or are unable to do so on favorable terms. If we fail to enter into such collaborative agreements on favorable terms, it could materially delay or impair our ability to develop and commercialize, and increase the costs of development and commercialization of, our technology. </p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We could become subject to product liability claims, product recalls, and warranty claims that could be </b></i><i><b>expensive, divert management&#146;s attention and harm our business reputation and financial results.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our business exposes us to potential liability risks that are inherent in the marketing and sale of products used in patient care. We may be held liable if the Nanox System or if any other product that integrates our X-ray source technology causes injury or death or is found otherwise unsuitable during usage. The Nanox System currently under development incorporates sophisticated components and computer software. Complex software can contain errors, particularly when first introduced. In addition, new products or enhancements may contain undetected errors or performance problems that, despite testing, are discovered only after installation. Patients could allege or possibly prove defects of our products or other products that integrate our technology. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A product liability claim, regardless of its merit or eventual outcome, could result in significant legal defense costs and divert management&#146;s attention. Regardless of merit or eventual outcome, liability claims may result in:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">decreased demand for the Nanox System;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">injury to our reputation;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">costs of related litigation;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">substantial monetary awards to patients and others;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">loss of revenue; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the inability to commercialize future products.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Any of these outcomes may have an adverse effect on our business, financial condition and results of operations, and may increase the volatility of our share price.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The coverage limits of our insurance policies we may choose to purchase to cover related risks may not be sufficient to cover future claims. If sales of the Nanox System or other products integrating our technology increase or we suffer future product liability claims, we may be unable to maintain product liability insurance at </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">20</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">satisfactory rates or with adequate amounts or at all. A product liability claim, any product recalls or excessive warranty claims, whether arising from defects in design or manufacture or otherwise, could negatively affect our sales or require a change in the design or manufacturing process, any of which could harm our relationship with our customers and partners, and have a material adverse impact on our reputation and business, financial condition, results of operations and prospects.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, if the Nanox System or other products integrating our technology are defective, we, our future customers or partners may be required to notify regulatory authorities and/or to recall the products. See &#147;&#8212;Risks Related to Government Regulation&#8212;Our products may cause or contribute to adverse medical events or be subject to failures or malfunctions that we are required to report to the FDA, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial condition and results of operations. The discovery of serious safety issues with our products, or a recall of our products either voluntarily or at the direction of the FDA or another governmental authority, could have a negative impact on us.&#148; Any recall would divert management&#146;s attention and financial resources and harm our reputation with customers, patients, medical professionals and third-party payors. A recall involving the Nanox System would be particularly harmful to our business. The adverse publicity resulting from any of these actions could adversely affect the perception of our customers or partners. These investigations or recalls, especially if accompanied by unfavorable publicity, could result in our incurring substantial costs, losing revenues and damaging our reputation, each of which would harm our business, financial condition, results of operations and prospects.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We are highly dependent on </b></i><i><b>key members of our executive management team</b></i><i><b>. Our inability to retain these </b></i><i><b>individuals could impede our business plan and growth strategies, which could have a negative impact on our </b></i><i><b>business and the value of your investment.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our ability to implement our business plan depends on the continued services of key members of our senior management. In particular, and to a critical extent, we are dependent on the continued efforts and services of the members of management named in the &#147;Management&#148; section. If we lose the services of such key members of our management team, we would likely be forced to expend significant time and money in the pursuit of replacement individuals, which may result in a delay in the implementation of our business plan and plan of operations. We may not be able to find satisfactory replacements on terms that would not be unduly expensive or burdensome to us. We do not currently carry a key-man life insurance policy that would assist us in recouping our costs in the event of the death or disability of our management team. The loss of members of our management team, or our inability to attract or retain other qualified individuals, could have a material adverse effect on our business, results of operations and financial condition. </p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>The mishandling or the perceived mishandling of sensitive information</b></i><i><b>, </b></i><i><b>or</b></i><i><b> the occ</b></i><i><b>urrenc</b></i><i><b>e of data security </b></i><i><b>breaches,</b></i><i><b> could harm our business.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We expect that the Nanox System will enable us to accumulate a significant amount of highly sensitive and/or confidential information, including medical images and other medical information. These images could be received by our customers or collaborators, such as medical AI-analytics companies, to increase the probability of early disease detection. While employee contracts generally contain standard confidentiality provisions, our employees, customers or collaborators may not properly handle or process sensitive or confidential data. The improper handling of sensitive or confidential data, or even the perception of such mishandling (whether or not valid), or other security lapses by us, our customers or collaborators, could reduce demand for such products or otherwise expose us to financial or reputational harm or legal liability.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, any security breach, including personal data breaches, or incident, including cybersecurity incidents, that we experience could result in unauthorized access to, misuse of, or unauthorized acquisition of the sensitive or confidential information and data (including medical information), the loss, corruption, or alteration of this data, interruptions in our operations, or damage to our systems. Any such incidents could expose us to claims, litigation, regulatory or other governmental investigations, administrative fines and potential liability. An increasing number of digital platforms have disclosed breaches of their security, some of which have involved sophisticated and highly targeted attacks on portions of their services. Because the techniques used to obtain unauthorized access, disable or degrade service, or sabotage systems change frequently and often are not foreseeable or recognized until launched against a target, we may be unable to anticipate these techniques or to implement adequate preventative measures. If an actual or perceived breach of our security occurs, public perception of the effectiveness of our security measures and brand could be harmed and our results of operations </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">21</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">could be negatively affected. Data security breaches and other incidents may also result from non-technical means (e.g., actions by employees or contractors). Any compromise of our security could result in a violation of applicable security, privacy or data protection, consumer and other laws, regulatory or other governmental investigations, enforcement actions, and legal and financial exposure, including potential contractual liability. Any such compromise could also result in damage to our reputation and a loss of confidence in our security and privacy or data protection measures. Any of these effects could materially and adversely affect our business, financial condition and results of operations.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our business and operations would suffer in the event of computer system failures, cyber-attacks or </b></i><i><b>deficiencies in our cyber-security.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our ability to execute our business strategy depends, in part, on the continued and uninterrupted performance of our IT systems, which support our operations. Despite the implementation of security measures, our internal computer systems, and those of third parties on which we rely, are vulnerable to damage from, among others, computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization or similar disruptive problems. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs. Any such security breach may compromise information stored on our networks and may result in significant data losses or theft of personally identifiable information. A cybersecurity breach could also hurt our reputation by adversely affecting the patients&#146; perception of the security of their information. A number of proposed and enacted federal, state and international laws and regulations obligate companies to notify individuals of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by third parties, including collaborators, vendors, contractors or other organizations with which we expect to form strategic relationships. In addition, a cybersecurity attack could result in other negative consequences, including disruption of our internal operations, increased cyber security protection costs, lost revenue, regulatory actions or litigations.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Exchange rate fluctuations between the U.S. dollar, Japanese Yen </b></i><i><b>and the </b></i><i><b>New </b></i><i><b>Israeli </b></i><i><b>Shekel </b></i><i><b>and inflation </b></i><i><b>may negatively affect our results of operations, and we may not be able to hedge our currency exchange risks </b></i><i><b>successfully.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The U.S. dollar is our functional and reporting currency. However, a portion of our operating expenses, including personnel and facilities related expenses, are incurred in NIS and Yen. As a result, we are exposed to the risks that the NIS and Yen may appreciate relative to the U.S. dollar, or, if the NIS or Yen instead devalues relative to the U.S. dollar, that the inflation rate in Israel may exceed such rate of devaluation of the NIS or Yen, or that the timing of such devaluation may lag behind inflation in Israel. In any such event, the dollar cost of our operations in Israel would increase and our dollar-denominated results of operations would be adversely affected. Given our general lack of currency hedging arrangements to protect us from fluctuations in the exchange rates of the NIS and Yen and other foreign currencies in relation to the U.S. dollar (and/or from inflation of such foreign currencies), we may be exposed to material adverse effects from such movements. Our exchange rate exposure may change over time as our business evolves and could result in increased costs or reduced revenue and could affect our actual cash flow. Changes in the relative values of currencies occur regularly and, in some instances, may have a significant impact on our operating results. The rate of inflation in Israel or in currency exchange rates may materially change and we might not be able to effectively mitigate these risks.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>If significant tariffs or other restrictions </b></i><i><b>related to &#147;trade wars&#148; </b></i><i><b>are placed on Chinese imports or any related </b></i><i><b>counter-measures are taken by China, our revenue and results of operations may be materially harmed.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have, and expect to enter into, agreements with manufacturers and/or suppliers in China for the production of our X-ray tube, the Nanox.Arc and some of their respective components. If significant tariffs or other restrictions are placed by the United States government on Chinese imports or any related counter-measures are taken by China, our business, financial condition and results of operations may be materially harmed. In July 2018, the Trump Administration announced a list of thousands of categories of goods that could face tariffs. If these duties or any other forms of duties or tariffs are imposed on the Nanox.Arc, our X-ray tube or their </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">22</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">components, we may be required to charge higher prices in the United States than we expect, which may result in fewer customers and harm our operating performance. Alternatively, we may seek to shift production outside of China, resulting in significant costs and disruption to our operations and business. Additionally, the Trump Administration continues to signal that it may alter trade agreements and terms between China and the United States, including limiting trade with China, and may impose additional tariffs on imports from China. Our business could also be impacted by retaliatory trade measures taken by China or other countries in response to existing or future tariffs, causing us to raise prices or make changes to our operations, any of which could materially harm our business, financial condition and results of operations.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our business may be impacted by changes in general economic conditions.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our business is subject to risks arising from changes in domestic and global economic conditions, including adverse economic conditions in markets in which we operate, which may harm our business. If our future customers significantly reduce spending in areas in which our technology and products are utilized, or prioritize other expenditures over our technology and products, our business, financial condition, results of operations and prospects would be materially adversely affected.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Disruption to the global economy could also result in a number of follow-on effects on our business, including a possible slow-down resulting from lower customer expenditures; inability of customers to pay for products, solutions or services on time, if at all; more restrictive export regulations which could limit our potential customer base; negative impact on our liquidity, financial condition and share price, which may impact our ability to raise capital in the market, obtain financing and secure other sources of funding in the future on terms favorable to us.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, the occurrence of catastrophic events, such as hurricanes, storms, earthquakes, tsunamis, floods and other catastrophes that adversely affect the business climate in any of our markets could have a material adverse effect on our business, financial condition and results of operations. Some of our operations are located in areas that have been in the past, and may be in the future, susceptible to such occurrences.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>The outcome of any future claims and litigation could have a material adverse impact on our business, </b></i><i><b>financial condition and results of operations.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We may, from time to time, be party to litigation in the normal course of business, including class action lawsuits. Due to the inherent uncertainties of litigation, the final outcome of these lawsuits may differ substantially from our expectations and we may not be able to determine the amount of any potential losses we may incur. In the event we are required or determine to pay amounts in connection with any such lawsuits, such amounts could be significant and could have a material adverse impact on our liquidity, business, financial condition and results of operations. </p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We do not expect to carry any business interruption insurance or any other insurance (except for </b></i><i><b>director and </b></i><i><b>officer</b></i><i><b> </b></i><i><b>and product </b></i><i><b>liability insurance). As a result, we may incur uninsured losses, increasing the possibility </b></i><i><b>that you would lose your entire investment in our company.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our products and services are in the medical imaging field and so may be subject to claims. We are not immune from product liability or other product claim risks, and we may not be able to maintain insurance on acceptable terms against such risks or that such insurance will be sufficient to protect us against potential claims or that insurance will be available in the future in amounts sufficient to protect us. A product liability claim or other claim, as well as any claims for uninsured liabilities or in excess of insured liabilities, could have a material adverse effect on our business, financial condition, results of operations and prospects. </p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Certain of our </b></i><i><b>directors</b></i><i><b> and/or officers</b></i><i><b> may have interests that compete with ours.</b></i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Certain of our directors currently own, operate and manage other entities, which may have similar or different objectives than ours. Such activities could detract from the time these people have to allocate to our affairs. In addition, we had previously entered into a certain consulting agreement and a certain service agreement with an entity owned by Ran Poliakine. See &#147;Certain Relationships and Related Party Transactions&#8212;Agreements With Directors and Officers&#8212;Relationship With Six-Eye Interactive Ltd.&#148; The terms of such agreements may not be as favorable to us as those that could be obtained from a third party. Moreover, certain of our directors and officers are affiliated with our current shareholders, and may have different interests </p>

			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">23</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">than other shareholders. For additional information regarding related party transactions and potential conflicts of interest, see &#147;Certain Relationships and Related Party Transactions.&#148; Under the Companies Law, office holders must promptly disclose to us any direct or indirect personal interest that he or she may have and all related material information or documents known to him or her relating to any existing or proposed transaction by us. See &#147;Fiduciary Duties and Approval of Specified Related Party Transactions and Compensation Under Israeli Law&#8212;Disclosure of Personal Interests of an Office Holder and Approval of Certain Transactions.&#148; In addition, on the closing of this offering, we will adopt a code of ethics and conduct that will require our employees, officers and directors to disclose any situation that reasonably would be expected to give rise to a conflict of interest.</p>

				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our management team has limited experience managing a public company.</b></i><i><b> </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Most members of our management team have limited experience managing a publicly traded company, interacting with public company investors and complying with the increasingly complex laws pertaining to public companies in the United States. Our management team may not successfully or efficiently manage our transition to being a public company subject to significant regulatory oversight and reporting obligations under the U.S. federal securities laws and the continuous scrutiny of securities analysts and investors. These new obligations and constituents will require significant attention from our senior management and could divert their attention away from the day-to-day management of our business, which could adversely affect our business, financial condition, results of operations and prospects.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Risks Related to Our Intellectual Property</b></p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>It is difficult and costly to protect our intellectual property and our proprietary technologies, and we may not</b></i><i><b> </b></i><i><b>be able to ensure their protection.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We rely upon a combination of patents and trade secrets to protect the intellectual property related to our proprietary technologies. Our success depends significantly on our ability to obtain and maintain intellectual property protection with respect to our technology and products. Patents and other proprietary rights provide uncertain protections, and we may be unable to protect our intellectual property for reasons including those that result from complex factual and legal issues such as those that create uncertainty as to the validity, scope and enforceability of any particular patent that we hold or for which we have applied. As a result, we may be unsuccessful in defending our patents and other proprietary rights against third-party challenges, which could have a material adverse effect on our business.</p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Although we are attempting to obtain patent coverage for our technology where available and where we believe appropriate, there are aspects of the technology for which patent coverage may never be sought or received. Additionally, we have obtained, and may in the future obtain, certain intellectual property related to our technology from third parties, and we cannot be certain that such third parties took the necessary actions to maintain such rights or that the transfer of such rights to us was proper and effective. We may, as a result, be subject to claims challenging the ownership or enforceability of such rights. Furthermore, we may not possess the resources to, or for other reasons may not choose to, pursue patent protection on every invention or in any or every country where we may eventually decide to sell our future products. Our ability to prevent others from making or selling duplicate or similar technologies will be impaired for those technologies with respect to which, and in those countries where, we have no patent protection. In addition, there is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found, which can prevent a patent from issuing from a pending patent application or later invalidate or narrow the scope of an issued patent. Even if patents do successfully issue and even if such patents cover our technology, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated, or held unenforceable. Any successful challenge to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of our technology.</p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, for patents that do issue based on our applications or future applications, any issued patents may not provide us with any competitive advantages. Competitors may be able to design around our patents and develop products that provide outcomes comparable or superior to ours. Any changes we make to our product or any future products, including designs that may be required for commercialization or that cause them to have what we view as more advantageous properties, may not be covered by patents and patent applications we have licensed or own, and we may be required to file new applications and/or seek other forms of protection for any </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">24</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">such altered products if any such protection is available. In addition, the patent prosecution process is expensive, time-consuming and complicated, and we and our current or future licensors, licensees or collaborators may not be able to prepare, file, prosecute and maintain all necessary or desirable patents or patent applications at a reasonable cost or in a timely manner. It is also possible that we or our current or future licensors, licensees or collaborators will fail to identify patentable aspects of inventions before it is too late to obtain patent protection for them. In addition, if we choose to and are able to secure patent protection in countries outside the U.S., the laws of some foreign countries may not protect our intellectual property rights to the same extent as do the laws of the United States. For instance, the legal systems of some countries, including India, China and other developing countries, do not favor the enforcement of patents and other intellectual property rights. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions and enforce our intellectual property rights, and more generally could affect the value of our intellectual property. Our efforts to seek patent protection for our technology could be negatively impacted by any such changes, which could have a material adverse effect on our existing patent rights and our ability to protect and enforce our intellectual property in the future. In particular, our ability to stop third parties from making, using, selling, offering to sell or importing products that infringe our intellectual property will depend in part on our success in obtaining and enforcing patent claims that cover our technology, inventions and improvements.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We may come to believe that third parties are infringing on, otherwise violating, our patents or other proprietary rights. To prevent infringement or unathorized use, we may need to file infringement and/or misappropriation suits, which are very expensive and time-consuming, could result in meritorious counterclaims against us and would distract management&#146;s attention. Also, in an infringement or misappropration proceeding, a court may decide that one or more of our patents is invalid, unenforceable, or both, in which case third parties may be able to use our technology without paying license fees or royalties. Even if the validity of our patents is upheld, a court may refuse to stop the other party from using the technology at issue on the grounds that the other party&#146;s activities are not covered by our patents. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition to patents, we rely on trade secrets to protect our technology; however, the policies we use to protect our trade secrets may not be effective in preventing misappropriation of our trade secrets by others. In addition, confidentiality agreements executed by our employees, consultants and advisors may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure. Litigating a trade secret claim is expensive and time consuming, and the outcome may be unexpected. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop knowledge, methods and know-how that allow them to create substantially similar products or services without misappropriating our trade secrets. If we are unable to protect our trade secrets, we may be unable to prevent competitors from using our own inventions and intellectual property to compete against us, and our business may be harmed.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Patent terms may be inadequate to protect our competitive position on our future products for an adequate</b></i><i><b> </b></i><i><b>amount of time.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our future products are obtained, once the patent life has expired, we may be open to competition from competitive products.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Given the amount of time required for the development, testing and regulatory review of new products, patents protecting our future products might expire before or shortly after we or our future partners commercialize those products. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours for a sufficient amount of time, and, as a result, we may not be able to obtain adequate protection from our patent portfolio against competition, in spite of the time and effort invested in the commercialization of our future products. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">25</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">

<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Claims that our </b></i><i><b>technology or our </b></i><i><b>future products or the sale or use of our future products infringe the </b></i><i><b>patents or other</b></i><i><b> </b></i><i><b>intellectual property rights of third parties could result in costly litigation or could require </b></i><i><b>substantial time</b></i><i><b> </b></i><i><b>and money to resolve, even if litigation is avoided.</b></i></p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Because our industry is characterized by competing intellectual property, we may be subject to legal actions for violating the intellectual property rights of others, including claims that former employees, collaborators or third parties have an interest in our patents, trade secrets or other intellectual property. For example, we may have inventorship or ownership disputes arising from conflicting obligations of employees, consultants or others who are involved in developing our technology or our products. </p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We also may be required to participate in interference, derivation or opposition proceedings that concern disputes regarding priority of inventions disclosed in our patents. Determining whether a product infringes a patent, as well as priority of inventions and other patent-related disputes, involves complex legal and factual issues and the outcome is often uncertain. We have not conducted any significant search of patents issued to third parties, and third-party patents containing claims covering our technology or methods that predate our patents may exist. Because of the number of patents issued and patent applications filed in our technical areas or fields (including some pertaining specifically to medical imaging technologies), our competitors or other third parties may assert that our technology and the methods we employ in the use of products incorporating our technology are covered by United States or foreign patents held by them. In addition, because patent applications can take many years to issue and because publication schedules for pending applications vary by jurisdiction, there may be applications now pending of which we are unaware, and which may result in issued patents that our technology or other future products would infringe. Also, because the claims of published patent applications can change between publication and patent grant, there may be published patent applications that may ultimately issue with claims that we infringe. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As the number of competitors in the market for medical imaging technologies increases, and as the number of patents issued in this area grows, the possibility of patent infringement claims against us increases. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can, including if they have substantially greater resources. Defending against such litigation is costly and time consuming, and would distract our management from our business. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In the event that we become subject to a patent infringement or other intellectual property lawsuit and if the relevant patents or other intellectual property were upheld as valid and enforceable and we were found to infringe or violate those rights or the terms of a license to which we are a party, we could be prevented from selling any infringing products of ours unless we could obtain a license or were able to redesign the product to avoid infringement. If we were unable to obtain a license or successfully redesign, we might be prevented from selling our technology or other future products. If we are able to redesign, we may need to invest substantial resources in the redesign process. If there is an allegation or determination that we have infringed the intellectual property rights of a competitor or other person, we may be required to pay damages, or a settlement or ongoing royalties, or we may be required to enter into cross-licenses with our competitors. In any of these circumstances, we may be unable to sell our products at competitive prices or at all, and our business, financial condition, results of operations and prospects could be harmed.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, we may be required to indemnify our customers and distributors against claims relating to the infringement of intellectual property rights of third parties related to our products. Third parties may assert infringement claims against our customers or distributors. These claims may require us to initiate or defend protracted and costly litigation on behalf of our customers or distributors, regardless of the merits of these claims. If any of these claims succeed, we may be forced to pay damages on behalf of our customers or distributors, or may be required to obtain licenses for the products or services they use. If we cannot obtain all necessary licenses on commercially reasonable terms, our distributors may be forced to stop distributing our products or services, and our customers may be forced to stop using our products or services. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">26</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">during discovery. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, which could have a material adverse effect on the price of our ordinary shares. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our ordinary shares.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Obtaining and maintaining patent protection depends on compliance with various procedural, document</b></i><i><b> </b></i><i><b>submission, fee payment and other requirements imposed by governmental patent agencies, and our patent</b></i><i><b> </b></i><i><b>protection could be reduced or eliminated if we or our future licensors do not comply with these requirements.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on a patent and patent application are due to be paid to the patent offices and agencies in several stages over the lifetime of the patent and patent application. The U.S. Patent and Trademark Office and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In certain circumstances, we may be required to rely on our licensing partners to take the necessary action to comply with these requirements with respect to patents or other intellectual property they have licensed to us. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance, which could include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents, can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors may be able to enter the market and compete with our products, which would have a material adverse effect on our business.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We may be subject to claims that our employees, consultants or advisers have wrongfully used or disclosed</b></i><i><b> </b></i><i><b>alleged trade secrets of their former employers or claims asserting ownership of what we regard as our own</b></i><i><b> </b></i><i><b>intellectual property.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Many of our employees, consultants and advisers, including our senior management, were previously employed at other companies that may have proprietary rights related to our business. Some of these employees, consultants and advisers, including members of our senior management, executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure that such individuals do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#146;s former employer. We are not aware of any such disclosures, or threatened or pending claims related to these matters, but in the future, litigation may be necessary to defend against such claims. If we fail in defending any such claims, we may lose valuable intellectual property rights or personnel, in addition to possibly paying monetary damages and being enjoined from conducting our business as contemplated. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Additionally, a licensor, collaborator, employee, consultant, adviser or other third party may dispute our or our licensor&#146;s ownership of certain intellectual property rights. We seek to address these concerns in our contractual agreements; however, we may not have contractual arrangements with the party in question and/or such provisions may not be effective. If these provisions prove to be ineffective, we may not be able to achieve our business objectives. If we or our licensors fail in defending any such claims, we may have to pay monetary damages and may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property which could adversely impact our business, financial condition and results of operations. </p>
				<p class="risk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>If our trademarks and trade names are not adequately protected, then we may not be able to build name </b></i><i><b>recognition in our markets of interest and our business may be adversely affected.</b></i><i><b> </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our unregistered trademarks or trade names are valuable assets and may be challenged, infringed, circumvented or declared generic or determined to infringe third party&#146;s marks. We may not be able to protect our rights to these trademarks and trade names, which may be necessary to build name recognition among potential collaborators or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations of our unregistered trademarks or trade names. We </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">27</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">have not conducted any registrability studies for possible future trademarks to assess whether such marks would be successfully registered. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. In addition, we may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and adversely affect our competitive position, business, financial condition, results of operations and prospects.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our rights to develop and commercialize our products may be subject to the terms and conditions of licenses</b></i><i><b> </b></i><i><b>and sublicenses granted to us by third parties</b></i><i><b>.</b></i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We rely on licenses and sublicenses to certain patent rights and other intellectual property from third parties that are important or necessary to the development of our products, including the software modules that we expect to integrate into the Nanox.Cloud. These and other licenses may not provide exclusive rights to use such intellectual property in all relevant fields of use and in all territories in which we may wish to develop or commercialize our products and the underlying patents may fail to provide the intended exclusivity. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in the markets that we hope to address. Moreover, we would not own at least some of the underlying intellectual property rights related to these products, and as a result our rights would be subject to the continuation and compliance with the terms of those agreements. If such in-licenses were terminated, competitors would have the freedom to develop, seek regulatory approval of, and to market, products similar or identical to ours.</p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, these license agreements may not grant us the right to control the preparation, filing, prosecution or maintenance of patents and patent applications covering our products. Therefore, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted or maintained in a manner consistent with the best interests of our business. If our current or future licensing partners fail to file, prosecute or maintain such patents, including the payment of applicable fees, or otherwise lose rights to those patents or patent applications, the intellectual property we have licensed or exclusivity we have been granted may be reduced or eliminated, and our right to develop and commercialize any of our future products that are subject of such licensed rights, and our ability to prevent competitors from developing or commercializing such products, could be adversely affected. In addition, even where we have the right to control patent prosecution and maintenance of patents and patent applications we have licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensees, our licensors and their counsel that took place prior to the date upon which we assumed control over patent prosecution.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Pursuant to the terms of such license agreements, the licensors may also have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity or unenforceability of these patents. Even if we are permitted to pursue the enforcement or defense of our licensed patents, we may require the cooperation of our future licensors or collaboration partners and any other applicable patent owners and we cannot be certain that such cooperation will be provided to us. We also cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate our business. If we lose any of our licensed intellectual property, our right to develop and commercialize any of our products that are subject of such licensed rights could be adversely affected.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, our future licensors may rely on third-party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents we in-license. If other third parties have ownership rights to our in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technologies. In addition, if our licensors have not obtained adequate rights from these third parties, we may need to obtain additional rights from these third parties or we could be prevented from developing and commercializing the related products. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">28</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, in which event we may have to cease developing, manufacturing or marketing any product covered by these agreements and we may face other additional penalties or be required to grant our licensors additional rights. In addition, we may seek to obtain additional licenses from our licensors and, in connection with obtaining such licenses, we may agree to amend our existing licenses in a manner that may be more favorable to the licensors, including by agreeing to terms that could enable third parties (potentially including our competitors) to receive licenses to a portion of the intellectual property that is subject to our existing licenses. Any of these events could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We may be required to pay certain milestones and royalties and fulfill other obligations under our license</b></i><i><b> </b></i><i><b>agreements with third-party licensors.</b></i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We may be required to pay milestones and royalties related to our development or commercialization activities of our products utilizing the technologies licensed or sublicensed from third parties under license agreements we may enter into with them. These payments could adversely affect our overall profitability related to any future products that we may seek to develop or commercialize. In order to maintain our license rights under our license agreements, we may need to meet certain specified milestones or fulfill certain obligations, including to devote a certain amount of resources, in the development of our products. Failure to satisfy such obligations could result in the termination of our rights under such agreements.</p>

				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>If we choose to license our technology to third parties, this could result in disputes or otherwise limit our </b></i><i><b>future operations.</b></i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We may also in the future, as one of our strategies, deploy our technology into the market and license patents and other intellectual proprietary rights to third parties. Disputes with our licensees may arise, including regarding the scope and content of these licenses. Additionally, a licensee may use our intellectual property without our permission, dispute our ownership of certain intellectual property rights or argue that our intellectual property does not cover our product. Regardless of whether we pursue legal action to enforce any such dispute, a dispute with a licensee or customer over intellectual property rights may damage our relationship with that licensee or customer and may also harm our reputation in the industry. Our ability to expand into additional fields with our technologies also may be restricted by licenses or other rights we may grant to third parties in the future, including if the licenses are exclusive, the licensee is assigned ownership of intellectual property that we develop or rights of first negotiation or refusal are granted. For instance, pursuant to the Right of First Negotiation Agreement with FUJIFILM Corporation, dated May 21, 2019, we granted FUJIFILM Corporation a right of first negotiation to obtain an exclusive license to certain of our intellectual property for use in the field of mammography. See &#147;Business&#8212;Our Business Model&#8212;The Licensing Model&#148; for a description of the terms of such agreement. While we do not currently plan to use this intellectual property in this field, if we chose to do so in the future, our ability would be limited by these rights and any related rights granted in the future to FUJIFILM Corporation.</p>

				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Risks Related to Government Regulation</b></p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>Our product</b></i><i><b> candidates</b></i><i><b> and operations are subject to extensive government regulation and oversight both in the </b></i><i><b>United States and abroad, and our failure to comply with applicable requirements could harm our business.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We expect the Nanox.Arc and other future products we develop to be regulated by the FDA as medical devices. Our product candidate is subject to extensive regulation in the United States and elsewhere, including by the FDA and its foreign counterparts, the U.S. Department of Justice (the &#147;DOJ&#148;) and the U.S. Health and Human Services-Office of the Inspector General (&#147;HHS&#148;). The FDA and foreign regulatory agencies regulate, among other things, with respect to medical devices: design, development and manufacturing; testing, labeling, content and language of instructions for use and storage; clinical trials; product safety; establishment registration and device listing; marketing, sales and distribution; pre-market clearance and approval; conformity assessment procedures; record keeping procedures; advertising and promotion; recalls and field safety corrective actions; post-market surveillance, including reporting of deaths or serious injuries and malfunctions that, if they were to occur, could lead to death or serious injury; post-market approval studies; and product import and export.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The regulations our product candidate is subject to are complex and have tended to become more stringent over time. Regulatory changes could result in restrictions on our ability to carry on or expand our operations, </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">29</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">higher than anticipated costs or lower than anticipated sales for any approved product. Failure to comply with applicable regulations could jeopardize our ability to sell our future products, if cleared or approved, and result in enforcement actions such as: warning or untitled letters; fines; injunctions; consent decrees; civil penalties; customer notifications; termination of distribution; recalls or seizures of products; administrative detention of medical devices believed to be adulterated or misbranded; delays in the introduction of products into the market; operating restrictions; total or partial suspension of production; refusal to grant future clearances or approvals for new products, new intended uses or modifications to our products; withdrawals or suspensions of current approvals, resulting in prohibitions on sales of our products; and in the most serious cases, criminal prosecution or penalties. The occurrence of any of these events would have a material adverse effect on our business, financial condition and results of operations and could result in shareholders losing their entire investment.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We may not receive, or may be delayed in receiving, the necessary clearances or approvals for our future </b></i><i><b>products</b></i><i><b>, and failure to timely obtain necessary clearances or approvals for our future products </b></i><i><b>would </b></i><i><b>adversely affect our ability to grow our business.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In the United States, before we can market a new medical device, or a new use of, new claim for or significant modification to an existing product, we must first receive either clearance under Section 510(k) of the Federal Food, Drug, and Cosmetic Act (the &#147;FDCA&#148;) or approval of a pre-market approval application (a &#147;PMA&#148;) from the FDA, unless an exemption applies. In the 510(k) clearance process, before a device may be marketed, the FDA must determine that a proposed device is &#147;substantially equivalent&#148; to a legally-marketed &#147;predicate&#148; device, which includes a device that has been previously cleared through the 510(k) process, a device that was legally marketed prior to May 28, 1976 (pre-amendments device), a device that was originally on the U.S. market pursuant to an approved PMA and later down-classified, or a 510(k)-exempt device. To be &#147;substantially equivalent,&#148; the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. Clinical data are sometimes required to support substantial equivalence. In the process of obtaining PMA approval, the FDA must determine that a proposed device is safe and effective for its intended use based, in part, on extensive data, including, but not limited to, technical, pre-clinical, clinical trial, manufacturing and labeling data. The PMA process is typically required for devices that are deemed to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Modifications to products that are approved through a PMA application generally require FDA approval. Similarly, certain modifications made to products cleared through a 510(k) may require a new 510(k) clearance. Both the PMA approval and the 510(k) clearance process can be expensive, lengthy and uncertain. The FDA&#146;s 510(k) clearance process usually takes from three to 12 months, but can last longer. The process of obtaining a PMA is much more costly and uncertain than the 510(k) clearance process and generally takes from one to three years, or even longer, from the time the application is submitted to the FDA. In addition, a PMA generally requires the performance of one or more clinical trials. Despite the time, effort and cost, a device may not be approved or cleared by the FDA. Any delay or failure to obtain necessary regulatory clearances or approvals could harm our business. Furthermore, even if we are granted regulatory clearances or approvals, they may include significant limitations on the indicated uses for the device or other restrictions or requirements, which may limit the market for the device.</p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In the United States, we expect to take a multi-step approach to the regulatory clearance process. As a first step, we plan to submit a 510(k) application for a single-source version of the Nanox.Arc to the FDA in January 2020. If we receive FDA clearance, we will continue to optimize and develop further features of the Nanox.Arc, and plan to submit additional 510(k) applications to the FDA with respect to the Nanox.Arc. If cleared, any modification to these systems that has not been previously cleared may require us to submit a new 510(k) premarket notification and obtain clearance, or submit a PMA and obtain FDA approval prior to implementing the change. Specifically, any modification to a 510(k)-cleared device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, design or manufacture, requires a new 510(k) clearance or, possibly, approval of a PMA. The FDA requires every manufacturer to make this determination in the first instance, but the FDA may review any manufacturer&#146;s decision. The FDA may not agree with our decisions regarding whether new clearances or approvals are necessary. We may make modifications or add additional features in the future that we believe do not require a new 510(k) clearance or approval of a PMA. If the FDA disagrees with our determination and requires us to submit new 510(k) notifications or PMA applications for modifications to our previously cleared products for which we have </p>

			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">30</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">concluded that new clearances or approvals are unnecessary, we may be required to cease marketing or to recall the modified product until we obtain clearance or approval, and we may be subject to significant regulatory fines or penalties. If the FDA requires us to go through a lengthier, more rigorous examination for future products or modifications to existing products than we had expected, product introductions or modifications could be delayed or canceled, which could adversely affect our ability to grow our business.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The FDA can delay, limit or deny clearance or approval of a medical device for many reasons, including:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our inability to demonstrate to the satisfaction of the FDA or the applicable regulatory entity or notified body that our product candidates are safe or effective for their intended uses;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the disagreement of the FDA or the applicable foreign regulatory body with the design or implementation of our clinical trials or the interpretation of data from pre-clinical studies or clinical trials;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">serious and unexpected adverse effects experienced by participants in our clinical trials;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the data from our pre-clinical studies and clinical trials may be insufficient to support clearance or approval, where required;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our inability to demonstrate that the clinical and other benefits of the device outweigh the risks;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the manufacturing process or facilities we use may not meet applicable requirements; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the potential for approval policies or regulations of the FDA or applicable foreign regulatory bodies to change significantly in a manner rendering our clinical data or regulatory filings insufficient for clearance or approval.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In order to sell our products in member countries of the European Economic Area (&#147;EEA&#148;), our products must comply with the essential requirements of the EU Medical Devices Directive (Council Directive 93/42/EEC). Compliance with these requirements is a prerequisite to be able to affix the Conformit&#233; Europ&#233;ene (&#147;CE&#148;) mark to our products, without which they cannot be sold or marketed in the EEA. To demonstrate compliance with the essential requirements we must undergo a conformity assessment procedure, which varies according to the type of medical device and its classification. Except for low-risk medical devices (Class I non-sterile, non-measuring devices), where the manufacturer can issue a European Community (&#147;EC&#148;) Declaration of Conformity based on a self-assessment of the conformity of its products with the essential requirements of the EU Medical Devices Directive, a conformity assessment procedure requires the intervention of an organization accredited by a member state of the EEA to conduct conformity assessments, or a Notified Body. Depending on the relevant conformity assessment procedure, the Notified Body would typically audit and examine the technical file and the quality system for the manufacture, design and final inspection of our devices. The Notified Body issues a certificate of conformity following successful completion of a conformity assessment procedure conducted in relation to the medical device and its manufacturer and their conformity with the essential requirements. This certificate entitles the manufacturer to affix the CE mark to its medical devices after having prepared and signed a related EC Declaration of Conformity.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As a general rule, demonstration of conformity of medical devices and their manufacturers with the essential requirements must be based, among other things, on the evaluation of clinical data supporting the safety and performance of the products during normal conditions of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions of use, that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended performance, and that any claims made about the performance and safety of the device are supported by suitable evidence. If we fail to remain in compliance with applicable European laws and directives, we would be unable to continue to affix the CE mark to our products, which would prevent us from selling them within the EEA.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Failure to comply with post-marketing regulatory requirements could subject us to enforcement actions, </b></i><i><b>including substantial penalties, and might require us to recall or withdraw a product from the market.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If we receive regulatory clearance or approval of the Nanox.Arc or other future products, we will remain subject to ongoing and pervasive regulatory requirements governing, among other things, the manufacture, marketing, advertising, medical device reporting, sale, promotion, import, export, registration, and listing of devices. For example, we will be required to submit periodic reports to the FDA as a condition of 510(k) clearance. These reports include information about failures and certain adverse events associated with the </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">31</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">device after its clearance. Failure to submit such reports, or failure to submit the reports in a timely manner, could result in enforcement action by the FDA. Following its review of the periodic reports, the FDA might ask for additional information or initiate further investigation.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The regulations to which we are subject are complex and have become more stringent over time. Regulatory changes could result in restrictions on our ability to continue or expand our operations, higher than anticipated costs, or lower than anticipated sales. Even after we have obtained the proper regulatory clearance to market a device, we have ongoing responsibilities under FDA regulations and applicable foreign laws and regulations. The FDA, state and foreign regulatory authorities have broad enforcement powers. Our failure to comply with applicable regulatory requirements could result in enforcement action by the FDA, state or foreign regulatory authorities, which may include any of the following sanctions:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">untitled letters or warning letters;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">fines, injunctions, consent decrees and civil penalties;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">recalls, termination of distribution, administrative detention, or seizure of our products;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">customer notifications or repair, replacement or refunds;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">operating restrictions or partial suspension or total shutdown of production;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">delays in or refusal to grant our requests for future clearances or approvals or foreign marketing authorizations of new products, new intended uses, or modifications to existing products;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">withdrawals or suspensions of product clearances or approvals, resulting in prohibitions on sales of our products;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">FDA refusal to issue certificates to foreign governments needed to export products for sale in other countries; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">criminal prosecution.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Any of these sanctions could result in higher than anticipated costs or lower than anticipated sales and have a material adverse effect on our reputation, business, financial condition and results of operations.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, the FDA or state or foreign authorities may change their clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions, which may prevent or delay clearance or approval of our future products under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain new clearances or approvals, increase the costs of compliance or restrict our ability to maintain any approvals we are able to obtain. For example, the FDA recently announced forthcoming steps that the FDA intends to take to modernize the premarket notification pathway under Section 510(k) of the FDCA. For more information, see &#147;&#8212;Legislative or regulatory reforms in the United States or the EU may make it more difficult and costly for us to obtain regulatory clearances or approvals for our products or to manufacture, market or distribute our products after clearance or approval is obtained.&#148; </p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our products must be manufactured in accordance with federal</b></i><i><b>,</b></i><i><b> state </b></i><i><b>and foreign </b></i><i><b>regulations, and we could </b></i><i><b>be forced to recall our devices or terminate production if we fail to comply with these regulations.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The methods used in, and the facilities used for, the manufacture of our products must comply with the Quality System Regulation (&#147;QSR&#148;), which is a complex regulatory scheme that covers the procedures and documentation of the design, testing, production, process controls, quality assurance, labeling, packaging, handling, storage, distribution, installation, servicing and shipping of medical devices. As manufacturers of electron radiation-emitting products, we are also responsible for compliance with the radiological health regulations and certain radiation safety performance standards.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Furthermore, we are required to verify that our suppliers maintain facilities, procedures and operations that comply with our quality standards and applicable regulatory requirements. The FDA enforces the QSR through periodic announced or unannounced inspections of medical device manufacturing facilities, which may include the facilities of subcontractors. Our products are also subject to similar state regulations and various laws and regulations of foreign countries governing manufacturing.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">32</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our third-party manufacturers may not take the necessary steps to comply with applicable regulations, which could cause delays in the delivery of our products. In addition, failure to comply with applicable FDA or state or foreign requirements or later discovery of previously unknown problems with our products or manufacturing processes could result in, among other things: warning letters or untitled letters; fines, injunctions or civil penalties; suspension or withdrawal of approvals; seizures or recalls of our products; total or partial suspension of production or distribution; administrative or judicially imposed sanctions; the FDA&#146;s refusal to grant pending or future clearances or approvals for our products; clinical holds; refusal to permit the import or export of our products; and criminal prosecution of us, our suppliers or our employees.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Any of these actions could significantly and negatively affect supply of our products. If any of these events occurs, our reputation could be harmed, we could be exposed to product liability claims and we could lose customers and experience reduced sales and increased costs.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>The misuse or off-label use of our products may harm our reputation in the marketplace, result in injuries </b></i><i><b>that lead to product liability suits or result in costly investigations, fines or sanctions by regulatory bodies if </b></i><i><b>we are deemed to have engaged in the promotion of these uses, any of which could be costly to our business.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Advertising and promotion of our future products that obtains approval in the United States may be heavily scrutinized by the FDA, the DOJ, HHS, state attorneys general, members of Congress, and the public. In addition, advertising and promotion of any future product that obtains approval outside of the United States will be heavily scrutinized by comparable foreign regulatory authorities.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We expect that, if cleared or approved, our products, including the Nanox.Arc, will be cleared by the requisite regulatory authorities for specific indications. We expect to train our marketing personnel and direct sales force to not promote our devices for uses outside of the FDA-approved indications for use, known as &#147;off-label uses.&#148; We cannot, however, prevent a physician from using our devices off-label, when in the physician&#146;s independent professional medical judgment he or she deems it appropriate. There may be increased risk of injury to patients if physicians attempt to use our devices off-label. Furthermore, the use of our devices for indications other than those approved by the FDA or approved by any foreign regulatory body may not effectively treat such conditions, which could harm our reputation in the marketplace among healthcare providers and patients.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If the FDA or any state or foreign regulatory body determines that our promotional materials or training constitute promotion of an off-label use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance or imposition of an untitled letter, which is used for violators that do not necessitate a warning letter, injunction, seizure, civil fine or criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action under other regulatory authority, such as false claims laws, if they consider our business activities to constitute promotion of an off-label use, which could result in significant penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, exclusion from participation in government healthcare programs and the curtailment of our operations. We may become subject to such actions and, if we are not successful in defending against such actions, those actions may have a material adverse effect on our business, financial condition and results of operations. Equivalent laws and potential consequences exist in foreign jurisdictions.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, if our products are cleared or approved, healthcare providers may misuse our products or use improper techniques if they are not adequately trained, potentially leading to injury and an increased risk of product liability. If our devices are misused or used with improper technique, we may become subject to costly litigation by our customers or their patients. As described above, product liability claims could divert management&#146;s attention from our core business, be expensive to defend and result in sizeable damage awards against us that may not be covered by insurance. </p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our products may cause or contribute to adverse medical events or be subject to failures or malfunctions that </b></i><i><b>we are required to report to the FDA, and if we fail to do so, we would be subject to sanctions that could </b></i><i><b>harm our reputation, business, financial condition and results of operations. The discovery of serious safety </b></i><i><b>issues with our products, or a recall of our products either voluntarily or at the direction of the FDA or </b></i><i><b>another governmental authority, could have a negative impact on us.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If the Nanox.Arc or our other future products receive clearance or approval, we will be subject to the FDA&#146;s medical device reporting regulations and similar foreign regulations, which require us to report to the FDA when </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">33</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">we receive or become aware of information that reasonably suggests that one or more of our products may have caused or contributed to a death or serious injury or malfunctioned in a way that, if the malfunction were to recur, it could cause or contribute to a death or serious injury. The timing of our obligation to report is triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events of which we become aware within the prescribed timeframe. We may also fail to recognize that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of the product. If we fail to comply with our reporting obligations, the FDA or other regulatory bodies could take action, including warning letters, untitled letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of our device clearance or approval, seizure of our products or delay in clearance or approval of future products.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The FDA and foreign regulatory bodies have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture of a product or in the event that a product poses an unacceptable risk to health. The FDA&#146;s authority to require a recall must be based on a finding that there is reasonable probability that the device could cause serious injury or death. We may also choose to voluntarily recall a product if any material deficiency is found. A government-mandated or voluntary recall by us could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing defects, labeling or design deficiencies, packaging defects or other deficiencies or failures to comply with applicable regulations. Product defects or other errors may occur in the future.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Depending on the corrective action we take to redress a product&#146;s deficiencies or defects, the FDA may require, or we may decide, that we will need to obtain new clearances or approvals for the device before we may market or distribute the corrected device. Seeking such clearances or approvals may delay our ability to replace the recalled devices in a timely manner. Moreover, if we do not adequately address problems associated with our devices, we may face additional regulatory enforcement action, including FDA warning letters, product seizure, injunctions, administrative penalties or civil or criminal fines.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Companies are required to maintain certain records of recalls and corrections, even if they are not reportable to the FDA. We may initiate voluntary withdrawals or corrections for our products in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, it could require us to report those actions as recalls and we may be subject to enforcement action. A future recall announcement could harm our reputation with customers, potentially lead to product liability claims against us and negatively affect our sales. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of our time and capital, distract management from operating our business and may harm our reputation and financial results.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and </b></i><i><b>abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, </b></i><i><b>contractual damages, reputational harm and diminished profits and future earnings.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Physicians, other healthcare providers, and third-party payors will play a primary role with respect to any future products for which we obtain marketing approval. Our arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our product. Restrictions under applicable federal and state healthcare laws and regulations include the following:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The U.S. federal healthcare program Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly and practices that involve remuneration to those who prescribe, purchase, or recommend medical devices, including certain discounts, or engaging consultants as speakers or consultants, may be subject to scrutiny if they do not fit squarely within the exemption or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from anti-kickback liability. Moreover, there are no safe harbors for many common practices, such as educational and research grants. Liability may be established without a person or entity having actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it. In addition, the </td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">34</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="bl" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act. Due to the breadth of these laws, the narrowness of statutory exceptions and regulatory safe harbors available, and the range of interpretations to which they are subject, it is possible that some of our current or future practices might be challenged under one or more of these laws, including, without limitation, our proposed Subscription Model, and our advisory, consulting and royalty agreements with certain physicians who receive compensation, in part, in the form of stock or stock options.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The federal civil False Claims Act prohibits, among other things, any person from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds, or knowingly making, using, or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government. In recent years, several healthcare companies have faced enforcement actions under the federal False Claims Act for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product or causing false claims to be submitted because of the company&#8217;s marketing the product for unapproved, and thus non-reimbursable, uses. False Claims Act liability is potentially significant in the healthcare industry because the statute provides for treble damages and mandatory penalties of tens of thousands of dollars per false claim or statement. Healthcare companies also are subject to other federal false claims laws, including, among others, federal criminal healthcare fraud and false statement statutes that extend to non-government health benefit programs.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The Health Insurance Portability and Accountability Act of 1996 (&#147;HIPAA&#148;), as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#147;HITECH&#148;), imposes criminal and civil liability for knowingly and willfully executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services. In addition, HIPAA, as amended by HITECH, and their respective implementing regulations impose obligations, including mandatory contractual terms, on covered healthcare providers, health plans, as well as their business associates, with respect to safeguarding the privacy, security and transmission of individually identifiable health information.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The Physician Payment Sunshine Act, implemented as the Open Payments program, requires manufacturers of certain products reimbursed by Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to track and report to the federal government payments and transfers of value that they make to physicians and teaching hospitals, certain other healthcare professionals beginning in 2022, group purchasing organizations, and ownership interests held by physicians and their families, and provides for public disclosures of these data. Manufacturers are required to submit annual reports to the government and failure to do so may result in civil monetary penalties for all payments, transfers of value and ownership or investment interests not reported in an annual submission, and may result in liability under other federal laws and regulations. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Many states have adopted laws and regulations analogous to the federal laws cited above, including state anti-kickback and false claims laws, which may apply to items or services reimbursed under Medicaid and other state programs or, in several states, regardless of the payer. Several states have enacted legislation requiring medical device companies to, among other things, establish marketing compliance programs; file periodic reports with the state, including reports on gifts and payments to individual health care providers; make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities; and/or register their sales representatives. Some states prohibit specified sales and marketing practices, including the provision of gifts, meals, or other items to certain health care providers. </td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations involve substantial costs. Additionally, it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">35</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">to significant civil, criminal and administrative penalties, damages, fines, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. Exclusion, suspension and debarment from government funded healthcare programs would significantly impact our ability to commercialize, sell or distribute any product. If any of the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. </p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Changes in laws or regulations relating to data protection, or any actual or perceived failure by us to comply </b></i><i><b>with such laws and regulations or our privacy policies, could materially and adversely affect our business or </b></i><i><b>could lead to government enforcement actions and significant penalties against us, and adversely impact our </b></i><i><b>operating results.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We expect to receive health information and other highly sensitive or confidential information and data of patients and other third parties (e.g., healthcare providers who refer patients for scans), which we expect to compile and analyze. Collection and use of this data might raise privacy and data protection concerns, which could negatively impact our business. There are numerous federal, state and international laws and regulations regarding privacy, data protection, information security, and the collection, storing, sharing, use, processing, transfer, disclosure, and protection of personal information and other data, and the scope of such laws and regulations may change, be subject to differing interpretations, and may be inconsistent among countries and regions we intend to operate in (e.g., the United States, the European Union and Israel), or conflict with other laws and regulations. The regulatory framework for privacy and data protection worldwide is, and is likely to remain for the foreseeable future, uncertain and complex, and this or other actual or alleged obligations may be interpreted and applied in a manner that we may not anticipate or that is inconsistent from one jurisdiction to another and may conflict with other rules or practices including ours. Further, any significant change to applicable laws, regulations, or industry practices regarding the collection, use, retention, security, or disclosure of data, or their interpretation, or any changes regarding the manner in which the consent of relevant users for the collection, use, retention, or disclosure of such data must be obtained, could increase our costs and require us to modify our services and candidate products, possibly in a material manner, which we may be unable to complete, and may limit our ability to store and process patients&#146; data or develop new services and features.</p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In particular, we will be subject to U.S. data protection laws and regulations (i.e., laws and regulations that address privacy and data security) at both the federal and state levels. The legislative and regulatory landscape for data protection continues to evolve, and in recent years there has been an increasing focus on privacy and data security issues. Numerous federal and state laws, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws, govern the collection, use, and disclosure of health-related and other personal information. Failure to comply with such laws and regulations could result in government enforcement actions and create liability for us (including the imposition of significant civil or criminal penalties), private litigation and/or adverse publicity that could negatively affect our business. For instance, California enacted the California Consumer Privacy Act (CCPA) on June 28, 2018, which took effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal data. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability, and many similar laws have been proposed at the federal level and in other states.</p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, we expect to obtain health information that are subject to privacy and security requirements under HITECH and its implementing regulations. The Privacy Standards and Security Standards under HIPAA establish a set of standards for the protection of individually identifiable health information by health plans, health care clearinghouses and certain health care providers, referred to as Covered Entities, and the business associates with whom Covered Entities enter into service relationships pursuant to which individually identifiable health information may be exchanged. Notably, whereas HIPAA previously directly regulated only Covered Entities, HITECH makes certain of HIPAA&#146;s privacy and security standards also directly applicable to Covered Entities&#146; business associates. As a result, both Covered Entities and business associates are now subject to significant civil and criminal penalties for failure to comply with Privacy Standards and Security Standards. As part of our normal operations, we expect to collect, process and retain personal identifying information regarding patients, including as a business associate of Covered Entities, so we expect to be subject to HIPAA, including changes implemented through HITECH, and we could be subject to criminal penalties if we knowingly obtain or </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">36</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">disclose individually identifiable health information in a manner that is not authorized or permitted by HIPAA. A data breach affecting sensitive personal information, including health information, also could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">HIPAA requires Covered Entities (like many of our potential customers) and business associates, like us, to develop and maintain policies and procedures with respect to protected health information that is used or disclosed, including the adoption of administrative, physical and technical safeguards to protect such information. HITECH expands the notification requirement for breaches of patient-identifiable health information, restricts certain disclosures and sales of patient-identifiable health information and provides for civil monetary penalties for HIPAA violations. HITECH also increased the civil and criminal penalties that may be imposed against Covered Entities and business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and its implementing regulations and seek attorney&#146;s fees and costs associated with pursuing federal civil actions. Additionally, certain states have adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Internationally, many jurisdictions have or are considering enacting privacy or data protection laws or regulations relating to the collection, use, storage, transfer, disclosure and/or other processing of personal data, as well as certification requirements for the hosting of health data specifically. Such laws and regulations may include data hosting, data residency or data localization requirements (which generally require that certain types of data collected within a certain country be stored and processed within that country), data export restrictions, international transfer laws (which prohibit or impose conditions upon the transfer of such data from one country to another), or may require companies to implement privacy or data protection and security policies, enable users to access, correct and delete personal data stored or maintained by such companies, inform individuals of security breaches that affect their personal data or obtain individuals&#146; consent to use their personal data. For example, European legislators adopted the European Union&#146;s General Data Protection Regulation (2016/679) (&#147;GDPR&#148;), which became effective on May 25, 2018, and are now in the process of finalizing the ePrivacy Regulation to replace the European ePrivacy Directive (Directive 2002/58/EC as amended by Directive 2009/136/EC). The GDPR, supplemented by national laws and further implemented through binding guidance from the European Data Protection Board, imposes more stringent European Union data protection requirements and provides for significant penalties for noncompliance. Further, the United Kingdom&#146;s initiating a process to leave the European Union has created uncertainty with regard to the regulation of data protection in the United Kingdom. In particular, the United Kingdom has brought the GDPR into domestic law with the Data Protection Act 2018 which will remain in force, even if and when the United Kingdom leaves the European Union. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Virtually every jurisdiction in which we expect to operate has established its own data security and privacy legal framework with which we must, and our target customers will need to, comply, including the rules and regulation mentioned above. We may also need to comply with varying and possibly conflicting privacy laws and regulations in other jurisdictions. As a result, we could face regulatory actions, including significant fines or penalties, adverse publicity and possible loss of business.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">While we are preparing to implement various measures intended to enable us to comply with applicable privacy or data protection laws, regulations and contractual obligations, these measures may not always be effective and do not guarantee compliance. Any failure or perceived failure by us to comply with our contractual or legal obligations or regulatory requirements relating to privacy, data protection, or information security may result in governmental investigations or enforcement actions, litigation, claims, or public statements against us by consumer advocacy groups or others and could result in significant liability, cause our customers, partners or patients to lose trust in us, and otherwise materially and adversely affect our reputation and business. Furthermore, the costs of compliance with, and other burdens imposed by, the laws, regulations, and policies that are applicable to the businesses of our customers or partners may limit the adoption and use of, and reduce the overall demand for, our products and services. Additionally, if third parties we work with violate applicable laws, regulations, or agreements, such violations may put the data we have received at risk, could result in governmental investigations or enforcement actions, fines, litigation, claims, or public statements against us by consumer advocacy groups or others and could result in significant liability, cause our customers, partners or patients to lose trust in us, and otherwise materially and adversely affect our reputation and business. Further, public scrutiny of, or complaints about, technology companies or their data handling or data protection practices, </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">37</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">even if unrelated to our business, industry or operations, may lead to increased scrutiny of technology companies, including us, and may cause government agencies to enact additional regulatory requirements, or to modify their enforcement or investigation activities, which may increase our costs and risks.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>If we do not obtain and maintain international regulatory registrations, clearances or approvals for our </b></i><i><b>products, we will be unable to market and sell our products outside of the United States.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Sales of our products outside of the United States are subject to foreign regulatory requirements that vary widely from country to country. Approval procedures vary among countries and can involve additional testing. The time required to obtain approval outside of the United States may differ substantially from that required to obtain FDA approval. In addition, the FDA regulates exports of medical devices from the United States. While the regulations of some countries may not impose barriers to marketing and selling our products or only require notification, others require that we obtain the clearance or approval of a specified regulatory body. Complying with foreign regulatory requirements, including obtaining registrations, clearances or approvals, can be expensive and time-consuming, and we may not receive regulatory clearances or approvals in each country in which we plan to market our products or we may be unable to do so on a timely basis. The time required to obtain registrations, clearances or approvals, if required by other countries, may be longer than that required for FDA clearance or approval, and requirements for such registrations, clearances or approvals may significantly differ from FDA requirements. If we modify our products, we may need to apply for additional regulatory clearances or approvals before we are permitted to sell the modified product. In addition, we may not continue to meet the quality and safety standards required to maintain the authorizations that we have received. If we are unable to maintain our authorizations in a particular country, we will no longer be able to sell the applicable product in that country.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Regulatory clearance or approval by the FDA does not ensure registration, clearance or approval by regulatory authorities in other countries, and registration, clearance or approval by one or more foreign regulatory authorities does not ensure registration, clearance or approval by regulatory authorities in other foreign countries or by the FDA. However, a failure or delay in obtaining registration or regulatory clearance or approval in one country may have a negative effect on the regulatory process in others.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Legislative or regulatory reforms in the United States or the EU may make it more difficult and costly for us </b></i><i><b>to obtain regulatory clearances or approvals for our products or to manufacture, market or distribute our </b></i><i><b>products after clearance or approval is obtained.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulation of medical devices. In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions, which may prevent or delay approval or clearance of our future products under development or impact our ability to modify our currently cleared products on a timely basis. Over the last several years, the FDA has proposed reforms to its 510(k) clearance process, and such proposals could include increased requirements for clinical data and a longer review period, or could make it more difficult for manufacturers to utilize the 510(k) clearance process for their products. For example, in November 2018, FDA officials announced forthcoming steps that the FDA intends to take to modernize the premarket notification pathway under Section 510(k) of the FDCA. Among other things, the FDA announced that it planned to develop proposals to drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates. These proposals included plans to potentially sunset certain older devices that were used as predicates under the 510(k) clearance pathway, and to potentially publish a list of devices that have been cleared on the basis of demonstrated substantial equivalence to predicate devices that are more than 10 years old. In May 2019, the FDA solicited public feedback on these proposals. The FDA requested public feedback on whether it should consider certain actions that might require new authority, such as whether to sunset certain older devices that were used as predicates under the 510(k) clearance pathway. These proposals have not yet been finalized or adopted, and the FDA may work with Congress to implement such proposals through legislation. Accordingly, it is unclear the extent to which any proposals, if adopted, could impose additional regulatory requirements on us that could delay our ability to obtain new 510(k) clearances, increase the costs of compliance, or restrict our ability to maintain our current clearances, or otherwise create competition that may negatively affect our business.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">More recently, in September 2019, the FDA finalized guidance describing an optional &#147;safety and performance based&#148; premarket review pathway for manufacturers of &#147;certain, well-understood device types&#148; to </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">38</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">demonstrate substantial equivalence under the 510(k) clearance pathway by showing that such device meets objective safety and performance criteria established by the FDA, thereby obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate devices in the clearance process. The FDA intends to develop and maintain a list device types appropriate for the &#147;safety and performance based&#148; pathway and will continue to develop product-specific guidance documents that identify the performance criteria for each such device type, as well as the testing methods recommended in the guidance documents, where feasible. The FDA may establish performance criteria for classes of devices for which we or our competitors seek or currently have received clearance, and it is unclear the extent to which such performance standards, if established, could impact our ability to obtain new 510(k) clearances or otherwise create competition that may negatively affect our business.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new statutes, regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of any future products or make it more difficult to obtain clearance or approval for, manufacture, market or distribute our products. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things, require: additional testing prior to obtaining clearance or approval; changes to manufacturing methods; recall, replacement or discontinuance of our products; or additional record keeping.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The FDA&#146;s and other regulatory authorities&#146; policies may change and additional government regulations may be promulgated that could prevent, limit or delay regulatory clearance or approval of our future products. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. For example, certain policies of the Trump administration may impact our business and industry. Namely, the Trump administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, FDA&#146;s ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these executive actions will be implemented, and the extent to which they will impact the FDA&#146;s ability to exercise its regulatory authority. If these executive actions impose restrictions on the FDA&#146;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval or clearance that we may have obtained and we may not achieve or sustain profitability.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">On April 5, 2017, the European Parliament passed the Medical Devices Regulation (Regulation 2017/745), which repeals and replaces the EU Medical Devices Directive. Unlike directives, which must be implemented into the national laws of the EEA member states, the regulations would be directly applicable, i.e., without the need for adoption of EEA member state laws implementing them, in all EEA member states and are intended to eliminate current differences in the regulation of medical devices among EEA member States. The Medical Devices Regulation, among other things, is intended to establish a uniform, transparent, predictable and sustainable regulatory framework across the EEA for medical devices and ensure a high level of safety and health while supporting innovation.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Medical Devices Regulation will, however, only become applicable three years after publication (in 2020). Once applicable, the new regulations will among other things:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">strengthen the rules on placing devices on the market and reinforce surveillance once they are available;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">establish explicit provisions on manufacturers&#8217; responsibilities for follow-up regarding the quality, performance and safety of devices placed on the market;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">improve the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">set up a central database to provide patients, healthcare professionals and the public with comprehensive information on products available in the EU; and</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">39</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">strengthened rules for the assessment of certain high-risk devices, which may have to undergo an additional check by experts before they are placed on the market.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">These modifications may have an effect on the way we conduct our business in the EEA.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Healthcare reform laws could adversely affect our products and financial condition.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">During the past several years, the U.S. healthcare industry has been subject to an increase in governmental regulation at both the federal and state levels. Efforts to control healthcare costs, including limiting access to care, alternative delivery models and changes in the methods used to determine reimbursement scenarios and rates, are ongoing at the federal and state government levels. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In March 2010, former President Obama signed into law the Patient Protection and Affordable Care Act, and the Health Care and Education Reconciliation Act of 2010 (collectively, the &#147;ACA&#148;), which included measures that significantly changed the way healthcare is financed by both governmental and private insurers. While a primary goal of these healthcare reform efforts was to expand coverage to more individuals, it also involved additional regulatory mandates and other measures designed to constrain medical costs. The ACA significantly impacts the medical device industry. Among other things, the ACA:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
Imposes an annual excise tax of 2.3% on any entity that manufactures or imports medical devices offered for sale in the United States, which, through a series of legislative amendments, was suspended, effective January 1, 2016 and subsequently repealed altogether on December 20, 2019;
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Establishes a new Patient-Centered Outcomes Research Institute to oversee and identify priorities in comparative clinical effectiveness research in an effort to coordinate and develop such research; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Implements Medicare payment system reforms including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, the ACA and related healthcare reform laws, regulations and initiatives have significantly increased regulation of managed care plans and decreased reimbursement under Medicare managed care. Moreover, to alleviate budget shortfalls, states have reduced or frozen payments to Medicaid managed care plans. We cannot accurately predict the complete impact of these healthcare reform initiatives, but they could lead to a decreased demand for medical devices and other outcomes that could adversely impact our business and financial results.</p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Some of the provisions of the ACA have yet to be fully implemented, and certain provisions have been subject to judicial and Congressional challenges. In addition, there have been efforts by the Trump administration to repeal or replace certain aspects of the ACA and to alter the implementation of the ACA and related laws. For example, the Tax Cuts and Jobs Act enacted on December 22, 2017, or TCJA, eliminated the shared responsibility payment for individuals who fail to maintain minimum essential coverage under section 5000A of the Internal Revenue Code of 1986, commonly referred to as the &#147;individual mandate,&#148; effective January 1, 2019. On December 14, 2018, a U.S. District Court Judge in the Northern District of Texas, or the Texas District Court Judge, ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the ACA are invalid as well. This decision was subsequently appealed, and on December 18, 2019, the U.S. Court of Appeals for the Fifth Circuit affirmed the decision of the district court that the individual mandate, as amended by the TCJA, was unconstitutional. The Fifth Circuit remanded the case to the district court to consider a remedy, including to consider and explain which provisions of the ACA are inseverable and invalid. It is unclear how this litigation, including all future hearings and appeals, and other efforts to challenge, repeal or replace the ACA, or portions thereof, will affect our future products or our business. It is possible that the ACA, as currently enacted or as it may be amended in the future, and other healthcare reform measures that may be adopted in the future, could have an adverse effect on our industry generally and on our ability to commercialize our future products and achieve profitability.</p>

				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain </b></i><i><b>key leadership and other personnel, or otherwise prevent new products and services from being developed or </b></i><i><b>commercialized in a timely manner, which could negatively impact our business.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">40</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Disruptions at the FDA and other agencies may also slow the time necessary for new devices to be reviewed and/or approved or cleared by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Risks Related to Employee Matters</b></p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>Under applicable employment laws, we may not be able to enforce covenants not to compete and therefore may be </b></i><i><b>unable to prevent our competitors from benefiting from the expertise of some of our former employees. </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our employment agreements generally include covenants not to compete. These agreements prohibit our employees, if they cease working for us, from competing directly with us or working for our competitors for a limited period. We may be unable to enforce these agreements under the laws of the jurisdictions in which our employees work at all or for a sufficient duration of time to prevent members of our management team from competing with us. For example, Israeli courts have required employers seeking to enforce covenants not to compete to demonstrate that the competitive activities of a former employee will harm one of a limited number of material interests of the employer, such as the secrecy of a company&#146;s confidential commercial information or the protection of its intellectual property. In Israel, if we cannot demonstrate that such an interest will be harmed, we may be unable to prevent our competitors from benefiting from the expertise of our former employees or consultants and our competitiveness may be diminished. </p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We may not be able to attract and retain the highly skilled employees we need to support our planned growth. </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">To continue to execute our business and our growth plan, we must attract and retain highly qualified personnel. Competition for these personnel is intense. We may not be successful in attracting and retaining qualified personnel. If we fail to attract new personnel or fail to retain and motivate our current personnel, our business, financial condition, results of operations and future growth prospects could be severely harmed.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Risks Related to this Offering and Owning Our Ordinary Shares</b></p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>Our share price may be volatile, and you may lose all or part of your investment.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The initial public offering price for our shares will be determined by negotiations between us and representatives of the underwriters based on several factors. This price may vary from the market price of our shares after this offering and the price of our ordinary shares may decline. You may be unable to sell your shares at or above the initial offering price. The market price for our shares may be volatile and subject to wide fluctuations in response to factors including the following:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">actual or anticipated fluctuations in results of operations;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">actual or anticipated changes in our growth rate relative to our competitors, as well as announcements by us or our competitors of significant business developments, changes in relationships with our target customers, manufacturers or suppliers, acquisitions or expansion plans;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">failure to meet or exceed financial estimates and projections of the investment community or that we provide to the public, as well as variance in our financial performance from the expectations of market analysts;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">issuance of new or updated research or reports by securities analysts;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">additions or departures of key management or other personnel;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our involvement in litigation;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">41</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">disputes or other developments related to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technology;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">announcement or expectation of additional debt or equity financing efforts;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">sales of our ordinary shares or other securities by us, our insiders or our other shareholders, or the perception that these sales may occur in the future; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the trading volume of our ordinary shares;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">market conditions in our industry; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">changes in the estimation of the future size and growth rate of our markets; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">general economic, market or political conditions in the United States or elsewhere.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In particular, the market prices of pre-commercial-stage companies like ours have been highly volatile due to factors, including, but not limited to:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to develop and commercialize our technology and future products or services;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">developments or disputes concerning our product&#8217;s intellectual property rights;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our or our competitors&#8217; technological innovations;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">fluctuations in the valuation of companies perceived by investors to be comparable to us;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">announcements by us or our competitors of significant contracts, acquisitions, strategic partnerships, joint ventures, capital commitments, new technologies or patents;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">failure to complete significant transactions or collaborate with vendors in manufacturing our product; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">proposals for legislation that would place restrictions on the price of medical therapies.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">These and other market and industry factors may cause the market price and demand for our ordinary shares to fluctuate substantially, regardless of our actual operating performance, which may limit or prevent investors from readily selling their ordinary shares and may otherwise negatively affect the liquidity of our ordinary shares. In addition, the stock market in general, and Nasdaq Capital Markets and emerging growth companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Such broad market fluctuations, and other factors (such as variations in quarterly and yearly operating results, general trends in the medical imaging industry, and changes in state, federal or other applicable regulations affecting us and our industry) may adversely affect the market price of our ordinary shares, if a market for them develops. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In the past, when the market price of shares has been volatile, holders of those shares have instituted securities class action litigation against the company that issued the shares. If any of our shareholders brought a lawsuit against us, we could incur substantial costs defending the lawsuit. Such a lawsuit could also divert resources and the time and attention of our management.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Prior to the completion of our initial public offering, there was no public trading market for our ordinary shares.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The offering under this prospectus is an initial public offering of our ordinary shares. Prior to the closing of the offering, there was no public market for our ordinary shares. While we plan to list our ordinary shares on the Nasdaq Capital Market, our listing application may not be approved. If our application to the Nasdaq Capital Market is not approved or we otherwise determine that we will not be able to secure the listing of the ordinary shares on the Nasdaq Capital Market, we will not complete the offering. In addition, an active trading market may not develop following the closing of this offering or, if developed, may not be sustained. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. An inactive market may also impair our ability to raise capital by selling ordinary shares and may impair our ability to acquire other companies by using our shares as consideration. </p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We are an &#147;emerging growth company&#148; under the JOBS Act and we cannot be certain if the reduced disclosure </b></i><i><b>requirements applicable to emerging growth companies will make our ordinary shares less attractive to investors.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are an &#147;emerging growth company,&#148; as defined in the JOBS Act, and for so long as we continue to be an &#147;emerging growth company&#148; we may take advantage of certain exemptions from various reporting </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">42</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">requirements that are applicable to other public companies that are not &#147;emerging growth companies&#148; including, but not limited to, not being required to comply with the auditor attestation requirements of section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised financial accounting standards until such time as those standards apply to private companies. We have elected to &#147;opt out&#148; of this provision and, as a result, we will comply with new or revised accounting standards as required when they are adopted for public companies. </p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our status as an &#147;emerging growth company&#148; under the JOBS Act may make it more difficult to raise capital </b></i><i><b>as and when we need it.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Because of the exemptions from various reporting requirements provided to us as an &#147;emerging growth company,&#148; we may be less attractive to investors and it may be difficult for us to raise additional capital as and when we need it. Investors may be unable to compare our business with other companies in our industry if they believe that our reporting is not as transparent as the reporting of other companies in our industry. If we are unable to raise additional capital as and when we need it, our financial condition and results of operations may be materially and adversely affected.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We will remain an emerging growth company until the earliest of: (i) the last day of our fiscal year during which we have total annual gross revenue of at least $1.07 billion; (ii) the last day of our fiscal year following the fifth anniversary of the completion of this offering; (iii) the date on which we have, during the previous three-year period, issued more than $1.0 billion in non-convertible debt; or (iv) the date on which we are deemed to be a &#147;large accelerated filer&#148; under the Exchange Act. Once we cease to be an emerging growth company, we will not be entitled to the exemptions provided to emerging growth companies under the JOBS Act.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>As a foreign private issuer, we are exempt from certain requirements that apply to </b></i><i><b>domestic</b></i><i><b> issuers and we are </b></i><i><b>permitted to follow certain home country corporate governance practices instead of applicable SEC and </b></i><i><b>Nasdaq requirements, which may result in less protection than is accorded to shareholders under rules </b></i><i><b>applicable to domestic issuers.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Upon the closing of this offering, we will report under the Exchange Act as a non-U.S. company with foreign private issuer status. Because we qualify as a foreign private issuer under the Exchange Act, we are exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including (1) the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act, (2) the sections of the Exchange Act requiring insiders to file public reports of their share ownership and trading activities and liability for insiders who profit from trades made in a short period of time and (3) the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing unaudited financial and other specified information, although we intend to furnish comparable quarterly information on Form 6-K. In addition, foreign private issuers are not required to file their annual report on Form 20-F until 120 days after the end of each fiscal year, while U.S. domestic issuers that are accelerated filers are required to file their annual report on Form 10-K within 75 days after the end of each fiscal year and U.S. domestic issuers that are large accelerated filers are required to file their annual report on Form 10-K within 60 days after the end of each fiscal year. Foreign private issuers are also exempt from Regulation FD, which is intended to prevent issuers from making selective disclosures of material information.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, as a foreign private issuer, we will be permitted to follow certain home country corporate governance practices instead of those otherwise required under the listing rules of the Nasdaq Stock Market for domestic issuers. For instance, we may follow home country practice in Israel with regard to, among other things, composition of the board of directors, director nomination procedure, approval of compensation of officers, and quorum at shareholders&#146; meetings. For example, under Israeli law, as currently applicable to us, there is no requirement for a majority of our directors to be independent. In addition, we may follow our home country law, instead of the listing rules of the Nasdaq Stock Market, which require that we obtain shareholder approval for certain dilutive events, such as for the establishment or amendment of certain equity based compensation plans, an issuance that will result in a change of control of the company, certain transactions other than a public offering involving issuances of a 20% or more interest in the company and certain acquisitions of the stock or assets of another company. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">43</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As a result of all of the above, you may not have the same protections afforded to shareholders of a company that is not a foreign private issuer.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We may lose our foreign private issuer status which would then require us to comply with the Exchange Act&#146;s </b></i><i><b>domestic reporting regime and cause us to incur significant legal, accounting and other expenses.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As discussed above, we are a foreign private issuer and therefore we are not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to U.S. domestic issuers. We will remain a foreign private issuer until our board determines that we no longer meet the qualification set forth in Securities Act Rule 405 and Exchange Act Rule 3b-4, with such determinations to be made on an annual basis as of the end of our second fiscal quarter. In order to maintain our current status as a foreign private issuer, either (a) a majority of our ordinary shares must be either directly or indirectly owned of record by non-residents of the United States or (b)(i) a majority of our executive officers or directors must not be U.S. citizens or residents, (ii) more than 50 percent of our assets cannot be located in the United States and (iii) our business must be administered principally outside the United States. If we lose this status, we would be required to comply with the Exchange Act reporting and other requirements applicable to U.S. domestic issuers, which are more detailed and extensive than the requirements for foreign private issuers. We may also be required to make changes in our corporate governance practices in accordance with various SEC and Nasdaq rules. The regulatory and compliance costs to us under U.S. securities laws if we are required to comply with the reporting requirements applicable to a U.S. domestic issuer may be significantly higher than the costs we would incur as a foreign private issuer. As a result, we expect that a loss of foreign private issuer status would increase our legal and financial compliance costs and would make some activities highly time consuming and costly. We also expect that if we were required to comply with the rules and regulations applicable to U.S. domestic issuers, it would make it more difficult and expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These rules and regulations could also make it more difficult for us to attract and retain qualified members of our board of directors.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We have not paid dividends in the past and have no immediate plans to pay dividends.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We plan to reinvest all of our future earnings, to the extent we have earnings, in order to develop and commercialize our technology and products and to cover operating costs, finance operations and to otherwise become and remain competitive. We have never declared or paid any dividends on our ordinary shares and we do not plan to pay any cash dividends with respect to our securities in the foreseeable future. As we are a development-stage company with limited operating history, we may not be able to generate, at any time, sufficient surplus cash that would be available for distribution to the holders of our ordinary shares as a dividend. Therefore, you should not expect to receive cash dividends on the ordinary shares we are offering. Consequently, investors may need to rely on sales of their ordinary shares after price appreciation, which may never occur, as the only way to realize any future gains on their investment. In addition, the Companies Law imposes restrictions on our ability to declare and pay dividends. See &#147;Description of Share Capital&#8212;Dividend and Liquidation Rights&#148; for additional information.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We will incur significant increased costs as a result of becoming a public company that reports to the </b></i><i><b>Securities and Exchange Commission and our management will be required to devote substantial time to meet </b></i><i><b>compliance obligations.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As a public company reporting to the SEC, we will incur significant legal, insurance, director compensation, accounting and other expenses that we did not incur as a private company. We will be subject to reporting requirements of the Exchange Act and the Sarbanes-Oxley Act, as well as rules subsequently implemented by the SEC that impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. In addition, the Dodd-Frank Wall Street Reform and Consumer Protection Act (the &#147;Dodd-Frank Act&#148;) impose various other requirements on public companies. There are significant corporate governance and executive compensation-related provisions in the Dodd-Frank Act that are expected to increase our legal and financial compliance costs, make some activities more difficult, time-consuming or costly and may also place undue strain on our personnel, systems and resources. Our management and other personnel will need to devote a substantial amount of time to these new compliance initiatives. In addition, we expect these rules and regulations to make it </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">44</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult and expensive for us to attract and retain qualified people to serve on our board of directors, our board committees or as executive officers.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We also anticipate that we will incur costs associated with corporate governance requirements, including requirements under rules implemented by the SEC and the Nasdaq Capital Market, and provisions of Israeli corporate law applicable to public companies. We expect that these rules and regulations will increase our legal and financial compliance costs, introduce new costs such as investor relations and stock exchange listing fees, and will make some activities more time-consuming and costly. Our board and other personnel will need to devote a substantial amount of time to these initiatives. We are currently evaluating and monitoring developments with respect to these rules, and we cannot estimate the amount of additional costs we may incur or the timing of such costs.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As an &#147;emerging growth company,&#148; as defined in the JOBS Act, we may take advantage of certain temporary exemptions from various reporting requirements, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act (and the rules and regulations of the SEC thereunder). When these exemptions cease to apply, we expect to incur additional expenses and devote increased management effort toward ensuring compliance with them. We cannot estimate the amount of additional costs we may incur as a result of becoming a public company or the timing of such costs.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Pursuant to Section 404 of the Sarbanes-Oxley Act and the related rules adopted by the SEC and the Public Company Accounting Oversight Board, starting with the second annual report that we file with the SEC after the closing of this offering, our management will be required to report on the effectiveness of our internal control over financial reporting. In addition, once we no longer qualify as an &#147;emerging growth company&#148; under the JOBS Act and lose the ability to rely on the exemptions related thereto discussed above and depending on our status as per Rule 12b-2 of the Exchange Act, our independent registered public accounting firm may also need to attest to the effectiveness of our internal control over financial reporting under Section 404. We have not yet commenced the process of determining whether our existing internal controls over financial reporting systems are compliant with Section 404. This process will require the investment of substantial time and resources, including by our chief financial officer and other members of our senior management. As a result, this process may divert internal resources and take a significant amount of time and effort to complete. In addition, the outcome of this determination may be unexpected and we may need to implement remedial actions in order to implement effective controls over financial reporting. The determination and any remedial actions required could result in us incurring additional costs that we did not anticipate, including the hiring of outside consultants. Irrespective of compliance with Section 404, any failure of our internal controls could have a material adverse effect on our stated results of operations and harm our reputation. As a result, we may experience higher than anticipated operating expenses, as well as higher independent auditor fees during and after the implementation of these changes. If we are unable to implement any of the required changes to our internal control over financial reporting effectively or efficiently or are required to do so earlier than anticipated, it could adversely affect our operations, financial reporting and/or results of operations and could result in an adverse opinion on internal controls from our independent auditors.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Assuming a market for our ordinary shares develops, shares eligible for future sale may adversely affect the </b></i><i><b>market for our ordinary shares. </b></i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">From time to time after we have been subject to the reporting requirements of section 13 or section 15(d) of the Exchange Act for at least 90 days, certain of our shareholders may be eligible to sell all or some of their ordinary shares by means of ordinary brokerage transactions in the open market pursuant to Rule 144, promulgated under the Securities Act, subject to certain limitations. In general, pursuant to Rule 144, non-affiliate shareholders may sell freely after six months subject only to the current public information requirement (which disappears after one year). Of the &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares expected to be outstanding following completion of the offering, approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares will be held by &#147;non-affiliates&#148; and will be freely tradable without restriction pursuant to Rule 144, although all but&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of such shares will be subject to either a &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lock-up. In addition, certain shareholders will have the ability to cause us to register the resale of their shares under the Registration Rights Agreement or the terms of certain warrants. See &#147;Description of Share Capital&#8212;Registration Rights&#148; for a description of the registration rights.</p>

			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">45</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Any substantial sale of our ordinary shares pursuant to Rule 144 or pursuant to any resale prospectus (including sales by investors of securities acquired in connection with this offering) may have a material adverse effect on the market price of our ordinary shares.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We may allocate the net proceeds from this offering in ways that differ from the estimates discussed in the </b></i><i><b>section titled &#147;Use of Proceeds&#148; and with which you may not agree.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The allocation of net proceeds of the offering set forth in the &#147;Use of Proceeds&#148; section below represents our estimates based upon our current plans and assumptions regarding industry and general economic conditions, and our future revenues and expenditures. The amounts and timing of our actual expenditures will depend on numerous factors, including market conditions, cash generated by our operations, business developments and rate of growth. Management has broad discretion over the use of proceeds of this offering and we may find it necessary or advisable to use all or portions of the proceeds from this offering for other purposes. Circumstances that may give rise to a change in the use of proceeds and the alternate purposes for which the proceeds may be used are discussed in the section entitled &#147;Use of Proceeds.&#148; You may not have an opportunity to evaluate the economic, financial or other information on which we base our decisions on how to use our proceeds. As a result, you and other shareholders may not agree with our decisions. Our failure to apply these funds effectively could have a material adverse effect on our business, financial condition, results of operations and prospects. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or preserve value. See &#147;Use of Proceeds&#148; for additional information.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>You will experience immediate dilution in the book value per share of the ordinary shares you purchase.</b></i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Because the price per share of our ordinary shares being offered is substantially higher than the net tangible book value per share of our ordinary shares, you will experience substantial dilution in the pro forma net tangible book value of the ordinary shares you purchase in this offering. Based on the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the range set forth on the cover page of this prospectus, if you purchase ordinary shares in this offering, you will experience immediate and substantial dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share based on the pro forma net tangible book value of the ordinary shares as of December 31, 2019. See &#147;Dilution&#148; for a more detailed discussion of the dilution you will incur if you purchase ordinary shares in this offering. Moreover, we expect, in the future, to issue additional options to purchase our ordinary shares to compensate employees, consultants and directors and may issue additional shares to raise capital, to pay for services, or for other corporate purposes. To the extent our outstanding options or warrants are exercised or ordinary shares are issued at a price below net tangible book value per share, there will be additional dilution to our then-shareholders.</p>

				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>The purchase price of the ordinary shares may not reflect our actual value.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The purchase price of the ordinary shares is and will be determined through negotiations between us and representatives of the underwriters. The price of our ordinary shares may not be indicative of our actual value or any future market price for our securities. This price may not accurately reflect the value of the ordinary shares or the value that potential investors will realize upon their disposition of ordinary shares. The price does not necessarily bear any relationship to our assets, earnings, book value per share or other generally accepted criteria of value.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>If equity research analysts do not publish research or reports about us or our business or if they issue </b></i><i><b>unfavorable commentary or downgrade our ordinary shares, the price of our ordinary shares could decline.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The trading market for our ordinary shares will rely in part on the research and reports that equity research analysts publish about us and our business. The analysts&#146; estimates are based upon their own opinions and are often different from our estimates or expectations. If our results of operations are below the estimates or expectations of public market analysts and investors, the price of our ordinary shares could decline. Moreover, the price of our ordinary shares could decline if one or more securities analysts downgrade our ordinary shares or if those analysts issue other unfavorable commentary or cease publishing reports about us or our business.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">46</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We have identified material weaknesses in our internal control over financial reporting that could, if</b></i><i><b> </b></i><i><b>not </b></i><i><b>remediated, result in material misstatements in our financial statements. </b></i><i><b>If we fail to maintain an effective </b></i><i><b>system of internal control over financial reporting, we may not be able to accurately report our financial </b></i><i><b>results or prevent fraud. As a result, shareholders could lose confidence in our financial and other public </b></i><i><b>reporting, which would harm our business and the trading price of our ordinary shares.</b></i><i><b> </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures are designed to prevent fraud. Our management will be required to assess the effectiveness of our internal controls and procedures and disclose changes in these controls on an annual basis. However, for as long as we are an &#147;emerging growth company&#148; under the JOBS Act, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section 404. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our ordinary shares. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have identified a material weakness in our internal control over financial reporting in connection with the audit of our financial statements as of and for the year ended December 31, 2018. As defined in Regulation 12b-2 under the Exchange Act, a &#147;material weakness&#148; is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual financial statements will not be prevented, or detected on a timely basis. Specifically, we determined that the material weakness is related to having an insufficient number of financial reporting personnel with an appropriate level of knowledge, experience and training in application of U.S. GAAP and SEC rules and regulations commensurate with our reporting requirements. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have taken action toward remediating this material weakness by hiring additional qualified personnel with US GAAP accounting and reporting experience, and intend to provide enhanced training to existing financial and accounting employees on related US GAAP issues. However, the implementation of these initiatives may not fully address any material weakness or other deficiencies that we may have in our internal control over financial reporting.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Furthermore, we have not yet commenced the process of determining whether our existing internal control over financial reporting systems are compliant with Section 404 and whether there are any other material weaknesses or significant deficiencies in our existing internal controls. These controls and other procedures are designed to ensure that information required to be disclosed by us in the reports that we file with the SEC is disclosed accurately and is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Even if we develop effective internal control over financial reporting, these controls may become inadequate because of changes in conditions or the degree of compliance with these policies or procedures may deteriorate, and material weaknesses and deficiencies may be discovered in them. We are working with our legal, independent accounting and financial advisors to identify those areas in which changes should be made to our financial and management control systems to manage our growth and our obligations as a public company. These areas include corporate governance, corporate control, disclosure controls and procedures and financial reporting. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have made, and will continue to make, changes in these and other areas. In any event, the process of determining whether our existing internal controls are compliant with Section 404 and sufficiently effective will require the investment of substantial time and resources, including by our chief financial officer and other members of our senior management. As a result, this process may divert internal resources and take a significant amount of time and effort to complete, even more so after we are no longer an &#147;Emerging Growth Company.&#148; In addition, we cannot predict the outcome of this process and whether we will need to implement remedial actions in order to implement effective controls over financial reporting. The determination of whether or not our internal controls are sufficient and any remedial actions required could result in us incurring additional costs that </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">47</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">we did not anticipate, including the hiring of outside consultants. We may also fail to complete our evaluation, testing and any required remediation needed to comply with Section 404 in a timely fashion. Irrespective of compliance with Section 404, any additional failure of our internal controls could have a material adverse effect on our stated results of operations and harm our reputation. As a result, we may experience higher than anticipated operating expenses, as well as higher independent auditor fees during and after the implementation of these changes. If we are unable to implement any of the required changes to our internal control over financial reporting effectively or efficiently or are required to do so earlier than anticipated, it could adversely affect our operations, financial reporting or results of operations and could result in an adverse opinion on internal controls from our independent auditors.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Furthermore, if we are unable to certify that our internal control over financial reporting is effective and in compliance with Section 404, we may be subject to sanctions or investigations by regulatory authorities, such as the SEC or stock exchanges, and we could lose investor confidence in the accuracy and completeness of our financial reports, which could hurt our business, the price of our ordinary shares and our ability to access the capital markets.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>It is </b></i><i><b>likely that we will be classified as a passive foreign investment company, or PFIC, for U.S. federal </b></i><i><b>income tax purposes for the current taxable year and possibly for future taxable years, which could result in </b></i><i><b>adverse U.S. federal income tax consequences to U.S. </b></i><i><b>H</b></i><i><b>olders of our ordinary shares. </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A non-U.S. corporation will be a PFIC for any taxable year if either (1) at least 75% of its gross income for such year consists of certain types of passive income; or (2) at least 50% of the value of its assets (generally determined based on an average of the quarterly values of the assets) during such year is attributable to assets that produce passive income or are held for the production of passive income. For this purpose, cash and assets readily convertible into cash are categorized as passive assets and our goodwill and other unbooked intangibles will generally be taken into account in determining our asset value. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A non-U.S. corporation&#146;s PFIC status is a factual determination made annually after the close of each taxable year. Based upon our current and projected income and assets (including goodwill and taking into account our cash balances, including the anticipated proceeds from this offering) and the anticipated market price of our ordinary shares in this offering, it is likely that we will be classified as a PFIC for the current and future taxable years at least until we start generating a substantial amount of active revenue. In addition, it is possible that any subsidiary that we own would also be classified as a PFIC for such taxable years. Accordingly, prospective investors should be willing to assume the risks of investing in a PFIC.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If we were to be, or become, classified as a PFIC for any taxable year during which a U.S. Holder (as defined in the section headed &#147;Material Tax Considerations&#8212;U.S. Federal Income Tax Consequences&#148;) holds our ordinary shares, certain adverse U.S. federal income tax consequences could apply to such U.S. Holder. See &#147;Material Tax Considerations&#8212;U.S. Federal Income Tax Consequences.&#148;</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">You are strongly urged to consult your tax advisors regarding the impact of our being a PFIC in any taxable year on your investment in our ordinary shares as well as the application of the PFIC rules.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Risks Related to Our Operations in Israel</b></p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>Conditions in Israel could materially and adversely affect our business.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our executive offices are located in Neve Ilan, Israel. In addition, a number of our officers and directors are residents of Israel. Accordingly, political, economic and military conditions in Israel and the surrounding region may directly affect our business and operations. Since the establishment of the State of Israel in 1948, a number of armed conflicts have taken place between Israel and its neighboring countries, as well as terrorist acts committed within Israel by hostile elements. During the last decade, there have been extended hostilities in 2009, 2012 through 2014, with additional small flare-ups as recently as 2018 and 2019. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Since February 2011, Egypt has experienced political turbulence and an increase in terrorist activity in the Sinai Peninsula. Such political turbulence and violence may damage peaceful and diplomatic relations between Israel and Egypt, and could affect the region as a whole. Similar civil unrest and political turbulence has occurred in other countries in the region, including Syria, which shares a common border with Israel, and is affecting the political stability of those countries. Since April 2011, internal conflict in Syria has escalated and chemical weapons have been used in the region. Foreign actors have intervened and may continue to intervene in </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">48</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">Syria. This instability and any intervention may lead to deterioration of the political and economic relationships that exist between the State of Israel and some of these countries and may lead to additional conflicts in the region. In addition, Iran has threatened to attack Israel and may be developing nuclear weapons. Iran also has a strong influence among extremist groups in the region, including Hamas in Gaza, Hezbollah in Lebanon and various rebel militia groups in Syria. These situations have escalated at various points in recent years and may escalate in the future to more violent events, which may affect Israel and us. Any armed conflicts, terrorist activities or political instability in the region could adversely affect business conditions and could harm our results of operations and could make it more difficult for us to raise capital. In addition, the political and security situation in Israel may result in parties with whom we have agreements involving performance in Israel claiming that they are not obligated to perform their commitments under those agreements pursuant to force majeure provisions in such agreements. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We currently do not, and we do not expect to, carry any commercial insurance that covers losses resulting from events associated with war and terrorism. Although the Israeli government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot be assured that this government coverage will be maintained or, if maintained, that it will be sufficient to compensate us fully for damages incurred and the government may cease providing such coverage or the coverage might not suffice to cover potential damages. Any losses or damages incurred by us could have a material adverse effect on our business. Any armed conflicts or political instability in the region would likely negatively affect business conditions and could harm our results of operations. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Further, in the past, the State of Israel and Israeli companies have been subjected to economic boycotts. Several countries still restrict business with the State of Israel and with Israeli companies. These restrictive laws and policies may have an adverse impact on our operating results, financial condition or the expansion of our business. A campaign of boycotts, divestment and sanctions has been undertaken against Israel, which could also adversely impact our business. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, many Israeli citizens are obligated to perform several days, and in some cases more, of annual military reserve duty each year until they reach the age of 40 (or older for certain reservists) and, in the event of a military conflict, may be called to active duty. In response to increases in terrorist activity, there have been periods of significant call-ups of military reservists. It is possible that there will be military reserve duty call-ups in the future. Our operations could be disrupted by such call-ups, which may include the call-up of members of our management. Such disruption could materially adversely affect our business, prospects, financial condition and results of operations. </p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>The termination or reduction of tax and other incentives that the Israeli government provides to Israeli </b></i><i><b>companies may increase our costs and taxes.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Israeli government currently provides tax and capital investment incentives to Israeli companies, as well as grant and loan programs relating to research and development and marketing and export activities (see &#147;Material Tax Considerations&#8212;Israeli Tax Considerations and Government Programs&#148;). In recent years, the Israeli government has reduced the benefits available under these programs and the Israeli governmental authorities may in the future further reduce or eliminate the benefits of these programs. We may take advantage of these benefits and programs in the future; however, there can be no assurance that such benefits and programs will be available to us. If we qualify for such benefits and programs and fail to meet the conditions thereof, the benefits could be canceled and we could be required to refund any benefits we might already have enjoyed and become subject to penalties. Additionally, if we qualify for such benefits and programs and they are subsequently terminated or reduced, it could have an adverse effect on our financial condition and results of operations. </p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>It may be difficult to enforce a U.S. judgment against us, our officers and directors named in this prospectus </b></i><i><b>in Israel or the United States, or to assert U.S. securities laws claims in Israel or serve process on our officers </b></i><i><b>and directors. </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Many of our directors or officers are not residents of the United States and a significant portion of their and our assets are located outside the United States. Service of process upon us or our non-U.S. resident directors and officers may be difficult to obtain within the United States. We have been informed by our legal counsel in Israel that it may be difficult to assert claims under U.S. securities laws in original actions instituted in Israel or obtain a judgment based on the civil liability provisions of U.S. federal securities laws. Israeli courts may refuse </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">49</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">to hear a claim based on a violation of U.S. securities laws against us or our officers and directors because Israel may not be the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact, which can be a time-consuming and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding case law in Israel addressing the matters described above. Additionally, Israeli courts might not enforce judgments obtained in the United States against us or our directors and executive officers, which may make it difficult to collect on judgments rendered against us or our officers and directors. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Moreover, an Israeli court will not enforce a non-Israeli judgment if it was given in a state whose laws do not provide for the enforcement of judgments of Israeli courts (subject to exceptional cases), if its enforcement is likely to prejudice the sovereignty or security of the State of Israel, if it was obtained by fraud or in the absence of due process, if it is at variance with another valid judgment that was given in the same matter between the same parties, or if a suit in the same matter between the same parties was pending before a court or tribunal in Israel at the time the foreign action was brought. For more information, see &#147;Enforceability of civil liabilities.&#148; </p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Your rights and responsibilities as our shareholder will be governed by Israeli law, which may differ in some </b></i><i><b>respects from the rights and responsibilities of shareholders of U.S. corporations. </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are incorporated under Israeli law. The rights and responsibilities of holders of our ordinary shares are governed by our amended and restated articles of association to be effective upon the closing of this offering and the Israeli Companies Law, 5759-1999 (the &#147;Companies Law&#148;). These rights and responsibilities differ in some respects from the rights and responsibilities of shareholders in typical U.S. corporations. In particular, pursuant to the Companies Law, each shareholder of an Israeli company has to act in good faith and in a customary manner in exercising his or her rights and fulfilling his or her obligations toward the company and other shareholders and to refrain from abusing his or her power in the company, including, among other things, in voting at the general meeting of shareholders on amendments to a company&#146;s articles of association, increases in a company&#146;s authorized share capital, mergers and certain transactions requiring shareholders&#146; approval under the Companies Law. In addition, under Israeli law, a controlling shareholder of an Israeli company or a shareholder who knows that it possesses the power to determine the outcome of a shareholder vote or who has the power to appoint or prevent the appointment of a director or officer in the company or has other powers toward the company has a duty of fairness toward the company. However, Israeli law does not define the substance of this duty of fairness. There is little case law available in Israel to assist in understanding the implications of these provisions that govern shareholder behavior. </p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Provisions of our amended and restated articles of association and Israeli law and tax considerations may </b></i><i><b>delay, prevent or make difficult an acquisition of us, which could prevent a change of control and negatively </b></i><i><b>affect the price of our ordinary shares.</b></i><i><b> </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Israeli corporate law regulates mergers, requires tender offers for acquisitions of shares if such acquisitions cause the acquirer to hold more than specified thresholds, requires special approvals for certain transactions involving directors, officers or significant shareholders and regulates other matters that may be relevant to these types of transactions. For example, under Israeli law, a merger may not be consummated unless at least 50 days have passed from the date that a merger proposal was filed by each merging company with the Israel Registrar of Companies and at least 30 days have passed from the date that the shareholders of both merging companies approved the merger. See &#147;Description of Share Capital&#8212;Acquisitions under Israeli Law.&#148;</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Furthermore, Israeli tax considerations may make potential transactions unappealing to us or to our shareholders, especially for those shareholders whose country of residence for tax purposes does not have a tax treaty with Israel which exempts such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free share exchanges to the same extent as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances but makes the deferral contingent on the fulfillment of a number of conditions, including, in some cases, a holding period of two years from the date of the transaction during which sales and dispositions of shares of the participating companies are subject to certain restrictions. Moreover, with respect to certain share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes payable even if no disposition of the shares has occurred. In order to benefit from the tax deferral, a pre-ruling from the Israeli Tax Authority may be required.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">50</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">These provisions of Israeli law and Israeli tax laws may delay, prevent or make difficult a merger with, or an acquisition of us, or all or a significant portion of our assets, which could prevent a change of control and may make it more difficult for a third party to acquire us, even if doing so would be beneficial to our shareholders. These provisions may limit the price that investors may be willing to pay in the future for our ordinary shares and therefore depress the price of our shares.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our amended and restated articles of association provide that our directors (other than external directors) are elected on a staggered basis, such that a potential acquirer cannot readily replace our entire board of directors at a single annual general shareholders meeting. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">51</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 105-special -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tSN"></a><b>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">This prospectus contains forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this prospectus are forward-looking statements. These forward-looking statements include information about possible or assumed future results of our business, financial condition, results of operations, prospects, liquidity, plans and objectives. In some cases, you can identify forward-looking statements by terminology such as &#147;can,&#148; &#147;might,&#148; &#147;believe,&#148; &#147;may,&#148; &#147;estimate,&#148; &#147;continue,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;should,&#148; &#147;plan,&#148; &#147;should,&#148; &#147;could,&#148; &#147;expect,&#148; &#147;predict,&#148; &#147;potential,&#148; or the negative of these terms or other similar expressions. Forward-looking statements are based on information we have when those statements are made or our management&#146;s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Forward-looking statements include, but are not limited to, statements concerning: </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The initiation, timing, progress and results of our research and development, manufacturing and commercialization activities with respect to our X-ray source technology, the Nanox.Arc, the Nanox.Cloud and the Nanox System;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to successfully demonstrate the feasibility of our technology for commercial applications;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our expectations regarding the necessity of, timing of filing for, and receipt of, regulatory clearances or approvals regarding our technology, the Nanox.Arc and the Nanox.Cloud;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to secure and maintain required FDA clearance and similar approvals from regulatory agencies worldwide and comply with applicable quality standards and regulatory requirements;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">
&#8226;
</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
our ability to manufacture the Nanox.Arc, if cleared, at substantially lower costs compared to medical imaging systems that use a legacy analog X-ray source;
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">
&#8226;
</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
our ability to manufacture, market and deploy approximately 15,000 Nanox.Arc units within the contemplated timeframe;
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">
&#8226;
</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
our ability to meet our planned deployment schedule for the Nanox System units within the contemplated timeframe;
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the pricing structure of our products and services, if such products and services receive regulatory clearance or approval;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the implementation of our business models;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our expectations regarding collaborations with third-parties and their potential benefits;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to enter into and maintain our arrangements with third-party manufacturers and suppliers;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to conduct business globally;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our expectations regarding when certain patents may be issued and the protection and enforcement of our intellectual property rights;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to operate our business without infringing the intellectual property rights and propriety technology of third parties;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">regulatory developments in the United States and other jurisdictions;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">estimates of our expenses, future revenues, capital requirements and our needs for additional financing;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the rate and degree of market acceptance of our technology and our products;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">development relating to our competitors and the medical imaging industry;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our estimates of the adoption of the MSaaS-based model by market participants;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our estimates regarding the market opportunities for our technology and our products;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to attract, motivate and retain key executive managers;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">52</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to comply with data protection laws, regulations and similar rules and to establish and maintain adequate cyber-security and data protection;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to obtain third-party payor coverage or reimbursement of our Nanox System;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to continue as a going concern;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our expectation regarding the maintenance of our foreign private issuer and emerging growth company status;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our expectations regarding the use of proceeds from this offering; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our success at managing other risks and uncertainties, including those listed under &#147;Risk Factors.&#148; </td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Many important factors, in addition to the factors described above and in other sections of this prospectus, could adversely impact our business and financial performance. The forward-looking statements contained in this prospectus speak only as of the date of this prospectus and are subject to a number of known and unknown risks, uncertainties and assumptions, including those described under the sections in this prospectus entitled &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and elsewhere in this prospectus. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. Moreover, we operate in an evolving environment. New risks and uncertainties emerge from time to time, and it is not possible for our management to predict all risks and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from estimates or forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements after the date of this prospectus to conform these statements to actual results or to changes in our expectations.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">53</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tUP"></a><b>USE OF PROCEEDS</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We expect that we will receive net proceeds from this offering of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the mid-point of the estimated range of the initial public offering price shown on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. If the underwriters exercise their option to purchase additional ordinary shares in full, our net proceeds will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We intend to use the net proceeds from our sale of ordinary shares in this offering, together with our existing cash, cash equivalents and short-term investments, as follows:</p>

				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">
&#8226;
</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million will be used for the manufacturing of the initial wave of Nanox.Arc units planned for global deployment; to the extent the cost-per-unit of the Nanox.Arc is higher than we expected or the amount of proceeds we receive is lower than we expected, we plan to reduce the number of units to be manufactured with such proceeds accordingly;
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">
&#8226;
</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million will be used for the shipping, installation, deployment and maintenance costs of the Nanox System; to the extent the number of units of the Nanox.Arc to be manufactured is reduced for the reasons described above, the amount of proceeds to be used for shipping, installation and deployment will be reduced accordingly;
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">
&#8226;
</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million will be used for the continued research and development of the Nanox.Arc, the development of the Nanox.Cloud and for regulatory clearance, which we expect will be sufficient for obtaining the 510(k) medical device clearance with respect to the Nanox.Arc with the FDA;
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">
&#8226;
</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million will be used for sales and marketing expenses in connection with the deployment of the Nanox System; and
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">
&#8226;
</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
the remaining funds, if any, to be used for general and administrative expenses and general corporate purposes.
</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Pending such use of the net proceeds from this offering, we intend to hold some amounts as cash and to invest the remaining net proceeds in a variety of capital preservation investments, including short-term, investment-grade, interest-bearing instruments denominated in currencies and with maturities that match our contracted expenditures and financial plans.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The amounts and timing of our actual expenditures will depend on numerous factors, including market conditions, results from our research and development efforts, business developments and opportunities and customer facing and product support activities. Accordingly, our management will have broad discretion in the application of the net proceeds, and investors will be relying on the judgment of our management regarding the application of the proceeds from this offering. We may find it necessary or advisable to use portions of the proceeds from this offering for other purposes. Circumstances that may give rise to a change in the use of proceeds and the alternate purposes for which the proceeds may be used include:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the existence of unforeseen or other opportunities or the need to take advantage of changes in timing of our existing activities;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the need or desire on our part to accelerate, increase, reduce or eliminate one or more existing initiatives due to, among other things, changing market conditions or competitive developments or interim results of research and development efforts;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">results from our business development and marketing efforts;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the effect of federal, state, and local regulation on our business; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the presentation of strategic opportunities of which we are not currently aware (including acquisitions, joint ventures, licensing and other similar transactions).</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">From time to time, we evaluate these and other factors and we anticipate continuing to make such evaluations to determine if the existing allocation of resources, including the proceeds of this offering, is being optimized.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">54</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A $1.00 increase or decrease in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, the net proceeds to us from this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming the number of shares offered by us remains the same as set forth on the cover page of this prospectus and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">55</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tDP"></a><b>DIVIDEND POLICY</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have never declared or paid any cash dividends on our ordinary shares and we anticipate that, for the foreseeable future, we will retain any future earnings to support operations and to finance the growth and development of our business. Therefore, we do not expect to pay cash dividends for at least the next several years.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The distribution of dividends may also be limited by the Companies Law, which permits the distribution of dividends only out of retained earnings or earnings derived over the two most recent fiscal years, whichever is higher, provided that there is no reasonable concern that payment of a dividend will prevent a company from satisfying its existing and foreseeable obligations as they become due. Our amended and restated articles of association provide that dividends will be paid at the discretion of, and upon resolution by, our board of directors, subject to the provision of the Companies Law. See &#147;Description of Share Capital&#8212;Dividend and Liquidation Rights.&#148;</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">56</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tC"></a><b>CAPITALIZATION</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table sets forth our cash and cash equivalents and total capitalization as of December 31, 2019. Our capitalization is presented on:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">an actual basis;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a pro forma basis to give effect to the receipt of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pursuant to the exercise of warrants held by certain of our shareholders and the related issuance of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares as a result thereof immediately prior to the closing of this offering; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">on a pro forma as adjusted basis to give further effect to the issuance and sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares by us in this offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">You should read this table in conjunction with our audited consolidated financial statements and related notes as appearing elsewhere in this prospectus and the sections of this prospectus titled &#147;Selected Consolidated Financial Data,&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; included elsewhere in this prospectus.</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.47px; ">&#160;</div></td>
	<td colspan="9" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.47px; padding-right: 0px; "><b>As of December 31, 2019</b></div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.47px; ">&#160;</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.47px; padding-right: 3.47px; "><b>Actual</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.47px; padding-right: 3.47px; "><b>Pro Forma</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.47px; padding-right: 0px; "><b>Pro Forma<br> </b><b>As Adjusted</b><b><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></b></div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.47px; ">&#160;</div></td>
	<td colspan="9" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.47px; padding-right: 0px; "><b>($ in thousands, except share and<br> </b><b>per share amounts)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.47px; ">Cash and cash equivalents</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&nbsp;&nbsp;&nbsp;&#8201;&nbsp;&nbsp;&nbsp;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&nbsp;&nbsp;&nbsp;&#8201;&nbsp;&nbsp;&nbsp;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&nbsp;&nbsp;&nbsp;&#8201;&nbsp;&nbsp;&nbsp;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.47px; ">Shareholders&#8217; equity (deficit):<br> </div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.47px; ">Ordinary Shares, par value NIS 0.01 per share;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares authorized, actual;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares authorized, pro forma and pro forma as adjusted;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares issued and outstanding, actual;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares issued and outstanding, pro forma;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares issued and outstanding, pro forma as adjusted</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.47px; ">Additional paid-in capital<br> </div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.47px; ">Accumulated deficit<br> </div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.47px; ">Total shareholders&#8217; equity </div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.47px; ">Total capitalization</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">$</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">$</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">$</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(1)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">Each $1.00 increase or decrease in the assumed initial public offering price of&#8201; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (which is the midpoint of the price range set forth on the cover page of this prospectus) would increase or decrease the amount of each of cash and cash equivalents, additional paid-in capital, total shareholders&#8217; equity and total capitalization on a pro forma as adjusted basis by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase or decrease of 1.0 million in the number of ordinary shares we are offering would increase or decrease the pro forma as adjusted amount of each of cash and cash equivalents, additional paid-in capital, total shareholders&#8217; equity and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming no change in the assumed initial public offering price and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.</td></tr></table><div style="clear: both"></div>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As of December 31, 2019, we did not have any liabilities. </p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The table above excludes:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">
&#8226;
</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the exercise of options to purchase ordinary shares outstanding under the 2019 Equity Incentive Plan as of December 31, 2019, at a weighted average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share;
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">
&#8226;
</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional ordinary shares reserved for future issuance under our 2019 Equity Incentive Plan as of December 31, 2019;
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">
&#8226;
</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the exercise of warrants to purchase ordinary shares as of December 31, 2019, at a weighted average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which warrants shall not expire upon the closing of this offering if not exercised; and
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">
&#8226;
</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the exercise of options to purchase ordinary shares to be granted to A-Labs Finance and Advisory Ltd, which provided certain consulting services for this offering, at the closing of this offering, at an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share.
</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">57</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tD"></a><b>DILUTION </b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If you invest in our ordinary shares in this offering, your ownership interest will be immediately diluted to the extent of the difference between the initial public offering price per share and the pro forma as adjusted net tangible book value per share after this offering. Our historical net tangible book value as of December 31, 2019 was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Historical net tangible book value per share was calculated by:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">subtracting our liabilities from our tangible assets as of December 31, 2019; and </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">dividing the difference by the number of ordinary shares outstanding as of December 31, 2019. </td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our pro forma net tangible book value as of December 31, 2019 was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. Pro forma net tangible book value per share gives further effect to the receipt of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pursuant to the exercise of warrants to purchase ordinary shares held by certain of our shareholders and the related issuance of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares as a result thereof immediately prior to the closing of this offering.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">After giving effect to the sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares that we are offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (which is the midpoint of the price range set forth on the cover page of this prospectus), after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of December 31, 2019 would have been $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. This amount represents an immediate increase in pro forma net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to our existing shareholders and an immediate dilution in pro forma net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to new investors purchasing ordinary shares in this offering. We determine dilution by subtracting the pro forma as adjusted net tangible book value per share after this offering from the initial public offering price per share paid by new investors in this offering. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table illustrates this dilution on a per share basis:</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr style="background-color: #cceeff;">
	<td colspan="1" width="79%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.47px; ">Assumed initial public offering price per share</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&nbsp;&nbsp;&nbsp;&#8201;&nbsp;&nbsp;&nbsp;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&nbsp;&nbsp;&nbsp;&#8201;&nbsp;&nbsp;&nbsp;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="79%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.47px; ">Historical net tangible book value per share as of December 31, 2019</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&nbsp;&nbsp;&nbsp;&#8201;&nbsp;&nbsp;&nbsp;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="79%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.47px; ">Increase per share attributable to the exercise of warrants to purchase our ordinary shares</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="79%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.47px; ">Pro forma net tangible book value (deficit) per share as of December 31, 2019</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="79%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.47px; ">Increase per share attributable to this offering</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="79%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.47px; ">Pro forma as adjusted net tangible book value per share after this offering</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">$</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="79%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.47px; ">Dilution per share to new investors in this offering</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">$</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A $1.00 increase or decrease in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (which is the midpoint of the price range set forth on the cover page of this prospectus) would increase or decrease the dilution to new investors by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase or decrease of 1.0 million shares in the number of shares offered by us would increase or decrease our pro forma as adjusted net tangible book value per share after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share and decrease or increase the dilution to new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, assuming that the assumed initial public offering price remains the same, and after deducting the estimated underwriting discounts and commissions and the estimated offering expenses payable by us. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If the underwriters exercise their option to purchase additional ordinary shares in full in this offering, the pro forma as adjusted net tangible book value after the offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the increase in net tangible book value per share to existing shareholders would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share and the dilution in net tangible book value per share to new investors would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, in each case assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (which is the midpoint of the price range set forth on the cover page of this prospectus). </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">58</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table summarizes, on a pro forma as adjusted basis, as of December 31, 2019, the differences between the number of shares purchased from us, the total consideration paid to us, and the average price per share that existing shareholders paid during the past five years, on the one hand, and the average price per share that new investors are paying in this offering at the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (which is the midpoint of the price range set forth on the cover page of this prospectus), before deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, on the other hand. </p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.97px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.97px; padding-right: 4.97px; "><b>Ordinary Shares Purchased</b></div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.97px; padding-right: 4.97px; "><b>Total Consideration</b></div></td>
	<td colspan="3" width="13%" rowspan="2" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.97px; padding-right: 0px; "><b>Average Price<br> </b><b>Per Share</b></div></td>
</tr>
<tr>
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.97px; ">&#160;</div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.97px; padding-right: 4.97px; "><b>Number</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.97px; padding-right: 4.97px; "><b>%</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.97px; padding-right: 4.97px; "><b>Amount</b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.97px; padding-right: 4.97px; "><b>%</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.97px; ">Existing shareholders</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&nbsp;&nbsp;&nbsp;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="11%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&nbsp;&nbsp;&nbsp;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.97px; ">New investors</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.97px; ">Total</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">100</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">100</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A $1.00 increase or decrease in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (which is the midpoint of the price range set forth on the cover page of this prospectus) would increase or decrease the total consideration paid by new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million and, in the case of an increase, would increase the percentage of total consideration paid by new investors by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; percentage points and, in the case of a decrease, would decrease the percentage of total consideration paid by new investors by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; percentage points, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same. An increase or decrease of 1.0 million shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase or decrease the total consideration paid by new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and, in the case of an increase, would increase the percentage of total consideration paid by new investors by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; percentage points and, in the case of a decrease, would decrease the percentage of total consideration paid by new investors by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; percentage points, assuming no change in the assumed initial public offering price.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If the underwriters exercise their option to purchase additional ordinary shares in full:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the percentage of ordinary shares held by existing shareholders will decrease to approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of our ordinary shares outstanding after this offering; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the number of shares held by new investors will increase to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , or approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; % of the total number of our ordinary shares outstanding after this offering. </td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The pro forma and pro forma as adjusted information discussed above is illustrative only. Our actual net tangible book value following the completion of this offering is subject to adjustment based on the actual initial public offering price of our ordinary shares and other terms of this offering determined at pricing.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities may result in further dilution to new investors participating in this offering.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The number of our ordinary shares outstanding after this offering is based on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares outstanding as of December 31, 2019 and excludes:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">
&#8226;
</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the exercise of options to purchase ordinary shares outstanding under the 2019 Equity Incentive Plan as of December 31, 2019, at a weighted average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share;
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">
&#8226;
</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional ordinary shares reserved for future issuance under our 2019 Equity Incentive Plan as of December 31, 2019;
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">
&#8226;
</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the exercise of warrants to purchase ordinary shares as of December 31, 2019, at a weighted average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which warrants shall not expire upon the closing of this offering if not exercised; and
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">
&#8226;
</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the exercise of options to purchase ordinary shares to be granted to A-Labs Finance and Advisory Ltd, which provided certain consulting services for this offering, at the closing of this offering, at an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share.
</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">59</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">To the extent any of these outstanding options or warrants are exercised, there will be further dilution to new investors. To the extent all of such outstanding options and warrants had been exercised as of December 31, 2019, the pro forma as adjusted net tangible book value per share after this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , and total dilution per share to new investors would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; .</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">60</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tSC"></a><b>SELECTED CONSOLIDATED FINANCIAL DATA</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following tables set forth our selected consolidated historical financial data which is derived from our audited financial statements, which have been prepared in accordance with U.S. GAAP. The selected statement of operations and balance sheet data for the years ended or as of December 31, 2019 and 2018 have been derived from our audited consolidated financial statements included elsewhere in this prospectus. For periods and at dates prior to the Asset Purchase, our financial statements were prepared based on the historical financial statements of Nanox Gibraltar, with certain adjustments as described under &#147;Basis of Presentation.&#148; You should read this selected consolidated financial data section in conjunction with, and it is qualified in its entirety by, reference to our historical financial information and other information provided in this prospectus including &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our audited consolidated financial statements and related notes included elsewhere in this prospectus. The historical results set forth below are not necessarily indicative of the results to be expected in future periods.</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2px; padding-right: 0px; "><b>Year ended December 31,</b></div></td>
</tr>
<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2px; padding-right: 2px; "><b>2019</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2px; padding-right: 0px; "><b>2018</b></div></td>
</tr>
<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 0px; "><b>($ in thousands, except</b><b> share and</b><br><b> </b><b>per share data)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; "><b>Consolidated Statement of Operations Data:<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Research and development expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">672</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Marketing, general and administrative expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">1,232</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Operating loss</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(1,904</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Financial expenses, net</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">5</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Net loss for the year</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">$</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">$</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(1,909</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Basic and diluted loss per ordinary share<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">$</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">$</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(0.09</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Weighted average number of ordinary shares outstanding&#8201;&#8211;&#8201;basic and diluted<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">20,792,973</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(1)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">Basic loss per share and diluted loss per share are the same because outstanding options would be anti-dilutive due to our net losses in these periods. See Note 9 to our financial statements appearing at the end of this prospectus for further details on the calculation of basic and diluted net loss per share attributable to our ordinary shareholders.</td></tr></table><div style="clear: both"></div>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2px; padding-right: 0px; "><b>As of December 31,</b></div></td>
</tr>
<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2px; padding-right: 2px; "><b>2019</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2px; padding-right: 0px; "><b>2018</b></div></td>
</tr>
<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 0px; "><b>($ in thousands)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; "><b>Consolidated Balance Sheet Data:<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Cash and cash equivalents</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Working capital<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(6,540</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Total assets </div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,855</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Total liabilities</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">8,239</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Accumulated deficit </div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(18,038</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Total shareholders&#8217; deficit</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(6,384</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(1)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">We define working capital as current assets less current liabilities.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">61</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 106-mda -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tMDA"></a><b>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION<br> </b><b>AND RESULTS OF OPERATIONS</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>You should read the following discussion and analysis of our financial condition and results of operations </i><i>together with the &#147;Selected Consolidated Financial Data&#148; section of this prospectus and our consolidated </i><i>financial statements and the related notes included elsewhere in this prospectus. Some of the information </i><i>contained in this discussion and analysis or set forth elsewhere in this prospectus, including information with </i><i>respect to our plans and strategy for our business and related financing, includes forward-looking statements that </i><i>involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#147;Risk </i><i>Factors&#148; section of this prospectus, our actual results could differ materially from the results described in or </i><i>implied by the forward-looking statements contained in the following discussion and analysis.</i></p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Overview</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Early detection saves lives&#8212;and we at Nanox are focused on applying our proprietary medical imaging technology to make diagnostic medicine more accessible and affordable across the globe. Our vision is to increase early detection of medical conditions that are discoverable by X-ray, which we believe is key to increasing early treatment, improving health outcomes and, ultimately, saving lives. </p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">To further our vision, we designed the Nanox.Arc, a medical imaging system incorporating our novel X-ray source, and we are developing the Nanox.Cloud, a companion cloud software. If cleared, we plan to market and deploy the Nanox System broadly across the globe at a substantially lower cost compared to currently available medical imaging systems, such as CT. We believe that, if cleared, our technology&#146;s relatively low cost will enable us to increase accessibility and affordability of early-detection medical imaging systems globally.</p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Since our inception, we have devoted substantially all of our financial resources to acquiring the base technology for our X-ray source and related know-how, conducting research and development activities, organizing and staffing our company, developing our business plan, securing related intellectual property rights and raising capital. We do not have any product approved for sale and have not generated any revenue from product sales. We have funded our operations to date primarily with proceeds from the sale of our ordinary shares and those of our predecessor company. During the years ended December 31, 2018 and 2019, we received net cash proceeds of $3.7 million and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million from the sales of our and our predecessor&#146;s ordinary shares.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have incurred significant operating losses since our inception. Our ability to achieve profitability depends on the successful development and commercialization of our technology and our products. We incurred net losses of $1.9 million and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million for the years ended December 31, 2018 and 2019, respectively. As of December 31, 2019, we had an accumulated deficit of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million. We expect to continue to incur significant expenses for at least the next several years as we advance the Nanox System through further development and regulatory approval. If we obtain marketing approval for the Nanox.Arc, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. In addition, upon the closing of this offering, we expect to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses that we did not incur as a private company.</p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We plan to jumpstart the MSaaS-based medical imaging market by producing and deploying an initial wave of approximately 15,000 Nanox.Arc units. We estimate that effectively stimulating market interest in our Nanox System will require deploying at least 5,000 to 10,000 Nanox.Arc units. In addition, we believe that a minimum installed base of at least 1,000 Nanox.Arc units will be required to support our business during the initial wave of deployment, assuming we enter into at least one licensing agreement on commercially reasonable terms. We expect to incur significant expenses for the manufacture, installation, deployment and maintenance of the Nanox System. As a result, we need substantial funding to support our continuing operations and pursue our business strategy before we can generate significant revenues. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, including collaborations, strategic partnerships or marketing, distribution or licensing arrangements with third parties. We may be unable to raise additional funds or enter into such other agreements </p>

			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">62</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our products or delay our pursuit of potential in-licenses or acquisitions.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As of December 31, 2019, we had cash and cash equivalents of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We believe that the anticipated net proceeds from this offering, together with our existing cash, cash equivalents and short-term investments, will enable us to fund our operating expenses and capital expenditure requirements for at least the next &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; months. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our capital resources sooner than we expect. See &#147;&#8212;Liquidity and Capital Resources.&#148; </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Asset Purchase</b></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Company (NANO-X IMAGING LTD), an Israeli limited liability company, was formed on December 20, 2018. Pursuant to the Asset Purchase Agreement, as amended on December 3, 2019 and December 31, 2019, substantially all of the assets of Nanox Gibraltar, including all patents, patent applications and all other intellectual property rights, but not including the shares of Nanox Japan, Inc., a wholly owned subsidiary of Nanox Gibraltar (&#147;Nanox Japan (predecessor)&#148;), were sold to the Company for an aggregate consideration of $13.2 million, reflecting the fair market value of the transferred assets, which was estimated to be $6.1 million (excluding cash) based on an independent valuation report, plus the cash balance less $200,000, which totaled $7.1 million as of the date of the Asset Purchase Agreement. </p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the terms of the Asset Purchase Agreement, the consideration for the transferred assets will be paid only on the occurrence of one of the following events: (a) the closing of a transaction involving the sale of all or substantially all of the Company&#146;s assets; (b) the acquisition of the Company by, or the merger of the Company with, another entity, consolidation, reorganization, recapitalization, sale, assignment or disposal by the Company of all or substantially all of the issued and outstanding shares of the Company; (c) the transfer, sale, lease, grant or other disposition of or the grant of an exclusive license over all or substantially all of Company&#146;s assets, including, but not limited to, intellectual property, with the same economic effect to that of a sale and/or cessation of its business; (d) any other transaction, except for a financing round, following which the shareholders of the Company prior to the closing of such transaction own, directly or indirectly, less than 50% of the voting power of the surviving entity; (e) the closing of the first underwritten public offering of the Company pursuant to a registration statement under the Securities Act or the Israeli Securities Law, 5728-1968, as amended (or under equivalent securities law of another jurisdiction) or any other securities laws world-wide with the same effects and results; and (f) an equity financing of the Company at a minimum pre-money valuation of $100.0 million, with proceeds to the Company of at least $30.0 million. In the events of (e) or (f) above, the Company will have the option to pay the consideration in cash or by the issuance to Nanox Gibraltar of the Company&#146;s securities of the same series to be issued upon such event, in an amount reflecting a 25% discount on the price per share to be determined in connection with (e) and (f) above. If the Company elects to pay such consideration in cash, Nanox Gibraltar will have the right, at its sole discretion and in good faith, to reject such payment in cash, and require that the Company pay such consideration in the form of the Company&#146;s securities in such amount and with such discount described above. In connection with this, the Company recorded a related party liability in an amount of $8.2 million in its financial statements as of and for the year ended December 31, 2018. </p>

				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Components of Our Results of Operations</b></p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>Revenue</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As of the date of this prospectus, we have not generated any revenue from product sales or otherwise. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">63</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Operating Expenses</b></i></p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Research and Development Expenses</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The table below summarizes our research and development expenses incurred during the periods presented:</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 8.21px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 8.21px; padding-right: 0px; "><b>Year ended December 31,</b></div></td>
</tr>
<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 8.21px; ">&#160;</div></td>
	<td colspan="3" width="15%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 8.21px; padding-right: 8.21px; "><b>2019</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 8.21px; padding-right: 0px; "><b>2018</b></div></td>
</tr>
<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 8.21px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 8.21px; padding-right: 0px; "><b>($ in thousands</b><b>)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 8.21px; "><b>Research and Development Expenses:<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="12%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 8.21px; ">R&amp;D - direct costs, laboratory expenses and other</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="12%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">519</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 8.21px; ">R&amp;D - salaries and wages</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="12%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">131</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 8.21px; ">Patent registration</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="12%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">22</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 8.21px; ">Total </div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">$</div></td><td width="12%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">$</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">672</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Research and development expenses consist primarily of costs incurred in connection with the research and development of our products. These expenses include: </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">expenses incurred in connection with the development of our products, including payments made pursuant to agreements with third parties, such as outside consultants related to process development and manufacturing activities, as well as patent registrations;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">costs of manufacturing components and materials, including payments made pursuant to agreements with third parties;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">costs of laboratory supplies incurred for each program;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">facilities, depreciation and other expenses, including direct or allocated expenses for rent and maintenance of facilities, as well as insurance costs; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">costs related to compliance with regulatory requirements; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">employee-related expenses, including salaries, related benefits and share-based compensation expenses for employees engaged in research and development activities.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our suppliers and service providers. Upfront payments, milestone payments (other than those deemed contingent consideration in a business combination) and annual maintenance fees under license agreements are expensed in the period in which they are incurred.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Research and development activities are central to our business. We expect that our research and development expenses will increase substantially over the next several years as we continue development of the Nanox System. We expect to continue to devote a substantial portion of our resources to the Nanox.Arc hardware, the Nanox.Cloud software and our underlying technology for the foreseeable future.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The successful development and commercialization of our products are highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the development of any of our products. This uncertainty is due to the numerous risks and uncertainties associated with product development and commercialization, including the uncertainty of:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the timing and progress of development activities;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to maintain our current research and development programs and to establish new ones;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the receipt of regulatory approvals from applicable regulatory authorities without the need for independent clinical trials or validation;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the timing, receipt and terms of any marketing approvals from applicable regulatory authorities;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to establish new licensing or collaboration arrangements;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the performance of our future collaborators, if any;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">64</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">launching commercial sales of our products, including the Nanox.Arc hardware and Nanox.Cloud software, whether alone or in collaboration with others; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">maintaining a continued acceptable safety profile of the products following approval.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Any changes in the outcome of any of these variables with respect to the development of our products could result in a significant change in the costs and timing associated with the development of these products. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials or other testing beyond what we currently expect, we could be required to expend significant additional financial resources and time to complete development of our products. We may never obtain regulatory approval for any of our products and third parties may never obtain regulatory approvals for any products containing our technology.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Marketing, General and Administrative Expenses</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Marketing expenses consist of public relations and general marketing expenses. General and administrative expenses consist primarily of salaries, related benefits and share-based compensation expense for personnel in executive, finance and administrative functions. General and administrative expenses also include facilities, depreciation and other expenses, which include direct or allocated expenses for rent and maintenance of facilities and insurance, as well as professional fees for legal, patent, consulting, investor and public relations, accounting and audit services. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We anticipate that our marketing, general and administrative expenses will increase as we increase our headcount to support our continued research activities and development of our products. Following the completion of this offering, we also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance, director and officer insurance and investor and public relations costs associated with being a public company.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Results of Operations</b></p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Research and Development Expenses</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Research and development expenses were $0.7 million for the year ended December 31, 2018.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Marketing, General and Administrative Expenses</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Marketing, general and administrative expenses were $1.2 million for the year ended December 31, 2018. Personnel-related costs for the year ended December 31, 2018 did not include any share-based compensation expense. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Liquidity and Capital Resources</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Since our inception, we have not generated any revenue from product sales or otherwise, and have incurred significant operating losses and negative cash flows from our operations. We have not yet commercialized any products or technologies, and we do not expect to generate revenue from sales of any products for several years, if at all. We have funded our operations to date primarily with proceeds from the sale of our and our predecessor company&#146;s ordinary shares.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Cash Flows</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table provides information regarding our cash flows for the periods presented:</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.37px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 7.37px; padding-right: 0px; "><b>Year ended December 31,</b></div></td>
</tr>
<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.37px; ">&#160;</div></td>
	<td colspan="3" width="15%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 7.37px; padding-right: 7.37px; "><b>2019</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 7.37px; padding-right: 0px; "><b>2018</b></div></td>
</tr>
<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.37px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 7.37px; padding-right: 0px; "><b>(U.S. Dollars in thousands)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.37px; ">Net cash provided by operating activities</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="12%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">13</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.37px; ">Net cash used in investing activities</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="12%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(73</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.37px; ">Net change in cash and cash equivalents</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="12%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(60</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Net Cash Provided by Operating Activities</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">During the year ended December 31, 2018, net cash provided by operating activities was $13,000, resulting from our net loss of $1.9 million, adjusted for non-cash charges and changes in components of working capital of $1.9 million. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">65</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Net Cash used in Investing Activities</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">During the year ended December 31, 2018, net cash used in investment activities was $73,000, primarily due to purchases of property, equipment and software.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Going Concern Consideration </b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our consolidated financial statements included elsewhere in this prospectus contain a going concern qualification. We are an early-stage company and have accumulated significant losses. Furthermore, we have a limited operating history and a history of negative cash flow from operating activities. Our ability to continue as a going concern is dependent upon our ability to raise additional capital, our ability to successfully develop and commercialize our technology and our products, and our ability to achieve sustainable revenues and profitable operations. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Funding Requirements</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of the Nanox System and seek marketing approval for this product. In addition, upon the closing of this offering, we expect to incur additional costs associated with operating as a public company. Our expenses will also increase if, and as, we:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">seek regulatory approvals for any additional products;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">seek to discover and develop additional products;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">establish a manufacturing, sales, marketing, medical affairs and distribution infrastructure to commercialize the Nanox System for which we may obtain marketing approval and intend to commercialize on our own or jointly;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">hire additional quality control and scientific personnel;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">expand our operational, financial and management systems and increase personnel, including personnel to support our clinical development, manufacturing and commercialization efforts and our operations as a public company;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">maintain, expand and protect our intellectual property portfolio; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">acquire or in-license other products and technologies.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We believe that the anticipated net proceeds from this offering, together with our existing cash, cash equivalents and short-term investments, will enable us to fund our operating expenses and capital expenditure requirements for at least the next &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;months. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Because of the numerous risks and uncertainties associated with manufacture, research, development and commercialization of products, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on, and could increase significantly as a result of, many factors, including:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the scope, progress, results and costs of researching and developing the Nanox System;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the costs, timing and outcome of regulatory review of the Nanox.Arc;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution, for the Nanox System for which we receive marketing approval;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">commercial manufacturing of the Nanox System and sufficient inventory to support commercial launch;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the revenue, if any, received from commercial sale of the Nanox System, should the Nanox.Arc receive marketing approval;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the cost and timing of hiring new employees to support our continued growth;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">66</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the ability to establish and maintain collaborations on favorable terms, if at all; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the timing, receipt and amount of sales of the Nanox System, if any.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A change in any of these or other variables with respect to the development of any of our products could significantly change the costs and timing associated with the development of that product. Further, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans. See &#147;&#8212;Going Concern Consideration.&#148;</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic partnerships or marketing, distribution or licensing arrangements with third parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect your rights as an ordinary shareholder. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specified actions, such as incurring additional debt, making capital expenditures or declaring dividends. In addition, debt financing would result in increased fixed payment obligations.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If we raise funds through collaborations, strategic partnerships or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or products or grant licenses on terms that may not be favorable to us.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If we are unable to raise additional funds when needed, we may be required to delay, reduce or eliminate our product development or future commercialization efforts, or grant rights to develop and market products that we would otherwise prefer to develop and market ourselves.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Contractual Obligations and Commitments</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table summarizes our contractual obligations as of December 31, 2019 and the effects that such obligations are expected to have on our liquidity and cash flows in future periods:</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.16px; ">&#160;</div></td>
	<td colspan="15" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.16px; padding-right: 0px; "><b>Payment due by period</b></div></td>
</tr>
<tr>
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 5.16px; "><b>Contractual Obligations</b></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 5.16px; padding-right: 5.16px; "><b>Total</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 5.16px; padding-right: 5.16px; "><b>Less than<br></b><b>1 year</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 5.16px; padding-right: 5.16px; "><b>1-3 years</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 5.16px; padding-right: 5.16px; "><b>3-5 years</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 5.16px; padding-right: 0px; "><b>More than<br></b><b>5 years</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.16px; ">Capital (Finance) Lease Obligations</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.16px; ">Operating Lease Obligations</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.16px; ">Purchase Obligations</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.16px; ">Total</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have entered into contracts in the normal course of business with third parties. These contracts do not contain any minimum purchase commitments and are cancelable by us upon prior notice and, as a result, are not included in the table of contractual obligations and commitments above. Payments due upon cancellation consist only of payments for services provided and expenses incurred, including non-cancelable obligations of our service providers, up to the date of cancellation. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Critical Accounting Policies and Significant Judgments and Estimates</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">While our significant accounting policies are described in more detail in Note 2 to our consolidated financial statements appearing elsewhere in this prospectus, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">67</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Use of Estimates in the Preparation of Financial Statements</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates and such differences may have a material impact on our financial statements. As applicable to the financial statements, the most significant estimates relate to fair value of share-based payments and the fair value of the liability to related party.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Functional Currency</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The U.S. dollar is the currency of the primary economic environment in which our operation is conducted. Revenues and substantial portion of the operational costs are denominated in U.S. dollars. Accordingly, our functional currency is the U.S. dollar (&#147;primary currency&#148;). </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Foreign currency assets and liabilities are translated into the primary currency using the exchange rates in effect on the consolidated balance sheet date. Equity accounts are translated at historical rates, except for the change in accumulated deficit during the year, which is the result of the income statement translation process. Revenue and expense accounts are translated using the weighted average exchange rates during the period. Currency transaction gains and losses are presented in financial expenses, as appropriate.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Cash and Cash Equivalents</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We consider all short-term, highly liquid investments as cash equivalents, which include short-term bank deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Property, Equipment and Software</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Property, equipment and software are stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated on a straight-line basis over the following estimated useful lives:</p>
				<table align="60" width="70%" style="margin-top: 4px; margin-left: 12%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.23px; ">&#160;</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.23px; padding-right: 0px; "><b>%</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.23px; ">Computers and software</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">10-33</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.23px; ">Office furniture and equipment</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">10-20</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Impairment of Long-Lived Assets</b></i><i><b> </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We test long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the long-lived asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the sum of the expected undiscounted cash flow is less than the carrying amount of the asset, we recognize an impairment loss, which is the excess of the carrying amount over the fair value of the asset, using the expected future discounted cash flows.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As of December 31, 2018, we did not recognize an impairment loss on its long-lived assets.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Legal and Other Contingencies</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Certain conditions, such as legal proceedings, may exist as of the date that the consolidated financial statements are issued and may result in a loss to us, but that will only be resolved when one or more future events occur or fail to occur. In assessing loss contingencies related to legal proceedings that are pending against us or unasserted claims that may result in such proceedings, our management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought. Such assessment inherently involves an exercise of judgment. Legal fees are expensed as incurred.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our management applies the guidance in ASC 450-20-25 when assessing losses resulting from contingencies. If the assessment of a contingency indicates that it is probable that a material loss would be </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">68</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">incurred and the amount of the liability can be estimated, then we would record an accrued expense in our financial statements based on its best estimate. Loss contingencies considered to be remote by management are generally not disclosed unless material. We are currently not a party to any material legal proceedings and are not aware of any pending or threatened material legal proceedings against us.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Research and Development Expenses</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Research and development expenses are charged to the statement of operations as incurred. </p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Income Tax</b></i><i><b> </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We account for income taxes in accordance with ASC 740, &#147;Income Taxes&#148; (&#147;ASC 740&#148;). ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We provide a valuation allowance, if necessary, to reduce deferred tax assets to the assets&#146; estimated realizable value if it is more likely than not that a portion or all of the deferred tax assets will not be realized, based on the weight of available positive and negative evidence. Deferred tax liabilities and assets are classified as non-current in accordance with ASU 2015-17.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Taxes that would apply in the event of disposal of investments in our subsidiary have not been taken into account in computing the deferred income taxes, as it is our intent and ability to hold these investments.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We account for uncertain tax positions in accordance with ASC 740-10. ASC 740-10 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative probability) likely to be realized upon ultimate settlement. We accrue interest and penalties related to unrecognized tax benefits under taxes on income (tax benefit). </p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Share-Based Compensation</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We account for stock-based compensation under ASC 718, &#147;Compensation&#8212;Stock Compensation,&#148; which requires the measurement and recognition of compensation expense based on estimated fair values for all share-based payment awards made to employees and directors.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant. The Company uses the Black-Scholes-Merton option-pricing model as part of such estimation. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We account for equity instruments issued to non-employees in accordance with the provisions of ASC 505-50, which requires that such equity instruments be recorded at their fair value on the measurement date on an accrual basis. The standard requires adjusting the unvested fair value of the share options at each balance sheet date such that the expense recognized is equal to the fair value of the vested award at the time the performance is complete, which is typical upon vesting. </p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Loss per Share</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Basic earnings per share are computed by dividing net income (loss) attributable to our ordinary stockholders by the weighted average number of ordinary shares outstanding for the reporting periods. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In computing our diluted earnings per share, the denominator for diluted earnings per share is a computation of the weighted-average number of ordinary shares and the potential dilutive ordinary shares outstanding during the period. Potential dilutive stock outstanding include the dilutive effect of in-the-money options using the treasury stock method.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Fair Value Measurement</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">69</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows: </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">Level 1:</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">Level 2:</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">Level 3:</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. </td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>JOBS Act</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The JOBS Act permits an &#147;emerging growth company&#148; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected not to &#147;opt out&#148; of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either (i) irrevocably elect to &#147;opt out&#148; of such extended transition period or (ii) no longer qualify as an emerging growth company. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Internal Control Over Financial Reporting</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In connection with the audit of our financial statements as of and for the year ended December 31, 2018, we identified a material weakness in our internal control over financial reporting. The material weakness is related to having an insufficient number of financial reporting personnel with an appropriate level of knowledge, experience and training in application of U.S. GAAP and SEC rules and regulations commensurate with our reporting requirements.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have taken action toward remediating this material weakness by hiring additional qualified personnel with U.S. GAAP accounting and reporting experience, and intend to provide enhanced training to existing financial and accounting employees on related U.S. GAAP issues. However, the measures we have taken to date and are continuing to implement may not be sufficient to remediate the material weakness we have identified or avoid potential future material weaknesses. If the steps we take do not correct the material weakness in a timely manner, we will be unable to conclude that we maintain effective internal control over financial reporting. Accordingly, there could continue to be a reasonable possibility that a material misstatement of our financial statements would not be prevented or detected on a timely basis. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Off-Balance Sheet Arrangements</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Recently Issued Accounting Pronouncements</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our consolidated financial statements, included elsewhere in this prospectus.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Quantitative and Qualitative Disclosures </b><b>A</b><b>bout Market Risks</b></p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>Interest Rate Risk</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As of December 31, 2019, we had cash equivalents consisting primarily of U.S. Dollar bank deposits. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. Consequently, changes in market interest rates would not have a material impact on our financial position or results of operations.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">70</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As of December 31, 2019, we had no debt outstanding and are therefore not exposed to interest rate risk with respect to the cost of servicing and repaying debt.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Inflation-related </b></i><i><b>R</b></i><i><b>isks</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We do not believe that the rate of inflation in Israel has had a material impact on our business to date, however, our costs in Israel will increase if the inflation rate in Israel exceeds the devaluation of the NIS against the U.S. dollar or if the timing of such devaluation lags behind inflation in Israel.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Foreign Currency Exchange Risk</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our statements of operations and cash flows could be adversely affected in the future due to changes in foreign exchange rates. We expect to have cash and cash equivalents denominated in U.S. Dollars. As a result, changes in foreign currency exchange rates would not have a material impact on our financial position or results of operations. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">71</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 107-bus -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tB"></a><b>BUSINESS</b></p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Overview</b><b> </b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Early detection saves lives&#8212;and we at Nanox are focused on applying our proprietary medical imaging technology to make diagnostic medicine more accessible and affordable across the globe. Our vision is to increase early detection of medical conditions that are discoverable by X-ray, which we believe is key to increasing early treatment, improving health outcomes and, ultimately, saving lives.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As a first step to producing a new class of affordable medical imaging systems, we have focused on identifying and developing a novel X-ray source. Our X-ray source is based on a novel digital MEMs semiconductor cathode that we believe can achieve the same functionalities as legacy X-ray analog cathodes, while allowing for lower-cost production than existing medical imaging systems. We developed this technology over eight years to reach commercial applicability. This novel digital X-ray source is the basis of core technology in the Nanox.Arc, the imaging system we are developing, and we believe it also has the potential to replace the legacy X-ray source in other existing imaging systems.</p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our solution, which we refer to as the Nanox System, has two integrated components&#8212;hardware (Nanox.Arc) and software (Nanox.Cloud). We are developing a prototype of the Nanox.Arc, a medical imaging system incorporating our novel digital X-ray source. Subject to receiving regulatory clearance, the first version of the Nanox.Arc will be a 3D tomosynthesis imaging system. Tomosynthesis is an imaging technique widely used for early detection, that is designed to produce a high-resolution, 3D X-ray image reconstruction of the scanned human body part for review by a professional diagnostics expert. In parallel, we are developing Nanox.Cloud, a companion cloud-based software that is designed to provide an end-to-end medical imaging service, including services such as image repository, radiologist matching, online and offline diagnostics review and annotation, connectivity to diagnostic assistive AI systems, billing and reporting. The Nanox System is designed to enable MSaaS to improve accessibility and affordability of early-detection services worldwide.</p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If cleared, we plan to market and deploy the Nanox System globally at a substantially lower cost than currently available medical imaging systems, such as CT, because our digital X-ray source will allow the Nanox.Arc to have a more simplified structure without the costly cooling equipment or the complex rotating mechanism used in legacy CT devices. See &#147;&#8212;Our Technology&#8212;The Nanox System.&#148; We believe that the Nanox System could increase the accessibility and affordability of early-detection medical imaging systems worldwide.</p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As we continue to develop the Nanox.Arc, we expect to take a multi-step approach to the regulatory clearance process. As a first step, we plan to submit a 510(k) application for a single-source version of the Nanox.Arc to the FDA in January 2020. If we receive FDA clearance, we will continue to optimize and develop further features of the Nanox.Arc, and plan to submit additional 510(k) applications to the FDA with respect to the Nanox.Arc. We believe that neither our novel digital X-ray source nor the Nanox.Cloud will require regulatory approval or clearance. However, to date, we have not obtained feedback from the FDA regarding our regulatory strategy. We plan to introduce a working prototype of the Nanox.Arc in and, if cleared, we plan to deploy the first Nanox.Arc in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, with wide deployment expected to be achieved in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </p>

				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Limitation of Current Medical Imaging Systems and Our Market Opportunity</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The main categories of current medical imaging systems that use X-ray sources include CT, mammography, fluoroscopy, angiogram and dental. The analog X-ray source used by these systems produces X-rays by accelerating electrons to high energies, causing them to hit a metal target from which the X-rays are emitted. This requires a significant amount of electrical energy to be transferred to the X-ray tube. Due to the heat generated by this process, one of the most complex mechanical challenges is cooling the analog X-ray source. In addition, for CTs, the mechanical structure is even more complex because the analog X-ray source needs to rotate in a heavy gantry at high speed. We believe these are key factors leading to the high cost and complexity of existing medical imaging systems, which in turn significantly limits the availability of medical imaging for early detection globally. According to a report from the Pan-American Health Organization and WHO in 2012, approximately two-thirds of the world population did not have access to medical imaging, while many people with access to medical imaging face substantial wait times for scanning.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, most market participants, including medical imaging manufacturing companies, medical imaging providers and radiologists, among others, have not provided the same level of end-to-end medical imaging </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">72</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">services. One of the reasons is that the scanning process is currently not integrated with the diagnostics process, which contributes to extended wait times for image diagnostics by experts.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We estimate that the total annual capital expenditures on existing X-ray-based medical imaging systems, not including support, maintenance, insurance and ancillary services, will reach approximately $21 billion by 2021, which we believe represents a significant market opportunity for the Nanox System. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Our Solution</b><b> </b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We believe the Nanox System addresses the limitations of existing medical imaging systems on three levels:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
<b>Digital X-ray source with the potential to significantly reduce the costs of medical imaging </b><b>systems</b>. We believe our digital X-ray source technology will allow us to manufacture the Nanox.Arc, if cleared, at substantially lower costs compared to medical imaging systems that use a legacy analog X-ray source without sacrificing imaging quality. The availability of a lower cost device has the potential to substantially increase medical imaging availability and improve accessibility of early-detection services broadly across the globe.
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Technology designed to improve upon the industry standard with integrated radiology diagnostics </b><b>via a cloud-based MSaaS platform</b>. The Nanox.Arc employs our novel digital X-ray source that is designed to be energy-efficient, smaller and can be more precisely controlled compared to existing X-ray source. By integrating the Nanox.Cloud, we believe the Nanox System could provide a streamlined process where each scanned image is uploaded automatically to the cloud system and matched to a human radiology expert and decision assistive AI algorithms to provide scan reviews and diagnostics in a significantly shorter time frame than current diagnostics, which could substantially reduce wait-times for imaging results and increase early detection rates compared to currently employed imaging process protocols.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Business model designed to increase the availability of medical imaging</b>. Our primary business model is based on a pay-per-scan pricing structure as opposed to the existing capital expenditure-based business model of existing medical imaging manufacturing companies. We believe our business model will significantly reduce the price per scan compared to the current global average cost of $300 per scan, and has the potential to commoditize medical imaging services at prices that are affordable to a greater number of people. </td></tr></table><div style="clear: both"></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Our Strategy</b><b> </b></p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
<b>Secure regulatory clearance for </b><b>our medical imaging system</b>. We expect to take a multi-step approach to the regulatory clearance process. As a first step, we plan to submit a 510(k) application to the FDA in January 2020. If we receive FDA clearance, we will continue to optimize and develop further features of the Nanox.Arc, and plan to submit additional 510(k) applications to the FDA with respect to the Nanox.Arc.
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
<b>Jumpstart the MSaaS-based medical imaging market with strategic partnerships</b>. We plan to produce and deploy an initial wave of approximately 15,000 Nanox.Arc units over &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to jumpstart the MSaaS-based medical imaging market. We are in negotiations with global manufacturers to begin commercial production and assembly of the Nanox.Arc and with strategic regional partners for the deployment, operation and marketing of the Nanox System broadly across the globe, including in the United States, certain Asian countries and the rest of the world, including the EU and Africa. We plan to work with these partners to achieve local integrations into health maintenance organizations, electronic health record systems, payment methods and insurance coverage companies. In addition, we are also actively seeking collaboration opportunities with leading cloud-based enterprises, as we anticipate an industry shift to a digital and cloud-based subscription model will bring more digital healthcare disruptors into the market.
</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">73</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Maximize the commercial potential of our technology with simultaneous business models</b>. We plan to commercialize our novel X-ray source technology by pursuing three simultaneous business models, which we believe will provide us the flexibility and long-term sustainability to monetize our technology.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><i>Subscription Model:</i> In certain countries, if permitted by the laws in the applicable jurisdiction, our primary sales strategy will be based on a pay-per-scan pricing structure, where we expect to sell the Nanox System at low cost or at no cost, with a suggested retail price per scan that is substantially lower than the current global average charge, and receive a portion of the proceeds from each scan as the right-to-use licensing fee.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><i>Sales Model:</i> In certain countries, to accommodate specific local regulatory requirements, we expect to sell the Nanox.Arc for a one-time charge at a price that is substantially less than current market offerings.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><i>Licensing Model:</i> For certain medical imaging market participants, we plan to tailor our X-ray source technology to their specific imaging systems to replace the legacy X-ray source. We expect to charge a one-time licensing fee upfront and receive recurring royalty payments for each system sold.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Leverage the Nanox System to bring added value to our collaborators</b>. We expect that the Nanox System will enable us to accumulate a significant number of medical images, which have the potential to be used by collaborators, such as medical AI-analytics companies, through machine learning algorithms to increase the probability of early disease detection. </td></tr></table><div style="clear: both"></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Our Technology</b></p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>Legacy Analog X-ray Source and Limitations of Existing Medical Imaging Systems</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The X-ray tube technology has essentially remained unchanged since its inception in 1895. For any type of imaging system to generate X-rays, the system must use X-ray tubes as a source for the X-rays. The X-ray tube converts electrical power into X-rays by accelerating electrons to high energies, causing them to hit a metal target from which the X-rays are emitted. X-rays can only be produced if the X-ray tube is energized, which has historically required a significant amount of electrical energy to be transferred to the X-ray tube. However, only a small amount of the energy deposited into the X-ray tube is actually converted into X-rays; the majority of the energy turns into heat. This is called a thermionic (heat-based) mode of operation where a metal filament needs to be heated up to approximately 2,000&#176;C to generate the electron stream (a &#147;cathode&#148;) that will hit a metal target (an &#147;anode&#148;) to generate the photon-based X-ray stream resulting from that high-energy impact. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Heating the filament to approximately 2,000&#176;C requires the mechanical cathode support systems to withstand high temperatures within a high vacuum, high voltage environment. Tungsten was introduced into the X-ray tube in 1903 for its properties of a high melting point and ductility. The tungsten filaments still used today are critical components of X-ray tubes, but they limit the lifetime of the X-ray tube due to the progressive evaporation of filament material under these high temperatures. At temperatures of up to 2,000&#176;C, the filament evaporates in a hot spot close to the peak temperature location which over time can cause a catastrophic failure of the filament.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We believe that the use of the legacy analog X-ray source is one of the key factors for the high cost of existing medical imaging systems. The main categories of medical imaging systems that use X-ray sources include CT (3D cross-sectional 360&#176; &#147;slicing&#148; X-ray imaging), mammography (2D and 3D breast X-ray imaging), fluoroscopy (real-time X-ray video imaging), angiogram (blood vessels, contrast X-ray imaging) and dental (2D and panoramic X-ray imaging). CT scanners, for example, are complex diagnostic imaging systems that use X-rays to take pictures of a patient&#146;s internal structures and organs. Due to the limitations of the analog X-ray source described above, general radiographic X-ray tubes are not well suited for use in a CT scanner. CT scanners instead use a specialized X-ray tube designed to withstand the excessive amount of heat produced by continuous energization. This X-ray tube is located in the gantry, which is the largest part of a CT scanner and consists of the X-ray detectors, the mechanical supports and the scanner housing. Due to the heat generated by this process, one of the most complex mechanical challenges is cooling the analog X-ray source while rotating it in a heavy gantry at high-speed. One solution used is the rotating anode, where a tungsten metal disk rotates at high revolutions per minute so the electron beam hits a different spot on the disk on a continuous basis to prevent the concentration of heat in one spot on the disk and reduce the likelihood of </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">74</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">overheating or burning. In addition, CT scanners require a long continuous exposure time to create 3D photographs of the patient&#146;s body using multiple X-ray images, which means that the X-ray tube must be continually energized and that patients are continuously exposed to radiation throughout that period. As a result of these complexities, most high-quality X-ray tubes for a CT scanner weigh between approximately 50 and 100 kilograms with the cooling mechanism and generally cost over $150,000 each.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>Our Novel </b></i><i><b>Digital </b></i><i><b>X-ray Source</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Realizing that the X-ray tube technology has essentially not changed in more than 100 years and remains a significant source of complexity and cost-driver of existing X-ray-based medical imaging systems, we developed a novel digital X-ray source that we believe addresses these drawbacks and will enable a new class of medical imaging systems that can be produced at a significantly lower cost than the existing systems. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our technology has its roots in field emission display (&#147;FED&#148;) technology. FED technology was originally developed by Sony with other technology partners, for television screens and monitors, offering a novel way of lighting screen pixels compared to traditional cathode-ray tubes that were based on a one-source electron gun beam. The field emission display innovation used multiple nano-scale electron guns to achieve a much higher quality image with significantly reduced motion blur effects. In 2009, after having invested substantial resources in the development of this technology for over a decade including through a joint venture called Field Emission Technologies, Inc. (&#147;FET&#148;), Sony ceased development of the project.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In 2009, FET dissolved and transferred certain assets to FET Japan Inc. (&#147;FETJ&#148;). Scientists on our team, who worked at FETJ, applied their expertise to develop non-display related applications, including our X-ray source technology. In 2011, our predecessor company acquired certain non-display related know-how from FETJ and certain members of the FETJ technical team joined us.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">After acquiring the technology, we spent over eight years developing a digital X-ray source for the medical imaging industry that could be produced on a commercial scale. Our X-ray source is a MEMs-based semiconductor cathode that achieves electron emission by a non-thermionic low-voltage trigger to approximately 100 million nano-scale molybdenum cones that act as multiple electron &#147;guns,&#148; instead of a single heated filament. The cathode is housed in a customized X-ray tube. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We believe our X-ray source has the following technological advantages over the analog X-ray source:</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Reduced </i><i>duration of </i><i>radiation exposure</i>. Our X-ray source uses a digital chip that is designed to provide better control and enables near-instantaneous on/off toggling of the electron beam. This source control also enables a precise &#147;stop and start&#148; operation, which we believe can potentially result in significantly reduced duration of radiation exposure compared to an analog X-ray source that exposes patients to continuous radiation exposure. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Multi-spectral imaging capacity using one X-ray source</i>. Our X-ray source is designed to create multi-spectral imaging using one X-ray source chip because there is complete independence and separation between the strength of X-ray penetration and the amount of photons for illumination (referred to as &#147;KvP / MA&#148;). KvP represents the speed of electrons that gives the X-ray its penetrating power, and higher KvP means the X-rays can penetrate higher density materials such as bones. MA represents the amount of photons or brightness levels of the X-ray image. For legacy X-ray sources, KvP / MA ratios were codependent in a linear relationship and each X-ray source could only produce one set of KvP / MA combinations dedicated for a particular use (for example, either tissue images or bone images, but not both simultaneously). We believe our X-ray source technology can produce multi-spectral imaging from one X-ray source, which allows for variable energy levels to be controlled during one scan. With multi-spectral imaging, one source chip can be used for </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">75</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">multiple types of scans, such as head-scans, abdomen, mammography and angiograms, involving both soft and hard tissues at variable densities, simultaneously. We believe this multi-spectral imaging could also be applied to real-time video imaging. The image below is a general illustration of the functionality and capability of multi-spectral imaging. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10006151x2_graphic7.jpg" alt="" style="height: 334.40px; width: 592.80px; scale: ">&#8201;<br></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Higher frequency use over a longer lifetime</i>. Our X-ray source is based on a field of multiple electron guns on our MEMs-based cathode that spread the load of electron generation among many &#147;producers&#148; compared to a single filament that heats to a high temperature in the analog X-ray tube. As a result, our digital X-ray source is designed to shoot an electron beam at different locations on a stationary anode during each duty cycle without the need for the complex, high precision rotating mechanism. In addition, the near instant on/off toggling feature of our digital X-ray source is designed to allow us to reduce the duration of each operation. As a result, we believe our medical imaging system will have higher stability and a longer lifetime, with a longer mean time between failures. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Simplified hardware structure</i>. Because our X-ray source is designed to direct an electron beam at different locations for each duty-cycle as described above, we are able to have multiple stationary tubes arranged around the patient as opposed to one tube that rotates around the patient. We believe this could reduce the complexity and cost of the Nanox.Arc compared to legacy CT devices. In addition, the current approach to increase durability of the tungsten anode in CT devices, the rotating anode mechanism discussed above, requires both a significant increase in tube size and cost to allow for the complex movements of the components. In contrast, we believe by using our X-ray source we will be able to significantly reduce the size of X-ray tubes and simplify the structure of our medical imaging system.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We believe our X-ray source has the potential to replace the legacy X-ray source in other existing imaging systems, as well as the X-ray source in systems used in other industries, such as security scanners. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">76</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>The </b></i><i><b>Nanox System</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Nanox System has two integrated components &#8212; hardware (Nanox.Arc) and software (Nanox.Cloud).</p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are developing a prototype of the Nanox.Arc, a medical device that integrates our proprietary and novel X-ray source. Subject to receiving regulatory clearance, the first version of the Nanox.Arc is expected to be a 3D tomosynthesis imaging system that produces a 3D reconstruction of the scanned human body part, as illustrated in the image below. The Nanox.Arc, using our X-ray source, is being designed to produce partial and full-body scans, with remote operation capability, and to have a full 15 to 130 KvP energy range with up to 240 MA, multi-spectral imaging range, as well as quiet operation, cloud connectivity and standard compliance safety mechanisms. It is being designed for easy setup and operation with multiple stationary X-ray tubes arranged around the patient. The substantial majority of operational software that we anticipate will be used to run the Nanox.Arc will be cloud-computing based and integrated with the Nanox.Cloud, as further explained below.</p>

				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10006151x2_graphic3.jpg" alt="" style="height: 213.33px; width: 388.27px; scale: ">&#8201;<br></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition to the Nanox.Arc, we are developing the Nanox.Cloud, a companion cloud software that will allow for the delivery of medical screening as a service. With the Nanox.Cloud, we anticipate that the high-cost components of existing medical imaging systems, such as analytics and computing software that are traditionally installed via multiple licenses on-premise and on a per-system basis, will become centralized through the cloud. We believe this will significantly reduce on-going software and IT licensing costs and enable a wide range of functionalities, such as per-body-part vertical analysis, multiple AI diagnostics and remote support. The Nanox.Cloud is also expected to be able to provide an end-to-end medical imaging service, including services such as image repository, radiologist matching, online and offline diagnostics review and annotation, connectivity to medical imaging AI systems and billing and reporting. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A reliable and streamlined, post-scan imaging service is central to the delivery of effective clinical services. Today, even patients in developed countries experience delays of weeks and sometimes months for medical imaging and subsequent diagnostics results. For example, in Canada, access to medical imaging procedures is a growing problem with months of reported wait times for magnetic resonance imaging (&#147;MRI&#148;) and CT screening. Long wait times not only negatively impact patient outcomes but also add significant costs to the Canadian healthcare system each year due to delays in detection and treatment. Wait times for a CT scan can be longer than six weeks in Scotland, over 12 months in Ireland, and in the UK, tens of thousands of suspected cancer patients face month-long wait times to discover whether they have a particular illness due to delays in analyzing scans and X-rays. The Nanox System is designed to address such gaps and inefficiencies between completion of the scan and follow-on diagnostics.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">77</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We believe the Nanox System, if successfully developed, will streamline the entire medical screening process ranging from scanning to support diagnostics, and solve the bottleneck of imaging-to-diagnostics. The image below illustrates the potential interplay among the Nanox.Arc, the Nanox.Cloud and third-party participants. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10006151x2_graphic6.jpg" alt="" style="height: 219.60px; width: 562.80px; scale: ">&#8201;<br> </p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We also expect to be able to offer the Nanox System for a substantially lower cost than existing medical imaging systems, which we believe is key to achieving our goal of making early-detection medical imaging systems more accessible globally. We believe our novel X-ray source is crucial to our ability to substantially reduce the manufacturing cost of the Nanox.Arc. Our digital X-ray source generates X-ray radiation that is measurably identical in all key metrics to the X-ray radiation generated by existing analog X-ray sources, but without creating the high temperature that results from the filament used in the analog X-ray tube, thereby eliminating the need for the costly cooling equipment. In addition, our digital X-ray source is designed to enable the Nanox.Arc to have multiple stationary tubes arranged around the patient, which allows for a more simplified structure, as opposed to requiring the heavy, complex, high-precision rotating mechanisms used in legacy CT devices. We currently estimate the aggregate cost of purchasing and assembling the components of the Nanox.Arc will be approximately $8,000 to $12,000 per unit, assuming at least 15,000 Nanox.Arc units will be manufactured. We believe this will enable us to offer the Nanox System at a substantially lower cost than the cost of existing medical imaging systems based on analog X-ray sources. For example, a new high-end CT scanner sells for $1,350,000 to $2,100,000, with an additional $35,000 to $100,000 for cardiac software, $15,500 to $35,000 for lung software and approximately 10% to 14% of the capital expenditure cost for annual support and maintenance services, reaching a total cost of ownership in the millions of dollars. </p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our estimated manufacturing costs of the Nanox.Arc are subject to a number of assumptions and uncertainties and the actual cost per unit could vary significantly from our estimate, which would have a negative impact on our business. See &#147;Risk Factors&#8212;We are a development-stage company with limited operating history. We may never be able to effectuate our business plan or achieve any revenue or reach profitability. Therefore, at this stage of our business, potential investors have a high probability of losing their entire investment,&#148; &#147;Risk Factors&#8212;The success of our primary business model, the Subscription Model, is subject to numerous risks and uncertainties,&#148; &#147;Risk Factors&#8212;We may experience development or manufacturing problems and higher costs, or delays that could limit our revenue, if any, or increase our losses&#148; and &#147;Risk Factors&#8212;We may not be able to successfully execute our business models.&#148;</p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We do not believe that our novel digital X-ray source will require regulatory approval or clearance because we believe it falls within a category of radiology vacuum tubes converting electrical input power into X-rays that utilize the same energy levels, radiation types and throughputs as already existing and approved X-ray tubes applied in a wide range of radiology medical procedures. As a result, we expect that there will be no novel claim or methodology related to the X-ray radiation produced by the digital X-ray source. In addition, we do not believe that the Nanox.Cloud will require regulatory approval or clearance because we expect that it will utilize software modules already cleared by the FDA for purposes of image transfer, upload, display and review. As we continue to develop the Nanox.Arc, we expect to take a multi-step approach to the regulatory clearance process. As a first step, we plan to submit a 510(k) application to the FDA in January 2020 to seek clearance of a medical imaging system that incorporates a single digital X-ray source. The submission will be based on a </p>

			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">

<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">78</p>

			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">predicate filing for an equivalence claim to an existing FDA-approved X-ray imaging system by another market participant. Because our novel digital X-ray source incorporated into this system generates X-ray radiation that is measurably identical in all key characteristics to the X-ray radiation generated by the analog X-ray source incorporated into existing FDA-cleared X-ray imaging systems, we expect to make no new claims as to the operation, image quality or functionality of this system versus the predicate device. If we receive FDA clearance, we will continue to optimize and develop further features of the Nanox.Arc, and plan to submit additional 510(k) applications to the FDA with respect to the Nanox.Arc. To date, we have not obtained feedback from the FDA regarding the regulatory pathways for any of our product candidates. </p>

				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our Business Model</b></i><i><b> </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We plan to commercialize our X-ray source technology through three simultaneous business models: (i) the Subscription Model, (ii) the Sales Model and (iii) the Licensing Model. The chart below illustrates the various revenue streams we expect to derive from these three business models. We expect the Subscription Model to be our primary business model and the key vehicle to achieving our vision of increasing early-detection of medical conditions that are discoverable by X-ray. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10006151x2_graphic2.jpg" alt="" style="height: 354.67px; width: 577.33px; scale: ">&#8201;<br> </p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0%; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">*</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">We expect to contract with third parties to provide maintenance and support services. </td></tr></table><div style="clear: both"></div>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>The Subscription Model</b></i><i><b> </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The foundation of the Subscription Model is our integrated offering of the Nanox.Arc and the Nanox.Cloud, which we refer to as the &#147;Nanox System.&#148; Under the Subscription Model, we expect to sell the Nanox System, if cleared or approved by the requisite regulatory authorities, either at low cost or at no cost, and to receive a portion of the proceeds from each scan as the right-to-use licensing fee, with the remaining amount allocated among our partners, including the local operators, radiologists, cloud storage providers, medical AI software providers and others, on a case by case basis. While the actual pricing charged by local operators may be greater than our suggested retail price, the retail price per scan in all markets other than the United States is still expected to be substantially less than the global average of approximately $300. In the United States, we expect the retail price to represent a significant reduction compared to the $3,275 average cost of a CT scan. We expect the Nanox System will be operated by local operators independent from us, but we would contract with third parties to provide the day-to-day maintenance of the Nanox System. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">While we believe our novel X-ray source could provide existing market participants with the paradigm shift needed for preventive healthcare disruption, we also believe existing market participants are not likely to </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">79</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">undertake the change-leadership route and will be slow to adopt the MSaaS model. Accordingly, we plan to produce and deploy approximately 15,000 Nanox.Arc units broadly across the globe over &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to jumpstart the MSaaS-based medical imaging market, including in the United States, certain Asian countries such as India and Saudi Arabia, as well as the rest of the world, including the EU and Africa. We estimate that effectively stimulating market interest in our Nanox System will require deploying 5,000 to 10,000 Nanox.Arc units. We believe that this strategy will help initiate market disruption and accelerate the adoption of our novel X-ray source technology by traditional industry leaders.</p>

				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>The Sales Model</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In certain countries, such as China, we intend to commercialize our technology using the Sales Model to accommodate specific local regulatory requirements. Under this model, we expect to sell the Nanox System, if cleared or approved by the requisite regulatory authorities, for a one-time charge. We expect this retail price to be higher than the upfront sales price under the Subscription Model but still substantially lower than the cost of existing medical imaging systems. We expect to enter into arrangements with third-party cloud vendors which will be responsible for providing the Nanox.Cloud services, and be paid separately by the owner-operators of the Nanox Systems. In addition, we expect to contract with third-party service providers to provide maintenance services for the Nanox Systems at the owner-operators&#146; own costs.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>The Licensing Model</b></i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">While we believe the medical imaging industry will eventually migrate towards the recurring revenue-based MSaaS model, we expect certain leading market participants will be slower to adopt this model. For these market participants, we expect to provide an intermediate solution through which they will adopt our X-ray source technology for their existing systems. Under the Licensing Model, we would be engaged to tailor our X-ray source to the specific systems of medical imaging device manufacturers for a one-time licensing fee upfront for the X-ray source, as well as recurring royalty payments for each system sold. The licensees would be responsible for the operation of the medical imaging systems integrating our X-ray source. Although we expect to initially rely on the Licensing Model, in part, we view the Licensing Model as a transitional phase, aimed at maximizing the commercial value of our technology and strategic buy-in from market participants to our vision through partnership and commercial relationships.</p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">FUJIFILM Corporation was the first medical imaging device manufacturer to participate in our licensing model. On May 21, 2019, Nanox Gibraltar, our predecessor company, entered into a Right of First Negotiation Agreement with FUJIFILM Corporation. Under the terms of such agreement, the parties agreed to exclusively negotiate in good faith the terms and conditions of a potential commercial agreement until December 31, 2019. The terms of the commercial agreement are intended to cover the exclusive, worldwide licensing of certain patents and know-hows related to mammography medical devices and solutions owned by us to FUJIFILM Corporation to develop, manufacture, market, distribute, operate and use mammography equipment and services (the &#147;field of use&#148;). Under the Right of First Negotiation Agreement, if such commercial agreement was not entered into by December 31, 2019, and if we later become involved in any negotiation to enter into an agreement for the grant of license of the patents covered by the agreement in the field of use to any third party, FUJIFILM Corporation would have a right of first negotiation for six months with respect to such proposed transaction under terms and conditions no less favorable to us than those proposed or offered by or to such third party. Under the terms of the Right of First Negotiation Agreement, Nanox Gibraltar agrees to cause us to assume all of its obligations under such agreement upon the transfer of the assets to us. We are discussing the terms of a potential commercial agreement with FUJIFILM Corporation.</p>

				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Sales and Marketing</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We plan to commercialize our technology using the three simultaneous business models described above broadly across the globe by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, including in the United States, certain Asian countries such as China, India and Saudi Arabia, and the rest of the world, including the EU and Africa. Our sales and marketing strategy varies depending on specific geographical regions, as different regions generally require different marketing approaches. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In most countries, other than the United States, we expect to primarily market through local partnerships with strong national branding and operational market participants in the target region. These local partners would </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">80</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">be engaged in deploying and operating our medical imaging systems, training and recruiting a local medical professional workforce to operate the systems and providing medical imaging diagnostics for the systems&#146; scan results. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In the United States, because we expect our systems will be relatively simple and cost effective to deploy compared to existing medical imaging systems, many retail locations could potentially become medical imaging service providers with the support of the appropriate partners and radiologists. We have already initiated discussions with some of the largest private clinic chains and retail locations for the potential deployment of thousands of units in the United States. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, we also expect to engage local value-added resellers or integrators in different geographic regions to facilitate the local integration of our systems with health maintenance organizations, electronic health record systems, payment methods and insurance coverage companies. We estimate that it will take approximately three to six months of integration and localization efforts before we can generate sales in a given region. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Manufacturing and Supply</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have optimized the MEMs proprietary manufacturing process and currently use our own equipment in the clean rooms located at the University of Tokyo to manufacture the MEMs X-ray chip, as shown in the picture below. As we further expand our business in connection with the commercialization of our technology, we expect to obtain access to other clean rooms provided by third parties. We plan to retain our core X-ray source technology production activities for the foreseeable future, and we believe we have sufficient manufacturing capacity for our currently anticipated needs.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10006151x2_graphic5.jpg" alt="" style="height: 394.67px; width: 537.33px; scale: ">&#8201;<br></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have entered into arrangements with a manufacturer for the production of our X-ray tubes. We also expect to rely on third-party manufacturers for the commercial production of the other components of the Nanox.Arc, if cleared or approved by the requisite regulatory authorities. We are in negotiations with a global manufacturer to assemble approximately 15,000 Nanox.Arc units that we plan to deploy in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We expect that we or the manufacturer will subcontract with other third parties for the commercial supply of certain components of the Nanox.Arc.</p>

			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">81</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have entered into an agreement with Comm-IT Software Ltd, an IT services company (&#147;Comm-IT&#148;), for the design, architecture, development, testing and integration of the Nanox.Cloud software. Under the terms of the agreement, we will own all intellectual property rights with respect to the work products prepared by Comm-IT.</p>


<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Collaboration Agreement with Hadasit</b></p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have entered into a Collaboration Agreement, dated September 8, 2019, with Hadasit Medical Research Services and Development Ltd. (&#147;Hadasit&#148;), a wholly owned subsidiary of the Hadassah Medical Organization (&#147;HMO&#148;). Under the terms of the agreement, the parties agreed to collaborate with respect to our medical imaging technology and resulting medical images devices (the &#147;Company Products&#148;), by way of (a) joint research and development projects (each, a &#147;Research Project&#148;); and (b) the provision by Hadasit of services in connection with Company Products, such as testing and consulting work, where no innovative research will be carried out (each, a &#147;Service&#148;). Each Research Project and Service will be rendered under a separate project agreement to be entered into between the parties in writing from time to time (collectively, the &#147;Project Agreements&#148;). Prior to entering into any Project Agreement, a joint steering committee to be established shall be responsible for determining whether such Project Agreement constitutes a Research Project or a Service. The parties envisage the collaboration to continue over a period of five years, unless extended in writing. Under this agreement, Hadasit has agreed to extend competitive prices comparable to prices that it offers to other commercial entities with respect to the Research Projects and Services. We made a non-refundable payment to Hadasit as an advance on account of the Research Projects and Services in the amount of $250,000, plus value-added tax, which amount will be credited against payments due from time to time to Hadasit under the Project Agreements. We have no obligation to enter into any Project Agreements with Hadasit that will cause us to pay Hadasit any payments in excess of the amount advanced, and we are not permitted to use funding from the Israel Innovation Authority for any Research Projects or Services.</p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under this agreement, Hadasit has granted us an exclusive, worldwide license, with the right to sublicense, under Hadasit's rights in proprietary information created within the framework of a Research Project (collectively, the &#147;Collaboration Intellectual Property&#148;), to develop, have developed, manufacture, have manufactured, use, market, offer for sale, sell, have sold, distribute, export and import Company Products. Notwithstanding the foregoing, Hadasit reserves for itself, HMO and other non-commercial third parties, rights to Collaboration Intellectual Property for teaching or academic research purposes.</p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In consideration for Hadasit's license to us, Hadasit is entitled to compensation, on a country-by-country basis, for all commercial scans (each, a &#147;Scan&#148;) carried out with the use of Covered Products (as defined below) throughout the applicable revenue sharing period at the rate of ten cents per Scan, which period commences upon the first Scan conducted in a country and ending on the later of: (i) the expiration of the last to expire valid claim of the applicable jointly owned patent; and (ii) 15 years from the date of the first Scan conducted in such country with a Covered Product after receipt of required regulatory approvals in such country. No royalty is due for Scans that are carried out with the use of Covered Products without consideration for internal, testing, training or demonstration purposes. &#147;Covered Products&#148; are those Company Products which (i) comprise, contain or incorporate, and/or use, in whole or in part, Collaboration Intellectual Property; (ii) the development, production and/or sale of which, is based on, or involves, in whole or in part, the use of the Collaboration Intellectual Property; or (iii) are produced or manufactured in whole or in part, using a process, method or system covered by, or included within the Collaboration Intellectual Property. If we, our affiliate or sublicensee challenges the validity, enforceability or scope of any patents jointly owned by us and Hadasit, Hadasit may terminate such license with respect to Covered Products covered by such patents and double the revenue sharing rate owed Hadasit under the agreement as described above.</p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, under this agreement, we have granted Hadasit a royalty-free, worldwide, non-exclusive license, with the right to sublicense only to permitted contractors, to use, copy, maintain, modify and prepare derivative works of our intellectual property as necessary to conduct the Research Projects and Services.</p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The term of the agreement will continue until the expiration of all payment obligations thereunder. The agreement may be terminated by mutual consent, by the non-breaching party in case of a material breach of a party's material obligations, or by either party in case of the bankruptcy or insolvency of the other party.</p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We also granted Hadasit a warrant to purchase 23,957 of our ordinary shares at a price of $20.87 per share with a total exercise price of $500,000. The shares will be fully vested after two years, with one third vested on </p>

			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">

<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">82</p>

			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">September 8, 2019, another one third to be vested on September 8, 2020 and the remainder after September 8, 2021. The warrant may be exercised from the date of the Collaboration Agreement and until the earlier of (i) 48 months from the date of the full vesting of the shares and (ii) the closing of an &#147;Exit Event,&#148; which includes the consummation of this offering.</p>

				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Competition</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Several large companies, such as General Electric, Siemens, Philips, Hologic, Varian, Fuji, Toshiba and Hitachi currently dominate the medical imaging market. High regulatory, distribution, manufacturing and service-related long-term contractual costs represent significant barriers to entry for any new player. We expect that the existing market participants will remain key players in the future and we aim to form alliances with several of these leading market participants, including through licensing.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Over time, we anticipate that the evolution in the industry will bring new players into the market. Digital healthcare disruptors such as cloud computing companies or leading IT companies may enter the industry and we believe that they may become strong partners through our Subscription Model. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As a general matter, we view competition on two levels:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Competing digital X-ray sources with same or better attributes; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Competing enterprises operating an MSaaS business model.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In terms of digital X-ray sources, the field emission display technology is known and a wide range of industry leaders have used it to attempt to create an alternative, digital source of X-ray. We are not aware of any competing company that has achieved a commercial grade, stable digital X-ray source, either based on field emission display technology or otherwise. The most well-known attempt was the use of carbon nano tubes (&#147;CNT&#148;) as the base material for a potential field emission-based solution. To our knowledge, there are several companies currently in the process of developing this technology, including Carestream, XinRay Systems and Varex Imaging. Branded as a &#147;cold cathode,&#148; CNT solutions have been proven to be unstable and, to date, no commercially available solution has been implemented after significant investment.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">There are two main differences between our MEMs-based X-ray source and CNT-based X-ray sources. First, carbon, which is used in CNT-based X-ray sources, is much easier to burn than metal, which is used in our X-ray source. The carbon edges of CNT are extremely small. If these carbon edges are not controlled precisely, so that the maximum current is below their burn temperature, they burn out. Further, the edges of CNT are randomly positioned and cannot position nano-tubes in precise locations. Therefore, the edges burn first under high electric field voltage and cause a chain reaction of all edges burning, which renders the CNT useless. In contrast, we believe our molybdenum cones are a far more resistant base and our X-ray source positions metal cone edges in the precise location of the electric field using our MEMs with negligible positioning error deviation. Second, others have tried to prevent the deterioration of the CNT-based X-ray sources by using &#147;mesh&#148; as an electric field to extract electrons. &#147;Mesh&#148; is a grid-electrode set a few millimeters above of CNTs. However, the distance between the metal edges and their gates is extremely large compared to our X-ray source, and it requires 1,000 volts to extract electrons, while our X-ray source only needs 50 volts. High voltage is costly and imprecise. Moreover, the mesh grid traps 50% of the electron emission, meaning the mesh-based solution is costly and extracts only a small number of electrons, many of which are wasted.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In terms of the MSaaS business model, we currently seek a first-mover advantage by introducing the Subscription Model, as the main pre-requisite for this model is the low cost of the X-ray source. However, the primary competition comes from established market participants. While in developing countries we are experiencing keen interest, the United States and other Western regions already have major market participants that are well entrenched in the market with strong political influence and the ability to delay deployment of our systems.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">83</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Intellectual Property</b><b> </b></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As of January 8, 2020, we had three issued patents in the United States and 10 provisional or pending U.S. patent applications. We also had three patents issued in each of Israel, Japan and China, three pending patent applications in the European Patent Office, three pending patent applications in Korea and three pending Patent Cooperation Treaty patent applications, which are the counterparts of our U.S. patent applications. Our issued patents expire between the years 2032 and 2034, and are directed to various features and combinations of features of the Nanox.Arc. </p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We intend to continue filing for patents on new technologies as they are developed and to actively pursue any infringement upon our patents. We believe that our know-how and trade secrets represent de facto barriers to potential competition.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Security and Data Privacy</b><b> </b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Nanox System is being designed and developed with personal privacy, data security and protection in mind as a top priority for all development parties. Medical imaging information and other health information is highly personal and sensitive and thus regarded as a prime target for hacks and malicious theft. As part of our normal operations, we expect to collect, process and retain personal identifying information regarding patients. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We believe we will likely be subject to U.S. rules and regulations governing data protection, including HIPAA. See &#147;&#8212;Government Regulation&#8212;Healthcare Regulatory Laws&#8212;Data Privacy and Security.&#148; </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, we believe we will likely be subject to the GDPR to the extent that our business involves personal data of persons within the EU. Data protection legislation, including the GDPR, regulates the manner in which we may hold and communicate personal data of our employees and patients (including, in our case, sensitive health data). We are likely to be defined as a &#147;Data Controller&#148; with respect to the personal data of patients that we intend to collect and are therefore likely to be subject to a number of key legal obligations under the GDPR. In addition to reflecting existing requirements that already existed under the old data protection regime, such as, among other things, requirements to provide users with a &#147;fair processing notice&#148; if we process their data, ensure that inaccurate data is corrected, only retain data for so long as is necessary and not transfer data outside the EEA to jurisdictions which do not ensure an adequate level of protection of personal data without taking certain safeguards, the GDPR also implemented new, more stringent operational and procedural requirements for our use of personal data. These include expanded prior information requirements in light of the transparency principle to tell patients how we may use their personal data, increased controls on profiling such persons, increased rights for patients to access, control and delete their personal data and mandatory data breach notification requirements. In addition, there are significantly increased administrative fines of the greater of &#8364;20 million and 4% of global turnover (as well as the right to compensation for financial or non-financial damages claimed by any individuals under Article 82 of the GDPR).</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Separate from, and in addition to, the GDPR requirements, certification requirements for the hosting of health data will vary by jurisdiction (and may or may not apply to hosts of health data). As the Nanox System is projected to operate in various EEA countries, we may be required to comply with other national healthcare regulations or regulatory requirements. For example, in France, there is a procedure as of April 1, 2018, for hosts of health data to obtain a prior certification with the competent certification body. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are dedicated to making our systems and software both HIPAA and GDPR compliant. We intend to submit our systems to an independent external audit on a regular basis as required by HHS. We also intend to develop our privacy protocols to comply with the GDPR. In addition, we are undertaking intendant measures to ensure a high-level of imaging data encryption, complete separation between the imaging data and personal information (anonymization) as well as three-factor authentication procedures during on-boarding and usage of the Nanox System. We also intend to undertake to perform periodic Pen-Tests by external cyber security professionals and publish the results of such audits publicly and without delay on our website and via public relations channels. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">84</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Government Regulation</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Nanox System and our operations will be subject to extensive regulation by the FDA, and other federal and state authorities in the United States, as well as comparable authorities in foreign jurisdictions. The Nanox.Arc will be subject to regulation as medical devices and radiation-emitting devices in the United States under the FDCA, as implemented and enforced by the FDA, and under comparable regulatory schemes in foreign jurisdictions.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>FDA Regulation of Medical Devices</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The FDA regulates the development, design, non-clinical and clinical research, manufacturing, safety, efficacy, labeling, packaging, storage, installation, servicing, recordkeeping, premarket clearance or approval, adverse event reporting, advertising, promotion, marketing and distribution, and import and export of medical devices to ensure that medical devices distributed within the United States are safe and effective for their intended uses and otherwise meet the requirements of the FDCA.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>FDA Premarket Clearance and Approval Requirements</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Subject to certain exceptions, each medical device commercially distributed in the United States requires either FDA clearance of a 510(k) premarket notification, or approval of a PMA application. Under the FDCA, medical devices are classified into one of three classes&#8212;Class I, Class II or Class III&#8212;depending on the degree of risk associated with each medical device and the extent of manufacturer and regulatory control needed to ensure its safety and effectiveness. Class I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be assured by adherence to the FDA&#146;s General Controls for medical devices, which include compliance with the applicable portions of QSR, facility registration and product listing, reporting of adverse medical events and truthful and non-misleading labeling, advertising and promotional materials. Class II devices are subject to the FDA&#146;s General Controls, and special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device. These special controls can include performance standards, post-market surveillance, patient registries and FDA guidance documents. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">While most Class I devices are exempt from the 510(k) premarket notification requirement, manufacturers of most Class II devices are required to submit to the FDA a premarket notification under Section 510(k) of the FDCA requesting permission to commercially distribute the device. The FDA&#146;s permission to commercially distribute a device subject to a 510(k) premarket notification is generally known as 510(k) clearance. Devices deemed by the FDA to pose the greatest risks, such as life sustaining, life supporting or some implantable devices, or devices that have a new intended use, or use advanced technology that is not substantially equivalent to that of a legally marketed device, are placed in Class III, requiring approval of a PMA. Some pre-amendment devices are unclassified, but are subject to the FDA&#146;s premarket notification and clearance process in order to be commercially distributed. </p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>510(k) Clearance Marketing Pathway</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We expect the Nanox.Arc will be a Class II device subject to premarket notification and clearance under section 510(k) of the FDCA. To obtain 510(k) clearance, we must submit to the FDA a premarket notification submission demonstrating that the proposed device is &#147;substantially equivalent&#148; to a predicate device already on the market. A predicate device is a legally marketed device that is not subject to premarket approval, i.e., a device that was legally marketed prior to May 28, 1976 (pre-amendments device) and for which a PMA is not required, a device that has been reclassified from Class III to Class II or I, or a device that was found substantially equivalent through the 510(k) process. The FDA&#146;s 510(k) clearance process usually takes from three to twelve months, but often takes longer. The FDA may require additional information, including clinical data, to make a determination regarding substantial equivalence. In addition, the FDA collects user fees for certain medical device submissions and annual fees and for medical device establishments. For fiscal year 2020, the standard user fee for a 510(k) premarket notification application is $11,594. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If the FDA agrees that the device is substantially equivalent to a predicate device currently on the market, it will grant 510(k) clearance to commercially market the device. If the FDA determines that the device is &#147;not substantially equivalent&#148; to a previously cleared device, the device is automatically designated as a Class III device. The device sponsor must then fulfill more rigorous PMA requirements, or can request a risk-based classification determination for the device in accordance with the &#147;<i>de novo</i>&#148; process, which is a route to market for novel medical devices that are low to moderate risk and are not substantially equivalent to a predicate device. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">85</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">After a device receives 510(k) marketing clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change or modification in its intended use, will require a new 510(k) clearance or, depending on the modification, PMA approval or <i>de novo</i> reclassification. The FDA requires each manufacturer to determine whether the proposed change requires submission of a 510(k), a <i>de novo</i> request or a PMA in the first instance, but the FDA can review any such decision and disagree with a manufacturer&#146;s determination. If the FDA disagrees with a manufacturer&#146;s determination, the FDA can require the manufacturer to cease marketing and/or request the recall of the modified device until 510(k) marketing clearance or until PMA approval is obtained or a <i>de novo</i> request is granted. Also, in these circumstances, the manufacturer may be subject to significant regulatory fines or penalties. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Over the last several years, the FDA has proposed reforms to its 510(k) clearance process, and such proposals could include increased requirements for clinical data and a longer review period, or could make it more difficult for manufacturers to utilize the 510(k) clearance process for their products. For example, in November 2018, the FDA officials announced forthcoming steps that the FDA intends to take to modernize the premarket notification pathway under Section 510(k) of the FDCA. Among other things, the FDA announced that it planned to develop proposals to drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates. These proposals included plans to potentially sunset certain older devices that were used as predicates under the 510(k) clearance pathway, and to potentially publish a list of devices that have been cleared on the basis of demonstrated substantial equivalence to predicate devices that are more than 10 years old. In May 2019, the FDA solicited public feedback on these proposals. The FDA requested public feedback on whether it should consider certain actions that might require new authority, such as whether to sunset certain older devices that were used as predicates under the 510(k) clearance pathway. These proposals have not yet been finalized or adopted, and the FDA may work with Congress to implement such proposals through legislation. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">More recently, in September 2019, the FDA finalized guidance describing an optional &#147;safety and performance based&#148; premarket review pathway for manufacturers of &#147;certain, well-understood device types&#148; to demonstrate substantial equivalence under the 510(k) clearance pathway by showing that such device meets objective safety and performance criteria established by the FDA, thereby obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate devices in the clearance process. The FDA intends to develop and maintain a list of device types appropriate for the &#147;safety and performance based&#148; pathway and will continue to develop product-specific guidance documents that identify the performance criteria for each such device type, as well as the testing methods recommended in the guidance documents, where feasible. </p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>PMA Approval Pathway</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Class III devices require PMA approval before they can be marketed, although some pre-amendment Class III devices for which the FDA has not yet required a PMA are cleared through the 510(k) process. The PMA process is more demanding than the 510(k) premarket notification process. In a PMA, the manufacturer must demonstrate that the device is safe and effective, and the PMA must be supported by extensive data, including data from preclinical studies and human clinical trials. The PMA must also contain a full description of the device and its components, a full description of the methods, facilities and controls used for manufacturing and proposed labeling. Following receipt of a PMA, the FDA determines whether the application is sufficiently complete to permit a substantive review. If the FDA accepts the application for review, it has 180 days under the FDCA to complete its review of a PMA, although in practice, the FDA&#146;s review often takes significantly longer, and can take up to several years. An advisory panel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device. The FDA may or may not accept the panel&#146;s recommendation. In addition, the FDA will generally conduct a pre-approval inspection of the applicant or its third-party manufacturers&#146; or suppliers&#146; manufacturing facility or facilities to ensure compliance with the QSR. PMA devices are also subject to the payment of user fees, which for fiscal year 2020 includes a standard application fee of $340,995 and an annual establishment registration fee of $5,236. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The FDA will approve the new device for commercial distribution if it determines that the data and information in the PMA constitute valid scientific evidence and that there is reasonable assurance that the device is safe and effective for its intended use(s). The FDA may approve a PMA with post-approval conditions intended to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution and collection of long-term follow-up data from patients in the clinical </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">86</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">study that supported PMA approval or requirements to conduct additional clinical studies post-approval. The FDA may condition PMA approval on some form of post-market surveillance when deemed necessary to protect the public health or to provide additional safety and efficacy data for the device in a larger population or for a longer period of use. In such cases, the manufacturer might be required to follow certain patient groups for a number of years and to make periodic reports to the FDA on the clinical status of those patients. Failure to comply with the conditions of approval can result in material adverse enforcement action, including withdrawal of the approval.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Certain changes to an approved device, such as changes in manufacturing facilities, methods or quality control procedures, or changes in the design performance specifications, which affect the safety or effectiveness of the device, require submission of a PMA supplement. PMA supplements often require submission of the same type of information as a PMA, except that the supplement is limited to information needed to support any changes from the device covered by the original PMA and may not require as extensive clinical data or the convening of an advisory panel. Certain other changes to an approved device require the submission of a new PMA, such as when the design change causes a different intended use, mode of operation, and technical basis of operation, or when the design change is so significant that a new generation of the device will be developed, and the data that were submitted with the original PMA are not applicable for the change in demonstrating a reasonable assurance of safety and effectiveness. We do not expect any of our products to be marketed pursuant to a PMA. </p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Clinical Trials</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Clinical trials are almost always required to support a PMA and are sometimes required to support a 510(k) submission. All clinical investigations of devices to determine safety and effectiveness must be conducted in accordance with the FDA&#146;s investigational device exemption (&#147;IDE&#148;) regulations which govern investigational device labeling, prohibit promotion of the investigational device and specify an array of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If the device presents a &#147;significant risk&#148; to human health, as defined by the FDA, the FDA requires the device sponsor to submit an IDE application to the FDA, which must become effective prior to commencing human clinical trials. If the device under evaluation does not present a significant risk to human health, then the device sponsor is not required to submit an IDE application to the FDA before initiating human clinical trials, but must still comply with abbreviated IDE requirements when conducting such trials. A significant risk device is one that presents a potential for serious risk to the health, safety or welfare of a patient and either is implanted, used in supporting or sustaining human life, substantially important in diagnosing, curing, mitigating or treating disease or otherwise preventing impairment of human health, or otherwise presents a potential for serious risk to a subject. An IDE application must be supported by appropriate data, such as animal and laboratory test results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE will automatically become effective 30 days after receipt by the FDA unless the FDA notifies the company that the investigation may not begin. If the FDA determines that there are deficiencies or other concerns with an IDE for which it requires modification, the FDA may permit a clinical trial to proceed under a conditional approval. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Regardless of the degree of risk presented by the medical device, clinical studies must be approved by, and conducted under the oversight of, an Institutional Review Board (&#147;IRB&#148;) for each clinical site. The IRB is responsible for the initial and continuing review of the IDE, and may pose additional requirements for the conduct of the study. If an IDE application is approved by the FDA and one or more IRBs, human clinical trials may begin at a specific number of investigational sites with a specific number of patients, as approved by the FDA. If the device presents a non-significant risk to the patient, a sponsor may begin the clinical trial after obtaining approval for the trial by one or more IRBs without separate approval from the FDA, but must still follow abbreviated IDE requirements, such as monitoring the investigation, ensuring that the investigators obtain informed consent and labeling and record-keeping requirements. Acceptance of an IDE application for review does not guarantee that the FDA will allow the IDE to become effective and, if it does become effective, the FDA may or may not determine that the data derived from the trials support the safety and effectiveness of the device or warrant the continuation of clinical trials. An IDE supplement must be submitted to, and approved by, the FDA before a sponsor or investigator may make a change to the investigational plan that may affect its scientific soundness, study plan or the rights, safety or welfare of human subjects.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">During a study, the sponsor is required to comply with the applicable FDA requirements, including, for example, trial monitoring, selecting clinical investigators and providing them with the investigational plan, </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">87</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">ensuring IRB review, adverse event reporting, record keeping and prohibitions on the promotion of investigational devices or on making safety or effectiveness claims for them. The clinical investigators in the clinical study are also subject to FDA regulations and must obtain patient informed consent, rigorously follow the investigational plan and study protocol, control the disposition of the investigational device and comply with all reporting and recordkeeping requirements. Additionally, after a trial begins, we, the FDA or the IRB could suspend or terminate a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the anticipated benefits. </p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Post-market Regulation</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">After a device is cleared or approved for marketing, numerous and pervasive regulatory requirements continue to apply. These include:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">establishment registration and device listing with the FDA;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">QSR requirements, which require manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the design and manufacturing process;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">labeling regulations and FDA prohibitions against the promotion of investigational products, or the promotion of &#147;off-label&#148; uses of cleared or approved products;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">requirements related to promotional activities;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">clearance or approval of product modifications to 510(k)-cleared devices that could significantly affect safety or effectiveness or that would constitute a major change in intended use of one of our cleared devices, or approval of certain modifications to PMA-approved devices;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">medical device reporting regulations, which require that a manufacturer report to the FDA if a device it markets may have caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">correction, removal and recall reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the FDA&#8217;s recall authority, whereby the agency can order device manufacturers to recall from the market a product that is in violation of governing laws and regulations; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">post-market surveillance activities and regulations, which apply when deemed by the FDA to be necessary to protect the public health or to provide additional safety and effectiveness data for the device.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our manufacturing processes are required to comply with the applicable portions of the QSR, which cover the methods and the facilities and controls for the design, manufacture, testing, production, processes, controls, quality assurance, labeling, packaging, distribution, installation and servicing of finished devices intended for human use. The QSR also requires, among other things, maintenance of a device master file, device history file and complaint files. As a manufacturer, we will be subject to periodic scheduled or unscheduled inspections by the FDA. Our failure to maintain compliance with the QSR requirements could result in the shut-down of, or restrictions on, our manufacturing operations and the recall or seizure of our products, which would have a material adverse effect on our business. The discovery of previously unknown problems with any of our products, including unanticipated adverse events or adverse events of increasing severity or frequency, whether resulting from the use of the device within the scope of its clearance or off-label by a physician in the practice of medicine, could result in restrictions on the device, including the removal of the product from the market or voluntary or mandatory device recalls.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The FDA has broad regulatory compliance and enforcement powers. If the FDA determines that we failed to comply with applicable regulatory requirements, it can take a variety of compliance or enforcement actions, which may result in any of the following sanctions:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">warning letters, untitled letters, fines, injunctions, consent decrees and civil penalties;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">recalls, withdrawals or administrative detention or seizure of our products;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">88</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">operating restrictions or partial suspension or total shutdown of production;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">refusing or delaying requests for 510(k) marketing clearance or PMA approvals of new products or modified products;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">withdrawing 510(k) clearances or PMA approvals that have already been granted;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">refusal to grant export approvals for our products; or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">criminal prosecution.</td></tr></table><div style="clear: both"></div>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Radiological </i><i>Devices</i><i> </i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We and our products will also be regulated by the FDA under the Electronic Product Radiation Control provisions of the FDCA because the Nanox.Arc contains radiation emitting components, and because we assemble these components during manufacturing and service activities. The Electronic Product Radiation Control provisions require radiation-producing products to comply with certain regulations and applicable performance standards. Manufacturers are required to certify in product labeling and reports to the FDA that their products comply with all necessary standards as well as maintain manufacturing, testing and sales records for their products. The Electronic Product Radiation Control provisions also require manufacturers to report product defects and affix appropriate labeling to covered products. Failure to comply with these requirements could result in enforcement action by the FDA, which can include any of the sanctions described above.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Healthcare Regulatory Laws </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Within the United States, our products and our customers will be subject to extensive regulation by a wide range of federal and state agencies that govern business practices in the medical device industry. These laws include federal and state anti-kickback, fraud and abuse, false claims, transparency and anti-corruption statutes and regulations. Internationally, other governments also impose regulations in connection with their healthcare reimbursement programs and the delivery of healthcare items and services. </p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">U.S. federal healthcare fraud and abuse laws will generally apply to our activities, among other reasons because we expect that our products will be covered under federal healthcare programs such as Medicare and Medicaid. The Anti-Kickback Statute is particularly relevant because of its broad applicability. Specifically, the Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in exchange for, or to induce, either the referral of an individual, or the furnishing, arranging for or recommending a good or service for which payment may be made in whole or part under federal healthcare programs, such as the Medicare and Medicaid programs. Almost any financial interaction with a healthcare provider, patient or customer will implicate the Anti-Kickback Statute. Statutory exceptions and regulatory safe harbors protect certain interactions if specific requirements are met. However, only those interactions that represent fair market value exchanges generally are protected by a safe harbor or exception. The government can exercise enforcement discretion in taking action against unprotected activities. Further, a person or entity does not need to have actual knowledge of the Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act or federal civil money penalties statute. Penalties for Anti-Kickback Statute violations may include both criminal penalties such as imprisonment and civil sanctions such as fines, imprisonment and possible exclusion from Medicare, Medicaid and other federal healthcare programs. Exclusion would mean that diagnostic tests using our products would no longer be eligible for reimbursement under federal healthcare programs. </p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Many states have adopted laws similar to the Anti-Kickback Statute. Some of these state prohibitions apply to referral of patients for healthcare items or services reimbursed by any payor, not only federal healthcare programs. Insurance companies may also bring a private cause of action for treble damages against a manufacturer for a pattern of causing false claims to be filed under the federal Racketeer Influenced and Corrupt Organizations Act. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Another development affecting the healthcare industry is the increased use of the federal Civil False Claims Act and, in particular, actions brought pursuant to the False Claims Act&#146;s &#147;whistleblower&#148; or &#147;qui tam&#148; provisions. The False Claims Act imposes liability on any person or entity that, among other things, knowingly </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">89</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">presents, or causes to be presented, a false or fraudulent claim for payment by a federal healthcare program. The qui tam provisions of the False Claims Act allow a private individual to bring actions on behalf of the federal government alleging that the defendant has submitted a false claim to the federal government, and to share in any monetary recovery. In recent years, the number of suits brought against healthcare providers by private individuals has increased dramatically. In addition, various states have enacted false claim laws analogous to the Civil False Claims Act, although many of these state laws apply where a claim is submitted to any third-party payor and not merely a federal healthcare program.</p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, among other things, created two new federal crimes: healthcare fraud and false statements relating to healthcare matters. The HIPAA healthcare fraud statute prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private payors. A violation of this statute is a felony and may result in fines, imprisonment and/or exclusion from government-sponsored programs. The HIPAA false statements statute prohibits, among other things, knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation in connection with the delivery of or payment for healthcare benefits, items or services. A violation of this statute is a felony and may result in fines and/or imprisonment. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statutes or specific intent to violate them in order to have committed a violation.</p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Laws and regulations have also been enacted by the federal government and various states to regulate the sales and marketing practices of medical device and pharmaceutical manufacturers. The laws and regulations generally limit financial interactions between manufacturers and healthcare providers, require pharmaceutical and medical device companies to comply with voluntary compliance standards issued by industry associations and the relevant compliance guidance promulgated by the U.S. federal government and/or require disclosure to the government and/or public of financial interactions (so-called &#147;sunshine laws&#148;). Many of these laws and regulations contain ambiguous requirements or require administrative guidance for implementation. Manufacturers must adopt reasonable interpretations of requirements if there is ambiguity and those interpretations could be challenged. Given the lack of clarity in laws and their implementation, our activities could be subject to the penalty provisions of the pertinent federal and state laws and regulations.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Coverage and Reimbursement</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Over the past few years, the growth rate of advanced imaging volumes has slowed in part due to additional patient-related cost-sharing programs and an increasing trend of third-party payors intensifying their utilization management efforts, for example, through benefit managers who require prior authorizations to control the growth rate of imaging services generally. We expect that these trends will continue. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">By way of example, in the United States, the Protecting Access to Medicare Act of 2014 required CMS, in conjunction with medical specialty societies, to adopt appropriate use criteria (&#147;AUC&#148;) for certain advanced diagnostic imaging services, including MRI, CT, nuclear medicine (including position emission tomography). Beginning in 2020, payment will be made to the furnishing professional for an applicable advanced diagnostic imaging service only if the claim indicates that the ordering professional consulted a qualified clinical decision support mechanism, as identified by HHS, as to whether the ordered service adheres to the applicable AUC. Applicable settings include physician offices, hospital outpatient departments, including emergency departments, ambulatory surgical centers and independent diagnostic testing facilities. Advanced imaging services ordered by certain physicians identified as having outlier-ordering partners will be subject to prior authorization for applicable imaging services provided to Medicare beneficiaries. The outlier methodology used by CMS will be subject to future notice and comment rulemaking before the prior authorization component is implemented. We cannot predict the full impact of this project.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Third-party payors may impose limits on coverage or reimbursement for diagnostic imaging services, including denying reimbursement for tests that do not follow recommended diagnostic procedures or can only be billed using an unlisted or miscellaneous code. To the extent our customers will depend on third-party payors, unfavorable coding, coverage and reimbursement policies may constrict the profit margins of our provider customers, which may force us to lower our fees to attract and retain customers. If we are required to request new billing codes that more precisely identify and describe our imaging services, coverage is limited or reimbursement rates are inadequate, a healthcare provider might find it financially unattractive to own diagnostic </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">90</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">imaging systems. It is possible that third-party payor coding, coverage and reimbursement policies will affect the need or prices for our products in the future, which could significantly affect our financial performance and our ability to conduct our business.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Healthcare Reform</i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In the United States and certain foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system. In March 2010, the ACA was signed into law and substantially changed the way healthcare is financed by both governmental and private insurers in the United States. The ACA contains a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement adjustments and fraud and abuse changes. Additionally, the ACA imposed, among other things, a new federal excise tax on the sale of certain medical devices, which, through a series of legislative amendments, was suspended, effective January 1, 2016, and subsequently repealed altogether on December 20, 2019, provided incentives to programs that increase the federal government&#146;s comparative effectiveness research and implemented payment system reforms including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. </p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. By way of example, in 2017, Congress enacted the TCJA, which eliminated the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#147;individual mandate.&#148; On December 14, 2018, a Texas U.S. District Court Judge ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the TCJA, the remaining provisions of the ACA are invalid as well. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit ruled that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. It is unclear how these decisions, future decisions, subsequent appeals, and other efforts to repeal and replace the ACA will impact the ACA.</p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year and reduced payments to several types of Medicare providers. We believe the overall escalating cost of medical products and services being paid for by the government and private health insurance has led to, and will continue to lead to, increased pressures on the healthcare and medical device industry to reduce the costs of products and services. </p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Data Privacy and Security</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Medical device companies may be subject to U.S. federal and state and foreign health information privacy, security and data breach notification laws, which may govern the collection, use, disclosure and protection of health-related and other personal information. In the United States, HIPAA imposes privacy, security and breach reporting obligations with respect to individually identifiable health information upon &#147;covered entities&#148; (health plans, health care clearinghouses and certain health care providers), and their respective business associates, individuals or entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HIPAA and its respective implementing regulations, including the final omnibus rule published on January 25, 2013, imposes specified requirements relating to the privacy, security and transmission of individually identifiable health information. HIPAA mandates the reporting of certain breaches of health information to HHS, affected individuals and if the breach is large enough, the media. Entities that are found to be in violation of HIPAA as the result of a breach of unsecured protected health information (&#147;PHI&#148;), a complaint about privacy practices or an audit by HHS, may be subject to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance. The Health Information Technology and Clinical Health Act also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#146;s fees and costs associated with pursuing federal civil actions.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">91</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Even when HIPAA does not apply, according to the Federal Trade Commission or the FTC, failing to take appropriate steps to keep consumers&#146; personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act, 15 U.S.C &#167; 45(a). The FTC expects a company&#146;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. The FTC&#146;s guidance for appropriately securing consumers&#146; personal information is similar to what is required by the HIPAA Security Rule.</p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, certain state and non-U.S. laws, such as the GDPR, govern the privacy and security of health information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Further, &#147;business associates,&#148; defined as independent contractors or agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity, are also subject to certain HIPAA privacy and security standards. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. For example, California recently enacted legislation, the California Consumer Privacy Act (&#147;CCPA&#148;), which went into effect January 1, 2020. The CCPA, among other things, creates new data privacy obligations for covered companies and provides new privacy rights to California residents, including the right to opt out of certain disclosures of their information. The CCPA also creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. Although the law includes limited exceptions, including for PHI maintained by a covered entity or business associate, it may regulate or impact our expected processing of personal information depending on the context. In Europe, the GDPR went into effect in May 2018 and introduces strict requirements for processing the personal data of European Union data subjects. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. The State of Israel has also implemented data protection laws and regulations, including the Israeli Protection of Privacy Law of 1981. </p>

				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Foreign Regulation</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As we plan to market and deploy our Nanox System broadly across the globe, we will be subject to regulations applicable to medical and radiation-emitting devices in the jurisdictions in which we operate, which regulations vary among countries. While some countries&#146; regulations may not impose barriers to marketing and selling our products or only require certain notification, others may require that we obtain the clearance, registration or approval of a specified regulatory body. Process for obtaining such clearance, registration or approvals may involve additional testing and time. Furthermore, complying with foreign regulatory requirements can be expensive and time-consuming, and we will need to seek for regulatory clearances or approvals in each country in which we plan to market our products.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, depending on the country, if we modify our products, we may need to apply for additional regulatory clearances or approvals before we are permitted to sell the modified product. Also, for maintaining our authorizations in a particular country, we will need to continue meeting quality and safety standards required in such country. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Finally, while regulatory clearance or approval by the FDA does not ensure registration, clearance or approval by regulatory authorities in other countries, registration or regulatory clearance or approval in one country, or denial thereof, may have effects on the regulatory process in others. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">92</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Employees</b></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As of December 31, 2019, we had 14 employees based in Israel and six employees based in Japan. We have never experienced any employment-related work stoppages and believe our relationship with our employees is good.</p>

				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="85%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 8.28px; "><b>Area of Activity </b></div>
							</td>
							<td width="15%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 8.28px; padding-right: 0px; ">
<b>As of<br></b><b> </b><b>December 31</b><b>,<br> </b><b>2019</b>
</div>
							</td>
						</tr>


						<tr style="background-color: #cceeff;">
							<td width="85%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 8.28px; ">General and Administrative </div>
							</td>
							<td width="15%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 8.28px; padding-right: 0px; ">10</div>
							</td>
						</tr>
						<tr>
							<td width="85%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 8.28px; ">Research, Development and Quality Assurance </div>
							</td>
							<td width="15%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 8.28px; padding-right: 0px; ">9</div>
							</td>
						</tr>
						<tr style="background-color: #cceeff;">
							<td width="85%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 8.28px; ">Sales and Marketing</div>
							</td>
							<td width="15%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 8.28px; padding-right: 0px; ">1</div>
							</td>
						</tr>
						<tr>
							<td width="85%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 8.28px; ">Total</div>
							</td>
							<td width="15%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 8.28px; padding-right: 0px; ">20</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Facilities</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our principal executive offices are located in a leased facility in Neve Ilan, Israel. We lease approximately 550 square meters (approximately 5,920 square feet) of office space and warehouses. The lease expires in December 2021, and we have the option to extend our lease for an additional 24 months so long as we meet the terms of the original lease agreement. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, Nanox Japan (predecessor) leases additional facilities of approximately 740 square feet of lab space and approximately 190 square feet of space in a clean room at the premises of the University of Tokyo for research and development activities. The lease automatically renews on a semi-annual basis.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We believe this office space will be sufficient to meet our needs for the next 12-18 months and that suitable additional space will be available as and when needed.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Legal Proceedings</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are currently not subject to any material legal proceedings.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">93</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 108-manage -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tM"></a><b>MANAGEMENT</b></p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Executive Officers, Directors </b><b>and Director Nominees</b></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table sets forth information concerning our executive officers, directors and director nominees, including their ages as of December 31, 2019:</p>

				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; padding-right: 6px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 6px; "><b>Name </b></div>
							</td>
							<td width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6px; padding-right: 6px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 6px; padding-right: 6px; "><b>Age </b></div>
							</td>
							<td width="50%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 6px; padding-right: 0px; "><b>Position </b></div>
							</td>
						</tr>


						<tr>
							<td width="41%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 6px; "><b>Executive Officers</b></div>
							</td>
							<td width="9%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6px; padding-right: 6px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 6px; padding-right: 6px; ">&#160;</div>
							</td>
							<td width="50%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 6px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="41%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 6px; ">Ran Poliakine</div>
							</td>
							<td width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6px; padding-right: 6px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 6px; padding-right: 6px; ">52</div>
							</td>
							<td width="50%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 6px; padding-right: 0px; ">Founder, Chief Executive Officer and Director</div>
							</td>
						</tr>
						<tr>
							<td width="41%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 6px; ">Itzhak Maayan</div>
							</td>
							<td width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6px; padding-right: 6px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 6px; padding-right: 6px; ">54 </div>
							</td>
							<td width="50%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 6px; padding-right: 0px; ">Chief Financial Officer</div>
							</td>
						</tr>
						<tr>
							<td width="41%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 6px; ">Tal Shank</div>
							</td>
							<td width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6px; padding-right: 6px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 6px; padding-right: 6px; ">42 </div>
							</td>
							<td width="50%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 6px; padding-right: 0px; ">Vice President Corporate Development</div>
							</td>
						</tr>
						<tr>
							<td width="41%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 6px; ">Yoel Raab</div>
							</td>
							<td width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6px; padding-right: 6px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 6px; padding-right: 6px; ">65 </div>
							</td>
							<td width="50%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 6px; padding-right: 0px; ">Chief Technology Officer</div>
							</td>
						</tr>
						<tr>
							<td width="41%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 6px; ">Anat Kaphan</div>
							</td>
							<td width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6px; padding-right: 6px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 6px; padding-right: 6px; ">49 </div>
							</td>
							<td width="50%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 6px; padding-right: 0px; ">Vice President Product Marketing</div>
							</td>
						</tr>
						<tr>
							<td width="41%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 6px; ">&#160;</div>
							</td>
							<td width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6px; padding-right: 6px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 6px; padding-right: 6px; ">&#160;</div>
							</td>
							<td width="50%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 6px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="41%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 6px; "><b>Non-Employee Directors</b></div>
							</td>
							<td width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6px; padding-right: 6px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 6px; padding-right: 6px; ">&#160;</div>
							</td>
							<td width="50%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 6px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="41%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 6px; ">Onn Fenig </div>
							</td>
							<td width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6px; padding-right: 6px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 6px; padding-right: 6px; ">45 </div>
							</td>
							<td width="50%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 6px; padding-right: 0px; ">Director</div>
							</td>
						</tr>
						<tr>
							<td width="41%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 6px; ">
Erez Meltzer
</div>
							</td>
							<td width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6px; padding-right: 6px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 6px; padding-right: 6px; ">
52
</div>
							</td>
							<td width="50%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 6px; padding-right: 0px; ">
Director
</div>
							</td>
						</tr>
						<tr>
							<td width="41%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 6px; ">Richard Stone</div>
							</td>
							<td width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6px; padding-right: 6px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 6px; padding-right: 6px; ">77</div>
							</td>
							<td width="50%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 6px; padding-right: 0px; ">Director</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Executive Officers</b></i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>Ran Poliakine</b>, our founder, has served as a member of our board of directors since our inception. Mr. Poliakine has served as our Chief Executive Officer since September 2019, and served as Chief Executive Officer of Nanox Gibraltar since August 2018. Prior to that, he served as Chief Strategy Officer in Nanox Gibraltar from June 2015 to August 2018. Mr. Poliakine is a serial entrepreneur and has founded numerous companies over the past two decades, including Powermat Technologies, Wellsense Technologies Ltd., Tap Systems, Inc., Illumigyn, Ltd. (&#147;Illumigyn&#148;) and Musashi AI Ltd. Mr. Poliakine is a member of the board of directors of Powermat Technologies, Tap Systems, Inc. and Musashi AI Ltd. In addition, Mr. Poliakine currently serves as a member of senior management of Illumigyn.</p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>Itzhak Maayan</b> has served as our Chief Financial Officer since November 2019. Prior to joining us, Mr. Maayan served in different finance leadership roles in Perrigo Company from 2007 to 2019, including Vice President, Financial Services and European Investor Relations, Vice President, International Finance, and Vice President and Chief Financial Officer, Perrigo Israel. Prior to Perrigo Company, Mr. Maayan held various finance leadership roles at Cisco Systems Israel from 2003 to 2007, Xtivia, Inc. from 1999 to 2003, Kulick &amp; Soffa from 1995 to 1999 and Elscint Ltd. from 1993 to 1995. Mr. Maayan received his bachelor&#146;s degree in economics and accounting from Haifa University, and is a Certified Public Accountant in Israel. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>Tal Shank</b> has served as our Vice President of Corporate Development since September 2019. Mr. Shank has served as Head of Corporate Development at Illumigyn from 2017 to date. From 2016 to 2017, Mr. Shank was responsible for the corporate and governance aspects of Head Start, a company supplier of services to technology portfolio companies related to Ran Poliakine. Prior to that, Mr. Shank served as Deputy CEO &amp; Legal Counsel of Speech Modules Holdings Ltd. from 2014 to 2015. From 2009 to 2014, Mr. Shank worked at Guy, Bachar &amp; Co. Law Firm, where he started as an associate and became partner in 2011. Mr. Shank has practiced corporate and securities law in Israel since 2003, and he holds an M.B.A. and a LL.M. from Tel Aviv University.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>Yoel Raab</b> has served as our Chief Technology Officer since September 2019. Mr. Raab serves as Chief Technology Officer of Six-Eye Interactive Ltd. (&#147;Six-Eye&#148;), of which Ran Poliakine is the sole owner, and served as Vice President of Research and Development of Wellsense from 2014 to 2018. Prior to that, Mr. Raab served as R&amp;D manager and Chief Technology Officer of Powermat Technologies from 2007 to 2014. Mr. Raab also served as Vice President of Research &amp; Development at Magink from 2006 to 2007. From 2003 to 2006, Mr. Raab served as a consultant and managed the gamma detectors department at Orbotech Medical. From 2011 to 2013, he served as Vice President of Research &amp; Development at Phone-Or. Prior to that, Mr. Raab worked at </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">94</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">Intel as a process engineer and served in various development and engineering positions from 1982 to 2001. From 1996 to 2001, Mr. Raab managed the Yield department at the Intel Fab in Qiryat Gat, Israel. Mr. Raab received his bachelor&#146;s degree and his master&#146;s degree in applied physics, microelectronics from the Hebrew University in Jerusalem.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>Anat Kaphan</b> has served as our Vice President of Product Marketing since September 2019. Prior to joining us, Ms. Kaphan served as Vice President of Product and Marketing at Mazor Robotics Ltd. from 2015 to 2018, and General Manager at Essence Group from 2014 to 2015. She also served as Marketing Director at Phillips from 2011 to 2014. Prior to that, Ms. Kaphan served as Business Development Director at Lumenis from 2001 to 2011 and Product Manager at Elscint Ltd. from 1991 to 2001. Ms. Kaphan holds an M.B.A. in International marketing from Tel Aviv University and received her bachelor&#146;s degree in economics and accounting from Haifa University. </p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Directors</b></i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>Onn Fenig</b> has served as a member of our board of directors since November 2019. Mr. Fenig has served as the chairman of the board of directors of &#147;Beit Meitar&#148; Waldorf Education Association since 2018. Mr. Fenig has served as Chief Executive Officer and a member of the board of directors of Rioglass Solar systems Ltd. since 2014, and as Chief Executive Officer of Rioglass Solar Receivers BU from 2016 to 2018. Prior to that, Mr. Fenig co-founded and served as a member of the board of directors of DUTYFREEBEE LTD from 2013 to 2015. From 2011 to 2014, Mr. Fenig served as Commercial Director, Project Acquisition Finance at Siemens, where he managed finance and commercial matters relating to engineering procurement and construction projects. Prior to joining Siemens, Mr. Fenig served as Finance Manager, Inside Sales European Markets at Cisco Systems from 2008 to 2010, Service Fulfilment Delivery Manager at Amdocs UK from 2006 to 2008, and Systems Analyst, Cyber Security Department at Israeli Ministry of the Prime Minister from 2001 to 2005. Mr. Fenig received his bachelor&#146;s degree in computer science from the Interdisciplinary Center Herzliya in Herzliya, Israel, and holds an M.B.A. from the University of Chicago Booth School of Business in Chicago, Illinois. </p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>Erez Meltzer</b> has served as a member of our board of directors since December 2019. Mr. Meltzer serves as the Executive Chairman of the board of directors of Hadassah Medical and University Center. Since 2008, Mr. Meltzer has served as a teaching professor at the Tel Aviv Faculty of Medicine in the area of crisis management. Meltzer served as Executive Vice Chairman and Chief Executive Officer of Gadot Chemicals &amp; Shipping Group from 2008 to 2013. Prior to that, he served as Chief Executive Officer of Africa-Israel Ltd from 2006 to 2008 and President and Chief Executive Officer of Netafim Ltd from 2001 to 2006. Mr. Meltzer also served as Chief Executive Officer of Creo Scitex from 1996 to 2001. </p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>Richard Stone </b>has served as a member of our board of directors since November 2019. Professor Stone has taught at Columbia University Law School since 1974, and became Professor Emeritus in 2018. Professor Stone has taught courses in several fields of business law, specializing in federal income taxation. From 1969 to 1973, Professor Stone served in the United States Justice Department as Assistant to the Solicitor General of the United States. Beginning in 1981, Professor Stone began providing consulting to private and public technology start-ups, primarily in the biotechnology field. Professor Stone co-founded several biotechnology companies, including Lev Pharmaceuticals, Siga Technologies and OptMed. In 2007, Professor Stone began working primarily with Israeli technology companies, mostly in the medical space. He is a member of the board of directors of Powermat Technologies, Wellsense, Cardiologics, Quality In Flow, Dario Health and Illumigyn. Professor Stone received his bachelor&#146;s degree, Magna Cum Laude from Harvard College, and his Juris Doctor degree, Magna Cum Laude, from Harvard Law School. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Compensation of Executive Officers and Directors</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">For so long as we qualify as a foreign private issuer, we are not required to comply with the proxy rules applicable to U.S. domestic companies, including the requirement applicable to emerging growth companies to disclose the compensation of our chief executive officer and other two most highly compensated executive officers on an individual, rather than an aggregate, basis. The aggregate compensation, including share based compensation, paid by us to our executive officers and directors for the year ended December 31, 2019 was approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million. This amount includes approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million set aside or accrued to provide pension, severance, retirement or similar benefits or expenses, but does not include business travel, relocation, professional and business association dues, meals and expenses reimbursed to officers, and other </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">95</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">benefits commonly reimbursed or paid by companies in Israel, on the same basis for all full-time employees generally. See &#147;&#8212;Equity Incentive Plan&#148; for a discussion of our 2019 Equity Incentive Plan and grants to our executive officers and directors. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Corporate Governance Practices and Foreign Private Issuer</b></p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>Foreign Private Issuer </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Companies incorporated under the laws of the State of Israel, whose shares are publicly traded, including companies with shares listed on the Nasdaq, are considered public companies under the Companies Law and are required to comply with various corporate governance requirements relating to such matters as the composition and responsibilities of the audit committee and the compensation committee, and a requirement to have an internal auditor. This is the case even if our ordinary shares are not listed on the Tel Aviv Stock Exchange, which our ordinary shares are not expected to be. These requirements are in addition to the corporate governance requirements imposed by Nasdaq rules and other applicable provisions of U.S. securities laws to which we will become subject (as a foreign private issuer) upon the closing of this offering and the listing of our ordinary shares on the Nasdaq.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">After the consummation of this offering, we will be a &#147;foreign private issuer&#148; under the U.S. securities laws and the Nasdaq corporate governance rules. As a foreign private issuer, we will be exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders will be exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. Also, we are not required to comply with Regulation FD, which restricts the selective disclosure of material information. However, we will file with the SEC, within 120 days after the end of each fiscal year, or such applicable time as required by the SEC, an annual report on Form 20-F containing financial statements audited by an independent registered public accounting firm, and will submit to the SEC from time to time, on Form 6-K, reports of information that would likely be material to an investment decision in our ordinary shares.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As a foreign private issuer, we are permitted to follow certain Israeli corporate governance practices instead of the Nasdaq corporate governance rules, provided that we disclose which requirements we are not following and the equivalent Israeli requirement. Pursuant to the &#147;foreign private issuer exemption&#148;:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">we intend to comply with Israeli law, which permits a company to determine in its articles of association the number of shareholders and percentage of holdings required for such a quorum. Our amended and restated articles of association provide that a quorum of one or more shareholders holding at least one-third of the voting rights in person or by proxy is required for commencement of business at a general shareholders meeting. Nasdaq also permits this as a quorum. While the quorum set forth in our amended and restated articles of association with respect to an adjourned meeting is identical to the quorum for any other meeting (as described in the initial sentence), if, within half an hour from the time appointed for the adjourned meeting, a quorum is not present, a quorum shall thereafter consist of at least two shareholders present in person or by proxy, regardless of the number or percentage of our outstanding shares held by them;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">with the exception of our external directors and directors elected by our board of directors due to a vacancy, in accordance with the staggered nomination as described under &#147;&#8212;Board of Directors and Officers,&#148; we intend to elect our directors to hold office until the annual general meeting of our shareholders that occurs in the third year following his or her election and until his or her successor shall be elected and qualified. The nominations for directors, which are presented to our shareholders by our board of directors, are generally made by the board of directors itself, in accordance with the provisions of our amended and restated articles of association and the Companies Law;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">we intend to adopt and approve material changes to equity incentive plans in accordance with the Companies Law, which does not impose a requirement of shareholder approval for such actions. In addition, we intend to follow Israeli corporate governance practice, which requires shareholder approval prior to an issuance of securities in connection with equity-based compensation of officers, directors, employees or consultants only under certain circumstances, in lieu of Nasdaq Marketplace Rule 5635(c);</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">96</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">as opposed to making periodic reports to shareholders and proxy solicitation materials available to shareholders in the manner specified by the Nasdaq corporate governance rules, the Companies Law does not require us to distribute periodic reports directly to shareholders, and the generally accepted business practice in Israel is not to distribute such reports to shareholders but to make such reports available through a public website. We will only mail such reports to shareholders upon request. As a foreign private issuer, we are generally exempt from the SEC&#8217;s proxy solicitation rules; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">we will follow Israeli corporate governance practices instead of Nasdaq requirements to obtain shareholder approval for all corporate actions requiring such approval under the requirements of the Companies Law such as (i) transactions with directors concerning the terms of their service or indemnification, exemption and insurance for their service (or for any other position that they may hold at our company), (ii) extraordinary transactions with controlling shareholders, (iii) terms of employment or other engagement of the controlling shareholder of the company or such controlling shareholder&#8217;s relative, (iv) private placements that will result in a change of control, (v) certain transactions, other than a public offering, involving issuances of a 20% or greater interest in us and (vi) certain acquisitions of the stock or assets of another company. </td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Otherwise, we intend to comply with the rules generally applicable to U.S. domestic companies listed on the Nasdaq. We may in the future decide to use the foreign private issuer exemption with respect to some or all of the other Nasdaq corporate governance rules. Following the closing of this offering, we also intend to comply with Israeli corporate governance requirements under the Companies Law applicable to us.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Board of Directors and Officers</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the Companies Law, the management of our business is vested in our board of directors. Our board of directors may exercise all powers and may take all actions that are not specifically granted to our shareholders or to management. Our executive officers are responsible for our day-to-day management and have individual responsibilities that are established by our board of directors, subject to the terms of their respective employment agreements.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Upon the closing of this offering, our board of directors will consist of&#8201;seven directors, including two directors, who are intended to qualify as external directors and whose appointment fulfills the requirements of the Companies Law for the company to have two external directors (see &#147;&#8212;External Directors&#148;). These two directors, as well as one additional director, will qualify as independent directors under the corporate governance standards of the Nasdaq corporate governance rules and the independence requirements of Rule 10A-3 of the Exchange Act.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under our amended and restated articles of association, which will become effective upon the closing of this offering, the number of directors on our board of directors will be no less than seven and must include at least two external directors. The minimum and maximum number of directors may be changed, at any time and from time to time, by vote of our shareholders.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Other than external directors, for whom special election requirements apply under the Companies Law, as detailed below, our directors are divided into three classes with staggered three-year terms. Each class of directors consists, as nearly as possible, of one-third of the total number of directors constituting the entire board of directors (other than the external directors). At each annual general meeting of our shareholders, the election or re-election of directors following the expiration of the term of office of the directors of that class of directors will be for a term of office that expires on the third annual general meeting following such election or re-election, such that from 2020 and after, at each annual general meeting, the term of office of only one class of directors will expire. Each director holds office until the third annual general meeting of our shareholders and until his or her successor is duly appointed, unless the tenure of such director expires earlier pursuant to the Companies Law or unless removed from office as described below, except that our external directors have a term of office of three years under Israeli law (see &#147;&#8212;External directors&#8212;Election and Dismissal of External Directors&#148;).</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Upon the closing of this offering, our directors will be divided among three classes as follows: the Class I director, consisting of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, will hold office until our annual general meeting of shareholders to be held in 2020; the Class II directors, consisting of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , will hold office until our annual general meeting of shareholders to be held in 2021; and the Class III directors, consisting of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , will hold office until our annual general meeting of shareholders to be held in 2022.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">97</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under our amended and restated articles of association, which will become effective upon the closing of this offering, our board of directors may appoint directors to fill vacancies on our board of directors, including if the number of directors is below the maximum number of directors who may serve as provided in our amended and restated articles, for a term of office equal to the remaining period of the term of office of the director(s) whose office(s) has been vacated. External directors are elected for an initial term of three years and may be elected for up to two additional three-year terms under the circumstances described below. External directors may be removed from office only under the limited circumstances set forth in the Companies Law. See &#147;&#8212; External Directors.&#148;</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under Israeli law, the chief executive officer or a relative of the chief executive officer of a public company may not serve as the chairman of the board of directors of the company and the chairman or a relative of the chairman may not be vested with the authority of the chief executive officer, in each case, unless approved by a special majority of our shareholders as required under the Companies Law. The shareholders&#146; approval can be provided for a period of five years following an initial public offering, and subsequently, for additional periods of up to three years. In addition, a person who is subordinated, directly or indirectly, to the chief executive officer may not serve as the chairman of the board of directors; the chairman of the board of directors may not be vested with authorities that are granted to persons who are subordinated to the chief executive officer; and the chairman of the board of directors may not serve in any other position in the company or in a controlled subsidiary, but he or she may serve as a director or chairman of a controlled subsidiary. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, under the Companies Law, our board of directors must determine the minimum number of directors who are required to have financial and accounting expertise. Under applicable regulations, a director with financial and accounting expertise is a director who, by reason of his or her education, professional experience and skill, has a high level of proficiency in and understanding of business accounting matters and financial statements. See &#147;&#8212;External Directors&#8212;Qualifications of External Directors.&#148; He or she must be able to thoroughly comprehend the financial statements of the company and initiate debate regarding the manner in which financial information is presented. In determining the number of directors required to have such expertise, the board of directors must consider, among other things, the type and size of the company and the scope and complexity of its operations. Our board of directors has determined that&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; we require at least one director with the requisite financial and accounting expertise and that has such expertise.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">There are no family relationships among any of our office holders (including directors). </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>External Directors</b></p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>Qualifications of External Directors</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the Companies Law, companies incorporated under the laws of the State of Israel, whose shares are publicly traded, including companies with shares listed on the Nasdaq, are required to appoint at least two external directors who meet the qualification requirements set forth in the Companies Law, subject to certain exceptions that are not currently available to us. We have appointed&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as our external directors, subject to ratification of their election as an external director under the Companies Law by our shareholders within three months following this offering. Our board of directors has determined that they both are independent in accordance with the corporate governance standards of the Nasdaq corporate governance rules and the independence requirements of Rule 10A-3 of the Exchange Act. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A person may not be appointed as an external director if the person is a relative of a controlling shareholder or if on the date of the person&#146;s appointment or within the preceding two years the person or his or her relatives, partners, employers or anyone to whom that person is subordinate, whether directly or indirectly, or entities under the person&#146;s control have or had any affiliation with any of&#8201; (each an &#147;Affiliated Party&#148;): (1) us; (2) any person or entity controlling us on the date of such appointment; (3) any relative of a controlling shareholder; or (4) any entity controlled, on the date of such appointment or within the preceding two years, by us or by a controlling shareholder. If there is no controlling shareholder or any shareholder holding 25% or more of voting rights in the company, a person may not be appointed as an external director if the person has any affiliation to the chairman of the board of directors, the general manager (chief executive officer), any shareholder holding 5% or more of the company&#146;s shares or voting rights or the senior financial officer as of the date of the person&#146;s appointment.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">98</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The term affiliation includes:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">an employment relationship;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a business or professional relationship maintained on a regular basis;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">control; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">service as an office holder, excluding service as a director in a private company prior to the first offering of its shares to the public if such director was appointed as a director of the private company in order to serve as an external director following the initial public offering.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The term &#147;relative&#148; is defined as a spouse, sibling, parent, grandparent, descendant, spouse&#146;s descendant, sibling and parent and the spouse of each of the foregoing.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A person may not serve as an external director if that person or that person&#146;s relative, partner, employer, a person to whom such person is subordinate (directly or indirectly) or any entity under the person&#146;s control has a business or professional relationship with any entity that has an affiliation or other prohibited relationship with any Affiliated Party, even if such relationship is intermittent (excluding insignificant relationships). Additionally, any person who has received compensation intermittently (excluding insignificant relationships) other than compensation permitted under the Companies Law may not continue to serve as an external director. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">No person can serve as an external director if the person&#146;s position or other affairs create, or may create, a conflict of interest with the person&#146;s responsibilities as a director or may otherwise interfere with the person&#146;s ability to serve as an external director or if such a person is an employee of the Israel Securities Authority or of an Israeli stock exchange. If at the time an external director is appointed all current members of the board of directors, who are not controlling shareholders or relatives of controlling shareholders, are of the same gender, then the external director to be appointed must be of the other gender. In addition, a person who is a director of a company may not be elected as an external director of another company if, at that time, a director of the other company is acting as an external director of the first company.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Companies Law provides that an external director must meet certain &#147;professional qualifications&#148; or have &#147;financial and accounting expertise&#148; and that at least one external director must have &#147;financial and accounting expertise.&#148; However, if at least one of our other directors (1) meets the independence requirements of the Exchange Act, (2) meets the standards of the Nasdaq corporate governance rules for membership on the audit committee and (3) has &#147;financial and accounting expertise&#148; as defined in the Companies Law and applicable regulations, then none of our external directors is required to possess financial and accounting expertise as long as they possess other requisite professional qualifications. The determination of whether a director possesses &#147;financial and accounting expertise&#148; is made by the board of directors. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The regulations promulgated under the Companies Law define an external director with requisite professional qualifications as a director who satisfies one of the following requirements: (1) the director holds an academic degree in either economics, business administration, accounting, law or public administration, (2) the director either holds an academic degree in any other field or has completed another form of higher education in the company&#146;s primary field of business or in an area which is relevant to his or her office as an external director in the company, or (3) the director has at least five years of experience serving in any one of the following, or at least five years of cumulative experience serving in two or more of the following capacities: (a) a senior business management position in a company with a substantial scope of business, (b) a senior position in the company&#146;s primary field of business or (c) a senior position in public administration. The determination of whether a director possesses the requisite &#147;professional qualifications&#148; is made by the board of directors.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Until the lapse of a two-year period from the date that an external director of a company ceases to act in such capacity, the company in which such external director served, and its controlling shareholder (as defined below) or any entity under control of such controlling shareholder, may not, directly or indirectly, grant such former external director, or his or her spouse or child, any benefit, including via (i) the appointment of such former director or his or her spouse or his child as an officer in the company or in an entity controlled by the company&#146;s controlling shareholder, (ii) the employment of such former director, and (iii) the engagement, directly or indirectly, of such former director as a provider of professional services for compensation, directly or indirectly, including via an entity under his or her control. With respect to a relative who is not a spouse or a child, such limitations shall only apply for one year from the date such external director ceased to be engaged in such capacity.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">99</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The term &#147;controlling shareholder&#148; means a shareholder with the ability to direct the activities of the company, other than by virtue of being an office holder. A shareholder is presumed to have &#147;control&#148; of the company and thus to be a controlling shareholder of the company if the shareholder holds 50% or more of the &#147;means of control&#148; of the company. &#147;Means of control&#148; is defined as (1) the right to vote at a general meeting of a company or a corresponding body of another corporation; or (2) the right to appoint directors of the corporation or its general manager. For the purpose of approving certain related-party transactions, the term also includes any shareholder that holds 25% or more of the voting rights of the company if the company has no shareholder that owns more than 50% of its voting rights. For the purpose of determining the holding percentage stated above, two or more shareholders who have a personal interest in a transaction that is brought for the company&#146;s approval are deemed as joint holders. The term &#147;office holder&#148; is defined as a chief executive officer (referred to in the Companies Law as a general manager), chief business manager, deputy general manager, vice general manager, director or manager directly subordinate to the general manager or any other person assuming the responsibilities of any of the foregoing positions, without regard to such person&#146;s title.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Election and Dismissal of External Directors</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under Israeli law, external directors are elected by a majority vote at a shareholders&#146; meeting; provided that either:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the majority of the shares voted at the meeting in favor of the election of the external director, excluding abstentions, include at least a majority of the votes of shareholders who are not controlling shareholders and do not have a personal interest in the appointment (excluding a personal interest that did not result from the shareholder&#8217;s relationship with the controlling shareholder); or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the total number of shares held by non-controlling shareholders or any one on their behalf that are voted against the election of the external director does not exceed 2% of the aggregate voting rights in the company.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under Israeli law, the initial term of an external director of an Israeli public company is three years. The external director may be re-elected, subject to certain circumstances and conditions, for up to two consecutive additional terms of three years each, and thereafter, the term, may be extended of additional three-year terms; provided that the external director is reelected subject to the same shareholder vote requirements as if elected for the first time (as described above). Each re-election is subject to one of the following: </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">his or her service for each such additional term is recommended by one or more shareholders holding at least 1% of the company&#8217;s voting rights and is approved at a shareholders meeting by a disinterested majority, where the total number of shares held by non-controlling, disinterested shareholders voting for such reelection exceeds 2% of the aggregate voting rights in the company and subject to additional restrictions set forth in the Companies Law with respect to the affiliation of the external director nominee;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the external director proposed his or her own nomination, and such nomination was approved in accordance with the requirements described in the paragraph above; or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">his or her service for each such additional term is recommended by the board of directors and is approved at a meeting of shareholders by the same majority required for the initial election of an external director (as described above).</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">An external director may be removed by the same special majority of the shareholders required for his or her election, if he or she ceases to meet the statutory qualifications for appointment or if he or she violates his or her duty of loyalty to the company. An external director may also be removed by order of an Israeli court if the court finds that the external director is unable to exercise his or her office, has ceased to meet the statutory qualifications for his or her appointment, has violated his or her duty of loyalty to the company, or has been convicted by a court outside Israel of certain offenses detailed in the Companies Law.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If the vacancy of an external directorship causes a company to have fewer than two external directors, the company&#146;s board of directors is required under the Companies Law to call a special general meeting of the company&#146;s shareholders as soon as possible to appoint such number of new external directors so that the company thereafter has at least two external directors.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">100</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our board of directors has determined that &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; has accounting and financial expertise and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; possesses professional qualifications as required under the Companies Law.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Additional Provisions</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the Companies Law, each committee authorized to exercise any of the powers of the board of directors is required to include at least one external director and its audit and compensation committees are required to include all of the external directors.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">An external director is entitled to compensation and reimbursement of expenses in accordance with regulations promulgated under the Companies Law and is prohibited from receiving any other compensation, directly or indirectly, in connection with serving as a director except for certain exculpation, indemnification and insurance provided by the company, as specifically allowed by the Companies Law.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Audit Committee</b></p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>Companies Law Requirements</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the Companies Law, the board of directors of a public company must also appoint an audit committee comprised of at least three directors, including all of the external directors. The audit committee may not include:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the chairman of the board of directors; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a controlling shareholder or a relative of a controlling shareholder;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">any director employed by the company or by one of its controlling shareholders or by an entity controlled by one of its controlling shareholders (other than as a member of the board of directors);</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">any director who regularly provides services to the company, to one of its controlling shareholders or to an entity controlled by one of its controlling shareholders; or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a director who derives most of his or her income from a controlling shareholder.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">According to the Companies Law, the majority of the members of the audit committee, as well as the majority of members present at audit committee meetings, will be required to be &#147;independent&#148; (as defined below) and the chairman of the audit committee will be required to be an external director. Any persons not qualified from serving as a member of the audit committee may not be present at the audit committee meetings, unless the chairman of the audit committee has determined that such person is required to be present at the meeting or if such person qualifies under one of the exemptions of the Companies Law.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The term &#147;independent director&#148; is defined under the Companies Law as an external director or a director who meets the following conditions and who is appointed or classified as such according to the Companies Law: (1) he or she meets the qualifications for being appointed as an external director, except for (i) the requirement that the director be an Israeli resident (which does not apply to companies such as ours whose securities have been offered outside of Israel or are listed outside of Israel); and (ii) the requirement for &#147;financial and accounting expertise&#148; or professional qualifications, and the audit committee approves the director having met such conditions and (2) he or she has not served as a director of the company for over nine consecutive years with any interruption of up to two years of his or her service not being deemed a disruption to the continuity of his or her service.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Nasdaq Listing Requirements </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the Nasdaq corporate governance rules, we are required to maintain an audit committee consisting of at least three independent directors, all of whom are financially literate and one of whom has accounting or related financial management expertise. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our audit committee will consist of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . All members of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and the Nasdaq corporate governance rules. Our board of directors has determined, in its business judgment, that is an audit committee financial expert as defined by the SEC rules and has the requisite financial experience as defined by the Nasdaq corporate governance rules.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Each of the members of the audit committee is required to be &#147;independent&#148; as such term is defined in Rule 10A-3(b)(1) under the Exchange Act.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">101</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Approval of Transactions with Related Parties</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The approval of the audit committee is required to effect specified actions and transactions with office holders and controlling shareholders and their relatives, or in which they have a personal interest. See &#147;&#8212;Fiduciary Duties and Approval of Specified Related Party Transactions and Compensation under Israeli Law.&#148; The audit committee may not approve an action or a transaction with a controlling shareholder or with an office holder unless, among other things, at the time of approval the audit committee meets the composition requirements under the Companies Law.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Audit Committee Role</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our board of directors plans to adopt an audit committee charter, which will become effective upon the listing of our ordinary shares on the Nasdaq, setting forth the responsibilities of the audit committee consistent with the rules of the SEC and the Nasdaq corporate governance rules, as well as the requirements for such committee under the Companies Law, which include:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">recommending the retention and termination of our independent registered public accounting firm to the board of directors in accordance with Israeli law;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">recommending to the board of directors in accordance with Israeli law the appointment, compensation, retention and oversight of any accounting firm engaged for the purpose of preparing or issuing an audit report or performing other audit services;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">recommending the terms of audit and non-audit services to be provided by the independent registered public accounting firm for pre-approval by our board of directors;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">recommending the engagement or termination of the person filling the office of our internal auditor;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">reviewing with management and our independent directors our financial statements prior to their submission to the SEC; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">approval of certain transactions with office holders and controlling shareholders, as described below, and other related party transactions.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Additionally, under the Companies Law, the role of the audit committee includes the identification of irregularities in our business management, among other things, by consulting with the internal auditor or our independent auditors and suggesting an appropriate course of action to the board of directors. The audit committee is also required to adopt procedures with respect to processing of employees&#146; complaints in connection with deficiencies in the management of the company, and the appropriate means of protection afforded to such employees. In addition, the audit committee or the board of directors, as set forth in the articles of association of the company, is required to approve the yearly or periodic work plan proposed by the internal auditor, and where the board of directors approves such work plan, to examine such work plan before its submission to the board of directors and propose amendments thereto. The audit committee is required to assess the company&#146;s internal audit system and the performance of its internal auditor. The Companies Law also requires that the audit committee assess the scope of the work and compensation of the company&#146;s external auditor. In addition, the audit committee is required to determine whether certain related party actions and transactions are &#147;material&#148; or &#147;extraordinary&#148; for the purpose of the requisite approval procedures under the Companies Law and whether certain transactions with a controlling shareholder will be subject to a competitive procedure.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The audit committee charter states that in fulfilling its role the committee is empowered to conduct or authorize investigations into any matters within its scope of responsibilities.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Compensation Committee</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the Companies Law, public companies are required to appoint a compensation committee in accordance with the guidelines set forth thereunder.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our compensation committee must consist of at least three members. All of the external directors must serve on the committee and constitute a majority of its members. The chairman of the compensation committee must be an external director. The remaining members are not required to be external directors, but must be directors who would qualify to serve as members of the audit committee (as described above).</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">102</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The compensation committee will consist of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , and will assist the board of directors in determining compensation for our directors and officers.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; will serve as the chairman of the compensation committee.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In accordance with the Companies Law, the roles of the compensation committee are, among others, as follows:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">1.</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">to recommend to the board of directors the compensation policy for directors and officers, and, once every three years, or five years from a company&#8217;s initial public offering, to recommend to the board of directors, whether the compensation policy that had been approved should be extended for a longer period of time;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">2.</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">to recommend to the board of directors updates to the compensation policy, from time to time, and examine its implementation;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">3.</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">to decide whether to approve the terms of office and employment of directors and officers that require approval of the compensation committee; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">4.</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">to decide whether the compensation terms of the chief executive officer, which were determined pursuant to the compensation policy, will be exempted from approval by the shareholders because such approval would harm the ability to engage the chief executive officer.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition to the roles mentioned above, our compensation committee may also make recommendations to our board of directors regarding the awarding of employee equity grants.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In general, under the Companies Law, a public company must have a compensation policy approved by the board of directors after receiving and considering the recommendations of the compensation committee. In addition, the compensation policy requires the approval of the general meeting of the shareholders. In public companies such as our company, shareholder approval by a majority vote of the ordinary shares present and voting at a meeting of shareholders called for such purpose, provided that either: (i) such majority includes the majority of the votes of those shareholders who are non-controlling shareholders and do not have a personal interest in the approval of the compensation policy, who voted at the meeting (excluding abstentions) or (ii) the total number of votes against the proposal among the shareholders mentioned in paragraph (i) does exceed two percent (2%) of the voting rights in the company. Under special circumstances, the board of directors may approve the compensation policy despite the objection of the shareholders on the condition that the compensation committee and then the board of directors decide, on the basis of detailed arguments and after discussing again the compensation policy, that approval of the compensation policy, despite the objection of the meeting of shareholders.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">However, if a company initially offering its securities to the public, like us, adopts a compensation policy in advance of its initial public offering, and describes the compensation policy in the prospectus relating to the offering, then the compensation policy is deemed a validly adopted policy in accordance with the Companies Law requirements described above and will be valid for a term of five years from the date such company becomes public company.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The compensation policy must be based on certain considerations, include certain provisions and needs to reference certain matters as set forth in the Companies Law.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The compensation policy must serve as the basis for decisions concerning the financial terms of employment or engagement of office holders, including exculpation, insurance, indemnification or any monetary payment or obligation of payment in respect of employment or engagement. The compensation policy must relate to certain factors, including advancement of the company&#146;s objectives, business plan and long-term strategy, and creation of appropriate incentives for office holders. It must also consider, among other things, the company&#146;s risk management, size and the nature of its operations. The compensation policy must furthermore consider the following additional factors:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the education, skills, experience, expertise and accomplishments of the relevant office holder;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the office holder&#8217;s position, responsibilities and prior compensation agreements with him or her;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">103</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the ratio between the cost of the terms of employment of an office holder and the cost of the employment of other employees of the company, including employees employed through contractors who provide services to the company, in particular the ratio between such cost, the average and median salary of the employees of the company, as well as the impact of such disparities on the work relationships in the company;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">if the terms of employment include variable components &#8212; the possibility of reducing variable components at the discretion of the board of directors and the possibility of setting a limit on the exercise value of non-cash variable equity-based components; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">if the terms of employment include severance compensation &#8212; the term of employment or office of the office holder, the terms of his or her compensation during such period, the company&#8217;s performance during the such period, his or her individual contribution to the achievement of the company goals and the maximization of its profits and the circumstances under which the office he or she is leaving the company.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The compensation policy must also include, among others:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">with regard to variable components:</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; text-align: left; ">&#9675;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; text-align: left; "><font style="font-size: 13.33px;">with the exception of office holders which report directly to the chief executive officer, </font><font style="font-size: 13.33px;">determining the variable components on long-term performance basis and on measurable criteria; </font><font style="font-size: 13.33px;">however, the company may determine that an immaterial part of the variable components of the </font><font style="font-size: 13.33px;">compensation package of an office holder shall be awarded based on non-measurable criteria, if </font><font style="font-size: 13.33px;">such amount is not higher than three monthly salaries per annum while taking into account the </font><font style="font-size: 13.33px;">office holder&#8217;s contribution to the company;</font></td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; text-align: left; ">&#9675;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; text-align: left; "><font style="font-size: 13.33px;">the ratio between variable and fixed components, as well as the limit of the values of variable </font><font style="font-size: 13.33px;">components at the time of their grant.</font></td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a condition under which the office holder will return to the company, according to conditions to be set forth in the compensation policy, any amounts paid as part of his or her terms of employment, if such amounts were paid based on information later to be discovered to be wrong, and such information was than re-presented in the company&#8217;s financial statements;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the minimum holding or vesting period of variable equity-based components, while taking into consideration long-term incentives; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a limit to retirement grants.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our compensation policy, which will become effective immediately prior to the closing of this offering, is designed to promote retention and motivation of directors and executive officers, incentivize superior individual excellence, align the interests of our directors and executive officers with our long term performance and provide a risk management tool. To that end, a portion of an executive officer compensation package is targeted to reflect our short and long-term goals, as well as the executive officer&#146;s individual performance. On the other hand, our compensation policy includes measures designed to reduce the executive officer&#146;s incentives to take excessive risks that may harm the Company in the long-term, such as limits on the value of cash bonuses and equity-based compensation, limitations on the ratio between the variable and the total compensation of an executive officer and minimum vesting periods for equity-based compensation.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our compensation policy also addresses our executive officer&#146;s individual characteristics (such as his or her respective position, education, scope of responsibilities and contribution to the attainment of our goals) as the basis for compensation variation among our executive officers, and considers the internal ratios between compensation of our executive officers and directors and other employees. Pursuant to our compensation policy, the compensation that may be granted to an executive officer may include: base salary, annual bonuses and other cash bonuses (such as relocation, signing and special bonuses) as well as change of control related bonuses, equity-based compensation, benefits and retirement and termination of employment arrangements. All cash bonuses are limited to a maximum amount linked to the executive officer&#146;s base salary (or to the total annual compensation in the case of the special bonus for special achievements).</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">104</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">An annual cash bonus may be awarded to executive officers upon the attainment of pre-set periodic objectives and individual targets. The annual cash bonus that may be granted to our executive officers other than our chief executive officer will be based on performance objectives and a discretionary evaluation of the executive officer&#146;s overall performance by our chief executive officer and subject to minimum thresholds. Furthermore, the performance objectives will be recommended by our chief executive officer and approved by our compensation committee (and, if required by law, by our board of directors).</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The performance measurable objectives of our chief executive officer will be determined annually by our compensation committee and board of directors, will include the weight to be assigned to each achievement in the overall evaluation. A less significant portion of the chief executive officer&#146;s annual cash bonus may be based on a discretionary evaluation of the chief executive officer&#146;s overall performance by the compensation committee and the board of directors based on quantitative and qualitative criteria.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The equity-based compensation under our compensation policy for our executive officers is designed in a manner consistent with the underlying objectives in determining the base salary and the annual cash bonus, with its main objectives being to enhance the alignment between the executive officers&#146; interests with our long term interests and those of our shareholders and to strengthen the retention and the motivation of executive officers in the long term. Our compensation policy entitles our executive officers to compensation in the form of share options or other equity-based awards, such as restricted share units, in accordance with our share incentive plan then in place (subject to the compensation committee approval or the approval of the board of directors). All equity-based incentives granted to executive officers shall be subject to vesting periods in order to promote long-term retention of the awarded executive officers. The equity-based compensation shall be granted from time to time and be individually determined and awarded according to the performance, educational background, prior business experience, qualifications, role and the personal responsibilities of the executive officer.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, our compensation policy contains compensation recovery provisions which allows us under certain conditions to recover bonuses paid in excess, enables our chief executive officer to approve an immaterial change in the terms of employment of an executive officer (provided that the changes of the terms of employment are in accordance our compensation policy) and allows us to exculpate, indemnify and insure our executive officers and directors subject to certain limitations set forth thereto.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our compensation policy also governs the compensation of the members of our board of directors and determines that the compensation of the directors shall be in accordance with the Companies Regulations (Rules Regarding the Compensation and Expenses of an External Director), 5760-2000, as amended by the Companies Regulations (Relief for Public Companies Traded in Stock Exchange Outside of Israel), 5760-2000, or the compensation of directors regulations, as such regulations may be amended from time to time, provided, however, that under special circumstances such as in the case of a professional director, an expert director or a director who makes a unique contribution to the Company, such director&#146;s compensation may be different than the compensation of all other directors and maybe greater than the maximum amount allowed, in our case, by the compensation of directors regulations or, in accordance with the amounts determined in our compensation policy. Our directors may also be entitled to receive equity-based compensation in the form of share options subject to an annual maximum and to a vesting period in order to promote long-term retention of the awarded director as well as to the approval of our shareholders as required under the Companies Law. Furthermore, the chairman of our board of directors may be entitled to a higher base compensation or equity-based compensation.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our compensation policy was approved by our board of directors and our shareholders, will be in effect for a period of five years from the closing of this offering, and is filed as an exhibit to the registration statement of which this prospectus forms a part.</p>

<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Code of Ethics and Conduct</b></p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">On the closing of this offering, we will adopt a code of ethics and conduct, which is applicable to all of our directors, officers and employees. We will make our code of ethics publicly available on our website.</p>

				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Internal Auditor</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the Companies Law, the board of directors of a public company must appoint an internal auditor based on the recommendation of the audit committee. The role of the internal auditor is, among other things, to examine whether a company&#146;s actions comply with applicable law and orderly business procedure. Under the </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">105</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">Companies Law, the internal auditor may not be an interested party or an office holder or a relative of an interested party or of an office holder, nor may the internal auditor be the company&#146;s independent auditor or the representative of the same.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">An &#147;interested party&#148; is defined in the Companies Law as (i) a holder of 5% or more of the issued share capital or voting power in a company, (ii) any person or entity who has the right to designate one or more directors or to designate the chief executive officer of the company, or (iii) any person who serves as a director or as a chief executive officer of the company. As of the date of this prospectus, we have not yet appointed our internal auditor, but we intend to appoint an internal auditor following the closing of this offering.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Fiduciary Duties and Approval of Specified Related Party Transactions and Compensation </b><b>U</b><b>nder Israeli Law</b></p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>Fiduciary Duties of Office Holders</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Companies Law imposes a duty of care and a duty of loyalty on all office holders of a company. The duty of care of an office holder is based on the duty of care set forth in connection with the tort of negligence under the Israeli Torts Ordinance (New Version) 5728-1968. This duty of care requires an office holder to act with the degree of proficiency with which a reasonable office holder in the same position would have acted under the same circumstances. The duty of care includes, among other things, a duty to use reasonable means, in light of the circumstances, to obtain:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">information on the business advisability of a given action brought for his or her approval or performed by virtue of his or her position; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">all other important information pertaining to such action.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The duty of loyalty incumbent on an office holder requires him or her to act in good faith and for the benefit of the company, and includes, among other things, the duty to:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">refrain from any act involving a conflict of interest between the performance of his or her duties in the company and his or her other duties or personal affairs;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">refrain from any activity that is competitive with the business of the company;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">refrain from exploiting any business opportunity of the company for the purpose of gaining a personal advantage for himself or herself or others; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">disclose to the company any information or documents relating to the company&#8217;s affairs which the office holder received as a result of his or her position as an office holder.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the Companies Law, a company may approve an act specified above which would otherwise constitute a breach of the office holder&#146;s fiduciary duty; provided that the office holder acted in good faith, the act or its approval does not harm the company, and the office holder discloses his or her personal interest a sufficient time before the approval of such act. Any such approval is subject to the terms of the Companies Law, setting forth, among other things, the appropriate parties of the company entitled to provide such approval, and the methods of obtaining such approval.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Disclosure of Personal Interests of an Office Holder and Approval of Certain Transactions</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Companies Law requires that an office holder promptly disclose to the company any direct or indirect personal interest that he or she may have and all related material information or documents known to him or her relating to any existing or proposed transaction by the company. An interested office holder&#146;s disclosure must be made promptly and in any event no later than the first meeting of the board of directors at which the transaction is considered. An office holder is not obliged to disclose such information if the personal interest of the office holder derives solely from the personal interest of his or her relative in a transaction that is not considered an extraordinary transaction.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the Companies Law, once an office holder has complied with the above disclosure requirement, a company may approve a transaction between the company and the office holder or a third party in which the office holder has a personal interest. However, a company may not approve a transaction or action that is not to the company&#146;s benefit or that is not performed by the office holder in good faith.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">106</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If the transaction is an extraordinary transaction, the office holder must also disclose any personal interest held by:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the office holder&#8217;s relatives (spouse, siblings, parents, grandparents, descendants, spouse&#8217;s descendants and the spouses of any of these people); or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">any company in which the office holder or his or her relatives holds 5% or more of the shares or voting rights, serves as a director or general manager or has the right to appoint at least one director or the general manager.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the Companies Law, unless the articles of association of a company provide otherwise, a transaction with an office holder or with a third party in which the office holder has a personal interest, which is not an extraordinary transaction, requires approval by the board of directors. Our amended and restated articles of association provide that such a transaction, which is not an extraordinary transaction, shall be approved by the board of directors or a committee of the board of directors or any other entity (which has no personal interest in the transaction) authorized by the board of directors. If the transaction considered is an extraordinary transaction with an office holder or third party in which the office holder has a personal interest, then audit committee approval is required prior to approval by the board of directors. Under specific circumstances, shareholder approval may also be required. For the approval of compensation arrangements with directors and executive officers, see &#147;&#8212;Rules Applicable to Compensation of Directors and Executive Officers.&#148;</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Any persons who have a personal interest in the approval of a transaction that is brought before a meeting of the board of directors or the audit committee may not be present at the meeting or vote on the matter. However, if the chairman of the board of directors or the chairman of the audit committee, as applicable, has determined that the presence of an office holder with a personal interest is required for the purpose of presenting the matter, such office holder may be present at the meeting. Notwithstanding the foregoing, a director who has a personal interest may be present at the meeting and vote on the matter if a majority of the directors or members of the audit committee, as applicable, have a personal interest in the approval of such transaction. If a majority of the directors at a board of directors meeting or members of the audit committee, as applicable, have a personal interest in the transaction, such transaction also requires approval of the shareholders of the company.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A &#147;personal interest&#148; is defined under the Companies Law as the personal interest of a person in an action or in a transaction of the company, including the personal interest of such person&#146;s relative or the interest of any other corporate body in which the person and/or such person&#146;s relative is a director or general manager, a 5% shareholder or holds 5% or more of the voting rights, or has the right to appoint at least one director or the general manager, but excluding a personal interest stemming solely from the fact of holding shares in the company. A personal interest also includes (1) a personal interest of a person who votes according to a proxy of another person, including in the event that the other person has no personal interest, and (2) a personal interest of a person who gave a proxy to another person to vote on his or her behalf regardless of whether the discretion of how to vote lies with the person voting or not.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">An &#147;extraordinary transaction&#148; is defined under the Companies Law as any of the following:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a transaction other than in the ordinary course of business;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a transaction that is not on market terms; or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a transaction that may have a material impact on the company&#8217;s profitability, assets or liabilities.</td></tr></table><div style="clear: both"></div>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Disclosure of Personal Interests of a Controlling Shareholder and Approval of Certain Transactions</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Companies Law also requires that a controlling shareholder promptly disclose to the company any personal interest that he or she may have and all related material information or documents relating to any existing or proposed transaction by the company. A controlling shareholder&#146;s disclosure must be made promptly and in any event no later than the first meeting of the board of directors at which the transaction is considered. For the purpose of approving transactions with controlling shareholders, the term also includes any shareholder that holds 25% or more of the voting rights of the company if the company has no shareholder that owns more than 50% of its voting rights. For the purpose of determining the holding percentage stated above, two or more shareholders who have a personal interest in a transaction that is brought for the company&#146;s approval are deemed as joint holders. Extraordinary transactions with a controlling shareholder or in which a controlling shareholder has a personal interest, including a private placement in which a controlling shareholder has a personal interest, and the terms of engagement of the company, directly or indirectly, with a controlling shareholder or a controlling shareholder&#146;s relative (including through a corporation controlled by a controlling shareholder), </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">107</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">regarding the company&#146;s receipt of services from the controlling shareholder, and if such controlling shareholder is also an office holder or employee of the company, regarding his or her terms of employment, require the approval of each of (i) the audit committee or the compensation committee with respect to the terms of the engagement as an office holder or employee, including insurance, indemnification and compensation, (ii) the board of directors and (iii) the shareholders, in that order. In addition, the shareholder approval must fulfill one of the following requirements:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a majority of the shares held by shareholders who have no personal interest in the transaction and are voting at the meeting must be voted in favor of approving the transaction, excluding abstentions; or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the shares voted by shareholders who have no personal interest in the transaction who vote against the transaction represent no more than two percent (2%) of the voting rights in the company.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, any extraordinary transaction with a controlling shareholder or in which a controlling shareholder has a personal interest, and an engagement of the company, directly or indirectly, with a controlling shareholder or a controlling shareholder&#146;s relative (including through a corporation controlled by a controlling shareholder), regarding the company&#146;s receipt of services from the controlling shareholder, and if such controlling shareholder is also an office holder or employee of the company, regarding his or her terms of employment, in each case, with a term of more than three years requires the abovementioned approval every three years, however, such transactions not involving the receipt of services or compensation can be approved for a longer term, provided that the audit committee determines that such longer term is reasonable under the circumstances. In addition, transactions with a controlling shareholder or a controlling shareholder&#146;s relative who serves as an officer in a company, directly or indirectly (including through a corporation under his or her control), involving the receipt of services by a company or their compensation can have a term of five years from the company&#146;s initial public offering under certain circumstances.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Companies Law requires that every shareholder that participates, in person, by proxy or by voting instrument, in a vote regarding a transaction with a controlling shareholder, must indicate in advance or in the ballot whether or not that shareholder has a personal interest in the vote in question. Failure to so indicate will generally result in the invalidation of that shareholder&#146;s vote.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Disclosure of Compensation of Executive Officers</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">For so long as we qualify as a foreign private issuer, we are not required to comply with the proxy rules applicable to U.S. domestic companies, including the requirement applicable to emerging growth companies to disclose the compensation of our chief executive officer and other two most highly compensated executive officers on an individual, rather than an aggregate, basis. Nevertheless, regulations promulgated under the Companies Law will require us, after we become a public company, to disclose the annual compensation of our five most highly compensated office holders on an individual basis, rather than on an aggregate basis. This disclosure will not be as extensive as that required of a U.S. domestic issuer. We intend to commence providing such disclosure, at the latest, in the proxy statement for our first annual general meeting of shareholders following this offering, which will be furnished under cover of a Form 6-K and we may provide such information at an earlier date.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Rule</b></i><i><b>s</b></i><i><b> Applicable to Compensation of Directors and Executive Officers</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Directors</i>. Under the Companies Law, the compensation of our directors requires the approval of our compensation committee, the subsequent approval of the board of directors and, unless exempted under the regulations promulgated under the Companies Law, the approval of the shareholders at a general meeting. If the compensation of our directors is inconsistent with our stated compensation policy, then, the compensation committee and the board of directors may approve such compensation, provided that those provisions that must be included in the compensation policy according to the Companies Law have been considered by the compensation committee and board of directors. Furthermore, shareholder approval will also be required, provided that:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">at least a majority of the shares held by all shareholders who are not controlling shareholders and do not have a personal interest in such matter, present and voting at such meeting, are voted in favor of the compensation package, excluding abstentions; or</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">108</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the total number of shares of non-controlling shareholders and shareholders who do not have a personal interest in such matter voting against the compensation package does not exceed two percent (2%) of the aggregate voting rights in the company.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Executive officers other than the chief executive officer</i>. The Companies Law requires the approval of the compensation of a public company&#146;s executive officers (other than the chief executive officer) in the following order: (i) the compensation committee, (ii) the company&#146;s board of directors, and (iii) if such compensation arrangement is inconsistent with the company&#146;s stated compensation policy, the company&#146;s shareholders (by a special majority vote as discussed above with respect to the approval of director compensation). However, if the shareholders of the company do not approve a compensation arrangement with an executive officer that is inconsistent with the company&#146;s stated compensation policy, the compensation committee and board of directors may override the shareholders&#146; decision if each of the compensation committee and the board of directors provide detailed reasons for their decision.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Chief executive officer</i>. Under the Companies Law, the compensation of a public company&#146;s chief executive officer is required to be approved by: (i) the company&#146;s compensation committee; (ii) the company&#146;s board of directors, and (iii) the company&#146;s shareholders (by a special majority vote as discussed above with respect to the approval of director compensation). However, if the shareholders of the company do not approve the compensation arrangement with the chief executive officer, the compensation committee and board of directors may override the shareholders&#146; decision if each of the compensation committee and the board of directors provide a detailed report for their decision. The approval of each of the compensation committee and the board of directors should be in accordance with the company&#146;s stated compensation policy; however, in special circumstances, they may approve compensation terms of a chief executive officer that are inconsistent with such policy provided that they have considered those provisions that must be included in the compensation policy according to the Companies Law and that shareholder approval was obtained (by a special majority vote as discussed above with respect to the approval of director compensation). In addition, the compensation committee may waive the shareholder approval requirement with regards to the approval of the engagement terms of a candidate for the chief executive officer position, if they determine that the compensation arrangement is consistent with the company&#146;s stated compensation policy, and that the chief executive officer did not have a prior business relationship with the company or a controlling shareholder of the company and that subjecting the approval of the engagement to a shareholder vote would impede the company&#146;s ability to employ the chief executive officer candidate.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Duties of Shareholders</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the Companies Law, a shareholder has a duty to refrain from abusing its power in the company and to act in good faith and in an acceptable manner in exercising its rights and performing its obligations to the company and other shareholders, including, among other things, when voting at meetings of shareholders on the following matters:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">an amendment to the articles of association;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">an increase in the company&#8217;s authorized share capital;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a merger; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the approval of related party transactions and acts of office holders that require shareholder approval.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A shareholder also has a general duty to refrain from discriminating against other shareholders.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The remedies generally available upon a breach of contract will also apply to a breach of the shareholder duties mentioned above, and in the event of discrimination against other shareholders, additional remedies may be available to the injured shareholder.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, any controlling shareholder, any shareholder that knows that its vote can determine the outcome of a shareholder vote and any shareholder that, under a company&#146;s articles of association, has the power to appoint or prevent the appointment of an office holder, or any other power with respect to a company, is under a duty to act with fairness towards the company. The Companies Law does not describe the substance of this duty except to state that the remedies generally available upon a breach of contract will also apply in the event of a breach of the duty to act with fairness, taking the shareholder&#146;s position in the company into account.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">109</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Approval of Private Placements</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the Companies Law and the regulations promulgated thereunder, a private placement of securities or an Israeli public company whose shares are traded solely outside of Israel, like we will be upon completion of this offering, does not require approval at a general meeting of the shareholders of a company; provided, however, that in special circumstances, such as a private placement completed in lieu of a special tender offer (see &#147;Description of Share Capital&#8212;Acquisitions Under Israeli Law&#148;) or a private placement which qualifies as a related party transaction, as discussed above, approval at a general meeting of the shareholders of a company is required. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Exculpation, Insurance and Indemnification of Directors and Officers</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the Companies Law, a company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate an office holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of duty of care but only if a provision authorizing such exculpation is included in its articles of association. Our amended and restated articles of association, which will become effective upon the closing of this offering, include such a provision. The company may not exculpate in advance a director from liability arising from a breach of his or her duty of care in connection with a prohibited dividend or distribution to shareholders.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the Companies Law and the Israeli Securities Law, 5728-1968 (the &#147;Securities Law&#148;), our amended and restated articles of association, which will become effective upon the closing of this offering, provide that we may indemnify an office holder in respect of the following liabilities, payments and expenses incurred for acts performed by him or her as an office holder, either in advance of an event or following an event, provided its articles of association include a provision authorizing such indemnification:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a monetary liability incurred by or imposed on the office holder in favor of another person pursuant to a court judgment, including pursuant to a settlement confirmed as judgment or arbitrator&#8217;s decision approved by a competent court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company&#8217;s activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and amount or criteria;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">reasonable litigation expenses, including reasonable attorneys&#8217; fees, which were incurred by the office holder as a result of an investigation or proceeding filed against the office holder by an authority authorized to conduct such investigation or proceeding; provided that such investigation or proceeding was either (i) concluded without the filing of an indictment against such office holder and without the imposition on him of any monetary obligation in lieu of a criminal proceeding; (ii) concluded without the filing of an indictment against the office holder but with the imposition of a monetary obligation on the office holder in lieu of criminal proceedings for an offense that does not require proof of criminal intent; or (iii) in connection with a monetary sanction;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a monetary liability imposed on the office holder in favor of a payment for a breach offended at an Administrative Procedure (as defined below) as set forth in Section 52(54)(a)(1)(a) to the Securities Law; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">expenses expended by the office holder with respect to an Administrative Procedure under the Securities Law, including reasonable litigation expenses and reasonable attorneys&#8217; fees;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office holder or which were imposed on the office holder by a court (i) in a proceeding instituted against him or her by the company, on its behalf, or by a third party, (ii) in connection with criminal indictment of which the office holder was acquitted, or (iii) in a criminal indictment which the office holder was convicted of an offense that does not require proof of criminal intent; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">any other obligation or expense in respect of which it is permitted or will be permitted under applicable law to indemnify an office holder, including, without limitation, matters referenced in Section 56H(b)(1) of the Securities Law.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">110</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">An &#147;Administrative Procedure&#148; is defined as a procedure pursuant to chapters H3 (Monetary Sanction by the Israeli Securities Authority), H4 (Administrative Enforcement Procedures of the Administrative Enforcement Committee) or I1 (Arrangement to prevent Procedures or Interruption of procedures subject to conditions) to the Securities Law.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As permitted under the Companies Law and the Securities Law, our amended and restated articles of association, which will become effective upon the closing of this offering, provide that we may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder if and to the extent provided in the company&#146;s articles of association:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a breach of the duty of loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a breach of duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a monetary liability imposed on the office holder in favor of a third party;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a monetary liability imposed on the office holder in favor of an injured party at an Administrative Procedure pursuant to Section 52(54)(a)(1)(a) of the Securities Law; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">expenses incurred by an office holder in connection with an Administrative Procedure, including reasonable litigation expenses and reasonable attorneys&#8217; fees.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the Companies Law, a company may not indemnify, exculpate or insure an office holder against any of the following:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a breach of duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">an act or omission committed with intent to derive illegal personal benefit; or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a fine or forfeit levied against the office holder.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the Companies Law, exculpation, indemnification and insurance of office holders must be approved by the compensation committee and the board of directors and, with respect to directors or controlling shareholders, their relatives and third parties in which such controlling shareholders have a personal interest, also by the shareholders.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our amended and restated articles of association permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted or to be permitted by law. Our office holders are currently covered by a directors&#146; and officers&#146; liability insurance policy. As of the date of this prospectus, no claims for directors&#146; and officers&#146; liability insurance have been filed under this policy and we are not aware of any pending or threatened litigation or proceeding involving any of our office holders, including our directors, in which indemnification is sought.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Employment </b><b>Agreements with Executive Officers</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have entered into written employment agreements with certain of our executive officers, including our Chief Executive Officer. See &#147;Certain Relationships and Related Party Transactions&#8212;Employment Agreements&#148; for additional information.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Director</b><b>&#146;s</b><b> Service Contract</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have entered into an employment agreement with Ran Poliakine, our founder, director and Chief Executive Officer. Pursuant to the agreement, if the Company terminates Ran Poliakine&#146;s employment and waives his obligation to perform services during the notice period of 180 days, Ran Poliakine will be entitled to receive payments of his base salary and social benefits in lieu of notice for the waived period, up to the full notice period for an immediate termination. The agreement provides Ran Poliakine with a gross monthly base salary equal to $40,000 which will be increased to $60,000 upon the consummation of this initial public offering.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">111</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tPGEIP"></a><b>Equity Incentive Plans</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">On September 3, 2019, we adopted the 2019 Equity Incentive Plan and its U.S. sub-Plan (the &#147;2019 Equity Incentive Plan&#148; or &#147;Plan&#148;). The 2019 Equity Incentive Plan is intended to afford an incentive to any of our affiliate&#146;s employees, directors, officers, consultants, advisors and any other person or entity who provides services to us, to continue as service providers, to increase their efforts on our and our affiliates behalf and to promote our success, by providing such persons with opportunities to acquire a proprietary interest in us. The U.S. sub-Plan applies to our and any of our affiliate&#146;s employees, directors, officers, consultants, advisors and any other person or entity who provides services to the Company who are in the United States.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We may issue under the 2019 Equity Incentive Plan and its U.S. sub-Plan up to 8,041,936 of our ordinary shares, subject to adjustment if particular capital changes affect our share capital or such other number as our board of directors may determine from time to time, and such number is approved by our shareholders. Any awards that are scheduled to vest over a period of more than one calendar year shall be applied pro rata for purposes of the foregoing limit based on the number of years over which such awards are scheduled to vest. Ordinary shares subject to outstanding awards under the 2019 Equity Incentive Plan and its U.S. sub-Plan that subsequently expire, are cancelled, forfeited or terminated for any reason before being exercised will be automatically, and without any further action, returned to the share reserve under the plan and will again be available for grant.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A share option is the right to purchase a specified number of ordinary shares in the future at a specified exercise price and subject to the other terms and conditions specified in the option agreement and the applicable equity incentive plan. The exercise price of each option granted under the 2019 Equity Incentive Plan will be determined in accordance with the limitation set forth under such equity incentive plan. The exercise price of any share options granted under one of our equity incentive plans may be paid in cash, through the surrender of ordinary shares by the option holder or any other method that may be approved by our compensation committee, which may include procedures for cashless exercise.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our compensation committee may also grant, or recommend that our board of directors grant, other forms of equity incentive awards under the 2019 Equity Incentive Plan, such as restricted shares, restricted share units (&#147;RSUs&#148;), which represent the right to receive shares of our ordinary shares in the future, and other forms of share-based compensation.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Israeli participants in the 2019 Equity Incentive Plan may be granted options or other equity awards subject to Section 102 of the Israeli Income Tax Ordinance (New Version), 1961 (the &#147;Israeli Tax Ordinance&#148;). Section 102 of the Israeli Tax Ordinance allows employees, directors and officers who are not controlling shareholders and are considered Israeli residents to receive favorable tax treatment for compensation in the form of shares or options. Our Israeli non-employee service providers and controlling shareholders, for these purposes under the Israeli Tax Ordinance, may only be granted options or other equity awards under another section of the Israeli Tax Ordinance, which does not provide for similar tax benefits. Section 102 includes two alternatives for tax treatment involving the issuance of options or shares to a trustee for the benefit of the grantees and also includes an additional alternative for the issuance of options or shares directly to the grantee. The most favorable tax treatment for the grantees is under Section 102(b)(2) of the Israeli Tax Ordinance, the issuance to a trustee under the &#147;capital gain track.&#148; However, under this track we are not allowed to deduct an expense with respect to the issuance of the options or shares to our employees. Any options granted under the 2019 Equity Incentive Plan to participants in the United States will be either &#147;incentive stock options,&#148; which may be eligible for special tax treatment under the Internal Revenue Code of 1986, as amended, or options other than incentive stock options (referred to as &#147;nonqualified stock options&#148;), as determined by our compensation committee or our board of directors and stated in the option agreement.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">All awards, amounts or benefits received or outstanding under the 2019 Equity Incentive Plan and the U.S. sub-Plan will be subject to clawback, cancellation, recoupment, rescission, payback, reduction or other similar action in accordance with the terms of any clawback or similar policy that we adopt or any applicable law related to such actions, as may be in effect from time to time. A participant&#146;s acceptance of an award under the 2019 Equity Incentive Plan and the U.S. sub-Plan will be deemed to constitute the participant&#146;s acknowledgement of and consent to our application, implementation and enforcement of any applicable clawback </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">112</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">or similar policy that may apply to the participant, and any provision of applicable law relating to clawback, cancellation, recoupment, rescission, payback or reduction of compensation, and the participant&#146;s agreement that we may take such actions as may be necessary to effectuate any such policy or applicable law, without further consideration or action.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The 2019 Equity Incentive Plan and the U.S. sub-Plan have been designed to include a number of provisions that promote best practices by reinforcing the alignment between equity compensation arrangements for eligible employees and non-employee directors and stockholders&#146; interests. These provisions include, but are not limited to, the following:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><i>Forfeiture </i><i>U</i><i>pon Cause Termination</i>. All awards held by a participant will be forfeited upon the participant&#8217;s termination for cause.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><i>No Repricing </i><i>W</i><i>ithout Shareholder Approval</i>. Without prior shareholder approval, we will not (i) reduce the exercise price of a stock option, (ii) take any other action that is treated as repricing under U.S. GAAP or (ii) repurchase for cash or cancel a stock option when its exercise price is greater than the fair market value of the underlying shares in exchange for another, unless the cancellation and exchange occurs in connection with a change in capitalization or a similar change.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><i>No Transferability</i>. Awards generally may not be transferred, except by will or the laws of descent and distribution, unless otherwise determined by the compensation committee. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><i>No Automatic Grants</i>. The Plan does not provide for automatic grants to any participant.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><i>No Tax Gross-Ups</i>. The Plan does not provide for any tax gross-ups.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our compensation committee will administer the 2019 Equity Incentive Plan and the U.S. sub-Plan, or if determined otherwise by our board of directors, the equity incentive plans will be administered by our board of directors or other designated committee on its behalf. Even if the compensation committee or any other committee was appointed by our board of directors in order to administer the equity incentive plans, our board of directors may, subject to any legal limitations, exercise any powers or duties of the compensation committee or any other committee concerning the equity incentive plans. The compensation committee will, among others, select which eligible persons will receive options or other awards under the equity incentive plans and will determine, or recommend to our board of directors, the number of ordinary shares covered by those options or other awards, the terms under which such options or other awards may be exercised (however, options generally may not be exercised later than ten years from the grant date of an option) or may be settled or paid, and the other terms and conditions of such options and other awards under the equity incentive plans. All awards granted under the equity incentive plans shall not be transferable other than by will or by the laws of descent and distribution, unless otherwise determined by our compensation committee.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">To the extent permitted under applicable law, our compensation committee will have the authority to accelerate the vesting of any outstanding options, restricted shares and RSUs at such time and under such circumstances as it, in its sole discretion, deems appropriate. In the event of a merger or sale, as defined in the Plan, any award then outstanding shall be assumed or an equivalent award shall be substituted by the successor corporation of the merger or sale or any parent or affiliate thereof as determined by our board of directors. In the event that the awards are not assumed or substituted, our compensation committee may, in its discretion, accelerate the vesting, exercisability of the outstanding award, or provide for the cancellation of such award and payment of cash consideration, as determined to be fair in the circumstances.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Subject to particular limitations specified in the 2019 Equity Incentive Plan and the U.S. sub-Plan and under applicable law, our board of directors may amend or terminate each of the equity incentive plans, and the compensation committee may amend awards outstanding under the Plan. The Plan will continue in effect until all ordinary shares available under the Plan are delivered and all restrictions on those shares have lapsed, unless the 2019 Equity Incentive Plan is terminated earlier by our board of directors. No awards may be granted under the 2019 Equity Incentive Plan and the U.S. sub-Plan, on or after the tenth anniversary of the date of adoption.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Any equity award to an office holder, director or controlling shareholder, whether under the 2019 Equity Incentive Plan and the U.S. sub-Plan or otherwise, may be subject to further approvals in addition to the </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">113</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">approval of the compensation committee as described above. As of December 31, 2019, there were &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the exercise of options to purchase ordinary shares outstanding under our 2019 Equity Incentive Plan, at an average exercise price of $2.21 per share.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table sets forth, as of December 31, 2019, the total number of ordinary shares issuable upon exercise of the options granted to each of our executive officers and our non-employee directors as a group, the exercise price of such options, the grant date and the expiration date.</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="26%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; border-bottom: 1pt solid #000000; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.71px; "><b>Name</b></div></td>
	<td colspan="3" width="15%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 9.71px; padding-right: 9.71px; "><b>Number of<br> </b><b>Options</b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 9.71px; padding-right: 9.71px; "><b>Exercise<br> </b><b>Price</b></div></td>
	<td colspan="1" width="24%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 9.71px; padding-right: 9.71px; "><b>Date of<br></b><b>Grant</b></div></td>
	<td colspan="1" width="24%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 9.71px; padding-right: 0px; "><b>Expiration<br></b><b>Date</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="26%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.71px; ">Ran Poliakine </div></td>
	<td width="2%" valign="top" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="12%" valign="top" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,206,290</div></td><td width="1%" valign="top" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="top" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="9%" valign="top" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2.21</div></td><td width="1%" valign="top" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="24%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 9.71px; padding-right: 9.71px; ">November 25, 2019</div></td>
	<td colspan="1" width="24%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 9.71px; padding-right: 0px; ">November 25, 2029</div></td>
</tr>
<tr>
	<td colspan="1" width="26%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.71px; ">Onn Fenig </div></td>
	<td width="2%" valign="top" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="12%" valign="top" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">40,234</div></td><td width="1%" valign="top" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="top" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="9%" valign="top" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2.21</div></td><td width="1%" valign="top" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="24%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 9.71px; padding-right: 9.71px; ">November 25, 2019</div></td>
	<td colspan="1" width="24%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 9.71px; padding-right: 0px; ">
November 25, 2029
</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="26%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.71px; ">
Erez Meltzer
</div></td>
	<td width="2%" valign="top" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="12%" valign="top" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 0 </div></td><td width="1%" valign="top" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="top" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="top" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> N/A </div></td><td width="1%" valign="top" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="24%" valign="top" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 9.71px; padding-right: 9.71px; ">
N/A
</div></td>
	<td colspan="1" width="24%" valign="top" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 9.71px; padding-right: 0px; ">
N/A
</div></td>
</tr>
<tr>
	<td colspan="1" width="26%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.71px; ">Prof. Richard Stone </div></td>
	<td width="2%" valign="top" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="12%" valign="top" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">100,584</div></td><td width="1%" valign="top" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="top" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="9%" valign="top" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2.21</div></td><td width="1%" valign="top" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="24%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 9.71px; padding-right: 9.71px; ">November 25, 2019 </div></td>
	<td colspan="1" width="24%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 9.71px; padding-right: 0px; ">November 25, 2029 </div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="26%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.71px; ">Itzhak Maayan</div></td>
	<td width="2%" valign="top" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="12%" valign="top" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">161,107</div></td><td width="1%" valign="top" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="top" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="9%" valign="top" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2.21</div></td><td width="1%" valign="top" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="24%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 9.71px; padding-right: 9.71px; ">November 25, 2019</div></td>
	<td colspan="1" width="24%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 9.71px; padding-right: 0px; ">November 25, 2029 </div></td>
</tr>
<tr>
	<td colspan="1" width="26%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.71px; ">Anat Kaphan</div></td>
	<td width="2%" valign="top" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="12%" valign="top" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">112,754</div></td><td width="1%" valign="top" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="top" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="9%" valign="top" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2.21</div></td><td width="1%" valign="top" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="24%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 9.71px; padding-right: 9.71px; ">November 25, 2019</div></td>
	<td colspan="1" width="24%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 9.71px; padding-right: 0px; ">November 25, 2029 </div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="26%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.71px; ">Yoel Raab</div></td>
	<td width="2%" valign="top" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="12%" valign="top" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">112,754</div></td><td width="1%" valign="top" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="top" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="9%" valign="top" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2.21</div></td><td width="1%" valign="top" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="24%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 9.71px; padding-right: 9.71px; ">November 25, 2019</div></td>
	<td colspan="1" width="24%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 9.71px; padding-right: 0px; ">November 25, 2029 </div></td>
</tr>
<tr>
	<td colspan="1" width="26%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.71px; ">Tal Shank</div></td>
	<td width="2%" valign="top" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="12%" valign="top" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">74,362</div></td><td width="1%" valign="top" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="top" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="9%" valign="top" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2.21</div></td><td width="1%" valign="top" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="24%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 9.71px; padding-right: 9.71px; ">November 25, 2019</div></td>
	<td colspan="1" width="24%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 9.71px; padding-right: 0px; ">November 25, 2029</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">114</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tPS"></a><b>PRINCIPAL SHAREHOLDERS</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table sets forth information with respect to the beneficial ownership of our ordinary shares as of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2020 by:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">each person or entity known by us to own beneficially more than 5% of our outstanding ordinary shares;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">each of our directors, executive officers and director nominees; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">all of our executive officers and directors as a group.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The beneficial ownership of our ordinary shares is determined in accordance with the rules of the SEC. Under these rules, a person is deemed to be a beneficial owner of a security if that person has or shares voting power, which includes the power to vote or to direct the voting of the security, or investment power, which includes the power to dispose of or to direct the disposition of the security. In determining beneficial ownership percentages, we deem ordinary shares issuable pursuant to options or warrants that are currently exercisable or exercisable within 60 days of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, if any, to be outstanding and to be beneficially owned by the person holding the options or warrants for the purposes of computing the percentage ownership of that person, but we do not treat them as outstanding for the purpose of computing the percentage ownership of any other person. The percentage of ordinary shares beneficially owned prior to the offering is based on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares outstanding as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. The percentage of ordinary shares beneficially owned after the offering is based on the number of shares outstanding prior to the offering plus the ordinary shares that we are selling in this offering. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The percentages of ordinary shares beneficially owned after the offering assume that the underwriters will not exercise their option to purchase additional ordinary shares in the offering. Except where otherwise indicated, we believe, based on information furnished to us by such owners, that the beneficial owners of the ordinary shares listed below have sole investment and voting power with respect to such shares.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Upon the closing of this offering, none of our shareholders will have different voting rights from other shareholders. To the best of our knowledge, we are not owned or controlled, directly or indirectly, by another corporation or by any foreign government. We are not aware of any arrangement that may, at a subsequent date, result in a change of control of our company. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Unless otherwise noted below, the address for each beneficial owner is c/o Communications Center, Neve Ilan, Israel 9085000.</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.55px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.55px; padding-right: 4.55px; "><b>Shares Beneficially Owned<br> </b><b>Prior to the Offering</b></div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.55px; padding-right: 0px; "><b>Shares Beneficially Owned<br> </b><b>After the Offering</b></div></td>
</tr>
<tr>
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 4.55px; "><b>Name of Beneficial Owner</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4.55px; padding-right: 4.55px; "><b>Number</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4.55px; padding-right: 4.55px; "><b>Percentage</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4.55px; padding-right: 4.55px; "><b>Number</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4.55px; padding-right: 0px; "><b>Percentage</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.55px; "><i><b>5% or greater shareholders<br></b></i></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.55px; ">Ran Poliakine<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.55px; ">
Moshe Moalem<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup>
</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.55px; ">
SK Telecom TMT Investment Corp and Affiliates<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup>
</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.55px; ">
Tsuri Limited and Everhart Finance Limited<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup>
</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.55px; "><i><b>Directors and executive officers<br></b></i></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.55px; ">Ran Poliakine<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.55px; ">Onn Fenig</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.55px; ">
Erez Meltzer
</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.55px; ">
Richard Stone<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)</sup>
</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.55px; ">Itzhak Maayan</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.55px; ">Yoel Raab</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.55px; ">Anat Kaphan</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.55px; ">Tal Shank</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.55px; ">
<i><b>All directors and executive officers as a group </b></i><i><b>(</b></i><i><b>8</b></i><i><b> persons)</b></i>
</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">
*
</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">
Amount represents less than 1% of outstanding ordinary shares.
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(1)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">
Represents (a) 7,897,339 ordinary shares of the Company held in trust by Shay Zuckerman &amp; Co. Law Firm (&#147;Shay Zuckerman&#148;), pursuant to an Escrow Agreement, dated September 1, 2019 (the &#147;Escrow Agreement&#148;), between the Company and Shay Zuckerman, as trustee, and (b) warrants to purchase 452,489 ordinary shares held by Ran Poliakine. 50% of the ordinary shares held by Shay
</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">

<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">115</p>

			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">

<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Zuckerman are held in trust for the benefit of Ran Poliakine and Profiscope Limited (&#147;Profiscope&#148;), of which each of Ran Poliakine and Moshe Moalem is a 50% shareholder, and the remaining 50% ordinary shares are held in trust for the benefit of Moshe Moalem and Profiscope. Each of Ran Poliakine and Moshe Moalem may be deemed to have voting and dispositive power of all the ordinary shares held in trust by Shay Zuckerman. </p>

				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">
(2)
</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">
Represents 7,897,339 ordinary shares of the Company held in trust by Shay Zuckerman, pursuant to the Escrow Agreement. 50% of the ordinary shares are held in trust for the benefit of Ran Poliakine and Profiscope, of which each of Ran Poliakine and Moshe Moalem is a 50% shareholder, and the remaining 50% ordinary shares are held in trust for the benefit of Moshe Moalem and Profiscope. Each of Ran Poliakine and Moshe Moalem may be deemed to have voting and dispositive power of all the ordinary shares held in trust by Shay Zuckerman.
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">
(3)
</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">
Represents 1,357,466 ordinary shares held by SK Telecom TMT Investment Corp (&#147;SKT&#148;), 49,733 ordinary shares held by Pureun Partners Asset Management Co., Ltd. (&#147;Pureun&#148;), 855,204 ordinary shares held by EBEST-PPAM Fund No. 9 (&#147;EBEST&#148;), and warrants held by SK Telecom TMT Investment Corp to purchase 2,262,443 ordinary shares. SKT has the voting and dispositive power of the shares held by Pureun and EBEST pursuant to a proxy.
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">
(4)
</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">
Represents 1,647,452 ordinary shares held by Tsuri Limited and 920,064 ordinary shares held by Everhart Finance Limited. The voting and dispositive power over such ordinary shares are ultimately held by Elie Douer and Marie Douer, and each of Elie Douer and Marie Douer may be deemed to share voting and dispositive power over the shares held by Tsuri Limited and Everhart Finance Limited.
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">
(5)
</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">
Consists of 333,333 ordinary shares, options to purchase 100,584 ordinary shares, and warrants to purchase 466,777 ordinary shares held by Richard Stone, 696,196 ordinary shares and warrants to purchase 298,642 ordinary shares held by Stone Isra Ventures LLC, and 221,719 ordinary shares and warrants to purchase 443,438 ordinary shares held by Adhoc Investors LLC. Richard Stone is the sole shareholder of Stone Isra Ventures LLC and Adhoc Investors LLC, and may be deemed to have voting and dispositive power of the ordinary shares held by Stone Isra Ventures LLC and Adhoc Investors LLC.
</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of our outstanding ordinary shares are held by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; record holders in the United States.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">None of our shareholders has different voting rights from other shareholders after the closing of this offering. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">116</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 109-certain -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tCR"></a><b>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our policy is to enter into transactions with related parties on terms that, on the whole, are no more favorable, or no less favorable, than those available from unaffiliated third parties. Based on our experience in the business sectors in which we operate and the terms of our transactions with unaffiliated third parties, we believe that all of the transactions described below met this policy standard at the time they occurred. The following is a description of material transactions, or series of related material transactions, since January 1, 2017, to which we were or will be a party and in which the other parties included or will include our directors, executive officers, holders of more than 5% of our voting securities or any member of the immediate family of any of the foregoing persons.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Asset Purchase by the Company </b><b>F</b><b>rom Nanox Gibraltar</b></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Company (NANO-X IMAGING LTD), an Israeli limited liability company, was formed on December 20, 2018. Pursuant to the Asset Purchase Agreement, as amended on December 3, 2019 and December 31, 2019, substantially all of the assets of Nanox Gibraltar, including all patents, patent applications and all other intellectual property rights, but not including the shares of Nanox Japan (predecessor), were sold to the Company for an aggregate consideration of $13.2 million, reflecting the fair market value of the transferred assets, which was estimated to be $6.1 million (excluding cash) based on an independent valuation report, plus the cash balance less $200,000, which totaled $7.1 million as of the date of the Asset Purchase Agreement. Following the Asset Purchase, substantially all the employees of Nanox Japan (predecessor) dedicated to the Company&#146;s business have become employees of Nanox Imaging, Inc., our wholly owned Japanese subsidiary incorporated on September 19, 2019, in December 2019.</p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the terms of the Asset Purchase Agreement, the consideration for the transferred assets will be paid only on the occurrence of one of the following events: (a) the closing of a transaction involving the sale of all or substantially all of the Company&#146;s assets; (b) the acquisition of the Company by, or the merger of the Company with, another entity, consolidation, reorganization, recapitalization, sale, assignment or disposal by the Company of all or substantially all of the issued and outstanding shares of the Company; (c) the transfer, sale, lease, grant or other disposition of or the grant of an exclusive license over all or substantially all of Company&#146;s assets, including, but not limited to, intellectual property, with the same economic effect to that of a sale and/or cessation of its business; (d) any other transaction, except for a financing round, following which the shareholders of the Company prior to the closing of such transaction own, directly or indirectly, less than 50% of the voting power of the surviving entity; (e) the closing of the first underwritten public offering of the Company pursuant to a registration statement under the Securities Act or the Israeli Securities Law, 5728-1968, as amended (or under equivalent securities law of another jurisdiction) or any other securities laws world-wide with the same effects and results; (f) an equity financing of the Company at a minimum pre-money valuation of $100.0 million, with proceeds to the Company of at least $30.0 million. In the events of (e) or (f) above, the Company will have the option to pay the consideration in cash or by the issuance to Nanox Gibraltar of the Company&#146;s securities of the same series to be issued upon such event, in an amount reflecting a 25% discount on the price per share to be determined in connection with (e) and (f) above. If the Company elects to pay such consideration in cash, Nanox Gibraltar will have the right, at its sole discretion and in good faith, to reject such payment in cash, and require that the Company pay such consideration in the form of the Company&#146;s securities in such amount and with such discount described above.</p>

				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Relationship </b><b>W</b><b>ith </b><b>SK Telecom</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">On June 17, 2019, Nanox Gibraltar entered into a Strategic Share Purchase Agreement with SK Telecom TMT Investment Corp., Pureun Partners Asset Management Co., Ltd. and EBEST-PPAM Fund No. 9 (collectively, the &#147;SKT Entities&#148;), pursuant to which Nanox Gibraltar sold 2,262,443 ordinary shares to the SKT Entities for an aggregate purchase price of approximately $5.0 million. In connection with such transaction, Nanox Gibraltar also issued a warrant to SK Telecom TMT Investment Corp. to acquire 2,262,443 ordinary shares at an exercise price of $20.87 per share. </p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In connection with the transactions described above, Nanox Gibraltar also entered into an investor rights agreement with the SKT Entities. The agreement provides for the rights to nominate a member of our board of directors, as well as certain registration rights. Pursuant to the investor rights agreement, so long as the SKT Entities hold at least 5% of Nanox Gibraltar&#146;s outstanding shares or any SKT Entity is otherwise deemed an affiliate of Nanox Gibraltar under Rule 144 of Securities Act, it shall be entitled to the same piggyback </p>

			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">117</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">registration rights as the most favorable registration rights that Nanox Gibraltar has provided to any of its current shareholders or provides to future shareholders, and shall be made a party to any investor rights agreement or registration rights agreement that Nanox Gibraltar thereafter enters into. The rights under the investor rights agreement will terminate upon the closing of this offering. The SKT Entities are expected to become parties to the Registration Rights Agreement (as defined below) prior to the closing of this offering so long as they meet the requirements described above. See &#147;Description of Share Capital&#8212;Registration Rights&#148; for detailed description of the registration rights. </p>

				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Agreements </b><b>W</b><b>ith Directors and Officers</b></p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Relationship </i><i>W</i><i>ith Six-Eye Interactive Ltd.</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">On June 1, 2015, Nanox Gibraltar entered into a consulting agreement (the &#147;Consulting Agreement&#148;) with Six-Eye, pursuant to which Ran Poliakine, the sole owner of Six-Eye, agreed to provide services as Chief Strategy Officer and a member of the Executive Committee to Nanox Gibraltar. The Consulting Agreement was terminated and on September 1, 2019, Ran Poliakine executed an employment agreement with the Company.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">On May 1, 2017, Nanox Gibraltar entered into a services agreement with Six-Eye, of which Ran Poliakine is the sole owner, pursuant to which Six-Eye agreed to provide certain services to Nanox Gibraltar, including research and development, equipped facilities, management and administration, operational and supply and financial and accounting services (the &#147;Original Services Agreement&#148;). Following the Asset Purchase, all of the terms of the Original Services Agreement were terminated.</p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">During the years ended December 31, 2018 and 2019, the total expenses paid to Six-Eye under the Consulting Agreement and Original Services Agreement were $1.8 million and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, respectively. </p>


<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Relationship With Illumigyn, Ltd.</i></p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Since November 1, 2019, Illumigyn has sub-leased approximately 1,800 square feet of private office space, including access to shared public spaces, from us in Neve Ilan, Israel. Illumigyn pays approximately $12,000 per month and during year ended December 31, 2019, the total payment received from Illumigyn was approximately $23,000. Mr. Poliakine currently serves as a member of senior management of Illumigyn and is a significant shareholder primarily through indirect holdings, and he served as a member of the board of directors of Illumigyn until August 2019.</p>

				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Direct</i><i>or</i><i>ship</i><i> Agreement</i><i>s</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have entered into directorship agreements with each of our directors, pursuant to which such directors will serve on our board of directors. Pursuant to these agreements, each director was granted options under our 2019 Equity Incentive Plan in the number and terms set out under &#147;Management&#8212;Equity Incentive Plans.&#148; </p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Employment Agreements</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have entered into written employment agreements with certain of our executive officers. These agreements provide for notice periods of varying duration for termination of the agreement by us or by the relevant executive officer, during which time the executive officer will continue to receive base salary and benefits. These agreements also contain customary provisions regarding non-competition, confidentiality of information and assignment of inventions. However, the enforceability of the non-competition provisions may be limited under applicable law. See &#147;Risk Factors&#8212;Risks Relating to Employee Matters&#8212;Under applicable employment laws, we may not be able to enforce covenants not to compete and therefore may be unable to prevent our competitors from benefitting from the expertise of some of our former employees&#148; for a further description of the enforceability of non-competition clauses. </p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Equity Incentive Plans</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">For a description of our equity incentive plans with members of our board of directors and executive officers, see &#147;Management&#8212;Equity Incentive Plans.&#148;</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Directors and Officers Insurance Policy and Indemnification Agreements</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our amended and restated articles of association, which will become effective upon completion of this offering, permit us to exculpate, indemnify and insure each of our directors and officers to the fullest extent </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">118</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">permitted by the Companies Law. We have obtained Directors and Officers insurance for each of our executive officers and directors. For further information, see &#147;Management&#8212;Exculpation, Insurance and Indemnification of Directors and Officers.&#148;</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have entered into agreements with each of our current directors and officers exculpating them from a breach of their duty of care to us to the fullest extent permitted by law, subject to limited exceptions, and undertaking to indemnify them to the fullest extent permitted by law including, with respect to liabilities resulting from this offering, to the extent that these liabilities are not covered by insurance, all subject to limited exceptions This indemnification is limited, with respect to any monetary liability imposed in favor of a third party, to events determined as foreseeable by the board of directors based on our current or expected activities. The maximum aggregate amount of indemnification that we may pay to our directors and officers based on such indemnification agreement shall not exceed the greater of (i) in relation to indemnity in connection with an offering to the public of our securities, the aggregate amount of proceeds from the sale by us and/or any of our shareholders in connection with such public offering, (ii) 25% of our total shareholders&#146; equity pursuant to our most recent financial statements as of the time of the actual payment of indemnification, and (iii) $50 million (in each case as may be increased from time to time by shareholders&#146; approval). Such indemnification amounts are in addition to any insurance amounts. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">However, in the opinion of the SEC, indemnification of office holders for liabilities arising under the Securities Act is against public policy and therefore unenforceable.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">119</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 110-descrip -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tDS"></a><b>DESCRIPTION OF SHARE CAPITAL</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following description of our share capital and provisions of our amended and restated articles of association are summaries and are qualified in their entirety by reference to the amended and restated articles of association, which will become effective upon the closing of this offering. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>General</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Upon the closing of this offering, our authorized share capital will consist of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares, par value NIS 0.01 per share, of which, effective upon closing of this offering, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares will be issued and outstanding (assuming that the underwriters do not exercise their option to purchase additional ordinary shares). </p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">All of our outstanding ordinary shares will be validly issued, fully paid and non-assessable. Our ordinary shares are not redeemable and do not have any preemptive rights. </p>


<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Warrants to Purchase Ordinary Shares</b><b> </b></p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As of December 31, 2019, warrants to purchase a total of 6,072,098 shares of our ordinary shares were outstanding with exercise prices ranging from $0.01 per share to $20.87 per share. These warrants are exercisable immediately and expire on various dates. </p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The warrants were issued to certain persons in connection with certain corporate, financing and consulting transactions. Collectively, we refer to these warrants as the &#147;ordinary shares warrants.&#148; Some of the ordinary shares warrants provide that, unless earlier exercised, they will be expired or exercised, on a cashless basis, immediately prior to the closing of this offering, so long as the fair market value of our ordinary shares at the closing of this offering exceeds the exercise price of the applicable warrant. The fair market value in connection with any cashless exercise prior to the consummation of this offering shall be the initial public offering price of our ordinary shares. </p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Assuming the closing of this offering occurs, the fair market value of one share of our ordinary shares in connection with any cashless exercise shall be the closing price or last sale price per share of our ordinary shares on the Nasdaq Capital Market or other public trading market on which our ordinary shares are traded on the business day immediately prior to the date such holder elects to exercise such warrant on a cashless basis. </p>

				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Registration Number and Purposes of the Company </b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our registration number with the Israeli Registrar of Companies is 515942076. Following the closing of this offering, our registration number may be changed by the Israeli Registrar of Companies to indicate that we are a public company. Our purpose as set forth in our amended and restated articles of association is to engage in any lawful activity.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Voting Rights </b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Upon the closing of this offering, all of our ordinary shares will have identical voting and other rights in all respects.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Transfer of Shares </b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our fully paid ordinary shares are issued in registered form and may be freely transferred under our amended and restated articles of association, unless the transfer is restricted or prohibited by another instrument, applicable law or the rules of a stock exchange on which the shares are listed for trade. The ownership or voting of our ordinary shares by non-residents of Israel is not restricted in any way by our amended and restated articles of association or the laws of the State of Israel, except for ownership by nationals of some countries that are, or have been, in a state of war with Israel. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Election of Directors </b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our ordinary shares do not have cumulative voting rights for the election of directors. As a result, the holders of a majority of the voting power represented at a shareholders meeting have the power to elect all of our directors, subject to the special approval requirements for external directors under the Companies Law described under &#147;Management&#8212;External Directors.&#148; </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">120</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under our amended and restated articles of association, which will become effective immediately prior to the closing of this offering, our board of directors must consist of seven directors, including two external directors as required by the Companies Law. Pursuant to our amended and restated articles of association, other than the external directors, for whom special election requirements apply under the Companies Law, the vote required to appoint a director is a simple majority vote of holders of our voting shares participating and voting at the relevant meeting. In addition, our amended and restated articles of association allow our board of directors to appoint new directors to fill vacancies on the board of directors if the number of directors falls below the minimum number provided in our amended and restated articles so the number of directors in office shall be at least the minimum number. In such case, a shareholders meeting shall be held within six months of such appointment in order to elect directors. Furthermore, under our amended and restated articles of association, our directors, other than external directors, are divided into three classes with staggered three-year terms. Each class of directors consists, as nearly as possible, of 1/3 of the total number of directors constituting the entire board of directors (other than the external directors). For a more detailed description on the composition of our board of election procedures of our directors, other than our external directors see &#147;Management&#8212;Board of Directors and Officers.&#148; External directors are elected for an initial term of three years, may be elected for additional terms of three years each under certain circumstances, and may be removed from office pursuant to the terms of the Companies Law, for further information on the election and removal of external directors see &#147;Management &#8212; External Directors&#8212;Election and Dismissal of External Directors.&#148;</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Dividend and Liquidation Rights </b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have never declared or paid any cash dividends on our ordinary shares.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We may declare a dividend to be paid to the holders of our ordinary shares in proportion to their respective shareholdings. See &#147;Dividend Policy&#148; for more information with respect to the requirements under Israeli law for the declaration and payment of dividends to our shareholders. Under the Companies Law, dividend distributions are determined by the board of directors and do not require the approval of the shareholders of a company unless the company&#146;s articles of association provide otherwise. Our amended and restated articles of association, which will become effective immediately prior to the closing of this offering, do not require shareholder approval of a dividend distribution and provide that dividend distributions may be determined by our board of directors. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Pursuant to the Companies Law, the distribution amount is limited to the greater of retained earnings or earnings generated over the previous two years, according to our then last reviewed or audited financial statements, provided that the date of the financial statements is not more than six months prior to the date of the distribution, or we may distribute dividends that do not meet such criteria only with court approval. In each case, we are only permitted to distribute a dividend if our board of directors and the court, if applicable, determines that there is no reasonable concern that payment of the dividend will prevent us from satisfying our existing and foreseeable obligations as they become due. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In the event of our liquidation, after satisfaction of liabilities to creditors and other payments due as per applicable law, our assets will be distributed to the holders of our ordinary shares in proportion to their shareholdings. This right, as well as the right to receive dividends, may be affected by the grant of preferential dividend or distribution rights to the holders of a class of shares with preferential rights that may be authorized in the future. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Exchange Controls </b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">There are currently no Israeli currency control restrictions on remittances of dividends on our ordinary shares, proceeds from the sale of the shares or interest or other payments to non-residents of Israel, except for shareholders who are subjects of certain countries that have been, or are considered to be in a state of war with Israel. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Shareholder Meetings </b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under Israeli law, we are required to hold an annual general meeting of our shareholders once every calendar year that must be held no later than 15 months after the date of the previous annual general meeting. All general meetings other than the annual meeting of shareholders are referred to in our amended and restated articles of association as special meetings. Our board of directors may call special meetings whenever it sees fit, at such time and place, within or outside of Israel, as it may determine. In addition, the Companies Law provides </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">121</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">that our board of directors is required to convene a special general meeting upon the written request of (i) any two or more of our directors or one-quarter or more of the members of our board of directors or (ii) one or more shareholders holding, in the aggregate, either (a) 10% or more of our outstanding issued shares and 1% or more of our outstanding voting power or (b) 10% or more of our outstanding voting power. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under Israeli law, one or more shareholders holding at least 1% of the voting rights at the general meeting may request that the board of directors include a matter in the agenda of a general meeting to be convened in the future, provided that it is appropriate to discuss such a matter at the general meeting. Our amended and restated articles of association contain procedural guidelines and disclosure items with respect to the submission of shareholder proposals for shareholder meetings.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Subject to the provisions of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings are the shareholders of record on a date to be decided by the board of directors, which may be between four and 40 days prior to the date of the meeting. Furthermore, the Companies Law requires that resolutions regarding, among other things, the following matters must be passed at a general meeting of our shareholders:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">amendments to our amended and restated articles of association;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">appointment or termination of our auditors;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">election of directors, including external directors (if applicable);</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">approval of certain related party transactions;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">increases or reductions of our authorized share capital;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">mergers; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the exercise of our board of director&#8217;s powers by a general meeting, if our board of directors is unable to exercise its powers and the exercise of any of its powers is required for our proper management.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under our amended and restated articles of association, we are required to give notice to our registered shareholders not less than five days prior to the meeting unless the right to such notice is waived in writing by all of the Shareholders as to a particular meeting. The Companies Law requires that a notice of any annual general meeting or special general meeting be provided to shareholders at least 21 days prior to the meeting and if the agenda of the meeting includes the appointment or removal of directors, the approval of transactions with office holders or interested or related parties, or an approval of a merger, or as otherwise required under applicable law, notice must be provided at least 35 days prior to the meeting. Under the Companies Law, shareholders of a public company are not permitted to take action by written consent in lieu of a meeting. Under Companies Law, whenever we cannot convene or conduct a general meeting in the manner prescribed under the law or our articles of association, the court may, upon our, shareholders&#146; or directors&#146; request, order that we convene and conduct a general meeting in the manner the court deems appropriate.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Voting Rights</b></p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>Quorum Requirements </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Pursuant to our amended and restated articles of association, which will become effective immediately prior to the closing of this offering, holders of our ordinary shares have one vote for each ordinary share held on all matters submitted to a vote before the shareholders at a general meeting. In any meeting of shareholders, we will follow the quorum requirements for general meetings under the Nasdaq Marketplace Rules, pursuant to which the quorum required for our general meetings of shareholders will consist of at least one shareholder present in person, by proxy or written ballot. A meeting adjourned for lack of a quorum will generally be adjourned to the same day of the following week at the same time and place, or to such other day, time or place as indicated by our board of directors if so specified in the notice of the meeting. At the reconvened meeting, any number of shareholders present in person or by proxy shall constitute a lawful quorum, instead of one-third of the issued share capital as required under the Nasdaq Marketplace Rules. </p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Vote Requirements </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our amended and restated articles of association provide that all resolutions of our shareholders require a simple majority vote, unless otherwise required by the Companies Law or by our amended and restated articles of association. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">122</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">Pursuant to our amended and restated articles of association, an amendment to our amended and restated articles of association regarding any change of the composition or election procedures of our directors will require a simple shareholders majority of the voting power represented at the meeting in person or by proxy and voting thereon. Under the Companies Law, among others, each of&#8201; (i) the approval of an extraordinary transaction with a controlling shareholder and (ii) the terms of employment or other engagement of the controlling shareholder of the company or such controlling shareholder&#146;s relative (even if such terms are not extraordinary) requires the approval described above under &#147;Management&#8212;Fiduciary duties and approval of specified related party transactions and compensation under Israeli law&#8212;Disclosure of personal interests of a controlling shareholder and approval of certain transactions.&#148; Certain transactions with respect to remuneration of our office holders and directors, the approval and extension of a compensation policy and certain deviations therefrom require further approvals described above under &#147;Management&#8212;Fiduciary duties and approval of specified related party transactions and compensation under Israeli law&#8212;Rules Applicable to Compensation of directors and executive officers.&#148; Under our amended and restated articles of association, any change to the rights and privileges of the holders of any class of our shares requires a simple majority of the class so affected (or such other percentage of the relevant class that may be set forth in the governing documents relevant to such class), in addition to the ordinary majority vote of all classes of shares voting together as a single class at a shareholder meeting. Another exception to the simple majority vote requirement is a resolution for the voluntary winding up, or an approval of a scheme of arrangement or reorganization, of the company pursuant to Section 350 of the Companies Law, that governs the settlement of debts and reorganization of a company, which requires the approval of holders of 75% of the voting rights represented at the meeting, in person, by proxy or by voting deed and voting on the resolution.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Access to Corporate Records </b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the Companies Law, shareholders generally have the right to review minutes of our general meetings, our shareholders register and principal shareholders register, our amended and restated articles of association, our annual audited financial statements and any document that we are required by law to file publicly with the Israeli Registrar of Companies or the Israel Securities Authority. In addition, shareholders may request to be provided with any document related to an action or transaction requiring shareholder approval under the related party transaction provisions of the Companies Law. We may deny this request if we believe it has not been made in good faith or if such denial is necessary to protect our interests or protect a trade secret or patent. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Modification of Class Rights </b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the Companies Law and our amended and restated articles of association, the rights attached to any class of share, such as voting, liquidation and dividend rights, may be amended by adoption of a resolution by the holders of a majority of the shares of that class present at a separate class meeting, or otherwise in accordance with the rights attached to such class of shares, as set forth in our amended and restated articles of association. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Registration Rights</b></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Prior to the closing of this offering, we intend to enter into a registration rights agreement (the &#147;Registration Rights Agreement&#148;) with holders of approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of our ordinary shares. Under the terms of such registration rights agreement, and subject to the limitations specified therein, if we register our ordinary shares under the Securities Act for sale to the public (including with respect to our initial public offering), either for our own account or for the account of other security holders or both, the holders of registrable securities are entitled to notice of the intended registration and to include any or all of their registrable securities in the registration. The right of holders of registrable securities to include shares in an underwritten offering is subject to the right of the underwriters to limit the number of shares included in such offering. Holders of registrable securities are generally required to pay all expenses of registration, including the fees and disbursements of its counsel and all underwriting discounts and commissions. </p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, holders of warrants to purchase an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of which will be exercised prior to the closing of this offering, are entitled to piggyback registration rights under the terms of such warrants substantially similar to the registration rights described in the preceding paragraph. </p>

				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Acquisitions </b><b>U</b><b>nder Israeli Law </b></p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>Full Tender Offer </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A person wishing to acquire shares of an Israeli public company and who would as a result hold over 90% of the target company&#146;s issued and outstanding share capital is required by the Companies Law to make a tender </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">123</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">offer to all of the company&#146;s shareholders for the purchase of all of the issued and outstanding shares of the company. A person wishing to acquire shares of a public Israeli company and who would as a result hold over 90% of the issued and outstanding share capital of a certain class of shares is required to make a tender offer to all of the shareholders who hold shares of the relevant class for the purchase of all of the issued and outstanding shares of that class. If the shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company or of the applicable class, and more than half of the shareholders who do not have a personal interest in the offer accept the offer, all of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law. However, a tender offer will also be accepted if the shareholders who do not accept the offer hold less than 2% of the issued and outstanding share capital of the company or of the applicable class of shares. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Upon a successful completion of such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder accepted the tender offer or not, may, within six months from the date of acceptance of the tender offer, petition an Israeli court to determine whether the tender offer was for less than fair value and that the fair value should be paid as determined by the court. However, under certain conditions, the offeror may include in the terms of the tender offer that an offeree who accepted the offer will not be entitled to petition the Israeli court as described above. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If (a) the shareholders who did not respond or accept the tender offer hold at least 5% of the issued and outstanding share capital of the company or of the applicable class or the shareholders who accept the offer constitute less than a majority of the offerees that do not have a personal interest in the acceptance of the tender offer, or (b) the shareholders who did not accept the tender offer hold 2% or more of the issued and outstanding share capital of the company (or of the applicable class), the acquirer may not acquire shares of the company that will increase its holdings to more than 90% of the company&#146;s issued and outstanding share capital or of the applicable class from shareholders who accepted the tender offer. </p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Special Tender Offer </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of 25% or more of the voting rights in the company. This requirement does not apply if there is already another holder of at least 25% of the voting rights in the company. Similarly, the Companies Law provides that an acquisition of shares in a public company must be made by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of more than 45% of the voting rights in the company, if there is no other shareholder of the company who holds more than 45% of the voting rights in the company, subject to certain exceptions. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A special tender offer must be extended to all shareholders of a company but the offeror is not required to purchase shares representing more than 5% of the voting power attached to the company&#146;s outstanding shares, regardless of how many shares are tendered by shareholders. A special tender offer may be consummated only if (i) at least 5% of the voting power attached to the company&#146;s outstanding shares will be acquired by the offeror and (ii) the number of shares tendered by shareholders who accept the offer exceeds the number of shares whose holders objected to the offer (excluding the purchaser and its controlling shareholders, holders of 25% or more of the voting rights in the company or any person having a personal interest in the acceptance of the tender offer or any other person acting on their behalf, including relatives and entities under such person&#146;s control). If a special tender offer is accepted, then the purchaser or any person or entity controlling it or under common control with the purchaser or such controlling person or entity may not make a subsequent tender offer for the purchase of shares of the target company and may not enter into a merger with the target company for a period of one year from the date of the offer, unless the purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer. Shares purchased in contradiction to the tender offer rules under the Companies Law, will have no rights and will become dormant shares.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Merger </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Companies Law permits merger transactions if approved by each party&#146;s board of directors and, unless certain requirements described under the Companies Law are met, by a majority vote of each party&#146;s shares, and, in the case of the target company, a majority vote of each class of its shares voted on the proposed merger at a shareholders meeting. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">124</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">For purposes of the shareholder vote, unless a court rules otherwise, the merger will not be deemed approved if a majority of the votes of the shares represented at the shareholders meeting that are held by parties other than the other party to the merger, or by any person (or group of persons acting in concert) who holds (or hold, as the case may be) 25% or more of the voting rights or the right to appoint 25% or more of the directors of the other party, vote against the merger. If, however, the merger involves a merger with a company&#146;s own controlling shareholder or if the controlling shareholder has a personal interest in the merger, then the merger is instead subject to the same special majority approval that governs all extraordinary transactions with controlling shareholders (as described under &#147;Management&#8212;Fiduciary Duties and Approval of Specified Related Party Transactions and Compensation Under Israeli Law&#8212;Disclosure of Personal Interests of a Controlling Shareholder and Approval of Certain Transactions&#148;). </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If the transaction would have been approved by the shareholders of a merging company but for the separate approval of each class or the exclusion of the votes of certain shareholders as provided above, a court may still approve the merger upon the request of holders of at least 25% of the voting rights of a company, if the court holds that the merger is fair and reasonable, taking into account the value to the parties to the merger and the consideration offered to the shareholders of the target company. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Upon the request of a creditor of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern that, as a result of the merger, the surviving company will be unable to satisfy the obligations of the merging entities, and may further give instructions to secure the rights of creditors. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, a merger may not be consummated unless at least 50 days have passed from the date on which a proposal for approval of the merger was filed by each party with the Israeli Registrar of Companies and at least 30 days have passed from the date on which the merger was approved by the shareholders of each party. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Israeli tax law treats some acquisitions, such as share for share exchanges between an Israeli company and a foreign company, less favorably than U.S. tax laws. For example, Israeli tax law may, under certain circumstances, subject a shareholder who exchanges his ordinary shares for shares in another corporation to taxation prior to the sale of the shares received in such share for share swap.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Anti-Takeover Measures </b></i><i><b>U</b></i><i><b>nder Israeli Law </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Companies Law allows us to create and issue shares having rights different from those attached to our ordinary shares, including shares providing certain preferred rights with respect to voting, distributions or other matters and shares having preemptive rights. As of the closing of this offering, no preferred shares will be authorized under our amended and restated articles of association. In the future, if we do authorize, create and issue a specific class of preferred shares, such class of shares, depending on the specific rights that may be attached to it, may have the ability to frustrate or prevent a takeover or otherwise prevent our shareholders from realizing a potential premium over the market value of their ordinary shares. The authorization and designation of a class of preferred shares will require an amendment to our amended and restated articles of association, which requires the prior approval of the holders of a majority of the voting power attaching to our issued and outstanding shares at a general meeting. The convening of the meeting, the shareholders entitled to participate and the majority vote required to be obtained at such a meeting will be subject to the requirements set forth in the Companies Law as described above in &#147;&#8212;Voting Rights.&#148; </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Borrowing Powers </b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Pursuant to the Companies Law and our amended and restated articles of association, our board of directors may exercise all powers and take all actions that are not required under law or under our amended and restated articles of association to be exercised or taken by our shareholders, including the power to borrow money for company purposes. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Changes in Capital </b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our amended and restated articles of association enable us to increase or reduce our share capital. Any such changes are subject to the provisions of the Companies Law and must be approved by a resolution duly adopted by our shareholders at a general meeting. In addition, transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the absence of sufficient retained earnings or profits, require the approval of both our board of directors and an Israeli court. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">125</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Establishment </b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We were incorporated under the laws of the State of Israel on December 20, 2018. We are registered with the Israeli Registrar of Companies in Jerusalem. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Transfer Agent and Registrar </b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The transfer agent and registrar for our ordinary shares is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Listing </b></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We intend to apply to list our ordinary shares on The Nasdaq Capital Market under the symbol &#147;NNOX.&#148; </p>

			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">126</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tSE"></a><b>SHARES ELIGIBLE FOR FUTURE SALE</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Prior to this offering, no public market existed for our ordinary shares. Sales of substantial amounts of our ordinary shares following this offering, including shares issued upon the exercise of outstanding options or warrants, or the perception that these sales could occur, could adversely affect prevailing market prices of our ordinary shares and could impair our future ability to obtain capital, especially through an offering of equity securities. Assuming that the underwriters do not exercise their option to purchase additional ordinary shares in this offering, we will have an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares outstanding upon the closing of this offering. Of these shares, the ordinary shares sold in this offering will be freely tradable without restriction or further registration under the Securities Act, unless purchased by &#147;affiliates&#148; (as that term is defined under Rule 144 of the Securities Act (&#147;Rule 144&#148;)), who may sell only the volume of shares described below and whose sales would be subject to additional restrictions described below. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The remaining &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares will be held by our existing shareholders and will be deemed to be &#147;restricted securities&#148; (as that term is defined under Rule 144). Subject to certain contractual restrictions, including the lock-up agreements described below, restricted securities may only be sold in the public market pursuant to an effective registration statement under the Securities Act or pursuant to an exemption from registration such as under Rule 144 under the Securities Act. These rules are summarized below. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Lock-up Agreements </b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our officers, directors and substantially all holders of our outstanding share capital and equity securities have signed lock-up agreements pursuant to which, subject to certain exceptions, such persons have agreed not to sell or otherwise dispose of ordinary shares or any securities convertible into or exchangeable for ordinary shares for a period of &nbsp;&nbsp;&nbsp; days after the date of this prospectus without the prior written consent of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; may, at any time without prior notice, release all or any portion of the ordinary shares from the restrictions in any such agreement. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Rule 144 </b></p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>Shares Held </b></i><i><b>f</b></i><i><b>or Six Months </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In general, under Rule 144 under the Securities Act, as currently in effect, and subject to the terms of any lock-up agreement, commencing 90 days following the closing of this offering, a person, including an affiliate, who has beneficially owned our ordinary shares for six months or more, including the holding period of any prior owner other than one of our affiliates (i.e., commencing when the shares were acquired from us or from an affiliate of us as restricted securities), is entitled to sell our shares, subject to the availability of current public information about us (which information will be deemed to be available as long as we continue to file required reports with the SEC). In the case of an affiliate shareholder, the right to sell is also subject to the fulfillment of certain additional conditions, including manner of sale provisions, notice requirements, and a volume limitation that limits the number of shares that may be sold thereby, within any three-month period, to the greater of:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">1% of the number of ordinary shares then outstanding; or </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the greater of 1% or the average weekly trading volume of our ordinary shares on the Nasdaq during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Rule 144 under the Securities Act also provides that affiliates that sell our ordinary shares that are not restricted securities must nonetheless comply with the same restrictions applicable to restricted securities, other than the holding period requirement. </p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Shares Held by Non-Affiliates for One Year </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under Rule 144 as currently in effect, a person who is not considered to have been one of our affiliates at any time during the three months preceding a sale and who has beneficially owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than one of our affiliates, is entitled to sell his, her or its shares under Rule 144 without complying with the provisions relating to the availability of current public information or with any other conditions under Rule 144. Therefore, unless subject to a lock-up agreement or otherwise restricted, such shares may be sold immediately upon the closing of this offering. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">127</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Rule 701 </b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In general, under Rule 701 as currently in effect, each of our employees, consultants or advisors who purchases our ordinary shares from us in connection with a compensatory stock plan or other written agreement executed prior to the closing of this offering is eligible to resell such ordinary shares in reliance on Rule 144, but without compliance with some of the restrictions, as described below. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Rule 701 will apply to the options granted under our 2019 Equity Incentive Plan prior to the closing of this offering, along with the shares acquired upon exercise of these options, including exercises or vesting following the closing of this offering. Securities issued in reliance on Rule 701 are restricted securities and, subject to any contractual restrictions, including the lock-up agreements described above, may be sold beginning 90 days following the closing of this offering in reliance on Rule 144 by:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">persons other than affiliates, without restriction; and </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">affiliates, subject to the manner-of-sale, current public information and filing requirements of Rule 144, in each case, without compliance with the six-month holding period requirement of Rule 144.</td></tr></table><div style="clear: both"></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Form S-8 Registration Statements </b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Following the closing of this offering, we intend to file one or more registration statements on Form S-8 under the Securities Act to register, in the aggregate, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares, issued or reserved for issuance under our 2019 Equity Incentive Plan. The registration statement on Form S-8 will become effective automatically upon filing. Ordinary shares issued upon exercise of a share option or other award and registered pursuant to the Form S-8 registration statement will, subject to vesting provisions and Rule 144 volume limitations applicable to our affiliates, be available for sale in the open market immediately unless they are subject to the &nbsp;&nbsp;&nbsp;-day lock-up. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Registration Rights</b></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Prior to the closing of this offering, we intend to enter into the Registration Rights Agreement that will entitle holders of approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of our ordinary shares to certain piggyback registration rights following the closing of this offering. In addition, holders of warrants to purchase an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of which will be exercised prior to the closing of this offering, are entitled to piggyback registration rights under the terms of such warrants substantially similar to the registration rights provided in the Registration Rights Agreement. See &#147;Description of Share Capital&#8212;Registration Rights.&#148;</p>

			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">128</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 111-material -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tMT"></a><b>MATERIAL TAX CONSIDERATIONS </b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following description is not intended to constitute a complete analysis of all tax consequences relating to the acquisition, ownership and disposition of our ordinary shares. You should consult your own tax advisor concerning the tax consequences of your particular situation, as well as any tax consequences that may arise under the laws of any state, local, foreign or other taxing jurisdiction. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Israeli Tax Considerations and Government Programs</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following is a summary of the material Israeli tax laws applicable to us, and some Israeli Government programs benefiting us. This section also contains a discussion of some Israeli tax consequences to persons owning our ordinary shares. This summary does not discuss all the aspects of Israeli tax law that may be relevant to a particular investor in light of his or her personal investment circumstances or to some types of investors subject to special treatment under Israeli law. Examples of this kind of investor include traders in securities or persons that own, directly or indirectly, 10% or more of our outstanding voting capital, all of whom are subject to special tax regimes not covered in this discussion. Some parts of this discussion are based on tax legislation which has not been subject to judicial or administrative interpretation. The discussion should not be construed as legal or professional tax advice and does not cover all possible tax considerations. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">YOU ARE URGED TO CONSULT YOUR OWN TAX ADVISORS AS TO THE ISRAELI OR OTHER TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR ORDINARY SHARES, INCLUDING, IN PARTICULAR, THE EFFECT OF ANY FOREIGN, STATE OR LOCAL TAXES. </p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>General Corporate Tax Structure in Israel</b></i><i><b> </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Israeli resident companies are generally subject to corporate tax, currently at the rate of 23% of a company&#146;s taxable income. However, the effective tax rate payable by a company that derives income from a Benefited Enterprise, a Preferred Enterprise, or a Preferred Technological Enterprise (as discussed below) may be considerably less. Capital gains derived by an Israeli resident company are subject to tax at the regular corporate tax rate. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under Israeli tax legislation, a corporation will be considered as an &#147;Israeli resident company&#148; if it meets one of the following: (i) it was incorporated in Israel; or (ii) the control and management of its business are exercised in Israel. </p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Law for the Encouragement of Industry (Taxes), 5729-1969</b></i><i><b> </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Law for the Encouragement of Industry (Taxes), 5729-1969, generally referred to as the Industry Encouragement Law, provides several tax benefits for &#147;Industrial Companies.&#148; </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Industry Encouragement Law defines an &#147;Industrial Company&#148; as a company resident in Israel and which was incorporated in Israel, of which 90% or more of its income in any tax year, other than income from defense loans, is derived from an &#147;Industrial Enterprise&#148; owned by it and located in Israel or in the &#147;Area,&#148; as such terms are defined in the Israeli Income Tax Ordinance (New Version) 1961, or the Ordinance. An &#147;Industrial Enterprise&#148; is defined as an enterprise which is held by an Industrial Company whose principal activity in a given tax year is industrial production. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following corporate tax benefits, among others, are available to Industrial Companies: </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Amortization over an eight-year period of the cost of purchased know-how and patents and rights to use a patent and know-how which are used for the development or advancement of the Industrial Enterprise, commencing from the tax year where the Industrial Enterprise began to use them.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Under limited conditions, an election to file consolidated tax returns with related Israeli Industrial Companies; and </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Expenses related to a public offering are deductible in equal amounts from income attributed to the Industrial Enterprise over three years commencing in the year of the offering. </td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Although, as of the date of this prospectus, we do not have industrial production activities, we may qualify as an Industrial Company in the future and may be eligible for the benefits described above. However, we cannot assure that we will qualify as an Industrial Company or that the benefits described above will be available to us.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">129</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Tax Benefits and Grants for Research and Development</b></i><i><b> </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Israeli tax law allows, under certain conditions, a tax deduction for expenditures related to scientific research and development projects, including capital expenditures, for the year in which they are incurred. Expenditures are deemed related to scientific research and development projects, if:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The expenditures are approved by the relevant Israeli government ministry, determined by the field of research; or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The research and development is for the promotion of the company and is carried out by or on behalf of the company seeking such tax deduction. </td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The amount of such deductible expenses is reduced by the sum of any funds received through government grants for the financing of such scientific research and development projects. No deduction under these research and development deduction rules is allowed if such deduction is related to an expense invested in an asset depreciable under the general depreciation rules of the Ordinance. Expenditures not so approved are deductible in equal amounts over three years. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">From time to time, we may apply to the Israeli Innovation Authority, or the IIA, for approval to allow a tax deduction for research and development expenses during the year incurred. There can be no assurance that such application will be accepted. </p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Law for the Encouragement of Capital Investments, 5719-1959</b></i><i><b> </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Law for the Encouragement of Capital Investments, 5719-1959, or the Investment Law, provides certain incentives for capital investments in production facilities (or other eligible assets) by &#147;Industrial Enterprises&#148; (as defined under the Investment Law). The benefits available under the Investment Law are subject to the fulfillment of conditions stipulated therein. If a company does not meet these conditions, it may be required to refund the amount of tax benefits, as adjusted by the Israeli consumer price index, and interest, or other monetary penalties.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Tax Benefits Subsequent to the 2005 Amendment</b></i><i><b> </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">An amendment to the Investment Law, which became effective as of April 1, 2005, or the 2005 Amendment, changed certain provisions of the Investment Law. An eligible investment program under the 2005 Amendment qualifies for benefits as a &#147;Benefited Enterprise.&#148; Prior to the 2005 Amendment, investment programs under the Investment Law were called &#147;Approved Enterprises.&#148; The extent of the tax benefits available under the 2005 Amendment to qualifying income of a Benefited Enterprise depend on, among other things, the geographic location of the Benefited Enterprise in Israel. The location will also determine the period for which tax benefits are available. Such tax benefits include an exemption from corporate tax on undistributed income for a period of between two to ten years, depending on the geographic location of the Benefited Enterprise in Israel, and a reduced corporate tax rate of between 10% and the applicable corporate tax rate for the remainder of the benefits period, depending on the level of foreign investment in the company in each year during the benefits period. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are not entitled to tax benefits under the 2005 Amendment.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Tax Benefits Under the 2011 Amendment </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Investment Law was significantly amended as of January 1, 2011, or the 2011 Amendment. The 2011 Amendment introduced new benefits to replace those granted in accordance with the provisions of the Investment Law in effect prior to the 2011 Amendment. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The 2011 Amendment introduced new tax benefits for income generated by a &#147;Preferred Company&#148; through its &#147;Preferred Enterprise,&#148; in accordance with the definition of such terms in the Investment Law. The definition of a Preferred Company, includes, <i>inter alia</i>, a company incorporated in Israel that (1) is not wholly owned by a government entity, (2) owns a Preferred Enterprise and (3) is controlled and managed from Israel and is subject to further conditions set forth in the Investment Law. Moreover, a Preferred Company needs to meet certain conditions stipulated in the Investment Law such as being an industrial company (including a minimum threshold of 25% export). </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">130</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A Preferred Company is entitled to a reduced corporate tax rate of 16% with respect to the income attributed to its Preferred Enterprise, unless the Preferred Enterprise is located in development area &#147;A,&#148; in which case the rate will be 7.5%. Our operations are currently not located in development area &#147;A.&#148;</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Dividends distributed from income which is attributed to a &#147;Preferred Enterprise&#148; will be subject to withholding tax at the following rates: (i) Israeli resident individuals &#8212; 20% (iii) non-Israeli residents &#8212; 20%, subject to a reduced tax rate under the provisions of an applicable double tax treaty and subject to the receipt in advance of valid certificate from the Israeli Tax Authority, or the ITA. If such dividends are paid to an Israeli company, no tax is required to be withheld. However, if such dividends are subsequently distributed by such Israeli company to individuals or a non-Israeli company, withholding tax at a rate of 20% or such lower rate as may be provided in an applicable tax treaty will apply.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The provisions of the 2011 Amendment do not apply to existing &#147;Benefited Enterprises&#148; or &#147;Approved Enterprises,&#148; which will continue to be entitled to the tax benefits under the Investment Law, as in effect prior to the 2011 Amendment, unless the company owning such enterprises had made an election to apply the provisions of the 2011 Amendment (such election cannot be later rescinded), which is to be filed with the ITA, not later than the date prescribed for the filing of the company&#146;s annual Israeli tax return for the respective year.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are currently not entitled to tax benefits under the 2011 Amendment.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Tax Benefits Under the 2017 Amendment</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Additional amendments to the Investment Law became effective in January 2017, or the 2017 Amendment. The 2017 Amendment provides new tax benefits for two types of &#147;Technological Enterprises,&#148; as described below, and is in addition to the other existing tax benefit programs under the Investment Law.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The 2017 Amendment provides that a technological company satisfying certain conditions may qualify as a &#147;Preferred Technological Enterprise&#148; and thereby enjoy a reduced corporate tax rate of 12% on income that qualifies as &#147;Preferred Technological Income,&#148; as defined in the Investment Law. The tax rate is further reduced to 7.5% for a Preferred Technological Enterprise located in development area &#147;A.&#148; In addition, a Preferred Technological Company will enjoy a reduced corporate tax rate of 12% on capital gain derived from the sale of certain &#147;Benefited Intangible Assets&#148; (as defined in the Investment Law) to a related foreign company if the Benefited Intangible Assets were acquired from a foreign company on or after January 1, 2017, for at least NIS 200 million, and the sale receives prior approval from the IIA. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The 2017 Amendment further provides that a technological company satisfying certain conditions may qualify as a &#147;Special Preferred Technological Enterprise&#148; and thereby enjoy a reduced corporate tax rate of 6% on &#147;Preferred Technological Income&#148; regardless of the company&#146;s geographic location within Israel. In addition, a Special Preferred Technological Enterprise will enjoy a reduced corporate tax rate of 6% on capital gain derived from the sale of certain &#147;Benefited Intangible Assets&#148; to a related foreign company if the Benefited Intangible Assets were either developed by an Israeli company or acquired from a foreign company on or after January 1, 2017, and the sale received prior approval from the IIA. A Special Preferred Technological Enterprise that acquires Benefited Intangible Assets from a foreign company for more than NIS 500 million may be eligible for these benefits for a period of at least ten years, subject to certain approvals as specified in the Investment Law.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Dividends distributed by a Preferred Technological Enterprise or a Special Preferred Technological Enterprise, paid out of Preferred Technological Income or income attributed to production are generally subject to withholding tax at the rate of 20% or such lower rate, as may be provided in an applicable tax treaty (subject to the receipt in advance of a valid certificate from the ITA allowing for a reduced tax rate). However, if such dividends are paid to an Israeli company, no tax is required to be withheld. However, if such dividends are subsequently distributed by such Israeli company to individuals or a non-Israeli company, withholding tax at a rate of 20% or such lower rate as may be provided in an applicable tax treaty will apply. If dividends paid out of Preferred Technological Income are distributed to a foreign company and other conditions are met, the withholding tax rate will be 4% (or a lower rate under a tax treaty, if applicable, subject to the receipt in advance of a valid certificate from the ITA allowing for a reduced tax rate).</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are currently not entitled to tax benefits under the 2017 Amendment.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">131</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Taxation of Our Shareholders</b></i><i><b> </b></i></p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Capital Gains </i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Capital gain tax is imposed on the disposition of capital assets by an Israeli resident for tax purposes, and on the disposition of such assets by a non-Israeli resident for tax purposes if those assets are (i) located in Israel; (ii) are shares or a right to a share in an Israeli resident corporation, or (iii) represent, directly or indirectly, rights to assets located in Israel. The Ordinance distinguishes between &#147;Real Capital Gain&#148; and the &#147;Inflationary Surplus.&#148; Real Capital Gain is the excess of the total capital gain over Inflationary Surplus computed generally on the basis of the increase in the Israeli consumer price index or, in certain circumstances, a foreign currency exchange rate, between the date of purchase and the date of disposition. Inflationary Surplus is not currently subject to tax in Israel. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Real Capital Gain accrued by individuals on the sale of our ordinary shares will be taxed at the rate of 25%. However, if the individual shareholder is a &#147;Controlling Shareholder&#148; (i.e., a person who holds, directly or indirectly, alone or together with another, 10% or more of one of the Israeli resident company&#146;s &#147;means of control,&#148; which includes, among other things, the right to receive profits of the company, voting rights, the rights to receive proceeds upon the company&#146;s liquidation and the right to appoint a director) at the time of sale or at any time during the preceding 12-month period, such capital gain will be taxed at the rate of 30%. Furthermore, where an individual claimed real interest expenses and linkage differentials on securities, the capital gain on the sale of the securities will taxed at a rate of 30%.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Real Capital Gain derived by corporations will be generally subject to the corporate tax rate (23% in 2018 and thereafter). </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Individual and corporate shareholder dealing in securities in Israel are taxed at the tax rates applicable to business income &#8212; 23% for corporations in 2018 and thereafter and a marginal tax rate of up to 47% in 2019 for individuals, not including excess tax (described below). Notwithstanding the foregoing, Real Capital Gain derived from the sale of our ordinary shares by a non-Israeli shareholder may be exempt under the Ordinance from Israeli taxation provided that the following cumulative conditions are met: (i) the shares were purchased upon or after the registration of the shares on the stock exchange, (ii) the seller does not have a permanent establishment in Israel to which the derived capital gain is attributable, (iii) if the seller is a corporation, no more than 25% of its means of control are held, directly and indirectly, by Israeli residents, and (iv) if the seller is a corporation, there is no Israeli resident that is entitled to 25% or more of the revenues or profits of the corporation, directly or indirectly. In addition, such exemption would not be available to a person whose capital gains from selling or otherwise disposing of the securities are deemed to be business income. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, the sale of shares may be exempt from Israeli capital gain tax under the provisions of an applicable tax treaty. For example, the Convention Between the Government of the United States and the Government of the State of Israel with respect to Taxes of Income, as amended, or the U.S.-Israel Double Tax Treaty, exempts U.S. residents for the purposes of the treaty from Israeli capital gain tax in connection with such sale, provided (i) the U.S. resident owned, directly or indirectly, less than 10% of the Israeli resident company&#146;s voting power at any time within the 12-month period preceding such sale; (ii) the seller, being an individual, is present in Israel for a period or periods of less than 183 days during the taxable year; and (iii) the capital gain from the sale was not derived through a permanent establishment of the U.S. resident in Israel. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Shareholders may be liable for Israeli tax on the sale of their ordinary shares and the payment of the consideration may be subject to withholding of Israeli tax. Shareholders may be required to demonstrate that they are exempt from tax on their capital gains in order to avoid withholding at the time of sale. For example, in transactions involving a sale of all of the shares of an Israeli resident company, in the form of a merger or otherwise, the ITA may require from shareholders who are not liable for Israeli tax to sign declarations in forms specified by this authority or obtain a specific exemption from the ITA to confirm their status as a non-Israeli resident, and, in the absence of such declarations or exemptions, may require the purchaser of the shares to withhold taxes.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The purchaser, the Israeli stockbrokers or financial institutions through which the shares are held is obligated, subject to the above mentioned exemptions, to withhold tax on the amount of consideration paid upon the sale of the shares (or on the Real Capital Gain on the sale, if known) at the rate of 25% in respect of an individual and 23% in respect of a corporation. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">132</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Upon the sale of securities traded on a stock exchange, a detailed return, including a computation of the tax due, must be filed and an advanced payment must be paid on January 31 and July 31 of every calendar year in respect of sales of securities made within the previous six months. However, if all tax due was withheld according to applicable provisions of the Ordinance and regulations promulgated thereunder the aforementioned return need not be filed and no advance payment must be paid. Capital gain is also reportable on the annual income tax return. </p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Dividends </i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have never paid cash dividends. A distribution of dividend by our company from income attributed to a Preferred Enterprise to Israeli residents will generally be subject to withholding tax in Israel at the following tax rates: Israeli resident individuals &#8212; 20%; Israeli resident companies &#8212; 0% (although, if such dividends are subsequently distributed to individuals or a non-Israeli company, withholding tax at a rate of 20% or such lower rate as may be provided if an applicable tax treaty will apply (subject to the receipt in advance of a valid tax certificate from the ITA allowing for a reduced tax rate)). A distribution of dividends from income, which is not attributed to a Preferred Enterprise to an Israeli resident individual, will generally be subject to withholding tax at a rate of 25% or 30% if the dividend recipient is a &#147;Controlling Shareholder&#148; (as defined above) at the time of distribution or at any time during the preceding 12-month period. If the recipient of the dividend is an Israeli resident corporation, such dividend will be exempt from income tax provided the income from which such dividend is distributed was derived or accrued within Israel (although, if such dividends are subsequently distributed to individuals or a non-Israeli company, withholding tax at a rate of 25% or such lower rate as may be provided if an applicable tax treaty will apply (subject to the receipt in advance of a valid tax certificate from the ITA allowing for a reduced tax rate)). </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A non-Israeli resident (either individual or corporation) is generally subject to Israeli withholding tax on the receipt of dividends at the rate of 25% (30% if the dividends recipient is a &#147;Controlling Shareholder&#148; (as defined above), at the time of distribution or at any time during the preceding 12-month period); those rates are subject to a reduced tax rate under the provisions of an applicable double tax treaty (subject to the receipt in advance of a valid certificate from the ITA allowing for a reduced tax rate). Under the U.S.-Israel Double Tax Treaty, the following withholding rates will apply in respect of dividends distributed by an Israeli resident company to a U.S. resident: (i) if the U.S. resident is a corporation which holds during that portion of the taxable year which precedes the date of payment of the dividend and during the whole of its prior taxable year (if any), at least 10% of the outstanding voting shares of the Israeli resident paying corporation and not more than 25% of the gross income of the Israeli resident paying corporation for such prior taxable year (if any) consists of certain type of interest or dividends &#8212; the tax rate is 12.5%, (ii) if both the conditions mentioned in (i) above are met and the dividend is paid from an Israeli resident company&#146;s income which was entitled to a reduced tax rate applicable to an Approved Enterprise, Benefited Enterprise or Preferred Enterprise &#8212; the tax rate is 15% if a certificate for a reduced withholding tax rate would be provided in advance from the ITA and (iii) in all other cases, the tax rate is 25%. The aforementioned rates under the U.S.-Israel Double Tax Treaty will not apply if the dividend income was derived through a permanent establishment of the U.S. resident in Israel. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A non-Israeli resident who receives dividends from which tax was withheld is generally exempt from the obligation to file tax returns in Israel with respect to such income, provided that (i) such income was not generated from business conducted in Israel by the taxpayer and (ii) the taxpayer has no other taxable sources of income in Israel with respect to which a tax return is required to be filed.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Excess Tax </i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Individuals who are subject to tax in Israel (whether such individual is an Israeli resident or non-Israeli resident) are also subject to an additional tax on annual income exceeding a certain threshold (NIS 649,560, for 2019), which amount is linked to the Israeli consumer price index, at a rate of 3%, including, but not limited to, income derived from dividends, interest and capital gains. </p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Foreign Exchange Regulations </i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Non-residents of Israel who hold our ordinary shares are able to receive any dividends, and any amounts payable upon the dissolution, liquidation and winding up of our affairs, repayable in non-Israeli currency at the rate of exchange prevailing at the time of conversion. However, Israeli income tax is generally required to have been paid or withheld on these amounts. In addition, the statutory framework for the potential imposition of currency exchange control has not been eliminated, and may be restored at any time by administrative action. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">133</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Estate and Gift Tax </i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Israeli law presently does not impose estate or gift taxes. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>U.S. Federal Income Tax Consequences </b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following discussion is a summary of U.S. federal income tax considerations generally applicable to the ownership and disposition of our ordinary shares by a U.S. Holder (as defined below) that acquires our ordinary shares in this offering and holds them as &#147;capital assets&#148; (generally, property held for investment) under the U.S. Internal Revenue Code of 1986, as amended (the &#147;Code&#148;). This discussion is based upon existing U.S. federal tax law, which is subject to differing interpretations or change, possibly with retroactive effect. No ruling has been sought from the Internal Revenue Service, or the IRS, with respect to any U.S. federal income tax consequences described below, and there can be no assurance that the IRS or a court will not take a contrary position. This discussion, moreover, does not address the U.S. federal estate, gift, Medicare, and alternative minimum tax considerations, any withholding or information reporting requirements, or any state, local and non-U.S. tax considerations relating to the ownership or disposition of our ordinary shares. The following summary does not address all aspects of U.S. federal income taxation that may be important to particular investors in light of their individual circumstances or to persons in special tax situations such as:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">banks and other financial institutions;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">insurance companies;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">pension plans;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">cooperatives;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">regulated investment companies; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">real estate investment trusts; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">broker-dealers; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">traders that elect to use a mark-to-market method of accounting; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">certain former U.S. citizens or long-term residents; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">tax-exempt entities (including private foundations); </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">holders who acquire our ordinary shares pursuant to any employee share option or otherwise as compensation; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">investors that will hold our ordinary shares as part of a straddle, hedge, conversion, constructive sale or other integrated transaction for U.S. federal income tax purposes; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">persons holding our ordinary shares in connection with a trade or business outside the United States; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">persons that actually or constructively own 10% or more of our stock (by vote or value); </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">investors required to accelerate the recognition of any item of gross income with respect to our ordinary shares as a result of such income being recognized on an applicable financial statement; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">investors that have a functional currency other than the U.S. dollar; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">partnerships or other entities taxable as partnerships for U.S. federal income tax purposes, or persons holding our ordinary shares through such entities, all of whom may be subject to tax rules that differ significantly from those discussed below. </td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">INVESTORS ARE URGED TO CONSULT THEIR TAX ADVISORS ABOUT THE APPLICATION OF THE U.S. FEDERAL TAX RULES TO THEIR PARTICULAR CIRCUMSTANCES AS WELL AS THE STATE, LOCAL, NON-U.S. AND OTHER TAX CONSEQUENCES TO THEM OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR ORDINARY SHARES. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">134</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>General </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">For purposes of this discussion, a &#147;U.S. Holder&#148; is a beneficial owner of our ordinary shares that is, for U.S. federal income tax purposes:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">an individual who is a citizen or resident of the United States; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) created in, or organized under the law of, the United States or any state thereof or the District of Columbia;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">an estate the income of which is includible in gross income for U.S. federal income tax purposes regardless of its source; or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a trust (A) the administration of which is subject to the primary supervision of a U.S. court and which has one or more U.S. persons who have the authority to control all substantial decisions of the trust or (B) that has otherwise validly elected to be treated as a U.S. person under the Code. </td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If a partnership (or other entity treated as a partnership for U.S. federal income tax purposes) is a beneficial owner of our ordinary shares, the tax treatment of a partner in the partnership will generally depend upon the status of the partner and the activities of the partnership. Partnerships holding our ordinary shares and their partners are urged to consult their tax advisors regarding an investment in our ordinary shares. </p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Passive Foreign Investment Company Considerations </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A non-U.S. corporation, such as our company, will be classified as a PFIC for U.S. federal income tax purposes for any taxable year, if either (i) 75% or more of its gross income for such year consists of certain types of passive income or (ii) 50% or more of the value of its assets (generally determined on the basis of a quarterly average) during such year is attributable to assets that produce or are held for the production of passive income. For this purpose, cash and assets readily convertible into cash are generally classified as passive assets and goodwill and other unbooked intangibles associated with active business activities may generally be classified as non-passive assets. Passive income generally includes, among other things, dividends, interest, royalties and rents (other than certain royalties and rents derived in the active conduct of a trade or business and not derived from a related person), and gains from the disposition of passive assets. We will be treated as owning a proportionate share of the assets and earning a proportionate share of the income of any other corporation in which we own, directly or indirectly, at least 25% (by value) of the stock.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Whether we are, or will be, classified as a PFIC is a factual determination made annually that will depend, in part, upon the composition of our income and assets. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Based upon our current and projected income and assets (including goodwill and taking into account our cash balances, including the anticipated proceeds from this offering) and the anticipated market price of the ordinary shares in this offering, it is likely that we will be classified as a PFIC for the current taxable and future taxable years at least until we start generating a substantial amount of active revenue. Accordingly, prospective investors should be willing to assume the risks of investing in a PFIC. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If we are classified as a PFIC for any year during which a U.S. Holder holds our ordinary shares, the PFIC rules discussed below under &#147;&#8212;Passive Foreign Investment Company Rules&#148; generally will apply to such U.S. Holder for such taxable year, and unless the U.S. Holder makes certain elections, will apply in future years even if we cease to be classified as a PFIC. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Because it is likely that we will be classified as a PFIC for the current and future taxable years, at least until we start generating a substantial amount of active revenue, U.S. Holders should not assume that any dividends will qualify for the lower tax rate described under &#147;&#8212;Dividends&#148; below. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Furthermore, because there are uncertainties in the application of the relevant rules, it is possible that the IRS may challenge our classification of certain income or assets as non-passive, or our valuation of our goodwill and other unbooked intangibles, each of which may increase the likelihood of us becoming classified as a PFIC for the current or subsequent taxable years. If we are classified as a PFIC for any taxable year during which a U.S. Holder holds our ordinary shares, we generally will continue to be treated as a PFIC with respect to such U.S. Holder for all succeeding years during which the holder holds our ordinary shares. However, if we cease to be classified as a PFIC, provided that the U.S. Holder has not made a mark-to-market election, as described below under &#147;&#8212;Passive Foreign Investment Company Rules,&#148; such holder may avoid some of the adverse </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">135</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">effects of the PFIC regime by making a &#147;deemed sale&#148; election with respect to the ordinary shares. If such election is made, the U.S. Holder will be deemed to have sold our ordinary shares it holds on the last day of the last taxable year in which we were classified as a PF1C at their fair market value and any gain from such deemed sale would be subject to the rules described below under &#147;&#8212;Passive Foreign Investment Company Rules.&#148; After the deemed sale election, so long as we do not become classified as a PFIC in a subsequent taxable year, the ordinary shares with respect to which such election was made will not be treated as shares in a PFIC and the U.S. Holder will not be subject to the rules described below under &#147;&#8212;Passive Foreign Investment Company Rules&#148; with respect to any &#147;excess distribution&#148; received from us or any gain from an actual sale or other disposition of the ordinary shares. The rules dealing with deemed sale elections are very complex. Investors are strongly urged to consult their tax advisors as to the possibility and consequences of making a deemed sale election if we cease to be classified as a PFIC and such election becomes available to holders of ordinary shares.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Dividends </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Subject to the discussion below under &#147;&#8212;Passive Foreign Investment Company Rules,&#148; any cash distributions (including the amount of any Israeli tax withheld) paid on our ordinary shares out of our current or accumulated earnings and profits, as determined under U.S. federal income tax principles, will generally be includible in the gross income of a U.S. Holder as dividend income on the day actually or constructively received by the U.S. Holder. Because we do not intend to determine our earnings and profits on the basis of U.S. federal income tax principles, any distribution we pay will generally be treated as a &#147;dividend&#148; for U.S. federal income tax purposes. Dividends received on our ordinary shares will not be eligible for the dividends received deduction allowed to corporations in respect of dividends received from U.S. corporations.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Individuals and other non-corporate U.S. Holders may be subject to tax at the lower capital gains tax rate applicable to &#147;qualified dividend income,&#148; provided that certain conditions are satisfied, including that (1) the ordinary shares on which the dividends are paid are readily tradable on an established securities market in the United States, or we are eligible for the benefit of the U.S.-Israel Double Tax Treaty, (2) we are neither classified as a PFIC nor treated as such with respect to a U.S. Holder (as discussed above and below) for the taxable year in which the dividend is paid or the preceding taxable year, and (3) certain holding period and other requirements are met. Our ordinary shares have been approved for listing on the Nasdaq Capital Market. Provided this listing is approved, we believe that our ordinary shares will generally be considered to be readily tradable on an established securities market in the United States. There can be no assurance that the ordinary shares will continue to be considered readily tradable on an established securities market in later years. U.S. Holders are urged to consult their tax advisors regarding the availability of the lower rate for dividends paid with respect to our ordinary shares. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">For U.S. foreign tax credit purposes, dividends paid on our ordinary shares generally will be treated as income from foreign sources and generally will constitute passive category income. A U.S. Holder may be subject to Israeli withholding taxes on dividends paid on our ordinary shares (see &#147;Material Tax Considerations&#8212;Israeli Tax Considerations and Government Programs&#8212;Taxation of Our Shareholders&#8212;Dividends&#148;). Depending on the U.S. Holder&#146;s particular facts and circumstances and subject to a number of complex conditions and limitations, Israeli withholding taxes on dividends not in excess of any applicable rate under the U.S.-Israel Double Tax Treaty may be treated as foreign taxes eligible for credit against a U.S. Holder&#146;s U.S. federal income tax liability. A U.S. Holder who does not elect to claim a foreign tax credit for foreign tax withheld may instead claim a deduction for U.S. federal income tax purposes in respect of such withholding, but only for a year in which such holder elects to do so for all creditable foreign income taxes. The rules governing the foreign tax credit are complex and each U.S. Holder is urged to consult its tax advisor regarding the availability of the foreign tax credit under its particular circumstances. </p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Sale or Other Disposition </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A U.S. Holder will generally recognize gain or loss upon the sale or other disposition of our ordinary shares in an amount equal to the difference between the amount realized upon the disposition and the U.S. Holder&#146;s adjusted tax basis in such ordinary shares. Subject to the discussion under &#147;&#8212;Passive Foreign Investment Company Rules,&#148; the gain or loss will generally be capital gain or loss and individuals and other non-corporate U.S. Holders who have held the ordinary shares for more than one year will generally be eligible for reduced tax rates. However, as described above under &#147;&#8212;Passive Foreign Investment Company Considerations,&#148; it is likely that we will be classified as a PFIC for the current and future taxable years, at least until we start generating a </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">136</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">substantial amount of active revenue, in which case gains will be taxed as described in &#147;&#8212;Passive Foreign Investment Company Rules.&#148; The deductibility of a capital loss may be subject to limitations. Any such gain or loss that the U.S. Holder recognizes will generally be treated as U.S. source income or loss for foreign tax credit limitation purposes, such that the U.S. Holder may not be able to use the foreign tax credit arising from any Israeli tax imposed on the disposition of our ordinary shares unless such credit can be applied (subject to applicable limitations) against U.S. federal income tax due on other income derived from foreign sources in the same income category (generally, the passive category). Each U.S. Holder is urged to consult its tax advisor regarding the tax consequences if a foreign tax is imposed on a disposition of our ordinary shares, including the availability of the foreign tax credit under its particular circumstances. </p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Passive Foreign Investment Company Rules </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If we are classified as a PFIC for any taxable year during which a U.S. Holder holds our ordinary shares, unless the U.S. Holder makes a mark-to-market election (as described below), the U.S. Holder will generally be subject to special tax rules on (i) any excess distribution that we make to the U.S. Holder (which generally means any distribution paid during a taxable year to a U.S. Holder that is greater than 125% of the average annual distributions paid in the three preceding taxable years or, if shorter, the U.S. Holder&#146;s holding period for the ordinary shares), and (ii) any gain realized on the sale or other disposition of our ordinary shares. Under the PFIC rules:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the excess distribution or gain will be allocated ratably over the U.S. Holder&#8217;s holding period for the ordinary shares; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the amount allocated to the taxable year of the excess distribution, sale or other disposition and to any taxable years in the U.S. Holder&#8217;s holding period prior to the first taxable year in which we are classified as a PFIC (each, a &#147;pre-PFIC year&#148;), will be taxable as ordinary income; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the amount allocated to each prior taxable year, other than a pre-PFIC year, will be subject to tax at the highest tax rate in effect for individuals or corporations, as appropriate, for that year; and </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the interest charge generally applicable to underpayments of tax will be imposed on the tax attributable to each prior taxable year, other than a pre-PFIC year. </td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If we are classified as a PFIC for any year during which a U.S. Holder holds our ordinary shares, we will generally continue to be treated as a PFIC with respect to the U.S. Holder for all succeeding years during which the U.S. Holder owns the ordinary shares even if we cease to meet the threshold requirements for PFIC status unless the U.S. Holder makes a &#147;deemed sale&#148; election as discussed above under &#147;&#8212;Passive Foreign Investment Company Considerations&#148; in which case any gain on the deemed sale will be taxed under the PFIC rules described above. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If we are classified as a PFIC for any taxable year during which a U.S. Holder holds our ordinary shares and any subsidiary we own is also classified as a PFIC, such U.S. Holder would be treated as owning a proportionate amount (by value) of the shares of the lower-tier PFIC for purposes of the application of these rules. As a result, such U.S. Holder may incur liability for the deferred tax and interest charge described above if either (1) we receive any excess distribution from, or dispose of all or part of our interest in, the lower-tier PFIC or (2) the U.S. Holder disposes of all or part of our ordinary shares. It is possible that any subsidiary we own would be a PFIC for the current taxable year or future taxable years. U.S. Holders are urged to consult their tax advisors regarding the application of the PFIC rules to any subsidiary we own. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As an alternative to the foregoing rules, a U.S. Holder of &#147;marketable stock&#148; (as defined below) in a PFIC may make a mark-to-market election with respect to such stock. If a U.S. Holder makes this election with respect to our ordinary shares, the holder will generally (i) include as ordinary income for each taxable year that we are classified as a PFIC the excess, if any, of the fair market value of the ordinary shares held at the end of the taxable year over the adjusted tax basis of such ordinary shares and (ii) deduct as an ordinary loss in each such taxable year the excess, if any, of the adjusted tax basis of the ordinary shares over the fair market value of such ordinary shares held at the end of the taxable year, but such deduction will only be allowed to the extent of the amount previously included in income as a result of the mark-to-market election. The U.S. Holder&#146;s adjusted tax basis in the ordinary shares would be adjusted to reflect any income or loss resulting from the mark-to-market election. If a U.S. Holder makes a mark-to-market election in respect of our ordinary shares and we cease to be classified as a PFIC, the holder will not be required to take into account the gain or loss described above during </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">137</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">any period that we are not classified as a PFIC. If a U.S. Holder makes a mark-to-market election, any gain such U.S. Holder recognizes upon the sale or other disposition of our ordinary shares in a year when we are classified as a PFIC will be treated as ordinary income and any loss will be treated as ordinary loss, but such loss will only be treated as ordinary loss to the extent of the net amount previously included in income as a result of the mark-to-market election. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The mark-to-market election is available only for &#147;marketable stock,&#148; which is stock that is regularly traded on a qualified exchange or other market, as defined in applicable U.S. Treasury regulations. Our ordinary shares will be treated as traded on a qualified exchange or other market upon their listing on the Nasdaq Capital Market. We anticipate that our ordinary shares should qualify as being regularly traded, but no assurances may be given in this regard. If any subsidiary we own is, or becomes, classified as a PFIC, the mark-to-market election will likely not be available with respect to the shares of such subsidiary that are treated as owned by a U.S. Holder. Consequently, a U.S. Holder could be subject to the PFIC rules with respect to income of a lower-tier PFIC the value of which already had been taken into account indirectly via mark-to-market adjustments. U.S. Holders are urged to consult their tax advisors as to the availability and desirability of a mark-to-market election, as well as the impact of such election on interests in any lower-tier PFIC. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We do not intend to provide information necessary for U.S. Holders to make qualified electing fund elections, which, if available, would result in tax treatment different from (and generally less adverse than) the general tax treatment for PFICs described above.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If a U.S. Holder owns our ordinary shares during any taxable year that we are classified as a PFIC, the holder must generally file an annual IRS Form 8621 regarding distributions received on, and any gain realized on the disposition of, our ordinary shares. U.S. Holders are urged to consult their tax advisor regarding our PFIC status and the U.S. federal income tax consequences of owning and disposing of our ordinary shares if we are, or become, classified as a PFIC including the possibility of making a market-to-market or deemed sale election. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Information Reporting and Backup Withholding </b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Dividend payments with respect to ordinary shares and proceeds from the sale, exchange or redemption of ordinary shares may be subject to information reporting to the IRS and possible U.S. backup withholding. Backup withholding will not apply, however, to a U.S. Holder that furnishes a correct taxpayer identification number and makes any other required certification or that is otherwise exempt from backup withholding. U.S. Holders that are required to establish their exempt status generally must provide such certification on IRS Form W-9. U.S. Holders should consult their tax advisor regarding the application of the U.S. information reporting and backup withholding rules. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Backup withholding is not an additional tax. Amounts withheld as backup withholding may be credited against a U.S. Holder&#146;s U.S. federal income tax liability, and such holder may obtain a refund of any excess amounts withheld under the backup withholding rules by filing the appropriate claim for refund with the IRS and furnishing any required information in a timely manner. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Information with respect to Foreign Financial Assets </b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Certain U.S. Holders may be required to report information relating to an interest in our ordinary shares, subject to certain exceptions (including an exception for ordinary shares held in accounts maintained by certain U.S. financial institutions). Penalties can apply if U.S. Holders fail to satisfy such reporting requirements. U.S. Holders should consult their tax advisor regarding the effect, if any, of this requirement on their ownership and disposition of our ordinary shares. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">THE SUMMARY OF U.S. FEDERAL INCOME TAX CONSEQUENCES SET OUT ABOVE IS FOR GENERAL INFORMATIONAL PURPOSES ONLY. INVESTORS ARE URGED TO CONSULT THEIR TAX ADVISORS ABOUT THE APPLICATION OF THE U.S. FEDERAL TAX RULES TO THEIR PARTICULAR CIRCUMSTANCES AS WELL AS THE STATE, LOCAL, NON-U.S. AND OTHER TAX CONSEQUENCES TO THEM OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR ORDINARY SHARES. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">138</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 112-under -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tU"></a><b>UNDERWRITING</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are offering the ordinary shares described in this prospectus through the underwriters. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; is acting as representative of the underwriters. We have entered into an underwriting agreement with the underwriters.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to the underwriters, and each underwriter has severally agreed to purchase, at the public offering price less the underwriting discounts and commissions set forth on the cover page of this prospectus, the number of ordinary shares listed next to its name in the following table:</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 7.37px; "><b>Name </b></div></td>
	<td colspan="3" width="18%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 7.37px; padding-right: 0px; "><b>Number of shares</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.37px; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.37px; ">Total</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The underwriters are committed to purchase all the ordinary shares offered by us if they purchase any shares. The underwriting agreement also provides that if an underwriter defaults, the purchase commitments of non-defaulting underwriters may also be increased or the offering may be terminated.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The underwriters propose to offer the ordinary shares directly to the public at the initial public offering price set forth on the cover page of this prospectus and to certain dealers at that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. Any such dealers may resell shares to certain other brokers or dealers at a discount of up to $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share from the initial public offering price. After the initial offering of the shares to the public, if all of the ordinary shares are not sold at the initial public offering price, the underwriters may change the offering price and the other selling terms. The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the underwriters&#146; right to reject any order in whole or in part. Sales of shares made outside of the United States may be made by affiliates of the underwriters.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The underwriters have an option to buy up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional ordinary shares from us to cover sales of shares by the underwriters which exceed the number of shares specified in the table above. The underwriters have 30 days from the date of this prospectus to exercise this option to purchase additional shares. If any shares are purchased with this option to purchase additional shares, the underwriters will purchase shares in approximately the same proportion as shown in the table above. If any additional ordinary shares are purchased, the underwriters will offer the additional shares on the same terms as those on which the shares are being offered.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The underwriting fee is equal to the public offering price per ordinary share less the amount paid by the underwriters to us per ordinary shares. The underwriting fee is $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares.</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="62%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.23px; ">&#160;</div></td>
	<td colspan="3" width="19%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 7.23px; padding-right: 7.23px; "><b>Without option to<br> </b><b>purchase additional<br> </b><b>shares exercise</b></div></td>
	<td colspan="3" width="19%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 7.23px; padding-right: 0px; "><b>With full option to<br> </b><b>purchase additional<br> </b><b>shares exercise</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="62%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.23px; ">Per Share</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="16%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="16%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="62%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.23px; ">Total</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="16%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="16%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We estimate that the total expenses of this offering, including registration, filing and listing fees, printing fees and legal and accounting expenses, but excluding the estimated underwriting discounts and commissions, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . We have also agreed to reimburse the underwriters for certain of their expenses in an amount up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; .</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A prospectus in electronic format may be made available on the web sites maintained by one or more underwriters, or selling group members, if any, participating in the offering. The underwriters may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to underwriters and selling group members that may make Internet distributions on the same basis as other allocations.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">139</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our officers, directors and substantially all holders of our outstanding share capital and equity securities have agreed, subject to specified exceptions, not to directly or indirectly:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any of our ordinary shares or any securities convertible into or exercisable or exchangeable for our ordinary shares (including without limitation, ordinary shares or such other securities which may be deemed to be beneficially owned by the such persons in accordance with the rules and regulations of the SEC and securities which may be issued upon exercise of a share option or warrant); </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any of the economic consequences of ownership of our ordinary shares or such other securities; or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">make any demand for or exercise any right with respect to the registration of any of our ordinary shares or any security convertible into or exercisable or exchangeable for our ordinary shares, or publicly disclose the intention to do any of the foregoing.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">This restriction terminates after the close of business on and including the &nbsp;&nbsp;&nbsp; day after the date of this prospectus. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; may, in its sole discretion and at any time or from time to time before the termination of the &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; period release all or any portion of the securities subject to lock-up agreements. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, we have agreed, for the 180 days after the date of this prospectus and subject to specified exceptions, not to:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the SEC a registration statement under the Securities Act relating to, any of our ordinary shares or any securities convertible into or exercisable or exchangeable for our ordinary shares, or publicly disclose the intention to undertake any of the foregoing; or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of our ordinary shares or any such other securities, without the prior written consent of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have also agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or contribute to payments the underwriters may be required to make in respect of these liabilities.</p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We intend to apply to have our ordinary shares approved for listing on The Nasdaq Capital Market under the symbol &#147;NNOX.&#148;</p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In connection with this offering, the underwriters may engage in stabilizing transactions, which involves making bids for, purchasing and selling ordinary shares in the open market for the purpose of preventing or retarding a decline in the market price of the ordinary shares while this offering is in progress. These stabilizing transactions may include making short sales of the ordinary shares, which involves the sale by the underwriters of a greater number of ordinary shares than they are required to purchase in this offering, and purchasing ordinary shares on the open market to cover positions created by short sales. Short sales may be &#147;covered&#148; shorts, which are short positions in an amount not greater than the underwriters&#146; option to purchase additional shares referred to above, or may be &#147;naked&#148; shorts, which are short positions in excess of that amount. The underwriters may close out any covered short position either by exercising their option to purchase additional shares, in whole or in part, or by purchasing shares in the open market. In making this determination, the underwriters will consider, among other things, the price of shares available for purchase in the open market compared to the price at which the underwriters may purchase shares through the option to purchase additional shares. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the ordinary shares in the open market that could adversely affect investors who purchase in this offering. To the extent that the underwriters create a naked short position, they will purchase shares in the open market to cover the position.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The underwriters have advised us that, pursuant to Regulation M of the Securities Act, they may also engage in other activities that stabilize, maintain or otherwise affect the price of the ordinary shares, including </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">140</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">the imposition of penalty bids. This means that if the representatives of the underwriters purchase ordinary shares in the open market in stabilizing transactions or to cover short sales, the representatives can require the underwriters that sold those shares as part of this offering to repay the underwriting discount received by them.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">These activities may have the effect of raising or maintaining the market price of the ordinary shares or preventing or retarding a decline in the market price of the ordinary shares, and, as a result, the price of the ordinary shares may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities, they may discontinue them at any time. The underwriters may carry out these transactions on The Nasdaq Capital Market, in the over-the-counter market or otherwise.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Prior to this offering, there has been no public market for our ordinary shares. The initial public offering price will be determined by negotiations between us and the representative of the underwriters. In determining the initial public offering price, we and the representative of the underwriters expect to consider a number of factors including:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the information set forth in this prospectus and otherwise available to the representative;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our prospects and the history and prospects for the industry in which we compete;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">an assessment of our management;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our prospects for future earnings;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the general condition of the securities markets at the time of this offering;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the recent market prices of, and demand for, publicly traded equity securities of generally comparable companies; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">other factors deemed relevant by the underwriters and us.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Neither we nor the underwriters can assure investors that an active trading market will develop for our ordinary shares, or that our ordinary shares will trade in the public market at or above the initial public offering price.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Other </b><b>R</b><b>elationships</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Certain of the underwriters and their affiliates have provided in the past to us and our affiliates and may provide from time to time in the future certain commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received and may continue to receive customary fees and commissions. In addition, from time to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of customers, and actively trade or hold on behalf of themselves or their customers, long or short positions in our debt or equity securities (or relative derivatives or other financial instruments) or loans, and may do so in the future. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire, long or short positions in such securities or instruments.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Selling </b><b>R</b><b>estrictions</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Notice to prospective investors in Israel</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">This document does not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Securities Law, and has not been filed with or approved by the Israel Securities Authority. In the State of Israel, </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">141</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">this document is being distributed only to, and is directed only at, and any offer of the securities offered hereby is directed only at, (i) a limited number of persons in accordance with the Securities Law and (ii) investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50 million and &#147;qualified individuals,&#148; each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified investors (in each case purchasing for their own account or, where permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors will be required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Notice to prospective investors in the European Economic Area</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive, or a Relevant Member State, with effect from and including the date on which the Prospectus Directive is implemented in that Relevant Member State, no offer of shares may be made to the public in that Relevant Member State other than:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">to any legal entity which is a qualified investor as defined in the Prospectus Directive;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), subject to obtaining the prior consent of the underwriters; or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">in any other circumstances falling within Article 3(2) of the Prospectus Directive,</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">provided that no such offer of shares shall require the company or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the underwriters and the company that it is a &#147;qualified investor&#148; within the meaning of the law in that Relevant Member State implementing Article 2(1)(e) of the Prospectus Directive.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In the case of any shares being offered to a financial intermediary as that term is used in Article 3(2) of the Prospectus Directive, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares to the public other than their offer or resale in a Relevant Member State to qualified investors as so defined or in circumstances in which the prior consent of the representatives has been obtained to each such proposed offer or resale.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">For the purposes of this provision, the expression an &#147;offer of shares to the public&#148; in relation to any shares in any Relevant Member State means the communication in any form and by means of sufficient information on the terms of the offer and the shares to be offered so as to enable an investor to decide to purchase shares, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (as amended, including by Directive 2010/73/EU), and includes any relevant implementing measure in the Relevant Member State.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Notice to prospective investors in the United Kingdom</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus Directive) (1) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, or the Order, and/or (2) who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as relevant persons) or otherwise in circumstances which have not resulted and will not result in an offer to the public of the shares in the United Kingdom within the meaning of the Financial Services and Markets Act 2000.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Any person in the United Kingdom that is not a relevant person should not act or rely on the information included in this document or use it as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">142</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Notice to prospective investors in Canada</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts, or NI 33-105, the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Notice to prospective investors in Japan</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The shares have not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Act. Accordingly, none of the shares nor any interest therein may be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any &#147;resident&#148; of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant time.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Notice to prospective investors in Hong Kong</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (1) to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance or (2) in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the shares has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance and any rules made under that Ordinance.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Notice to prospective investors in Singapore</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (1) to an institutional investor under Section 274 of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA, (2) to a relevant person pursuant to Section 275(1), or any person pursuant to Section 275(1A), and in accordance with the conditions specified in Section 275 of the SFA, or (3) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. Where the shares are subscribed or purchased under Section 275 of the SFA by a relevant person which is:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(a)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">143</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(b)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, securities (as defined in Section 239(1) of the SFA) of that corporation or the beneficiaries&#8217; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section 275 of the SFA except:</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(a)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">to an institutional investor or to a relevant person defined in Section 275(2) of the SFA, or to any person arising from an offer referred to in Section 275(1A) or Section 276(4)(i)(B) of the SFA;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(b)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">where no consideration is or will be given for the transfer;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(c)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">where the transfer is by operation of law;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(d)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">as specified in Section 276(7) of the SFA; or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(e)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Solely for the purposes of its obligations pursuant to Section 309B of the SFA, we have determined, and hereby notify all relevant persons (as defined in the CMP Regulations 2018), that the shares are &#147;prescribed capital markets products&#148; (as defined in the CMP Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA 04-N12: Notice on the Sale of Investment Products and MAS Notice FAA-N16: Notice on Recommendations on Investment Products).</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">144</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tER"></a><b>EXPENSES RELATED TO OFFERING</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table sets forth the costs and expenses, other than underwriting discounts and commissions, payable by us in connection with the offer and sale of ordinary shares in this offering. All amounts listed below are estimates except the SEC registration fee, Nasdaq listing fee and the FINRA filing fee. </p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 6.33px; "><b>Itemized expense </b></div></td>
	<td colspan="3" width="18%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 6.33px; padding-right: 0px; "><b>Amount</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.33px; ">SEC registration fee </div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.33px; ">FINRA filing fee </div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.33px; ">Nasdaq listing fee </div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.33px; ">Printing and engraving expenses </div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.33px; ">Legal fees and expenses </div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.33px; ">Transfer agent and registrar fees </div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.33px; ">Accounting fees and expenses </div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.33px; ">Miscellaneous </div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">*</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.33px; ">Total </div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">$</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">*</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">*</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">To be filed by amendment.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">145</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tLM"></a><b>LEGAL MATTERS</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The validity of the ordinary shares being offered by this prospectus and other legal matters concerning this offering relating to Israeli law will be passed upon for us by Amit, Pollak, Matalon &amp; Co., Tel Aviv, Israel. Certain legal matters in connection with this offering relating to U.S. law will be passed upon for us by Skadden, Arps, Slate, Meagher &amp; Flom LLP, New York, New York. Certain legal matters concerning this offering will be passed upon for the underwriters by Gornitzky &amp; Co., Tel Aviv, Israel, relating to Israeli law, and by Latham and Watkins LLP, New York, New York, relating to U.S. law.</p>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tE"></a><b>EXPERTS</b></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The consolidated financial statements as of December 31, 2018 and for the year ended December 31, 2018 included in this prospectus have been so included in reliance on the report (which contains an explanatory paragraph relating to the Company&#146;s ability to continue as a going concern as described in Note 1C to the financial statements) of Kesselman &amp; Kesselman, a member firm of PricewaterhouseCoopers International Limited (PwC Israel), an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. The offices of PwC Israel are located at Hamered 25 Tel-Aviv.</p>

			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">146</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tEC"></a><b>ENFORCEABILITY OF CIVIL LIABILITIES</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are incorporated under the laws of the State of Israel. Service of process upon us and upon our directors and officers and the Israeli experts named in this prospectus, many of whom reside outside of the United States, may be difficult to obtain within the United States. Furthermore, because substantially all of our assets and substantially all of our directors and officers are located outside the United States, any judgment obtained in the United States against us or any of our directors and officers may be difficult to collect within the United States </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have irrevocably appointed&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as our agent to receive service of process in any action against us in any U.S. federal or state court arising out of this offering or any purchase or sale of securities in connection with this offering. The address of our agent is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have been informed by our legal counsel in Israel, Amit, Pollak, Matalon &amp; Co., that it may be difficult to initiate an action with respect to U.S. securities laws in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws on the basis that Israel is not the most appropriate forum in which to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. There is little binding case law in Israel addressing these matters. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact by expert witnesses which can be a time-consuming and costly process. Certain matters of procedure may also be governed by Israeli law. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Subject to certain time limitations and legal procedures, Israeli courts may enforce a U.S. judgment in a civil matter which, subject to certain exceptions, is non-appealable, including judgments based upon the civil liability provisions of the Securities Act and the Exchange Act and including a monetary or compensatory judgment in a non-civil matter, provided that, among other things: </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the judgment was rendered by a court which was, according to the laws of the state of the court, competent to render the judgment; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the obligation imposed by the judgment is enforceable according to the rules relating to the enforceability of judgments in Israel and the substance of the judgment is not contrary to public policy; and </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the judgment is executory in the state in which it was given. </td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Even if these conditions are met, an Israeli court will not declare a foreign civil judgment enforceable if: </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the judgment was given in a state whose laws do not provide for the enforcement of judgments of Israeli courts (subject to exceptional cases); </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the enforcement of the judgment is likely to prejudice the sovereignty or security of the State of Israel; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the judgment was obtained by fraud; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the opportunity given to the defendant to bring its arguments and evidence before the court was not reasonable in the opinion of the Israeli court; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the judgment was rendered by a court not competent to render it according to the laws of private international law as they apply in Israel; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the judgment is contradictory to another judgment that was given in the same matter between the same parties and that is still valid; or </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">at the time the action was brought in the foreign court, a lawsuit in the same matter and between the same parties was pending before a court or tribunal in Israel. </td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If a foreign judgment is enforced by an Israeli court, it generally will be payable in Israeli currency, which can then be converted into non-Israeli currency and transferred out of Israel. Under existing Israeli law, a foreign judgment payable in foreign currency may be paid in Israeli currency at the rate of exchange in force on the date of the payment. Current Israeli exchange control regulations also permit a judgment debtor to make payment in foreign currency. Pending collection, the amount of the judgment of an Israeli court stated in Israeli currency ordinarily will be linked to the Israeli consumer price index plus interest at the annual statutory rate set by Israeli regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable exchange rates.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">147</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tWY"></a><b>WHERE YOU CAN FIND ADDITIONAL INFORMATION</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have filed with the SEC a registration statement on Form F-1 under the Securities Act relating to this offering of our ordinary shares. This prospectus does not contain all of the information contained in the registration statement. The rules and regulations of the SEC allow us to omit certain information from this prospectus that is included in the registration statement. Statements made in this prospectus concerning the contents of any contract, agreement or other document are summaries of all material information about the documents summarized, but are not complete descriptions of all terms of these documents. If we filed any of these documents as an exhibit to the registration statement, you may read the document itself for a complete description of its terms. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">You may read and copy the registration statement, including the related exhibits and schedules, and any document we file with the SEC at its web site at: http://www.sec.gov. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are not currently subject to the informational requirements of the Exchange Act. Upon completion of this offering, we will become subject to the information reporting requirements of the Exchange Act applicable to foreign private issuers and will fulfill the obligations of those requirements by filing reports with the SEC. As a foreign private issuer, we will be exempt from the rules under the Exchange Act relating to the furnishing and content of proxy statements, and our officers, directors and principal shareholders will be exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we will not be required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. However, we intend to file with the SEC, within 120 days after the end of our fiscal year, or such applicable time as required by the SEC, an annual report on Form 20-F containing financial statements which will be audited and reported on, with an opinion expressed, by an independent registered public accounting firm. We also intend to file with the SEC reports on Form 6-K containing unaudited financial information for the first three quarters of each fiscal year. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We maintain a corporate website at <u>www.nanox.vision</u>. Information contained on, or that can be accessed through our website does not constitute a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">148</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 200-fintoc -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tIC"></a><b>NANO-X IMAGING LTD. </b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">CONSOLIDATED FINANCIAL STATEMENTS </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">AS OF AND FOR THE YEAR ENDED DECEMBER 31, 2018</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">U.S. DOLLARS</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">&nbsp;&nbsp;&nbsp;</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">INDEX</p>
				<a name="TOC"></a><table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; ">&#160;</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 6.52px; padding-right: 0px; "><b>Page </b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; "><a href="#fROI"><b>Report of Independent Registered Public Accounting Firm </b></a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#fROI">F-2 </a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; ">&nbsp;&nbsp;&nbsp;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; "><a href="#fCBS"><b>Consolidated Balance Sheet </b></a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#fCBS">F-4 </a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; ">&nbsp;&nbsp;&nbsp;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; "><a href="#fCSO"><b>Consolidated Statement of Operations </b></a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#fCSO">F-5 </a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; ">&nbsp;&nbsp;&nbsp;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; "><a href="#fCSOC"><b>Consolidated Statement of Changes in Shareholders' Equity </b></a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#fCSOC">F-6 </a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; ">&nbsp;&nbsp;&nbsp;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; "><a href="#fCSCF"><b>Consolidated Statement of Cash Flows </b></a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#fCSCF">F-7 </a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; ">&nbsp;&nbsp;&nbsp;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.52px; "><a href="#fNOTES"><b>Notes to the Consolidated Financial Statements </b></a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#fNOTES">F-8</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-1</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 201-fintab01 -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="fROI"></a><b>Report of Independent Registered Public Accounting Firm</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Asset Purchase Transaction accounted for as transfer of net assets under common control as described in Note 1b to the consolidated financial statements was consummated on September 3, 2019. This transfer of net assets under common control has not been included in a set of financial statements prepared in accordance with accounting principles generally accepted in the United States of America covering a period in which the transfer of net assets under common control occurred. Once a set of financial statements that reflect the transfer of net assets under common control in 2019 are issued, we will be in a position to furnish the following report.</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="100%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 0px; ">/s/ Kesselman &amp; Kesselman</div>
							</td>
						</tr>
						<tr>
							<td width="100%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 0px; ">Certified Public Accountants (Isr.)</div>
							</td>
						</tr>
						<tr>
							<td width="100%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 0px; ">A member firm of PricewaterhouseCoopers International Limited</div>
							</td>
						</tr>
						<tr>
							<td width="100%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="100%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 0px; ">Tel Aviv, Israel</div>
							</td>
						</tr>
						<tr>
							<td width="100%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 0px; ">December 3, 2019</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 13.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-2</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>&#147;Report of Independent Registered Public Accounting Firm </b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">To the Board of Directors and Shareholders of Nano-X Imaging Ltd. </p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Opinion on the Financial Statements</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have audited the accompanying consolidated balance sheet of Nano-X Imaging Ltd. and its subsidiary (the &#147;Company&#148;) as of December 31, 2018 and the related consolidated statement of operations, changes in shareholders&#146; equity and cash flows for the year ended December 31, 2018, including the related notes (collectively referred to as the &#147;consolidated financial statements&#148;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2018 and the results of its operations and its cash flows for the year ended December 31, 2018 in conformity with accounting principles generally accepted in the United States of America. </p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Substantial Doubt About the Company&#146;s Ability to Continue as a Going Concern</i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1c to the consolidated financial statements, the Company has suffered recurring losses from operations and negative working capital that raise substantial doubt about its ability to continue as a going concern. Management&#146;s plans in regard to these matters are also described in Note 1c. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Basis for Opinion</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">These consolidated financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">&nbsp;&nbsp;&nbsp;</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Tel Aviv, Israel<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019<br>We have served as the Company&#8217;s auditor since 2019.&#148;</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-3</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="fCBS"></a><b>NANO-X IMAGING LTD.</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">CONSOLIDATED BALANCE SHEET</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">&#160;</div></td>
	<td colspan="3" width="18%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 12.28px; padding-right: 0px; "><b>December 31,</b><br><b> </b><b>2018</b><b><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(*)</sup></b></div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">&#160;</div></td>
	<td colspan="3" width="18%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 12.28px; padding-right: 0px; "><b>U.S. Dollars<br> </b><b>in thousands</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; "><b>Assets<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; "><b>CURRENT ASSETS:<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">Cash and cash equivalents</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">Related party receivables</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">1,694</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; "><b>TOTAL CURRENT ASSETS</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">1,699</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">&nbsp;&nbsp;&nbsp;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; "><b>NON-CURRENT ASSETS:<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">Property, equipment and software, net</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">156</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; "><b>TOTAL NON-CURRENT ASSETS</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">156</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">&nbsp;&nbsp;&nbsp;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; "><b>TOTAL ASSETS</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">1,855</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">&nbsp;&nbsp;&nbsp;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; "><b>Liabilities and shareholders&#8217; equity<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; "><b>CURRENT LIABILITIES:<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">Accounts payable</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">82</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">Related party liability</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">8,157</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; "><b>TOTAL LIABILITIES<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">8,239</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; "><b>COMMITMENTS<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; "><b>SHAREHOLDERS&#8217; EQUITY:<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; padding-left: 26.67px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">Ordinary Shares, par value NIS 0.01 per share, 30,000,000 Shares authorized;<br> 21,924,208 issued and outstanding.</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">58</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">Additional paid-in capital</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">11,596</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">Accumulated deficit</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(18,038</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; "><b>TOTAL SHAREHOLDERS&#8217; EQUITY</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(6,384</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; "><b>TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">1,855</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(*)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">The financial statements as of and for the year ended December 31, 2018 reflect a retrospective application of transaction under common control - see note 1b</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 18.93px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>The accompanying notes are an integral part of these financial statements<br></b> </p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-4</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="fCSO"></a><b>NANO-X IMAGING LTD.</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">CONSOLIDATED STATEMENT OF OPERATIONS </p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">&#160;</div></td>
	<td colspan="3" width="18%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 12.28px; padding-right: 0px; "><b>Year ended<br> </b><b>December 31,</b><br><b> </b><b>2018</b><b><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(*)</sup></b></div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">&#160;</div></td>
	<td colspan="3" width="18%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 12.28px; padding-right: 0px; "><b>U.S. Dollars<br> </b><b>in thousands</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; "><b>OPERATING EXPENSES:<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">Research and development</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">672</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">Marketing, general and administrative</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">1,232</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; "><b>TOTAL OPERATING EXPENSES</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">1,904</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; "><b>OPERATING LOSS</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(1,904</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; "><b>FINANCIAL EXPENSES, </b>net</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">5</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; "><b>NET LOSS FOR THE YEAR</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(1,909</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">&nbsp;&nbsp;&nbsp;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; "><b>BASIC AND DILUTED LOSS PER SHARE</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">(0.09</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(*)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">The financial statements as of and for the year ended December 31, 2018 reflect a retrospective application of transaction under common control - see note 1b </td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 18.93px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>The accompanying notes are an integral part of these financial statements<br></b> </p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-5</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="fCSOC"></a><b>NANO-X IMAGING LTD.</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS&#146; EQUITY (*)</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.96px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.96px; padding-right: 5.96px; "><b>Ordinary shares</b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.96px; padding-right: 5.96px; "><b>Additional<br> </b><b>paid-in</b><br><b> </b><b>capital</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.96px; padding-right: 5.96px; "><b>Accumulated<br> </b><b>deficit</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.96px; padding-right: 0px; "><b>Total</b></div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.96px; ">&#160;</div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.96px; padding-right: 5.96px; "><b>Number<br> </b><b>of shares</b></div></td>
	<td colspan="12" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.96px; padding-right: 0px; "><b>U.S. Dollars</b><b> </b><b>in thousands</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.96px; "><b>BALANCE AT DECEMBER 31, 2017</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">20,257,434</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">41</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">7,814</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(16,129</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(8,274</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.96px; "><b>CHANGES DURING 2018:<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.96px; ">Issuance of ordinary shares, see note 6a1)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,666,774</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">17</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3,667</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3,684</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.96px; ">Share-based compensation, see note 6a2)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">115</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">115</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.96px; ">Net loss for the year</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(1,909</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(1,909</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.96px; "><b>BALANCE AT DECEMBER 31, 2018</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">21,924,208</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">58</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">11,596</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">(18,038</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">(6,384</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(*)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">The financial statements as of and for the year ended December 31, 2018, reflects a retrospective application of transaction under common control - see note 1b</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 18.93px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>The accompanying notes are an integral part of these financial statements<br></b> </p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-6</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="fCSCF"></a><b>NANO-X IMAGING LTD.</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">CONSOLIDATED STATEMENT OF CASH FLOWS </p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">&#160;</div></td>
	<td colspan="3" width="18%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 12.28px; padding-right: 0px; "><b>Year ended<br> </b><b>December 31,</b><br><b> </b><b>2018</b><b><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(*)</sup></b></div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">&#160;</div></td>
	<td colspan="3" width="18%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 12.28px; padding-right: 0px; "><b>U.S. Dollars<br> </b><b>in thousands</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; "><b>CASH FLOWS FROM OPERATING ACTIVITIES:<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">Net loss for the year</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(1,909</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">Adjustments required to reconcile net loss to net cash used in operating activities:<br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 26.67px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">Share-based compensation</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">115</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 26.67px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">Depreciation</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">35</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 26.67px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">Changes in operating assets and liabilities:<br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 26.67px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">Decrease in other receivable</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">66</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 26.67px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">Decrease in related parties</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,840</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 26.67px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">Decrease in accounts payable</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(134</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">Net cash used in operating activities</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">13</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">&nbsp;&nbsp;&nbsp;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; "><b>CASH FLOWS FROM INVESTING ACTIVITIES:<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">Purchase of Property, equipment and software</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(73</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">Net cash used in investing activities</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(73</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">&nbsp;&nbsp;&nbsp;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; "><b>NET CHANGE IN CASH AND CASH EQUIVALENTS</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(60</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; "><b>CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">65</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">&nbsp;&nbsp;&nbsp;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; "><b>CASH AND CASH EQUIVALENTS AT END OF THE YEAR</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">5</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; "><b>SUPPLEMENTARY INFORMATION ON ACTIVITIES NOT INVOLVING CASH </b><b>FLOWS:<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 12.28px; ">Issuance of Ordinary Shares</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">3,684</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(*)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">The financial statements as of and for the year ended December 31, 2018, reflects a retrospective application of transaction under common control - see note 1b</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 18.93px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>The accompanying notes are an integral part of these financial statements<br></b> </p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-7</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 202-finnote01 -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="fNOTES"></a><b>NANO-X IMAGING LTD.<br></b>NOTES TO THE FINANCIAL STATEMENTS<br> (U.S. Dollars in thousands) </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>NOTE 1 - GENERAL:</b></p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>a.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Nano-X Imaging Ltd, an Israeli company (hereinafter &#147;the Company&#148; or &#147;Nanox IL&#148; or &#147;the Successor Company&#148;), was incorporated on December 20, 2018 and commenced its operations on September 3, 2019. </td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">On September 19, 2019, Nanox IL established Nanox Imaging Inc. (hereinafter &#147;Nanox Inc.&#148;) a wholly owned subsidiary in Japan. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Nanox Imaging PLC is a public limited company incorporated in Gibraltar in 2012 (hereinafter &#147;Nanox PLC&#148; or &#147;the predecessor company&#148;). </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Nanox PLC developed certain technological capabilities aimed to design and build various applications for x-ray based imaging. Nanox PLC has been a development-stage company since its inception. Nanox PLC has a wholly owned subsidiary, Nanox Japan Inc. (hereinafter &#147;Nanox Japan&#148;). Nanox Japan primarily provides research and development services to Nanox PLC.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>b.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">On September 3, 2019 (hereinafter &#147;Transaction Date&#148;), Nanox IL signed an Asset Purchase Agreement which was later amended on December 3, 2019 (hereinafter &#147;the APA&#148;) with Nanox PLC. </td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the terms of the APA, Nanox IL purchased from Nanox PLC patents, patent applications and all other intellectual property rights, as well as all cash of Nanox PLC (less an amount of $200 thousand), with an exclusion of certain assets as those are defined in the APA (hereinafter &#147;Acquired Assets&#148;). </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the terms of the APA, Nanox IL shall pay Nanox PLC $6.127 million as consideration for the purchase of the Acquired Assets, which reflects the fair value of the Acquired Assets (excluding cash) plus the cash balance as of the date of the APA, less $200. The purchase price shall be due and payable upon the closing of one of the following events: (a) an M&amp;A event (as defined in the APA) of Nanox IL, (b) an IPO (as defined in the APA) of Nanox IL (c) a qualified equity financing (as defined in the APA) of Nanox IL at a minimum company pre-money valuation of $100 million, with proceeds totaling at least $30 million. In the event of an IPO or a qualified equity financing, Nanox IL has the option to pay for the Acquired Assets in cash or by the issuance of Nanox IL securities of the same series to be issued upon such event, in an amount reflecting a 25% discount on the per share price to be determined in such IPO or qualified equity financing. If Nanox IL chooses to pay for the Acquired Assets in cash in any of the two equity financing events described above, then Nanox PLC has the right, at its sole discretion and in good faith, to reject such payment in cash, and require Nanox IL to pay for the Acquired Assets by the issuance of securities of the same series to be issued upon such equity financing events, in such amount which shall reflect a 25% discount on the per share price to be determined in such equity financing events. As such, the Company recorded a Related Party Liability in an amount of $8,157 thousand.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As of September 3 2019, Nanox IL and Nanox PLC had the same shareholders and therefore the transaction was treated as a transaction under common control for accounting purposes. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The financial statements of the Company prior to the Transaction Date are the historical financial statements of Nanox PLC, which have been adjusted to reflect:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">1.</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">only the net assets that were transferred in the transaction according to the APA. Net assets which were not transferred in the transaction are not reflected in these financial statements.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">2.</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the consideration in the transaction (the &#147;Related Party Liability&#148;) as was created at the beginning of the earliest period presented, against a decrease in the shareholders' equity.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">3.</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">all of the share-related information and amounts of shareholders' equity and earnings per share (number of shares, par values and amount recorded) as the shares of Nanox IL.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>c.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">These financial statements have been prepared assuming the Company will continue as a going concern, assuming the realization of assets and the satisfaction of liabilities and commitments will occur in the normal course of business. In accordance with Accounting Standards Update (&#147;ASU&#148;) 2014-15, Presentation of Financial Statements&#8211;Going Concern (Subtopic 205-40): Disclosure of Uncertainties About an Entity&#8217;s Ability to Continue as a Going Concern, management is required to perform a two-step analysis </td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-8</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>NANO-X IMAGING LTD.<br></b>NOTES TO THE FINANCIAL STATEMENTS&nbsp;(continued)<br> (U.S. Dollars in thousands)<br> </p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>NOTE 1 - GENERAL&nbsp;</b><b>(continued):</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: -4px; margin-bottom: 0px; "></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">of its ability to continue as a going concern. Management must first evaluate whether there are conditions and events that raise substantial doubt about the Company&#146;s ability to continue as a going concern (step 1). If management concludes that substantial doubt is raised, management is also required to consider whether its plans alleviate that doubt (step 2).</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In order to complete its technology development program, the Company will require significant funding (see note 10b below). Moreover, the Company has experienced net losses and negative cash flows from operations since its inception and has relied on its ability to fund its operations primarily through equity financings. As of December 31, 2018, the Company had an accumulated deficit of $18 million and cash and cash equivalents of $5 thousand. The Company anticipates such losses will continue until its product candidates reach commercial profitability. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In order to meet the financing requirements, the Company is in the process of raising funds. During October and November 2019, the Company signed a number of non-binding term sheets with potential investors. The Company is in the process of completing the financing round and signing binding investment agreements with these investors. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If the Company is unable to successfully commercialize its product candidates and reach profitability, or obtain sufficient future financing from its shareholders or other investors, it will be required to delay some of its planned research and development programs as well as curtail, discontinue or, in the extreme case, cease operations. These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES:</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#147;U.S. GAAP&#148;). The significant accounting policies used in the preparation of the consolidated financial statements are as follows:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>a.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Use of estimates in the preparation of financial statements</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates and such differences may have a material impact on the Company&#146;s financial statements. As applicable to these financial statements, the most significant estimates relate to fair value of share-based payments and the fair value of the liability to related party (see note 4).</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>b.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Functional currency</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The U.S. dollar is the currency of the primary economic environment in which the operation of the Company and its subsidiary is conducted. Revenues and substantial portion of the operational costs are denominated in U.S. dollars. Accordingly, the functional currency of the Company is the U.S. dollar (&#147;primary currency&#148;). </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Foreign currency assets and liabilities are translated into the primary currency using the exchange rates in effect on the consolidated balance sheet date. Equity accounts are translated at historical rates, except for the change in accumulated deficit during the year, which is the result of the income statement translation process. Revenue and expense accounts are translated using the weighted average exchange rate during the period. Currency transaction gains and losses are presented in financial expenses, as appropriate.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-9</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>NANO-X IMAGING LTD.<br></b>NOTES TO THE FINANCIAL STATEMENTS&nbsp;(continued)<br> (U.S. Dollars in thousands)<br> </p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES&nbsp;</b><b>(continued):</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: -4px; margin-bottom: 0px; "></p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>c.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Cash and cash equivalents</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>d.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Property, equipment and software</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Property and equipment is stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated on a straight-line basis over the following estimated useful lives:</p>
				<table align="40" width="88%" style="margin-top: 4px; margin-left: 8%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="79%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 10.89px; ">&#160;</div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 10.89px; padding-right: 0px; "><b>%</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="79%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 10.89px; ">Computers and software</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">10-33</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="79%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 10.89px; ">Office furniture and equipment</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">10-20</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>e.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Impairment of long-lived assets </b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Company tests long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the long-lived asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the sum of the expected undiscounted cash flow is less than the carrying amount of the asset, the Company recognizes an impairment loss, which is the excess of the carrying amount over the fair value of the asset, using the expected future discounted cash flows.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As of December 31, 2018, the Company did not recognize an impairment loss on its long-lived assets.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>f.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Legal and other contingencies</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Certain conditions, such as legal proceedings, may exist as of the date the consolidated financial statements are issued that may result in a loss to the Company, but that will only be resolved when one or more future events occur or fail to occur. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company&#146;s management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought. Such assessment inherently involves an exercise of judgment. Legal fees are expensed as incurred.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Management applies the guidance in ASC 450-20-25 when assessing losses resulting from contingencies. If the assessment of a contingency indicates that it is probable that a material loss would be incurred and the amount of the liability can be estimated, then the Company would record an accrued expense in the Company&#146;s financial statements based on its best estimate. Loss contingencies considered to be remote by management are generally not disclosed unless material. The Company is currently not a party to any material legal proceedings and, is not aware of any material pending or threatened material legal proceedings against the Company.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>g.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Research and development expenses</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Research and development expenses are charged to the statement of operations as incurred. </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>h.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Income tax </b></td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">1)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The Company accounts for income taxes in accordance with ASC 740, &#147;Income Taxes&#148; (&#147;ASC 740&#148;). ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will </td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-10</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>NANO-X IMAGING LTD.<br></b>NOTES TO THE FINANCIAL STATEMENTS&nbsp;(continued)<br> (U.S. Dollars in thousands)<br> </p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES&nbsp;</b><b>(continued):</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: -4px; margin-bottom: 0px; "></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 80px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more likely than not that a portion or all of the deferred tax assets will not be realized, based on the weight of available positive and negative evidence. Deferred tax liabilities and assets are classified as non-current in accordance with ASU 2015-17.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">2)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Taxes that would apply in the event of disposal of investments in subsidiaries have not been taken into account in computing the deferred income taxes, as it is the Company&#8217;s intent and ability to hold these investments.</td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 80px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Company accounts for uncertain tax positions in accordance with ASC 740-10. ASC 740-10 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative probability) likely to be realized upon ultimate settlement. The Company accrues interest and penalties related to unrecognized tax benefits under taxes on income (tax benefit).</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>i.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Share-based compensation</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Company accounts for share-based compensation under ASC 718, &#147;Compensation - Stock Compensation,&#148; which requires the measurement and recognition of compensation expense based on estimated fair values for all share-based payment awards made to employees and directors.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant. The Company uses the Black-Scholes-Merton option-pricing model as part of such estimation. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Company accounts for equity instruments issued to non-employees in accordance with the provisions of ASC 505-50, which requires that such equity instruments be recorded at their fair value on the measurement date on an accrual basis. The standard requires adjusting the unvested fair value of the share options at each balance sheet date, such that the expense recognized is equal to the fair value of the vested award at the time the performance is complete, which is typical upon vesting.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>j.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Loss per share</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Basic earnings per share is computed by dividing net income (loss) attributable to holders of ordinary shares of the Company, by the weighted average number of ordinary shares outstanding for the reporting periods.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In computing the Company&#146;s diluted earnings per share, the denominator for diluted earnings per share is a computation of the weighted-average number of ordinary shares and the potential dilutive ordinary shares outstanding during the period. Potential dilutive ordinary shares outstanding include the dilutive effect of in-the-money options using the treasury stock method.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-11</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>NANO-X IMAGING LTD.<br></b>NOTES TO THE FINANCIAL STATEMENTS&nbsp;(continued)<br> (U.S. Dollars in thousands)<br> </p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES&nbsp;</b><b>(continued):</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: -4px; margin-bottom: 0px; "></p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>k.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Fair value measurement</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows: </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">Level 1:</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">Level 2:</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">Level 3:</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. </td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>l.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Newly issued and recently adopted accounting pronouncements:</b></td></tr></table><div style="clear: both"></div>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>Accounting pronouncements issued but not yet adopted:</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which supersedes the existing guidance for lease accounting, Leases (Topic 840). The guidance requires entities to record lease assets and lease liabilities on the balance sheet and disclose key information about leasing arrangements. In September 2017, the FASB issued additional amendments providing clarification and implementation guidance. The guidance will become effective for interim and annual periods beginning after December 15, 2018 (early adoption is permitted) and is required to be adopted at the earliest period presented using a modified retrospective approach. In January 2018, the FASB issued an update that permits an entity to elect an optional transition practical expedient to not evaluate land easements that existed or expired before the entity&#146;s adoption of the new standard and that were not previously accounted for as leases. In July 2018, the FASB issued codification improvements, which clarify how to apply certain aspects of the new lease standard. In July 2018, the FASB issued targeted improvements, which provides with an additional (and optional) transition method to adopt the new lease requirements by allowing entities to initially apply the requirements by recognizing a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company will adopt this standard as of January 1, 2019. The Company has assessed topic 842 potential impacts on its financial statements and concluded that the implementation will not have material effect. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In June 2018, the FASB issued guidance which simplifies the accounting for non-employee share-based payment transactions. The amendments specify that ASC 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor&#146;s own operations by issuing share-based payment awards. The guidance will be effective for fiscal years beginning after December 31, 2018, although early adoption is permitted. The Company has assessed ASC-718 potential impacts on its financial statements and concluded that the implementation will not have material effect. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-12</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>NANO-X IMAGING LTD.<br></b>NOTES TO THE FINANCIAL STATEMENTS&nbsp;(continued)<br> (U.S. Dollars in thousands)<br> </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>NOTE 3 - PROPERTY, EQUIPMENT AND SOFTWARE NET:</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Composition of property and equipment grouped by major classifications is as follows:</p>
				<table align="20" width="94%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="79%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.61px; ">&#160;</div></td>
	<td colspan="3" width="16%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 9.61px; padding-right: 0px; "><b>December 31,<br></b><b>2018<br></b><b>(</b><b>U.S. Dollars<br> </b><b>in thousands</b><b>)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="79%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.61px; ">Lab Equipment</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">217</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="79%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.61px; ">Computers &amp; Equipment; Software</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">22</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="79%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.61px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">239</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="79%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.61px; ">Less: accumulated depreciation </div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">83</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="79%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.61px; ">Total property and equipment, net</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">156</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Total depreciation and amortization in respect of property and equipment were $35 thousand for the year ended December 31, 2018.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>NOTE 4 &#8211; RELATED PARTY LIABILITY:</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As of December 31, 2018, the outstanding balance retrospectively reflects the amount to be paid in accordance with the APA for the Acquired Assets. The outstanding balance reflects the expected future payment of such liability using the Company's securities (see note 1b).</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">According to ASC 480, &#147;Distinguishing Liabilities From Equity,&#148; a financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability if, at inception, the monetary value of the obligation is based solely or predominantly on a fixed monetary amount known at inception. These liabilities are measured subsequently at fair value with changes in fair value recognized in earnings.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Company analyzed the instrument&#146;s provisions and concluded that it meets the above ASC 480 criteria and therefore accounted the expected future payment under the APA in accordance with ASC 480. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>NOTE 5 - COMMITMENTS:</b></p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>a.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Nanox Japan has been using two rooms and one clean room at the premises of the University of Tokyo since 2012. Such rental commitment is automatically renewed every six months with semi-annual payments of approx. Yen 4,185 thousand (approx. $76 thousand annually). </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>b.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">As to the agreements for services with Six-Eye Interactive Ltd. (&#147;Six-Eye&#148;) &#8211; refer to note 8c.</td></tr></table><div style="clear: both"></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>NOTE 6 - SHAREHOLDERS&#146; EQUITY:</b></p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>a.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Share capital</b></td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">1)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Ordinary Shares </td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Each holder of the Company&#146;s ordinary shares is entitled to one vote. The holders of ordinary shares are also entitled to receive dividends whenever funds are legally available, and declared by the Company&#146;s Board of Directors. Since inception, the Company has not declared any dividends.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">During the year ended December 31, 2018, Nanox PLC entered into several agreements with certain investors, pursuant to which Nanox PLC raised an aggregate amount of $3,684 thousand at a purchase price of $2.21 per share. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-13</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>NANO-X IMAGING LTD.<br></b>NOTES TO THE FINANCIAL STATEMENTS&nbsp;(continued)<br> (U.S. Dollars in thousands)<br> </p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>NOTE 6 - SHAREHOLDERS&#8217; EQUITY&nbsp;</b><b>(continued):</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: -4px; margin-bottom: 0px; "></p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">2)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Share-based compensation &#8211; for non-employees </td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Share-based compensation has been granted to third parties that provided services to the Company. The exercise prices of these share-based payments are based on the prices specified in the respective agreements. Changes in the number of share-based payments are as followed: </p>
				<p class="h5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><u>Equity settled</u>: </p>
				<table align="40" width="88%" style="margin-top: 4px; margin-left: 8%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.54px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.54px; padding-right: 0px; "><b>Year ended December 31</b><b>,</b></div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.54px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.54px; padding-right: 0px; "><b>2018</b></div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.54px; ">&#160;</div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.54px; padding-right: 5.54px; "><b>Number of<br></b><b>Share</b><b>-</b><b>based<br></b><b>payments</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.54px; padding-right: 0px; "><b>Weighted<br> </b><b>average<br> </b><b>exercise<br></b><b>price *</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.54px; ">Outstanding at beginning of year </div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,751,140</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1.40</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.54px; ">Changes during the year:<br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.54px; ">Granted</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.54px; ">Exercised</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.54px; ">Forfeited</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.54px; ">Expired</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.54px; ">Cancelled </div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(158,266</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">2.21</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.54px; ">Outstanding at end of year </div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">1,592,874</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">1.32</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.54px; ">Exercisable at end of year </div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">1,592,874</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">1.32</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0%; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">*</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">In dollars per ordinary share.</td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The fair value of each granted option is estimated at the date of grant, and as of future reporting periods, using the Black- Scholes option-pricing model. The assumptions used as of December 31, 2018 are as follows:</p>
				<table align="40" width="88%" style="margin-top: 4px; margin-left: 8%; border-collapse: collapse; ">

						<tr style="background-color: #cceeff;">
							<td width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 9.01px; ">Fair value of one ordinary share</div>
							</td>
							<td width="20%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 9.01px; padding-right: 0px; ">$2.21</div>
							</td>
						</tr>
						<tr>
							<td width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 9.01px; ">Dividend yield</div>
							</td>
							<td width="20%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 9.01px; padding-right: 0px; ">0%</div>
							</td>
						</tr>
						<tr style="background-color: #cceeff;">
							<td width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 9.01px; ">Expected volatility </div>
							</td>
							<td width="20%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 9.01px; padding-right: 0px; ">51.97%-72.25%</div>
							</td>
						</tr>
						<tr>
							<td width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 9.01px; ">Risk-free interest rate </div>
							</td>
							<td width="20%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 9.01px; padding-right: 0px; ">1.52%-2.94%</div>
							</td>
						</tr>
						<tr style="background-color: #cceeff;">
							<td width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 9.01px; ">Contractual term (years)</div>
							</td>
							<td width="20%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 9.01px; padding-right: 0px; ">1.05-6.00</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The expected volatility is based on the historical volatility of comparable companies. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term of the options granted in dollar terms. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Since the Company&#146;s ordinary shares are not publicly traded, the early exercise multiple (&#147;EEM&#148;) was based on academic empirical findings. The EEM of grantees in private companies is expected to be higher due to the lack of marketability that leads to a longer exercise period for options.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As of December 31, 2018, the Company has no unvested options. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-14</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>NANO-X IMAGING LTD.<br></b>NOTES TO THE FINANCIAL STATEMENTS&nbsp;(continued)<br> (U.S. Dollars in thousands)<br> </p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>NOTE 6 - SHAREHOLDERS&#8217; EQUITY&nbsp;</b><b>(continued):</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: -4px; margin-bottom: 0px; "></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table summarizes information concerning outstanding and exercisable options as of December 31, 2018:</p>
				<table align="40" width="88%" style="margin-top: 4px; margin-left: 8%; border-collapse: collapse; ">

						<tr>
							<td colspan="5" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 0px; "><b>December 31, 2018</b></div>
							</td>
						</tr>
						<tr>
							<td colspan="3" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 2px; "><b>Options outstanding</b></div>
							</td>
							<td colspan="2" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 0px; "><b>Options exercisable</b></div>
							</td>
						</tr>
						<tr>
							<td width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 2px; "><b>Exercise<br></b><b>prices*</b></div>
							</td>
							<td width="19%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 2px; "><b>Number of<br></b><b>options<br></b><b>outstanding<br></b><b>at end of<br></b><b>year</b></div>
							</td>
							<td width="19%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 2px; "><b>Weighted<br></b><b>options<br></b><b>remaining<br></b><b>contractual<br></b><b>l</b><b>ife (years) </b></div>
							</td>
							<td width="19%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 2px; "><b>Number of<br></b><b>options<br></b><b>exercisable<br></b><b>at end of<br></b><b>year</b></div>
							</td>
							<td width="19%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 0px; "><b>Weighted<br></b><b>average<br></b><b>remaining<br></b><b>contractual<br></b><b>life </b></div>
							</td>
						</tr>


						<tr style="background-color: #cceeff;">
							<td width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2px; ">$0.01</div>
							</td>
							<td width="19%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 2px; ">186,815</div>
							</td>
							<td width="19%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 2px; ">2.33</div>
							</td>
							<td width="19%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 2px; ">186,815</div>
							</td>
							<td width="19%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 0px; ">2.33</div>
							</td>
						</tr>
						<tr>
							<td width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2px; ">$0.30</div>
							</td>
							<td width="19%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 2px; ">454,166</div>
							</td>
							<td width="19%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 2px; ">0.5-1.06</div>
							</td>
							<td width="19%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 2px; ">454,166</div>
							</td>
							<td width="19%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 0px; ">0.5-1.06</div>
							</td>
						</tr>
						<tr style="background-color: #cceeff;">
							<td width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2px; ">$1.92</div>
							</td>
							<td width="19%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 2px; ">472,606</div>
							</td>
							<td width="19%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 2px; ">2.04-3.33</div>
							</td>
							<td width="19%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 2px; ">472,606</div>
							</td>
							<td width="19%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 0px; ">2.04-3.33</div>
							</td>
						</tr>
						<tr>
							<td width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2px; ">$2.21</div>
							</td>
							<td width="19%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 2px; ">479,287</div>
							</td>
							<td width="19%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 2px; ">2.5-5.11</div>
							</td>
							<td width="19%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 2px; ">479,287</div>
							</td>
							<td width="19%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 0px; ">2.5-5.11</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0%; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">*</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">In dollars per ordinary share.</td></tr></table><div style="clear: both"></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>NOTE 7 - INCOME TAX:</b></p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>a.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Basis of taxation:</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Current tax is calculated with reference to the profit of the Company and its subsidiary in their respective countries of operation. Set out below are details in respect of the significant jurisdictions where the Company and its subsidiary operates and the factors that influenced the current and deferred taxation in those jurisdictions:</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Israel</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Company is taxed under the laws of the State of Israel.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In December 2016, the Economic Efficiency Law (Legislative Amendments for Implementing the Economic Policy for the 2017 and 2018 Budget Year), 2016 was published, introducing a gradual reduction in corporate tax rate from 25% to 23%. However, the law also included a temporary provision setting the corporate tax rate in 2017 at 24%. As a result, the corporate tax rate was 24% in 2017 and 23% in 2018 and thereafter.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Gibraltar</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Gibraltar companies are subject to a corporate tax rate of 10%. In 2018, the Company is at a loss position and therefore has no corporate tax liability. </p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Japan</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Nanox Japan is subject to national corporate income tax, inhabitants&#146; tax, and enterprise tax in Japan, which, in the aggregate, resulted in effective tax rate of approximately 33.80% for the year ended December 31, 2018. Amendments to the Japanese tax regulations were enacted into law on March 29, 2016. As a result, the effective tax rate is scheduled to be reduced to approximately 33.59% effective from the year ending December 31, 2019.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under Japanese tax law and regulations, every company is required to submit an annual tax return to tax authorities. The statute of limitations to request a correction of prior year tax liabilities is five years from when the original tax return was filed. After filling of tax return, the tax authorities may conduct tax inspections on an irregular basis.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>b.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Tax assessments</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Nanox IL. Nanox PLC, Nanox Japan and Nanox Inc. have not been assessed since inception. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-15</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>NANO-X IMAGING LTD.<br></b>NOTES TO THE FINANCIAL STATEMENTS&nbsp;(continued)<br> (U.S. Dollars in thousands)<br> </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>NOTE 8 - RELATED PARTIES - TRANSACTIONS AND BALANCES:</b></p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>a.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Balances with related parties:</b></td></tr></table><div style="clear: both"></div>
				<table align="40" width="88%" style="margin-top: 4px; margin-left: 8%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 8.75px; ">&#160;</div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 8.75px; padding-right: 0px; "><b>December 31,<br></b><b>2018</b></div></td>
</tr>
<tr>
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 8.75px; ">&#160;</div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 8.75px; padding-right: 0px; "><b>(U.S. Dollars in<br> </b><b>thousands)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 8.75px; ">Related parties receivables &#8211; See d below</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">1,694</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 8.75px; ">Related party liability, refer to note 4</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">8,157</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>b.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Related parties transaction:</b></td></tr></table><div style="clear: both"></div>
				<table align="40" width="88%" style="margin-top: 4px; margin-left: 8%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 8.75px; ">&#160;</div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 8.75px; padding-right: 0px; "><b>Year ended<br> </b><b>December 31,<br></b><b>2018</b></div></td>
</tr>
<tr>
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 8.75px; ">&#160;</div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 8.75px; padding-right: 0px; "><b>(U.S. Dollars in<br> </b><b>thousands)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 8.75px; ">Research and development</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">860</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 8.75px; ">Marketing, general and administrative</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">892</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>c.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Six</b><b>-E</b><b>ye agreement</b><b>s</b><b> for services </b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">On June 1, 2015, Nanox PLC entered into a consulting agreement (the &#147;Consulting Agreement&#148;) with Six-Eye, a company owned by Ran Poliakine, pursuant to which Ran Poliakine agreed to provide services as Chief Strategy Officer and a member of the Executive Committee to Nanox Gibraltar. On May 1, 2017, Nanox PLC signed a services agreement with Six-Eye for the supply of ongoing services which include research and development services, general and financial management (including accountancy), office management services and operational and supply services. According to the agreement between the parties, Nanox PLC reimburses Six-Eye for its actual direct expenses plus a 12% surplus charge. During 2018, the total marketing, general and administrative expenses paid to Six-Eye according to these agreements amounted to $1,840 thousand. </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>d.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The related parties receivables reflects the funds received by Six-Eye on account of the 2018 equity funding of the Company, (refer to note 6a) less amounts payable in accordance with Six-Eye service agreement (see c above). </td></tr></table><div style="clear: both"></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>NOTE 9 - LOSS PER SHARE:</b></p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>a.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Basic</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Basic loss per share is calculated by dividing the loss attributable to the Company&#146;s owners by the weighted average number of ordinary shares in issue.</p>
				<table align="40" width="88%" style="margin-top: 4px; margin-left: 8%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 10.95px; ">&#160;</div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 10.95px; padding-right: 0px; "><b>Year ended<br> </b><b>December 31,<br> </b><b>2018</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 10.95px; ">Loss attributable to Company&#8217;s owners (U.S. Dollars in thousands)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(1,909</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 10.95px; ">The weighted average of the number of ordinary shares in issue (thousands)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">20,793</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 10.95px; ">Basic and diluted loss per share in USD </div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">(0.09</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">For the calculation of loss per share, the Company used the weighted average number of the Company&#146;s ordinary shares, divided by the loss attributable to Company&#146;s owners. The number of shares used in the calculation is the weighted average number of Company&#146;s ordinary shares for the year ended December 31, 2018. </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>b.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Diluted</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">When calculating the diluted loss per share for the year ended December 31, 2018, the Company did not take into account any dilutive instruments (share-based payments) since their effect, on a fully diluted basis, is anti-dilutive.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-16</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>NANO-X IMAGING LTD.<br></b>NOTES TO THE FINANCIAL STATEMENTS&nbsp;(continued)<br> (U.S. Dollars in thousands)<br> </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>NOTE 10 - SUBSEQUENT EVENTS:</b></p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>a.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">For the APA signed by Nanox IL and Nanox PLC on September 3, 2019 - see note 1b. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>b.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">During May and June of 2019, Nanox PLC issued 1,583,710 and 2,262,443 ordinary shares, to FUJIFILM Corporation and SK Telecom TMT Investment Corporation and certain of its affiliates, respectively, for an aggregate purchase price of approximately $3.5 million and $5.0 million, respectively. SK Telecom TMT Investment Corporation and certain of its affiliates, were also granted warrants to acquire 2,262,443 of the Company's ordinary shares at an exercise price of $20.87 per share.</td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, during 2019, Nanox PLC entered into several agreements with certain investors, pursuant to which Nanox PLC raised an aggregated amount of $613 thousand at a purchase price of $2.21 per share. In addition, Nanox PLC received $136 thousand at a purchase price of $0.30 per share, resulting from the exercise of warrants granted during 2013 and 2014. </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>c.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">ESOP agreement </td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">On September 2, 2019, Nanox IL Board of Directors resolved to adopt an equity incentive plan (the &#147;Plan&#148;). Based on such Plan, each option will be exercisable for one ordinary share of the Company and will become exercisable at such terms and during such periods, as the Board shall determine. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Company&#146;s Board of Directors also approved the Plan for the purpose of selecting the capital gains tax track, under Section 102 of the Israeli Income Tax Ordinance, for options granted to the Company's Israeli employees.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>d.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Lease agreement </td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">On September 3, 2019, Nanox IL signed an operating lease agreement for the premises it uses from a company owned by related party. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As of 1 November 2019, the operating lease agreement with the related party was ceased and was replaced by a direct agreement with the lessor. The agreement is for 26 months with an option to extend the period for an additional 24 months. The monthly rent is approximately $11 thousand including management fees. </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>e.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Nanox IL entered into an advisory agreement with A-Labs Finance and Advisory Ltd. (&#147;A-Labs&#148;), effective February 1, 2019, as amended on October 18, 2019, pursuant to which A-Labs will provide the Company consulting services through December 31, 2020 regarding an initial public offering, a private placement transaction and/or a merger and acquisition transaction. In consideration for providing these services, the Company agreed to pay A-Labs an advance payment of $1 million in addition to 1.5% of all amounts actually received by the Company or its shareholders in connection with a &#147;Transaction&#148; (as defined in the advisory agreement); However, in case (a) the fundraising totals at least $150 million with (b) a Company pre-money valuation of $400 million, then such percentage shall increase to 2.5% (collectively, the &#147;Transaction Fee&#148;). All payments made to A-Labs prior to the date of the amendment shall be deducted from the Transaction Fee. A-Labs will be granted options to purchase shares of the Company equal to 2.5% of all the shares actually issued by the Company to the investors in the Transaction, exercisable at the price per share set forth in the Transaction documents and exercisable until the earlier of (a) a period of five (5) years and (b) an &#147;M&amp;A&#148; Event (as defined in the advisory agreement).</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>f.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">During September 2019, the Company entered into a Service Agreement with RMD AP Limited, a company registered under the laws of Hong Kong (RMD). RMD undertook to provide the Company with services related to the Asia Pacific region, including, among others, operational and business development related matters. The agreement is for a period of one year and the agreed budget for the services to be financed by the Company during such year is $800 thousand. RMD will bear all costs and expenses incurred beyond such agreed budget.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-17</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>NANO-X IMAGING LTD.<br></b>NOTES TO THE FINANCIAL STATEMENTS&nbsp;(continued)<br> (U.S. Dollars in thousands)<br> </p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>NOTE 10 - SUBSEQUENT EVENTS&nbsp;</b><b>(continued):</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: -4px; margin-bottom: 0px; "></p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>g.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">During September 2019, Nanox IL entered a Collaboration Agreement with Hadasit Medical Research Services and Development Ltd. (hereinafter, &#147;Hadasit&#148;), a wholly owned subsidiary of the Hadassah Medical Organization. The parties agreed to collaborate with respect to the Company's medical imaging technology and resulting medical imaging devices (the &#147;Company Products&#148;), by way of (a) joint research and development projects (each, a &#147;Research Project&#148;); and (b) the provision by Hadasit of services in connection with Company Products, such as testing and consulting work, where no innovative research will be carried out (each, a &#147;Service&#148;). Each Research Project and Service shall be rendered under a separate project agreement concluded between the parties in writing from time to time (collectively, the &#147;Project Agreements&#148;). The parties envisage the collaboration to continue over a period of five years, unless an extension is agreed to by the parties in writing. Under such agreement, the Company shall make a non-refundable advance payment to Hadasit on the account of the Research Projects and Services in the amount of $250 thousand. Such amount shall be credited against payments due from time to time to Hadasit under the Project Agreements. Nanox IL has no obligation to enter into Project Agreements with Hadasit in excess of such advanced payment.</td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Nanox IL also granted Hadasit a warrant to purchase 23,957 ordinary shares at a price of $20.87 per share and for a total exercise price of $500 thousand. </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>h</b><b>.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">On October 28, 2019 (&#147;the effective date&#148;), Nanox IL signed an executive employment agreement with Ran Poliakine (&#147;the CEO&#148;) to serve as the Company's CEO (&#147;the CEO agreement&#148;). According to the CEO agreement, the CEO will be entitled to a monthly gross salary of $40 thousand, which will be increased to $60 thousand upon the Company&#8217;s consummation of an IPO. The CEO will be entitled to other benefits as described in the CEO agreement including annual bonus subject to performance criteria. The CEO will be granted options to purchase 1,206,290 ordinary shares with an exercise price of $2.21. 301,572 of the options vested as of the grant date and the remaining 904,718 options will vest in equal monthly installments over a period of three years from the grant date. The vested options will be exercisable in accordance to the terms specified in the agreement. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>i</b><b>.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">On October 28, 2019 (&#147;the effective date&#148;), Nanox IL signed an agreement with Dr. Ilung Kim, according to which Dr. Kim will provide certain services to the Company. Dr. Kim will not receive any cash compensation but will be granted options to purchase 1,206,290 ordinary shares with an exercise price of $2.21. 301,572 of the options vested as of the grant date and the remaining 904,718 options will vest in equal monthly installments over a period of three years from the grant date. The vested options will be exercisable in accordance to the terms specified in the agreement. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>j</b><b>.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">On September 3, 2019, the Company signed an agreement with a consultant regarding the provision of services as specified in the agreement. The agreement applied to all services already provided as of January 1, 2019 with respect of the establishment of the Company and planning its activities. The agreement was terminated on September 30, 2019 (&#147;the termination date&#148;) and the total payment for the services was $180 thousand. In addition, the consultant is entitled to:</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(a)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Warrants to purchase 123,629 ordinary shares with exercise price of $2.21. The options have an exercise period until August 30, 2023. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(b)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Warrants to purchase 115,454 ordinary shares with exercise price of $2.21. The options will have an exercise period of 9 months following the termination date.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-18</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 300-bcv -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-frill" style="width: 100%; margin-left: 0%; ">
				<div class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 17.37px; line-height: 5.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><div class="hr-full" style="height: 0px; border-bottom: 2pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 0px; "> </div><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 4px; "> </div></div>
			</div>

<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 18.67px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 48px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SHARES</b></p>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 17.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 128px; margin-bottom: 0px; "><b>NANO-X IMAGING LTD</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="logo_nanox.jpg" alt="" style="height: 61.33px; width: 253.33px; scale: ">&#8201;<br></p>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ORDINARY SHARES</b></p>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 64px; margin-bottom: 0px; "><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 39%; margin: auto; margin-bottom: 12px; margin-top: 12px; "> </div></div>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 16px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>PRELIMINARY PROSPECTUS</b></p>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</b></p>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 39%; margin: auto; margin-bottom: 12px; margin-top: 12px; "> </div></div>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 18.67px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 160px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b></p>
			<div style="clear: both;"></div></div>



<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<div class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 17.37px; line-height: 5.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 0px; "> </div><div class="hr-full" style="height: 0px; border-bottom: 2pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 4px; "> </div></div>
			</div>



<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 301-part2 -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>PART II<br> </b><b>INFORMATION NOT REQUIRED IN PROSPECTUS</b></p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="66.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>Item 6.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Exculpation, Insurance and Indemnification of Office Holders (</b><b>I</b><b>ncluding Directors and Officers).</b></td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the Companies Law, a company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate an office holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of duty of care but only if a provision authorizing such exculpation is included in its articles of association. Our amended and restated articles of association, that will become effective immediately prior to the completion of the offering, include such a provision. The company may not exculpate a director in advance from liability arising out of a breach of his or her duty of care in connection with a prohibited dividend or distribution to shareholders. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As permitted under the Companies Law and the Securities Law, and provided its articles of association include a provision authorizing such indemnification, a company may indemnify an office holder in respect of the following liabilities, payments and expenses incurred for acts performed by him or her as an office holder, either in advance of an event or following an event: </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a monetary liability incurred by or imposed on the office holder in favor of another person pursuant to a court judgment, including pursuant to a settlement confirmed as judgment or arbitrator&#8217;s decision approved by a competent court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company&#8217;s activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and amount or criteria; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">reasonable litigation expenses, including reasonable attorneys&#8217; fees, which were incurred by the office holder as a result of an investigation or proceeding filed against the office holder by an authority authorized to conduct such investigation or proceeding, provided that such investigation or proceeding; was either (i) concluded without the filing of an indictment against such office holder and without the imposition on him of any monetary obligation in lieu of a criminal proceeding; (ii) concluded without the filing of an indictment against the office holder but with the imposition of a monetary obligation on the office holder in lieu of criminal proceedings for an offense that does not require proof of criminal intent; or (iii) in connection with a monetary sanction; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a monetary liability imposed on the office holder in favor of all the injured parties by the breach in an Administrative Procedure (as defined below) as set forth in Section 52(54)(a)(1)(a) to the Securities Law; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">expenses expended by the office holder with respect to an Administrative Procedure under the Securities Law, including reasonable litigation expenses and reasonable attorneys&#8217; fees;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office holder or which were imposed on the office holder by a court (i) in a proceeding instituted against him or her by the company, on its behalf, or by a third party, (ii) in connection with criminal indictment of which the office holder was acquitted, or (iii) in a criminal indictment which the office holder was convicted of an offense that does not require proof of criminal intent; and </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Any other obligation or expense in respect of which it is permitted or will be permitted under applicable law to indemnify an office holder, including, without limitation, matters referenced in Section 56H(b)(1) of the Securities Law. </td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">An &#147;Administrative Procedure&#148; is defined as a procedure pursuant to chapters H3 (Monetary Sanction by the Israeli Securities Authority), H4 (Administrative Enforcement Procedures of the Administrative Enforcement Committee) or I1 (Arrangement to prevent Procedures or Interruption of procedures subject to conditions) to the Securities Law.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">II-1</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As permitted under the Companies Law and the Securities Law, our amended and restated articles of association, which will become effective upon the closing of this offering, provide that we may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder if and to the extent provided in the company&#146;s articles of association: </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a breach of the duty of loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a breach of duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a monetary liability imposed on the office holder in favor of a third party; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a monetary liability imposed on the office holder in favor of an injured party at an Administrative Procedure pursuant to Section 52(54)(a)(1)(a) of the Securities Law; and </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">expenses incurred by an office holder in connection with an Administrative Procedure, including reasonable litigation expenses and reasonable attorneys&#8217; fees. </td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the Companies Law, a company may not indemnify, exculpate or insure an office holder against any of the following: </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a breach of duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">an act or omission committed with intent to derive illegal personal benefit; or </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a fine or forfeit levied against the office holder. </td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the Companies Law, exculpation, indemnification and insurance of office holders in a public company must be approved by the compensation committee and the board of directors and, with respect to directors or controlling shareholders, their relatives and third parties in which such controlling shareholders have a personal interest, also by the shareholders. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our amended and restated articles of association permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted or to be permitted by law. Our office holders are currently covered by a directors&#146; and officers&#146; liability insurance policy. As of the date of this registration statement, no claims for directors&#146; and officers&#146; liability insurance have been filed under this policy and we are not aware of any pending or threatened litigation or proceeding involving any of our office holders, including our directors, in which indemnification is sought. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have entered into agreements with each of our current office holders exculpating them from a breach of their duty of care to us to the fullest extent permitted by law, subject to limited exceptions, and undertaking to indemnify them to the fullest extent permitted by law, subject to limited exceptions, including, with respect to liabilities resulting from this offering, to the extent that these liabilities are not covered by insurance. This indemnification is limited, with respect to any monetary liability imposed in favor of a third party, to events determined as foreseeable by the board of directors based on our activities. The maximum aggregate amount of indemnification that we may pay to our office holders based on such indemnification agreement shall not exceed the greatest of (i) in relation to indemnity in connection with an offering to the public of the Company&#146;s securities, the aggregate amount of proceeds from the sale by the Company and/or any shareholder of the Company in connection with such public offering; (ii) 25% of the Company&#146;s total shareholders&#146; equity pursuant to the Company&#146;s most recent financial statements as of the time of the actual payment of indemnification, and (iii) $15 million prior to the public sale of the Company&#146;s securities and $50 million thereafter (in each case, as may be increased from time to time by shareholders&#146; approval). Such indemnification amounts are in addition to any insurance amounts. Each office holder who agrees to receive this letter of indemnification also gives his approval to the termination of all previous letters of indemnification that we have provided to him or her in the past, if any. However, in the opinion of the SEC, indemnification of office holders for liabilities arising under the Securities Act is against public policy and therefore unenforceable.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">II-2</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="66.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>Item 7.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Recent Sales of Unregistered Securities. </b></td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following is a summary of transactions during the preceding three years involving sales of our securities and securities of Nanox Gibraltar, our predecessor company, that were not registered under the Securities Act. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Since January 1, 2017, we have granted share options to employees, directors, director nominees and consultants under our predecessor share option plans covering an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares, with a weighted average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. As of the date of this registration statement, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of these options have been exercised with exercise prices ranging from &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, while &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of these options have been forfeited and canceled without being exercised.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In December 2018, in connection with our formation, we issued 100 ordinary shares to Ran Poliakine for no cash consideration. In addition, on September 2, 2019, we issued 27,054,754 ordinary shares and 59 warrants to purchase 5,150,712 ordinary shares to the then existing shareholders of Nanox Gibraltar for no consideration.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In May 2019, Nanox Gibraltar issued 1,583,710 ordinary shares to FUJIFILM Corporation for an aggregate purchase price of approximately $3.5 million. In June 2019, Nanox Gibraltar issued 2,262,443 ordinary shares to the SKT Entities for an aggregate purchase price of approximately $5.0 million, as well as a warrant to SK Telecom TMT Investment Corp. to acquire 2,262,443 ordinary shares at an exercise price of $20.87 per share.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition to the above, since January 1, 2017, we have issued &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares to certain investors, for an aggregate purchase price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , as well as warrants to certain investors, employees, consultants and finders to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares at a weighted average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">No underwriter or underwriting discount or commission was involved in any of the transactions set forth in Item 7. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">All of the foregoing issuances were made outside of the U.S. pursuant to Regulation S or to U.S. entities pursuant to Section 4(a)(2) of the Securities Act.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="66.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>Item 8.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Exhibits and Financial Statement Schedules.</b></td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(a)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Exhibits</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The exhibits of the registration statement are listed in the Exhibit Index to this registration statement and are incorporated herein by reference.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(b)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Financial Statement Schedules</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the consolidated financial statements or the notes thereto.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="66.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>Item 9.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Undertakings. </b></td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(a)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(b)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">II-3</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(c)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The undersigned registrant hereby undertakes that: </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">1.</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">2.</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">II-4</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Exhibit Index </b></p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="8%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 2px; "><b>Exhibit </b><b>No. </b></div>
							</td>
							<td width="92%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 0px; "><b>Description</b></div>
							</td>
						</tr>


						<tr style="background-color: #cceeff;">
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2px; ">1.1* </div>
							</td>
							<td width="92%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 0px; ">Form of Underwriting Agreement</div>
							</td>
						</tr>
						<tr>
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2px; ">2.1*</div>
							</td>
							<td width="92%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 0px; ">Asset Purchase Agreement, dated September 3, 2019, by and between the Registrant and Nanox Imaging PLC</div>
							</td>
						</tr>
						<tr style="background-color: #cceeff;">
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2px; ">
2.2*
</div>
							</td>
							<td width="92%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 0px; ">
Amendment to the Asset Purchase Agreement, dated December 3, 2019, by and between the Registrant and Nanox Imaging PLC
</div>
							</td>
						</tr>
						<tr>
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2px; ">
2.3*
</div>
							</td>
							<td width="92%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 0px; ">
Amendment to the Asset Purchase Agreement, dated December 31, 2019, by and between the Registrant and Nanox Imaging PLC
</div>
							</td>
						</tr>
						<tr style="background-color: #cceeff;">
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2px; ">3.1* </div>
							</td>
							<td width="92%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 0px; ">Articles of Association of the Registrant</div>
							</td>
						</tr>
						<tr>
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2px; ">3.2*</div>
							</td>
							<td width="92%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 0px; ">Form of Amended and Restated Articles of Association of the Registrant to become effective upon the closing of this offering</div>
							</td>
						</tr>
						<tr style="background-color: #cceeff;">
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2px; ">4.1* </div>
							</td>
							<td width="92%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 0px; ">Specimen share certificate</div>
							</td>
						</tr>
						<tr>
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2px; ">
4.2*
</div>
							</td>
							<td width="92%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 0px; ">
Form of warrants
</div>
							</td>
						</tr>
						<tr style="background-color: #cceeff;">
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2px; ">5.1* </div>
							</td>
							<td width="92%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 0px; ">
Opinion of Amit, Pollak, Matalon &amp; Co., counsel to the Registrant, as to the validity of the ordinary shares (including consent)
</div>
							</td>
						</tr>
						<tr>
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2px; ">
10.1*
</div>
							</td>
							<td width="92%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 0px; ">
Registration Rights Agreement by and among the Registrant and the certain shareholders named therein
</div>
							</td>
						</tr>
						<tr style="background-color: #cceeff;">
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2px; ">10.2* </div>
							</td>
							<td width="92%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 0px; ">2019 Equity Incentive Plan</div>
							</td>
						</tr>
						<tr>
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2px; ">10.3* </div>
							</td>
							<td width="92%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 0px; ">Form of Indemnification Agreement between the Registrant and each director and executive officer</div>
							</td>
						</tr>
						<tr style="background-color: #cceeff;">
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2px; ">10.4*</div>
							</td>
							<td width="92%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 0px; ">Compensation Policy</div>
							</td>
						</tr>
						<tr>
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2px; ">21.1* </div>
							</td>
							<td width="92%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 0px; ">List of subsidiaries of the Registrant</div>
							</td>
						</tr>
						<tr style="background-color: #cceeff;">
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2px; ">23.1* </div>
							</td>
							<td width="92%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 0px; ">Consent of PricewaterhouseCoopers International Limited, an independent registered public accounting firm</div>
							</td>
						</tr>
						<tr>
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2px; ">23.2*</div>
							</td>
							<td width="92%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 0px; ">Consent of Amit, Pollak, Matalon &amp; Co. (included in Exhibit 5.1)</div>
							</td>
						</tr>
						<tr style="background-color: #cceeff;">
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2px; ">24.1*</div>
							</td>
							<td width="92%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 0px; ">Power of Attorney (included in signature page to Registration Statement)</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">*</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">To be filed by amendment </td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">II-5</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 302-sig -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>SIGNATURES </b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Neve Ilan, State of Israel on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. </p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="46%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td colspan="2" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; "><b>NANO-X IMAGING LTD</b></div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="5%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="49%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="5%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">By </div>
							</td>
							<td width="49%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="5%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="49%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Name: Ron Poliakine </div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="5%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="49%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Title: Chief Executive Officer</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>POWER OF ATTORNEY </b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Each person whose signature appears below constitutes and appoints Ron Poliakine and Itzhak Maayan, and each of them, as attorney-in-fact with full power of substitution, for him or her in any and all capacities, to do any and all acts and all things and to execute any and all instruments which said attorney and agent may deem necessary or desirable to enable the registrant to comply with the Securities Act, and any rules, regulations and requirements of the Securities and Exchange Commission thereunder, in connection with the registration under the Securities Act of ordinary shares of the registrant (the &#147;Shares&#148;), including, without limitation, the power and authority to sign the name of each of the undersigned in the capacities indicated below to the Registration Statement on Form F-1 (the &#147;Registration Statement&#148;) to be filed with the Securities and Exchange Commission with respect to such Shares, to any and all amendments or supplements to such Registration Statement, whether such amendments or supplements are filed before or after the effective date of such Registration Statement, to any related Registration Statement filed pursuant to Rule 462(b) under the Securities Act, and to any and all instruments or documents filed as part of or in connection with such Registration Statement or any and all amendments thereto, whether such amendments are filed before or after the effective date of such Registration Statement, and each of the undersigned hereby ratifies and confirms all that such attorney and agent shall do or cause to be done by virtue hereof. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated. </p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="23%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; padding-right: 1.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 1.67px; "><b>Signatures</b></div>
							</td>
							<td width="58%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.67px; padding-right: 1.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 1.67px; padding-right: 1.67px; "><b>Title</b></div>
							</td>
							<td width="19%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 1.67px; padding-right: 0px; "><b>Date</b></div>
							</td>
						</tr>


						<tr>
							<td width="23%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.67px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 1.67px; ">&#160;</div>
							</td>
							<td width="58%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.67px; padding-right: 1.67px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.67px; padding-right: 1.67px; ">&#160;</div>
							</td>
							<td width="19%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.67px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.67px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="23%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 1.67px; ">&#160;</div>
							</td>
							<td width="58%" rowspan="2" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 1.67px; padding-right: 1.67px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.67px; padding-right: 1.67px; ">Director and Chief Executive Officer<br> (Principal Executive Officer)</div>
							</td>
							<td width="19%" rowspan="2" valign="top" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 1.67px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.67px; padding-right: 0px; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</div>
							</td>
						</tr>
						<tr>
							<td width="23%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.67px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 1.67px; ">Ran Poliakine</div>
							</td>
						</tr>
						<tr>
							<td width="23%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.67px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 1.67px; ">&#160;</div>
							</td>
							<td width="58%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.67px; padding-right: 1.67px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.67px; padding-right: 1.67px; ">&#160;</div>
							</td>
							<td width="19%" valign="top" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.67px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.67px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="23%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 1.67px; ">&#160;</div>
							</td>
							<td width="58%" rowspan="2" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 1.67px; padding-right: 1.67px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.67px; padding-right: 1.67px; ">Chief Financial Officer<br> (Principal Financial Officer and Principal Accounting Officer)</div>
							</td>
							<td width="19%" rowspan="2" valign="top" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 1.67px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.67px; padding-right: 0px; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</div>
							</td>
						</tr>
						<tr>
							<td width="23%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.67px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 1.67px; ">Itzhak Maayan</div>
							</td>
						</tr>
						<tr>
							<td width="23%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.67px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 1.67px; ">&#160;</div>
							</td>
							<td width="58%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.67px; padding-right: 1.67px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.67px; padding-right: 1.67px; ">&#160;</div>
							</td>
							<td width="19%" valign="top" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.67px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.67px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="23%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 1.67px; ">&#160;</div>
							</td>
							<td width="58%" rowspan="2" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 1.67px; padding-right: 1.67px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.67px; padding-right: 1.67px; ">Director </div>
							</td>
							<td width="19%" rowspan="2" valign="top" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 1.67px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.67px; padding-right: 0px; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 </div>
							</td>
						</tr>
						<tr>
							<td width="23%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.67px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 1.67px; ">Onn Fenig </div>
							</td>
						</tr>
						<tr>
							<td width="23%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.67px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 1.67px; ">&#160;</div>
							</td>
							<td width="58%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.67px; padding-right: 1.67px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.67px; padding-right: 1.67px; ">&#160;</div>
							</td>
							<td width="19%" valign="top" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.67px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.67px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="23%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 1.67px; ">&#160;</div>
							</td>
							<td width="58%" rowspan="2" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 1.67px; padding-right: 1.67px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.67px; padding-right: 1.67px; ">
Director
</div>
							</td>
							<td width="19%" rowspan="2" valign="top" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 1.67px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.67px; padding-right: 0px; ">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020
</div>
							</td>
						</tr>
						<tr>
							<td width="23%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.67px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 1.67px; ">
Erez Meltzer<br>
</div>
							</td>
						</tr>
						<tr>
							<td width="23%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.67px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 1.67px; ">&#160;</div>
							</td>
							<td width="58%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.67px; padding-right: 1.67px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.67px; padding-right: 1.67px; ">&#160;</div>
							</td>
							<td width="19%" valign="top" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.67px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.67px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="23%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 1.67px; ">&#160;</div>
							</td>
							<td width="58%" rowspan="2" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 1.67px; padding-right: 1.67px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.67px; padding-right: 1.67px; ">Director</div>
							</td>
							<td width="19%" rowspan="2" valign="top" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 1.67px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.67px; padding-right: 0px; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</div>
							</td>
						</tr>
						<tr>
							<td width="23%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.67px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 1.67px; ">Richard Stone<br> </div>
							</td>
						</tr>
						<tr>
							<td width="23%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.67px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 1.67px; ">&#160;</div>
							</td>
							<td width="58%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.67px; padding-right: 1.67px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.67px; padding-right: 1.67px; ">&#160;</div>
							</td>
							<td width="19%" valign="top" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.67px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.67px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant&#146;s duly authorized representative has signed this registration statement on Form F-1 in on this &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;day of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020.</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="46%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="5%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">By:</div>
							</td>
							<td colspan="2" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="5%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="8%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="5%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">By:</div>
							</td>
							<td colspan="2" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="5%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="8%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Name:</div>
							</td>
							<td width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="5%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="8%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Title:</div>
							</td>
							<td width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>

<div class="block-pagebreak" style="width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo_nanox.jpg
<TEXT>
begin 644 logo_nanox.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( 'H!^ ,!(@ "$0$#$0'_Q  ?   ! P0# 0
M    "0H+ @,$!@4'" '_Q !C$  ! P($ P0%!08+$@X# 0 ! @,$!1$ !@<(
M$B$Q"0H3010B46%Q%3*!D;$C.7*AM? 6-SA"571VLK31TQ<8&1HD)3-%4E18
M<Y25L\'4X30U-D-35F)U=X*3MM+Q)F-D9?_$ !<! 0$! 0
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MD_\ V?%U7>]-D8:"TT62IPVNWQS@0//UO1S\<,A?Z"SVEW^##4O9_P .C?\
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M]'VC HR6[YC^D7H/^V:W_"F<-].ZUI![4;3XGJ&9I'^:U_QX<$]\O/%H9H2
M#9+]:43[+RFO]7LPWN[KM.B0NU%TY#SZ4+DM3A'2H@%SAI2^*U[$V/L_W8&(
MGBZSV_ E?!\Y7T?9BK%I*P5J'P(^K%W V&#!C'4^$*(4+6Z&]_C?_?; 3Y$P
M^V1^]V[A?W/I_?JQ#4PO^4D#_P 0&O\ W&,3*';'O!SLZMPJT%)_K @'B(2
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M<)!43?D +XU^*C/^JF83Z-#S9GG-M7DMMH3Z/5:JY(D/+"$@.E,CP05*YD$
M#KTP^O[NMV"N9,H9CROO1W54@TFJ0$B;D+(E1B\3D;QT>&XZZZ+*XE MO!+J
M+I/(>W EX;I1>&H>-*WHZWACS?:KI_,TMV]:39(FLA$NB92HJ);*>$!#CM-B
MJ4"$\KA15Q#K>]^>/2B;<(MTMBVPRVPTVTTD);;:;:;0.B&FTA#: /()0 /H
MQ>P-15O%_08,&+;JN!M2K7(!L/;RP*6'YD=EEY]UP-LL,NOO+)L$,LH+CBS[
MDH22?8,1G/>D>TO?W(;@(^UG3:O.*T_TE?D,9D>I\E28M:>FH2ZE+H:4$J,5
MYM2?6*N:;<N8P_XWU5'6V#M;U2=V\TMRHZOR\OSXV78C3C:%AMV,^U,X5.W;
MXS'4HI!]:]N'GTAN=;]-->(.NV9,I:O95S)%U:S/G*1$EPY\*:IZ9(J56<0V
M6I*VBEU#0?"KMJ4E*0.@Z#,RH?B)E.O:CG(4$[%#LY*_VA6[C*V7%0GE:59'
MJD*I9YJA9*XJ/ *)D%M1L KQ'6> V4;W)5[#+NZ:Y$R]IGDK+>0\J4]BFT'+
M%*A4R'&C(2VR/1(S;"UA"0D7<4WQ'EUN<(?=WY[."D[$MGV7*I6*0B-JQJ;3
MXU3S>^\PD24-%7I-.25J'$DB.\ 0FQ/+KA?M* +6%K<S[S?I]OXL")-0I\47
M+)S+FLMPRYCSON<T%RAN9T6S[HQG6%'FT+.%'E1'$R&D.):DAAT0W$A0N%(?
M*%"UNG+KCT1CCWFBX%I(N7""3TX2DW'UX&F[>^2N0K_:4;(,Z;"=U&?M#<Q,
M2%TAFL2IF5:RXPIEF;'F..34AGD4WBH<0D%*C8@$8=;=T^[3M<*J5'8YJK7G
M'5/EI.FDBIS5*XN +ESVFW'G#8#DD)4KI;A'EA3;O//9EQMSNV]>XO3VBH<U
M0TCCORY1A1^.95XTM:$NE80GB(CQVU$FRK"W3F3'^]G[D?=%6=U.FE2VP93S
M'.U'ROFJ,PXN''EQV8S34]IJJB1+4V(Z1X"'A9Q7.Q2.?+ ROXQ>M\8LLL.G
MH380=3ZH)'K<TV4% I/S57'DH=#YXN8Z:T6D9QEZ69#D9^BF'G)67:4WF&.5
MI66YK<%A#O$I'JDEP+)MY\\=QI%DBYORZX&YG<>I5@P8, &#!@P 8I4E*P4J
M%P4J2?@H6/XL58, )$;@NPX[.#<YJOF76K6/1)O,NH>;/!^7*T:S.CF5X#7@
MM_<FB$(X6^7+XX]>;1-CFW'8[D9_3O;CDH9*RI)7QNT\37YO$KQ%.?V202OY
MZE'V<\>N\& A9!@P8, &#K@P8 \);SNS@VE;^FLI-;G=.DY\;R3Z7^AT*J$F
M#Z%Z<09%O1R./C*1UZ8Z*VV]BCV>.T_4ZE:OZ(:,(RKGNB\9@585B=)+/B(+
M:SX3RN W2;&XPK%@P$+(I2D)  %@ !] %A^+%6#!@#X0"+'IBCPD$!)3<#R/
MF/8?<?,8N8, )N[J^R<V+;S:^C-.ONC%,S/F!"TK^5([RZ8^XI-K%U4-"2Z0
M$BW&;V]_/'K';SMUTIVMZ7T+1[1G+PRSD++B'44FD"0Y)$=+R_$<^ZNW6JZN
M=R<=XX,!'P&#!@P 8,&# '7>JFEF3-9LB5_3C/\ 3/E?*>9HRHE8I_BK9])8
M4"E2/$00I-P3T]N$T=!>P[[-O;AGYC4S2[06GT[-\28_4(T^H3Y%4;:E27%.
M/.B--#C)4I:RH7'JGF.>%<L& ,9B'&BM-,1V6V&6&T----)2VVVVA(0A*4("
M4@)2   !TQD  "P%AC[@P$!CX0#R(OC[@P GQO#[+_9MOLJ=!J^Y73)&>9V6
M_&^2'55&5"]&](2$N^K'("N( =<=<;6NQJV ;-]3HVK^@.CR,H9\AI<3'JPJ
M\V7X:762PNS+Y*.;:BGW7O[,*G8,!"R  #I\?I/7!@P8 ,&#!@#J76_1'3K<
M/IKF/2752BC,&1LULH8K=)+SD<2FFU<21XK9"T6/.XPDAEWNZW91Y6K])S+1
M=OB(M8HE3;J].D_+]27X,]J2F6A[A4JRK/H2NQY<K87)P8$A.ZDPJ;3XM)IT
M"E06_"A4R%%I\-J]_#BPF&XT=NYYG@:;0FYZVQFX,&!0P$7Y'!@P!BNQ&7OG
M@]".1(Z]>A\_SZXT'/VDVGVIN69>4L^94H^:*#-;4T_#JL&-+44+OQ!MV0TX
MMOK>Z% _5CLC!@!%+/7=].RNU"KDG,&8MNT)=1EN*>?,:KS8K16L\1*66>%"
M1<GU1R'3RQIBN[=]DDHI/\[HV"GH17ZG_P#+\_9A>#!@(65[B$']+=]DC_@Y
MM?Y_J7\> =V[[)($D;=&^?\ _OU+\7/"[^# D+)=A,G;OV0>P#:Y4V:SI!H1
M0Z34V5A;<JHJ^6%(6.B@)[;B4D'F+<_/WX4IBTZ%"9:CQ(L>+'92E#4>,TAA
MAM*0 $H:;2E"0 /UJ1C-P8%#!@P8 ,! (L>8.#!@#',9HW)0DW!!X@% @]00
M>1!\P>1\\>)]9.SJVA:]ZE96U:U-TAH59S[D^4J90ZTRRU"+4E12HNR&F&0F
M2H%"2GQN(I(N#CW!@P$&%!IT2FQ8\.$RAB-%C,0V&6P$MMQXS:664)2+ !+:
M$IY>S&8 $BP_&;X^X, &*%-I5S/VXKP8 X#,>6*'FRA57+>8(#-3HM:AOP*C
M!DH2XU(C2&ELNH4E:5#FA:@#:Z38CF,>4-M_9_[4-ITRO3]#=)Z)E2?F28[.
MJLY33<^2Y)>><?<6R]):+C'$ZXNX:*1S]PQ[.P8 L-QFFTA*$V'L\OJ^SV8O
MX,& #!@P8 ,&#!@ P8,4JOY>?(_3RO\ 1@"GQ6RKAXV^(=4\8XA_Y>N*E+2D
M$J4E('FI02/I)PSG[;/?MOU[-/>%I-J;EK,$RK;7,^5V/#JF7A#CIC1(P>BP
MWEO3N%:VPEQU:_6*;\-L:[VKW;A:OUB/M>T=[/FN)J.JFM;4%.87J4IB>[2G
M%)@.R.-LI<20A#[U[V("3S(P(W&N7J/.$NMJ%TK0H>U"@H?6.6+F/(FS3+NL
M>6]NFF=-UTKSF8=5GZ0S/S;57&4,J=>G--2FVBTW=M!9#A;/#S)'.QQZZ'(
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MZAR-ZK2E@D.)YI\C@4> -56GOO%AF? ?='(M,3&'7A\6T+*_CZN,_B'M^O\
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( !@P8, ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>nt10006151x2_graphic2.jpg
<TEXT>
begin 644 nt10006151x2_graphic2.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
M+0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0":
M )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L \ #V /L! 0$' 0T!
M$P$9 1\!)0$K 3(!. $^ 44!3 %2 5D!8 %G 6X!=0%\ 8,!BP&2 9H!H0&I
M ;$!N0'! <D!T0'9 >$!Z0'R ?H" P(, A0"'0(F B\". )! DL"5 )= F<"
M<0)Z H0"C@*8 J("K *V L$"RP+5 N "ZP+U P #"P,6 R$#+0,X T,#3P-:
M V8#<@-^ XH#E@.B ZX#N@/' ],#X /L _D$!@03!" $+00[!$@$501C!'$$
M?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6 5G!7<%A@66!:8%M07%
M!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M$&XP;U!P<'&0<K!ST'
M3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC[
M"1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*
M\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS #-D,\PT-
M#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/
M>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('
M$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E% 84)Q1)%&H4BQ2M%,X4
M\!42%3055A5X%9L5O17@%@,6)A9)%FP6CQ:R%M86^A<=%T$791>)%ZX7TA?W
M&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;
M8QN*&[(;VAP"'"H<4AQ['*,<S!SU'1X=1QUP'9D=PQWL'A8>0!YJ'I0>OA[I
M'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B<B52*"(J\B
MW2,*(S@C9B.4(\(C\"0?)$TD?"2K)-HE"24X)6@EER7')?<F)R97)H<FMR;H
M)Q@G22=Z)ZLGW"@-*#\H<2BB*-0I!BDX*6LIG2G0*@(J-2IH*ILJSRL"*S8K
M:2N=*]$L!2PY+&XLHBS7+0PM02UV+:LMX2X6+DPN@BZW+NXO)"]:+Y$OQR_^
M,#4P;#"D,-LQ$C%*,8(QNC'R,BHR8S*;,M0S#3-&,W\SN#/Q-"LT932>--@U
M$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.% XC#C(.04Y0CE_.;PY^3HV
M.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B ^8#Z@/N _(3]A/Z(_
MXD C0&1 ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:
M1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+
MXDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q
M4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9
M&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV %
M8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUG
MDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>
M;WAOT7 K<(9PX'$Z<95Q\')+<J9S 7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW
M5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W^$
M?^6 1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B 2(
M:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI &D&Z0UI$_
MD:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:
MU9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16
MI,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVN
MH:\6KXNP +!UL.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1
MN4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'# [,%GP>/"7\+;PUC#
MU,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZV
MSS?/N- YT+K1/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':
M=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-
MYI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_R
MC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<
M_VW____; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! ?_  !$( L8$@@,!(@ "$0$#$0'_Q  ?  $  0,% 0$
M    !P()"@$$!@@+ P7_Q !L$  ! @,#! 42#PT%!@4$ @,  0(#! 4&!Q$(
M$B'1"1,Q49(4%A<9(C0V05)66'%SE)66L;(:4U1787)T=H&1D[/"TM05(S(S
M-S@Y=:&TM<'3&$)5X? *)#5%=X(E)D-B8R=D@_%$9BA&I/_$ !T! 0 " P$!
M 0$            ! @,$!P4&"0C_Q !2$0 "  ,"!PL&"P0* P$  P   0(#
M$00A!1(Q87'1\ 83%$%14X&1H;'!,F.2E,+2!Q87(C-#4E56<I,V<W6S(S0U
M0F)TLK3A\16"Q"0E9*+_V@ , P$  A$#$0 _ ,;2G7YWQQI2%$?;9%>[.SEX
M@@IBN.!O>3=?#UZM[P@ZB&J.[.I\!V&'X2?%_P#L_3/[JP'N6W+S\"X)G18
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M_M91\M:/IYW[R/O8 ![AA
M   /G&_Y?^O*+^_P3TPKIOT-DC_TUG_W1YYGL;_E_P"O*+^_P3TPKIOT-DC_
M --9_P#='G$OAG^AW)?QU=TDW[!EG?NGWGFC1^?*Y[Y[1_Q::/D?6/SY7/?/
M:/\ BTT?([;Q+\L/^E&@
M  41/Q<3VCO-4]'/8 ?T55G/>W;CYN?/.,B?BXGM'>:IZ.>P _HJK.>]NW'S
M<^<:^'#]E+!_';+_ "+0;V#_ *=_NXN^$\_C*/\ SAKX_?;5_P")SA"Q-.4?
M^<-?'[[:O_$YPA8ZW8?ZC8O\G9?Y$LTGE>E]X !M$
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M_5/T1W,_L[@+^$V#_:RCY:T?3SOWD?>P #W#"
M                   ?.-_R_P#7E%_?X)Z85TWZ&R1_Z:S_ .Z//,]C?\O_
M %Y1?W^">F%=-^ALD?\ IK/_ +H\XE\,_P!#N2_CJ[I)OV#+._=/O/-&C\^5
MSWSVC_BTT?(^L?GRN>^>T?\ %IH^1VWB7Y8?]*-
M                      HB?BXGM'>:IZ.>P _HJK.>]NW'S<^><9$_%Q/:
M.\U3T<]@!_156<][=N/FY\XU\.'[*6#^.V7^1:#>P?\ 3O\ =Q=\)Y_&4?\
MG#7Q^^VK_P 3G"%B:<H_\X:^/WVU?^)SA"QUNP_U&Q?Y.R_R)9I/*]+[P #:
M(                           )DR=OS@[G??=1_XG)GH*[/Q^BFM/[VK#
M^93SSZLG;\X.YWWW4?\ B<F>@KL_'Z*:T_O:L/YE/.(_"5^VWP<?Q#_[[(>C
M9/ZO:='LL\X.'^+A^T;YJ%91#_%P_:-\U"L[<><
M            2/<S^62Z_P!^- _C,D>@5L_7Z*"<]ZE@_F*<>?K<S^62Z_WX
MT#^,R1Z!6S]?HH)SWJ6#^8IQQ?X1_P!M?@W_ (D_]Q8CT+)]!:/RON/.L9^!
M#[G#\QI44L_ A]SA^8TJ.T'G@
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MM-'R/K'Y\KGOGM'_ !::/D=MXE^6'_2C0       !K@N\OQ &@    PQW
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M.CV6><'#_%P_:-\U"LHA_BX?M&^:A6=N/.       !K@N\OQ* : UP5-U%-
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MR\AB1UBE3E!K%0H-2A[34Z7%= G8"JB[5&8Y6NAXIH54<BM71HPW-_OOD(Y
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M1O-Q6M<_/5N.AJ%M[F?2X2)TT2$Q$7MHC<%^$T7#I-:WV&-:U/B:B&;!6X[
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M+<G_ /0E!'"L6*8L7_##F8LK>X8DU'%C-4=8*?W:OES94K\IQ[M;G2[72_8
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MJ?HCN9_9W 7\)L'^UE'RUH^GG?O(^]@ 'N&$
M                  ^<;_E_Z\HO[_!/3"NF_0V2/_36?_='GF>QO^7_ *\H
MO[_!/3"NF_0V2/\ TUG_ -T><2^&?Z'<E_'5W23?L&6=^Z?>>:-'Y\KGOGM'
M_%IH^1]8_/E<]\]H_P"+31\CMO$ORP_Z4:          -4P3I-7VS47RZ30
M#X$3V$3!                              41/Q<3VCO-4]'/8 ?T55G/
M>W;CYN?/.,B?BXGM'>:IZ.>P _HJK.>]NW'S<^<:^'#]E+!_';+_ "+0;V#_
M *=_NXN^$\_C*/\ SAKX_?;5_P")SA"Q-.4?^<-?'[[:O_$YPA8ZW8?ZC8O\
MG9?Y$LTGE>E]X !M$   #''=                       !,F3M^<'<[[[J
M/_$Y,]!79^/T4UI_>U8?S*>>?5D[?G!W.^^ZC_Q.3/05V?C]%-:?WM6'\RGG
M$?A*_;;X./XA_P#?9#T;)_5[3H]EGG!P_P 7#]HWS4*RB'^+A^T;YJ%9VX\X
M            #XO@1$\@        ^!/A1%^+'<^            $CW,_EDNO
M]^- _C,D>@5L_7Z*"<]ZE@_F*<>?K<S^62Z_WXT#^,R1Z!6S]?HH)SWJ6#^8
MIQQ?X1_VU^#?^)/_ '%B/0LGT%H_*^X\ZQGX$/N</S&E12S\"'W.'YC2H[0>
M>                                    #Y1]RG_ *]HG\1@'U/E'W*?
M^O:)_$8!J80_L^W_ .2M/\J(M!Y</YH>]&5%9KH<L_\ J2E?N$ "S70Y9_\
M4E*_<( /S=F?23/SQ?ZF?6K(M"[C%-HG_#8';?\ 1/U3\JB?\-@=M_T3]4_1
M'<S^SN OX38/]K*/EK1]/._>1][  /<,(
M              !\XW_+_P!>47]_@GIA73?H;)'_ *:S_P"Z//,]C?\ +_UY
M1?W^">F%=-^ALD?^FL_^Z/.)?#/]#N2_CJ[I)OV#+._=/O/-&C\^5SWSVC_B
MTT?(^L?GRN>^>T?\6FCY';>)?EA_THT
M             "B)^+B>T=YJGHY[ #^BJLY[V[<?-SYYQD3\7$]H[S5/1SV
M']%59SWMVX^;GSC7PX?LI8/X[9?Y%H-[!_T[_=Q=\)Y_&4?^<-?'[[:O_$YP
MA8FG*/\ SAKX_?;5_P")SA"QUNP_U&Q?Y.R_R)9I/*]+[P #:(
M                 )DR=OS@[G??=1_XG)GH*[/Q^BFM/[VK#^93SSZLG;\X
M.YWWW4?^)R9Z"NS\?HIK3^]JP_F4\XC\)7[;?!Q_$/\ [[(>C9/ZO:='LL\X
M.'^+A^T;YJ%91#_%P_:-\U"L[<><
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M_P!$_5/T1W,_L[@+^$V#_:RCY:T?3SOWD?>P #W#"
M                       ?.-_R_P#7E%_?X)Z85TWZ&R1_Z:S_ .Z//,]C
M?\O_ %Y1?W^">F%=-^ALD?\ IK/_ +J\XE\,_P!#N2_CJ[I)OV#+._=/O/-&
MC\^5SWSVC_BTT?(^L?GRN>^>T?\ %IH^1VWB7Y8?]*-
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M]D/1LG]7M.CV6><'#_%P_:-\U"LHA_BX?M&^:A6=N/.
M                )'N9_+)=?[\:!_&9(] K9^OT4$Y[U+!_,4X\_6YG\LEU
M_OQH'\9DCT"MGZ_103GO4L'\Q3CB_P (_P"VOP;_ ,2?^XL1Z%D^@M'Y7W'G
M6,_ A]SA^8TJ*6?@0^YP_,:5':#SP
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M=VZ[)1/%IGUQZ$[MUV2B>+3/KCY5MP7W[!ZI;,WF,^U]' [1S?;#KVIHKB"
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MBWMD]_DFLY[:;^<)H(7R>_R36<]M-_.$T&=9%H7<:,?E/H[D  25
M                                  -4W?@7R*9#6P8<YWT=NB_3,>5-
MWX%\BF0UL&'.=]';HOTP2LCT>*,@4  @
M              $^6%Z&H?<XWTB R?+"]#4/N<;Z12/)T^#+P9>CQ1!U0Y_F
M^ZN\KC:&[J'/\WW5WE<;0LLBT+N*  $@                           W
M=/Y_E.ZM\K2=+<=#,;N4'R$%T_G^4[JWRM)TMOT,Q^Y0?Y%7Y<O\R[T2LCT>
M*(  !8@                                 W$ISU+]VA^<A.5M^AAW<
M8'D:0;*<]2_=H?G(3E;?H8=W&!Y&E(LL.GQ1=>0].H@4 %R@
M                        (!RKOS9;V?<LEY[B?B <J[\V6]GW+)>>X$K*
MM*[S#^G.?)OW3'^=<!.<^3?NF/\ .N!KF^6]LGO\DUG/;3?SA-!"^3W^2:SG
MMIOYPF@SK(M"[C1C\I]'<@ "2H
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M_<H/\B"Z?S_*=U;Y6DZ6WZ&8_<H/\BK\N7^9=Z)61Z/%$   L0
M                       ;B4YZE^[0_.0G*V_0P[N,#R-(-E.>I?NT/SD)
MRMOT,.[C \C2D66'3XHNO(>G40* "Y0
M       $ Y5WYLM[/N62\]Q/Q .5=^;+>S[EDO/<"5E6E=YA_3G/DW[IC_.N
M G.?)OW3'^=<#7-\M[9/?Y)K.>VF_G":"%\GO\DUG/;3?SA-!G61:%W&C'Y3
MZ.Y  $E0                                         #5-WX%\BF0U
ML&'.=]';HOTS'E3=^!?(ID-;!ASG?1VZ+],$K(]'BC(%  (
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M\G3X,O!EZ/%$'5#G^;[J[RN-H;NH<_S?=7>5QM"RR+0NXH  2
M                #=T_G^4[JWRM)TMOT,Q^Y0?Y$%T_G^4[JWRM)TMOT,Q^
MY0?Y%7Y<O\R[T2LCT>*(  !8@                                 W$
MISU+]VA^<A.5M^AAW<8'D:0;*<]2_=H?G(3E;?H8=W&!Y&E(LL.GQ1=>0].H
M@4 %R@                                    (!RKOS9;V?<LEY[B?B
M <J[\V6]GW+)>>X$K*M*[S#^G.?)OW3'^=<!.<^3?NF/\ZX&N;Y;VR>_R36<
M]M-_.$T$+Y/?Y)K.>VF_G":#.LBT+N-&/RGT=R  )*@
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M:A]SC?2*1Y.GP9>#+T>*(.J'/\WW5WE<;0W=0Y_F^ZN\KC:%ED6A=Q0  D
M           #2NXBKOK@N"=M=Q/A             !NZ?S_*=U;Y6DZ6WZ&8
M_<H/\B"Z?S_*=U;Y6DZ6WZ&8_<H/\BK\N7^9=Z)61Z/%$   L0
M                       ;B4YZE^[0_.0G*V_0P[N,#R-(-E.>I?NT/SD)
MRMOT,.[C \C2D66'3XHNO(>G40* "Y0                   )I7!$55]A%
M7R;AJC55<$1,=Y51/VKT_8W>D : JS789RHB)N;J9W!W?A_SPI
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M^CMT7Z9CRIN_ OD4R&M@PYSOH[=%^F2%D>CQ1D"@ $
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MG\_RG=6^5I.EM^AF/W*#_(J_+E_F7>B5D>CQ1   +$
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MBI-WX%\BF0UL&'.=]';HOTS'E3=^!?(ID-;!ASG?1VZ+],D+(]'BC(%  (
M                                        !/EA>AJ'W.-](@,GRPO0
MU#[G&^D4CR=/@R\&7H\40=4.?YONKO*XVANZAS_-]U=Y7&T++(M"[B@ !(
M     7V-WI=M-S]H !91V:_8]K09;=R%GJK<]38,"_NPTRD&S-8DF092I/@5
M:<A0JC%=.-2$]=HE,YR(^*NA,$P)XV*W('A9!63U*V4M)-MK][]K9:7CWBVI
MF&(^H3D>"](TK!B3#EB1'<3HYT%%2*J8-WBYNBJFE-"[^&)IVU55WU557XU(
MHJUXRV/%BXG%6O==H5*C< !)4            W=/Y_E.ZM\K2=+;]#,?N4'^
M1!=/Y_E.ZM\K2=+;]#,?N4'^15^7+_,N]$K(]'BB   6(
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MY29C2L1?_P D%['?M*  5OBQ8F"19B:F<W\%TW,QIJ(F_P W&>]W[2@
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M!EX,O1XH@ZH<_P WW5WE<;0W=0Y_F^ZN\KC:%ED6A=Q0  D
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MLY[:;^<)H(7R>_R36<]M-_.$T&=9%H7<:,?E/H[D  25
M                          -4W?@7R*9#6P8<YWT=NB_3,>5-WX%\BF0U
ML&'.=]';HOTP2LCT>*,@4  @9T.&R:F(RYL&0I\_5(KEW$ATZ6B3;T7MMA*A
M9/R**[7,L;+7O]RE;7+%G+OKFZA(4FYNE1E<^GP(LRR+2JXYD)?O455CPL_&
M(Q<UR(J:2])4I>).4BT4G!7"+-V8M!+0\-U7QJ7-0VM3VSG(A:[V/:R-I[F,
MFR\FF63LPVN7B0ZU:**^BOC,DXLQ,SU7GHDA%BQXN")M2Q&1&H[%%PP(XUU]
MQDANAB>2*Y)\B;O>3HRDR98N4Q3+N7T6YZAU:<D[;V_XI^Z%6ITA,5-UE:=*
M??9F''9+LB-8DY).>QBQ%9F)^#I1"V+L3EE["S>7YEHVJN]='G[.4GC+="K,
MTR89,STW-2#FU6+$293;H:,F%BN1'K@B8HFA"Y_DP7<7FV?LI>'>%?O8"3J%
M^%KY>H08LK/QI2?Q8K9F!26RL1S8L"4VJ7?!1ZP<S/PYK3N]:-CFR;LH3)YO
M<RHK87J6$@4J4OQA15H-2@SLFYM.B2DO.-D<($OU;XL%-*)AN^P0\L.FN3-Q
M_P#7<$TH8TFLBXU>VX:TZ#K[&L9;#*CV7NT,K)7C3_(OR:HDM'FZ? A1EID.
M+:"F[:V%$S(FTQ<9ABM151R-7%<$707]*C5)6ATJMUNHQ6PY*A6>JTRZ.]41
MF=3:='B2[E5<$17NA(K4T;N@M<;'KDUWZW(7BY05L;WJ4R1B7FUB!,0ZL^-+
M3,Q6I24FH[Y/3#5T2!M$!T-,%72F"'=#*LLO>);;)QO-L;=1#6)>!:&7E)6A
ML;$APG/@.>YD\S;(BM:W/@.<U<Y=*?ME55>5WTU9.*F41M-PJJQ4H4FM"K?D
MRU+0.2-?)1KJKN\L79(;RI9TW"MY6Z=1+*+'<]L6:GJ55)F@23)9VEZ(Z82"
MU=K3#3S6@[ VFMWE!NR);0Y8UX-NWV&MIQ5)5"SEE8DM">RCTR/4D;*PG146
M'#F'521="S<]F+5>F'-)I_(G<@2\ZVNQMT/)BK$5EG[?42NP;12M(9M,5D2/
M M!#KDQ"C1V.2%%6:6&J(L3',5V@DB]RX2_C*ZNINZN!MA0^1!==064B!>2Z
M!-0:CQS-LX^5?2\UD%61)9L5\JBN2%H7;,'8D7Z*I9.5Y>)M?\LLW#5-4IC4
M=>*%4I19>KC720!?IE-90Z9.F3)E8V<M7'LO(UVK/I]OK(/D8<1M6E4JLM3(
M<T^:B(W:&NA.?,HC6Z<[!-\["6WRRK6ORX\G2YZSD%)6Z2VMG9J>KU:<]G$]
M8F66?@ST58;WM1465FWO148Y<51$P)/RULE*JWT9+=#R>+HG0[.0:3&LU"DY
MJ&R&_B&5I$Y*19^*UC\W%T["EWN54P5JNZ:D490F0S;*UU>R08=T]7^XL&Y*
M0GY:U]I4AL?,3'%\K+0YF&](KDC/2,K(T-%1SLQ'X)N8"_EKDZ;U7)D27>R$
MX'2J2\I=%$TWTY.^AV7N+Y)<]?A?O6:K;&):2Z6-%HS;!T]TFV7ATQT-CF5!
ML&,G-S&?&TJO2P."9<^5Q5<G&0N\L!=U3?N]?9?1//D;"TQCT;$E9>3F84.K
M3+D<CH>$"5B.CX143'-P13NS9JS=+LE0Z;9^C0FPY20EX*/?I5\Q-*QJS46(
M]>;=GQD<Y$<JHW%40M]Y7N3-;VVV43DZY3]WU.;:N=N2BUW[J6*BQ(4O#J,.
MM0F2[5AS$;F(6U,18G,,Q5=U4+/,5A:<2<5$DM";2NK2F5ZB(<K&]*]_(TGL
MFZTCKP8EK[37F3D*':VS'$C(42K.GXTI#VB"U%?M?W,XJ<UZP6<VD/%<-TXG
M?5?[?='V1:[VY&Z2V4>/2)BS+YVU5D(4DQ\.GSU7LU#G9"+,S;L4A\33,9(J
M-<J(]69N'23L94LEVW.4AE-6'RB+_(*4&Q-T4G/Q+LKKWO9-P5J50D-JCNBS
MD%>;VN=9#BLXH8J(J8-T:37)1R6+>6%RG<I/*5O@@0XUI;RXM E[".>L*,ZD
MT^CPG2:M@.9G)#1\HD-JX9BX)IQZ5:15RW575F:OS=/27K"H7Y+B4-]UU6TJ
M<CHNIY.)$WY*EVV45=W3;;IE&7F<DFMUR>9%LW$^YTO3THLMQ2]Z2R-EG*V+
MFP',@JY<,53'=Q.B6R+Y2%ZET^4YDKW7736SC2M1O'GJU"M'8Z5D4FHD^DIM
M+I9T2,B.= ;#:[;%7!$5,<5+SC4YICGN<N$1L5V<JN57(Y'JF[HQ5.EY"W+1
M<E"UEI]D&M;E5WG2D&:LK92GMAW,RTPL*/#DYN:I#Y.?<R%B[-5TSF.QB-33
MI1<4TR\EU>+)E[65A:QFXJ*YW)75N2HNWK9UGHE[>493=DBH%@JW>FZJW=TR
MS,_7;V;&I38$.6LI"D[,NJ=/9'J#=#W3NUJJ(U45KEPP54)HR<KZ;R\N^I7O
M7A4NM1;O,G^Q#*W"L ](21^.>;H;)V!4(J156'&@-E)V45_WQSD>FYBBX'&[
MB,D2^];^,LF\:]Y$ILI?E(RE/LA6ML@1XT.'*2$U)0FP&PE6+ ;FQ(37(BM1
M4T+H-A<)<3E27&Y+56R0[(V7ATJK/JE>XBO99-R;E6D6DJLQ-U#&FXX.<LC,
MOA8N>KD7FDTD*O'7([KNC+FY>/*6;A?V:K%5;J4=&WQ5IDY:9R7MC8RD;:90
MUA[T).VLZM;C78UJ-3:9:?:VPH=;@NJ4Q*HR&UB9F,M#A-ANP<Y55-.E22,L
M#*BG;C'W=W:6#D4K5\]\\S'E+%4]CVMB24&2BL95)IS7(YB[1+1'1T2(U,<S
M1I4D#)*R9;*9)ES%%NHLO'^Z,S F9RI6BKSF.9&K-1J4TZ?F=M:_.>B09F+$
M1N+G)A^#@F@ZB9<63;?K:/**R><JZX>EMMI6;F(M;;5[OXL>!*0ZG!K4.'*(
MK)N97:X"PH>=%Q8W%RH3?1<MW_+*K$<;XH;Z<2;2NKIR\70394[!92%WUL[L
M[1RUN5K=AZ;1:W:&_&L3$O EH6;#IJU&1DF0(KM"P'-B2RNE_P +!%720[DY
MWTWE9=\]>S>+2JU%N]R?[%RM6;8![8:1TM//42#-P:G'VY=KC0&RL_*+$P>J
MM<FAJ8:#M+3Z3?;?/8RUM-O/ICKM*=:BS\U3Y:S,*:A5!\*<CT^++JCIV75'
M*G%#T7!RX(FC<TG26X:XG*EN/R6:MDA61LM#I%66J5Y)*]F'-2CE^X]HZI,S
M,^CJ8JHBKQ!,O@\T_.155R:1UT:ZLE/^GEOJ2FJ.M,:L/5<V^1N[4?@Y/.5]
M?S>=DE92-H+/2T6V5X%S,^Z!9FO060X7W:IC*E-0:DZ#"1JL<Z0D(#D5$SWN
M<W1S2G(\A>]"UN5#1KM;Y;"WO1:A9NBP;9NOTL3.4_B6=I<Y36S$.12,V:<V
M:AMAS,"(YBLAM;$:W%,4P)%NWR<+T\CFS-SUWMP-'@VWL33$M1,WUOC.EY=]
MJYNON?,-AQTF\^(B0IF/':F;GMP7<1,,/Q,G?(_MA=+:W*WO?LG2EL#,7^4>
M#+68NUEYAL>1I<Y"I\U*3;X#VN;+PW3D:,L9RI#9I=I5<"+[K]-V;7M1$MP4
M=%"JTH^/B3JKJ?:S-'5'(0L7;/*'V0;*1RD:G>)4:K=_==5Z-)V DHD&/]SY
MGBA(LA58<NBQ%@HD&)#P>J-7<Q.Q-B[Q:E;'9@;R;+T2*L:SMAY.F\<&TZ8+
M'S]#5TOMSFXIBY^*-SEW=PWV0M8&\+(4R4[93-^M+A4FT#Y^TT:6ID*)!G*A
M7YVNU*>?1G*Z6SX[T@QIB [2CT8BZ<$.;[';DVVJN\;>GE&WMP'0[X,H*H0Y
MJIR<Q@^/1:72)F,VC81$547;Z<^$N#4:J(N#L5Q"XERWO;+EIIH\Y#:3C=U$
ME##2E^2KS\;R/*7+?[\7NT;#M;8[#]AJ/]+[*]-?A!8Q GRPO0U#[G&^D0&3
MY87H:A]SC?2*1Y.GP9>#+T>*(.J'/\WW5WE<;0W=0Y_F^ZN\KC:%ED6A=Q0
M D                           &[I_/\ *=U;Y6DZ6WZ&8_<H/\B"Z?S_
M "G=6^5I.EM^AF/W*#_(J_+E_F7>B5D>CQ1   +$
M             &XE.>I?NT/SD)RMOT,.[C \C2#93GJ7[M#\Y"<K;]##NXP/
M(TI%EAT^*+KR'IU$"@ N4                                    ! .
M5=^;+>S[EDO/<3\0#E7?FRWL^Y9+SW E95I7>8?TYSY-^Z8_SK@)SGR;]TQ_
MG7 US?+>V3W^2:SGMIOYPF@A?)[_ "36<]M-_.$T&=9%H7<:,?E/H[D  25
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M]'BB#JAS_-]U=Y7&T-W4.?YONKO*XVA99%H7<4  )
M        !NZ?S_*=U;Y6DZ6WZ&8_<H/\B"Z?S_*=U;Y6DZ6WZ&8_<H/\BK\N
M7^9=Z)61Z/%$   L0                                 ;B4YZE^[0_
M.0G*V_0P[N,#R-(-E.>I?NT/SD)RMOT,.[C \C2D66'3XHNO(>G40* "Y0
M                                  $ Y5WYLM[/N62\]Q/Q .5=^;+>
MS[EDO/<"5E6E=YA_3G/DW[IC_.N G.?)OW3'^=<#7-\M[9/?Y)K.>VF_G":"
M%\GO\DUG/;3?SA-!G61:%W&C'Y3Z.Y  $E0
M                #5-WX%\BF0UL&'.=]';HOTS'E3=^!?(ID-;!ASG?1VZ+
M],$K(]'BC(%  (                                          !/EA
M>AJ'W.-](@,GRPO0U#[G&^D4CR=/@R\&7H\40=4.?YONKO*XVANZAS_-]U=Y
M7&T++(M"[B@ !(                           -W3^?Y3NK?*TG2V_0S'
M[E!_D073^?Y3NK?*TG2V_0S'[E!_D5?ER_S+O1*R/1XH@  %B
M                      #<2G/4OW:'YR$Y6WZ&'=Q@>1I!LISU+]VA^<A.
M5M^AAW<8'D:4BRPZ?%%UY#TZB!0 7*
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MK,?U+OB74,Q_4NX*Z@"D%68_J7<%=0S']2[@KJ *059C^I=P5U#,?U+N"NH
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MN$F(DU=59R+%7.>KIK3_ /E)A(7R>_R36<]M-_.$T&PLBT+N-&/RGQ7UZ[P
M"2H                                         !JF[\"^13(:V##G.
M^CMT7Z9CRIN_ OD4R&M@PYSOH[=%^F"5QZ/%&0*  0
M                        ">[#(BV9AHNXL.,GG$"$^6%Z&H?<XWTBD>3I
M\&7@R]'BB#9Y$;.S34W$BNP^%RXFU-W4.?YONKO*XVA97I/,4  )
M                   !NZ?S_*=U;Y6DXVZ8CK-Q'=3#A*FG?P^/<(.I_/\
M*=U;Y6DZ6WZ&8_<H/\BK\J#\R[T65V-^7O:1   +%0
M              #<2G/4OW:'YR$Y6WZ&'=Q@>1I!LISU+]VA^<A.5M^AAW<8
M'D:4BRPZ?%%UY#TZB!0 7*                                     @
M'*N_-EO9]RR7GN)^(!RKOS9;V?<LEY[@2LJTKO,/Z<Y\F_=,?YUP$YSY-^Z8
M_P ZX&N;Y;VR>_R36<]M-_.$T$+Y/?Y)K.>VF_G":#.LBT+N-&/RGT=R  )*
M@                                         &J;OP+Y%,AK8,.<[Z.
MW1?IF/*F[\"^13(:V##G.^CMT7Z8)61Z/%&0*  0
M                      "?+"]#4/N<;Z1 9/EA>AJ'W.-](I'DZ?!EX,O1
MXH@ZH<_S?=7>5QM#=U#G^;[J[RN-H661:%W%  "0
M       ;NG\_RG=6^5I.EM^AF/W*#_(@NG\_RG=6^5I.EM^AF/W*#_(J_+E_
MF7>B5D>CQ1   +$                                 &XE.>I?NT/SD
M)RMOT,.[C \C2#93GJ7[M#\Y"<K;]##NXP/(TI%EAT^*+KR'IU$"@ N4
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M'W2975Y5@[!4IM$LM2'T_P"Y]-8]8C8&W2V?$1'NTKBX5OIFJ12ZO0=(  2
M     #5-WX%\BF0UL&'.=]';HOTS'E3=^!?(ID-;!ASG?1VZ+],$K(]'BC(%
M  (                                          !/EA>AJ'W.-](@,
MGRPO0U#[G&^D4CR=/@R\&7H\40=4.?YONKO*XVANZAS_ #?=7>5QM"RR+0NX
MH  2                           #=T_G^4[JWRM)TMOT,Q^Y0?Y$%T_G
M^4[JWRM)TMOT,Q^Y0?Y%7Y<O\R[T2LCT>*(  !8@
M             W$ISU+]VA^<A.5M^AAW<8'D:0;*<]2_=H?G(3E;?H8=W&!Y
M&E(LL.GQ1=>0].H@4 %R@                                    (!R
MKOS9;V?<LEY[B?B <J[\V6]GW+)>>X$K*M*[S#^G.?)OW3'^=<!.<^3?NF/\
MZX&N;Y;VR>_R36<]M-_.$T$+Y/?Y)K.>VF_G":#.LBT+N-&/RGT=R  )*@
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MG^4[JWRM)TMOT,Q^Y0?Y%7Y<O\R[T2LCT>*(  !8@
M              W$ISU+]VA^<A.5M^AAW<8'D:0;*<]2_=H?G(3E;?H8=W&!
MY&E(LL.GQ1=>0].H@4 %R@                                    (!
MRKOS9;V?<LEY[B?B <J[\V6]GW+)>>X$K*M*[S#^G.?)OW3'^=<!.<^3?NF/
M\ZX&N;Y;VR>_R36<]M-_.$T$+Y/?Y)K.>VF_G":#.LBT+N-&/RGT=R  )*@
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M12/)T^#+P9>CQ1!U0Y_F^ZN\KC:&[J'/\WW5WE<;0LLBT+N*  $@
M                   W=/Y_E.ZM\K2=+;]#,?N4'^1!=/Y_E.ZM\K2=+;]#
M,?N4'^15^7+_ #+O1*R/1XH@  %B
M #<2G/4OW:'YR$Y6WZ&'=Q@>1I!LISU+]VA^<A.5M^AAW<8'D:4BRPZ?%%UY
M#TZB!0 7*                                     @'*N_-EO9]RR7G
MN)^(!RKOS9;V?<LEY[@2LJTKO,/Z<Y\F_=,?YUP$YSY-^Z8_SK@:YOEO;)[_
M "36<]M-_.$T$+Y/?Y)K.>VF_G":#.LBT+N-&/RGT=R  )*@
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M3NK?*TG2V_0S'[E!_D5?ER_S+O1*R/1XH@  %B
M           #<2G/4OW:'YR$Y6WZ&'=Q@>1I!LISU+]VA^<A.5M^AAW<8'D:
M4BRPZ?%%UY#TZB!0 7*                                     @'*N
M_-EO9]RR7GN)^(!RKOS9;V?<LEY[@2LJTKO,/Z<Y\F_=,?YUP$YSY-^Z8_SK
M@:YOEO;)[_)-9SVTW\X300OD]_DFLY[:;^<)H,ZR+0NXT8_*?1W(  DJ
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M-;!ASG?1VZ+],$K(]'BC(%  (
M       !/EA>AJ'W.-](@,GRPO0U#[G&^D4CR=/@R\&7H\40=4.?YONKO*XV
MANZAS_-]U=Y7&T++(M"[B@ !(                           -W3^?Y3N
MK?*TG2V_0S'[E!_D073^?Y3NK?*TG2V_0S'[E!_D5?ER_P R[T2LCT>*(  !
M8@                                 W$ISU+]VA^<A.5M^AAW<8'D:0
M;*<]2_=H?G(3E;?H8=W&!Y&E(LL.GQ1=>0].H@4 %R@
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M]';HOTS'E3=^!?(ID-;!ASG?1VZ+],$K(]'BC(%  (
M                        !/EA>AJ'W.-](@,GRPO0U#[G&^D4CR=/@R\&
M7H\40=4.?YONKO*XVANZAS_-]U=Y7&T++(M"[B@ !(
M         -W3^?Y3NK?*TG2V_0S'[E!_D073^?Y3NK?*TG2V_0S'[E!_D5?E
MR_S+O1*R/1XH@  %B                                 #<2G/4OW:'
MYR$Y6WZ&'=Q@>1I!LISU+]VA^<A.5M^AAW<8'D:4BRPZ?%%UY#TZB!0 7*
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MX%\BF0UL&'.=]';HOTS'E3=^!?(ID-;!ASG?1VZ+],$K(]'BC(%  (
M                                    !/EA>AJ'W.-](@,GRPO0U#[G
M&^D4CR=/@R\&7H\40=4.?YONKO*XVANZAS_-]U=Y7&T++(M"[B@ !(
M                     -W3^?Y3NK?*TG2V_0S'[E!_D073^?Y3NK?*TG2V
M_0S'[E!_D5?ER_S+O1*R/1XH@  %B
M  #<2G/4OW:'YR$Y6WZ&'=Q@>1I!LISU+]VA^<A.5M^AAW<8'D:4BRPZ?%%U
MY#TZB!0 7*                                     @'*N_-EO9]RR7
MGN)^(!RKOS9;V?<LEY[@2LJTKO,/Z<Y\F_=,?YUP$YSY-^Z8_P ZX&N;Y;VR
M>_R36<]M-_.$T$+Y/?Y)K.>VF_G":#.LBT+N-&/RGT=R  )*@
M                              &J;OP+Y%,AK8,.<[Z.W1?IF/*F[\"^
M13(:V##G.^CMT7Z8)61Z/%&0*  0
M          "?+"]#4/N<;Z1 9/EA>AJ'W.-](I'DZ?!EX,O1XH@ZH<_S?=7>
M5QM#=U#G^;[J[RN-H661:%W%  "0                           ;NG\_
MRG=6^5I.EM^AF/W*#_(@NG\_RG=6^5I.EM^AF/W*#_(J_+E_F7>B5D>CQ1
M +$                                 &XE.>I?NT/SD)RMOT,.[C \C
M2#93GJ7[M#\Y"<K;]##NXP/(TI%EAT^*+KR'IU$"@ N4
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M5F/ZEW!74,Q_4NX*Z@"D%68_J7<%=0S']2[@KJ *059C^I=P5U#,?U+N"NH
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M4,9YNK1JVNIF7\N%R!O3Z#XK0OL(Y<+D#>GT'Q6A?83#0S6]0S@-U#-;U#.
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MEZ]=4#O:GZRX!S7ID7Y1VL<UZ9%^4=K&_>;E^BLVK:B'!_/6C]6+-J?66_\
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MEZ]=4#O:GZRX!S7ID7Y1VL<UZ9%^4=K&_>;E^BLVK:B'!_/6C]6+-J?66_\
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MLVI%O?)\55NFLXJJJKG3>E5Q7\83.0OD]_DFLY[:;^<)H,BR+0NXUX_*>W$
M 25                                          -4W?@7R*9#6P8<Y
MWT=NB_3,>5-WX%\BF0UL&'.=]';HOTP2LCT>*,@4  @
M                         $^6%Z&H?<XWTB R?+"]#4/N<;Z12/)T^#+P
M9>CQ1!U0Y_F^ZN\KC:&[J'/\WW5WE<;0LLBT+N*  $@
M          W=/Y_E.ZM\K2=+;]#,?N4'^1!=/Y_E.ZM\K2=+;]#,?N4'^15^
M7+_,N]$K(]'BB   6(                                 -Q*<]2_=H
M?G(3E;?H8=W&!Y&D&RG/4OW:'YR$Y6WZ&'=Q@>1I2++#I\477D/3J(% !<H
M                                   " <J[\V6]GW+)>>XGX@'*N_-E
MO9]RR7GN!*RK2N\P_ISGR;]TQ_G7 3G/DW[IC_.N!KF^6]LGO\DUG/;3?SA-
M!"^3W^2:SGMIOYPF@SK(M"[C1C\I]'<@ "2H
M                 !JF[\"^13(:V##G.^CMT7Z9CRIN_ OD4R&M@PYSOH[=
M%^F"5D>CQ1D"@ $                                           GR
MPO0U#[G&^D0&3Y87H:A]SC?2*1Y.GP9>#+T>*(.J'/\ -]U=Y7&T-W4.?YON
MKO*XVA99%H7<4  )                           !NZ?S_*=U;Y6DZ6WZ
M&8_<H/\ (@NG\_RG=6^5I.EM^AF/W*#_ "*ORY?YEWHE9'H\40  "Q
M                           !N)3GJ7[M#\Y"<K;]##NXP/(T@V4YZE^[
M0_.0G*V_0P[N,#R-*198=/BBZ\AZ=1 H +E
M            0#E7?FRWL^Y9+SW$_$ Y5WYLM[/N62\]P)65:5WF'].<^3?N
MF/\ .N G.?)OW3'^=<#7-\M[9/?Y)K.>VF_G":"%\GO\DUG/;3?SA-!G61:%
MW&C'Y3Z.Y  $E0                                         #5-WX
M%\BF0UL&'.=]';HOTS'E3=^!?(ID-;!ASG?1VZ+],$K(]'BC(%  (
M                                   !/EA>AJ'W.-](@,GRPO0U#[G&
M^D4CR=/@R\&7H\40=4.?YONKO*XVANZAS_-]U=Y7&T++(M"[B@ !(
M                    -W3^?Y3NK?*TG2V_0S'[E!_D073^?Y3NK?*TG2V_
M0S'[E!_D5?ER_P R[T2LCT>*(  !8@
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MA.A2,=LL]TLV&YRP\Y^DN0[ZKNJJJO;72N"=)-Y$T)N(-),5%<KZ97RZ,P
M*@               GRPO0U#[G&^D0&3Y87H:A]SC?2*1Y.GP9>#+T>*(.J'
M/\WW5WE<;0W=0Y_F^ZN\KC:%ED6A=Q0  D
M &[I_/\ *=U;Y6DZ6WZ&8_<H/\B"Z?S_ "G=6^5I.EM^AF/W*#_(J_+E_F7>
MB5D>CQ1   +$             #_-?@3=7M)TUW$Z9^!(6KLK5ZQ.V=I-I:+4
M:_341U2I$I49.8FY%KFY^?&@PHSHK41B*YV<Q,$1570@!^^B8X\U#8UC71(D
M2,]L*##APTSGOB17X,8C6(J\TJ8X'7V@Y2MW=L;UYNZ*PD9UK:M1W9EIZU*,
MB_<RAQ'0UB0H<.=8CI.=6*YJL<D*,N8NA=XM:Y;66/>/?O?G3MCQR*ZA$BVU
MJ\PV7OKO0IJ-CRM@:8U&322ZN5%EX[ZE);?+8P8S70G:=#DT74LF_)VL'DQ7
M84>[:P\LV9C0)=L:TEI9M7S-2KM7F,)B?BQ)J95\W#:V==%5K=M5J-7-;S.!
M%:UIQ<>VVDNX<5)Q97D6;E?@B>NFOL*J?$N  )*            &XE.>I?NT
M/SD)RMOT,.[C \C2#93GJ7[M#\Y"<K;]##NXP/(TI%EAT^*+KR'IU$"@ N4
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M.RI+TW1ZG4X4['FV4]SXJK,;<QS,S;F8YFUHY/@3 4?SJ9&G=G)463EN5?\
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M]'BB#JAS_-]U=Y7&T-W4.?YONKO*XVA99%H7<4  )
M        !NZ?S_*=U;Y6DZ6WZ&8_<H/\B"Z?S_*=U;Y6DZ6WZ&8_<H/\BK\N
M7^9=Z)61Z/%$   L0            :+A@]%3%L6%$EXG25(4=JPXBHO25&.5
M45-*;J:4,+[9/K.926Q>9<D+*)R9)RUEJJ'E*\641:%!BU&J2LE&CR2TF)&9
M!BNF8<#:HLZZ(BI#AIS.*;F*9H1Q"TU@+$6TG*)4+768IMHINS;XD2A1*C+0
M)EM.B151T1\-D>'$;BYS47%,%1<,-)#547@BQ'5JJR-<I:_V(3(MCY,5P;KR
MKR(#ZEE"WY18UHKPZ]4&K%J<!L>9?/TR V)&SWP4ARTTD#"$YG,MP5.D7;D3
M#RJN^J[JKVS7I-1$:UK&,AL9#:C&,9#:C6,8QN#6M:U$1$1.D"4J*A6*)Q-M
M\?9F  !            !N)3GJ7[M#\Y"<K;]##NXP/(T@V4YZE^[0_.0G*V_
M0P[N,#R-*198=/BBZ\AZ=1 H +E
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MC]R@_P B"Z?S_*=U;Y6DZ6WZ&8_<H/\ (J_+E_F7>B5D>CQ1   +$
M                          &XE.>I?NT/SD)RMOT,.[C \C2#93GJ7[M#
M\Y"<K;]##NXP/(TI%EAT^*+KR'IU$"@ N4
M          ! .5=^;+>S[EDO/<3\0#E7?FRWL^Y9+SW E95I7>8?TYSY-^Z8
M_P ZX"<Y\F_=,?YUP-<WRWMD]_DFLY[:;^<)H(7R>_R36<]M-_.$T&=9%H7<
M:,?E/H[D  25                                          -4W?@7
MR*9#6P8<YWT=NB_3,>5-WX%\BF0UL&'.=]';HOTP2LCT>*,@4  @
M                                  $^6%Z&H?<XWTB R?+"]#4/N<;Z
M12/)T^#+P9>CQ1!U0Y_F^ZN\KC:&[J'/\WW5WE<;0LLBT+N*  $@
M                   W=/Y_E.ZM\K2=+;]#,?N4'^1!=/Y_E.ZM\K2=+;]#
M,?N4'^15^7+_ #+O1*R/1XH@  %B
M #<2G/4OW:'YR$Y6WZ&'=Q@>1I!LISU+]VA^<A.5M^AAW<8'D:4BRPZ?%%UY
M#TZB!0 7*                                     @'*N_-EO9]RR7G
MN)^(!RKOS9;V?<LEY[@2LJTKO,/Z<Y\F_=,?YUP$YSY-^Z8_SK@:YOEO;)[_
M "36<]M-_.$T$+Y/?Y)K.>VF_G":#.LBT+N-&/RGT=R  )*@
M                             &J;OP+Y%,AK8,.<[Z.W1?IF/*F[\"^1
M3(:V##G.^CMT7Z8)61Z/%&0*  0
M         "?+"]#4/N<;Z1 9/EA>AJ'W.-](I'DZ?!EX,O1XH@ZH<_S?=7>5
MQM#=U#G^;[J[RN-H661:%W%  "0                           ;NG\_R
MG=6^5I.EM^AF/W*#_(@NG\_RG=6^5I.EM^AF/W*#_(J_+E_F7>B5D>CQ1
M+$                                 &XE.>I?NT/SD)RMOT,.[C \C2
M#93GJ7[M#\Y"<K;]##NXP/(TI%EAT^*+KR'IU$"@ N4
M                   ! .5=^;+>S[EDO/<3\0#E7?FRWL^Y9+SW E95I7>8
M?TYSY-^Z8_SK@)SGR;]TQ_G7 US?+>V3W^2:SGMIOYPF@A?)[_)-9SVTW\X3
M09UD6A=QHQ^4^CN  )*@
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M3?3XT -S*<]2_=H?G(3E;?H8=W&!Y&D&2BIQ5+Z4_'0^G_[D)SMNJ<;#M/\
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#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>nt10006151x2_graphic3.jpg
<TEXT>
begin 644 nt10006151x2_graphic3.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( A8#R@,!(@ "$0$#$0'_Q  ?  $   8# 0$
M    ! 4&!P@) 0(#"@O_Q !T$  ! P(#! 4&!@@-#@@+!@<!  (#!!$%!B$'
M$C%!"!-187$4(H&1H? ),K'!T>$5%A@C0I73\0H7&3-24U5E<H*3E+,D)34W
M.%=B='62M+72U#1#1$9D@X7B)C8Y5F-F=H2BH[(:)T=SPL,H1526I,3C_\0
M'0$!  $% 0$!              $" P0%!@<("?_$ $01  $# @,%!@0% @0&
M 00#  $  A$#(00Q004246'P!A-Q@9&A(K'!T0<4,N'Q0E(5(S-B%B1#<H*2
ML@@74](T8Y/_V@ , P$  A$#$0 _ /OX1$1$1$1$1$1$1$1$1$1$1$1$1$1$
M1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$
M1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$
M1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$
M1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$
M1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$
M1='O9&TO>]C&MU+GN#&CQ<=!Z5)ILS9?IR6RXSAC7#B/+::X[OUSBB@$&X4\
M14W]M^6?W;PW^>4_Y1/MORS^[>&_SRG_ "B)(&9"J1%3?VWY9_=O#?YY3_E%
MV&;<M'AC>&_SRG_*(D@Y$*HD5.G-N6@+_9O#/YY3_E%U^V_+/[MX;_/*?\HB
MF0,S"J1%3?VWY9_=O#?YY3_E%R,W9:)L,;PW^>4_Y1%$CB/55&BI[[;,M?NW
MAG\\I_RBZ?;?EG]V\-_GE/\ E$4R/#Q52(J;^V_+/[MX;_/*?\HGVWY9_=O#
M?YY3_E$42.(]0JD14W]M^6?W;PW^>4_Y1/MORS^[>&_SRG_*(DCB/4*I$5-_
M;?EG]V\-_GE/^4789MRT>&-X;_/*?\HB2#D0JB14]]MF6OW<PS^>4_Y1/MLR
MU^[F&?SRG_*(I50HJ>^VS+7[N89_/*?\HGVV9:_=S#/YY3_E$15"BI[[;,M?
MNYAG\\I_RB?;9EK]W,,_GE/^41%4**GOMLRU^[F&?SRG_*)]MF6OW<PS^>4_
MY1$50HJ>^VS+7[N89_/*?\HGVV9:_=S#/YY3_E$2>H/6O4%5"BI[[;,M?NYA
MG\\I_P HGVV9:_=S#/YY3_E$2>H/6O4%5"BI[[;,M?NYAG\\I_RB?;9EK]W,
M,_GE/^41)Z@]:]054**GOMLRU^[F&?SRG_*)]MF6OW<PS^>4_P"41.LE4**G
MOMLRU^[>&?SRG_*+O'FG+LI 9C6&$DV']6TXU_E$13Y%YQ2Q3,$D,D<L9^*^
M)[9&$=SFD@^@E>B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MBZN!(\TV.FJ[+J\V:[MW7'U!$6#NV;/N:MH&TW#MAFS[&'8.^-SOMOQ6)@E=
M1Q.C$T#"S0@S,WF7:X6)N.Q570=$;(S8FG$Z_$\0JG-;U\YQ"MC$DMAUCPT3
M>;O/N;"PULK)[!=ZLZ9G2*DJ/OCZ(Y>Z@OU,8?2'>W;_ !;Z<-5L.QG&L.R]
MA-=C.+3MI</PZ"6IJYW?%BAB:9)'GN:QI/H14C+*(\] >M?58VCHE;-!P^R7
MXTKORZY^Y+V:_OE^-*[\NL=L4^%WZ N#8E681B.W' J?$*">6FJX"UI,,T+W
M1O:X];R<TCQ4O=\,9\'LWCMYP'_-;\\RDM(S"JTF#''=,?)9,_<E[-/WR_&=
M=^73[DO9I^^7XSKORZQG;\,5\'PX:;>, OV6;\O6_+9<CX8CX/LFWZ>V ^-F
M_E5(8Y^39T42.@5DO]R7LU_?+\:5WY=/N2]FO[Y?C2N_+K&UOPPGP?;N&W?
M?\UOY5<GX8+X/T?_ (ZX#X[K1_\ NJ13>3 :9\.NO!2LD?N2]FO[Y?C2N_+I
M]R7LU_?+\:5WY=8W?JP/P?Y&\-NF EO;NL^3K5V'PP'P?SN&W7 ?\UOY93W5
M0?T.3K)9'?<F;-/WS_&=<?DF7/W)FS0_NE^,ZX?+,L>#\+ET!"ULGZ>>!;KN
M!LSM[Y;_ "+LSX6_H#$BVW+ M?X'S3#VH*-4Y,=Z>'KGHJ2YK<S$_M]PLA?N
M2]FO[Y?C2N_+I]R7LU_?+\:5WY=8].^%SZ!#7!IVX8#KS\RW]*NX^%OZ!1!(
MVWX%IW,^7K??15##5SE2J'+)IUR0/8<G#U607W)>S7]\OQI7?ET^Y+V:_OE^
M-*[\NK!-^%JZ!CF[PVX8#X6;^5]_2%P/A:^@8>&V_ O&T?Y:Z?EJXL:-3_T/
MV4[S?[AZA7^^Y+V:_OE^-*[\NGW)>S7]\OQI7?EU8']5KZ!EK_IWX%VVLR_L
MF7#?A:^@8Z__ -]^!:=S/RJ?EZ__ .&I_P"I4%[!_4WAFK__ ')>S7]\OQI7
M?ET^Y+V:_OE^-*[\NK N^%KZ!C38[<,!\0&6_I5U;\+=T"G$@;<,!N.T,_*I
M^6KG_HO_ /4\ON.@J>]I_P![?7KB%D!]R7LU_?+\:5WY=/N2]FO[Y?C2N_+J
MP7ZK3T#2+_IWX#;^)^675WPMG0+;QVWX%ZF?ED_+5LNY?_Z'[*O>:8@B^5U?
M_P"Y+V:?OE^,Z[\NGW)>S7]\OQI7?EUCT[X7/H#M&NW' O"S/RJ\/U7OH"#C
MMPP,>AGY5/R]8?\ 2>/_ !('5U*R,^Y+V:_OE^-*[\NGW)>S7]\OQI7?EUCE
M^J^= 3^_C@7J9^579WPO70":+NVYX"/0W3_YJI-&H,Z;KQIG.7S19%_<E[-?
MWR_&E=^73[DO9K^^7XTKORZQQ_5?O@__ ._K@/\ FM_*KJ_X8'X/M@N=N^ 7
M[-UOI'Z\J>Y=_P#C-_\ ;;URZE4[S>/S62'W)>S7]\OQI7?ET^Y+V:_OE^-*
M[\NL:#\,3\'R#;]/; 2?!GY5<CX8CX/DC^WO@ ]#/RR=T[^SVZZ\"J@0<EDM
M]R7LU_?+\:5WY=/N2]FO[Y?C2N_+K&S]6&^#W_O]8!_F-_++J[X8?X/@<-O&
M '^*W\J52&$F SV_9.6O\?<+)7[DO9K^^7XTKORZ?<E[-?WR_&E=^76,I^&,
M^#W!(=MXP 6XZ-_*A9K[#^D)LFZ1658\Z;(LTTN:\N27#,0I !&2'%I&CG<'
M CCQ"0 <H/AQ0VL;==>_!4%]R7LU_?+\:5WY=0U3T2=GSXBVDJ,2II-TADGV
M2K7[C_P76,VNZ;&W/FLL41%@3DK->:=AFUG#]D^<\9EQ?*V:W2-RCB52W<,
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MB(;Y$[%*3K@^P;;RB+=O?2U^VP/#@OH+RUB^=_TXVY6CCAEV5#*C[8<:*'R
M#[ EY<*HL,9=UGG?&OO#B"L[#4*0!+@21   $:9GRX6"XKM/VDK;/Q.";3I4
MVMJ6>8(D2!:T2;R9,<5\[X;6L>YIQG'@]KRUS78SB +7--G CK@18BQ\.Y1K
M&UG+&,=/[+^O.(:6X?\ '\._Y%4VT9N'0[1<V0X8&MH&XO6]2UA!8T^4R[X;
M;CK<"W+AQ5.L(!LTFUN':+?-[?0LJBRB\DN8+&)!,YB)$<?8ZZ[NG4<^E2JS
M!J,#SK^IH,>?']U.,)=U4W65F*X[+3W#71_9K$1\?S0;]>>!U]'KN])D;+=)
M@5+CE7GS%XY:R[H\,&*X@YS3?@7-J+CC?4=P5E ;QN(&H' =NOOSM=2I]W;I
M+Y="?-,KRUIO^"TFP&G(=NJOG#TR!_EQP.9<9SGAP($2LBEB7TMX ,?)!^("
M1&8!C59)8EL[H&8!@V*TNT+%FU&)O=&*'[*UI,(ZQK YSO*20+'>UMW*?Y@V
M,4^5J7#*NNVJXG-]D8]\1QXG5OZG=:'6<&51-S>U^.E[+&1KGN9#]^G(;H 9
MI+-X'S6WLW^+ZU&.ZQ[1OU%5+8>:):F:0-N/P0][@.VP6TPU!H+(:#&YFT1D
M,[>^>616OQ+WO+JA.Z1)@9#EX*_V';-::NP_$L6_3*Q2.GPY@='&<2K-ZJ)O
MHT&I#A8\;#A96I=7U,4TL;,7QQ[(WN:U_P!F*^SP"1O6Z_G:_9JJ;:'M%A)4
M;I_!$TH:?$!UCZ0HJ&,O.@()[]>[CJMJUC6Y,8#;^D&<N76:U3\14:/U&YXF
M=,L_">>6:JJ'$:AT8W\4QLG_ "SB [/_ $WJ47#6OU'V1QR_#^S6(\#QXS^_
MCQDM/2.TN+WX?.??EVZJ=Q4;-/--[#M[CV:GG;UK/H89E8 N:V>3&G*-?".0
M]0,1V.J@D"1I.\9O'O\ 7R"B0Z4L+F8ICH<[6YQG$2.?_2/>RAVBL-_Z\8X!
M?2V,8@+C^74<8=V,6!] TT]/9?\ /Q[,II'MWF0U$Q'*G@DFL.>]U;3NZ:F_
MR\+_ .1PT?$YK76L6MC3C'IH+ZE6OS=4?]4D\#/ 7]9S]=5+I9ZB.U\2QQW?
M]FL0\?V[OX:@J'CK9!O[^(XV3Q_LU7Z?_.[];J9/I=XEP:0 #?>!!![P=1KR
M/ Z"Q4F?3%KWFQ]_6L2IAV,(!8T@P00 9%K^W'SSD,76M\49 GE\-XR (]5S
M+BDK19N(XV'=OV:Q#\O\G<I/+B=>XDG%L<M_EFNY?]>;+O44[P2ZVG>>0O[B
MZE4C3=WOP)/TCQ5!HTW#=W6B8ONBTP>O!9V%Q-2J02XC=(&9/#K]U'TCL3Q*
MM@P^FQ?&^MJ"0V^-5P W1<^<9[<->([+KMC.#9CP>66.IQ'&MR,-)F;C=<6N
M#AP&[4'4<-">'%2NF<]M3$Z-YC>+V<+@BX[1KZCVW4_K6X[4T/WS??3#4/=S
M%QKO&Y[]5J,31: ?@$MF(#<@!P^NF2V]"J9ASS!BYXSS_GQ5$5%7BC+$8OCE
MN9.,5Y^6?U:?7 G%:^Y8_&,<+C^_->/_ -_Q[+J85#9?BF]O3;4ZCMY*1R-
MJ&#B0?2?3V<EHJXW';P$21+2T6B/GI/%9L$C]<SE'@//Q^=U<G!\F9AQ2@CQ
M48OC!I)&R.#78_6!V[&#O>::G>UMV=FBI6H;&"\.Q/,3-QSFDOQ7%&MN"6FS
MC, 1?A:X/I72'$JZDDI6154T,76-O&'N+-VXOI<"Q%]%='.>+X-79<HX/+83
M/'&-YK*=L;W.T)NX $ZZWN3>Y*E[Z>Y!IML1)( F0,CPM'+V-+:)+C-5PM:!
M%[<U:/<I;;S\6QX=O]><2/J^_P#JXZ+O;"MSSL;QX.MK_7G$QK_+CU*H<OY
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MAV5NILNX]!E[['L(DD?1PU)?O/-M7BX(M?7Y-5J,8ZH&13SN3QB1!'A>ZWV
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M[I\0:&-<(H[4X += &V.AXCF.:[8;M+AP_+$F78<)I^N>\O=B+XX]X;TAD
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MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(NC^#OX#_D"[KH_@[^
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M1SA85#"1NB_Q3\NFO!\K6#3L-K=H[-++)G8C4O=E',755TE-5]3]ZBCC>X.
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M]?ELRUE9NZX#,ZGT5S5NMC!].%LE]4@X#P'R+E<#@/ ?(N5952UK=.$7VD[
M!^^6(_TD"V-87_8[#_\ $*/^@:M<W3@_MD[ /\I8C_20+8SA?]CL/_Q"C_H&
MHHU/@/JH]$1%*(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B+H_@[^
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M;=D.;6, T PC$?5I2CGW?.OVT/N?MC'][;*?X@PO_=4^Y^V,?WMLI_B#"_\
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MT_[13_R#/H13UQ6&_P!TCM/_ +S51^,G?["Y'20VH'AL:J/QD[_968_DM/\
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M"D^,?K(]*N4@#4;)B_UA6ZMV1QZZ^85N<?S7EK!HI&XYC<6&R2M>*?K+$[W
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M.(2;Q?64T8%]3O3,;;OX]A5#XAC3:6!TDDC6QAI+B7 6XGF;ZGB/FNK58!M
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MF^Z;:#4ZHH!Y'*?V4?=%;+9YC>)XS'B53B#W.A;+NTV\W=(:'N!Y#LLKEEP
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M(\0>M1XK3ATH9ZO*^VF26J<YE+6O:Z&0@AGFQM)&\-.)U]"F&2\ZP&6E!D
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MAL5#55)JG17#9'7#B+Z7O?E:RA3-\O;WG*/=4/G7#,T4E>S,. U+Y1!YSZ
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MQ.46N&-:2>1>"!V]OAX6UM\861"&G)O+-)*Z4\#J\N;I;OTN@+?B$F!N@7/
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M9BT<>(8542.D;3TSIK.<UTA>X;H<Y_F@>JQ646?<YQ8_E3$*^LE:6N;NAPJ
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M/]HDM.V PU4C 6ML\/<VUM3H#K<GLY]]EKL\O=#C58(X2V!M0YK26V! >[M
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MN/UK%O;'#UN<MAX(X8E';E_RBFOZC[5E!F3 Z([&\#Q1K7LJ'/87^>XBPJ&
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MR0/77H\5Y9<Q-F+1XPYCKQ@QCM!,1L1>VFHMZ%1<V*BKS(:.'5V^T;H-MT-
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M86Z@Z&_HT^72UU83I(R0NV/9JC\K9*XTS;-L+Z[PMH=?JT6VV-C=Y]1L_K
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M+FN(B=+_ '7QAM[:^UL3V_\ RSZM2MA1M6BP4OB(:"Y@, F)OK\UL$@KXZ;
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M=/O]^> [9M7>=8BYYQEK'/[:3=2DQ&HCE+VR<;<QK;V7]?BHJJK9WO-27W+
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M2 XD#47L?E'L' +M#B48!#W#>Y]G=[C3CW*V%7FRDC+_ +X+@FUB;^C6_?\
MG4%!G"CD=NW;KQ<'7X>/M6O=M*CD0W/EP&N1SX3Y76Z9L2N&APH%Y-B&B(N+
MD9\O&RO?%5 -+@ZX/"VEO'GZ?<PTU22PD<M>_P!1/SJW%)FNGW-ULS2.''AZ
M]-. TXKFHQ^%VC9+'G8FWT<#Z^*M_P")--V!N[$Z\N'IY\0JO\,KBQHEIX$9
M9>LS/4*>5M:/V5C?MY^CNYJ!;B3 X'?M;O[!:UN/OJJ%Q'&&-))DLTWMYW/7
MA?AK[.WBJ=9CN\\M!:1>P.\/I[%2[: >V) G./+(&,YO-@KK-D5RS?>T6BX
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ML/H53!O.:!J=5(S$Y2OF?SS^B4>E9FVHK'RTDT,D$A+1'4PL;;>-F@,:T6L
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MP8UE/4.+S^"6Q/M?W'HU7W-L)SJG83",)^)VQW-/_P#D0>6LQYKXOVB\8?\
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M\-CM:Q?K*:ER#71PDV:X3NN #IQB!Y>P\524'PRFUBG;U;\G8E?G:>6PU_\
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M!8TL.)P[*IID.9O38MB#G>(&:U'9S^!\Z-V>:H38_1&H@C:UE/1M=/%31,:
MW=$+'",Z 7\P*B1\!YT1!I]KM);LZMXOXZZK=.BQ:^(Q&)K&O6K5*E0_J<YQ
M,^1,>RRZ+&X=H91:*;1$!H %EI<;\!_T1 ;_ &N4O^8^_#3G\Z.^ _Z(CO\
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M*5?%XAHJ!U0-AA,&TW<;S?7*5\\=KNW.W,;5K[-H5:E##8>H*9%(NFI!;:0
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M>RVMS?E\JLG4[%J!\SC'O1L>X^;NN.@X>KB2LO7,:\6< 1WJ%DH*>0W+ #W
M+;87:^(PXW6O< ?, 2+ =>"PJF##CO1)GC$S%SH>>1\0L5Z+8E@\+VOF89[F
MY'G-%N_LN.&G8KUY5RC08%"(:&F; W0NL-3XD\3V=FG:J]CHH&'1H/<=;=FG
M#V**:QK?BM \%&)VMB,0W==4>X<)ALVO%IB%-+"M808 &O'UZRYKB-FXP-[%
MW1%J223)N2LP -  R%@B(B*41$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$
M1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1%X-JJ9Y+63PN<-"
MT2,N/1>Z(O=%(,PX_!E^B-;4,?)&VUPP.<;$VOYH/O[93A.?,OXLP=76-AE/
M&.4;A!_CV1%6JZO.ZUSKV#07$]PU/L"L]F+%\[TF)/JL$9'B&$W!#&217M;Q
M)U_,H2FVIU5.>HQO!IZ>XW7R>>X:Z'XK;<_4BB9%C\K>*N!%GC+DM3)2>7-9
M/$[=<QX+=;VT+K#T*1YJS%C-.(9LN,BKXQK,QLL8-M+6OKZN[O5)R4.S?-#W
M5,4QI:R75SG/DB.\X\+$M%[^CL"]SLTQ"G9UV!8^^)IU8"PR-(Y?&<1P][ZH
M@,#C]8\+YYZA053M#JJJAFH<;P::G9(VTDC'2.W;:7!8.W4#W%#T[,%E<[['
MYAJ*"0EQ9')',0"XZZO(&G"_8JPJJ;:%A+3%/118Q3CB_JX8RYHT_8DW(Y^C
MBJ=GQ'#)068YE62D>#9TD;GZ&^I^]M]/S]MUD1UX=%)G@.0/")SOGU=1%-A&
M;"T?8[$J;&6"Y$9C@:XC7C<%QOK=>SGU\,C8\=RCUPNUCI8Y&MM?3>M&WM-_
M JHLDRY)I<29-AM;-#5R?\DE$Q%['2\FGL^17R,<3P"8XW V(WF-/'4<0527
MDB(^OL?!27%T@CA>X)/&QTX^BM&W9A@.(T\=72";#W3,#MP32D,)%^&\.!/<
MJOROE7[78Y8I*LUK9+;O6-)W "?V9/:JP #18  =@%AZ@N50HC*\^-[\;S'D
MO$4U.'!X@B#QP<(V!P](%U[(B*8C)$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$
M1$1$1$1$1$1$1$1$1$1$16WS7/G+RV*DR] &4\@(?4 QBV@%[$<K]O>J29LV
MS#BLIFQK')1OF[HV@@:GA=KN7<KZVY\T11'._'J>O56RPK9;E_#W"2=DE7*-
M=Z21Y!/:0XD*;8_05F'T ;EJ@@\I/FC[W'IKQ\YO(:W]?:JW1%*L2,AYMQQS
M9L:QEU.TZFGC8&M /*["/>UE+\3P7)^2:AAQ"*?%*Z07;&3.X%P'=O-%SX+(
M92ZIPG#ZR9D]331S2,^*Y[0ZWH(**/OUIY_7563I<S9HQ*+R;*V ?8ZG=HR4
MEK;#]E9S6GU^Q>3LH8H]PQ'-69!!U3A*8 X7%G;V[9CQ?LX=JOZR"&)N[%''
M&+6\QC6Z?Q0%;;$]FU+B^)RUU;6S/AD<#Y,'R!HMRN'6U\.Q$B+"P^7K.=[J
M6U6U+!\.9%0X7'+BD\;1&-UD@!+1NCS@".7,\.U1^6LP9KQC$!/689Y%A>I\
M^1O C2]['CVV538=D_ L&B<:*@CZUK'%I>!(7/ )&K[G4VYJV5>W:-CM=/14
MK?L9AC7EF^T1ZL!-B +'A[/84$97C+4SH.,>QNKKXKFC!<&8Y];61M+6D[K"
M)#H+VLTW7AEG-5!FB*::@WNKA< 7.:YN]<D7&\!V?.J'PO99A\+O*L<JGU\Q
MLY_62/8T6U.A=;ZE4DV/Y3RE3N@AEAAW180Q#?+B.1++Z^Q%-]3[9CPN?W.J
MKQ>8EB+MP2,+_P!B'M+M.X&ZL769[S5C\KJ?+&&21Q..X*IV@ .F]9[1[/6I
M]EC+F)X-4'&\QXSO2N\]\$EFAEQP'G$'CV>**">&G7ER)5VD5K,?VGX;0/-)
MA;'8E6.T8R(.+;][@"/S64=DK%<SXJ^HJ,:I#2TKMTT['%I(%M;FP/K13,==
M<1DKBHJ;QK->"X%$^2MJXVN:"0QI#W$]EFDE>>6,S09FIGU5/"^*)ILTN#AO
MBY%P"!;@BGK7^%5"*%JZVEH8G354S(8V\7/<!Z@3<^A>=!B5'B<7744S9H[V
MWF\$11R+@D 7) ':38+AKFN%VN:X=K2"/6$1=D1$1$1$1$1$1$1$1$1$1$1$
M1._FB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B+@D-%W$ =I( ]91%RBX:YKA=K@X=K2"/6-%#5E;34$#JFJD$4+/
MC// 71%%(H.CQ"CQ")LU)/'-&[@6N:3Z@;J7Y@QIF X?)7R1.E9&1O-:"38F
MU[#734E$FT\/HIXBI3 \Y8'CK&^2U;!,1Y\,GWMS3S'GV4%G7$,PX?1QU. 4
M_E)9K, 1J+Z6O>^G8BB1U]>'AFJX70RQM(:Z1C7'@TO:"? $W5I,!VHTDSF4
M>/028;5CS2Y[7EKG#CYQ:&CUJ*S/@M7F9T.)9>QD1RTX+FQ1'>W[C2XWK<N8
M3KK]T)@CQCUZ^?!74O?4:A4_F',-)EVD\LK XQ#CNM<X\;<&@\%:*ES9G7+!
M$&8,.DJH(S8U#2"2V]KV8#RY*XN$9DP'.4#J7<$CP+2T\C#YI/\ "'C8]R)-
MO'7,:3?+D)U49@V=, QMC'4E:S?=Q9)][(/\:RD>:\:S/AM3%-A%$*RA WI"
MQ[=6@=USQOWJ#Q/99A$[W3X8]^'SF[@YCGD;W\$$#CK]?&DY*;:'E1YZDG%\
M.9P8X,!W?2"[AIWV50 @FUM#;T,_=//+WRX<=,O25/J3:SAKW&CQBEEPV9S3
M&XN9(X;S@6DWW0./>I$_*4E?4OQ3+69KRO=UHA+K\RX-#7/!]GS+K'F_+.,'
MR+->#>03_%,A8X;SCH3O-8.!_P +O4YPG(6$3U=-BV7L5D931NWW0M=(YKP;
M$"V_8>X4&-+==</N/(P?7AIKX\U+:C,&<L'9U&.8*<4HVV:YX+3OM&E]T!QT
MUM:Z@:.FR9G2N;21TD^%XF+[S&=>T-<1?B UNGJX+(/JF%C6/8Q^ZT-.\T.O
M86Y@\5 QX-AL54:V.DB94$W,C&-:>%N0')0H ,"\>'1]HX996AEV>YDP<F3
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MGE9$TFUWN#1[2%V ;#%8?$BC_P#A8WZ K XW78KGW,8P.@;-28;ATS34U N
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M[W9<7]7%=E9G/5;C>7<<H<<@EDDPO?W:B!HT:'68";=^ON5=;"\0AQ2AIZV
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MUL+*J41%  &2D&,9<PW&Y*>6LA#Y*5V]$\$AS3<'B-=;*>L8(V-8WXK&AH\
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$1%__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>nt10006151x2_graphic5.jpg
<TEXT>
begin 644 nt10006151x2_graphic5.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( Q8$,@,!(@ "$0$#$0'_Q  ?   !! ,! 0$!
M   (!08'"0 $"@,""P'_Q !G$  ! @,& P0'!@,$! <+!!,! @,$!1$ !@<2
M(3$(05$3(F%Q"10R@9&A\!4CL<'1X19"\0HD,U(7-&)R)4-S@I*3LQ@U1%-4
M9'2BLK32)C958V5U@Y2CPM,9A+4:=N(G*#>5I,/_Q  < 0 !!0$! 0
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M!:6AWAE(J/9^!%*BG.U7L'ME>(EK^O,4M6P2"I1+&E*FA-LLF$1Q$I F+V0
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M)H_TPWQ_\K'_ %;?ZVS_ $PWQ_\ *Q_U;?ZVA^B_'X_O;*+\?C^]K/[S%?\
M\1-_]9@7T1HG_P!(W?'D.4P?Z8;X_P#E8_ZMO];:[N,E]$D!$6CWM-_#Y]?S
MM$]%^/Q_>W]"*^U6OUYV7[S%?_Q$W_UF%])(J4I5H&&[KA$I?Z9[[_\ E;?_
M %2/UM]?Z9[Z?^5I_P"J;_6T4J21Y<C;X.Q\C9?O,5__ !$W_P!9AS*ED?:D
M:]T4I$KKQGOJ$Z1B:_\ )-_E]?&WPC&>^YK_ 'Q'O;0;1+0]#\#;[0*5KX?G
M9?O,5_\ Q$W_ -9A"5+MLI.=AN\<HE56,]^ ?]<1_P!6CY6\O]-5^:_ZX/\
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MZ^[Z^J4@K%XEQ_7FON4=>-[ZP67AY)#JDRKT9(W9\AT8D-['&_*:Y8Q( _\
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M(,X:EDEBG7&_6'="TT$YBK7E0&TJ+1VB14ZT'OT^O*S5CY+#1JG%1;0<2U[
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MX*M"*&I[(JU_.UB7C)9%"XU!X>%WX<(=MEAZW:.)&3<?TY@XI";VW/FC2D*
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MM<V@JI1[PN:7CU+LK]98["X>3*05?TTI">\?L#!.K6._>('&[(<CH9B&O?)
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MT.K"4K6VE:@ 5D"M4Z>/PM0E$>DGQ-D4SF,HCKO)B_48QZ'9>[9D%:&G5(!
M"#7NI _6VC(V=L;)</X[J</*,E1=1W4BW%B51B5A1;<1EIF[BCK6S_E:HY24
M(<0L(&@J% D>1U^O,VIVEWI3)ZP$_:%S$J.F;[].M>=0CQZ>.XL\H#TIT(7
MJ)N<4UH:^LJT]P1I]>%M!6(2A124JI1\LOGJD1BX=N'06*$%*M"=#YGEX4\[
M>(RJ[J:E2?#?ZY>ZU4:/2J79 4(BZRDD?RA]PD_!'UX[V4Y1Z4?#U]:UQEW7
M&4C>JWM13_<!^N0L":I*R%,:!VRHU#QSISI"?K^/4[K19^MRJBE7\NFWU[[:
M2P2:_'YVK\@_26X,QBAVD$I@GD>W//D<O([ [\K.V&](%@C&( #A;KH>Z_S_
M .;I4_+Y@VPS!"<M=UZ\3SA0:*UFB12E.>_RZ_*WSE!)*M :4/NW^OG86)3Q
ME8,3180W, UGT"BA[\Z#\OA9\P_$5A+$T6W>%DYOY"DBGAJ=_G9_J9?32VM=
MQUI5VZ=WW#S^<XFXI;%"5Z'G2GEIO_3W6\' AH:+S9M-MOKISM%S6-V&$5M/
MF  =M1Y<_?\ #PLIL8MX<Q!^[G\.HC^7II3>N_GXV&HN7V6&3.6H!RSW>,-Y
M1(#C&5",AJI5-Q3^F^U?F-/ );]<AVG 4NYAW:5Z;<O&HU_-O,XC7.C4E+,Y
MAU[9:E**T.M"3T\_A9U2B+A[PQC$7)4P\0W"&KRTOMZZ#=.8GD?'2S6IUUPH
M(4/TP3)0VE6IR@5YIT'+?7;SU\;;K,LA5=U2R*4TH?#0[?OR-D6(G[33X[-
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MV[^/.)5KU_$%5@ZRS!2^)AT5"&Z #6AK7<?O::T);(]J@\O$UM#>&#B4,Q5
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M Q E;\SE4J3"*8I1MQQI!*B:$4<RGE\[/./X<,1[FR5V;3>[Z8A#(JO+$-;
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M>O#<W#^3Q1+;AB#,(=#@2$ !MQ&<="/#\+4,1E][MSEIIV:133#^1(5JFN8
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M4(\PZ4N,H(!;7WB213*:Z=0+5KXL7^N) 8T0<@B)ZRS/XB:0B40ZCKF[5LT
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M8N=AS*Y<VZV 52\MI4%--#4NLM@ZJJ=[?$CQVN\[=6=-R^7M,Q\"SE@X544
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MOU!X!WM6TA2AG1HH?(?EU\^5J<_3+>C^N]Q?\/=XIY+)8P[B%<Z6Q$=*'&F
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MN82JA<<0U"EUHN%*R YDSZ"HT52FEA!Q*Q[O=>^6Q,)-5$JB6V4J<"4YG<@
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M[%M3GW*LV8+ S5((W&G+W<Z<D=ZN/['./OM,+PPU^(\MNS<>KP*5*[/L%11
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M^F2Q08O-QGXOX;3.5P;T-*(Z5*1&J:9[89VTNFJLF?\ E U5Y6_1DC/\%_\
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M?UO3GM91E,(X]$*?>)0TWKF--133>@&O[6TH* <?&:NU-^>VM>GZU\EMQQ2
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M ,QC_P#L%VX9?[-]=YNZ_$G>.4-H #$)!9U"@JI4 M1V\?J@MW-S+_O9,_\
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M4L-75@WJ5RI6A"ZJW![R#SU.N]MF&;NG+8@25J @(6.'^! MH9!3IFW2G0@
M&A%G.TRPE790P[)?M=L:D=:"NG4#X]+"G]O,G'R*@8J41%&R@(F/;NEDT8UH
MV/N^E0#K9XBNW$@02;\.A-77&F&RG8AE!TI0;#EIK:%<1B%R&>K$8U#);E<>
M5K+".\?57<NXH*<Z6FF-F*>R*<H(RFGERW\!X];#QBL[#1%SKT]JH@(E4<44
M.4@^K.GD;7,(3M\W/D.=X#''%?\ F4QB\7K^,NQ*'H%F:/ UR(2Y5YW+4^'T
M.L17BO--X2?P\I@6$!HN)J&R@I2-#4E(IKK\K:&*,TF)Q(OHE@J:87-XH*6"
M0598EW+4[[CK^Z%=U$2Y,51$42\[F1E<5WB!0<S4[&GPMM. !7+\<>MT+KX@
MN;HRB'OQ%2223=A+C*E)#R*#F4GEKUM>WP?7,D%Q8Z72V[L*&6FVDET"HU4W
MF-:]376U+W#] ]I>N =6WVR4*2JGN!-KY>'"'4F<&,0T AQ#0RZ=W*BE!L;9
MV,4EB7K5O'^,]U(7K"9QB\(,VQH0;YW<OL_=J8RUM6=AMI;O;I=3D4GVT@42
M"!OOTL -[?1F03/#3?2^LLBH^\&(,.P7B$JB@I];;BZD(SE'LBH 2;767AOW
M QDRC;B(ESWVFYV00K[P-J%,ZN]3L]O&Q,X;R%N7W5A(5<,RIF(0XF-ECK:%
MH=23K4K201OUWI:&"Q"@H #?E5P*5IZY7A1^?%A_@UB=/[UPEU7KE3E$>)N6
MHE]Z$BFVVT,1?M9UM)04Y$DUJ-.O/K/X?DG#'"V[UUE_ZY!P"1%!'_%+4A)
M(%14&H\^=K*KY878<0\(_'2VY4GA8I:'"N);@X5MP+<!!4%)9"JU)-:[V%B6
MX:-PKT2IN"S0[SA*U%5="LY0 >0VT]PM'%SU3% $&BA2V0RWC+\PH W&2YU[
M8^]4AQ2NW!.S!V$B7/7V6ZA996M+>NFOW>;EL?&SVNC@]<F=XF2K$>97.>=C
M9@87/#.)>4A,0VVAO,04%!^\J=N6F]K,;GX=R],+V(@D=DNA6AQ 6DZ\DJ!
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ME<+=Z5,$ZMPK0I0 G[M/+PY66$/%36HU!YU'P%/PKM;0AFBRQ+Q&'(!#,Y4
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M2$,,M-/.9U#NIJVD[TKY68E@\."W5M\6D_V;/T<YAX![B8Q.D(<6"R_=@1K
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MT/PL8O#Y@9.[_P ;-H.5);9#R6F8V9!3:7 V4E 4&P0LU36N76O2EJ*I)/\
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MMI 4LG**]-:?7.U$V-N,=W\,+NS&^-Y(YJ'899=<:9=< 6IP)50)03G/? U
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M:DQFEWH)MU&5IO+45SC4 G;?^G,"U?3U_L7\/T!J<2.*B9?"H*>V0^7,R0"
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M^0)T'K%LTJB(%^60\2HMHA5M54TV0$URZ4R"GM<@/"S&G$8RVE:FR'&DJ/\
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MW>6[Z1WB9C"C4TU,0V*[^/[$6:T+%1,Z=4XQ00C1-:J"-!6F]#RWUW^#>3/
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M\[DEA S%WG;]:AT(4(Y+*BIM*\N5E1#/=T70TZ[Z:V9=V9!=N/C'YO 1/:%
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M'B^L8AF!DLXF\,] Q;D3"C,BJ\QREP'0'8^%F]=OT*-U95+E_P :X@04+%J
MS -M.J;Z]UMPUT_:VHJ7V<IBJ>I*F22"4OE?<>'F:J.;"!5Z[,X4NYGRY.(-
MU3PK52W(Q*R=*\SM6G+:W9[AW.,8(+A8P?@L+F7%1 E;_K12EL?=96SWLX_R
M5WWUI85;K^BSX3[BNP;DXO>N\L8T\'U0J);%MU<96'$#.@D4*DTVM:!<6]DJ
MNS=F%N5=*1JAY5*H1R&@7' L@-EHHS .)J*@;5^%+9G:9PGT#+D3TJH*DAQ:
MP%;^&4&E]TA0=^7YZRB#+OSB],5<R9LWR"E3$OPG;IRA(0X'P55*.[J=33G:
MSW!A]7\#2D 96PP* FHUIK0_C^M@$CTK_@N<!^'2E]V,86XX*5[T54;4Y=-J
MV/'"%0;N%)B@E04S0G*>[2@3\?RMR8%0-[4Y UY<(M@M7/IQ$>XLO)%[(1*%
M:*S=-:)&OT*GI9HN*254-!W1SW\?G^ED_%"],N_TGPEWG8A*8]6=24$T)HV%
M4I7I3>EM:(B$I4%*%%FH"*[TTK7E\O=N2A(%N$4YJRI1=LO3PC:=HT,Z',H/
MCT^NF]DB(C"L*22#X:?F/K\-=;SY2Z5HR!%#[5=#L=ZC3ZYV1WXA*FU+2HJ4
MK0(&A\>OQUZ:VE H^7WBH*&<%/\ EH-*;:_6OG9(>C4MJ"%G0@A/AU\?QH1\
M/-V+2'>R*J'>M:4IK]<[-&;1S9>.5ZG9Z*!'PWI\OZJ%"C%1K=54U !-"HFH
M]YTH*_ARLU8N:M!E30:#C65?<I50J#I2A._AR\[)[\6XHDH6% ]32O6M?*EG
M?AA(DWCOU*X>)0'(93@[5KV@1IN!7<Z]//DI[(0"EZI<NU]D'SZ,&D)F*-10
M5H*49JGIH*[A3OI-I5=YV$AT/PT*5DIS-K0!]XHZ A-=?+2QXRO$J+<2E3K@
M6Z@'O%(2:$4UT^OC5K7>NQ=J52^%@H22L,MM-([1YM21G*D@FJ0 :U^.^MG:
MW=V[3R*-J2PI=0=]]O+^MN4GS2F8"4[8-2DU)MH>;1=E[.T-O[8>,GQ(:@27
M2ED+<IVG<14TKX?7E:199?Z F[&133)'^SE3KUTI[QTWZF"C<:5N#(S'@$['
MKK2FI^&EE: N'$0>5R%FU$ ZIIJ:Z?YB?#3\+"^JE8;Z #!W4*94#\_6\'44
M@#Z:R[I=N6[5]SM$[?;DO>;]6)2*<@O*=ZZD4.@U^A9ISV^T= PZH&4O%+20
MK,D*!UY:U^?GO9OJNM,"R@HBBIQ5:*K3ZTVLFFYDS#I]:?[$'4JS!6;_ -;X
MVS%*0%N)<LV_MTRN>.=8+**B"ZYA#Y',-\0QXB]$\B(PJB75KJL;N':OZ4Y>
M_E9YR>/5$$I=SI4&RI-"I55!-0?,Z6]5W+EC">TBH^M!6H034C8::ZG3]M+*
M4#,Y-+$@)@R^\@A*7#F3FY5(H!M_6UV5B):4@["=LW8$-7X)UMXQG.A.T%+!
MI<U!SH. @6+S1\RF5\'TQ<(\TU"K(0\H+"5!0('(#;SIKO;;4TGLR?#ZW_'\
MZ6FO$!Y,PA5/0\M9A=$EQY.3,3336@)M"R494Y5+KJ=A^/3W_P!.AP*]M!4=
M S4 <"^;[G/@[9JUJ6Q4U(2'FBEI7.OR^NOX60GDE*CIH!73X_@?H6>$4A&3
M*#Y:=*?#]!9"=:!K_M:4Y?G:X0_(O 9E4MD2']?:&)-WZM.43H-Z;_74CXTL
M$G%S,!!X$W\<1W%.0) 574=U8--.?Z:\K'!.88MY@X"@4.@!IK:O;COC&I9P
M^WP=!RI5"4572NJAS\3L#O:_A5$J;AQRJ?0[VH(%''Q$JSQLR<4:N_:,44'<
MIS1#E=3O7:T@W:A%*=9<S4H4UTWKX?K:-T.B(<C7136-?-=O^/7RYU%.G*TE
M2&*2T$-<^[0U\J_IK;74D;(4.'*C>L*+(^&F#7%QW<-2V$T(\4GX?GYVN3P1
MAEPT(5*'>TJ>M#XCE[[4^\($8U#1SS\8$ED]F,RB*#0@:'4^X6N:PWB6$07;
M0ZZMN:IR@FHKM7PKI;(Q1)8V<'@]'\:=&%$]S.++,@FKY7E4(982=.[5"@:Z
MFM18,.'O+%XOQKOM5B7<ZB*Y@<WY>7G74%!>.8(%TINH[>KJ .NY2H :^-A=
MX5U)>Q-FRE?^"/J*S2M YGH*_#RVM2DJ5+4G9M2]WM[O3-ZP@Y*=,Z>Q\W>&
M/Z86,:EW#XS!)<R)CHZ 0V@::F8,@TVJ23[CO:P/T;ES7(3A5P[JA2$N0*G#
MF1_F*5: [5W\[5@>FIF\,C"ZX$K&BHR<0RB HDY&IE#DU /336UO/!QCSA-<
M;ACPV@)P\W"O0TH82X5)6,SBVFJ#0<U$"VG,4N;)H.8%,M=[/Z08) -(-R"D
MQ<>2PV@Y4BA 2373Y>/RZV>/\$&)E4:MH-IB&4A39<<0TG6M=5J _IUM#$[X
M@9-([FQ5_P" @F6Y*AAQY,2X\E <2@*H0%T.ONM6S&\><ZQDBIG+;E3=$-#P
M;RVHJ&8>;#C:4K*3LI*U: G2V8)"E;3@N_K[CGZQ*G776^+%9Z[#R)QEN:1T
M,T\M:DH9;>;<43FRBN19-/R-J-/34WB#6%UW)2A[+ZWVQ30C4!Q"@:<]#7X6
M)J[<]G=X+[2EZ(F\7&0ZWZK2XIW*% @*'>50]ZORM75Z;2\#33-P9+F)4&XC
M/WB*]UI6WAO^]K,C#*VZ/O/!CO@*@'/66N<5&</,$J+OM)B>^M"P:TY4'AY_
M6ENH'T?4M2YB-&/E.9#++&4\D'U<_GOKY:VYEN%UQ*KWPSS0S!I-<M#R037Z
MVMT_^CI>$9-YU%HU6D,!1R^P E2?GYBFNEMPI.SLB^R ,WH/'1L\Q I4^4B8
MGZ[_ '/2C $-T><7#AQ698!S%!.I%*ZT^0MI*<<*P0/>#TUU_+RVM]H';9@R
MM)(K7,I* ?(J*0?+KRI;06XM"E(4K*M/\H-0?$*U%L3%29\DF801D[9'TZY:
M:YLJ;26^RIB*]X-6X;A2E]7C?,20=0:#\NIY[6_JX]+:24$)<(U5OOI^OYV0
MEO$U4HZ[$5TI[NOOJ;:SSR=**-?G\_=3RME3%+<';4Y?3=J(0=( "B&S>M&O
M;+.-]3K#Z5L/M-/M.'OMN-H74<]5@TW\OC0-&<W!P[G;F68W7@G$JH"0VVFI
MTUT1IKXZV4RI6;,#0U_/KX?,[V](A_*$ELU4E2:Z=:?I^FNEF2R@Y )L[#=#
M[2R/O4=[\/<16)Z1NZV'^'F#B8V[4H9E,SB%)"'6CE6@A](KW0DZ@_K88N#+
M%V8W:AY;"S:8/1D#'4;2TZM:DIS]W91/-0_K:6O2U3QY-R;KRM/^'&/T6@*W
MRO-G6GP\/?81<!81(BKI0?9=U]R%I0BH&9LG:AY_"VQ@V"0R0[!R!4U%#X0!
M1.T:GWRX>E:&+>)O?F;877BA;W7?C3ZO&J:>=ADG(%H(34:D;)416GPL7$LQ
MZN;B#(6(T1S,//NR0'X5Q8*BN@!H5$:U!.EH9OE@9 WTD$G7#/F$BH>!94",
MRPHJ90?9K3Y'6P27WPHOG<&8-1TG?BG'V'%*!05)00@\Q7+2@^=IG$+4M)H&
M(H!2"I=4N8230#=F/XYQ9%/(X1LK6MEPJ2.^ FM=#F&N].>UE;#J_L!-657>
MFL8EMUI03#+=-%(4DD@))UWISIISL"^&?$3#P#B)%?Z'7#$?=*?6%*232E31
M.7I4U]]G7>V>W:,<S/;LS5L:]LE#;V4J.BJ$9P?CXCK:^CO2PHW-.NOQ7;>3
MQ\[,^Y^,6IW9OA%2Z(1!1L8%,IH(=P_SIY:UUT/4VE;[=#J<SD0V&U@$#,G2
MHKO7]J_"U7^&^-UWKRPK4JGLP1 S:& 2RM:_:R\RJH3R&M;2_$W_ ':!F%F;
M<0R@42M#R304T- JO+F=+/"(?KKK>T&O$.RM]K,J(:2L:YLX\^O+E:.Y[>&!
MA5*0W%MK!T(SIII3\?C\["6N^\P<<*/M%020?YS0?^MU'OM%MX[TS9$2HIF"
MUI*JCO\ CM[6OZ#QLH0:VE/3\07LUO++V$*=*T9AJ.^-^?/Z&_2T<3&]RHY9
M"'1D37NA5:Z4_8];#\Q-8Z9,A3D:H*II4GWUUZ[#?IXZ+<S>ESZ@X\5<]:Z]
M>=/H4LH7I_!'7")CB(]<4[1(()Y_CKK3\;*DO@UK4@K<I0UU(ZU^O.T60M\9
M>VW]\K[SW[TY'3\;(D=B(["J6I#S;3(!HI3J1I3H34<O=9===><+,C1OGF?F
M":<F,J@V@EYQ < U)4-?W^JV8<ZOE*H4D9TK K[*_#H#RIU/A8*KX8]2B7+<
M;C9P&\M22DE6VH IXCQ^=AEO%Q'3B<S!$LN1 Q<V>=7V?:)0ZE(J:5[R:<ZC
ME\:64+CUT>JQ8G>/$F!A4.K:CFH="4FN9Q(H*&H%2"=*^^PJ7GQFF,^F9NU=
M<1+\*XX$14<CM*"IKW:C6IJ-#\M+1LUA3BI?Z&8B9T_%RYM]2'5,I"C1%4J*
M3E*3J-+%UA]<:[5U)7!P\;+@J80Z0'7U-J*W5:=XDI)Y==3Y64+ESZK"SAD)
MU 0[,(VTX>U2E7;&J25*U.N^BCSM-T5$.2Q-8D>L39V@9:3WB*Z;)!!H-=;;
M$E^S5P';PZ4,H":(JD(*>6E:$TTT'QLW+P7PNM<UAR9Q44)M/E)4(2'2"<JZ
M94C3,.8W'NLHD%$6\#[CAK^858MZ4W*EKE\;SQ3(?4DK1#.%/:#H FN8T!'*
MMAZC\;9M?*8.P]W)5$/PI64,N .)34&@IF30ZCF;>T/<B]V,4:U.[U//P,I2
MZ7&H DAM;>;NBB2D4H =1Y^,^PEVY1=&7)@Y=+8>'[)O_6<B"=$U)U3SI7KS
MLH('+:,*FKFAW= Q%4MF%]9=!EZ>1WV>EP9D0]$$D<@2G;IJ#[K.ZX"VYA?*
M[D>_$)[1R:06A4"32):%=]*_O4TM$%_;S+CHOU9!4X&RI.9)H!R]D'7IMY6]
ML+$31R_%V2%N>K?:T#0U-/\ 66JT\-!2SIN.(]8LR"-LT?NJY%K\A6.N.3?]
MZ)5_]K8'_P!U:LI62Y)_WFE'_P!JX#_W1JRI;7C)C+9;+990HRV6RV64*,LD
MQ[B8<*=/LY5%2NFAI7]?#KLK6:U[(UF E$8ZX:'LB=Z=37ZZ^%JN+5LRWVMF
M]7;2"2G,Q(9W(=M'KX7BMWB_Q!<E<KB8>&B:N.)<2@#NFFQK[C:BV^$>(N+?
M?6K.[$.*4K>M2HZ?,[;;VL)XO+Y+F,]?A&G>XVIT)0#O4:Z&FN@Y6K@BW67E
M+4XV2K,:*-10YC\_?;GT*VIH[SEQFYRK3Q_,;DPH,NX*@EDM=Z4I#:2PH.90
MFH'2G,?7ZUMO=BLH2DBB1L/U-1M940RG.-@--/P_;Y>&X&$&@)U\/VMIN:5-
MJ7M&>QS/6O.$5F'5[.3;;ZW\/ZV]%PV0Y2@ GG]:?76RTF'->[J!];?OYV_J
MH114%4V\/KZ^-FB) 8T%C#:#>59)2#2M!0:Z>7P^=*669=#L-0[SRQ5UPIJW
M0]:;Z_6MO14&<]2G4;4_33R-E6$AB-TTV\MM^FWGYG2SDDT<M^![BD!B'L>,
M-H;$S#&\]U5PZ7D1\N>4VE20<JVFEN#+4#F.5+<5N*-S9GAU?Z\=U9DE;)E,
MP?\ 5T+JE20IU:DY0==-.6U#;O0;;:R%M:<ZWDEI":4!2L%"J^%#I^=N=[TB
M/ -?V_.-\%>##.1N19O$^#'%@ (9&5(*E:9= HG][3EW.K?S UBW6D5#2!$%
M?RZ<%!.J_P"&)8X.T?!)6$%RHV-=$#K6GA9?O+'1\N]6DD%'=E!PS:4JB\@%
M3E!(%=S4$'7X<[TN'[T3,DN5=2,C+\QGK=ZYG+78AN%2A7]W?1#J6E![-102
M5$#EX6IKQRD\KN'B%.L-+U2]V C)/'.MMQ2DN#MF7'%*; H %=RE-2;79&(4
MA02=HCF<A3?NS@9?GOZSALX<W@B8Z(B)/$3!U,%!T=7%%*@@Y07"G/6AJ01O
M^%I#O/?9AF1.WBELO:FL%#_=1;54DI"5=EF*J$]X@D_1LRH&$A&99$P< &H*
M3NM@*BEJ2EQS,FE<RJ.;D\]C;>PSNC%NN1<A:6[.)3-UA+<+#MJB2X<RC3[L
M+4D9B23:?:#"6A82Q4"7L3]O"F\&*ZU $N12_A&Q=V\=W8R315ZGI8W*64I[
MRZ YBJJ% :#:I!I\K:]V;L8?7\C'(V6Q3C4T:+A4R4/!$0I=<OWAHB@W_86?
M]_<-X2[\G8NY-X=R2R^6A3\= %M9>B \>V:!2 '4TTTISM#MWKT5G$%)+J2M
M4GED,I1>CE E40AHYC7.$J34 CP!-J:<0I<DH+L -FEK>5-!%"63MI84VJOE
M:H\VZ$2_$7 BDR3^'5I:0W'%=4!3:%*#2LZ0I0.89O'D;0Q-[I7U@8AN[DHD
MK<#!NNH^]9=;B%O(2L*6K,FJDU%32OQLYKT8A,SN\3\' 1BY=V3:6FW$%3N9
MU+659W[I4L5WYT%;?6'<WO9+HR9S&8Q"GX.5(6MN)=2E>;M$K*>ZJIK^/C81
M)H7/@V0SSZR:+](;%_;SS601,DNZU"Q'80".SB\K"R%J?2,U5!%10UUJ=[?V
MXUW9BJ]WKDO6\W!Q39=B67%KW2UF "5*YGD!6MG]=*]%],19W1JZS4YE[D0I
M#\5$)9@D-MMJH%]HZ@5RI!/M:TL>&#EQ,$V+ZRA%]7F778IUE,0EI2PQ!O#(
ME+1=946EYEG(=:;^5G1,*%I5?-ZN&:CMT;5@,P;0"0 1F!4/2A;R/EJ*^&N$
M./F.][DR##^[<9!R. B$"(F[L/D:+94"L@OH2E8[IT!/OM>1@OP*W6NC)8F9
MX@%%XKR14#V78!LPB82)[ H30-]US[P@^[E8R\-Y-%2^.E5U;AW5@9%<Z&9:
M=C)NRW#%<:TMM+J#VF1+E=P:*)UUVM-UY8>%,?"O0\/ZO"-42HYJ]LX  HD>
M"P3M372UG$XQ4V7LJ[_= 8]ZS97Y-RA8:0F6LE* @"Q (JP\8Y@^(20P.&]^
M7KA7_DSYDGKBEP<8%NLH+*G.V0D+;]K*DA.JNE;/R'F]RX2X7J%V(*%DLBF$
M-EB9HI2"\M*$T))71U7.AJ=#I36UGW'5PXP&,-Q(R<P< V9Y(&TQ#3[2$]N^
MFN=0 2,YHA-*4KM[Z?KH<*V,./;DGNK=J'CY!=:6/.L36.=;6TEM"',JB$.]
MFI>8H4.Z=*Z<K4A4#*@IHP ;E&=VC@9DV9M2PKO* =+_ .VI9@&UXQ T/A%+
MY_.)Q,+I3Y$V[)U"F8!ECM51"G%'.F@*B.\3N*<]A9_3ZXMYWI)+;HM22)E\
MW@$NK<@W'5L&(2K[RN5>1)[M32FQTM>)P[<".%.!D) 1+,(J?7N4A+D3-(AQ
M[LDO-T4HF'=*FE:UV%-C4Z6;O&9@!,+TW?C,0KBE,!?"3LE6>%ADA*DH3E(+
M2 &S]VBFHUW%A3@HRE!+O1@/^0C3P<@R9(1-_J* J5U(L7<Z$?F\4U8.868@
M3>\3"U2L2>22]Y*X]]Y;>5?9*"@._ES@E)%17>MDOBAG,Y_TAER&$1+X: 9:
M:AXV$2XVTX6X=*5D%D)3RUU)K:;\%+\7IO W/Y+?:(<;A;MJ(F;J&/5^TRJ*
M@%+:2D[H(WU)/C;6GN),@Q&O S=:68?JG4C@EN,>OJ6ME-:%*EJB%(J0E2<U
M"OY6%AT+"E$[3;.8(T.>;'*T8:_K#&M+$S9*N\$[3-0AV^?D,#@]Q*CG+PS]
M%[(]<7*9=#K,,Y%.D9G"RX44;<5FJ' /SZ6D!K'W$273MZ>P!@GI8Q%Q#3++
ML)!J2VQVBFQWG$&I4BFO+E6T88H8?23#* 5>B14:5&N,^M0L*^5M0Z%+2E:5
M.MJ*%$)41Y^-G=<J388XAP$/)H:^C<K?RH<C6.R4L]JH!>7,5#^:H-.MK>O1
MY]?G9Q(,N4%(!2HH!)2X)-+D</+2#+A+U8@)PKF.*<KG*Y; S$P_K4L8;3D=
M0ET-O!K(0$U&8G(G2MJQ^*:]&&4SBX6\</(WVYP\FD;'O1$0X7H@I2@_=KS
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M) 405.#4@G??EXQ)"4DU2+:#=#IX>FX"X%X[OLR]EN$AH6(0E+3*4MAM.9-
MK*$U%*#8_.W71P]3UJ\F'<HBD+[4&&:S4/LT2FGS'URY![N4@IY"Q(TH\VI5
M*TT(VY:^5?.W3_P*WI$VP^8@@K_!8;&]>GP_#K:M()$\!RQ\WN-&RBPHO)4-
M[BNFS3\^1BJ'^TI8)?Q]PK05]8."#\3<]+B_6$(&=M+[Z :FE=0GQYV_.LO/
M *BY>6UI_P (K17Q0<I'7=/.WZR7I4[@-8B<%V+,G,.'W(>3E]M&3,26DN.Z
M:'491MXZ#E^4]>:7Q<+%3N!>:RF%FTT8(-!E#<8\A/3D.?QUMTY23)2 "4A-
M:%A;S]3NC&61M&HRSW"!L5 &'#AI4).A \_KW[<[);YR)53EUWVULZ9O$.P;
MCC(;JDDU5I0>_6O+ZTLS(EPK5W]*UUKU._Y<C;!FI#V KXL?R1SY0@"2FA9]
M]0Q_F"'X7ICZOB7!*.NJARW+9 /Q/OM>+P^H];OO&JB$YU+[+(".63R'+PIS
M\;4%8!QYE^(TI#)S*?>*:?+GX'ZY]$/#O+^QGZ)C$-Y"\VRH$\SV8^&_S\+&
ME) &U1R15JU;AP\\V@X R'@/B+\_0XW*:E_%/>R>(:""ZW#[) K_ '1::U\/
M"MNKR.HF!CB3E3ZK%J*O\H[)53[M3;F>]$8ZRO'*\ 2BBRA@YJ4)'JZ_#2GS
M]]NE2?&DEG1&A$FFA!'+^[/6VI/^FG@/00Y!%%!BPIQCCOXO\:<)+FX[8C0U
M[L8H.6I:BT]O+$D!UFF<Y"6W@L'<5(]UJO;]^D%X,;JQ42?X@B;S1L-F("8F
M8(0ZM->86I VVVM1-Z5B<3>)]()Q%P[LVF2H=J=L)2R(Z)2VD$N:)0' D5%=
MA:NK( % ]JX"E147'EK4=#_,HD[Z^?/I0FX=*P=HA[,]6I;UANNN58[3.%#B
MQP]XG7YV[<:[:(.!DY;2A]U:G\P75/\ QR-*Y>OETL7,\O+([JL)B9[$PTNA
M5!2:!MNJJU3ND TKTZ\[4@>A,0E=S[W-I0E )AM0D!1[Z]R!R^M[7*XB8;26
M_<O]2G3SB68;,:H4X"23FIW"#N-_HX.*3L*V ]+:FQ?^(-)(*AM$-3[C2QX>
MT)4[O%)9O=",B+OQ:8R'?B(<E0&E.W'7Q_*Q\X0K=%Q),C* EUI*JZ4 3E)I
MUT%JU82YD-=&Y\<U+0M<KAWX5",RE*)J\!_,:U!_6UD.$:^UN%)<P4$AM(2*
M$4!(K\OUZT&D;1;Q.G'2+8N(J6XZ<5X+"#B2NW>N(>RRI7:B(&8H (82BH37
MO=XDF@]UHQC?2+860<4A41&)>0>R25J[1L-%=$Z5'>U.X/OL.7IO;\R:[V*E
MU9<MDN*R112TEQ2#G#*% DIWJ==>NUN=:]F($_G:T"%<=2U$/MH:@&DE;BDA
M831*D=[;F!RMKR,.G8VF2K4T(#,16K99\7BC-!2LI4X-P"&I2H&EH[1+G<15
MQK\04+%2.:LQ9F*04,)50)VTS$\JTL^HV]3,&0MUA;2B.XZ*N).<> (YVJFX
M2\+E/\,L@O7*)7%P%]&H.(>2(AYXN/N!1+9[-Z@32@(%.>UF1@YQK8BRG'%[
M!O&9@P\,Y%&&E[L0VV*IH<N4A()W3N?#2MB_MY:TFB UC3<*>4#S_&N_KXN6
MNM!Q-^IU"W;D;1B9D^EUYY^N0H2TA3OLF@-$ Z69]^YO<>YT2_!WBO"XW-H5
M9;B(<P;J<BDDBA4*!0-#KTL[<.KY0-P;UP%[(5@.I;4RI;M:9V(I*4J&7<?=
MJ(Y_"QY3/#GA(QS(F\Z@(1N=1S+2XMHQ#B"7BVFJMTC4DFGC;,F*$E124@@,
M74!N+/GGG&AA4H(&VE)J;L^N? 5W13Y&8OX<AU#")DM.8Z+2TZ20/ ;Z<][$
M+PXXA8>Q%^6504^=];<<0TTPJ">5F6X,@ 4I.FI'/H3XF),>";A(E*&9C&*E
ML*P%%0[68$:9M/:<KIT_K:4;@8%\-5V(EN=W*NW#SJ,A"EQN90S[BD(4WLHI
M3F0=0=:\K&=,Q(.RE09VR:A:_MRB_-F2DH9*9:6%"D $T K?A:KQ-S+$1+&H
M.&=JMYQM+I!TS(<2%H)'+ND:=>5OX^8]Q9#3:DDZ@@Z#:OQK9*C9^[-YN]&M
M_P!W:92VTRT!49&T]F!6AI0"GC94$\2PWWU)"MSI7WG]+9:\%+7,3,"4@I!&
MR &UM<ZT#"L4%SPI)&SLD[)?2MA;A_,>+<5-H=2>T2X$BE3F/3P^M^HL[97.
M70M)6I= 4YJK(!]Q/O\ /:S+<O=!I2$**5BOM:#GK\-OHV3IE>>&;92M@A).
MNG/7Y6HS\(Q(;NC+(5&0=J4\<HA+G)05/WG:EZ@AF@G(&<PT4EA)7D%.1)Y:
M_GU\-:6])B]!I?0.W6X@] L4KXZ?*T+W2GJXV&0YNM(VKK4;:?7.WM-KT3H1
M#B&X-:DC1*DIKR/1-:\]Z=;8F,_9X1)F3&  8U#4;XSOZ6I<PJ#I)&[PKX]4
MI),PC(=ME24Y2#[-5@&OO/C_ %LTS-0I9A'%(;50K33*:A(K6HZ#ZK:+HR/G
M44H%Q,0@$FG<5\-J:'\.NV_+V8A;BC$I>2Z&G"API50403KS'D=1^.?@^T^R
ML6H2TKEI5<#:2Y--_6300A:ON"C;([FH7W>.^/J?7M@8]43*&7,T2SE2XD5U
MWIX';G\N2!!0 <3F[)5!S[W/G^8^C9B7,?A9A?:?0D7G4\TX@(7E40=%::::
M :Z^ZEI]3"M2]GM'G6$PP%55<1F*1R":A7NI7E;LL*$A#H V6N &L,P_"\4%
M(4#5)37,,+@#(=5AC.2H.:ALDCQI\OK:R5$2LI_XI0).AH=#R\Z:?M9YOWGD
M*5]G!-NQ+U:9$M.9<PZ+IEH3\O"R1%/7QF#@$ND:FV_^+6I210$^U10UIO3>
MUDN!3=U8P-:5,P!-K/\ %>M(8\TE*FX=UR(2A9R]TK4ENFG0D;:;\[5!^E!7
M'0O#]/V8-2G^W;REF&3G6 'NB*J-1U'ZVN<F>'-Y9PTI,[F2X="Z'LT-#4:=
MVJ"#IM706B'$WAVNE>*[*I?.Y;]JL/!0>[;,H*H=.XK,!]':MC8:9]-6TIB2
MUQ06W,_5X!K[]=6W1^>I H<AG'8>+AXEHJ><*^U9=;%2X2/:2*[GE:2)$4YU
M54"@9<IS:]=!6OA_2W6Y?7T7N!]_X.):;NTQ*8IS-2.1F3D*MCE 36EJW>('
MT0\PPONO-+[7,O,B.ELH2I]V'[-"2$5)RDJ63H!38&VL,6@I#@-H_#@+9\(4
M5H7"Q#G%THN :EKRBP^\VE38[I5WDC_>%?UMT#<.MXHN:7%E\=$L95J9025*
M!/>I4]3]4MSG2*6H<O#"PU:Q,'&AEWH%M.AM1'(ZI.WX:VZ$L B8:X<A:+N7
M.P.T %,U F@T\;4<2=JN1 (X4M=WUUW0H)B]<01<Z8+!KVC"ZC32B3\?KRM!
MW"$R7+V7PCJ5#<0R"=#H5*'R^/QM*U[G0W<.:NI5[,,NAK6G=-*5YZ^^T1<&
M#KCB[UOY\Y5%H[10&_WRP/$TY6JH%78&]=+>]N9AP6(,!]Z8V.$2<,90%=JA
M<U04I.A_UQA1T-?KPL1L$RW!X*W'A4,D%$! J"$N*05$(85R.VVGF-;!WZ6"
M/3-L8,'KOH57)-%%UH&N;[YA8J-?/PYZ"QD7M?A9'<:Y"5IRMM2^!S(J0/\
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MJDD;^7+?I3?K?T])P&(0I,T;:S0%3%ETU<BH=W\ZQD=HT(-BU#F]&KY:Q>M
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M5U;!J 5-IWIMKRW_ !M(G"U+DQF(-U$EJB8:A6BH_P B3S]VEMR7(4E 75-
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M@MOK3JD: H1Q'KXQRN>FVPUOC?GB*NV)#+776$>LCM4U*!6'17<$<J?M:LO
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MBB!,;LJ<" M+H#J2O0$I2![*1UYVL$P'P8ET=*ER*)E9DTDE092VDA5'P-2
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M_<K520*$D:[[Z'ZY6U'EJ*@A*?NTZ CZKN+9\Z?,6Q?99V;E=SYY6SB4;(B
M",NE.6A\S_06_BU%3@-*;GY?7]+:!)30Y3N/UMM(6%E-!2E1\K"22H.:G4Y]
M6Y0H<,* $ ZU)%/B/R]UG7#@Z'P'X<O>;-&%6 !7D10';I\_VZ6=D(ZE:0*B
MN@Y_1-I;2:N0]N;C\UA1O))*A4UW_"V/U[,TW_8VP:&NX',6^'W4)30D?'P^
MO?2T$J)4 6'5]\*&O&#OJH.?EII9)SA"5&E?KZ]U>EE*,=JI1&B17WZ5^'P-
MD)R(64J3EJ#^M?.TX*@O30=>_0CS6Z%!%$U&;73_ &A^%?=OX6MU]&Y%E%\0
M*T R4&NE4&H \?Z5M4DVM"F0,@J%"IYZ'W#86ME]''#YKX @T%6R1UJD_GY'
M>SRP\Y'+UIYQ.+^9TV(B[TX:(!#LECTTZYH-P4^=-[?E;>DZNRB2<96, [/+
MVTW*@@:"I4X=!MS^?B+?JGS*C4GF(.R95&D]-(19-?=O;\M[TK4>(SC5Q62U
MERMS2M!0YJ!==;=,K_20-$@>#17Z\A_,5"7K:3E6I32A0*W)UT\_KEN+-:XV
M%LROG,X6(9S-2SU@%]:D]T)"Q356]:4^=B>NMA)>?%^<P<ND$*ZIEUY*8EQ+
M>9+:$J&:I(IJ*UM9E*^%.ZMUKDLR2&(1>!IIKUMQ"%9NT711V- :U!Z6YZ>L
MI6&J"K-ZBG"_CI%B5AU3.=M^?IIJ*P(*\+(642&!AX M%IM@#.A(JI649LQ&
MN_6TF8$W[G^$<]92.U5+(IY(="5$("01_*-.?+]K$$G &>0,C2AMQR*9"5$*
M4#5(WT)5Y"GY6@">2B8W?BQ 1T(0VE9"7R!5&H(.WD-_P-AJF$@@ !\Q=V&I
M\B<VTB\B3-E))^FD!KUS ?3(DU;RCK*]"Q?F7WOQMG,7"O))>8AR4!0)S&%6
M3IN-?=OX6ZFI]K)9T/\ [#S0?&&=MQ)_V=^:1SG$[>Z <BE/0K;<-V2":A-8
M-9-*GP]UNVJ>**9+.U;E,IFI'_-AG2/PMN]EI;"I.T2ZC?@GT:,V:3MG:#'0
M6ZW1^/9Z5B"BX3C_ .(EUQEQ#+LZAREPI)!U=-02+5XMZ55F[N5516M=#KY>
M%K>?2(WPNG?/CZXB+FWH99A8Q$Z89@(I7=JM9< J0 #K0"I_2U9V)V%TUPSB
M4KBT+B9='A3D%%-@J:"",XJI-0-% :D69;[2AJ::%V\]Y.X5@<7[^AI32XMZ
MR@4),-3_ *Q?US-KM5AYQL--$)5V;Q5MK1)I4[6I$]#!$I-Q;SI7W.T]7R$Z
MA7WB_KWVNHFLZE-WEIB;P1K<NA5I=#3BU#ODIH!2H-:D?'X<YV@&F3/^0\@
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M @;6#!=V3==>F:C#8FP#* S*Y=VRE)"5)R%L:)IH2FFOAY=;)[M[IT[G<5+
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M^8M:"I2="5-9R?:KO[K,R!O0_C#B&XW-FW)C+(1:781YUQ2D!13G.5*JYCF
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M1E%,Q>4D.;BM"2==[22\Q'3=\NQ;E<VS*$AMIE(T2E*$T1H--$T/QHLL2U"
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M\ZV_*:XKKQ.7AQ_Q/G+*<RUWDBD9C34^NO(W.A]Q^'/KY,M*I2=H;5&J\12
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M0-Y(]R,9AY=#H["$9;2U1%-1E"36@%=B;7]E.G-S\YPHBL2Z&O3>"*F3A2B
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M["H+QZ\-=P(B(6[>N<@]@W]XA#B=*:[*._X\]-+3G>:>,&9E<&E*FFE9 D*
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M765_FNY)#\99"FSCM;%AP'I"C+9;+99X49;+9;+*%&'72U37'Q=QR+AHR-:
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MP<<A0_V5,K!'P)M^=I_98HQ41QE7Z2I0-&H.@K4_ZB[XUW/E;]$^+_U*-_\
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MI$+%1[+@)6AY"34A("T\QOI6Q#7.])#@9)KL,S^]<RC)G$NMAYU;D7'95N*
M)[N8IU4K:W)=QEO.O\8%](ES/Z@8U@E]04$ H;([JCIJH4T-I7:GHC<+8W/F
M2S#MM)AR2<RR54)377?YVMR<.O:>EJ>5:B!J41S-/+ISX-6+^,:/2#8>XD!N
M:79NJE$ <R43/UE=  <H6I"DBM-R"=:4-A4G<Z=Q=@HM^67H+;D4C^[MLCLN
MQ4!0H.12<U3IKK6U=MRIW+H;"F7,SZ8"7,NE\YEI)6I(=-*C0ITYFT?1G$E
M8?/J@+EQ:H]YJH"PM24YE:@]ZHY_*QQ("3W@YR9]VE[=&!$DWKE!+SRZTZNK
M%14OO,VY$YU'L8]Q[ME+KJ*(!4H<O=J3:*;US]=T9?ZS$0RDL%0"'36B\R@
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M6]A!234D5WV?=[7BN9RGH*:T^'AS!Y1T _#]+?+CJ@*'GMJ/R%D%$3WO\<_
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MEJ,^]_:(B<E-2*<OKE\^OA2VTQ*T =X$[ "FQ\?K7\9%7(R$J(3J.OQZ?/\
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MC*4K 5J--O"EK?X>:0#LA+<JE,-+89R%>04NM-12EI#:D@GM4E6VOOM4")_
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M*@E1S$GZ%K>%'WN*4R\(!,#;+FK:Y4;R:OI#1ED?"KB50\T<$.02$.*3H*_
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M8>Y*\ \@>(^J^?.GZVFN1/Y'8=>YTV.U*?7[6*-DI!VAX:^<1@O[F122EH/
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M<O6&E%B>&I'F/2-AMU*E@"M?*RRP*I3X"OX60442I*J#0V6V7DYA3;3F??\
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MZ-=1#PD#".Q44XMP(0TW#M*=!J2 .Z@^-/GHR"1PEVY1"2V!AT(9@V6VVVT
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MH'(<QTI]>5D_U)*!G"SE&QK\/KIX6R5J$H=X:V8;Z?S'0"5L@ ,P#"-,.31
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M/VG"'8JWR_TLQ -#4.#X0H_5#N2*7,NB.EV) /A*H2SGLV+D@BYET0=2+L2
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MH0=4UT-NI@J0\I(]7_E6VI2M4OH<3E6"#_LDC6N]J:\8>!R73SC1NMB(VVB
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M&9W#._9BH]D+SQS=70,_M>W0U 5TZ>5OJ]4QE.($TA8"43'[)@T !J "2M#
M2D9LZB0!6E1FIX6C^.6()[["E928]*@E;X9#A<"M]*$#*#OULGS-#%W(9V%@
M&E1<_CL@F$0E:D%DJ]CLQJ-0KO9"-=[2ZZZ\H<!R ;;K]:[HD>92R5W;EQE\
M@CD1TYC$4B(M/=+91M2I(VTT/*S(DF'T_FSSLPF1;>:AR77<SC:G':=X:9BL
M:I]]F6ZY]@,*;7'N*FCM%J;.9PL%P@@5JK-FKK3:VU"7JFDB;<4B,6J.BPD(
M9*B0FHIJ*TU!YU_&R@FP-_E\1,V$#LSC\7I$ZJ7JAY/*8@A:![+H&45J!KJ-
M=_#I:\638C89.J;:F\)V#[+#22@MN$9@V![01EUI4_(VJ>X+X7^+,16I=>AU
MIL9L[*,J2I RYU$E KK38^-K?;SW9N3!(9A(*1F8K0@AR+;#B%'04[H%3_6G
M*Q)>8ZZI#@-;SZRNV_*)RPWC+G3>!F$YE\$RW#PK2BV\E5%JS(4!1 HKD#UK
M:")O,FXN=3&)"7%,!U0:*LQ!%2DC74[_ %M93N8PB[DKCHYEIZ72UQ2 6'.T
MH054/MTKOY?G,EWY/<.\4N*/6&41KHJ!SSDU',<SKM3R.I(<.W1ZZO BN%Z
MG3D2P"W#.T- 2!MKM3\O"RLQ#2.=1(9CG2E5-RI6Y&N@/+I:;[W801S#;L1!
M(]8:2"IM:*:BFE .@VV^%AZB[OS"61JEO0[K2VCO16I^6U*6KGIX>%.)PVDL
M,MV.AW*K]IESME)H0*[5WK3SIYV0&;\3>Y;H1,(O[1ECF9#L*Y161 T !45$
MZ>5O[$3>(<(8=4NB= G,1N!O3Z\+,B>0*8A2EQ*,Z#JE.;-Y?.RA1K3^\5V+
MT3',V5P$&Z25- N$*41R I_-^MF-B^] W-PSB(AN+;@H.-;+:02 J("U9#J2
M%<]J_*VW#29,=,&TZ-Y%T; % *_"OG89>-J:IA+KRBZL5'ER,63ZJTVLIR%*
MTK%0@ZUT]JGEK90H@S#NX@1>9$ZD[RF/6'BZL$%2'\ZBHZJTUJ>N_3:Q:[]P
M5S2 AXQEKU=]M%7X< *[?0:C09>M!8%, 9V]#0D! 7K@G%,-EM+,8BJL@)&4
MJR"ITI6O36UE<'"WSELN@;P752F\$O4@%4.WV:%LMTHH*1WEJTTVWWLH41XJ
M[* \X&F>Q6"0I*M,I (Y@;_+WV8DYDDQAX@*1VCW>%2V",NH_P O3ZY6(2<3
MJ71T&(Q^!?ETQ(_O,*67-5B@-#E W!VLTEWE@H1LNM2K,""%.+*C30BN50TW
MKX64*&'!SIF4PD0N.?7DAX1]2VUJ5N&E$5J?TM0?CI,V+[XI7@BD@K08I02N
MI5HV5  $ZBM*6N7Q8CU_9,Q?A'2T(MM:54013."*>ZM.0M4W-\*9W&SJ:_9#
M@B(F+=SH?*4]PDE1%236M2DZ^5E"@:'Y,Y&Q(RLK9:;IVA2X1D"-CH1O3D/'
M0VE[A_B%0^/^%268R)#7\82%'^*X4FDTA 0>]0]-;;4RPPOM(T1D9,8 N0Z0
MD.%#B"5@C*#E1J*;Z#SMM8#R.:PN.N%RU0;R(55\I$6ZM+.3_A:$*N]EUUY_
M04*/U];B?_,>YO\ ^ZEW?_U1!V==FI<32X]S0=Q=2[N__P!J(.SKL<6'#J]8
M49;+9;+/"C+9;+990HU(Q)4P^!SAHA/O+:K?E)^G3NC/;L^DJQ]FD6@NRR?1
M4G,(M/\ Q?8PM"-#I4TK6G,];?JVQ9(8>TVAWS[^S5I;\T?TT-P+Q8C<<./I
MAF"ZW)'):ME! J0N%)64DT.E*Z'W&VKV5AAB9D\'_P"G(*QQVDBW.,[M'&2\
M'+EKF)*DKF!% ^R6=XJTX'N)R^G"]C1=2_5VY@]!,LS"'^T&T/%#;D.5H0L*
M[V71LJW&GX_IU\(/%/=;B1P9NQB'=^/AXQ,3 0PF\.V^E;K,0$(:45 $K!+N
M96P!UKUM^1_,'8V1Q#TM>/8JAWBA3V<%04EP@B@-4T(IO7IM;H,]"MZ3J,X=
M,2(#"V^DU<<N)>.)AX-7K400Q"+40EL@K41WG7!L12G*V5B%+$U<DA6PX#L6
M_MO6C$Z\0\'PDU$V4%R]H U&V[V>@.D?H-8LW6E=_P"2NP<8TEUTLJ5+G@D$
MMK"<QU ]K,$CO'38;6KG;C)I=*-C[H7@04NPSBDP[[@IG;4HJ12M!HBFQ^=C
MNNC?V O'))=,Y5'0\;+9S"-1<!',NH>;2AUM+N492K_.$ZG\*6AO&K#;^.I8
M_-Y: B=P"5+3V0HN*(&W=WHE/C3XVQ\3A!4 C:#$M=V#>1TC=P9(;;- _P!U
MZLQ%-*-Z4@,[U1BFD+4SE4%U-134&M+"[?F8J4EP*HDD'04%?AO:7YC-(Z%3
M$R.;LKA9M#%;90[5)50G7O <@#IUKSL.]]HMQ+;JE(HI&:M3]5_.NEL%22%;
M)<5:O58TYBI10>\E]G4&I 9F\7:("O+'U2\"?9S4'/7:T SB8'MUT/,T'UIN
M=C:1;U34EQVJ@D:U-=]^6VGUK6T)S&*25J<S<R?/?K]?A:Q*.R14 "[NS\&_
M(C-)&RS@FGL_RYWB/B-B?^,)K4[>%//2GT+:S;X6*TITI[OZ_O9$>C$K)3F%
M/?\ I3:G3KMO_8:)&8 GR\?/ZZBM-;*>20DA0>MB':FGOD#I W!L7AW0;U5I
MS>7UR_#\@^X%U&5-!O3GY?7CUZQU"/A:TI&I^OZ^%GI*E!2J UIRZ:VK97Y>
M'7*%$J2I_*$T'3ZW_2TN25]):;/+3>OA\/G\;0[*>\4D;#Z%I2E*EAL5 II3
M;PU^OA81/>S(I8YT-.GA1,,CB2F(;%2-NG/ZTV]]B#NY$ Y*G_+6I/AX4L-U
MWDYGFU+TI3GX?77WVG61.Y2A*37:GN_3:GAMT)M9/71X=G8 .]&B>X.)HFE=
M"D5KY?737QTMH1L2<Q%3M_4_#W^/1,@WR$))/(:C6GU] ;V](^*0&2JE2$ZG
MQ^=HJ4P=VL-W/=3V@$]/=%&[P>E68^41_>&(^^6:Z_7+3Y^_E6+9M$!(4I1K
M0Z;T'S^MK.^\4Q"5.DZ4J*?O]=#:()W-E%*D ^UMJ.OU^G7,Q:E$HV22*DD'
M>+\HJVN"(TIA,%$A*",O.IUU^M_&S:?BG 2D;:]#]?*M;:\5&I4*9M:FO]?C
MULA.Q:@HBNGCKK\/KY6YO%4G*<O]M<OM#A\X HC:+D94/ 7C?B(MVA214$]=
M_H_+W6R&BW0:)%/?M]>?/PLBNQA5778\Z>7/KSZ6]&8J@J% <_KZ^&M:!*:U
M&HKJU/#<(K$.2<B37(]>D.,Q+QT*K>[42ZKNDU'G3ZT_+WMWUY?_ (ROP_.E
MMJ'BBO-F6-/KQ%@%2B*DD<>'P(7=I1JAOMW#0:0YFI@ME0 &O6I/EO921.7]
M*(T'^U[_ #LS_64BM37QI]5^M;?UI]68D+TKM_7S]_N-B2I@EDD@%QGN(ZW1
M"9LL& OD;!AUT(D^!GSP4A%<J3OK7Z/SWTI9VP\X.8=^GX#G3I]>5H:AWRG*
ML&A%-OK6FYLNPTR %5J/@/KPT_'G8W[E)_L RL''DWO"EE@;5+<;.&B>I3-A
MFJ5"NG.GYD>%I#ED>EPIJ01OOUVI];6&J5S91*J'04TKM\^@/6TG26;(6$I#
MN5>G,5TVW/Q\?EH2IJ#+3WD!Q746;(>#9Q(J&1 Y_F)UAGLY20: =#\@!]:6
M<#+?:@=[NG<#7X\OWM$\+-RDH%:^).^W[=?.S[ELX04@E&OG7]0=/Z'2NA+6
MRD]]JBQ&ZERV5,N;PDXCO !+5 [J36VG5!=X> 5F0B';-%(YY14;'ZUTWI:-
M\3;IF]%V9U %Q34:)+-1!Q;8^\;<,&]0!2*$9E4% >7,4L_6XMIW(:93S/GX
M4&QMN+=1V+C:"'.U&18/-)%%)%1S22#7?X6O;82Q6M24@BH)UXVUBP9NV"G9
MHJSI.Z[Y6UC\W7%>Y5];G\2V+:)\_$HB(69Q9];B\R%O-J7$%O*'""NB*4 -
M>F]F;PQX!8M<0N/MV8:[=VIG,I7#3V'>BYEZL\S#=BS%(<6HK4T&R A"J=XV
M[+^)'T2=Q>(S'B#Q+C9LW(I+$/!^?2UF'4$QB6T) 0MQHHIF[W+^;>Q\X,\-
MN#F ,CAKN89W0ELM:@6D-F9"':=B'W !VB^U<;[4%2@H^US^.Y_UO#IPZI:0
MDK*0D%7W   %J/F/* X'LS##%'$3=D$AW#!JBAR.CTX4H@*P N3.\*\.[GWR
M@&9G+;N2V#2)6MO*6HI#3"B2XG6J7D9M=*CI2TI04DA)/",2:5-!F#A64-PS
M*=FFTH 2FN_=2 +/LLA9S. .(H<S>@%1L1^7Y<D]+.:+2&&U/1+R@VRPA)4:
MDY=Q7:M?PYVYE)FS9RC-&W*>@9U$N!QT:_"-.8I.VH2BH(%$AS0,(:@@(J*<
M;82TIQ_,4(0D$J)6:;"OG6OOM8)PQ\/WJBF[WWBA@H+RN0[#Z*Z\SW@=J@U(
M^>WK@+P[O=LS>F];&<* >AX5Q-*:523Y:'4:^%;'7!(,'#L03;00V 4I2A(0
M&DI]FH2 #4#Y5MUG9G9@(2LIV444D*%[4Y4WY;X'"DEIMHH8;:2U#MI[A% E
M*4C>IH!0#7337;:U)GI4>/.&PIN?,,',/9@U$W\O R["NQ,)$)*Y<BA[0K+:
MBD5:6=%$'SL2OI >.>[7"_A_,)7+8UB.Q#FT(_#2F6L.I6^VMQ!;4M0059"A
M*PL9P*TH#IKQAWTOM>W$.]=Y+UWNG3\=>2>13D7$Q$2M2Q+VRI;C3;>=12 6
MU!/=IL>ENPE(2$@* 0G9H2 ER ]V&7\B(U?D6\NN5JQ&\\E$RFT1&.S*.><F
M$8\_&S><K=)<=6M:GPDJ*B="2C11TWTW'N]%^(XH=E<.X%03!4U4@*4O+W2>
M]4D&E=.5G[?N^;\%+W(!I\DHS!3@4 I9S:UUKKJ!X>&EAW8;B9A$KC"0$FN5
M!-0JNY/(^-?>;>:?J?\ 4YPPG85"B$ET[23W59-1]U*'6T5\4I"4 $@585ZY
MZ!X:STU"U1"3W5ND '*13K4^/N\*VT'98ZRA#RGRXV\2:4T'/KOX^5GE&2A"
MW*N-!*5:E6@V%?C7Z-DMQQ!2J%2GN-5 -:TY'ZKRMY:O$?7"5FA-137F?$5C
M(&VI[D/F"0VZM<MV<1U&PZF7 0LY*T504IK3IY?ESM_8J%:1"$M',MP:4T-?
MZ[\R??99F+8[R4G0ZCW;ZZ_L?FALE\OI"TGLD$9:UI[N5K,G$*2A(_QW7J#2
MU<M/!X*D)2 X2".#U;+++@(0&(=# <$8WWC[!4/>=_/>R9$2MF-*_P"[ME)H
M/8177E6E?KRL_9LRB(REQL)0!3,G6M>6G[_.V@XW#PL.%,[G<FNE=-CU_"VA
M+QJ@Q0L@EF8L ::&GII2"I54#:S 9X@^?7$A^^XI+9S5(2$@4T\/R&UH9FUV
MT0KRNR9&8$4&7E7GR/4?M8KG@TLK[9PJ4JM-#0;\O ?A[K1E.9,'8DN!W*@'
M_(:4^M3;?P./G.TQ8(8 USI?3CYU@REJ#=Y3.!]Q;*]=P\+ZWW_V5N%4UQJW
M]*V\BDM0?*E/[@YX#?3;^OZ,L7_J$;_Z+&?]DJWYYG]E\A1#\:=_0"%#LH,9
M@G+KZ@[7\#\^MOT,XO\ U"-_]%C/^R5;T_LA8F8&6L9D[](NRRZ4UR+\:7.L
M<=_%R[3';$=(T(BT:^%5?7ZT%@?>!5%:&E7*GQ[UC6XNXC_^?>)--A&(]WM>
M'UT%@C<=K&)TT#G3_:\S;%FUFS2?\SZ"-&6&0FC4B5(=!]28'^5(^5#8 .,:
M'1]NW,F%0%>O)&>E*??-@<O#QWKXVL$A%!4,T!N4#RT ^>E?.P*\9\$D2213
M,@CU2.:.85TK$MCYD:^5H!Q4%N%(=U4Y5WD@6Y]-$H3YE43_ *-ZKJD0Z-1L
M*MM'Q^J5L8$B040KJ$/929>JJJ<A#&OQ^-@MED=]J06&;BC[;.5-=SE;;3\K
M&Q H++#Z1I_P>K+34T$,2?+>U13_ %DEBP54U8"G(6X<P\(BA858V&;915+?
MB[T''W\O#%QSPB&D.N.)13+7L\ZE5-:ZY?G8%KNPL/>/'>\$V@TEN!DJVVZ)
MS%.8M% H1_M#W\^5C(QHO,BZ)OK.WEI2MOMFH=*E!&9;Q6@4K2M21U^=AIX?
M(<,W=F%X8^!!FEXHEU;CI7500A]>4GG[!T\+;TBLL-X7R%V;T^8JKRM[^.G*
M/G%Y][U9CM%=]1(2!KH" -?+QM$4N2XT4+6@*2I-=:&GY[[^-IOQCA&DPL*N
M'7F;4222FE#4$@5U-#7STM"L"E2DA074)2>[3?3;^GSL;9.A\(&_7)_2'-*#
MVS$P>2*)0$ C7J1RY69<R?7_ !-*88IT[;4'GJD^_P O=:3+JKAS*9FMQD@A
M3>FNM%?#ZYZ6BR\D8VY?:4-LT; 6JIIM0"E=N=CH8)#ZEP1D_5^58"H$J<.P
MLUK#2"?6I+ ;H@ N,MTIX(%:CG]<MVU,85B(;<+I&8UJ@@'^OSMJ.3)>5(+V
M93+:/+5/R^M+(3\R<]LKJ234>%>FWUSM*:&V"G)0)84R-6\(AW@]6.\FC-2O
M U][(45="!BTO.=EE<(44A%=: DU /ZV"G$5T2R\4=""J""*5_V1]4V_"QQ*
MO$[ !V(;[R@A8 .VJ2*Z^==;5W8M3E<=>28Q;C@2XIS5(IH*D;#\/CXV4!U!
MJ\.!B8-0ZB!QI7JACPA8U$;V0[8#L%C.FG,D4U/U\K2^E$<9?"*@G"D!)*U)
M -0!J#SY4UZV&^41L.6$A'^*M:,RJZFBAU/UTL6EW(<MR6$<=:*TNMFIZ5 '
MY^1LZR*!QG[01+5 R;TB+#,H0N7A[6(#;I9"7 H$%2NS4G<].OO\@J=2E,VC
MBTLHRON$*&N8J4H[_II\;')?.3RIF5S.,$.3$.(4>XI0-:* )">GC8#<[C4Q
MB4450..>TE0(J5==3IS%D@ACQ^(BLL15NNJ>,>:UN+B7%.N$Y:$?7AK[[;#$
M6E*]$I(',@;C;7E]4MI+4 MPFHS;$@@:5_6WBPTLYJ>8(.G/Z\K$B.T2:DFK
MFM:QL1\;$+*'&B4NFH603J-A77W4\K*THBHJ RN)[_::K( !%>OQWZ^-FO$)
M65@A64)W'PTLZ)3D<8)<70I2,H.E2/&H^=*690<$7I""CM#O9UK[<^46"<$3
MKT=?V)]:BEH846@VBII4I-?YM-?JEC/XO&8B72>1H9<)RYRO+KHI22G;SZ>9
ML"7!I.H27WJBGEME;C:VN\G,0-#R37K_ $TL<>.,U:O8F6M *6 %'(I*J=T)
MT[P%-OSM14VT4EN'X@K@EGWP.V%*Q_I"N3&K0'F6HQ"GBLY,M%H.H5[_ *K6
M_J^^.CS$EELBNVA43&.2^'9:2T20RKL$ Z@$;Z^ZMJ'[B2I$?B'(I4S6"/K"
M0X "JHJFAJ*4TZ>.MKK[LW7E<B:ARRA,9$*AX>L2YWLI[-.R5YJ4VTY:6#,2
MDLX!O<#=#Q%B[FSN:-NSN^DR>=6X2\U!DG0$E5"4GEY636FI4\X(0-)@&?94
M\D9E&F@J ,VNF_PM-\_AHJ+;+4+5]Y0(0TG45/D:?A;;N%A+"..*G%\(@0C;
MR@IN#<207,IJ D@@_ >>MG!2F3LBA=V32C[J^$*(VN[A7,+VS%,-+^T9ES12
M3%J2JC@5J=54WVT/ESL5UU+B2JZ3*8)N%08]I S1Q&8J-*U"34>'Q\+2/*&8
M"72]J%E<,AN%H$MH2D9S30$JIFUK4;6\H\(D[<7-)[$(AH1* 4H7E"B*$"FH
M4>6WSYT)TY=$)!H&):M@V_Q),*$DQ*G&GF'VP\TJ@ILDY?"E!3RLI29]MD=E
MEHUK]T!0 TTUVTW\/G9I2^?RV<0JWY:K,SF4,PJ<W>(Y^[6OEULL03BE5 %#
M0T]]:'EY\[4J@Y@\WA14EZ0K%3$!J?0EP[F/QDQ?F"RP("&#@2R',NO=J"!F
MS'36FMFEPC\),^NC-6,1K\3%QV=18$2B'=2<T,5IU2030Z*H"1:TN98.72CK
MUF^4S@F8N>-56R\\@+2DY:;*"D[:<SH?=Y13 0J)"&LBA1(RBB*#094@!( '
MA\;:4E:=@#:!)NY#NP>]84-:/AUY5M-%);.0!= #0;^(ZFR#$@LU!60T  MR
ME0#X^_S\+*[W;B(H23J13\^8Y>%HSQ2Q9N?A)=F93:]<1#K;4R2B&[5 =4M(
M.4 ))5N1L-=J6N(26=L].!A0XII.91=N4/SN=1[#$K8:6ZX^ZXA.B 30 J!J
M2*:?E:F7BBXZHN\\S<N5AS$J8EC42F$=CFE$9RIT(-"0#J:CVC^%HDXB.*.>
MXO2V(EEWIB])[MEQU*89MQ55H[0@:U2L@TKMMMRL(UR</9_>2<0;<%!NQ\/Z
MTRMURB@5J[5*@2NE?:U)K^8L9*01WD^/77J%1.T<K6.[E%V6$UR+ZRS"257U
M?NLJ:.3AHJ^VWHU(/>50J#2R33O4\.=M]LP,F?9=BWUP\Z<*B&NR5&H;4O8!
M5%( ]XISM(]P9!C&WAE=^23:8,PES(&%#<)*RN&#E'$I!S+"NUT70]ZVZ[AS
M/Y&T50'9S*+C5([)MI+<4N%S$ 5*>T/>KN3W>9WM-DZ#K32(PT,ZW64N32(3
M-(XT+<N $.INI'9@%-*YAE)T%/"SB9DSLN:8O'>Z!1#0[:5*@I((@/+B:"B5
M**"5("-%T*>]9<C\-HNZ4,Y>.<P+DWO&4MK:E:5*:[&M-2453H.]0CE9HS.(
M6E:;T7D:?EF?*(>"*EQ(>RC)3LA7L@C3=/>-H,0U*#-A6P=C:U=;TO#,+YZT
M\83XJ=,7B?;?F\S4Q*0I29?*A"*ATT0:%*G$A!.M-5;TK4V\U,1T6\71 &#E
M,O4A<'$B-%4 4)*$!0*LY&M*D5\[;33#$_>]?CYHVY+"A1@H0PJ84U"#49@$
MJ3WNHKSLMW.NG'WPBX:43"4+D\@AU.K1>'ULNLPZ$G/0MI-'NURY:$G*32E;
M22S7<TS?(990_P",^OS'E(47CQ%G3S,JG3[#<O[(Q;L2THM0[3:14(>>[B^T
M0@@Y3:2[YWGED5+9?=Z&;5V4 E3$1$PZE(<BWE=W,>SHLA*P2!FIK2I%M&\%
MYH"3P/\ !ETX7/"LJ#43,V&RV[,%9M-0D+[J@1HH[^^SKNE<B"NU")OI?%&:
M%2GM8"5.FBWETU)/M"BJ*HH:[6EUUUOA0PXO"V=05TF9Y#WC;@ X%J5!.0Z.
MUB$*5IWUT6G(#OSKSM&@D\T2A,!(VC-9G%*RQ40E821KO2I"* G:E0"+2A?&
M\L9B/,DR^ 2[!YW U P[(64L)!RFJ4T3JD#50\2=[+<7+I5A%("M3J(Z]TR;
M';K[3,I@"E*(J4@E!Y<QUTM WN-6+9-SL^D)B<G&NA$#]/BS<=2F'F,UY8A(
M]8C@"Z(.HT!2D*0LJ22*UH-?,,.-C880YBG(E3DT>55EY;*D!DD]X:C*O."*
M#7+RM)DMA)S?&>*,/2(96YGC5.H3E0@=X_>N"F@KI7PLEXFSBZR!_#L+)VUJ
ME.0+F+;F4Q#JJ$@)2*]Q8(T)!LR3OTUR''C?<<B(=(+@M<C+0U/AX-$31S+L
M Q]L/0J(J+B/8S/)S(/LA114[[BHZ4ZV2C#B!:,^GKAI$ F&;*2,R@*)I3;*
M?<0*VD&4W.9F$"]>N=%4-*6$9E-..*!>*11K*V2%:*"<V4:C?2T57A3.)]%E
M;,S#L"DJ;@I4EE/W8%4).?<UT433G6Q(/!Y^CV9>GV)T='O-ELPBFUNQA6<I
M;R**$A)T%443IJ>=KP)G?&502D&7^KHB4J0C*KLW,Y20E7M5&NOQIN+54^C"
MPX<C9G/H&<Q;<',7 T>S!275(4%%- D@Z).NE?/G:E>'ANF<1,61(HUUPK?"
MB""-<X)]I7X?M8DO/E[PQ?(/UUF(W;_WD1-KJRV$:A6DOOI5VX:R(S&J2D]P
M#??PM 32Y[=Z+1,87MFVDE*NS"EFN7IJ1[^EIFQ.P_O+A_#281;3JWD().E4
MTHG4[C;KRL@2V-8O#+RRZ$!UM-%Z"H53I0>0WL0'S\\X8ASF"+=>OPT2G<C&
M=$="P\',W A1 0M+B02*4&M1K4:T_/6SYO"C#^8P7K<;,89DK02KNIKJ*[#7
M3Z\1&BY*B6.KBT$JR&J4IJ/#8608EQ4P5ECNV2P=,O:+ ^%1]=-[ +.6L\28
MMX.686Z\8>5[QAG !Y<).VG'3F*:(.XV&^FNGS'B-,POC*V8MQF$B/6D*4I(
M201E&U=:^>_XVE"*N#=>,2MQ3B@X02 IUS0TY54 =ZVA&\EQO47UN0#J4I"C
ML0NJ*Z^6E?JMFAV(N#&[#1B5QK42RO.%U-$G5)IH* GG^_4U[\2,%&SK$-YJ
M-=<<6RI!@TJK0=P$Y03R'/G:SG#7#4O)C;W3.+]2NK)6%O1#CXRI?7V9("<Y
M!T<%.[S]U@WOA(H?%&_\TO'(V.W@X=_LV&D:D(9JTI0&YJ$UVLH:$SA^0E :
ME$T81$)=RI4XXE(*$C:E17;H0:CK:Q&[#$;<P-1MU9B%)513T"]1Q!3IW0EX
MD#2M*#F-;"M(L.GH6#@YM)JLQ4-4QD.!19"2!2AU-0#J!SL7&&\-=J^,$IB(
M>,JGD,A+>5U2TAQ=,M0%%*>7B"#Y68D"Y@B&:K.^;;HG"57JPWO%#MHOA*81
MF:. )6\E2$57L59&P!H=??K;<G6!-S+U2YPW9G,,P^ZDJ0QD0-3JA.99%.0T
ML.EY\+IO+8XQ8?<=.8J;<0I12D#4&B214C;XV;#5^)_=N.1#&)B%I:(KE6L5
MRZC0'E9^$2[G^WR@6>,BZ5[<)X&$E$5*GEMS12THF+22MI"$*'>)0"@ I(.I
M'AI8&)*]ZDMMIHI>>B0:K)%0HC4$GIM0GX6O,O'>^68P7+CKO7K1#1A]66B
M+Z&^V94E*JD+4.T.PYVI5OE=*"N=?&:RD1!=0T^LL-)K5D*)*0"":U!'];*
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M7Q4G#<'?"#9:A8:9QL0$J?4@430K*1[*4CVO?;E5@J45WVF+\@W@/1HV1-2
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M2M-<PJ=%=+3/*V Z>TIW.8V_K^G*R2B'@H. :89:1"MLM-M,MIT3E;2$"@H
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M2O0HT/SW]UN&V\V(,1=R/EDON@E$3]F/-N1#K<4EET.-K2X* $+J5)UI[[=
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M_A9!==2W$):JEI1J$M902KKRJ-]*VIDES4M:I-K!_B%&O&!40>W?4$,@#2M
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MBI:$G:-3F'V6X$5W^44>3230T55N$(=:U(-*<Z_5*5TLVXIGU:'5!B$ 44D
M_F=_#3Q^-\K/H-,;V" W?Y*45U3ZBP:CSSZ6]8_T&&,\4@%-^VT.Z5/J+!K_
M .N?PZVIH_0'ZO1]O8\P)'^\/_;EOW&FMXB,'B!4**FKLJL;4(^-(YVG)3%.
M1!!2IM->[W*\Z]/Z_.WLY)'T.H*7QVI&@4C;D0:Z'04%NAECT&6-P2E#M^FC
M3G]GPU?CFZ>ZOQLD3/T#F-L62MG$)#2SL1+X<T__  AZZ>&EK"/T1^K]ICV1
M-2&OM).0WOG6['-Q###XI_L0Y]*/2HN?#6C\^$RNI$.0SD4TOM'$T4M*!0BG
M2FFH_K9LH>3V8"V<KK.9*TT%5<AK2NW/E2N^_10QZ!O'F&AUI1B,E3BQ159>
MP:C;FLC:R"C^S_XX.Q"G8C$)L!9)/_!\/N?)8YZTVZVMR_T5^JF(F=ESB*;)
M20Y# ,7+=;X?]OB__+3D,K4]-V@TCGJ["'>AGXE4-4\Q0GPW _?E9FNPL$E9
M7V2A4G0@FGAK\?VMTE?_ )@/')I+K;6(379KT%9=#?AG)WUVKY6;,9_9[,>7
MP2WB,TE1-2!+8;;P[_U\K6I7Z-_4J7![,Q % 64]*-1V#?#4B)P^*-I:0?"O
M=O<NVN^M(YNYG#0Q1F::/:Z4T-?=I\K-U"U0T0AYWNMI]H9="-*5TIMUT\;=
M*;G]G?Q]<;H<26\_7[-AM/(=I]?BWH[^SC<0$2TM(Q/;"E; 2R%ISZ.#EUKT
M-M&1^DNW_L7V9B ,RHAZL*/P<?$,,/BG^Q+TY?:2 .=7.^.=2:&!F""^PI#(
M2GOC)7,=AY:UV^>EHO?"&G75J>JWFH 4D[Z:?T]]NFA/]F[XA$PBF4XH("U;
MG[-ANO\ RE*62(S^S4<0+[(0C$]L.'=?V;#>8T[3E[_G;1E?I?MR2&3@)Y#-
M4@D [-<JCG8Z05$C$N-M V:%@=PIJ&X9/PC3^S;G_P#JYOJ$JS(#<)32FI@W
M>7AM]4'>7&?ZE'?^C1G_ &:K<UWHF_0\XN\">.,[Q'OI?--X99-6V4B'$&S#
M]GV;"V]VUJ)U5];6Z5GV5.0T0TD]YQE]M/FX@I'Y6]9_3&%Q&#[*E2,3+5*G
M)4HJ2HO0MH W#G&JBB0"-G=''?Q?0],>,0U92:QC9TV/M'33S^>FPL'[B77'
M$T/8I"M2:'2HUU\.NNQM?3CKZ-7%O$G$B]=[I7/$0\+-WTNPJ"RPK+3-6M5"
MO+?]+0/*?1!8RNQAB)W>1+C:%9DMI882%4U [J^N]=^=H+P6(FJ*TH9U750O
M0$\Z7'E%E,T@,:[]WC[151.9Q$7=NY'3662QZ=OMH;[-L!;=%'NU H:Z]!R^
M,0WHC+PWKPVF$RGLO<EKL0P\!">T:#, "1384W'E:^V+]%OC8I!@X"<P\)!]
MU-%0L(Z%I2*5(63KII:,+_\ HCN(>>2B(E,IO*TVA]LIS"%@TI!4#LG,*:G6
MGQLPP6*##Z:*,+%Z;.\:_BK1,S]P\+T&IZK'+[PH0 8QIC(904RJ$C#D!*N]
MVA5XZ&US=^81R&N->=X*(/V)%G,#O_<W*<_+>MI$P8] YQ(7(Q,CKWSJ]J'8
M-]Y+B&Q#0::4&M"E?PZ?B>U\?19XTSNZTZDT'>)*'YA+7H1M188.5;C"VP?:
M&Q5UM(83$[2298 S(%:M45WM1X0G D#9 #Z;FU/6Z/S3\5(J,.(5[5=NNBIO
M&TW.T4Z.ONWZ::6CDS6/;U[7-YM@CYC\??;JUO;_ &5/C.GUY9U-V,1FVV)A
M'1,2V@P$"2$.O+<":EWD%#?X4LTWO[)QQJ*-$XCM>?J$!S_^Z_'6G*VO*DK"
M %$\Z'+SO\Y175]Q;/3K?U6**,!8I47+XDK25/DH-0*#?_*-.7P\+%&IE:F2
M,IT0:Z:[:<C6UU^$W]F XO+DPC[<QQ :?=73+2!@DTH3_P#64U!&OASM-W_[
M./Q7%M:?XY;25)(']S@NE/\ QAU\?WLER%4 )%W>KVT]]8B*!AE33KWCF^;C
M1# ,5*%**Z[Z:GD/UL'6*T Y&WIBXAK[ZF4C77V17G\?VK;K77_9IN+)QU;B
MK_-D=\@>I0>N:M!_B:>^P_7H_LL/&M-9V_,H+$E#3;BJH;]1@B!04IJ[M3>P
MAAU[QQ!.G&'CE+<[1AS(M#K"QLH9R#XFE-OZ=;*,#>.<RQ21"1KKE230J50
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M;4)G:2$K8!R&K6]!KUX.=.'60":/DSZ?-NAV!0^/N$L6H(8OG+G%'8)?;/\
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MXQ&(% 5L*#J==!J@J'A9Z0<Q@XU"5PSI6DBH.HK[J_E:LGA4P.C\#9 J'O\
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MY<![Z1^M6G&?"Q20M-_9 I"@"%";0920=J'MZ6]3C!ACES&_4A">OVM!@?\
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ME1Z]:1=K=_B&P^C)<J8*O>)4O*%KAUH<4H'I51!J.>FOX-F=<=^%ET.T:_C
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M.G,"W;7Z.EGL.$S#=LC*1#.FA\74G\+=?V25)=)+C9IRV<K:<WBGVA.ES)"
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MS!U\[-A4UJ+T%.#UW5I2CP%:2RE UN*/[Q(N-W'OCSB)=68W_NG.8ZCS!$;
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M;VB6.X>,4X<KA7Y$\Z,PHYVB3H#72@/3KU\K4\4%B429:AH170\XG+QDO;#
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MN:=Y51MX6R>V/]"7_P#<_P#U,6\('6K_ (__ + >\.=22>XXE24(U"@3KSU
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M//=KYVAQ3)^A\="D Y=C^T58@L*9%Y,.8E81H\5.%&>NE=&!34'QY6(&Z_\
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M&61ZZRCNG4L)WK[A;^)6E>U?>"/QMQNW4_M%V)C+C+5X\/'W]NU6IX-$TW-
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M@TWUIM\K77JV/D?PL--\91)WIY,7GH)EQ]62KA;05&@ZY?SWKRMD=L?Z$O\
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MA2?NI"\CCS !214FCK@![M?':P1<3?I'<+[I3F7R"Z,SA+P]LX69N81U*4-
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ML=VKI[2%?3E*TKH*DG+JK?3YVI\QZD4ROOCK%WQET<Y$7>B(II;+!0HH0&Z
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M_C,.5K33_,*#8;BGZ GX6WY[#.(D<SIOZLL@UZ-JV^O=L+5YZ5+0G9[QVA4
M@BHT'&]WAYX<@$ L"/%N,!=ABXEF,O4DH!4@OT7X?>\_+KUM$>'K3L9>R_I)
M'WKK0;<ZCOA6GOIK3;W6G?#B6YH*]T2E-7<L033GE[7G:+<%I0Y'36]S[J5
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M*@QH[5WTI;,T]GK#0]&PTVQ="_TR30F,CGW&HQ.BG2U%OE("AJ:G*-3S\Q9
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MRN1_2T^Y2V34W]4A]H:B(_CH53F9932E*>'ETTZVCR\:7%L*9:0E:J*SJ)"
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M/GFNT$S-HA*2H4:CZ&^[/+**-N(3A/POX5)5'S^^LR1>&9Q2'1+)>$+A5MJ
M4FJ5M*)KW@KSTM7SA;=FZ6,+-[))+9O$2"]>1UR1-HBGTNQ  <<4UV@<05]R
MB1F)]KX'WZ6F^$UO1?*5&5MJBY \%*A'V5EQET*0D]TIS#>E!6M=-]Z]N%;!
M2_$SQBNY>V,AHF075@(@.QTRBLT*PEHA-!][V:7 JA&YT^;+ERSVY-2C% X/
MZBE(J=DHVJ#2PI1^,&PWTS*5]0%2OI]UO[2P:]*7_AHKGQ/P\OS(;X1MW(Z[
M,W?F3<4ZPJ)5"13PB<ZU);7VI:4"""#FS$#-4G2SQ3A)BG@YAW'7JFEXF[NP
MDZ;0EJ0NK8?4^AQ100J'4O,BB7,W>;'/I6W6GCBG!5G"Z\5[)%+;N7AO3(I,
M.P<AT0+D4]$B&4DN!"$K65-J2%5H=K<5>.6)5],0+U3N-O+,XA2&(^+;:@LR
MF&(-M#SB&DB'24M^P$@')N/CME<M,T)D@S 6'< W99\Z<2:!E?=_VJWY9 ^G
M1FF.Q QMP=P0?@[ML5NK>7.[&SF 99>B$'M2NH[!*GV^^LC0C3306!Z&QZQJ
MDS[D9++X3YI*GT+:SHC"I*RNI2$+5F[Y[NQ'A2U_GHO,*I7B;A+>.%Q#@DSV
M[)[ 2]J,3F;2>U5GR+6#09NAZ=+%#BQP7<.-UKOWBOZ_<Z"R2"&<BD0A64(6
MM*%K;H0D)-%)!I2GSMT>&1.$JB%#: I<U:NM*;J4BM,^]7'XCFPQ;QGF^*]R
MKM2S$"[$2;TPKB/_ )1/AP.Q;/:-ES[HM@ZM#+N2*VDR)X@<(L)</I?+<+;J
M)@,2%PZ!&SI]#A=;? 31:6HANG,ZITZ'2T#8Y8X/7JOXAR6P,-+9#=Z9.-04
MO;9:[S+#^0H4XE 404M@54*<[$Q$8%PG%[<" O/A5*6Y5?J4L-HFT!#A*TQ)
M 2VA171+22I*2J@UJ:>;)EXA$T/>A_NL6SK06;R!@=3?/0VM2E;O"-A+Q]8U
MRN=0<MO=.7IO=R9K,+-&72AMH0[_ -V*[@!"%G04VUM[\1>$=SKQ3:'CL/YU
M#1,-?I/:+ADE 3+GUH2ITJ*U4H7'%'6@]UD6Z? W?^Z\<J-QHBTW2N? *2N)
MB(@M%40AO4I0 I+AJ13NU/RIMN'"-[%""NQ=R9O_ ,(+2N#;G"G8DAEXL]F'
M$-K45)!>-: CSY6I8Y<U.*DAF#IX?V\]X-6##*+59<@I5_\ 4[P(%K7?@-1X
MP@8006'O!9$Q4MO]>.#CIA-PE]#[.1SLJ@NY26%+U2%@;\K25/\ B8PHOBV^
M]=R=,O36+8B6X=HJ+:EJ4VM  *SIO2FWY@'Q6<+.*-W+[.Q4E3,[]W7CQVTK
MF:5O$):6C.I(22XH9,P3J:Z=+!FSA+BG"3>&;ET@FDJBH9T+3&.N/H93J%+)
M+@2W1(&Q.M/*WH6',Q>"EJ*ALT!&9+ ^'CX1FD.,G/5].J0EXL0,W?Q-GT+$
MPKBGXV)4N'"4EY2PHE8RE()-04ZC2Q:\%US9G="^PO=?!H222E)J8]U+:'6R
MVI!)8>*,PIKJG]X'@HN^K>)LO4\B&G<_D:0M25>KY7REI)R$G,A1 3E.^M.E
M+)..&,U][^S7U*=P;UUDR[*R8"'/JXH $9@ID-9L],VQ%#[[**[UV<V?S ]X
MN(XA;S7,_P!%$XF^&*Y7,9NTRHQ$7!L0_K#2E*(S)"$E9H*TR]/$VH*FD\F$
MTCW8^:145'12WGO67WUNI*%!2@VD-+)RA.B=!O:2,-,4IW<&<LK,5%3&01WW
M4?*W5.1*74$9-E=H=*DZ"OXV>48QAE>;%"#BXAE<ENS,UI<FB>Q>4(<Y HG*
M$@G.LJJ0 !Y6F@))8@DDAJT'D]Z_$%EY\HLFX#+FP=\\)H_^+X1,]@TJ;$!"
M1+>?L4%XATI=6E1&FO\ 2Q>7DX:\'&H6)FS=TX-U$OA'XM3>B$I<:94ZFJJ
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M0\A3\H+^T\O405#2U@W.A#C+RXT\(Z(>(:_LXC))-IE=I7K$;W:!NAJDFBP
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M,.\39$S -$=DTY 2UP*&RO\ &54?"NM;537KN/,Y!/:*QHC8/M:*1"NH?2D
MIJ %J>"2$@[BS9F5U[VS!# A<<\J05%*>T2FG.A/K(I7Y?&UE:%*D_3E$RG(
M(*:,Q&F[UK4P=$_ZDHA3$T[V>3CX ]ZWCW4@;V,X/R^[DSOS*9I/4U]=08>
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MD6EF\LL<0.XF);*M=QF3OY&W#8M9_P"F8E(50[;)!9Z6;6^7*+6')$Z7L_Y
M%N(XMEE'4CPMQH>NU+4I6 ##L95:;94DZ?+RTM<1@ F6W=F)O3.9+]L2F$:[
M0IU4E*NS.I 2JG? .G+PM2+P@1B8BZLH=*24EAL9<VV@%:VOEX.7XR?WF5<J
M(;3&R*9([.(2MM*@V"V?YB%*%"3S^&P^7,1(^M^H3*")GUC,.R DER5) I5Z
MQVBIZ9>&2%D%)2Y)# ,!?@<AQO#HGW&]>^2S!U=TD(E]W8110S"(#=4$=T)
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M]$'#L*=?0I272H.LMAP&B@/\32M!;I>SBO'3T+)5M).T07!HSC7@S^L59F'
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M7=^6OAJ'R9'$Q;2%T"AG3I4)"O?YFT,8,RG#^_C$TNA>=!E<]BL[DFC4ON)
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M$-4FWO3>QUC2X ,.+XS'$UR>3*&<E]S'CEC8>8*3#P[[?9J0*)B,@WJ=CO\
M$]^-*[>#F!6$\^Q-NI=63/7I;AR8:*8$-%97G*H*^ZAQ((*BJIIRZVJ6XF.,
M.\4XB1*L,6C<N[LORL.-0: VZ5(2$G,4I;=/?377\+1GA9Q115[(>:X78WSI
MV:W2O'".-P<=%J4?4G&F5J!(J5G,Z4[GY5M<[([4P", 9*I>RM82D*V7(*@
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M#R3$^]A>4D*3V134]&JTI\_&V#V\XP\MB0\YZ?\ !HT>S5A$Y958RV__ "3
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M>0SZSWE("R5:*H1IX:=??9N8576B_MO^\(*7T.- (4V14%0!H2.GT18,V6A
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M8GPZV&J4<36(<=>6+AU0++,+ HCGWDB%AQ7,VXXU179#P-??:Q&[-Q^%;#C
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M[F0N95-9EI#/?.A 3I4 V)CAIXY\ D8JW"PWEF'D! 7(Q5F#)AHU2TKA6(R
M=;=("%-94+$2JE="5>-NFD**TI+,0S\F@\J7MI)46  ;*P#9^=WY1V&W-=<?
MNA=5]VO:O7;D;KF;?M')9"K77QS$U\;.2R=*"P95+## )AS+H)3 3[(95#ME
MH#P"*4Y4VLHVTHJQELMELLH49;+9;+*%'FY["_\ DW/P%N:?C^G"H/%F^&:.
M0PD=D<I4-DM:U!-=1M^]NE9\T;61_P"+=^2"?RMR!\=35XKZ<6^)TA<BG$RR
M!$.IIBN5"QZHI2@%5',?A:GB^SU]HG#R$._U@2V8-&MO@\B:B25+6-H;-JY$
M'+=RUBM^^LZ9GLRB42V*<C(@*5F9:0M9)%=!EJ/>.5B=X=KU?8UTX]J?^LRY
M$,IO[Q]MU*0"LZ]\)&U#[Z;TL'CF.^'>"4QF<%%71$;>2$<6D..1*UA2\RJ$
MA06G4#YTI2T#XE\<M^;TRF+E4DDS$H@(VB%H9+ 4$!5$G,E"5#KOTMZ-^G__
M  RQ$V3]:9+'[<@%:R&(53,Z@>G+-QWZJPDD*PXD]XC)V)H/&G1B]).+=P&$
MPR?XOA.V?0ML+44 MG+E-05TYZ5M07QT+@W\88Z.E$W:F+;ZLR(AH((5F:!/
MLJ4!38V&>*Q!O7%Q;:7IK%YW%*7V8B7  5][0A>FFVE.0'*S3O!%S6-BFGXR
M(<?4L'[UUU2U)IINM1)/(:_.U;MC]'X'LP+6A:015P0:TNZM[,,HJ]G]HIQA
MV4I4!79#<*'Q]('*_P!"NKCX@K05*2"20/:-*[TZTZ[>.K+N7B!-+KO1,"\V
MM4!%*"#F7HD5(T!J.>P&X]UIMO>ADJ:2&AF 5V[ZB #44TKI\-]C8>YM ,/Q
MCZ89WM$ _P"&E(!0K?EKO\;<:)LN0\M@22P+N7) %CT\::I<Q()==+.+'7XU
MWP06'M^8=^_LOA<N5HN(4VX%5S%0"B/B2#X\S:UF FQ=EZ&W*(95#I&<T54%
M&FE/EM\K4%W.C+Q2Z_DLAV4O(2I])"PT5J:0@@DTI4U3X5VY6NQN)>B23.00
M$*XS%1LR4VTV[$NL/P[:%&B:]](00->?+I;&Q,@3EMLOGN<4Z?>U&BWAIQ35
M1VF #4HXJQH<H0YM#LAY\#OMN.#(4@T!*MZ>?E\K9&R690TN;>ARLK(!0E)(
M"A6O+3;\K3E.\-X*32EJ>_:D/&LK2EV.A0IO/"(-"- HDZ&IH!J-[1U?:_=U
MG+N0\KN9&,OS*$0OM75405JK52?O#_+0BHKL+4$2E2E*!#@?;NRI?PI1N,36
ML$NE(23=A>S5K"=<AN8RAN8WDG, 78*'AW"M2G!W06U)!^.OGMOI7K>B8RB\
MF*$7/97.HJ!CV8PJAV07U(.55%)I4((H*4I3D+&Q*L1';Q7 GMU(1SM[S/)2
MVMIM-2*K5LI(RFJ3RL,D3@U-;G.PUZKS#L#&N/*AX=: E:CF())&NA-144\N
M5V624U#,6RLPT@9<E[FE@'TIQSW18KP_NL12KLWH,0E4?!(=3,%"B5 90VBH
M%*9P.0KKSM* O'+X[&N.>8>* ^&DE"LV8E+.4[ZD$[;Z:C0VK)E>,,\P\:;A
M94Q&OMQ#S*W7FF'5LH;0XE64K2DH2"G0DD>-BHFUY'9A+KMX\W?<0\B$2!>.
M6,N)SM^PP@D).:OM*T34<Z6-]%=%;3 UR-+:/T-[Q<5<%J&N5F^6BQ=,6TPI
M*"PI8I7/57.I)V/G]:;L/,H("M5I*C0_=KHG7X:>^PU,<7^"TANM)YS>N>PL
MN$;E;0V\/O YF2A8*31>BCN1MM8CKLWMNS?^[S,\NA%PTTE4P2A4-%L%LT"B
M 24@D@]:T_*T8=P<X@_B$FJ9-=%R<P(7%+A,JRA+933O@US4Z;T_46!=_B)F
M4$U!3!B4%_UM+K3]:#1ON:U3K37YVLVQXED%)<(9Z[',(B5L,H45E( 2'%$D
MDT-,H/7\#:K.+A;JS&YEW8N3/0K[Y<F C&&U-K6@EU02"*J(IR\!:2 ":Z0L
MZ4S\P_B.JB)MP\O(S>\2Z<J=5"I:BFG%0:$**4*+P.F73<<AY^%F$??59ELO
M]6;+JG(5MM"CI3(TE.N;RKKU\; OPLW3D/V?$?:24+;;4'$H5I0DE6V^A /X
M6+&<Q,/"@"&6D0[22$ "O= V^7+7\;$V4]'\P)2K-2A9\\MYW$UI6&I?29Q[
MTIBD/.=D\^R^0E)')"B!I[MORM3C>?%*;2"^,WD4PFST'"E]:4=Y24D*42=0
M1UZ_"UEM^[YPT.S$)==RE+;@22K;0@Z5_/G6U%?$?,'9E?I*H&(42]%?>);&
MJAF .HUV-:U\[%3+1L@[-WO$?JI30TSSW?QU5X8R3V(ETJ9FMU9XZ[/HTEZ&
M*'%+<S-$*-.\3IX4UL*[7%=BY)H],PO''3!]<M4E&9TN *3["1TV%/=7>TPW
M)AY9,<5[LR6/4N)AX %#T,M2U)08AI-:UK74U^-*<K!+S<)N%%Z8%3<9+FDB
M,:0M;B4*20HI"OY0-E&PF0"':^NAR>%O_B!?P[]([,'Y.N4F6-^O%DH$00V7
M<Q2:$'(55Z:_K:1.'&2X^\7>+,*Q*HJ<RJ1RV8P[RWVP\EEQM3@=(I5"2*)(
MZ6=]S.!?!B[,S^U8M/;@.)6VS1X)(2:TW/(<].HI:VCAVQ@N3P\0K:;GW0A$
M*"4)7$ -]HK( *U4@G8\SUL6;-0N6I( <L.3A[?SYP="G4*N7!>VF_\ #NT6
MOX8\/"HJ4W<NS.WGWDR^!;9C72RM)B%%A 558VU"@=2:FMIX@<"I7AG"Q\5<
MF5QHCU@+6@1L04N*%=:*50$YO=U%@DD?I.Y;+H=*3=M';#VCG"2#_O!O7W'K
M9Z07I1;O/+4(J1)!7H:K*O/^3D-/<+9:L.DJ1L) 93FK5( 'SQXQ/$*4MB7<
ME@;&PR(8:>,$E*<$+X8VI=@K_)7+)/F*689QT.E:0=>^#F220#WO <K25=_@
M4PGE$"_+XAQ+)6DI[0*6I0*N9(5FY[?E8%'?2PX5RB,,'&PD5!OJ/>4TS%.)
M%-33(T4]:T(IO9VR;TF^%MZG#$2J8/LMMZ+2ZS$IJI8RC5Q(._E3E;5^C,FH
M 6LL& "MS:<Q[0/#2/HK91!*B%.6=F'=Y-EF().5\#\%<:]AG=SKV-F!S%QI
MHPZ0$K(K0J<5J0H\]^0%HEQ8XC[Z8"7N;NW-XY<0V^I*1$PS"70E"$C^5E*@
M-_/F:6@_%OTATNN1=R8W@B+QLP<J#*W&E*<2%*(2HI 23F!S&F@K:C>\WI@Y
M7-+X3*9SN2-WFEZXA2)?%ON 94H44+*<Z%$A5/#6G6PQ*$D[*0S6.O7\Q<F-
M]0D;+AF9J!@8Z89=QHQ,==]^>K$0)?#M ?::V5M]FI54@]B4@J.;32U>V-'&
MC?QV\$)%0S<?.+KN1K;4?-5!Z%:98<>2@T;4D!0"20:'6E;5[W=]+UAE/Y*W
M=*.N@PQ K([5*72FIS9Q4I;!/U32SGO_ .D$P4O3<1JZ\-(H1*%)[[+8^]11
M68$NI;"M-]^5IJ0G9-/:M/7.*I(#G+K2+K(KC5X4;H8$7NN^N:2TWJFUV(D.
M9F\T08QZ =4$T(*BH.+I6G2N]J N"Z\'V[ASCK&-I5DBYO$/0BZ$?=.3&*6@
MBM-,BA;=PK@N$G$OUZ]=\)BZY&N,.A$O3&1I""&UH *&G,M$Z$U30CI8AL+;
MKX871PFOW&8;Q+3LNBU("FVZE38#S@14*JJHKSUZ[V I( H/6D,[D-45KI;I
MOB)MX;!EN$TWGJ0_$9JC:KZJ;_73J2/:17W?6WU^%APX= Y_!2>[]V77B'>M
M7B:4\#OH-[$(%J&@40+#AX]U;GSM_+>.91Y_7YV_E3UWLH@/]3PY6C9( W.O
M2GP_6WLR.\=*:"E?Z:[]+:Z%@C5-:<Z?5?RM[!Y*>6I\/WM3Q4]-$,"U,Z48
MV]-V^+>P ;5&G#X_,;1%=#9+CT )+E=133S^O'>VYV_A\OWLEQ+RE!0Y:CY>
M/E^]J" POGD7T_CH0H;L2\!F16NVGNU\O/\ '2S;B74,$J(U-:*UYZ;_ (^?
MQ78Q*,RB3J=_=^@^N5D&+;2\,E*TV-?K\/PK:<"%6<F["M[."^1T]:1H-M.N
MOI=K5 54?'\OHTK8>L9G@]>R3-+V+[8Y5'>0/G3W].=B8A8=33>4FFH*1SIN
M=SXV%[%=341B')X=)SE#R2I(\,I_$?TLLWSB6TY:A%+ ZB]OYOH1KXR5,_Q%
MAM!I0JOK<("!6BLSD/KII4;FUVC3B(? FX,N:64N/2E-$T)->P;.^NNOGYZ6
MI&XLHE<=B/AS"I>;::;CH0*;(02*+8ZZUYTWM?W(KLP<VP@NDX7$ER E+!30
M;YH=O0 '\_&EM7 DD!QK4\0UM_\ -8G,2#+!+$@M??H_#**I[_0+D'.GQ$5J
M5J(S:[ZBGNI3W==6)+W'&XLU)[%1V)Z?#G^MBEQ6N:[,I@X]#,=]*E)TTKE-
M*^.U;0\W<.8H<2D-*4ZHY4-@$FI.HK^VHZ6[S#XB7]!(("3L7M5@-6?C'/F1
M-"R0I3;1/QQ\O>"7X2FDN7QBY@ZFD/#-E9)J10-*Y\J_U-O*_P#!XD7KQIB9
MI=N?0S-W(2);#DN=8AG@I(T4 IZI&H)T%=:>-G;AQ*W<)+A3Z\4S'9Q<3!*4
MPE0[P[BAIST!%J[;AX]3B=XLS>5MQ3JHE<P(;05J0 DK42*$@'3SMRN.4?K*
M=08)4U0SEFJ/QPC:P:EI9LQ=JY/?\YZQ=F]!,HD]V7HAJ'5$H2H.]BEMLE8R
M FB/'IRTM N.L05Q*T() ;;334]VJ0?PT_&WK=Z^4?$S.[T'&ND)"3G!-02M
M*=P-!;PQK@77%.Q+-5H6TDDCGW!]?&V;(+F6:$E;$@@TI=M_0C045%)*G+6?
MS:FX'E 23.+<4^M;:LZ:G0G0;[=/RZC>WI)UK<>25I%:B@&@^OK:W]>@SVC@
M((!4=P>O7S]UEZ02QUQU(;2=]RDG?4_EM7\+=*)J4H2-D&@O<V?K?K4Y8$R;
M.'>4;#=E4]9P1&&<L;CGH1+H]M:*:=%#0=*:Z[BQ>8O/0%T\'8F9Q:0DPK+9
M2%'JJFGGX?.T 842E;<9+W%$A"5I!&2M*D#IU^5@#]+SQ7XBX4)NSAI<ILQ:
M9VVZ(F';4@%8:2AQ(U!U&NV]L7&D3U;,ON;.FY@3Q/6L6MG9[ND1'Q0XG0=X
M+A1WJ=5*2>SH%'93F0FGD=/H69.'=YYC<3AK?B;NQ[L!-8VJ@IM92HGU@G3O
M"M 36U?<GQ)O_?6Z,Q;O-!.2S.J'4CM"% J+@)U( U(ZUMK7WQQO==V[<!<]
MJ!??@8<5SM E*P2%"N5-/GX[6SY\J9L+7M[6RGFX:E.N<3E'OH+9@Z^D7F<*
MN(-^9K<F&CYU.WW(E2S13CA4JG:D:543[-/RMU\<#\9$1_#S=&)BG"Z^L/E2
MR:U^_H.9M^;IAQQR7@N%*H.7KD\5E;4A(:2E8_F'^QU.@_#>WZ!WHCL37\6N
M"/#.^KT.N'=F*8[,TNH4GLXLHUS 5^'+X1[(*OKK']OTSX[2?"GC6)XTGZ*'
M']U_;KVCGS_M'F'LJO3CO@[&QL.B(7#HG!.?7*DPR*[U&PMS//X>X>PT[#(E
M+:XDK2&W!FT->\=B/V^%ND?^TJSF^$GQNP@7=]A3D,\W.$Q*QEH@>KH'/K\;
M<T,)>^%@(M#UX<Z'H8J6X[D4H%2N\-A3?3>VM-G!"V4"0]&)&FX@O6GB\9Z1
MW 1<D^V3CKSD*^%TKC0,-!--R5F/B<G>;[3LZ: _(#ZY,>3W#NK,9RB(A+NH
M@EI.9S(\2"4BHU  &VXTWMNPU^Y9.(TQR988M [B"X^6@H>R#0Z#D;2_(6$L
M2:+G EPA.T35ML.9R0:@T5K73I_01Q22 G8)\35TOEQIPSA]_770?./9M-H>
M7QJ(%B#56' 0A*7"4ITIXCE]5L_[JP29C#/Q$1#EIV@++N4DIT->Z!4\AK:+
MW8F#<F:EY%(B77D]U2%+J2KQ'3P\K3_$NQEV[L0\=#+R/Q#84E(9S4RTY4/(
MV<%P#J 89@+ -?T9N)W^M$%MR=0BWFFHI:FB2D!<+30Z4!4GQWK97;EUXC+5
MI0\F'4\*A65&NNX&G7ZI9J2J]MY[P36$A@]VK:ET=1ZFEN@!T)5D'UTWM)EZ
MY?.6&(<0L5G4$5+20E)!(!(-/S%/PLH?,\FUJS\LX8S-V;QMN-(7'=KVCB2J
MF0?S [5\^7SM*47#3.'9AX;U'M^S0G,OUH-$$I!VJ/G\+(&'\GF4SFC;L>E7
M]WS%06O*DZ&A-3EY?J;*-YWYVN91"(>2)>AT$(0\F8-HS :$A.8;<QYZV4(<
M:?QI?/3@T;,%*9_,P^IB&<;>0@I;R1&<I!203HH[#6T5S>Z5ZF9W)98J,F+C
M46Y$J>2CU@4*3F2*I.M#TY=-K2W"8@M86R)$VF4D7$146M(9:#RG*_>!*M4A
M0Y]*;^=G/!\0,)-5O387-2PF4(;<;62%E2GD5YM]1^5+*&<4?-B/+GY6O$(3
M.XU]UN.P3*9LZIQZ$RD>M$A*5I.A%2:C?IS/*QY85\/>(%XVT1C<FFD0LB :
M9J[$( S9&UDUTV//;;?6T-78XG[U1\Z@U0USFPT^'^R<6PWIV*3E-%-:;:5T
M\;&Y@OQ:XXK$METIDC,,8V/90G^[0W^$S$#-3,T-D [>^EE" J^9W$6\_8TB
MPQ_A8O=%X=8?7'^QWJRZ'BWHUAR((SE_*^@$J.X/B?C;7/!A>^"N%..PNZVE
M^>/0J VN,920F&? S44H$Z:TY?BT<2^*3B!B+[*ELBF(A$2J#@4+R0[!H[%0
MJ-*9?\YVZ=-K>U[,7.(<W<N##32]KK<RC&YHN8(1#M(VJN'[J:#0$<C:N>FB
M77IUSAUW*X++W2&:W@F$0S+X9*H:&2A:HN#/9E;!!!^\KJ334BMI!P;X4XR6
MWWE,;'1DI0[""9.%CMH)Q20XVLYP,Y/^UM6GR&^"BL8XK#:?QT\OU'B9SR(A
MO45I:6"A$/$T<2G(OFC3E3XV=V"EU;R"\UX;Q3.],WBG99+LJ4$1:49WX-:2
M0 HIU/ASKO9E4!ZO2$SE/$9V^?+E!7P^#=W93.Y[,9Q?.5MIC7D)2X/57%LJ
M;41102Y4@$4H=*;;6F>X-S,,50=ZH%V_LNB'FX=I+T0AEH=GVC2LHJA1IFK3
M?4VKBN7A9%SF!FDTF,1.8Q49&12E-J>C@ !$+IE!6=Q0C*.GA:>[L8&0,@PW
MOK.96F:M1TT=EH)6[&K4D-O!*LN=1Y<AI8&$!,Y9_P!HU\7\GWY7BW./])-:
MU]N!S\S%MF$LDDER.'&/8D\<B)AG$QBD1J4Y [F><.E=]5?0L ;</,KR3&(@
MI5!.1\:Y%K$1V=31)=)2:I!'LZ_6A@21M5W^#N[\&XZYVJ67@ZZYF2LYGQJ:
M]X^^O6PLX<8MP.%TV?BX:&;CW8M+O><2%$*"5 'O9N9^/D+>(_\ B O _P#5
MD)Q(2I4L(4@&FP2Q!%AJ:N(T>Q2?I3:5JW@ ,OFT6C</5TS=:Y,"B)0VS%/I
M"G4K6E*D&M:*!(IN=_#?46KR]*Q?&&N%AG/+R14:S#J;A5B#(:0LEPIR=UP"
MH[Q&H)M F('%UBE*XF81\HFZF()\J4F$0E"0UEKD \S38<M=1:L/B>XT?],U
MQ+R8;XS1&9196F41"E4*EC,LC[JE>]EU).^PVMO=C?JSLJ?V;*P@*2J2G820
MQ_J, X:E37=PBO\ L)BIRUK< J*F+TKR]#%PWH0<2(R_F"DVBYI$.148J(<+
M+SCJG*(];=RTJ3E[@&E/P(M=K/(/MY)-&W3F6N6S 4(J"##.4%/?3W]+<XG]
MGSFK4/<>^UW6WL\%!Q#1@@=3V;D0ZM-*U.HH====K=)\<$+@HQ%:UA(M-/!3
M*P0?C^MO1NS=B9V2RRDJ*+.#6E&!TZO&=B4!,T,DBSYCE2UH_+F]+1)4RKBU
MQ(:['*RY,UJ->[_G4.0YD?TVJ-F':L]A$(*0 Z%J I4I:6#E\*@4\O*U['IS
M9*B2\55ZG&4]FJ)C%%P@4J<G=Y;ZZ^%J)78:.CW3!P<.[%1O:(#;+"%ND@J!
M-0BM-.O['!PJ5A>)"0I(V;5:I'&_S!5RRN0DI.R4$*OI3.U=,XZEO16\/,!Q
M;X.LN7)@E0%[KM);$04*6.V6MPA.9*LJ#HC2M1O:YZ"X%\>KLF"AHF6=JA">
MS6Z2RE+;=,I6=QHGO:T//>PU?V<^[XN-A^F.C6V8*831+8B(1U:&W04K(35"
MB%<Z@4_;J+QDO3#W9PVO-.HMYMLLR]Q3+A0D*27&E4HKSI0C\;<UVS^E^R<?
MA)^)QP0F8A*E J^XD.07<&C-2A+18P7:2Y:@C9V@"G;\F>@RZ,4%W\P]B<-8
M&0W+=OHEZ,FS^6.ER%I6F%=[5*D!12X4BBE4UI\M&!Q&7DQFN)=2#N',9N\+
MGQ,.E<)$0X2AEQI:$.K';-&@I7+[5:^.\ WPOB[/+R3:?O1+[D2_,(A;;CL0
MM79!I]826TJ40- #04T'.UG_  WX=0O&!@M$7)ODDK8DC81"3I:%%VKBR0 L
M=]000![5-[>.=F]C+[2QF+P&#F*3+EJ"9:E=VI:@?0$L?YC9Q&*EJ2X#!K!V
M:@M=L]WA% [L[B9%-V)M)G(KUQJ*;>;?9B75.K<0ZE13E"LRLZQEU!WIJ+23
MQ#8TPV*\HN5!WSNG$2V>213;<;,%MNAV.ALS(4K*EM)72'23IF(J=>5K(<;N
M$_ O@O95?>_\Q1>M]/:NRB2+2ZQE<;KV=2E2J@*RFBTZT%;4W8I<4T1B#BI(
M;P1,C@X>Z<MC!"L2IMMA(7"O*1#@+4AM*C1NFX)\0=+7T=E]I8+&?0FDJ2ED
M *7]S,FE:\J-06,49*G#@@9U(UWMH/Y@NH[CHP3X4;L2.,P"NRS'7LCX5")^
MHK6TZV\VVE%5(B$5U45<J6]+K>FZ1-X]B47\NV(9N8'U5^,#W^ J)^[0HH;0
M*A*E@UK04Z;Q]C/Z.:\>-LFE.+&"L&J"A;SPB'W)>"%(:6PT@+R]J: +5F-
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MTH0D4%--=.EE6+E,+#PZH& ;2B';2 4[@:'K]>[6TF40*%LN;==&,$@H7W@
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M:-J#82,BJU4O^4:>-K7N'B60[&'U_P"9RN&C(:01R&G89B+0^A*E%3A5E$0
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M02"%-$ZG\^EKUSC//;MR&403B5*9:ED(-5 :>KM]?RMM201+2"&IT_5F@*U
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MD?,XA^/2Z$-,(J08,(424FFA2"#ST'E92CI9.HJ/4\B8K;0M:DI2IG0:E/\
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MOG73M4ZUTT&]JS85:.V:AWP5Q*EE2G-1H"%)&FFQ %+608%M1D5=J$9$*XM
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M;R$F&AUQL&G.JB<H*>TK4$IY$?$VC^\?!3Q5WG<1'M2];LA S-0K+\/D531
MSH5I4@;V=4S!2V^HI)46(+5 I0\\S<>$3P_UE.E2*UJ&T%N-]+0,=XY#>J\4
M= 1T]C%3I!"EK47$L@!(JHFA 5H";/["?AVO#CM/(V17 RTEZ B(:06P6RM!
MKWE$:U!VK\;*DYP)QUP[6)9?R[BX%<:VXS(PJ*;5F5D4E1)2:;E*N][JV??!
M/B//.%3$N]"\48-2C-E-KERFW0Z <BE-I5V.<=XJ0.]MY6 V'F*>5.#/]M[@
M6)OR](L*3LEK6#.P<BS9;F\(:4ZX4+R8,31$JGA5]I13BE/NQ1 2T$**NZ7#
ME545]DG86B_$^X$_O4Y#RJ[4,F8H2RZAZ*'9I#:@C0 FO,$"AL37%[C_ 'RQ
MSO/ 0;<O7(&,[OV;$L@+7$(70BJ4)2H533VNO*F@\+F6(V'TB8AWX-Q3JZ5B
ME92MT*4"DZU4  >1YVE#*^T\.OQ 03G#7%"Z"5PTPE45"P[/;J9BNR+S;R>\
MI0!"2!TT//2UT_HR(J81G#]B.8UL0YAA"AQ*DA*E_?N &E >7B+0) XH1TUD
MDID]\X*$=E8;>2^ZMAA+B4N"I)4$9S2NFHKY6/KA4E=Q(3#&_(N1$H6Q&(87
M$LM!02A25K5KR]HGE32T%VYQ)/V>'IEO]N4'MP_O+3<B$-:(+C^5(2!7[Y6^
MFA&]/E8@&U%0J?K>P^8 .%VX[*5"G9NOA&FO^,:\O*Q!,434*UKRZ?7NWM5G
M*V4[1<L;#>0.%/.'2G:W6CV&77,*BVDLI%5)T(Y5_7WU^=ME2TT(KKK^GT:V
M3'7$YJ5YD_7E\;0!< ZU@B0P:/3ME'<FOUU_>WLA1/.H(K;Q0.Z/KG;U1O[O
MS%LF9]ZO^6KY],.4/76G#\QB5J"AKS_&VO%.J1FH=QKSY<_KK;V&X\Q;4C%I
MUJ12FOP\;1AE%@80Z)<*R3SW\:DV18AP(6E.]*[>/4^%?.RLM::*-137Z^M+
M-Y25N.Z5(!-=3J/S_I8DM6RIV=PW"H]A$49GJGH^0W9QZQ+JG6"A9 0$+HH4
MJ=/#;6GZV#'*',6HE"U9F6BLIZU[,^_EUL:BVFO5G:IV;6=3_LGW^/SL$2G8
M=O$^:NI43V><*YT^[5]:\K:<F6@C:8<",V<@^.^'4IJ7IP^3YP(M_.QFO%/=
MF$5"]JF'CTY7>T(H:(([H\A6UQ5_VT(DDH6XLH<$$PG*$[A+*$@$CH*:;<^M
MJ9H1;4;Q:RETQ0"&HX=U2=*E*0-2:<MQI^%KKK^0[[\L@ A"5M"$:.?NZ491
M3XT\/=:S3(,-(KK3M$FC'+H0+,R#A<KLDFH '3X<O/0^=M)/:.()6:(1R_IO
MSY4%EV8H4VLYTTUI6FF_O\K)[$&MX!)KF*@4@?S#-4Z#K6SBXXB'% QR+?!Y
M_F/3$R\(N?@'>Z\$<RHPL/!YDA*E))'?"B"GO5]]N6&,XB$SW$&9+DD1&PS/
MKD45-J=B"D%M:ZGOD ZCIMX6Z>.*V(8E/#M-H.8NI8A8R&RJ;4*E:0KO53OL
M3^'*W.#=+!^Y5_;RQ,ONE'I:G,4Y$);93#'.IQ>?-[7B?G8J4H27"=>GRRB1
M?*GG%S?!1B1'WIP%OG'+F3SWJK++84<W=)6M! ->9&]=;#_>:=3Q,TBUICXI
M"R^X4E+[@ !6HUT7TY'XVG[A/P:O'@G@-?>23EQ3JXY#+G?;"%)':K6*#<@A
M7+SL/TV8$1'1A.N5QS<4.ZJ[\A_32UN24E7VV8]:\X&HE(-;Z/DW7H(0&[Z7
MNAU(6S/(Q*TG3[YW\U^ ^'G:3+H8T8G0,<TEJ\$8$)("05J((T'-7OI^EHH9
MAVUQ"4#O!2B$CEIX\M?TTL\9; J1%(2V@!P$:U&@WTIO4:UM;G%"Y8.RW]IS
MJ&/.O/? 74$N%&II8-86]S[1=/P>XP7LCVYE-+P3%Z+8ED,I]25U(HAI2]JG
M3NCD;4S^D[XD[XXO7\:B[L//1,MN_&.0S,(E)(2I3@:5N-.\FNHM;!PA0[*+
MFWEBHANB3 J9=5L,JV5HK7_G?GY5UXG88W9@[WSP.ADLS.,=?:)*7!F0XMPT
M!)IWB-O'P%N:Q&)$C&(2$/L[S_M/ERW:Q;1)FK0E0-% %O#CKY[XKRET?-(^
M72QV]#CT%-&6"XS#A"EDJ" H:I[O33W4V(CQ>).(T3>3U6!NQ&340;F2&>"%
MM)6GV=BW36@WVUL4<>W#_P"E&6R@P*(IA"RV0D#+E"0!4 $:6,V5W5E-WX9$
MQ1)H0K>0@H5V#2BV0*$DY"?<=SK:SC.U96'$N;])W(:HT%W'C\P?_IR%,"E3
M%G<@@ZWRZTBL&=X^WPN@6H:\MUXN71#JV AH(==#O>2?:0BB=*#KK;]'OT(-
MZ7;X^CTPBGCT(N"5%-S$]@X"%)RQA ]H!0^M][<6LWNI=6^CS2)K(X2.B4N-
MAI?8MI*3F'()U(H!0=.=NY?T3EWX:[7!5AK*81A,,PPB-R,H2$A 7%UI0 >%
M/SLV$[91CYADI1L[*-NUVV0ULGK I^!EX9"5I2026R8TR')_YB@S^T5WA;NS
MC)A/'LN)3&=G-PA.3,I0,.@&A.U+<I=^YU?Z]D>[_"R7UO1"_O'%-$I"1N 5
MC+M4BGNMUE_VB2[=WYCBIA9,9M&F&>A$S/LD!M3F;,T@'NCI\^MJ)[ARNZZF
M$H81ZXZ:)),$MLH%=PK(*Z'Z%+2G*:8JC]-UR@"38:?+^+/X<8%2[&#,1'7,
M>F]]V'(B,;1F4R5%O.KD$Y3[M ?*S>E6$BY@PIZ2R;U"CE$-MQ-5+[U 2 0>
M==0=]=S8_<079#))?+X$(5%)="AV"4+;U73164:T)W/B?-$PVNQ"O7H@VVY&
M^EMY7:9%+=R$9<QW&7G];@6WN/7+CU:5;^60=N!\<M(']BYF(]QI? .M%282
M9)5VT.IY S(:Y54NHTM#=]9O$SZ\$LN6[)C!Q$SB$(5%MQ'::A:"5'+L-2=]
M:VL5QECH5<S$E:NB(A,M0 %)F'9T+B 3W01Y'G8?+HX:?Q+>Q^=PUV.S>EWW
MZ,T7VF4H1FT)_P!WEY6<+=@UX1-"S6R.[)J\*"Q,.>:W:FMP[I2B[$-,%I2A
MA#CCOJW;$]HE+HUH3I7ZY^^'L$F?3^7PKDT]<5#N!2F_L[)[)"M59-=17\;.
MIB\=Z[RQ;\&)0A2X;^[H2I3:RD-_=U%0?\M?'I8@,%;D3" C8Z<S&&;9,*RX
MO.66^XI31H0 -:'I7PM.$BJ2K2_-M;4KTT,W$-Z.:G+:F9B]!P<.VTCL&I>I
MY*B&TIU*4$#5)]_*SRP[=;8*9_>285D\(RZI?:0?8DI*%=4A7E0UMX0DQO3-
M)M,DIGZ3#J>4E"52=MPMA*R$BJFR>7R^,I_Z.[R3FXTS8CHIR/,6E"8=MF +
M&A5K_AI&X.OOM%1;KQB0&0R;?I\_B& ;Z<--ZX")AG&/69G'OGOAN(!*H9Q1
M(IEIKEIIMI9"?Q8P,E,9$0*+GF-3)NR90<SPKZP C_(2=:_6TL84\*D"J&9B
M8J2F'B81,4XI;F8=Y86I)H0*DZ4\;*TLX89A%O1T6W=]IQ43$I*'WE(:0X&7
M=#5P &@'7RUTM'ZF[S_$,0:ZM3IN&;'2-W#O&K#:2S2[\G@,.DQ"HAN,B0E2
ME'LBV@O(!"FS[9T\;'-=+BM1 83WEO; 880\KCFWH6%9;46_[VGUCU8'O,BN
M5)VUM#F&7#1/GKU&8"7RQGU-#38<<BX(94N-A!"4E8KIH:<_$V,'%7A^F4)A
MM=*1P<1*Y>W$O.NS!:WX*'2YD?2XD]]:0H=*$_.R^INA!VKU3YB*+@<2F(\9
M>ER-;N9"PLD@H!^)?B.QA5"$<<A%.,Y1V5:K<I6G77G;:N3Q1X^WO,L1+)3"
M,F,F<4'7E0T$<[$+%J"2<S8V;3OK0>(-ITNYA3*6[L3.1P5Z)*B>S:&A89IE
M,5 K6ZI" B@/:[BO+G9;NK@9=_"!-WX?$:]\'(74IF#B<Z&E=J(H*6A22E0V
M"P:\ZV6WNTZ^(8U#:YEO'H4,1K>3'[B!F]_+UPTNGS<%+X%J40[#:(2%<#3C
MS*&WB%A/^>NG+:S]QIQ,QSNAA]A!=IB\Y7,9\]&JF,2AAI*G4=NAQ(4A/LY4
M*/G;<NI=W 2$O!'0[N+3$=,)],(4P\(F!6I3G9O@A ="SI0C4\K3_P 0,%PX
M79O5A\Y?N_JX1$HAE.0\J$NBG@L.,-*J'&Z@5]K04UIY1*U$4I;7GG$@>[LO
MS _%;BL#S'74OW.H>(==OC%AR;"5]HTVA22T1V?:92E53FJ=!K[[1UQ7W;O_
M ">;8*W.E%[YBF!A%Q$1$0Z"]6(/W,00X0X"H$@CO5 !^)K7+QSX39_>:#D<
MDFD1'1<6]#M0K1@8]L9T*2D',I.6E:'\;/'B0O7@-=:_MVVIY=IZ\5Y##'['
M2CUI 8+L.FA(0DI]DI]KI9Y:5K4VVQV3DX%N)^2W"&([K<*WZ>D1Y?.:1$QP
M#3%1CI,<S+FFHA)-".R0E 44_P"T!7K4DFU/TTO VE42C..Z\X#WM?;(K\=O
MRK:V6^TTAIKAE/6H2!5+E+AU+$$HJ5V;925H'> V21X[6H?O5/3"3.9,J<*>
MQB71E).OWJCKT^N5O,?U'V8B;.F*6RU:D :-[P?!8A6%6S;5=H9%RPO[Y[HW
M+]7C<]7B$H5W4ITUY$:\_'2U0W%),5Q*(D_RC.2:BNA^.XV\-C8^[Y7K"VG%
M)> JA6Y&X3MKTU]]JM>(:=F(1'I*Q0A95J32E3R//;E^=N=[+[+0F:&0 Q<!
M[L1X[L[/I&Q/[00I(=#%@_>JY":9YU;\Q,OHG>(#_0;Q37?O-$Q0:@'(E9?;
M)RC*VVI)"CSK\.=NV*['ICL&[Q7Q?N;]S#14'"LI4^MY65:S#A1(S )WKUZ5
MM^:=<G$*+N9>5J?0I*%PSJP%)-" HE)VYT_0UI6Q42?'V?S2;.S^"BWH:+R(
MS+0X4J=H@)KF!!V\3OI;=[3[.QJ4IFR<1]"60-I !W9O?6G/*,XXI!_^GI<G
M-G_&<6D>G4QBAL=\4X>:W:=3,D/+=0VTTL*J5(0VFA34^'F:6 _@=PNF=RYC
M'W@OHEF0%WL7(1<2XV"H*3I0+*2="GX^ZT13Z^-Z\1HL1T"A4RF\JK$(#C@6
M5% #GLK)_P G3YV&?$3B$Q(O/'B7S2(>E+TK/8&&9/J].SHA-2UV85[(.N]N
MG[$E?0PP,P%:E)J2=0*[K6SBA-F5)9ML[)'@>MYRCJSP*O3#R:]#<Y1,H=YA
MIMQP+8?;S+#;:E Y4*)Z=?"U?O%#C<]B)CK>2-BH]R*1 NL-0J7'%I2P$-Y%
M4054.B:[>/,6IUP7XK\3,.KXR>*C[S13\C#R68J%.9_,RX4H(K51T378?M9#
M((W"7&O'NZK*)NF3RJ\?9KO!,'$NY$D,H4HE*BD"I*]B.HUI:A^H,)+Q4H A
M@Q[S/9KUX4MXTGA>XL$EPI0IIE[;O>+2/1@WRO7.<<8*[DI4]&R*; P\YAE5
M<A7V>P4@@I7F;%$DC;QM>)CQP'<+US)1/L99S*68=<"P)G&2\K>2B(B0CM::
M$)1]]O1)'ASM2G.N(W W@7<@I%PYL0EY+YK995$7C0[_ (3A0E:Z)?SHUS*2
M:*%IYP]](M..,&Z%YL&<0P)-.YK K;ET>7TE,2Z&EKRI0C*@:Y4[\^=N#Q6$
MD(PJ$I2)DQ+I4& )&T&-1ST-]T;%5!PLH!R9Q8#J]XKKXE>,^>W\7'7#N1#L
M79N#+7EPT)+8=ME9BVX9134Q 2EP4* K4U\[$MP=7&EO&E@].,)[RP;<#$29
M"4RN==DE;R'7'%+)*D)"R2I(&J]OA:KC$+"&^UV+_32Y*)9$1LW:CWS"LLI+
MBXIN*>6M"AD"O^+6%:5\Z5%NC7T5&"LQPLPZF4TO+ MRF;3=+"O5HMU##Z"%
MD5RN%*_Y@:4%=!M:QV9@):PA*T?2"V2H9D%G\:L,^$5U3%)"JV!&^C::\=&:
M\5I8D^APQ<DJHEJ23E,T2%J,,0VR@H9!)J25U)#8KJ:^-@PQBX;L.^'^Y43#
MWLO6J-Q(S!#LI94XVID]I1066',A&2I[PITMV<WN;3))7/)M,(L.HAI;&.LN
MMN!U"*PSA .0D:D "W#)Q87C?OQCE?V;//NN,,S):&VUN*6AT)<<;[J22$4
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M,:;U\;=UAE+^C+EDOLA(?7*HME$E3$%+!#4OM<.%+]&G?7*WC$RV71"DY2_
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M:&M::T]_AX?C8^'0E:V4' 2]]"![PVUW7  KEX^?I2/B953"/.E80E+3M/\
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M%O8\Y#SF'>4'0[VZ2@KHLJH$%Q2NZ!M:QK%7T5;E[XR,O3="\:H)J;--QH@
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ML42HDNM)03W -UDUL,%][^7GO9>.,G4SF+L2XU'NN0P54"'[-Y60)170"B:
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M_80XI2!$.I6GLE4&<O#VJ;FOQTMO70O#*,(H^?0D2ATON.YVVPTZ<YS+70*
MZG^FEIPX3[N1%Z+SWK@X*#0M<5,5!Q:<JEJ2E]RHI0JVT/RL<=^^&[#YEM,?
M,I"VN8A*2XM9*59R-24TUUUVMD3L&9BB%#:%-^FEANC3ES990E3M_P!P>_#+
M7G2*HAQ 3:]T[C(-2W9;!)HEMM:5#.,IV40#R'QI;[EE]HJ1S5J9M1"E.P[H
M5WE5J%*UU43R_IT,^\7#I<=2V8UJ1I;HJJW&E*105 %0BA-19JWOX8Y3,X*%
M?D3_ *GZPDA>9!S)RT T5J>FE#I8F$PW[90V4E()8V8BE0_6C6@,XJ743$D"
MK5=N[OSWWAVW/QRN5,O5$SJ8JAXI;8#J\SJT(HD5J$G+M7RL3EPK[X=3&(6)
M?>B'>)R@)203F/(C,2-3S_:P\X2\(,@A97&JO5$=LV^E*&HM:BWV?:52K90
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MO,5$+ 5OJ-+$9CU=S$:4<)=QY.W?:177O.N&=5'S)V'E:FBOM$+!0PM26E
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M4-Y0T:+U(J2*>[\^MB=X5\!K\XKWSD$3+I"]%78A8]AV81RNXRTVEY"P5*4
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M)E*&TO:%18$MD:\^#P CZQ"@6SK6Q#6X1U#>E)Q,N-A*JZ.+=U>&F"O^F_T
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MGNWU>F"4NQ$&85B'RJ6XNNM:$BB@#X:^=HGQ$GB8Z)@IC)XXM+;<3V\-0A)
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M>DGG,'/)O<Z]4W>B<.;QH=A'H:,>4ZAC*VMMHCM"HC[Q23I2OXP1"_96(/$
MBX<GO0EF6SZ/SPT2%4:;;?4'5"I4$T"5D;\O&U7M>;BI2ILQ)VB$@DJ (%.#
MBW5HMX5"5J5M D,&##,V8ZQTT>AEN5*X]N\=XED14$LMH,,X.TAU 9VQ]VH%
M"O@=:UUM=;>W +"J^*'!>"Y$KC6D*55Q,,PRHAPFNB&@=*T/E7RJMX+K[\/7
M!5=:5X?WEOU KO!-FV%N/)HLI6O*[KD<4DZ+H:G\:6N$NMC;A-?OLDW<O;+)
ME%/0;SC;1?98+BNQ4MON*<&M:<M]QK6Q/TWV@9@7M;)N[#-D@[5\^!MS;$RT
M2U!204TMPW>=:1S7^DDQ=:X?KP1.">#$I@;L2B-243A3#,.MQQ+B Z*J4@."
MF=6H(KS\0CX-<1[I0EZIIAOB3!0LQD=_T.LLQ\2A $)%%M=%"J24YHAP?S#7
M6EG7Z3%Z8SWB;O8_,F7&ELQ"0WF)[)20V0DMK-$+!2 >[7??:P28=R":SR^D
MB@I6W&O1+DT@4P[<-#OE;=(EL%0<;34"@).O7PMHS):)^)V)8(VU$D.34D?:
MG+/=PBLY57,MU\>\2SQ'\,-[L(+]Q\%+Y#'Q=W8A]4;)IE",O/LNL11]8 '9
M(6@!"7 !57ARLI8#<'N*^/<W0(.5/2.008[6/GT<!!(90VG/F0B([($C*0,I
MT/B1;L@P;P0NM,\&;BR^_P!=Z!O!&HE;2HM<6TRJ*0.R;4E*RM*W:Y=#4[ C
M2U&'I.\=Y[A??!6#N$\.Q<V[R4K9B')<TTVZM*VPM04MM*'.:AJ=K#QG9\N5
M)6-@ @.[#=7T@DG_ %$5_N$50XAX114FQA1AO=J^J[P7@DZDIEL:5%3<+%MM
MA92E:W%(/WB0G15#2GA8->*N]..KUXT7#QGFTPBGY*@(@W,ZV6RR4!3(26E9
M31L(V/SM)QG\^D=XH:\<LC(AV?HCF'7H]U2UNO*6\G,*KJ=1IOSM=;!\(5PN
M+;"^[U]\0(%#%Z50*4JF.506XH(2V%$-Y*T \M.M; [*2N8A245*31@3W0P'
MMPUB&(#*-K[CD'%]_OQY&IQ>6]LI:6Y+Y_,89#*@&DF,?4!10 T4X1N.G2MG
M_,,8))?O"J)N??F'5%7L@FA]DSEPK4O56=8*@"#W0!WE>5=K7.8U^AO;2Y'1
M=UKV$0:4J?4QZJ0$,M)*U@J4NGL ]"?,BU0N/DAP?POE,1AG($(F=^)<[V4S
MFJ>U3D6VYF(H04',D*30&G.VPM$Q 2%@O_:X.3:G@*@\8%+SY0XN&VYW#XFX
M,POAB#%0\1>.4YW6):\I:%13B5K[(:&@IE3R-F]-^-O$263M4+<A29'(90ZI
MJ7R]I#*VW64G**KRC=*0>]7?PLQ(?!Z"OCA0J^=T(YU<WE:"9S)V'%A0!7D0
M2@*[PH"K1/[#"&E,//,.))6RHI=:75*PI)(56O>J"#\+0 !))<[O#.VX6W02
M+,YGB.SQ@8;O2J<E,'?R[[*G&6,P*H]1)6<B4T0,J4:T!_*U<L]ETRD$S5+I
MJTJ"CH1UUE:"-5A*BA)T'-(KK9PX9SR]EV[V,3BY28J)F:0L(@F&EK;4"C*X
M'% *11**FJAXV]L0;P36\UX(F,GD)ZG."H&)94 DYJ> 'X>=H,RB+@UNQ%J6
MR_$$'VOF&;-]+9Y,^=16&.I.5) 4:'4^-:6Q&WO_ "%OFA5777F/+Z_I;Z1M
M[[3'V'C\0BVS2@-K[CRZ(C[M\^U5(J"#^OC;ZM]MD$D<^OE32S)+.=WN('']
M RH(4?,[]!7\[>C399"7%_>)77+4Z'2A%//3;E;S6I.4Z_(];+$DD,9>1Z'E
M<*5&(6XDBG(!0*C7RT]UB(41>FTH#1@6MX0RPZ."OCH<(ES!^ZCTYGT,^88E
MAE?:.I53)0:C4Z';3G^-K=\$(3">[T6B\N+,^3=>ZZ>R$*^IAQZBFNZ2A#=%
M@A8&VY ]XQX&X6Q4Q?EEVY'+7(Z9 (7&%A"E*4EL!9!*4G=.;XVE_&!B?Q\S
M@[A/</\ /I_+I,D-MAAV80Z(IUQ*25%3;%-%BNYWMT_9^%V2%) JD%SO"3E:
ML9T^8M:B"6 I3<S:QT?W,FW"#Q>\(T^PME-^8J\\MN; EV-B&H>80[R&5*5$
M4317:FB6R*)-J"+P0'HK[HSR)D41"S^:3*61,4Q,VR;RT+C*U((V4G522*C0
M>5K5/0@X?7Q9Q/G]R;RX S.YMT[SPAAXE4=%1#S3S9A'4HS%YI-*9QSYZV9'
MI"_1QXR7 QYG*^'_  )9O/)YI&*B'7&E0U$J?^]43VC2_P"9PBQ\2@)6&HQ&
M?_&_5HLX6J:U9*O)NLJQO>C#XHN *28K#!W#VY<TE</B&52Z),9]LO0\6$-*
M; /K3?9HKGIJ=S6Q!\3<5P(\)?%G<^XYX7(N?7CO!>*4Q,OO&B(F88;B8^)A
MGT1 2F'6R A;Z5D9@--;5]X-\#'I';N7_NK?&Z>!B)$Y)9E"1+[B1+4K8:[=
MI3M%EE*B"@*VUIYVZ4N*7A,XD>(2XW#[?JZUW97 8DW?BI:N^ZWY?+'XD-P<
M3!A?WS[=:AEIT50:]*:6'%A^#9UB^VZ[S,1=F[L1#,^KP[\BE#S#&OW#+LOA
MUM,ZT/W:%)1J >[K9=LBW;AHF"N[(8.-IZY"265PT70 #UEB!8:?H!H!VJ%Z
M#0<M++5K$ C+9;+990HRV6RV64*-:+_P'O\ D'_^R5;\X#TO=XXF7\=V.$.E
M+:F4Q,KSUR))_N^@J=?+P&UOT?XO_ >_Y!__ +)5OS9_3%RR&C^.S'#-#**T
M14J*G4N'7^[U]D:?K8,\ I#^CUI$%;1* ';:JW6L5K0&*+MVYW*)S#,JA(J$
M?"DQ#9/^'G2'0H@ $+14:\C\2EOU@C%8_.76QTPFC(>6SV'4PN?%#K3+@+"F
MVRI2%K05A02HF@->=2; ]/8*%3 EGU_0@?<]@:]W8!P@GI6A_#51N7BG?:ZD
M*97)IN_!RX43V+:^ZL#JG-I7R'PUMB]H8?$3I 3AG2O:%4^5+6Z,;O94S#29
M@5B4;8K0ATM2A%GO?7A%J]ZL)<(+TL78F]^)1#WAOG+84)G$<FK7:OM-(2UF
M2V,BBDIH=ZZFM+->9,-J9$LEDN8D\@15I$*Q#MA9;'=35Q"$KUZ[_.P;2/B*
MO++T4B6S%UIFSKU)&^I!.NIH:?I*<DXF9/&*2B:P(8B%:+)J4)---,N7;X[U
ML#!=CIDRU+[1(F+8%DLI65 !Z?Q%S%=JSYBC+P<GZ4FR=E.R *: .Q-2 W$1
M($YP_NWD:3'0S9ECP42%-]JO,1[6>A6.]K0D<J=3$MX>'RXMXH9Z$AY(W&.O
M'[B)<JTF'36JE%2P$^SKJ0>7.MB)NYB+AQ.X)3T9&LNDMJ4F#4JA=6 <J0HF
MJ=0!I8>+Z3?&K%&>N7/PWA8>X]UW%EE<Z]8A8EQ3!]I00X4N"HK2A&]:Z:9G
M:G:,\*3)P,M>&EI9)<+EA8##=>E&+^<7NR^PTK'U<7/VG[YVU]XNQ( 5:^F0
MXP(.+>"&#V'C(<BIHF-GJPM+4KEY<>47=D-J,,I5**(I5.MH+N5PMXHX@/1<
M\;AXF[EW6ZKAD.K*5.M=[+1*BAS4 &E"17PTMDN-PNW&PW"YO>5S^/+WOY77
MIC$ON%MM[VBI+"UN-:$[ :T^+OFS$TCG4L(0F&@6]&68=E+2$H% $D-!(4--
M#K7?K:79LW&39R4[*U!BZMFKTM?F;\*Q8QRL%A$$E/UMF@">]H!QRW#6D4T3
M>X>-.&C[KDECYD(9A1#2D/.$***BOM]:$>[G90N_Q-<2MRE]H]&S5UED@H2H
M.J "3KN%;T^MA;%.;N-14,&8N#0ZD#11;!-=^F_S\==6(_<N1/)4Q%2N&6V0
MH4+" :&NM2BNOC\K=<B4=D!2*LQ>AR<&WA^8XV;-E39BE2TE(_Q4* $AF%A6
M!:NGZ4#$N3+;:O) .Q(%$K[5D=X"@/\ Q9Y#I7IM6Q+79])#AS><);O5=N%6
MG0K"\J%5/M&J6P1KR^C',YX>+DSJ(<6N6,(2O8I0-,V^@2/H<M;0Q>_@]N\X
M"J3/%E[71 4*5VYTTY5\O&S*PZ% E3 6[UJ-K\P!1+T=C0$5!/@V@J_A%E$K
MXC^&O$-F#8=3#0*4G1H*4X65$^U7<ZU--/(6F>6IPPFS2577OW!!Y_)V;"RA
M!2!I3*XX#H-*D4YVHB;X9K]8?QD-.8.->BH!2ZK8234IJ!3+4JKKII4V_E][
MB8K2DJOE=J91\+!--I5$P;D4Y#);*4Y:H[1: K4'V=N7C0GXE,HIDH*"H42
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M!-EPK;1$LDI7EU'=S#4V&LEVRR M$AD<\SO_ )B 99Z,V^4/BE=J]<RQ&AS
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MHAYG'PQ]8B*"' !4H$]TZ)U&_2S1PLPQ*XEF9Q3)4%*04-E&M5>SE2*DZTT
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M.ETA9S$K(<KOM2TME5VZZW/I"BFB;\-_%E!W;P,E\\F=X%MSV;QTRO XB(B
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MZD[AQ<LAEK!\<RB#Y6<EML6' >D9L9;+9;+/"C+9;+990HUXK_ =IOV+]/\
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MWXF"</8.O(52@*75@#SH1RZ\_?;U$]ES)V'"UI3LA6QW2Y8,*C(G<;Q@_4F
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MO\;6+WGD5W419B(N""0\RE4*$J*B%9=?9VJ==?WMQ7Z_GRU3<)]%-"H%7#9
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M85WLWUKRIJTH:9ATMMS;TK^.$YQ"X@I@N9,-W.N&);!21],+"=Y^*:7#K"'
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M+)IH>MK,A*2IS2I+[^GA)(=B10\FI;X&]HL4N3>+#UR]T&\_+V4,.I9:22:
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M6.>(V(,RC89B7S600,NDRU/0?=<1)U03H'WH**+--:5L1.&/HN\1+F\">(^
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ME3'T>6/$85?QGQVRKMD]J7G$)EJ,B370=E,!7*--.E@JG)<T:WMIK#L'?/\
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M#0<S#\6H%500EJ(S$4)UHD=;%1B!Q"8)7,NBW/W8F&F)BTK5+Y?"I+3B%(-
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MK4Z=/B"TO"82;R O/1#*%MM,E"1ES*H$UU!'(4MY1^J,8F9VG/PR2Z) !3Y
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M_1\W=N%?OUO$N FEV\49Q#N1<4AMXE47#S%2PV,CJEFD0O(:&E/"TVXFX!\
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M#H)8:<4!]VXHD@$^R:$=#;13+EH2 KT)%.?6FM!6/Q2JK7M'*H)R=\O.*/\
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MYI*(U*2$L-M91F%:5):3N!EU/SL1,UA+BWA4W,[S(>D$:^<R$YWW<BU;=Q)
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M-O*T.W?P_,9=V/OI?B8_Q3',N.+A6RUZHVP>T4$T2CNFE$\MA;+9:ILCNTN
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B#AJX_=>[[RSM5;LIA%J-.7>4;.BV6RPX-&6RV6RRA1__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>nt10006151x2_graphic6.jpg
<TEXT>
begin 644 nt10006151x2_graphic6.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( >@$X@,!(@ "$0$#$0'_Q  ?  $   4% 0
M    ! <("0H! @,%!@O_Q !I$   !0," P0%!P4(#0@' PT  0(#! 4&$0<A
M"!(Q"1-!410B87&1%2,R@:'1\ H64K'!%T)3=96TT^$8&20S-C=55V*2D]3Q
M-$-6<H*4HJ4E)D=VEL/2-6-SA+4I.#E%5(6DLX.RXO_$ !P! 0$!  ,! 0$
M           ! @,$!@4'"/_$ $$1 0 ! @,%!@0% @4"!04    ! A$#(3$$
M05%A\ 42<8&1H0:QP=$3(D+A\3)2!Q058H(6,Q<C)'*30V.$DM+_V@ , P$
M A$#$0 _ ,_@
M
M
M
M
M
M
M
M
M
M
M
M
M
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M;YP6<Y_'N&U<II""6H\9Z%U 1(#A)]OE)7,7K="\?V 3[1Y];IY[?#S^H!S
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M#SCZO/R''Z4URI49[*\MS^'4!$@.)#R'#PD\_9^/QY#E
M
M
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M1*B)7,7CL9]>O_$1@
M
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M^ZKII:%_/P%4U5>@-R'8;AF:V'#;0:R/F))F9K,\Y+[P75.  +V=
M
M
M                        0TO)-&9*Y3(RP?7Q%O/6W@;HNHVJK>M%A76[
M86I2V7H]5JS,=R4508D1CB*2IOF2TDRCJ4C&^,[;BX;)):FC)!DE1J263WV,
M\'U]G069>)_M2J/PJ\8^GW#_ 'W;[QV9?KST=5SL]ZZBEN-,-K0;S;+:C23C
MSA%EQ22(LGT+('[?M[O4VWV4&F%)A55=7N-VM5>NRFYE6GN-ODJ1(0]W_/R<
MYF7KF>"+;!["K[AXX6;,X<:S>EP6HZJ1)O=NF-U0U&YA!4M'(S@G#/J77EQD
M26XR>,5W0W3[3^_M/VV+G@WG4*:PV_&D-FTJ/.F18^347.E)H0_ZQ9R1E@^H
MK0@ZAVFW$MYNLW!1J54:S2*=4$T^14H:'B<EPF9*TJ2MY"TX4YMDM^I 9>>G
MU43Z]]G/IAKKJ%<&I==GJBU2Y)5*DRV^1U:5+I2FS8+!*Y2R:-C(OZ_4_P!@
MG8"K]M?4!R:MNK6Q2)U'A-$3V#CSJ<=.<5DE8+YH\X]IBL6=>MHTUE$NJW11
M(;$@R3'-VI0D-N;\I=VI3Q$K.WT<^ BY=R6_ IB:U*K=):I;A$IJ>[4(C<52
M<[FV^ITFU^1DE1XV($WSS_A:[=[*W2^FM4F98-Q/VK?UO5"I5"EW2TW(<6AV
MJRE29*3:YR)>>=3>YG[,;B0'$+V=ENZ>Z>ZG:R7&N7JWJ%5%41V?M(C2$_)S
MJ$-R6DI4XK+#:>]-+9%S<N#Z[7R85V6K4Z>W4X%P4:3"6?*B8S/AK:->>7E4
MZEXTI/F]4LJW/8':C1)\E5.>F4R4\\GE<IBW8TDWD*3MSLFI>2-.Y92?Z@73
M+K)B>6+;5<XD>)'AX@V]6KCNBG60S<,"X(E0I%2IT>VFIL,XZ6">EH2B07*2
MFR4D_P![GJ8O7T[LWM+()4 CGJ4B@2CJ">=IY"4R'WBDK+G,RZ.Y+/3;P$'Q
MA\4MM<)TZ@65I)IU2+GULU+==CVW;U,BQ(,I#K*TI>?7*:8/D[M#I/&2S+F(
MC+.^U/WY]]I';-O7)=&J%+;3:;]%ESE)0]34KH*78+KT=)*9PX^:5*21XW]3
M?!GN3K3]OF[OC2X)[#A4#4K6F!;B[_K]89M]1TV+(<0Y!^1$MM-26G&C6;AL
MH:)XT)(C,T\HMH:<4^Y.);B5X9(M JEPW0]IC)K*+@.HTBHTR-;;:D)3'C=Y
M+;0U)+D:[HE$9_0SXB]#V<^K,^]^%&DW?JU<U.>G3*M7F)-0K3D1IIQMNK/L
MH:-N4LD+)",-EL?A[17E;E-TRI32J];"+1A,3L*74J<FDM>DN&9EZLECE]8U
M&9;+R9G@%22XF.%2S>):TJ'0;G?.FUFV6XCMO5M!K-5-F,DTXMSNT*22\N-)
MV,_WO04@*[+NT[JN*I73K!?A7W<51C1HL>3(:5!]%1 CE&A*:9[SE4;*$-GZ
MI>MR;]1=2>J]*,U,.5&"<@B)9L+E,M.)1CFYU<RR4E)H]8C,B(R+/0Q:;XSM
M=:M1.);AIM2P[WA?(]=GUEJY8%-EQI??FQW?<H=[AU9ER&9D>W7W!;KKY",F
M]E_!N219D&_M595Q6]IXY/.U:0<)]A$1FH*YEMFM#GSO(1)(C41],D/15SLN
M]'IE&J[<.:]#N*6_ D4FX<25+IK\%U+B%(;-1<W,I*2,LD6V^PFAQ]\5\[A.
MT/;OJETMZL5VHMTF#2FVTJ)#$J8MB)WKKA)6A"26ZE9FYA)$1Y/!9'A."/4W
MBYO>1*J.O%-I;]CU:+&J5OU^)5:3)0S&?8*2:'VX3BE-&VE:4'WN#R1YW(\#
M1&Z6=GK3K-UWH'$9?-]2;XU MV/Z+!?7'>BH98.*4)I"64N*:]6.E"3P63,L
MF)\<1G"A9G$?<5AUZ\W5'^8B:DB,R7>$EY%51R.I5W:B+9.<YR?B*B(5]6E*
M><C1+IH,AZ.OD>935(*G.;/*E*4D^I2SSL9$1XQ@QOFWM:,2>U2)]RT.+4W3
M+$1ZIPFG#YL&GF2I]*DY+!IR7K;8(!:YJ?9>T]MJOV7:6H\JWM*+JDPI->LU
MN*\\V^<-TGTH3([PE-$XX2C/D(B];?H*];=T/M6S]'4:'V_%^2[7:IKE.C)2
M:UFE,A!E*<R9DOYQ2E+/)Y(U>'46YN-GCCU7LK7&QN&S0&FQFKNN\IBTW3*F
MQ6::1PF$RB;*3,Q",W4?-EAWJ>V^PK]X7[EUFN'3:'(UOH[%/O6(2_2UQY46
M6S,2;ADAU#L0S9P;9<Q]V9E@]]@2^=K?+[W]D@+$[.K2NQJWI]5X$IQZ9IP]
M<$BF&??D1KN)3BI.,JP6#69_JP/$:C=EKHC?M3O:NUN8P=PW8_!DP9KQJ4Y3
MWX2^\2I+*UY>RHD^!XQY;BY!5[XM:C*9^5;FHE-):TH<:D5&$V\E1J)*4K0M
MY*TFHSP7-CK[A:UXI-7[OHW&YPS6=;=T>CVC=BZ^NK,QUH=ARVXT1#K)J>0K
MN\)ZD9&>"ZXP8<^LRT9Q[<-/Y54<,?";3^'=ZK55ZXF;@J]41&9>F-TY$-9,
MQ4=U'1ZI9/E:Y4Y\<"LHI+#?*M;S;32<J4MQ26T)_P"LM9D2?KQ[,CQJ+ZLM
MV1*AM750USZ?"2]*C)J4)3ADW'[Q1$GO\F>$GDB+KMX"S)QQ]H-;5<T8U:L_
M1N\(E OFU*S;E(J=43(;-V(BJU1N*XM"'%I)1&TI?T>A%G) J^LQ4(4GE]&E
M1Y!*SA;#J'FS,NI$MM2D[=#WZ[=1%&M)=3+\>T4/\*S-NZ7Z":?,W5J=3*[4
M*K ;G.W!/J,5DYC\Y+<A:$D_)//=K=-O8^OAX"JZ9=-M0H:)D^OTEFG.))3,
MURHQ4LND>#RTXIXD.==^51[]>H#V!.(5T,:DX@SP1Y,_Q@2\>ORRVX\>?^=U
M"BPWE<B3=JD%!O9,DD2$K?)6,[9+/VB.CWE:,JHMT>!=-%?J+J>=J%'J,.0\
MLC3S>JA#REGZN#V(^H#VW,G/+DL^0W#K8RDR%JYDFE;7COZQ'T/&Q=/'VCL@
M          $+)+F)*2Z_2SY<N_[,?6+?VOO!+0]6]2Z9K39UQO61JA2VY#!5
MIIEV1WK4EGT5U*F24EL\Q\IR><&9>(N 2B6:4DD^7)D1GMY^W^L4T7Q?&IU%
MU=M*W+?HD21952]*.MU-VH1([D9+31*0HF'5$ZO*LYY2]4BR9@*$J9V1^DR4
MW?5;CKKU:O>[7H4QZZ5ID-NPJA"7WS+S;'>'G#V%829$9EOMD>VK79T2;KH]
M#=OS5217+[M(C39-V^@N-.T5K))0A+"%X<^90VT?,>_+[1<1?OFRE3?13NR@
M-2XZ,N,G5H',2B1EPC2<C/J;YR1'ML.R@W;;-0ICE9B7!2)%*C\Q/3DU"&<9
MKE,R,ENDZ;:/6(R(C46<8("W77T6S[O[-<M2:=;U;OW4+Y?U2M1+S5OW=(IW
M_(F7\-J(HAJ-I7-'22-_+/4>F@]GLF!II7;/;OJ*FOW(RF/4ZY\B,_/,D9I,
MNX,N4C[I1I)1'M](MR%P&EW?:M60M='N2CU3'-R-1ZE$6LN0SYSPAY2L)P>5
M'M@L^ X_S\M)YV3"3=%!<FQ&UD[&358!NH>-)]TC!/Y-1KP1[9(SR8>!U\NN
MH6OF.RLMFEZ,(T5HE^.Q:1.DN2*])D0W)2YRERCEF4=;ZU+AX4I9%W"DX(R\
M"(5W:*</]N:(:-0=$[;D2)%$B4ZH4]V7(>>><651;<0^OG>6M9%EQ6"YS(LX
M+8B'7Z;ZCWW5+LONGW_ IE$M2CKB_(=875H*D2&G24:U+Y7"-DBVQWA^MG)9
MR)W4B[K4KA/M42OTBIOP<G(;B5"*\IHL&>5DV\K&Q&>3\-^G0+<U3[,#2298
MJ;6;J;L2JTVIRZM;-PI]([RCS9DY4]Y9-$OYTE/*+)*/&"'7QNS,MNY45NK:
MSWFO42[Y[42-3*X]'7$^3(T-!,-H;82LT&9QTH0:MC/E,SW%R%B];/J$QRG-
MW1053&E<CL5-5@FXE?Z."?R:ML&1%DSVQGKWCSL*/RONRV8\-M*E+DOO(;CD
MG'4W7%);21^!\V#ZD EOHII32=#].J'IO;ZC51;?1+.*X9J^=.2M3JBPHU*+
M"CZ9%C>-PXWQJSVB?$%4*;<E2L&'.^1&5U)$)]Z/58JJ>IN0T@R[MLB-HU-F
M9*_?>&POWE?-E+:FR$730_1J?COWTU2$MM!JSU4E\TGN6,$?F(:'-L1V.[>,
M"H6^AM[>7<#<B A*B;]4B>?)9%L1&E/.YX'@#DHJTP[.C1S2V];'OV@)-52L
MM%:0@LO$J>[76UM5!U2E*/'>*<<7A62+."Z#Q-W=F^P_=%XU33/41^R+6U$D
M1WKSMEJ,[(344,+YN[)\W"-GG-3F3019YMQ<6;OVS3I#E?.Z**FC,GRG4/E"
M'Z.H^;D5ASON3Z6W4]Q'0;HMF9 56X5P4AREN%E4Y-1BJC((MLJ=)[ND9\.9
M19QMN'+>* J#V:.B%M5NT)]/C&S#MB%5HJ81+?44YRLQE,SG5KYOWRUK<+FS
MU,O 2OMGLN+3LRYB:MF]H,#3^-/D5%NT"IK,AUJ1)?5*69R#-3Q&<A1KW(L]
M.FPN=+U!LUN*_.*Z:%Z#%0LG)AU2"37.LE)025=]RGZV"]4Q:WX<-=+EN?CD
MXA;:J]X195BVT=#72FERHYT^.B1#6XX92.][HN8\'NKK[<@/8UGLV+7NS6:E
M:NUZ[G)3MO,N,T*-%BN0?0U*C%&YGE,*1Z2G*4JPX2BP6.ACIX/9561,OZ[+
M_O2[':W7;D[E,=V-'=I[##+#:FDH<C1UI9>,FC)/,M)JYBSU,74*17J17H2)
MU'FQ*C#=6XE,F(ZT\UEM9I47,VI2?I),NO@/1MD?(1+PH_/V> <"WO\ 1:AJ
M/9B6K17;<KFE-SN6)?%M%/;9N9AEV2J:W4R4V^E<8UDDN5E2D%S9P9Y+H%*[
M*G2J.W!JM=K+E8O9508J==N9U#Z7JO(CR4RFN=HUGW?(I/*1<V,"[$&"/J60
M%L;6CLS-)M;+\J.HMQ2#17GXM*9IKA$[ST]ZCQFX\9Y!I47-E32%X]F#/&1+
MQ_LNHEWW=;5X:IZER;OGVG%GP:''=B/,IBPYD<XG=EAPTGR1R2G)ED\"[X&"
MZXW\P%J"Z^S#M6HZ2Q]&:!<Z:/:BYCDJH(5"5(=D=Y,.6:6GEGWK!DM1EEM1
M=?A67I'P]T#2#1>'HG07GG:!#ILRGIDON.O.J*<TI#ZS6\I3I;K49$:O5+8M
MA4H :"TO5>RQTZBT2B'95Q/6U>MN5"HU*C70VV^Z[$>J<M4F27=&X7-S<QHP
M:L$7383PX?>"NE:/7Y5]7+FK*[ZU.KK<9J9<3R%QU-MQ&NX;Y6C6I)<S/JGC
M&?'.!7O@O(O@0U!+1>^_K[*'=:."BR=:-3*9J96)JXU7@1)T1+:2=,C;G1#B
M.YY5$G^]J/V_:)>5;LY]+ZKHY9NC#TE:[8LJ=4YT9GE>(I"JM..;(2H^;F++
MAF6_U"Y*-,%Y%\ 5:$_M5%DTNXYLVRKACV]:M9<IKM8MY5-3+*2=-Y#:,WW<
MK+F6@U;>?B+HEHV?'M.BTB@P5)^3Z-&;CQVT()M"N5"4J5RETR:<X]H]P
M
M
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M'(K:UF?M-1F9^.1WXA4Q$-MM-M>HEE"&T>QMM))0DO<DB(OP0BB%4
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M+&WF(/6'0:W;MMFK3;<HT%J^VZ4[$H51=8:>7'Q&4PAI"'4F@B-OE;W\-\>
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MZ18(B\@&H
M
M
M                                -#+)&7F6!J #K4Q%)>)W!>H?J$18
M^EUR>=_:.R                                $*]&2ZM*\8-.Y&1X,S
M^H<"H[A*)7*A9*_OF$I2M1%L65D1&>/?]?EV( (),8FMT)RA/T6_:?7?/F>Y
M_#&,C1++B34]CF6>.5L]N7??!B. !UYQU+]=3:$G^_)*4DM?O61<QX]XB6B4
MDU(Y.5!$7*><Y\QS@
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MY_4-P
M
M                                           #A=)Q18:5A1'N?UE]
M7Z_$0[JE(2DE.&:L9,R+F^K;I^WS 1P"";<<6DN78M\F?J_ C(OQ\1O[U3:L
M+SOL6QF7^MX?M 10 6^X
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M)+1GE/);ECI[ '(
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M[EL8'77%<2
M                                       !PR'4,L/.N*Y4--..K5C.
M$-I-:SQXX21[>(PW>W(_*):3POR[@X;^&I3M1U36S(@5ZNF3D15%4XV?(I*)
M+9-NFI"E$1H/][US@AF1ODV;3B72RVM"T++S2LN52?K+88M':N_DYVDO'AJK
M;VL6GLE%D75-J*)%\2$(7)^5&&W6D\II4M*6OF4K+U2SOGJ0#Y[^GVEW&;VH
M.MCS--3=VIET5^I*7,J$A4\J93RDN&L^4WC5"Y4(49;'^\&9QV=7Y)[I9:5"
MHM\\7T[\X;F<2Q+.V5-N1VXBLDM32WXSG=JV/&Y;8]^,C3A.X)^$;LM="&FZ
M/3[8MMBWZ0AZZ+RJ:(:9<UYAGO'7&U3</$?>$X6&W#ZXZ8SC#]JY^50?F;7J
MQI/P7DW4%0ERJ?+O9EU/(EU/,V:FHTE!I,D+)1%R*,CP6,[ S:V>LY\(]M(9
M2%E\%W9W<)]&9;@V3IK:T: RVDWZO,HTE]7=)+*E-S3[U)Y+Q+)F8XJCQL]F
MS9+IP)-]:60%Q3[LVF:;1'B3C;!&EM1>&QE]H^4EJ-QB=H+QL7)*F3KTU$O2
M=57EJ53:/%K$*,UWAGRH2[!,F#(B/&2V/'M,=A;W9B=I-J'%36Z?IEJ+,9?^
M<)<JMU9I2N;?)I?62B#E\R^<Y3EEY];YR?5QH_%#V<NKO+38-TZ45@Y7S9(D
M0:#'-?-MCF<0DM\X$K=9>RF[.?BPHLPY.G-D5.3565DFJ4*HP$+;-Q)D3A-4
MY63,LYP7EMN/EIW?P$=I%HDVBKU;3_4NCLQ2[TEPJM6I1MD@L\V(ZS/;J1>(
MF1P_=J]VA/!9=%+53=0KQ8:I\A/IEOW#"F]VMIE1$IDY-4(RW22BR7F'A;+K
MK*3O91,Q/SMX^?GYLC'M#OR3.LVK#K]^\(=;54F8J)$YNT2BX5W:24Z;3<B4
MX:C,DD>#26>GF,6VP-4>,[LP=<$NPWKNT\N:VZH13Z3+=GJIU0*,[A2$$^:8
M?*M*#+U2,B)6>@SQ.RX_*==&^)R50=*^)1$73Z_Y9,06:Q,D%(BU&2O"%&XD
MDHBH):L$9*/'K>0N@=I+V2/#!VFVE$JH08%O4V^JC"1)MR_:(W%=RIY).$XM
MN"9-N&I!IR3BS,C/<$U_-&>D_+++PB][QX9RI9[$GMU[+[0^@T_2G4".Y1-=
M*/$CQI;!$[)145DWLX;K:"CM9:1SXSOG R7(Z32TDC/F,NIC'U['?L0-+>S5
MI$RXZL;5X:OU1Y?>7.:%1%Q667'$L?,DI;9YCJ)'4ONR"V2439$KK^/:?N!J
M+[]>776KE  !0                       #.>@T/H?N,0"G5-H(V2-1*,^
M8SV)._4SZ%^"QN AZM+8@QI,V;):A0H;+DB3)>6E#33#*#<<6M2S21821GN?
MA@8>_;(?E+5L\+U;JVBO"TJ->-_0TR(-3N"'(1W-*D&DTD9(6EQETR/F+96Q
MI\,BKO\ *->TUD<%W#3+T^L.HMIU'U,A2X,9V)+04J"TV?=OF24JYB-3+I^0
M^:EPUZ ZU\<W$#3M.+(BU*Y[UOJN*>JU5<-V4J&W)DG(?6ZX\:R(DLN.8(UI
MR2<%Y S,[HM,_+KU3IUW[4_CFXD[CG5>[-8+KEKJ#SBTTJC-RT$RVX9_-%\G
M+(CY4'R]"Z9\Q1A=EX:TW0T<>\:QJ)4J2LS<4S4F;@?BFKZ?K(D<S9DI?F7C
ML/I[=GI^3<<(O#=8]LU/62V8FHFI+T*/*JKDQ+C2&)+S:75M\AFXT?(:C1@O
M(78:UV4_ ;<-.52:CH+;BX2T)3EMIIM9<O3UTM<WO\3W B)B;WO]<HW[L^LV
M!1^35=D3'XL]4G>(C6ZTGY&F%ERHLJCQ*E'<98JCQ&:>8D.)+/=/MI,_541[
M_7],BS;:H-I4>);UM4^)1Z+2HS$.%3849J,TPRPA+2/[RA!*RE"3,\9]N3$M
M-">'?2[APM")8FD=M0;7M.$:_1Z;#:0CE[QPW%=XXE"5++F/)<V<="W$]D-)
M0I2D[<^#,L8]P+$6TZTCZ-73P@_'PWWZ^_(ZQ^,QW;C"V$R&Y"%(>;=(G&UM
MK3A25(41IPHC,C(R^([8R)18,LD-#21D98\,%\/,%84/Y2QV.5DW]I;7N+W0
MZUHU)OBV$+FW?%IL=*2GH<639+-#:4((T-DM9FE)^9^(PX>R3XP[GX*N,_3.
M\:'6)%(H50N)%&NZ!WJT1Y"W)"*<7?I49(^;6M75/GXCZ^O$585+U'T4U0L:
MKL-S8=:M6M=Y&=;):"4S392T'@R,E*)99+VEMYG\4SB<L=W2#B+U/MR)&FQ&
M[;O2H2J9).,^P33B:K(D-J1E"=DK2G!D>, S,:3'&+^UK\=WK=]O_3>\J=?U
MF6Q>%)ELS:=<-#I=09>8<0XV;DF$R^Z7,@S3LMPR,LYSD>]R1]#R/EJ]F]^4
MZ\1?"M3[4TXU=BNZ@:74?N8+2G9#3#L*$GE;-1J22Y"N[062(SSA/@0^@UP%
M]HEH-Q]Z6TG4C2"YH$J2]'0Y6[=[])3J:\K">[-EU1/K]?GW)OH6<[@M_+QM
MX^V]<0 <+3Z'B]7\>?M',"@       .O><-#IHY^4W-TI(LFK'N+;P$0PI2B
MYE$:2_1P9^SR]Q_@P$0 TR7M^!_<&2]OP/[@&H#3)>WX']P9+V_ _N :@-,E
M[?@?W!DO;\#^X!J TR7M^!_<&2]OP/[@&H#3)>WX']P9+V_ _N :@-IJP1GO
MT\C^X=4J3S+SWJ4J1DELF9$M7ERI/UCZ>!;%[ ';@.&.9*:29$9$>>N<_;N.
M8!M5GE/'7 \E<[_H%K71/;7RKCV[6Y#)].5QBG27$F1^!\R2W^OVCUQ]#]Q_
MJ'A=0R(M/;U4G8TVM<&/Y+E>6WX\0'Q;NT^U"N34/CDUWK-PU!Z=/5<C\>.[
M)<4Z4=N.^\RDFR6I22^;(D[8Z"WA,=6I26U+-9MY]<MN;/N\NFXJ_P"/]2E<
M7VN!J49G^==1+.3(\%-D%^/8*083/>.>L64X,SSOGER9[_MZ@SI>=>66N7SL
MB*- J-2G(BTV%,J$E9*),>%'>DOGMOAIA"UG@NOJ]!'U.G5FE/*@SH,N"9XY
MFID=V,\7CA33R$+(SR9%DB^(RK?R6G@FLKB/XF+@U$U&M2+<=GV:AM)Q9[).
M1'#F176D\W.DT[.$1EMU^(\I^4]\&E!X9N+>DW785LL6YI[>$IMZ%%ALI1&)
M,%IDWFD]VA"2YEF:>G4P)SSB/6/VOE_$9W8R";9N=RE%4GZ#6444R]2J)IDQ
M40\'U]))KNB+.V37C/B/(R$K:>]91JP985G<^4_?U(MC(9@M&XK^&IGL?7["
MD<*W>WXFD^C_ +H)QI!\CRY1D4@I7H9M[]3^?]@P_P"I&DYLPT%AIR9)>;+?
MU$./+4EO?^#29)SXF0)3>^ZUMT6X:=9_*_[^3:Z@U^T^TMTQAT>>[#CUJ1+;
MGQVU&3<I*(9I22T$9)/E(]LD>YYZCZY491.$PL]UJCL.*3CQ6VA1^'CG.WF/
MCV?D\G_[3W1+K_RV?X^<3R^H?84@D1,Q#QN<./GVX91@%IM%XC=;WAV(  -
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M9F65F>V1/\DI+H6/=D;@
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M[+_3O^ J7\FS?Z(5)_F=;'^0Z9_W*-_1!^9UL?Y#IG_<HW]$ IL_LO\ 3O\
M@*E_)LW^B#^R_P!._P" J7\FS?Z(5)_F=;'^0Z9_W*-_1!^9UL?Y#IG_ '*-
M_1 *;/[+_3O^ J7\FS?Z(/[+_3O^ J7\FS?Z(5)_F=;'^0Z9_P!RC?T0?F=;
M'^0Z9_W*-_1 *;/[+_3O^ J7\FS?Z(/[+_3O^ J7\FS?Z(5)_F=;'^0Z9_W*
M-_1!^9UL?Y#IG_<HW]$ IL_LO]._X"I?R;-_HAL<XP-/$MN*3'J1J2A9I+Y-
MFEE1),T[]SMOC)^!;BI;\SK8_P ATS_N4;^B&QRS+86VXW\ATSYQM39_W'&+
M99&D]^[VV,!;[TD[1.T=2-=).ASU J$"KK<--/J'H\MQAU)-FZKO'":[EDR2
M1$7.M.>F,["Y.TOO$$HRW^_\?@Q)6T]!=-[*KTVZ+?M>!$N">YWC]3-AM<CF
M+IW:U(-398V,D*+)"=C?-RES_2\?JV".MXWC8XHTH4I)<QD70;QP27";9=<4
MHDH;;6ZM1]"0VDU+S[.4C]P"0O$)Q&Z:\,^EU>U:U8N*%;=KV]$>E2GI3B$J
M=-"5&VTTV:B6LUK22#Y"5RFK<8%7'K^5M:J5Z[*Y9W"-;14&V84F3#C76<EI
MXYO=+4WWZ6)+1&V7,DS(LEG.V>HE1^5/]I5<VI^M2^$NPZ[(IUF6<XXW<S<"
M6M+=14ZVB0TAWNE)QR.)41$9F1EU%#/8@=A[=/:4UA6H=[3'+?T9H<AA50=4
MQWB:NE2U(-*'$J0Z1]XV9*Y3,_6SN#-[Z6F;:7\+<)TGZ+27%]QT\17&Y=+5
MZ:\7=4+EJ5..0N&AR.IN-%[Y.%)239=P>2(B,R+VC,\_(]^$2V%VGJ'Q+5^F
MLRZ[)7!1094J.E:HQI6]&?-E;B5$64EN:3(_/? O'4_\F9[.)JTF;7<L!I]Q
MEAMMV?Z3,2XXZ2?6</*\^LHC/&3V/R%V+@DX'-(.!330M+='*:BFVTE1J0RD
MUJ/=Q3F%+<,UJP:CZGX[!R(BVN=_IUY<]5911&\\RBR?V^S?J6.A>PAR]T18
M))X+.Y8^(Y0!IQH;Y%*5G/-C8;_$]_+;R&H  &  (%^GQI3$EB2VEUN6R['D
M)/HMEY"FW$>SF0HR/'F+,/$?V$' !Q'5BMW'=6ET*)<%94Z[)J;$A]"U2'N8
MU/*0UR\QDM1JW%ZP0KK/,OU2V7],_=TZY_'0!\W'M:_R82N<,EB5_7/A=J4B
M[+6HZ79U6M=B&HW(,;)GA"G5N..<J$J5ZJ3Z;BP-V9_:'ZQ]G9Q(V_>-N5>J
M1;9^7X],O.V'G7D174>DI@N$J.Z?=LDSEQ62:+.#/KN/LOW7:],NB@UBV*S#
M8J%(K5+G0I<.2VEYEXI$9UHB4EPE%DN?;;)'C ^//VX7#I1^%OM -7K)MBG(
MIU$G51JI4^*TDDMQG'4*FN*;21$6[B\Y(BQ@L S:VG[91OR^>F>^SZV7"QK_
M &KQ-:(6)K79\MI='O"D19/(TLG.ZE)9:*6DS(\_W]2RW(O(A4P70O'VC%-_
M)2=7KGU(X$%VW7Y+LR#9ZD-4WO%FHT$_,<YR29F:B(N4MO9@96"?HI_ZI?J!
M8SB.OM\FX  %   %(7&SJ%JII;PX:EWYHK;Z[FU(M^F*DT.F-K2VM2R0XIQ:
M>=*D&:$)Y^4T[X\3%DWLG>.7M,N):R+WKVL6CTB2W2JH_&I$V5.AP5+0W.?9
M6A+'=H4?(E!(SC<BYAD=WX2/S1N8S9;<(Z5-)274)<0K^Y7.J%D:5;;[E[/$
M4D\"\9"--*DMMF*QWM6J6T6,U&26*@_U2RA)'GQS[1+YVY7U^GU.NNOLA$ZE
M\71ED]'<?_SF)]PU_=*XNO\ ,[_YS#^X5WDVHDXY]_=^,^W8;>[7^F7P%%"7
M[I7%U_F=_P#.8?W!^Z5Q=?YG?_.8?W"NWNU_IE\ [M?Z9? #S^7VZOX6H2_=
M*XNO\SO_ )S#^X/W2N+K_,[_ .<P_N%=O=K_ $R^ =VO],O@!Y_+[=7\+4)?
MNE<77^9W_P YA_<'[I7%U_F=_P#.8?W"NWNU_IE\ [M?Z9? #S^7VZOX6H2_
M=*XNO\SO_G,/[@_=*XNO\SO_ )S#^X5V]VO],O@'=K_3+X >?R^W5_"U"1ZE
M\71?^QW_ ,YB?L+;/F*#N+/B#XU[%K%MU*SK!E,76<I+<6U(LIB4BJH<=:0[
MWDE"%-L]VVHU9619Z"^]W;G@LB/SP/./6?1)5416YD&-,JC.39D2&6WN[R1)
M]1+B3).Q>!%T$F+^4W$K>'BZM3;KTIMJO:MVR=I7O4(J7*G1#D(E''69)-)F
MZV1(/G(^8RQDC/ GVD\D1B"*.O;)IV\$D22(BZ$22V+'XP(U)8(B%&BOHG^.
MNP\-J)_@%>Z/ K4N#IY_)4H>Z462,B'A=0LJL6]\%N=J7!T\SI4D(UB^F\?$
M:X^E&KB[UP,_^EE3_GT@4ETQ;B%*4VUWW,XVQR9P9K?,FT$7UJ(5:\?:#;XO
M-<$JZE=E2^V;(,25T/LXK_U2T_L]$AJ.JM7/1D/K>6A#*&45&,;QN+<4E!$3
M?-G)[$"3%XY/HC=A7P]ZA\+_ &3=U:ZZ;VN[4M6-13IDBD4U"2:E/-PZH:7.
M5Q23/^\*ZXZ$.J_*"- [_P")/LOM.^(B^K.=H^J6GSKCE<IRR[Z2PF7566D&
MXX2"R2F4FKIT'MNT9[2Q'9/<"?#IIEPW7#;]:O9VV67),>!(ITUN*^<>(\[W
MS1*?;RKG7LI&<YQN/0<%?:&M=K)V:.M=H<0EPVW2K^:HR778M0DTR#W[C*GW
MF"9CJ6PC.$)/YM.<GN1!UU[G+7+CGEZ>JENWZ!;\C\F@GU9%"H_RP5(4VN8=
M,A^G)6S5%-KS*-GOLD9*+//D?/'F&?I,M)^$V7]6'U[>XA]$R\+AL:QNP#U&
MTS9NVA/W!1Y=7CM4=JI0E25MG<4DFS0RAXW%%W9)5ZJ,<NX^=E,P<J6K.ZIL
MP\>67U?9C $:1X0O=?D\VW:<:*J+JF;.Q_W0?83IQFIF-G]["B']:F4?UCX]
M?Y/.?_Z3G15.-SF3S^$0?83I_J,QC/HJ%$+ZTL(_K_K C6?'Z0[,  %!L<4:
M4Y+S(;QQ/?0^L@'1UAY]BE5:5&3SRXU*J$B(V7[^2Q%=<83];A)(8DVH=[S=
M7X?$U<^OFK%;L:\[<J$.+;]J)@3W$H95)?CM(9:CJ0W)*2RELS-+:N4E;^(R
MZ3,B(S/&.4R//3!E@R/V&77PQU%*-X\'?#;J3=[UYW19--J5PNK2Y+5'FI0W
M(6DL-G+B,&2#,L>J;J3QDS+J Q(;4U4UTJ=O:/:/G<%;L[3"&=R/TRJ$Q)B(
MJA\ZI*'W%EW*VS[TDK)"U>MS8W%1ED:JZHW]6["T8U^UDKEMZ3^DSVZ3>J*=
M,2BIH9<[Q*''HRDK1W3B4-$IQT^?P,QDIW_PH\.%T6G#I-Z6-3V;9M-A^5&[
MAXH*H3+9&^ZKTF.3;AD:6^8T\WK=#ST$I;(TSX+.)RR7['LZW(5RV?9$@XY.
MQ^^B.PWD2#2M+4XB)UXR>:42C2X?0\A]$C7GPX91Z^//A*W+.O"Y;&UVT/TQ
MT[U-J-PZ=3*3=3<FXCISZRR5,6J.^MQPU+5W;ADO=P]RZBEG23B"O[2Z_N(^
MP)]WUF_ZY7),-5 NST>7Z/"0TIYUQLHA=XTWR(,FM^7FY<^_)+M_AGT9MMBC
ML4BT6&FJ%'DQ:6;CRGWHS,ILV7TD^YEP^=!F6>;)>PQYVTN#_A[LJHW'4K=L
M*+$G70LG*T_(=5,6^M)J/*5ODLVB,U'DD&7D)Q\?#JT9>1O^777LQR)FL]^Z
MK/:6Z9Z[ZFUS37364=RO1;C9ITTDUIR,;CZ.\<BFTJ/Z,^E*2);F'.FXEO7M
M<=?9]LU'1.S]1;AK6E<6OTBF6QJ4FG3&G)4275&FI:4MGE]7(E?=&HW#\3(R
M&49J!PG:!ZCVE2+&NVQ(4ZA4A;ZZ:TROT5Z(I]PG7N24RE+OSBRRHN?IL>QB
M.H7#+H=;5J4BQZ38U/BV[0G">I[*DH==:=)TGDK7(4@W7#)U)*(UJ/<4\\O?
MU_9:6X,T:EZ%\;=T:%R;QJ]W615*);L]"I[$CNXCTBB-SGC2_(4X9]X^L\I)
M98/)&':&:DW+7>*?3/1:\KPJNF>CLYJJNS[CAQI3S$MR/$*2R2W8W(;7(^1)
M(C<+F,\;]!>DC:;65!NQ5[QZ)%8N=;+3"JUA!.$S'9[AI*E8(L(9(D%E6"(A
MY_5+0[2/7>F,TW46WZ?<K,11J8D,/-ID-*-9*5RS(^74Y-.%>OOT\07KKZL8
MZP[UOJM2N+'3.QN(:M_FK;,>WW+1NN51YA(;:0TX]*997(5ZQR.3N343F2-7
M,(*F:_:BZB\&[MOT;4>LVK<NEM;856)KT66Z=[LN5LEK2U,=-),$;+:BPVXK
M^^<N/ 9'U.X->'JDT"KVK"L&-&H->;:;J;#3ZDR)"6/[V3DM'*\K?S4>QXWW
M$.]P3\.LFQ(VFY:>Q8UHLO\ I/H;,A;;RG4/E)2IZ4@B>=+O2YL+498VZ;">
MWUT_>(3/+?S]/W6:].^)34+475?2*FT2IU2U+8K5KW!"FOOPI$DH,N%0S8*8
MMUU!&OOI*3?21JV,]CP* *Y?EUS-/N)KAVO:\:]?-2K]PT7T.]6F9QM$U\K+
MD$VB,R;C;!,MJ)HS2I/-RY/!C+=@</.D=/:IC=-M""TBE1'H,-;24MN,L/,]
MPXDEI02\K;]4U9(\Y/.1XNU>#3AZLU-?^0=/HC"KGD-R:RJ2Z<QV0ZTZ;R%)
M=?2M3>%F9^JKV=""V7#P7J^]CUZ%6EJU1ZAI)P]V1J-6(E*JE'KM2;D.4^0M
M3+U.@*J+;"I#Q\R>_=031<RRZ^/0^OH'$+QO:V'J%;L>-7+2F\+B:A'J<@XZ
MUE>C=4*0F'(;4:$)_N5#).80:_I8/?KDVTC0_3J@5B%7*1;42+4Z>A;<*8E*
M3<C(=1W;B4>J6"4C8R(RVV/8=_&T\MBG+JZZ;;]-BKKZ#:K;C<2.E520:5(Q
M(,FR-S"5*(C6:MC%^?5_E^YU\F(QPF:G\1U5U(TIOY_5FK(N.NW!6(EX4!^(
MX\3[,:<J+';6PM1I8)+)'A1-EDMQF'T@W%1X;BU<RWH$)Q_;&75QVU.*P?3*
MC,\%T/8_;31:W!7P[V5>:K[MRP685Q.O+DG+3+=4PT^X9FM;<17S*.91F9\J
M2W/)^VJJ.@VTDDTX)*4I3_U4D24IQ@NA$1?4 B
M
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MF?QM5/Y^^*KK^_P/N3^*9O\ -'A2CP,?XL9G\;53^?OC/Z_^/U%<   T
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MYWBZ^]#<2LE$C9!8Q[3\3P>Y9ZX]HC1"1D(3N186;;9+QTR22(]O//D0BP:
M
M                                                       !#R20
MIEQ+A<S:T*;<2>Y*0X1I6DR\<I,R&,QVE_Y./P]<>&IDC5^@U)JP[VJCJ7*T
M\Q%<>*>9$E&30E3;:32C)[$><_')N41*+!B&.-D^;FPLNBB+'Q\_$!9A[+?L
M:=!^S,H4^19"&;AORL(9*I7(MA;+QJ:R1&E#AKY/54:?5,MA>ACI-#1)5NK?
M)D6-SW\/@-Y-F6Y'ZWB?3/XW&\BP6/M\P&H
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MHOU-'_P B)X]>^G._-\?O^RSXR_\XNIG_=Z_]X?V6?&7_G%U,_V%?_\ J'V
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M?S]\577]_@?<G\4S?YH\*4>!C_%C,_C:J?S]\9_7_P ?J*X  !H
M           !Q&RA1F9EN?7?K@<H /,W-9ULWC39%(N>BTZN4V4CD>B5*(Q,
M;-)YV2F0AQ*>O@7VBF"7P#\)DV0Y)DZ+VFMYU1K6KY,A$1J49F9X)C!9,^A"
ML4 %&7]K]X1?\REI?R;"_H _M?O"+_F4M+^387] *S0 49?VOWA%_P REI?R
M;"_H!&4O@,X3Z/,14*?HQ:;,IMQ+B7#I<)6%H,E),DJ8QL8K! !TU&M^B6_!
M8IM$I4&DP(R";9B0(K$1A"4ERD7=L(0CH1>'7Q,=F3#:5$HBW3G&Y[9]@Y@
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ME/U") !HE))(B(L$0U
M
M
M                              'C;^_P/N3^*9O\T>%*/ Q_BQF?QM5/
MY^^*KK^_P/N3^*9O\T>%*/ Q_BQF?QM5/Y^^,_K_ ./U%<   T
M               !D  :&9%MX^1;F-AN)(^4U(YCZ)-:25\#_9D!R -,EXG@
M_;M\,XR-0
M
M
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M69I2R1>L9XP'7GE^ZQ,Z3ZQI.7\[K,G@M]P$.PI9EA>_M]WXQ_7D1 -
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M,SZ\IIZX/;;_ (\BC<22%FOE26.8L9-6>GNWZ_J 10#0CR1'YC4
M
M                                 ;341;&?ZQJ1D?0!J T,R+J-.9/F
M%[Z#< V\Z?/[#^X.=/3._P!8#< V\Z?/[#^X.9/G^L!N
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MX*C  <?>HY^[SZWD Y
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MP  XVP
M     $K-7J_1[8T\O"L5^I,4>EPZ1,6]4)+B&VFT>C.Y)2G%)3OTW/?/B*(.
MSFUCTOU%TNK+EFWA1JJB#5ZBW+4B=%2;*OE)])<Q&\9EE23P9B=_'3H6YQ&<
M,^I^E;=:D6_(K]%D-QJI&4XEV.IMAU>W=*0KUCP6Y]#%ACL9^R&F\/\ I9?#
MMRZN5FLSKAK<Y?=][,0B*AJJ231@D232?.D]\%G/7H)/&(O*7SMR^V_Z?LRC
M/E:B_P"6Z3_*$3^F#Y6HO^6J3_*$3^F%"I<#%*\-0*Q_MYW]/@<O]@Q3O^GU
M9_V\_P#W@9O5_;[^'7\2JN7Y6HO^6J3_ "A$_I@^5J+_ ):I/\H1/Z84-?V#
M%._Z?5G_ &\__> _L&*=_P!/JS_MY_\ O =ZK^WK+K^)%<ORM1?\M4G^4(G]
M,'RM1?\ +5)_E")_3"AK^P8IW_3ZL_[>?_O ?V#%._Z?5G_;S_\ > [U7]O6
M77\2*Y?E:B_Y:I/\H1/Z8/E:B_Y:I/\ *$3^F%#7]@Q3O^GU9_V\_P#W@/[!
MBG?]/JS_ +>?_O =ZK^WK+K^)%<ORM1?\M4G^4(G],'RM1?\M4G^4(G],*&O
M[!BG?]/JS_MY_P#O U+@9IQ;G?U9_P!O._W@+U?V_3AU_$BN3Y6HO^6Z3_*$
M3^F$F;OU[TPL"Y(%"N^XJ?2WJJX;=.G'+;<CNJP6SCB7.Z:W,B+G4G.1(+^P
M;IA[%?M7_P!O-_W@4?<379G7%J\5,L^BWS4J?07)+3U7KA.2'),5##R'FR;/
MON^(U\O*?=K+;KXC47WQ;SN3UU:5["DU"!5(+$^FS8U0AR$)<9E1'FWV'$*+
MF2:7&E+0>Q[X4?M'9"0W#UI%$T*TGMC36#6)-=9H,7N?E26MY;\E9\IK4HWU
MK<V5YJ/'A[)XLJ,S,C/;_C]PHB &U9&I)D1X/S$*I9J<[DCQR]5>\LE\/QY
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M$YG^V0OM^XI$^R+=D5'3FRF[6HLFEMM'BH^DMQ:>\YZ0;1N-=PX2EX(_6Z9
MC[^WGIP7,^);L_ZAK+J1*U/T_P!1UZ>7'66_1Z\EZGG5V)L/N?1EM,L/J[F/
MS1C6G+22P9YZD0\O%[+RP(EL:8V;^<3R[4LJ?*JMQ0B8?;;NBH2):9R'7O6]
M0F99&M*3)18/!8(Q53J;Q3V_I_PP_P!D1-@+;C*I<%Z+3%J6A1SZBE#33"EF
MDC3_ '2XE)J41>?3.+7%'[0_BHT^F6]J3K?ITS"T7O\ ;JC]"D-U2$Z=-9@H
M6<4^2.1OO'*4IO8R]3.X>6O5B;;^7&=^7ORS7ZX,&)!I\"FQFB8B1(+$2.VE
MOE0RS!80TC&"(O60V6>A^)[Y%$$KC"T?JNJ6IVC5;A1H4RS8C=+J=953_3))
M*KT1QEHT'W*G"QWG[U7PV%L%CM1.)JO0;CU>HNG23T9M*IT^#5'ESXJ>]C5:
M8F$PZ1+03Q<G-SX3N>,'L)64K6RET;B.U]UF=HK-=I-418TCY(4XEKG>F164
MK(W3(S^8<</PWQY 7TMI,7^7W7P.$OAJLS0^UZNNWY42N1;IG2*G%F2*8CO6
MO2)3DO;OD+<+!N[%DMR]@JZD4^-*)LI<.#/)'T5283$@V\'MR)=0OEQX8QM[
MACZUCM%.)"X;NO6SM$-.$(H&F4:C3:M+*?%P42H,(E+22'4Y]5LEI]4QU.I7
M;'5^52M-;7T\H3T;4"ZV:Q\N*:(Y7H;U"2:GD$@VU-J[[NW$Y+'+G)!"WZ]/
MOU9D2OT^$\P3+T."\R@BY6'X;#K",;X2RM!H3T\$EYCQEXW+3+#L^MW5(@Q5
M0J!$=EK89BML$3;;:W%DWW:$\A&2#SREOG<45\ ?&1,XJM+JU<5QT230;@M9
MN2JKH?2X1R$QE.I4XDE)0DB4EHU&E)9+(H(UTXU.(K73]W"D:"6:S-TVTUCJ
M@U^>N=$:5.3*:>8=,VI!$ZWW2T.=,YQ[C 7+]#^,31K6JC6[7XD:'2ZM=4ZI
MP:9"52"?<DN4J2N*^:IIL<R,*09^LOQ]XK,2P2C-9Q(S;*TH42BC-'DC(C(U
M83ZVW@?3V#&&X/N**V](=,M!85V68S)FU-_4";(FID$9TN7"D29!MI[M*N][
M]XC09I/">N,9$Z*_VB7&,SIU7N)JBZ9L.Z&Q:O&I]+BG5X#:G8B:E\FR7^91
M%((T8-SE,M_HD7F3PSZXSJR%"@TN0Z3BH$!Z0UGD?5!84Z@\8]5Q2#4GZE$8
MX5,1?G8\F'&DI=V-#D5IQ*R+..<E(,E$6V"41X%ANG]HAQ):]5:JL\-]A-3:
M3I_2&:K>LYRHQ&U.F_!]--HFI1$HN[-#C?,CKC(EQ&[6'7^^*+IK;E@Z:I5J
M1?4JX:>]"^4HZTQ)%!?6PXLG5H[E?/W:E8R1%TR"LC2+3X45M*6HS$9!9-#,
M9AN.A.=SPVTE*?;T]HC%O$C!)(R+'EC]8Q_Z'VFVMM.MJ\=++KLY"N(RCO4^
M-1Z64R.2)CM2=+E,WD%Z,WW+*TJ(E9YL>9CL;>[1CB,TM=O/337S3H_W5&:6
MFHV7'C3H\A=60[$7.<+DAH4AKT9DT?3^ECXDOG9?>J%4BQ(RG9DMF"WL1.R7
M&V4Y,]B)3AI(S/H6^_0MQ+:AZNV37;RJ%B4RK.2[JI'='.C^C.H:2EY'>-&E
M\R[I9&C?*#/88UW$+QH\1^NO ^5\V]*^1-08]V0(TVD-2X[$ZGL-W*U'0VZ@
ME-N?.L)P7,@LD9"HW3;M V]*8]UR=2K%;;U M2@6PQ*J29:5/5>H5:FLMPN?
MND^IAY:"R9F6YF?029W1K]+YJR&_25%L:5Y+8_5/K\!%-JYT$HR,L^>Q_#!"
MQ_;/%-QR6_I7?&N=^:=E)M%R,4VTJ3&G07GFHB^<VW"]'2IYS*#;69*0>"V,
M5-]GAQ675Q/Z8RKJO-QEBX69<EN11>=HI5.2F4XTVAYI&'$\R$[&M!9(47*
M$,QSJ^<4KJ7T?+Z_QT$2
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M)F\6O\ON[<Q$4Q.^;?)N  ',P
M                     #Q-^-_^J5S*,]E4J9TSL11G3^KZA2CP---_N:5
MT$:4+JU2]4U&HR,J@_G!GYBK*_O\#[D_BF;_ #1X4H\#'^+&9_&U4_G[XE_S
M6W6O[BMDF$ENG!'YD7X_4->1S^$', HX>1S^$#D<_A!S  X>1S^$#D<_A!S
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MW+#BD^/-C(OVG&-1GD\%\<^7XW\1L<8=4CE+_LD6QECV]=^I9 49\('#96=
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MS4M*EFCD(SV+.?'[OJ$:.%"%$HU&>"/HC&,>S]HY@
M
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M'=JFJ^L6MZ?;K=VIJO$1;0  '(R
M                       #QM_?X'W)_%,W^:/"E'@8_P 6,S^-JI_/WQ5=
M?W^!]R?Q3-_FCPI1X&/\6,S^-JI_/WQG]?\ Q^HK@  &@
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M-1%FH
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M%44?FBUZIF/_ &S:TQ;=,9PB  !Q.8
M                             !XV_O\  ^Y/XIF_S1X4H\#'^+&9_&U4
M_G[XJNO[_ ^Y/XIF_P T>%*/ Q_BQF?QM5/Y^^,_K_X_45P  #0
M               VF@C42O$AN !P+CMN*)9D?,1Y(\G^HC(<BFT+(B41&1>8
MW@ VFA)EC&WLV!*201)3T(;@
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M7X4VM,3&MYX<<\KWB8XWFV3E1]$OK_68W#8V>4$?O_68WC4Y9)3_ $QX1\@
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MS5_B8-%7*(](A$  #A<X
M                   #QM_?X'W)_%,W^:/"E'@8_P 6,S^-JI_/WQ5=?W^!
M]R?Q3-_FCPI1X&/\6,S^-JI_/WQG]?\ Q^HK@  &@
M    !H9D74QKGP\1P/EZAJQDRZ?< WI=0I1H(_63UV,NO3?VCD%-NL/%-H5H
M&B*O5S4.A6<]+YB:CRYD;OU\F"/+1NDXGP/=)9(2#/M1.!HB,SU\M@NG62QG
M?IL;N0%PKO4<W)G?W?6-R5I664GDA1WIEQQ<+6L%;8MNP-8;;N&O2U&4:(W,
MBM.NF19-*$F]ZQX\MS%7T91*:29;D>Y&6#(R/<C(RV,C+?("(
M          !IDCZ&0#4 SX>(
M                  #8OJGW_<.%Y)&AU)EZJFUI/_MH,OMST$09D74<$DR)
MLR]I?883%XF+7O%N/!F_YZ8B^4Q>WEKUR61]7K%J=K\1];K#B5,TRI.M.,NF
M1DA7(UZV%=.IXV/Q(3'H]^U*U:@Q+B2UH:YDF:"69D9%C.2R>,D6V?'85KZ^
MZ.IU'H"IM+PU7:<TZZPM*?7=-)&I1&>W4DX(NAG\!9UNBXZO09L^EU'G9G45
MQ3<YESU5&DE&39ISNK)),_5\#WR/S_M2K%[-VR-HB_=JJW7B+1$3SB//7EO_
M &#L3$P?B+8MD[/JB*L;9.]57-44U5?FIIHB,XF;97C/WR7DM.=:[=NV&J/6
M)C,:0EGN5)=4DR=)Q'(K)&9%L1_C)"U!Q>6=2K/U4:N&SG4FU5WS>F]P>4^J
M1*_>F9%U/ICK[1):1JQ(1$9FT6:XU.2:B..EQ2#,R/'B9=/=CSQG \O*U@JT
M^2:;MIJY;3A'B0Z]S&A*4[FGJ>_3ZATMI^)9VS!_!HII_%TIF8SBJT1$QE>G
MG.5K3XNUL/P15LG:&-7557.#:9FB+]V:<I_I]L\HO%HR5HZ'\32[0E1H)3%N
M,80EV.X:N0O5(CW/;J?A]7F+B-O\2]GU-""GRFXW,E&3-S;*BR>^VQ?#W"QS
M:-R6#7JW3H<2.B.Z^_ATR>5GZ19V^.Q?M,A6I.M"QR2TTVXM)J:;,S2\Z75*
M3_>J]ONWZF/L=A[1VC5$157$Z93.FEM<YGS_ &^+\0]C;#@3,_AU4SI>UIB,
MLKVRRTYQP78*'>5%KL5N93*HRY&<W09*2?GG&^?QU,=R[7Z6P1=[4&R/SR6_
MU?U^\6S+4NFFVE#;IL&6ZIAG/*E3RSQS;]35GQ\\?68]2YJ2P\9F;RUY\.\5
MM]OV?=D>LC:-._K$1%><?U1:)GYQZ/!5;%A=Z>[3B=V^7Y=UZ;;KSEKXJ_7;
MPH;"36JH-N8_>D9??N(']T*@X_OY9W_J^(H&1>[+KQ&3B_<;BOOQGRZ#N6[K
M)S&#WV_YS_CX>7U!.TQK%.7CX<N?UY)_I\U3>CO1I$]Z+7F)C=NRGA\[*UOW
M1**E"U9V+/7)YW\,?CW8V\W/U7ID5KOFMD\QD>YET/'C^#P6_@*=X]9](B*Y
MW"(^78L[^/M^SS^ \E577Y$)MI"C/G4H^8CQ@B,_#R^KXB5XT5Q:,IRG7J=Y
M.R5X-JYI[^<4]V8O'YN[:><YS;]D_+AU?-QI*X:N5)*(C+FZFHR+X_;MOXB6
M]QZD36\DZ9XD)3@^;I@M_;O[.G42.<J#R'Y$*6?=M-FV:'#/J9&2O//7'L]O
M4;+EF.U&+ ?;=(C0EQ)$1EN2<$7C[!JG:L/"BU=I_+.<VOI&4S/#CD[6#L>/
MBQ'<P;1-K1W>,T\8RY:_*WI)6H!%()/>JY3\C/Q+/A[?:.([O-YPU=^?*>-L
MG]N_Q^WJ*=:E57HLHR=/<CQGG+'V'X>(YFZVCNR<](21F7T>;<L%Y\WX\!TX
MVW9LK8D;K><4VW\^>42^G_H.VVC_ ,F8TTIM.[/2V76ZU1R*^4@O[_R\I;;^
M?UE^WSSN0B6ZR62)<KF3XED]_#<LG\3%-Z;EY6U'Z0DC3CE]8M__ !'Y'D;F
MKF6MLW#EI09?Z9;9/'F7WX,QV</;-EFF/S1,S>^<>D]9<5K[&VFC#B^#GK_1
M'&+9Z>^Z52ORVWDTE(P1>W]>Y9SX?=N.PI]<;4O'.6WM_J/Q]IBEK\YU%OZ>
MC_73OCZ]_P!8]/2+Q@J4A!RRY_WV#ZX+K^L^I_=J>T=GPYB*9IJFK72?[=9\
M)TBV[>^9'9VU435,X/"_Y;_JC..N%K*PJ356G"07,63]OM]OW>T3 COI=;1R
M]=LX\CW_ !^O&PI=MNZH+O=$B02B-6YF?U>?GMOM[1/VC5-AUI'(X1GREMS>
M>^,?J'/1C4XM-XBG.-T1:V6F[3Y\G5QHQ:+TU8<1%HCO=V(MIOM?=;QG6,DS
MH2N5)*\"+?\ X#@G2VU/PR/!I/G)7M_X9W^H=?'GF;"L<O0BSDOV#K)3BCDQ
M<G]'G,M_/[?QN-;OE'6CK33&<Q&6>[YO0RY3?HKIE@N1"N4O LD?W>W[^BM"
M9Z0A;2U8-+BS)P_8HU8^OIG.XXI#R54RHNN*Y7&6C-!'^^RDS/']7D)9VE=)
M/0'FLDB4EY1)W+FY4NGS?^')]/UCZ-%.'--/Y[7YZ91I?7/[;TKQ<3$CN4X=
M-J;1>*<YRB/&//EY>]NV4Q4:W#C$@N9O/+YK/!'GR\#\>ICMY,O#+49!X[I)
M$XG;)Y+"<_C]@DY+O&F3+UC(;?2E,'*7%9]5:UHP19]BNO7R\1W;UTL_*,J.
MMQ).OFT2"YB/!%C![;=.NVW0;IJP*>[$U<XO.>=K9:VX3;P,+!VCNY8<SGOC
M_P!MKWSW\M)ULX;C6ZJLTJ*WREA2U+W(\EDE%G!^7ZA%S*F129S1.(3R)927
MK)V,TD1_;GR$A[XO631K^IB5&IR$M+QN+3DR+#62\_'W9$K)NHT^?<\MF,;G
MH;SS/KF:BQR8\#]NQXST\1,;:=FP:(KG%M>J(O?2]IW3G;73<Y*=DVG&JBBG
M#F)RG373]HGZY*MW*CZ+(CQW5D?,T^I1<Y?P9FG.#]OUCH:74B*D29JCV><=
M0E6?HGSJ27U'T+]HIYN:X+JE5@CIBEH;-I"35L?_ #22/&3P6W4L?:-*7.O%
MN FF2'>:*;A.+/U"/9?/MC?KY>&XZT]K;'3>:L2)BFF;VG.8B+[IF-\QQ?5V
M?L?:ZH[L84S5,6B].7YK?6>.D39/%RMHID-IA:\+6:U+/H:N8S-.2/RS]0EQ
M7.(>#:+RZ/!?]-K3F$J82E7S23,NID1D?JGGJ6Y=1 U>5(J;A.2#-GE0E&,]
M2(DIR7EGKTS[AY=FQ;.*I'67(I/U1S!K?4M2NA8^B><?4/-=K=OX6U8,X'9]
M<TUS>,ZK3?+?&>49ZSXO2]E=A8F#,?Y[#IF+1^F)G6.6>[QC7*50UE:K5:IQ
M(\I#CAH=RI;:LE@SW\=]C/V[8\"R)FRKX55(RX$A2FU/)-+3B5'S)49;'ZIE
MXX,]^GO%.%'6S#Y6XB2;;(\)270OU]?^ ]5#EDJ<R3SA)2:BW,MBZ>/AU/X8
M'F=F[1Q=AIFG:L6JK$G*N9KF8OE;.9F]HG[N_B]D8&-7B8.!@T6KKB<*]%,5
M1'Y?Z<LM_CN==<SEPQ69U%JU2D*@34.(2\AQ>4H6D^O(KFS@\'O\>HMIWKH_
M6K0KDNKTF>NK4N<ZMQ$92L+:4HS,S-2E*7](\EG'LV(7:*M#CU)?HC2TNNK8
M<-*S,E'E+9J+8^F<?>+=.JM0F6_.JQRWRBG$-PS-U232X1<QD24*/!%@O#QW
M'EOB7M##IC"VC'BNNB*:[;XB+TWWSKE>V=MSW?PKV;7W9V/9XP\+$H[D8DVI
MIKJ[V435.4S:UL[[]\YR*@U"X+60[+G_ /)TI,\*,CY=CP6<G["WZ;#29J,Z
MBV)]>B/I;DMM.FR2W21SJ22R+EYMCW\,8S]M+MZZ\S:AZ;24M%W"%+(WN<BY
MB29]"VZXR6,_ LCP*]1[3NRTH]!J=052)L!2^5Q*G%$_SKR9'RF1$7ES'C?W
M$/']G]L;!7M48\X6)^'1WN_31$QK%HRIX7ORU?HFV=A[91L%6!WL'\2N*)HF
MN*<K33,VF<L[3?QG>HVUNXF]0*O=TRE7%-DQ8*WG&HR.8^[=1DTX(R,DF6,?
M''42&HS2W[D*7DU*D(<4E77/,@\[^.<[YSL9;D/3<8TFVH:* NER69,Q#I\K
MS1D2W/71UP>>A?OOMZB"TZ2Q5'J.X\1(6<=1GD^I]T6V?;MC?XC^D>P]IP-J
M[$[,G9Z:J+U1,S5>)JC+*K?/GJ_DGXLP-HV3M[M*C'JBJ*9RC#FT1>8O,6RR
M]7L;F]*1IG)B):)SE0ZLBR1X4E:ED>2SCIGH,D#L*]3Y5]<.,BRYKIJ<M5U1
M)R>>[)Z6M1%U,B(R(BZD,;^NU23'A5BDOT?NZ>PT;3<I;VRER$J2DR2K'[]1
M>SV8&1_V&VB]6TVT$KUXUA1I.\7T+A)_>DAB6YC!D9[<JBW'M]CP]GI^%]HV
MC#P\6C_U\4TS7$]VF<H_)NB*ISM&NN]^=;;C;'B?%5L'$C$_\FCO4WOIATWO
MNRF;1NBW%?NIG+S*018-LM_;T(O#\?8/51_H']7ZAYFFD9&:C+!J2GZRQG]8
M]-'^@?U?J'E\>;XDYW_+3S_3$O18']-65OSU9<-+>R(  '"Y@
M                                                'C;^_P #[D_B
MF;_-'A2CP,?XL9G\;53^?OBJZ_O\#[D_BF;_ #1X4H\#'^+&9_&U4_G[XS^O
M_C]17   -                     !]#\/:'0>>KM;;H5*K-6EX3%I%-FU%
MU7^C#C.23+IG<F\%]7MR'77!=EO6M'<J%S7!2J'$;P92:E/BPDF63(\%)=1S
M8VSCWB6:.(W1*3(.#$U3M"5/>9?*/&;KM+4XX\A"N5*4IEF9GS$1$6,F9D6P
MP >+GB4XX.V5[0R\N%/ATO2K67IC9M5>ICOR7)[LN1*%I><6MMQE984RI6ZO
M9D59:2_DQ'%M8>HUE7_6>*2[9L:WY2:E5::Y*GFV\3:D/N,*,ZBI)D?(M![>
M/B6P)-^'7[>,;UCG\HHU9UIU/[16][)I=>N2J4VEO,)H5"HDV<:>1Z&E1]TS
M </GYRY59)!]<D/;\)'8A7GQ \ FHG%+<]Y7[;5^VI ]-I]FR57 4R?\\ZDD
MMI4\A?T$$HB)M77R$1Q^Z^VQP4]LB[J7=MLQ[\IEA-TF+5J14.5;<]3%&9C*
M6X3Z'DF:EMJ6>4GN?M&9IPI]K'H9KCP(WGQ4T6P+6M2V[-I<=R=8*)5.834N
MZ4MA2%1N1HSRILS,CCJSS9/! G&<N<[]TY^'CPC)\TWA6NS7OAWXM]+7G*C?
M%IU%B^&::TW5Y5993+815F8JU=S,6VE:5M;_ $3+"O ?8@LOB(TTI&G]@HOC
M4>VJ)<,RUJ&_+C3ZO3F9)NN4R*XI3C3TE"T&KF,SR6=S\-Q\P+CV[1?3'M"N
M-[0BZ---+J9I=3[:O@H4^/34,<LUQ54C14NGW+#!'\XV;G0]S/S&2-Q>]@!Q
M)<8]_P!O:VV/Q#W):-OUNU+87&H4)^:VQ')JAPV\(2U-:27,99V1_6(OG;RC
M*VD3RG.?#R9D=J:F6)?*3*T+SH%P+;P;B*;58,IW!_\ W3#[BNGD6?UCW!*,
MUH)*24VKJK.,>!_:/FQ77I?Q^?D_G$CH_J+=VJ-P:A:+7C7&:;5FY\MQ<=YE
MZ1'@D?*\^^I/(M\SP1;F6-A]$;1+4RF:PZ6V)J11=H5UT*GU)*2,U8=D0V7G
MMSW+#CBO+ +$WZGZQ"<0  *#C=,R1DO,AR#:I)*+!@(!QTVT+6I1)2VA;BC/
M&$H0DU+4?_521F)=VGJC95ZS[@IMLW''K$RW<%6HK)I-4#91ESF2O]!77&Y&
M/<UMDBI-6P>#^2*D62R6,Q72SG/AGV>\8H?##Q)Z\:,<2G%U1=.-%*CJE39K
MJ">G?+JV&HF&I:DJ2ASO$IP9YPG![%MDP.NO5E$6EJC:-\U"M4BUJW'J=1MM
MQ#=;B-&DUQ%.J,D$LLF99P?@)A-OI3GJ:?;MOXXSO]7P&)7P4<<MP:)5/B;U
M OZRYD?5"\:Q1HUKZ>/U)UU3THYKL;NVY.%-M\IK0I1\A$8N46UVGE_VQ1[V
MI&M^D#]HZC42GL5*W+?:J!SWJVQ,85+:-LXS9\G=1S;4KU3Z[@EXZX\/=>P4
M_P R3)&249;?C;Q'25.MPZ+3I,^K23CQH:%.2Y1H5AE!$:B/'[[8O#RVZBQ_
M_;:;GIO#A2=:)NG*)5?K]6>I5-M8JHVF83ORK\FL]Z@D]\US&I"B)QLBQDQW
MU,[1F]45N9IEQ,:.KL=%VT8ZE:RUU8G_ )9BIIYSWFTFPE/=894E&YY]8S+V
MC*W*?JO!6E?]JWQ2FZK;U=8GTY]QUIB0HTL+<6RLT.I;;<42UX6DTGRYP8]8
MQ()PGD,<YN,X/F,CPHCZX,]NFXQ4-8.,?42B7IPH7'H-:TBV=+ZC4KZ>N2B)
MJ1OH?8I;ZC4MQU[UU=Z:'%I+!\O-@A5Y5NU?UQA696M<:1H&[4-$:+*HU)17
M4UAM)2WY4ENF2WNZ[OO2)F4:U&6,'@%75K2XJK3NWB"O'0&,R;=QV<40YCN5
MGS>EQ^_3L9<I>J6WZQ5@V\E:.;R,RW(RZ'CQ(AC#6-Q.LV=Q+:_<4"+=?JZY
M5'MJ>U;\8W7'E.2*26$$;2%+,F5++F42.A'D7B>!/B@KW%)I>J_+BI<>WWY$
MB9W%,*:S(EM-,27$?W0RDTNLGR))1$Z@C/?&X"NXY*"/&#^K</2$_HJ^!_<+
M1.M_'YJ3 UKN31_A_P!-%ZA2M.XSDR^I[<],,H+11%S&B-#J#)7.VVM/J'DL
M>X4QJ[9ZZ*G8]!J- T?>E7O7I53I[-LIJ)I<8DTF4J)(,WE-&7K*0I99(B,L
M^ #(*6^EQQ*$F:5]"S[<^[\> I6N[BIM.T^("R^'Z6T:KDO$IGH<C*R)/HC!
M2%[$7(>4GCJ7ZQ;BI7:S2RTQJ3EQ:?'&UIAR(,:#8Q3\N37JA*2RTGTI*>1O
MD2M"CR7L,4N4#5C5[4GM,M F=7=.U:?W PS59<:.J:W.2\Q-I2'V<.MI))?,
MJ2>#WWW 9-*34@UMFL^9?+R_7UQ^.@I1C<6=H2>(Z?PU--+3=D)#:W)7KFC"
MXWI1;<O)]#8MQ*?C4XSI?#K*LBQ+'M95[:M:@NN-6Y;K<GT93OH2D>D'WQI-
MLL-*->%>X65[>XNKBTTXY]2M5^(2Q?S%N&C0Z242BJDIE*J4JH4SN8K"'V48
M1EQ;:#,B/&=P.ONRLFWS2DDNY[PC42C,L%L?N_5M[?(Y(;4DTFKD+?*O B+<
MS,^A%CQ/WBQA:7:D:F6;<U&G\2ND3FGFE]\E49-HW0[4TRTKC04*<0LV&D$M
M/I.6B]<RQSY+H.RI7:#<0NL[EY5W2+11VJZ.QZ35RI=Z(JS;:7U-0I*$/IC+
M3WI<KZ2Z'Y;@?5>Q14&UO(0R^T^TK.'&'$O)+'4E&V:B(\E@R/?SWV$>4E'D
M?E_P+J,4K@][3+B!LJR+JM2\K'E7IJE<U?J#&G=#<J*6ER>XJCZ)*"?Y5H3W
M+1I^F9$9$*XD]K%=&G5H7W3M<-+%6GJW9C=.7%MA=1*0JL*JOKL)3(:03:.[
M;4@]B/KN'B+ZGI"?T5? _N'*A9++)"P[4^U"UGMK2BRM3+JT;?I3>IE23%M6
M.=0)UIN.U/;BR'I$A+?)'+NW"<3WYIYO Q>JTUN)^[+*M^XY),$_6*?&F.HC
MOMR6FUOL(=4@GFE*0HT&KE5@]CZ[@/=@
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MU;$?F6/#IU/ZMA679.ID66AEMA]:UJ(BQRK+;&<GDOCOX>0M%VO?, KC1WM
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M<B  !Q.0
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M'=G^NB)TC^J=+1?K=>7%73->M7#],<K\?)0679L\'2O6+1B@EGP[EG]7<_\
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M;U57G*+]W]^O=N)F,HF?6?NH./LU.# __8W0,>U#1_\ R0_M:G!@7_L;M_\
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MB;7F+:?;3R?O&4TT3%K3AT3%N=,:\XT1@  P
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MF5&I4>BP(=,AD28D",S%C((\\C+#:6FD9Z^JA*2(S\C#KKKP6.N?-VP
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MJ'.
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M+W$$?2%^2&7'):=_I_I%MCW?9Y??R,M=T6.;FZ^8Y@%
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M/&F"\B^ HX6.BO>7ZASA@BZ%@
M
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M9)+"2+.=NOF!)2DL$1$7EX#<
M
M #8M!+QGP_'L&TFDD9'Y?CS,<H            V+02\9\!O !P]PD_Q_6.1*
M226"&X!)B)U&F"\B^!#8IM*CST_'LP.0 B(C0<:6R2>2_'VF.0 %
M
M
M
M
M
M
M
M
M
M
M
@                                       ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>nt10006151x2_graphic7.jpg
<TEXT>
begin 644 nt10006151x2_graphic7.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( L $X ,!(@ "$0$#$0'_Q  ?   ! P4! 0$
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MZM?V=IO]V()H(0. ] DGB?4J=G])([6?^O5K^SM-_NP?I)':S_UZM?V=IO\
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M"E(OXD7WO\].?.$!L;CITB>'7SX+&,R=XYY<@,I\MY2D!(U'F>8WY#Y\OO@
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MJ%C:")ZBE20>2N5OGYOX=:4$$$1!:% OUM "1R@B2 BVQA;[';G]4)!$000
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M657\X<ELJ%[_ #\W@B:-K$\C?W6@4;DD0^R-][? 6MX;?&&!).X@DYQQ^B+
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M=6!KO^_MN'T5')V7I#W$3C_,CNI9W#.3LE*2E&DELMHE4+J<@95#RKI"-2G
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MK[PT%))3:QZ$WL?K]WO@K#^/!-Z$]!N80$$7$*? ^^$  Y01+!%,%6JQ\_=
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MIC8:*=/\Y:+@2A(NWH.Q58:K7,7 &IY<(_M^N1CP5.4;LC&8&X>/GKZK _\
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M@OUM[H6&J"U*(_6$].[;4YJ]Z01Y&W+I'H#+Y1J]%F4HY]XJ7= //Z)*0#[
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MAQ!W7TVV^'/PA @G:^_@-S]1BH$)78;VU $;DV)]:P)WL.@@H,<-<O5*E0!
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M30,6F<](3B%F=JC*YYQN80M2)8RK2#>SMUD6W,=;&$Z50,PN'Z5X0*U5'Y+
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M"=]N<3D]KW)3F/\ L=L2RDY,]^[@B1H1D2M(6M ?GF2L))W3LG>W/SB'#(0
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MB.>4^>8^?Y*SYA"5:QYBBD9B4"4]#<HB%*Q?*,O]TMMI2 AM8*2E2M: I1"
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MJ#QX[E)&LZ<(^VO\+1SA#E$HSD-*<6K\WZ]+SK;R0Z9=#KC,JX&4J6"+_K+
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M&E3[- P%6Z\\Y_X-JI]69;44W(.M<OIWY\[#V1<E .'\1S;5&IV050Q#6WW
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M*CM/)EU3:BGO5 $)M;H>9-]MX(K>.PO]FY^ W^J/ITVC56KN!NFT^:FEJ-@
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M<S?5F'6I3)_%51G:3A_!*0F0I<HJ8")A^HI#C@6N6*=5G=QJN >43IF#FBZ
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M2M8:06TN(3K!6I*3I)L3#^%;("H\46?> ,BJ5793#4[CN;7+-5R=<8;EI%*
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MGE)(UZ+)(*K#G$%C>%L6OMAZ6P?BV987J+;[&'*L\RXE/-3;K<J4+2!N5))
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MAA@RU&F#*,RAEF5-)9*=+.RKMMI3OX7$6=PY\3N=7"CF!*9FY&XPFL(8JE7
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M+%;1CK >,IB3,VVW+I9=ISC1"6"6TZWF_1G5 DV3K"+WM#S]>NO=.H73G/\
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M8)0ZB<J+2' FKSZW")I?K#U>YFD+*2"0=B+V@09,Z[L^/B.&NGT4C3P^G+W
M'C"Z$\ZN*6@<;%;R[:RSEVL1@R])9FTI:!3*-!F5;FG7GEI(0$("U^L1L#&L
MW:NY#X5XHDY+\+.",5RC%,RDDYE6+D2"V^XFIJNR[,VTV7&7$H*I=[4DZ2KU
MAN!$-62W%#F#PM4'$^#<OV792KUY(DSB9YH3"Z4PG4VM++3Z5W+K2BC4V04[
M$<HRKD5F/BG\Y%UR<J,Y4*A4YQ$S/STU,.%Z8=<=UW)=45!*2HZ4WLD;#:)#
M=QC0QG.9C7U$#YZFI.1(S$\-W6_Q5AU;^3V<254:6<K<5>D4R;2VEAD,RRG6
MPH!/TW'"M7/QL!&RV(NPTQ[PM\#>9.8&:L^JFYN4I%.>PO6IF82$*[V;/I(+
M/>ABY:(2 OW>,=-/9[9BTS$=:P[3ZW-*G)AUDD2A*BE"VVM205 E)N;<XT!_
ME4'%57<I>&K!^7;5,=_)N8[CX<]'FC+J912IMIQ'ZQJRB%^%]KD;]*DYF=V7
M(1PX*X  RZ^JXQJ;A#..3J29A.:TS3'6"XTY+2DOLL;H![QE8%K;@W]\2KY0
MYW42DY,X3P9CB;G*]F%@Z;4,)XJ7,S"9B3=J,XE4PKN4J)=U)(399( %@(@'
M;XJZS)(_[F4-37ZIG47)D.$A*!<W6";GQOO[><Y78G8+JG%-G).YI9CY4,Y@
M9$Y8S4@G&=/176Y6<E'ZM^IILPB39/ILREJ; =4&FU )3ZUA$R(TGEX<)XG7
MT41GK''+4?/+C_"G$X>N'W*"OSC6>W$8TO%52?DF'\/S,Y+OLJ9::EPEW4 #
M^P$@:P+VVO>(]>T1[1_+JA8EDLD,IJ.VC"]):GI!R42@I0\F;:*%:D.-@N:%
M*.DD*MTZ1TU9W8"P#0\-5*E4J5E)3"CM+97AZ504A26A+!:I:PLXDL[-J*AJ
M5IN0=XY6.,'('A\Q[AW&6+<-R3=#SNPLZIUAQ2G71.M*=5WB@A5F+IED$C97
MEO 9R8SW9"!XQEIEI"@Y >IXD@@D\_<Z+G@Q[E2[B.O5FK24FB1IDT\J;0LK
M2?6?4IURP-B+*4;"WN$?3X<<&U#"><&%TTB=*I^8J\FW*+2+!!,PTE2@+V7I
MO<@\QY[18V.\:XAIM>FJ<*VX_3'7E2Z9;T?N>[6P2V[=1 58K!W.QMMM&:L@
MQW>*,+XB,[W<[3:]1S+.:=:6$O5!@/%6]E@H)Y[#:&Z0?36?8_/Q,F&1)&?G
MINW:<^(WKI8[0#MB:#PI<-$GPGX&P[)UK/RMX;:DL5XS$DU)3$DQ.R:%M#UV
M-+_\T>4WJ2X2!O'$54ZE.U*<GIV>FGGYB=GIRH/DN+">^G9AR8= 3JL?761X
M=(FK[<+\@3F>N75;I#K$W-U/#\C^49Y@)!F5M4:52 H).Q201$(9;*UJZ;\_
MGY^$4X\C] 5<Z#G]X^B1*BJ]_+[X15RJV]MOAMO#THTJ()'M]T-4NQM:_P ^
MR)4)JP!:WG]T "?5]]]_G]\(I6JVUK0V")R@!:WVWAL.2F^YY> %U'_-3S/N
MO[(4V-P;I(L '4EI8]J5 * /0D>SQ@B9!#]&U];=O\]/X[PT%)44)2\ZKH)=
ME;Q)\/U87O!$D$?9DL/8@J:TM4W#V()QQ9 0&J+4%)).P]9,N0-R-XR[AKAF
MS]Q:I**'EC69A2A<%^7F)4$'<&[K*0-O.(D:_+/Y*8/\Y?-8)@C=:F=GIQ>U
M=M#LIE2A*%D!)F:S)2UR3;D\M%MSO?E&0)3LHN.N?+8ELI:<L.:;=UBFC.+
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M5<?:DJO,S"%%Q<L]Z.Z#+@!U(#NP*DBXL8ZONW#[3OBMX7^,K*_([(JH# N
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M[X=LF<J9MR8QAEQ3Y&7Q VIJ;0$N2ZI$N *>2E"MF%[H)'ATCF ]P'D  ![
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MLS;E,D))+JBI+:)&7=1++2E-D@!LC;EO%LTBDJJ)9E0R:LM)',>B"7.VZEV
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M "?I#V=?;X^4*-22FWT5N-M@<[]ZL) MSWO;VVAY1JL;@I'4&X-[=1_&,WY
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ME9B;Q#)]XU+"526IG3,*%])02-XB?GRX3[D[MZG=Y>>L=<O)23\-V/,13O\
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M-FLY89I5&3FV:MA9N@.5-N>,HAIJ52N:>2&)?NVTWO87]T-[.V>[6Z0Q#.8
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MPO>V\$2P0001-4G5:W2'#8 >$$,!5JMTWZ>VT$3X0FPO"P$7V,$2 WW$+"
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M?;4"A84#R-[F^\.O7KVR0:1Y@<\O/1<N ]5*57*E'9+;8+SJCR]5M%U*-SR
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M(R)C=N.IX'=EZ:E2S=ES@Z2G,W*]F-5Y=I%,P'(OJ*W-*6T.SDDZEHW-A?O
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M$DEW>FYM4B^A#81,-/,S"&U+"P XDI6"H$$<MO-X:Y1R_G/(C@K9_P#=^GT
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MRFD#K+Q_E2@=H[E9)TO!<IF'@U*F<-9A/)952&U*<;H"Y9]+'>)))&F=<47
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MD7%[#?S^K?X<[Q(&4<<LM)F?XT]EB.;YX1OW9#AE&_U&:S5D!Z,C.'"CDSI
M88J;J5+L05B54I'O"@"/=X1(]P05><Q)FQG$P[,K_+=5Q?@-$FBY[QYJ5JS
M-A>Y2EL;FQ 3$3^%*[^;N)J76@FWH9<"K*L2ET:5;\QM\\HWQX#<PY*E\<^7
MLP7T(PWC&M24M.H<4$->D:FFF5+U6%P\L$$VWM$'=X^N4?4+*-#GN^H.7S_E
M=.^6N&,7Y._R@FE/XOI"J?A?.W"N'6<-U3O$KDZBND8)EFYK4XC]4V6UJL4K
M4DE6T;)]O17Z5E5EFJCI=;;?FFIQTKV!7WQ*T;==E"QZB+;EZS5LR.U+QED?
M5F6ZKB3(JGX)JV6\^E;:)J1DJ[0Y6IU8(F$GO'DJE@4^LM6E&PVVB-#^4C<3
M])QWF72\NZ+4D+>I4HS)3TNTYJT/L2C#;NNQV)<0H;];[Q(RZZ\T/VYYCY?1
M<QU!J8J&(YVKS*C>9FEJ*])(L'%:?5Y<K=-K^,9MQ7B#_N'3))*M+\TI/<HO
MNH-K!/GR Y@;_5@["20T&4/2U]RLIN#<).HFX&UOQ,>RH5YS$6*Y.5EU=S+4
MMQ*6[>L/7TZA;KR-^O,^VQT ,\O;3<0>6G/?B'^]$Y &-^><[YCQG65]+%:Y
MJ7Q9A2HN,E"G XC6;>MZ@3<]!;\3'W\UJ@\Y2:+34V[IZ>D6%J%@5^DS+2+6
M'*VOPW]\5\RY90&&IA2_U;2T!OU=]UH!-^G7\.46[FE.2R:EA64;5J<-7H)>
M/2WILL?=87^&WC%#H8X%9&C0> 6X/$WD9B+*/"V0M5J;BEX;Q/3YR9HR%6#;
M)2PTY, (O8:U+L20"?;&J6.,7OM4N4I4LQIDU+0I*"18+;6E04DG=/K@':WG
M$M?:9585++#A7IC:DF2E:#-64D"R29.6)"2 .M[V-O?M$,N/@%?D"73<F8<*
M2!L0E*DCVG;X")52#E!TU''Z>JWYRCQVU.9/8L;JTJL5IUNG(E)Y#ZP%!"P
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MXNF:1-JD)NON2#3"$V7WVASNU!2=PD6/-0M#C[J!(?.0X<]#U/N%XNU$X5L
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MX*S=?3_S!<G/1'^8G[(2-ACPH<2VULE<:?13SH55\!_])B$_V*'$M_4MC/\
MT%5?]4BTCGZ'[*-D\NHX>*UZ@C87_8H<2W]2V,_]!57_ %2#_8H<2W]2V,_]
M!57_ %2$CGZ'[*=D]<X_^H+7J"-A?]BAQ+?U+8S_ -!57_5(/]BAQ+?U+8S_
M -!57_5(2.?H?LFR>N<?_4%KU!&PO^Q0XEOZEL9_Z"JO^J0HX3^)<WMDKC0V
M2I9M0JL;)0-2CM)GD(2.?H?LFR>O 'Z_-;Q=B-E)E_G?V@V <O<SJ UB;"-0
MPICZ:FZ0ZHI0],4_"\[-2CA(!-VGT(6/8(T$XD*%2\-9_9LT&BRHDJ52L55B
M4D)1))2Q+L5*9;:;!VV2A"1YVY1)MV5^0/%-@#/5>>^ J;-X-K>!:=5:2149
M9")A:,14]^F/)5+SJ4+39MU0W1[(TAXW<BLT\E<Z<23N:##RYO&=2FZHQ5 T
MD-3CDPZN:?(#0+:-*G2.>_E&_K=E>T-#!K?M'6PJ[IX'<N#*.(.9%%Y<7-:8
MG;#'N$,J.:UCR,B3"YVAVK[.7&-U^S5'%K.ICMLPOK8<UY-=@ 8YPG9V'5&-
M<'/IM>:C 9<T+3J"!.E0NE:#Y:DW^%X(T*Z!$$$$$1!!!!$00001$$$$$1!!
M!!$00001$$$$$1!!!!$00001$$$$$1!!!!$00001*!>^]K?7 !?80D$$1! -
MCXP01./*Q'38^7N_C#8(((B"""")02.4)!#AJ(L.7L'VP3RY>J;%8"]E'G\V
M,,"#R(Y]?#K]<."+$&^T$3X32+WZPI(O[>0^X>7\(0BXMR@B:LD6M%0CU ;Z
M2????Y$,0D@VVW^[Y^J'$=//[#!$_2+ =3N#T^?K]D(2JUB.77]_*'I)(%A>
MVW/V0IWV!%^HOY6\#U\H*I)G3(9S\]R$FZ=_?\^R*B2+!(38=1?Y]O.&#;:U
M@/XP](!-C!5D$ZZD1[3RW >.J]$N4>D2]TE8[]GU-[']8D6MR^K[XR1B&LO4
M:O.N2<IW3BY>72XA9U)(+*1]!8('C>W/Q,670)-4W5Y%EM.H]ZE9'3]6H+WO
MXVB_\P*2_-5YJIS[J9*3G&FTI<3I6'!+M)2H!*>6PM<05P(WSUYZJU:))3%9
MK0J+*%--RJPY-/F_=LJV*0%&R3J.P /A[[NS-GF9V5I+R&.ZFG4K2^Z%']?W
M5DI)3Y6'3?G#F:S)G ]5I=*E4RDKWTH._!NY,D/"ZM9]=-B+D7Y'PBVL8E;B
M:<EQ_O3+M#DG2!J2-O#;Q^_D0Y ^"L8 A04H@?P^%]OX0XJU$FUK<S[/>?/Y
M,*;) 5S\1\/KA+BYT7&JX)M>W4\_JY1;*1IH,YWY'<#X:>.:Q:C?N$9[XCEG
M!W^6\"-1&KPZ[>R%N+&X]8VL?#QN![?&WAYB%)'JZK>Z]SUY^/3[?%R3:ZCR
M2"3]OV Q8F3&[>=^ORW;_/)2!&N1@P-^G#CGQ"S)P]Y15O//-W"&7E#:6\N>
MF_RG4"E)T,R%%4F?FTN*Y)#DNTX-S>QVO'3QP19P8EQ'Q6XEEL"S8IV0^1^%
M9N2D:2TE*91$^<.OL5-;JO5[XJGV'%I[P*TJ^C:\0@\%>(G,DLK,\N("7E@Y
MB&F2<A3,(.A 6XDUA#E-FPP""3<.@$ ?C$Z79AY52M%X.LQ\9UI8I6/\R:;7
M)^<FIA5IEHNF=>92MM1"D=ZAX)3<)N#M&/K=X;N,+*! ZU@3]/;="YS>)ROO
M8_X@<>9HHGE5"5Q-6ZLQWBB=4O\ D^9F)<)W)-E%-ARVV$8WR_Q"[)X%Q]AU
M:0F7K1ERI5PG7W#BE)\SO;QCVU.E35(S$Q%A*M.+ 8K5==F0X"+][-S#K2A?
MZ.NX.W.+ *&9.5K0=F]* X Q*H2;* 41NM)\-_6Y@P3\==:K'A2I(4A6Q;<6
M".NZ]OGX12M8DW-CT\^7SX^<57EMZBJ^ZCOX)M?[?OA4+'T5)!2=P;VMS//G
MYQ8:'./23.N9X!8W;IR\SNWQ&N>7O"I<DVTZAU-A<==O;X0J=*G)-L"Z7*G3
M4J%[DI,VT"GEU!^!Y0XD;A.R>@\?G[H$V;=D%C<BI4]1%M@$331^P>RUQ$.Y
M>H$;M>LO52S)V?&8)DR(\LYX>*Z)>#S'K<]FW*\/+M1706,0TNG/X>>2I6AE
M^5IS<VZ+ I![UP >MX[;")2.VLRQSIF^S&X>TIE9VHNX>5B,U"<E9Y3<X_+?
ME))9<9DF7._F$I92%*+:5A"=U$ 1"3P6"0Q1VAF1LM4&"_3IFC5">F7$.J9#
M::10DS)3K24_2[HBU[6/7E'15VJV?]&S X9.$VJ8$Q#+8)K<L_C6EX4I<TVB
M=DL02LG.>AUUE]N9/HVI4NVXAM3R5*"EZD'4(@YB,QS'EUT5D;D2=Y^D9<M^
M?/S'"CA"N56G8NPY5VJA5/26*C*21U3DTAQ)>?;EW@6RL%&DDA0L+[W.YB3;
MM(\?*.7W#OE7(3BC+T>FU&:K";GO)I<\RS-M^D&^IS0I1TZRJT8>XD<F93"N
M8V LT*#130\(9A5F34[3D:G9>F3\E-2[<V_WI&FT_-E;J$V"4A5D[6BR./>J
MN3>>#5'6"E% HU%*$W)2!-4N74"D;@:@0;#IYPZ^_LH6E8"KA(WTW"M^@V'/
M?E\VA2!NE)N@?&_7Y_&'N<RH#=0%M_C\;QYM*OI'8W^_G\^Z\6@NTRCVTS)@
M??58C\)UG<<ARR Z&Y5CI"T@V5?KX?P\HR#E//OT[-C+2>D'UL3C&-,-AEY!
M*5(U5B3"@D@WMXVM&/K7-C;3["?C[XRIDEANJXMSARSH%!E')VLS.+*(_+2Z
M ;J3+525=<).X3I0"23T%X@B-_#WC[Y*6B<XB.'AGZ1.<Z^:[)L@V<P9_MS,
M<8ZH(>?I6'\IJ ]C2<(_565EF@R/>J7L3=/JF_/ERWY8.T%S'F\S.*[-*L3$
MT[,(:Q-466@M:G$H+4X^T0FY-@=.UOJY1W<9;Y8R^2U=XM,ZJ\TU(8MQWE=@
MF6HTT=*EH-+P@F3F4L.<E^KZJ]!VMOO'YV6<-4?J^<6/*B^_WKDUB>K++O\
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M_P!/LGQ?ZO=3,?I"O:>_UEX+_P#L9X._U"#](5[3W^LO!?\ ]C/!W^H1#/\
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M+2H&40[J]4@V!'/I8QJ]@O&6)<OL34S&&#ZFJC8CHZU.4ZI(2%KEE*MJ(2;
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M?\!;"/\ I&F?ZA!_M^&77_ 6PC_I&F?ZA'-CI/\ NK?_ #J/[T&D_P"ZM_\
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M&AC#5J/J%K!)#6EY)#023 RDE6HV]"W#A;T*- 5'=X\4:;*8>\@#;<& !SB
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ML/\ <F_^:3^$1W?/V_*G;Y>_XY=25U7_ )H_R:_^L.?_ -%XI_"#\T?Y-?\
MUAS_ /HO%/X1RH6'^Y-_\TG\(+#_ ')O_FD_A#N^?M^4V^7_ (CUNZDKJO\
MS1_DU_\ 6'/_ .B\4_A!^:/\FO\ ZPY__1>*?PCE0L/]R;_YI/X06'^Y-_\
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M_7Z_PSKPZ5E=!RTI;B'/5J-;I32QLD$&J-((\QN;Q@;&3K<YP^97K0-/HAK
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M#&=Z]SRQ@S#&[9):T2?A&0G19Z-"A1#OT]*C2;4>:C^Y8Q@J/< #4=L !SB
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M&.J5,5C+_%,V]*UF@U!A4RP&WW5I2N7G7FW!+]TITN'NE)U6%^<.I_&_GO\
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M_MK7'K_7W/?Z+EH/]M:X]?Z^Y[_1<M#X^BW[>/0S?#R_\7+\^RR%_M*W:/\
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M6D@$'T:J2KEC?GN+1W@]J=G=)Y?9/T/""7T,IEL$8?EFF$J"=)5191!LE/\
M2/D?'G:.$#(;$3&%,[<K<1K&ANG8HI7>$FR1WU0EDBYZ#?K]D="?;)YX3>)L
MP\-4JFS7>R4SAG#I6RT\%(L*-)$G8D;;D_-ZMUXZ1[#7=F?#S640!KI,P!D=
M2 HF*34&I_%/Y3F=31?F)IRY45ES6I11?K:Q'[HUMS%9$SFC54W22E*5.!(%
MD:6=2.6V]AY^^,Q42<;$T)I2A:5:<5SL"I39(V!')7OC%>$<+8QS+S,G9'"N
M'*OBFOU.<9DI>G4R0FIQ2U/J##?>*EVG>Y2G6#==A81!^62-R@>>6F@U/CP^
MZZZ^R:I"LJNQOXT,W)^S'YTTNB2LD\X-!5W<W,RAT.FQ5N0+).T<Z/"!3W:Q
MGRXX[=+IE\<33;@NK9Z3GG0;#G<'G\(Z5^*"G5O@0["?*+A]QK("@YFYSL5&
M:K=$4XE,Y+M2=61/2@?";*NIAT&RP"-Q:.=/L]5T^=XJ,&4&L3*).4Q/)URD
MM/N6*69RHTYV4EDJ)/-Q]Y(W/,WB%9188F5JQ/B8G=7Y?JZ%'QT5!\?='Q0G
M4"0=QY;^[V^7[XVXXY.%_'/"/Q'X_P I,=RJI>H2TZBL2$QZJFYV4KFJIL*;
M*24;,/H.Q)WWWC49!4DI)V(YCQ'U1;*!S.?AENSWZ%8R'$Z ^V_QUR]/)(W=
M 5_E#?R^?*%0I:%>'K [[\CR^'+E]<.44J*E)\MK\^?+V>R&[FP*;*O8F_PY
M_ ;^<-3EI,Y^\]3PS4 '<<\M_'=SRW>DB%-!V('$M2>'/BFJM<GT4UFHUFGS
M;-(J529EG6Y%X4QYHEOTE"D)4I2@ 1;?<&\?9X].([,K,_-O%#.,L1/5:0<G
MWWJ6$3 ]'2R\XM=FTMK[L)T$6 VZ6WB%NFU.;I%2IE0DIAV3?EZG3DKF&'%-
M.)EW)II,P I!2JRFBH$C?[I=.*')O"-4P=D[CG+>N.+.*Z>1B)F:2ZGT>898
M9;"TS$RK]?=PJ4K0;#D=HAL3$<\],_,;]>161VD^ RUC+3RT6H6$L.U/,#$=
M)POAVGSE4KM3G&I>3D9.7=FGWEN.H1]!E*U"VJY.FUMR><25<7>5_%%V>W#G
MAZG5/ U3PS1,^) FL8C4E3C4LQ(A!93,HT68+J7M #BD'?J8]?#],TCL\V\O
M.(:EUBBYD9D5]QY^E4UYN2<10TRJTHF>^:<[]E16T3I+J 01ZN\=$5<[3C@U
M[5?A:KW"_P 3\I2<.XSJ&'9V9I>(E2P0JDS](E')YE$LJ7::2WWKS#;9"%I!
MV!!$2\[AYZ1NRWQH)SXQSAC0,SOS\N'"><!?GM*25$DG_&../J//4M]1<6OP
M]92B;7V^,!6!SY^'[^7*+LQS0Y##6-\68;I$^FJT>C5RI25+J@&A,U)L3CS4
MN0C<@!E"!>YOM%JK!]8<R;;\N7S\\X"<C'"-P.D>/14. U/'CQ'*?0\TA618
M@WM?;POUZV^^\4%'5?2>=OG;RY?)BHD&Q!%K];\[>\_P@"6TC]]_L@>/'^=-
M/<_:LP,YSXZ1D#G$P1PY:ZIA44V"1>_/R-O/ZOO@)-N?/]_[^7P@!(O;KSA"
M-9 /D(C4C/@/IU]TD08])C6,P-8Y9\.*50T[GEX_N'*&I]9-^G7KS_&'NMV4
MI(.VWN_C[H1.@ H'EOX[WY6Z#;X0CJ/#[_)20"0)R&1SY9<MV[S3 H&]ND )
M/[-OGV0)L"0.EK_/E]Y\H!?6J^W+\/QOYQ$==>*AL_%'D3KK^/5-)TJOSN.7
MA\F$";;G:W(>,/(!OU(^?DF_W11L=_+G!7:9^O#3=RR3BK5Y'_WN7V><4U D
M;>V'005E2"5 CI[X?>Q-SL>7E8;PA)"O\G;IM[;PX@'G!%2()NH#;W>^&Q4-
M[Z1RY?'GSOXPU0 M:")L*+;WOY6A(((E2;$&%403MX0V%!(Y014TI(O<P^"&
M$JU;<MO8?._O@B?#=0O:'0FD7O;>")8((((B"""")I4!SA2+BWC 0#S]D+!%
M2T'Q$58(((B""""(AH4%<ND(2K5;I[.?CT/C#@ .4$2PS6//ZOQA\-T)\/K/
MXP1 6";;PZ&Z4CI]L.@B(((((B""""(@@@@B(((((B""""(@@@@BJ(YR_P#Z
M])?]8;CJ"[6\D=CGV5=C;^9YD?\ 7V(YCZ71:U67&FZ-1:Q6'&YV2+B:53)V
MH]T._03WQE&7>ZY>KKMJZ1U%]K+AO$4[V/G9824IAS$<U.,2>8_I$K+4.I/S
M,M_/V?\ PEAN74[+Z@+H[U*-72\4)SB8,?1WW"NT'7=E[$=>2Y8"39'K'Z">
MI\+0ESXGXF+E.#L7BP_,S&NR4C_XJ5KH+'G*#K>$_,[%W^\S&O\ 96L_ZI%I
M'$>H58/ ^A5MW/B?B8+GQ/Q,7)^9V+O]YF-?[*UG_5(/S.Q=_O,QK_96L_ZI
M"1Q'J$@\#Z%6W<^)^)@N?$_$Q<GYG8N_WF8U_LK6?]4@_,[%W^\S&O\ 96L_
MZI"1Q'J$@\#Z%6W<^)^)@N?$_$Q<GYG8N_WF8U_LK6?]4@_,[%W^\S&O]E:S
M_JD)'$>H2#P/H5<65&4>8&>.-)++W++#SV*<7U"6G)N4I##G=//2]/85-3;@
M<MR980IPCJ!;K%G5VBU+#=8J6'*U)B3JU(F'9.HR:TA2I>8:6IIQ"E6W*5I4
M+\]KQ-M_)_,)XAENTQRT>JF$L2RTFK!F90+M3PS4VY0*_-"?"0M<S*!I*BHC
M1J()4;)WYQM<56#<6_[)#.5UO!N+U2[N,JZ65L86K"FU)_*LWN-$EI";?1(.
MDBUC$;0F)'4_A3!C0R)X_P"G\^G):N-N.,H4VS,SK+:[:V6IQ]MA=C^VTE80
MK;Q3%.+E_,[%W^\S&O\ 96L_ZI!^9V+O]YF-?[*UG_5(G:&DB!IFHV3P.>9R
MU6:>%3.+ V1.<%&S!S$P SF5AF1[]N<PP_,^B-S#<PT6B2[I7;N[E8(3?;:)
MA_SM[''B> 57,/#A\Q94[A4PV]5JPTU,.]="-#-DJ5RM8>V(#_S/Q=_O,QK_
M &4K/^J0+P;BU?/!6-!YHPI64*OXA290*'QCI,([3UL*MG6+\/P?$[%]4UG6
MV)6-*L[;<&M<67+#3NJ4M:  RL TR0,UR>.]D*&-73,1IXICN#XC3HMH,NL)
MQ&M;M[MA<YC:MF_O;*M#G$DU*!<X9$Y!2D\6O9XY.9.94U+.W)?B,I696%F"
MVXW0VY)F2G.[F'0VA(;6^J9.DJ%SHZ;CI$2 -P#X@'XB\7@<.X_+!E/S?S*5
M)GZ4F[1L2.RBK&XO++9+.QY>IM81Y?S.Q=_O,QK_ &5K/^J1K\7OL/OKH5\/
MPREA%(TF-J6M&YK7%(U@7;=2FZN348UT@"F7.#8R.:V>!X?BF'69ML4Q>MCE
M<5GNI7E>UH6M84"&BG2JMMFMI5'L(<750QA?M9M$*VK@7)#B@.?=MJ<L3RU:
M0=(\S]T*"%)NE:2/#4+\[;I)V]AB0/@?Q1D]E7C2NN\2/#YC+,K"U<2RS+LJ
MHF(9+\E)[M2'7 9>14M9*E!6UCZMNMXDDJ/"3V7O$8M3>5N-\9Y)8FGBMQJB
M3.7^+ZFTV^\2I+/I4U*H:]51L3RY[QM,+[,OQBT;7LL7P87A<YO^&7=ZVRNS
MLNAIINN6T[>IMC,!M:1D"M/C':]F W[[?$,"[0&P:RF__&;'#W8C8#; +Q49
M:/JW='NB=EQ?;[)U!C-<[))/[*1UV2!?X<X;]X(/L.Q$27<8W9MXXX5:1A_$
MU,K6(,R,+8G,P:1/R.%I]IQ;3"@"7&&FG'&CZPV< )\.D1[G!N+QSP9C6]K_
M /Q4K7WR8C3XGAM[A%V^QQ&B;>ZIM8YU-SZ;_A>T.8X/IN>QS7-(<TM<06D%
M;[",7P_';&EB6%5_U5G6+VLJAE2G\5-Q94:YE5C*C',>"US7-!!!!"V=X7^.
M;B X13/2^45<D9.C5=;)K-(G*3(5!$^EE1*$%<XVYHZ\AR,29TGM@<G<TI=F
MB<5'"Y0<8)F0AJ=KTE,R=(60JR7'NZI\H@ZN9L">OC$%3F%<5-J <PCC!M1!
M/ZS#-70;)&YL90;) N3T%R8^(MIYE90ZVM#B+ZVGD%#J-/,+;6 M!&^Q /C&
MVPOMAV@PJ@VTM<0=4L6Y"PO*=*]L@TF7-%M<LJ4VM<9G8#3))E:3&.PG9C&K
MEU_>X6VEB+]<3L*U?#L0+@ &O==V=2C5>Y@ #=MS@  (A;S<<F)>#W%.)<,5
M;A(PT<+TR;3,.XIIIF)N8$NXIM)9;2N;W-EE0!0.GA&B?CY D^P"Y^J-C<O>
M$W/_ #5RSQ#G!@++^;K^7N%9RE4^NUN54D>B3=:FTR%-;[A(+CG?S2PV5)!"
M ;JL!'U,0<&?$?AC.>E</5;R]?DLW*[)L3E,PHJ::+DQ+34FB>97WZ06TZI1
MQ#I!W%['<1I<0OCB-Y7O'T+6V=6(>ZC94&VUJPAK6_Y5%OPL#HVB 8+G$B)A
M;_"\.&%V%M8,N;V\9;M+&W-_<.N[RH"YSO\ .KOA]0MG9:79AK6@DQ*Q32<G
M<TJ]A!6.J%@:M5G"J+ZJM3Y.:FD )7H59+#*[V4"#8QCV:EIN046I^1J=/=&
MRFYZ0FI0@]0>_:1;K$K&4_'!Q9]G14:GPWXKPM2#3\-EDUK ]3IE(G7&FIW^
M<I3^49B7<<7WJ5ZK@^K>-J97M%.S_P"(=M-/XE>%FGX<J<T4-S>)*?5G6@A:
MK!R83*TYAL"VZPD6!Y1TEC@W9O$K6AW7:=F'8BZFT5K;%K*M2M.^CXA1O;;O
MVADY UJ;2!KFN3Q#'^UN$WUR*_8]^+80VJXV]Y@>(T*U]^G^'9-QAUX+9W>:
MES:%:H,X;*Y]2;\BD^:2"/J_C!&S_%W+\.TOF]4$\+\RJ:RO6EER26L3(*%+
M9"G6OYU^M/=NDHN>=KB-8#M[R$CS*C8#VDQS-Y;_ *2ZKVIK4+CN*KJ7?VU0
M5;>KLF-NC4 &W3=_:Z!(W+L+&Z_76=M=BA<VWZFC3K?I[ND:-U1VV@]U7HDD
MTZK)A[),%; Y4<4N?V27<IRSS'J6'I:65J8D"5S,DW8A1"95UPL64=R.[W)Z
M1(_EQVVW$=299JE9NX;P[FS14H#3TO,T6B23SS=K$>D>B+=%QN57)'7G$24Y
MEUF!(T>1Q#,X*Q#^0:@%*DZM+TJ?F)9]*+:U)<;EU-V3XZHLY=VW"TXA^7<!
MLIN:9<EE@]04NI0;]+6^J-O8=HNTF"AC;/$\1M*>R-FW=4J&W<PP1_T>MM47
M,(T^"".2T6)]E.RG:#;?B&#X7?5=H@W+:5(73'M,.BZH%E>G4!U/>!P(6?>)
MC.6C9_9N5[,R@8,E\ 4RL=PIO#$JXAYF46VSH=*7&T(2>\7==@!:]N48"2E2
MU-)2+J=?9ET[V&I]Q+:23T *A<\AUAOP/F#<>XB#PZ6((MM8@W!'F#N#&FN;
MFK>7%:ZN'!]:XJ/K57-8RF'5'DN>0Q@:Q@))AK6AHT A;^TM:-E:V]G;-++>
MUHTZ%!KGOJN;2I-#&!U2HYU1Y  !<]SG.U)E2>2/9)\6N*,KL-YK8!HM)Q=1
M,0RKLTW)2]>I#<VPVBQLJ7#ZIG4>@* K;W1I?F+PXYZY533LGCK++$5*6PI2
M77):GSL\T-.Q(<EV%-D#??5RWY;Q<F5G%QQ&Y+^C_P"#O-"K4AB5(5+R3ZW)
MV5; -]*6)AQ;(!M:P18^R)'<N^V^XB*9)?DG.'">',V:0J3?E'&IFCT.1>6'
M65-)<[\2BW;H*M5[WVMRCKJ%/L+?4:3*MSCF!WFPP5*CZ5'%; U UH<^&&A<
MTVN(DB'D F%PUQ6_J5AM>M4I6O9OM)8][4=2HTZUS@F)-I.<2RF34%W:574V
MD-VRZD'$284*BVW&E*;=:=9<2;*:?;6RZ@^"VG E:#Y* AL9(S<Q[+9H9D8H
MQ[*4-K#DOB.9$PU1&%(4U(FY)2@H2E%B3^RD?"+$D))=0J%.IK1"7ZC/2LBV
M5D)2E<T^AA*U%5@ DK"C<@6!CCZC&"L^G1?WS!4<RE4#2SO6AQ#'[#OB;MB#
MLG,3!7=T:CW4*52O3[BJZBVI5I;8J=R_8#JE,O;\+N[)+=H9&)7DO86*$G_.
M0#]H^;PK*U2Y*I>8G)51YF5FWY<$6((LTM&QN;CE;WQ*WBSL<^+NG88I6,,%
MTRBX]H]3I[%0 D:_1DOM-/LH?"2PW,K=*@%6TE(((M;G&@N87#YG;E;-NR>.
M<M<14A;"E)==9IT[.LITGUB76)<MZ1;Z6JUMXV=]V?QS# 'WV%7]JP@.;5J6
M]04G-<)!;5:#3((X.6HPWM/V=Q@EF&XUAMY4:XM?1I7=$UFN:=DA]%SA4:09
M&;!OW+#9))))))W)42I1\RH[D^9B[<"8F:P;C+#V*WZ8W6&J%.-3:Z6X4I1.
MI;<0YW2E*!2-6D@D@C>+3(*24J2I"DFRD+24+2?!256*2.1!%P82-2Q[J;V5
M&F'L<U[20##FD.!(((.8T((.\+=5&-JTWTGB65&.8\21+7@M<)!!$@G,$$;C
M*Z )#M!NSQSZE92E<0W"I)87GTR<K(OXAD:R^G26&$,>D>C2#+=U'25D>-[;
MQ\',7A9[+?,_ .(\;Y&\0#6#ZW2))<Y+82F*34'US#W=K6B63,3;@W"DZ-0!
MYW(ZQ!!T^@G:U]202>G4?._C"-GN]7=N3#6OZ08?=90KG])#:DI(\B#UCLW]
MM*M[2=3QC!,!Q5SF%HNG6#+*]:<ME_ZBQ-#:<(D[;';6^)7 L_I_1L*U.K@/
M:/M+@C&5&/-G3Q)^(6#VAS2^G^FQ,708U[06_P"6]A;,C/-/?0VV_-MM+[QI
MB<FI9IRUN]:8>6TV\ >7>(2%VZ:K>967EIF;>3+R<M,3DRN_=RTHRY,3#EMU
M:&6DK<78;G2DQ1C+^0V:[V1V:V&,T&*%+XD>PTX\M-&FTM%B;2^D)6E8>0MH
M[?TT$#GM'(4&TJE>DRO5[BB^JQM6L&&H:5-S@'U!3!!?L-EP8""Z(E=U</K4
MK:L^WHBYN*=%[J-!U04A7JM833I.JD$4Q4< TO((;,QDL434K-2*N[GY"IR#
MO(HGJ?-2A!\^_:1;;SBB-)%PXFQ\% W]P-_=:.@1CM'. ;/T)D>(_A0IU"J$
MPTVQ,XAI]8=9"2E(07Q*T]AM)MNNPMORC#7$3DAV8U?RCQ/F;P\YP_DC%U*0
MP[3\O7*947%S2YA=ELB=FE  LCKIL>=N4=;<=D[5U"M=81VEP3$Z-&D^JZB^
MM4PV_#*;=IT6MZQG>/ !^"E5>2?V@KB+7MK=MN;>RQSLCVBPBO<5J=!M>E;L
MQ;#>\J.:UA=>8<^H:5/:(FI7I4FM&;H ,0P!)/*%3ZJK'K87A=1*21L0XM(Z
MW2E1"3R_: !CZ5.HU6K3PEJ)2YZKSUBHRLA+/3;]DIU$AEA"U[)%SZO+>.-#
M2XAK07$Y  223N &9/)=Z2&@EQ#0,R7$  <23  YE>(*4.1(A0?)%SU*4W]M
M[15FY6;IZBU4*=5:>ZDZ5(GJ;-RI2H$@@]^TW:UC'G2;D$*04GH%))\]AO?R
M._E$$$&#D>!U4@R 1F#H1F#X'1/(TDI/6V_A[HN3"6*\28%K\CBG"55<HU?I
MBU+D:DR#WDNH[*( /(VWWY?"+<OJ5=1V^[I^,"@H7-]O;X_5UBS'NIN:]CG,
M>PAS'M):YK@9!:X$$$',$9@JE1C:C'4WM:^F]I948]H<U['"',<T@AS7 D$$
M01DI0LL^U]XULO$R\G-8TI^,:0R$H5(U2@4J84ME-DZ%/S;+JS<"UR?'WY(S
MO[5:@\0.4&)\ XYX=Z%+8XK;4NB1QS(N2$HY).-JU/."5E)5L*+MK%-QSVY1
M#N@V'.W3WW)M]8]ONA?HB_,CQZ[\O9'3,[9=IFVM6R?B]U<VE:DZC4HWA9>L
M%.HW9(9^I95=3< 8:YCFN:?VD$2N/J=@NR#[ZC?T\"LK2]MZM.O2N+ /P]YJ
MTW->WO/T;Z+:K20-IE1KVO$AS3)2-C2"@_24XM=_):R0D?YHVY[V\HV-X7^'
M2N\46:4CE9AVN2.'ZE/H>4S4*@]+,2X6VR74H+DVXVR-9&FY5M>-;U**CJ M
MXV^>L?2IE4JM&F6JA1JG/4F?:.IJ<I\T_*S"#T(=8<;7RZ:MQL8T%G4MJ5U0
MJ7=!]S:LJL=7MZ=7N7UJ0/QL;6V7]VYPR#]EVR<P-RZ6_HW56TN66-RVTO*E
M)XM[JI2_44Z%8P&5'4-JGWK6DR:>VS:B)"DSS-[(/C5RZ$Q.2F#*?C&CL%11
M/TNO4J84XV+V4EB5?=7ZP%[ $^$:#8VRAS2RVF'9;'F!JWAPLJ*')F:DIL2@
M-])'I*V4L6OM],7O;<QGS+;CXXN,I>Y&$,W:AW+&G3+U1@55"DIZ*].6\#?K
M<;]8S#GSVGV>_$IDY-Y0YIT^BU!,V&=>))6CTF1FQW+H=!U2DNA^ZK &S@OU
MVY]1=L[$7-K7JV%7'L,O&TG/I6ETRVO[6K4 EM$75(T*M,.= VWTG1J<\CQU
MB?ZAVEW;4<2H=FL8P^I6ITZ]_95;W#+RA1<0'5_T59ES0K%HS[ME=FT=XW:L
M9&YG3.!,0,4B;?**%5WFP\\=Q(K0?U?=GZ20XX1JT$ WWN(WIS!>PRW-T;%5
M?K!J-,GNY-:2TM;;M+(T)D5L]VHNNA9*5+#8 %K*B*%*K!%E?XLH4#R]9)%C
MXC<=#X[\XWWX-<JJ/Q08W?P;F3G)+Y92-'9#='GYZ53-,3CCS)LA:7'$(]5>
ME 4LG2=Q:UHYFQL;C$;NA96C6.KW-3NZ3:E6G0IEQ!,&K6<RFS(&"]X$Y3F%
MV%_B-IA5E<7]ZZHRVM*?>5W4J-6X>& AI+:-!KZM2"1(8PF),0"MFJO(T;'T
MG*X=I-;:9*T,33%?6 IR?3*!,PVR0LZFBV$!HW-U;^R+@8K,Q)-B;IV+$*74
M4(D,=85>;2XBHMRZ1*R$PTZX2);T='Z\AE(UVLJ^T7U7>R7XJ,.)%5R?S!H&
M:M%E5/.R3;%;HE.=>:42I%D&<4XFZ;>J!Y6MM$?6>.4G%;P^5)W$>;F"9C"L
MK,ZF6)M-0:FY9S2.Y)2M@EMSF#<*5O[C&UQ'LMVAPECJN(81?4*#0'&X[EU2
MVV<@#^II=Y1C,0=N%I\)[9]E<;J-HX9CN'7-P\[+;7OVTKLN_P!W]+6[NOM#
M>.[D*X\[<B,-3L[..T#$<G,5)3*IR0> ;;]/)1W\PT05!*#+"Z+G=5MHC^?9
M+#[DNXJRV7ELN*Z:FU:#;H02.8]QM'W9[%N(9QP+F*G-..-E:F5!U8#27MU)
MV5NE0-K?='P"XIWUEN)42=2BHA)).ZMSSOU/._UZ"( .X]<O)=+,Y#(^66D_
M;Q]5M?PETR2F,08RK$]+>E-46FN%'JE6COI)T7L >9B]IBLIJF5N$YY"DJD*
M55*XT^P%[-"9J#C;84@&X)-MBD&/)P/8KPWA'%N,IG&BFFL(U>G.2$[,K 6A
MJ;F91V6D-AN0J9<0"4V">9,-P)E+B5VOX]RKG'#WTW4#7<,.)6%RDS(MS#M5
M6&WDJ+*2)8)!3JO?:UXCRG+COR_/@I @:SX"-V?O*PDF23,XJQ7@Y3:FVZK+
ML3$JE5[MEI@S!*0=_6\A;?G&$G6%RSSC#FHK0ZZV0H:2 VM21<>8M:-U<S,+
M-R[N#<V</A*II4TNE8BD=FN[1+.HIQ4X20$ I2I0V 5L0;&,1<0> OS/Q9*5
MF192<.XNE6'Z1,MD*:4\S+(7. %)(&EQ1!WW/C :]=>JAPD>G'CUQ6 P-0)
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MJV]04CS;5:#2<W_4'$<UJ,*[4=G<< _PG&L-OG.$]U0NJ1KMY/H%PJM/^ES
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M/01'V@(=F=S<J<;W]A'+V6C>[+^KG#^'6ZFV$]Q(>C.+2H).MH*2IU6]SZB
MHVZVVZ1(].'J%)ZGKK3FL+\2&')G#.9M12_-N3S=2#3[#RTE'TV@XI("C^SJ
MMX6$8(T$:5).ROB!\_7$IG%;E12LR\D<#\2>6509Q329-J9:QM*2H"9ZAN)<
M1*2^N3253+R7%A6X; 2D7.V\1:J( NC=M6XO<%)Z@BUTD<O(\^@B1H0=WAKE
MSG=NXK&1O$F1PUB-T1D..\C+1-4H)-D'ES\S\[??#TJ*5:E)]4>_YO[/OAI
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MLAGO5+[I6E1V)(]XOTY[1C%MM25;@?'VQF^KSS-+P;@&;FY94XRC\H@RW>%
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M%#?><I'?+,@LNN@EK4=.RCJV3;H(QN<&@94#.4-<9$ :Y;]WY*4Z0>2";A@
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MYY3K[3R\4A45"]][6'P\//YVC._"_07,0\0^4],:&MQRO2\RI/2TG,L/'<^
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M@)#=K6O8CI$TZQ8R!6V/B_::>T#H#G$:;CY:*E6V95>UQH=YM-:#4[TL+8B
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M6%G;6=+_ &5NQM-HB# '[CS.JS!2&[Y9/J*K@N( 'A^O'X^^/C(0"X/\P?\
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M F#Q*^:8SVIHX6'U,?QVM=70J,INPG FMH6]M4>YH-!]R_:=6?2/[R^-"6M
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M+=R;(/QM$_'%AF*JE<%%6R^0^E"ZY/T%N9;-BIQ+-59-E=39/6(+.#N27/\
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M^@*]&<8!2H .I*#J;(YW-^<=!@E6BRJ+>X<\4+QK62R?]N*U,,_:1! D Y$
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M<@I)F1IZ :KGV1Z9U7\T?/E?XG[H\-<4#A_#QO<@S1Y^"SS\.?*/)6U_[O\
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MIM!FFRUK6@D -  CQRTY+IZ--EO2+=K(ESG/>X ESBUSW$F-3GRS*R=2=/\
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MI8::>1+3-.#TF]W22W-J0^Z24*-]!Y [$F/J6#8HS$.XH73VONA3#7/;5IU
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MC4 =3JTWM>Q[3GM,<PEK@9F08(Y+LDPC2EY%YSYF4&0IWY=PU)SDI6%X>:?
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M2XIEE)N2F]R205;6CS8F:G=?#A[[ZD;>Y-5[*HI7%.&!S*=%I;M/=6<-EL.
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M0+7 5ROO%<Z5>LD_1VL=B;6V^>6_C#$@"R]K;^KS\NOC^X0A(<)!N".72_P
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M ,8/\TD'Q\K0[AO_ !Z1T_WN66G.)Z$=Z\D$T*H\AR_U'B1Y9Y:>?'"C^:>
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M22JWU1,DY#0QEZ#>HR\#QSY99:=!.5L+\BK?Q)MXWY0VUT7(VOO8[D_=:_\
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MK_1/R1Y7\8D-[+T6XL,*'K_/;^TRJC]7WQSW:D'_ -',;STPVYGA'=SEKO\
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!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
